{"6a86f3c83d4c9dbebd8703abaa149a2f6cb82714": [["ACE2 gene expression was also found to be higher in 194 smokers when compared to non-smokers.", [["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["ACE2", "PROTEIN", 0, 4], ["ACE2 gene expression", "TREATMENT", 0, 20]]], ["Few studies suggested that smoking history may play 195 an additional role in susceptibility of smokers towards COVID-19 infection [21, 22] .", [["smoking", "CHEMICAL", 27, 34], ["COVID-19", "CHEMICAL", 112, 120], ["infection", "DISEASE", 121, 130], ["COVID-19", "CHEMICAL", 112, 120], ["COVID-19", "ORGANISM", 112, 120], ["COVID-19", "SPECIES", 112, 120], ["Few studies", "TEST", 0, 11], ["COVID-19 infection", "PROBLEM", 112, 130]]], ["Some patients despite being asymptomatic or with minimum symptoms have reduced pulse 242 oximetry readings.", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["minimum symptoms", "PROBLEM", 49, 65], ["oximetry readings", "TEST", 89, 106]]], ["This condition has been referred to as \"Silent\" or \"apathetic hypoxia\" [38- The patients turned to be non-responders to therapy and were reported dead at different days of immunoglobulins are yet to be discovered for both prevention and treatment of COVID-19.579There are still many unresolved questions on SARS-CoV-2 that warrant investigation.", [["hypoxia", "DISEASE", 62, 69], ["COVID-19.579", "CHEMICAL", 250, 262], ["COVID-19.579", "CHEMICAL", 250, 262], ["patients", "ORGANISM", 80, 88], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 172, 187], ["immunoglobulins", "PROTEIN", 172, 187], ["patients", "SPECIES", 80, 88], ["\"apathetic hypoxia\"", "PROBLEM", 51, 70], ["therapy", "TREATMENT", 120, 127], ["immunoglobulins", "TREATMENT", 172, 187], ["COVID", "TEST", 250, 255], ["investigation", "TEST", 331, 344]]], ["Some of 580 the key questions that remain unresolved are:579It has been reported that COVID-19 can be spread from asymptomatic persons.", [["COVID-19", "GENE_OR_GENE_PRODUCT", 86, 94], ["persons", "ORGANISM", 127, 134], ["COVID-19", "DNA", 86, 94], ["persons", "SPECIES", 127, 134], ["COVID", "TEST", 86, 91]]], ["Quantitative It has been widely reported by many researchers and clinicians that older people are more", [["people", "ORGANISM", 87, 93], ["people", "SPECIES", 87, 93]]]], "2a423f15be9162d939e0402df6f74c31ee2e9486": [["IntroductionSolid organ transplantation is a therapeutic option for many human diseases.", [["Solid organ", "ANATOMY", 12, 23], ["organ", "ORGAN", 18, 23], ["human", "ORGANISM", 73, 78], ["human", "SPECIES", 73, 78], ["human", "SPECIES", 73, 78], ["IntroductionSolid organ transplantation", "TREATMENT", 0, 39], ["a therapeutic option", "TREATMENT", 43, 63], ["many human diseases", "PROBLEM", 68, 87]]], ["Liver, kidney, heart, and lung transplantations have become standard therapy for selected end-stage diseases.", [["Liver", "ANATOMY", 0, 5], ["kidney", "ANATOMY", 7, 13], ["heart", "ANATOMY", 15, 20], ["lung", "ANATOMY", 26, 30], ["Liver", "ORGAN", 0, 5], ["kidney", "ORGAN", 7, 13], ["heart", "ORGAN", 15, 20], ["lung", "ORGAN", 26, 30], ["lung transplantations", "TREATMENT", 26, 47], ["standard therapy", "TREATMENT", 60, 76], ["selected end-stage diseases", "PROBLEM", 81, 108], ["kidney", "ANATOMY", 7, 13], ["heart", "ANATOMY", 15, 20], ["lung", "ANATOMY", 26, 30], ["transplantations", "OBSERVATION", 31, 47], ["-stage", "OBSERVATION_MODIFIER", 93, 99], ["diseases", "OBSERVATION", 100, 108]]], ["However, complications such as infection and allograft rejection, which are related by immunosuppressive therapy, remain major causes of morbidity and mortality following solid organ transplantation.", [["allograft", "ANATOMY", 45, 54], ["organ", "ANATOMY", 177, 182], ["infection", "DISEASE", 31, 40], ["allograft", "ORGAN", 45, 54], ["organ", "ORGAN", 177, 182], ["complications", "PROBLEM", 9, 22], ["infection", "PROBLEM", 31, 40], ["allograft rejection", "PROBLEM", 45, 64], ["immunosuppressive therapy", "TREATMENT", 87, 112], ["morbidity", "PROBLEM", 137, 146], ["solid organ transplantation", "TREATMENT", 171, 198], ["complications", "OBSERVATION", 9, 22], ["infection", "OBSERVATION", 31, 40], ["allograft rejection", "OBSERVATION", 45, 64], ["immunosuppressive therapy", "OBSERVATION", 87, 112], ["morbidity", "OBSERVATION", 137, 146], ["transplantation", "OBSERVATION", 183, 198]]], ["Epidemiologically, some viral infections are the result of community exposures (influenza, adenovirus), whereas some are commonly transmitted with the allograft (cytomegalovirus, Epstein-Barr virus), and others are the result of more distant exposures reactivated in the setting of immune suppression (chicken pox and varicella zoster as shingles) [1] [2] [3] .", [["allograft", "ANATOMY", 151, 160], ["viral infections", "DISEASE", 24, 40], ["influenza, adenovirus)", "DISEASE", 80, 102], ["varicella zoster", "DISEASE", 318, 334], ["shingles", "DISEASE", 338, 346], ["adenovirus", "ORGANISM", 91, 101], ["allograft", "TISSUE", 151, 160], ["cytomegalovirus", "ORGANISM", 162, 177], ["Epstein-Barr virus", "ORGANISM", 179, 197], ["chicken", "ORGANISM", 302, 309], ["pox", "ORGANISM", 310, 313], ["varicella zoster", "ORGANISM", 318, 334], ["chicken pox", "SPECIES", 302, 313], ["varicella zoster", "SPECIES", 318, 334], ["Epstein-Barr virus", "SPECIES", 179, 197], ["chicken", "SPECIES", 302, 309], ["some viral infections", "PROBLEM", 19, 40], ["community exposures", "PROBLEM", 59, 78], ["influenza", "PROBLEM", 80, 89], ["adenovirus", "PROBLEM", 91, 101], ["the allograft (cytomegalovirus", "PROBLEM", 147, 177], ["Epstein-Barr virus", "PROBLEM", 179, 197], ["immune suppression", "PROBLEM", 282, 300], ["chicken pox", "TREATMENT", 302, 313], ["varicella zoster", "PROBLEM", 318, 334], ["viral", "OBSERVATION_MODIFIER", 24, 29], ["infections", "OBSERVATION", 30, 40], ["community exposures", "OBSERVATION", 59, 78], ["allograft", "OBSERVATION", 151, 160], ["immune suppression", "OBSERVATION", 282, 300]]], ["Multiple simultaneous infections, viral and nonviral, are also common, such as cytomegalovirus (CMV) and human herpes virus 6 or cytomegalovirus and pneumocystis [3] [4] [5] [6] .IntroductionThe effects of viral infection are classified as direct and indirect.", [["infections", "DISEASE", 22, 32], ["cytomegalovirus (CMV) and human herpes virus", "DISEASE", 79, 123], ["viral infection", "DISEASE", 206, 221], ["cytomegalovirus", "ORGANISM", 79, 94], ["CMV", "ORGANISM", 96, 99], ["human herpes virus 6", "ORGANISM", 105, 125], ["cytomegalovirus", "ORGANISM", 129, 144], ["pneumocystis [3] [4] [5] [6]", "SIMPLE_CHEMICAL", 149, 177], ["human herpes virus", "SPECIES", 105, 123], ["CMV", "SPECIES", 96, 99], ["human herpes virus", "SPECIES", 105, 123], ["Multiple simultaneous infections", "PROBLEM", 0, 32], ["viral and nonviral", "PROBLEM", 34, 52], ["cytomegalovirus (CMV)", "PROBLEM", 79, 100], ["human herpes virus", "PROBLEM", 105, 123], ["cytomegalovirus", "PROBLEM", 129, 144], ["pneumocystis", "PROBLEM", 149, 161], ["viral infection", "PROBLEM", 206, 221], ["simultaneous", "OBSERVATION_MODIFIER", 9, 21], ["infections", "OBSERVATION", 22, 32], ["cytomegalovirus", "OBSERVATION", 79, 94], ["viral", "OBSERVATION_MODIFIER", 206, 211], ["infection", "OBSERVATION", 212, 221]]], ["Fever and neutropenia syndrome and invasive disease such as pneumonia, enteritis, meningitis, or encephalitis are considered direct effects.", [["Fever", "DISEASE", 0, 5], ["neutropenia syndrome", "DISEASE", 10, 30], ["invasive disease", "DISEASE", 35, 51], ["pneumonia", "DISEASE", 60, 69], ["enteritis", "DISEASE", 71, 80], ["meningitis", "DISEASE", 82, 92], ["encephalitis", "DISEASE", 97, 109], ["Fever", "PROBLEM", 0, 5], ["neutropenia syndrome", "PROBLEM", 10, 30], ["invasive disease", "PROBLEM", 35, 51], ["pneumonia", "PROBLEM", 60, 69], ["enteritis", "PROBLEM", 71, 80], ["meningitis", "PROBLEM", 82, 92], ["encephalitis", "PROBLEM", 97, 109], ["neutropenia syndrome", "OBSERVATION", 10, 30], ["invasive", "OBSERVATION_MODIFIER", 35, 43], ["disease", "OBSERVATION", 44, 51], ["pneumonia", "OBSERVATION", 60, 69], ["enteritis", "OBSERVATION", 71, 80], ["meningitis", "OBSERVATION", 82, 92], ["encephalitis", "OBSERVATION", 97, 109]]], ["Indirect effects are due to release of cytokines, chemokines, and growth factors in response to viral infection of the body, which deepen immunosuppression and increase risk of other opportunistic infections [2, [7] [8] [9] [10] .", [["body", "ANATOMY", 119, 123], ["viral infection", "DISEASE", 96, 111], ["opportunistic infections", "DISEASE", 183, 207], ["body", "ORGANISM_SUBDIVISION", 119, 123], ["[7] [8] [9] [10]", "SIMPLE_CHEMICAL", 212, 228], ["cytokines", "PROTEIN", 39, 48], ["chemokines", "PROTEIN", 50, 60], ["growth factors", "PROTEIN", 66, 80], ["cytokines", "PROBLEM", 39, 48], ["chemokines", "TREATMENT", 50, 60], ["growth factors", "PROBLEM", 66, 80], ["viral infection of the body", "PROBLEM", 96, 123], ["deepen immunosuppression", "TREATMENT", 131, 155], ["other opportunistic infections", "PROBLEM", 177, 207], ["viral infection", "OBSERVATION", 96, 111], ["body", "ANATOMY", 119, 123]]], ["In addition, viral infection may alter expression of surface antigens (e.g., histocompatibility antigens), provoking graft rejection and/or causing dysregulated cellular proliferation (contributing to oncogenesis).", [["surface", "ANATOMY", 53, 60], ["graft", "ANATOMY", 117, 122], ["cellular", "ANATOMY", 161, 169], ["viral infection", "DISEASE", 13, 28], ["surface antigens", "GENE_OR_GENE_PRODUCT", 53, 69], ["histocompatibility antigens", "GENE_OR_GENE_PRODUCT", 77, 104], ["graft", "TISSUE", 117, 122], ["cellular", "CELL", 161, 169], ["surface antigens", "PROTEIN", 53, 69], ["histocompatibility antigens", "PROTEIN", 77, 104], ["viral infection", "PROBLEM", 13, 28], ["surface antigens (e.g., histocompatibility antigens", "PROBLEM", 53, 104], ["graft rejection", "PROBLEM", 117, 132], ["dysregulated cellular proliferation", "PROBLEM", 148, 183], ["viral", "OBSERVATION_MODIFIER", 13, 18], ["infection", "OBSERVATION", 19, 28], ["graft rejection", "OBSERVATION", 117, 132], ["dysregulated", "OBSERVATION_MODIFIER", 148, 160], ["cellular proliferation", "OBSERVATION", 161, 183]]], ["Multiple observational studies implicate infection with HHV 6 and/or HHV 7 as risk factors for CMV disease and CMV infection may trigger HHV 6 and HHV 7 reactivation [3-5, 11, 12] .", [["infection", "DISEASE", 41, 50], ["CMV disease", "DISEASE", 95, 106], ["CMV infection", "DISEASE", 111, 124], ["HHV 6", "ORGANISM", 56, 61], ["HHV 7", "ORGANISM", 69, 74], ["CMV", "ORGANISM", 95, 98], ["CMV", "ORGANISM", 111, 114], ["HHV 7", "ORGANISM", 147, 152], ["HHV", "SPECIES", 56, 59], ["HHV", "SPECIES", 69, 72], ["CMV", "SPECIES", 95, 98], ["CMV", "SPECIES", 111, 114], ["HHV", "SPECIES", 137, 140], ["HHV", "SPECIES", 147, 150], ["Multiple observational studies", "TEST", 0, 30], ["infection", "PROBLEM", 41, 50], ["HHV", "PROBLEM", 56, 59], ["HHV", "PROBLEM", 69, 72], ["CMV disease", "PROBLEM", 95, 106], ["CMV infection", "PROBLEM", 111, 124], ["HHV", "PROBLEM", 137, 140], ["HHV", "PROBLEM", 147, 150], ["infection", "OBSERVATION", 41, 50], ["CMV infection", "OBSERVATION", 111, 124]]], ["Recently, coinfection of polyoma virus and CMV has been reported in kidney transplant recipients.", [["kidney", "ANATOMY", 68, 74], ["coinfection of polyoma virus", "DISEASE", 10, 38], ["polyoma virus", "ORGANISM", 25, 38], ["CMV", "ORGANISM", 43, 46], ["kidney", "ORGAN", 68, 74], ["polyoma virus", "SPECIES", 25, 38], ["polyoma virus", "SPECIES", 25, 38], ["CMV", "SPECIES", 43, 46], ["polyoma virus", "PROBLEM", 25, 38], ["CMV", "PROBLEM", 43, 46], ["kidney transplant recipients", "TREATMENT", 68, 96], ["coinfection", "OBSERVATION", 10, 21], ["polyoma virus", "OBSERVATION", 25, 38], ["CMV", "OBSERVATION", 43, 46], ["kidney", "ANATOMY", 68, 74], ["transplant recipients", "OBSERVATION", 75, 96]]], ["Polyoma virus may induce CMV gene expression by stimulating cellular regulator proteins or by its own gene regulator proteins [13] [14] [15] .", [["cellular", "ANATOMY", 60, 68], ["Polyoma virus", "ORGANISM", 0, 13], ["CMV", "ORGANISM", 25, 28], ["cellular", "CELL", 60, 68], ["cellular regulator proteins", "PROTEIN", 60, 87], ["gene regulator proteins", "PROTEIN", 102, 125], ["Polyoma virus", "SPECIES", 0, 13], ["CMV", "SPECIES", 25, 28], ["Polyoma virus", "PROBLEM", 0, 13], ["CMV gene expression", "PROBLEM", 25, 44], ["stimulating cellular regulator proteins", "PROBLEM", 48, 87]]], ["Increased viral replication and persistence may contribute to allograft injury (fibrosis) or chronic rejection.", [["allograft", "ANATOMY", 62, 71], ["allograft injury", "DISEASE", 62, 78], ["fibrosis", "DISEASE", 80, 88], ["allograft", "TISSUE", 62, 71], ["Increased viral replication", "PROBLEM", 0, 27], ["allograft injury", "PROBLEM", 62, 78], ["fibrosis)", "PROBLEM", 80, 89], ["chronic rejection", "PROBLEM", 93, 110], ["viral replication", "OBSERVATION", 10, 27], ["may contribute to", "UNCERTAINTY", 44, 61], ["allograft", "OBSERVATION_MODIFIER", 62, 71], ["injury", "OBSERVATION", 72, 78], ["fibrosis", "OBSERVATION", 80, 88], ["chronic", "OBSERVATION_MODIFIER", 93, 100], ["rejection", "OBSERVATION", 101, 110]]], ["Virus-specific T cells cross-reactive with allo-antigens can alter the memory allospecific T cell pool and may modulate allograft survival and transplantation tolerance.", [["T cells", "ANATOMY", 15, 22], ["T cell", "ANATOMY", 91, 97], ["allograft", "ANATOMY", 120, 129], ["Virus", "ORGANISM", 0, 5], ["T cells", "CELL", 15, 22], ["allo-antigens", "GENE_OR_GENE_PRODUCT", 43, 56], ["T cell", "CELL", 91, 97], ["allograft", "TISSUE", 120, 129], ["T cells", "CELL_TYPE", 15, 22], ["allo-antigens", "PROTEIN", 43, 56], ["memory allospecific T cell pool", "CELL_TYPE", 71, 102], ["Virus", "PROBLEM", 0, 5], ["allo-antigens", "TREATMENT", 43, 56], ["modulate allograft survival", "TREATMENT", 111, 138], ["transplantation tolerance", "TREATMENT", 143, 168], ["allograft", "OBSERVATION", 120, 129]]], ["Viral infection can also lead to the generation of cross-reactive T cells directed against shared antigens between virus and graft (\"molecular mimicry\"), or neoantigens generated by viral expression within the allograft environment [16] [17] [18] [19] .", [["T cells", "ANATOMY", 66, 73], ["graft", "ANATOMY", 125, 130], ["allograft", "ANATOMY", 210, 219], ["Viral infection", "DISEASE", 0, 15], ["Viral", "ORGANISM", 0, 5], ["T cells", "CELL", 66, 73], ["graft", "TISSUE", 125, 130], ["cross-reactive T cells", "CELL_TYPE", 51, 73], ["Viral infection", "PROBLEM", 0, 15], ["cross-reactive T cells", "TREATMENT", 51, 73], ["graft", "TREATMENT", 125, 130], ["neoantigens", "PROBLEM", 157, 168], ["infection", "OBSERVATION", 6, 15], ["graft", "OBSERVATION", 125, 130]]], ["2 The Scientific World Journal Many viral infections after renal transplantation result from reactivation of \"latent\" viral infection in the host or from the graft.", [["renal", "ANATOMY", 59, 64], ["graft", "ANATOMY", 158, 163], ["viral infections", "DISEASE", 36, 52], ["viral infection", "DISEASE", 118, 133], ["renal", "ORGAN", 59, 64], ["graft", "TISSUE", 158, 163], ["viral infections", "PROBLEM", 36, 52], ["renal transplantation", "TREATMENT", 59, 80], ["\"latent\" viral infection in the host", "PROBLEM", 109, 145], ["the graft", "TREATMENT", 154, 163], ["viral", "OBSERVATION_MODIFIER", 36, 41], ["infections", "OBSERVATION", 42, 52], ["renal", "ANATOMY", 59, 64], ["transplantation", "OBSERVATION", 65, 80], ["latent", "OBSERVATION_MODIFIER", 110, 116], ["\"", "OBSERVATION_MODIFIER", 116, 117], ["viral", "OBSERVATION_MODIFIER", 118, 123], ["infection", "OBSERVATION", 124, 133], ["graft", "OBSERVATION", 158, 163]]], ["Whether the virus \"awakes\" depends on the nature of the virus, the tissue infected, and host immune response.", [["tissue", "ANATOMY", 67, 73], ["tissue", "TISSUE", 67, 73], ["the virus", "PROBLEM", 8, 17], ["the virus", "PROBLEM", 52, 61], ["the tissue infected", "PROBLEM", 63, 82], ["virus", "OBSERVATION", 12, 17], ["virus", "OBSERVATION", 56, 61], ["tissue", "ANATOMY", 67, 73], ["infected", "OBSERVATION", 74, 82]]], ["Some latent viruses are metabolically inactive, whereas others are constantly replicating at low levels determined by the effectiveness of the host's immune response.", [["Some latent viruses", "PROBLEM", 0, 19], ["latent", "OBSERVATION_MODIFIER", 5, 11], ["viruses", "OBSERVATION", 12, 19], ["metabolically", "OBSERVATION_MODIFIER", 24, 37], ["inactive", "OBSERVATION_MODIFIER", 38, 46]]], ["Multiple factors contribute to viral activation after transplantation, including immune suppression (especially reduction of cytotoxic immunity), graft rejection therapy, inflammation (cytokines), and tissue injury.", [["graft", "ANATOMY", 146, 151], ["tissue", "ANATOMY", 201, 207], ["inflammation", "DISEASE", 171, 183], ["tissue injury", "DISEASE", 201, 214], ["graft", "TISSUE", 146, 151], ["tissue", "TISSUE", 201, 207], ["cytokines", "PROTEIN", 185, 194], ["Multiple factors", "PROBLEM", 0, 16], ["viral activation", "PROBLEM", 31, 47], ["transplantation", "TREATMENT", 54, 69], ["immune suppression", "PROBLEM", 81, 99], ["cytotoxic immunity)", "TREATMENT", 125, 144], ["graft rejection therapy", "TREATMENT", 146, 169], ["inflammation (cytokines)", "PROBLEM", 171, 195], ["tissue injury", "PROBLEM", 201, 214], ["viral activation", "OBSERVATION", 31, 47], ["graft rejection", "OBSERVATION", 146, 161], ["inflammation", "OBSERVATION", 171, 183], ["tissue", "ANATOMY", 201, 207], ["injury", "OBSERVATION", 208, 214]]], ["The host response is also less effective because of the mismatch in major histocompatibility antigens between the organ donor and host, which reduces the efficacy of direct pathway antiviral cellular immune responses.", [["organ", "ANATOMY", 114, 119], ["cellular", "ANATOMY", 191, 199], ["histocompatibility antigens", "GENE_OR_GENE_PRODUCT", 74, 101], ["organ", "ORGAN", 114, 119], ["cellular", "CELL", 191, 199], ["major histocompatibility antigens", "PROTEIN", 68, 101], ["the mismatch in major histocompatibility antigens", "PROBLEM", 52, 101], ["host response", "OBSERVATION", 4, 17], ["less effective", "OBSERVATION_MODIFIER", 26, 40], ["mismatch", "OBSERVATION", 56, 64], ["antiviral cellular immune", "OBSERVATION", 181, 206]]], ["These factors render the allograft susceptible to invasive viral infection.IntroductionThe optimal approach to infection in the solid organ transplant recipient is prevention; failing this, its prompt and aggressive diagnosis and therapy are essential.", [["allograft", "ANATOMY", 25, 34], ["solid organ", "ANATOMY", 128, 139], ["viral infection", "DISEASE", 59, 74], ["infection", "DISEASE", 111, 120], ["allograft", "TISSUE", 25, 34], ["organ", "ORGAN", 134, 139], ["These factors", "PROBLEM", 0, 13], ["the allograft", "PROBLEM", 21, 34], ["invasive viral infection", "PROBLEM", 50, 74], ["The optimal approach", "TREATMENT", 87, 107], ["infection", "PROBLEM", 111, 120], ["the solid organ transplant recipient", "TREATMENT", 124, 160], ["therapy", "TREATMENT", 230, 237], ["allograft", "OBSERVATION", 25, 34], ["invasive", "OBSERVATION_MODIFIER", 50, 58], ["viral", "OBSERVATION_MODIFIER", 59, 64], ["infection", "OBSERVATION", 65, 74], ["infection", "OBSERVATION", 111, 120], ["solid organ", "ANATOMY", 128, 139], ["transplant", "OBSERVATION", 140, 150]]], ["The sources of infectious agents after transplantation include endogenous organisms, the allograft itself, and the environment.", [["allograft", "ANATOMY", 89, 98], ["allograft", "TISSUE", 89, 98], ["infectious agents", "TREATMENT", 15, 32], ["transplantation", "TREATMENT", 39, 54], ["endogenous organisms", "PROBLEM", 63, 83], ["the allograft itself", "TREATMENT", 85, 105], ["infectious", "OBSERVATION", 15, 25], ["allograft", "OBSERVATION", 89, 98]]], ["An important principle to consider when evaluating solid-organ transplant recipients (and other immunocompromised hosts) for infection is that the usual inflammatory response to an infectious organism may be attenuated due to immunosuppressive therapy and that therefore the signs and symptoms of infections may be blunted and diagnostic techniques may be compromised [1, 20] .IntroductionPretransplant screening of potential organ donors and recipients is an essential part of solid organ transplantation.", [["organ", "ANATOMY", 57, 62], ["organ", "ANATOMY", 426, 431], ["organ", "ANATOMY", 484, 489], ["infection", "DISEASE", 125, 134], ["infections", "DISEASE", 297, 307], ["organ", "ORGAN", 57, 62], ["organ", "ORGAN", 426, 431], ["donors", "ORGANISM", 432, 438], ["recipients", "ORGANISM", 443, 453], ["organ", "ORGAN", 484, 489], ["solid-organ transplant recipients", "TREATMENT", 51, 84], ["other immunocompromised hosts", "PROBLEM", 90, 119], ["infection", "PROBLEM", 125, 134], ["the usual inflammatory response", "PROBLEM", 143, 174], ["an infectious organism", "PROBLEM", 178, 200], ["immunosuppressive therapy", "TREATMENT", 226, 251], ["the signs and symptoms of infections", "PROBLEM", 271, 307], ["blunted", "PROBLEM", 315, 322], ["diagnostic techniques", "TEST", 327, 348], ["Pretransplant screening", "TEST", 389, 412], ["potential organ donors", "TREATMENT", 416, 438], ["recipients", "TREATMENT", 443, 453], ["solid organ transplantation", "TREATMENT", 478, 505], ["organ", "ANATOMY", 57, 62], ["transplant", "OBSERVATION", 63, 73], ["inflammatory", "OBSERVATION_MODIFIER", 153, 165], ["infectious", "OBSERVATION", 181, 191], ["transplantation", "OBSERVATION", 490, 505]]], ["Several guidelines for pretransplant screening have been published recently, including a consensus conference on the immunocompromised patient, the American Society for Transplantation clinical practice guidelines on the evaluation of renal transplant candidates, and the American Society of Transplant Physicians clinical practice guidelines on the evaluation of living renal transplant donors.", [["renal transplant", "ANATOMY", 235, 251], ["renal", "ANATOMY", 371, 376], ["patient", "ORGANISM", 135, 142], ["renal", "ORGAN", 235, 240], ["renal", "ORGAN", 371, 376], ["donors", "ORGANISM", 388, 394], ["patient", "SPECIES", 135, 142], ["pretransplant screening", "TEST", 23, 46], ["Transplantation clinical practice", "TREATMENT", 169, 202], ["the evaluation", "TEST", 217, 231], ["renal transplant", "TREATMENT", 235, 251], ["the evaluation", "TEST", 346, 360], ["living renal transplant donors", "TREATMENT", 364, 394], ["renal", "ANATOMY", 235, 240], ["transplant", "OBSERVATION", 241, 251], ["renal", "ANATOMY", 371, 376], ["transplant", "OBSERVATION", 377, 387]]], ["Pretransplant screening of the donor and recipient affords an opportunity to assess the safety of transplantation, to determine the prophylaxis and preventive strategies utilized after transplant, to detect and fully treat active infection in the potential recipient prior to transplant, to update the vaccination status of the potential recipient, and to educate the patient and family about preventive measures [21, 22] .IntroductionThe generosity and altruism of organ donation have no nationality and no frontiers.", [["organ", "ANATOMY", 466, 471], ["infection", "DISEASE", 230, 239], ["patient", "ORGANISM", 368, 375], ["organ", "ORGAN", 466, 471], ["patient", "SPECIES", 368, 375], ["Pretransplant screening", "TEST", 0, 23], ["the donor and recipient affords", "TREATMENT", 27, 58], ["transplantation", "TREATMENT", 98, 113], ["the prophylaxis", "TREATMENT", 128, 143], ["preventive strategies", "TREATMENT", 148, 169], ["transplant", "TREATMENT", 185, 195], ["active infection", "PROBLEM", 223, 239], ["transplant", "TREATMENT", 276, 286], ["organ donation", "TREATMENT", 466, 480], ["active", "OBSERVATION_MODIFIER", 223, 229], ["infection", "OBSERVATION", 230, 239], ["generosity", "OBSERVATION", 439, 449]]], ["Due to this, increases in migration and international travel have also led to a rise in the number of donors from foreign countries.", [["donors", "ORGANISM", 102, 108], ["increases", "OBSERVATION_MODIFIER", 13, 22], ["migration", "OBSERVATION_MODIFIER", 26, 35], ["foreign countries", "OBSERVATION", 114, 131]]], ["Linked to this is an increased risk of infections from specific areas of the world, which may persist in a latent or chronic form in the donor and may be transmitted during transplantation.", [["infections", "DISEASE", 39, 49], ["infections", "PROBLEM", 39, 49], ["transplantation", "TREATMENT", 173, 188], ["increased", "OBSERVATION_MODIFIER", 21, 30], ["infections", "OBSERVATION", 39, 49], ["chronic", "OBSERVATION_MODIFIER", 117, 124]]], ["Future advances will likely include the increasing use of rapid molecular diagnostic testing, based on genomics, proteomics, and metabolomics (the high-throughput measurement and analysis of metabolites) and possibly additional testing for emerging pathogen [23] [24] [25] [26] .", [["[23] [24] [25] [26]", "SIMPLE_CHEMICAL", 258, 277], ["rapid molecular diagnostic testing", "TEST", 58, 92], ["proteomics", "TEST", 113, 123], ["metabolomics", "TEST", 129, 141], ["analysis of metabolites", "TEST", 179, 202], ["additional testing", "TEST", 217, 235], ["emerging pathogen", "PROBLEM", 240, 257]]], ["This paper focusses on acute and recurrent viral infections that occur after adult renal transplantation (Table 1 ).CytomegalovirusHuman cytomegalovirus-human herpesvirus 5 (CMV) belongs to order Herpesvirales, family Herpesviridae, subfamily betaherpesvirinae, genus Cytomegalovirus, species Human herpesvirus 5 [27] .", [["renal", "ANATOMY", 83, 88], ["viral infections", "DISEASE", 43, 59], ["genus Cytomegalovirus", "DISEASE", 262, 283], ["renal", "ORGAN", 83, 88], ["CytomegalovirusHuman cytomegalovirus-", "ORGANISM", 116, 153], ["human herpesvirus 5", "ORGANISM", 153, 172], ["CMV", "ORGANISM", 174, 177], ["Herpesvirales", "GENE_OR_GENE_PRODUCT", 196, 209], ["Herpesviridae", "GENE_OR_GENE_PRODUCT", 218, 231], ["subfamily betaherpesvirinae", "ORGANISM", 233, 260], ["genus Cytomegalovirus", "ORGANISM", 262, 283], ["Human herpesvirus 5", "ORGANISM", 293, 312], ["cytomegalovirus-human herpesvirus", "SPECIES", 137, 170], ["subfamily betaherpesvirinae", "SPECIES", 233, 260], ["Human herpesvirus", "SPECIES", 293, 310], ["human herpesvirus 5", "SPECIES", 153, 172], ["CMV", "SPECIES", 174, 177], ["Human herpesvirus", "SPECIES", 293, 310], ["acute and recurrent viral infections", "PROBLEM", 23, 59], ["adult renal transplantation", "TREATMENT", 77, 104], ["CytomegalovirusHuman", "TEST", 116, 136], ["cytomegalovirus", "TEST", 137, 152], ["human herpesvirus", "PROBLEM", 153, 170], ["genus Cytomegalovirus", "PROBLEM", 262, 283], ["acute", "OBSERVATION_MODIFIER", 23, 28], ["recurrent", "OBSERVATION_MODIFIER", 33, 42], ["viral", "OBSERVATION_MODIFIER", 43, 48], ["infections", "OBSERVATION", 49, 59], ["renal", "ANATOMY", 83, 88], ["transplantation", "OBSERVATION", 89, 104]]], ["Symptomatic CMV infection occurs in 20 to 60% of all transplant recipients and is a significant cause of increased morbidity and mortality in this population [28, 29] .", [["CMV infection", "DISEASE", 12, 25], ["CMV", "ORGANISM", 12, 15], ["recipients", "ORGANISM", 64, 74], ["CMV", "SPECIES", 12, 15], ["Symptomatic CMV infection", "PROBLEM", 0, 25], ["all transplant recipients", "TREATMENT", 49, 74], ["increased morbidity", "PROBLEM", 105, 124], ["CMV", "OBSERVATION_MODIFIER", 12, 15], ["infection", "OBSERVATION", 16, 25], ["20 to", "OBSERVATION_MODIFIER", 36, 41], ["transplant", "OBSERVATION", 53, 63], ["significant", "OBSERVATION_MODIFIER", 84, 95], ["increased", "OBSERVATION_MODIFIER", 105, 114], ["morbidity", "OBSERVATION", 115, 124]]], ["When compared with other organ transplant recipients, renal transplant patients are at lower risk for CMV, in part due to the lower burden of latent virus in the renal allograft.", [["organ", "ANATOMY", 25, 30], ["renal transplant", "ANATOMY", 54, 70], ["renal allograft", "ANATOMY", 162, 177], ["organ", "ORGAN", 25, 30], ["renal", "ORGAN", 54, 59], ["patients", "ORGANISM", 71, 79], ["CMV", "ORGANISM", 102, 105], ["renal allograft", "MULTI-TISSUE_STRUCTURE", 162, 177], ["patients", "SPECIES", 71, 79], ["CMV", "SPECIES", 102, 105], ["other organ transplant recipients", "TREATMENT", 19, 52], ["renal transplant", "TREATMENT", 54, 70], ["CMV", "PROBLEM", 102, 105], ["the lower burden of latent virus in the renal allograft", "PROBLEM", 122, 177], ["recipients", "OBSERVATION", 42, 52], ["renal", "ANATOMY", 54, 59], ["transplant", "OBSERVATION", 60, 70], ["lower risk", "OBSERVATION_MODIFIER", 87, 97], ["CMV", "OBSERVATION", 102, 105], ["lower", "OBSERVATION_MODIFIER", 126, 131], ["burden", "OBSERVATION", 132, 138], ["latent", "OBSERVATION_MODIFIER", 142, 148], ["virus", "OBSERVATION", 149, 154], ["renal", "ANATOMY", 162, 167], ["allograft", "OBSERVATION", 168, 177]]], ["The incidence of CMV in the renal transplant population is estimated to be between 8 and 32 percent [1, 9] .", [["renal transplant", "ANATOMY", 28, 44], ["CMV", "ORGANISM", 17, 20], ["renal", "ORGAN", 28, 33], ["CMV", "SPECIES", 17, 20], ["CMV", "PROBLEM", 17, 20], ["the renal transplant population", "TREATMENT", 24, 55], ["CMV", "OBSERVATION", 17, 20], ["renal", "ANATOMY", 28, 33], ["transplant", "OBSERVATION", 34, 44]]], ["In the renal transplant population, infection can occur acutely or as reactivation of latent virus.", [["renal transplant", "ANATOMY", 7, 23], ["infection", "DISEASE", 36, 45], ["renal", "ORGAN", 7, 12], ["latent virus", "ORGANISM", 86, 98], ["the renal transplant population", "TREATMENT", 3, 34], ["infection", "PROBLEM", 36, 45], ["latent virus", "PROBLEM", 86, 98], ["renal", "ANATOMY", 7, 12], ["transplant", "OBSERVATION", 13, 23], ["infection", "OBSERVATION", 36, 45], ["latent", "OBSERVATION_MODIFIER", 86, 92], ["virus", "OBSERVATION", 93, 98]]], ["In the absence of prophylaxis, acute infection is most likely to occur between the first and third months following transplant, when immune suppression is at its maximum.", [["infection", "DISEASE", 37, 46], ["prophylaxis", "TREATMENT", 18, 29], ["acute infection", "PROBLEM", 31, 46], ["transplant", "TREATMENT", 116, 126], ["immune suppression", "PROBLEM", 133, 151], ["prophylaxis", "OBSERVATION", 18, 29], ["acute", "OBSERVATION_MODIFIER", 31, 36], ["infection", "OBSERVATION", 37, 46], ["most likely", "UNCERTAINTY", 50, 61], ["transplant", "OBSERVATION", 116, 126]]], ["However, the onset of acute infection has been delayed by the use of prophylactic antivirals in the early posttransplant period; currently CMV typically occurs after the cessation of antiviral prophylaxis, later in the first year [20, 30] .", [["acute infection", "DISEASE", 22, 37], ["CMV", "ORGANISM", 139, 142], ["CMV", "SPECIES", 139, 142], ["acute infection", "PROBLEM", 22, 37], ["prophylactic antivirals", "TREATMENT", 69, 92], ["CMV", "PROBLEM", 139, 142], ["antiviral prophylaxis", "TREATMENT", 183, 204], ["acute", "OBSERVATION_MODIFIER", 22, 27], ["infection", "OBSERVATION", 28, 37], ["CMV", "OBSERVATION", 139, 142], ["antiviral prophylaxis", "OBSERVATION", 183, 204]]], ["CMV may be transmitted to transplant recipients via infected donor organs or cellular blood products.", [["organs", "ANATOMY", 67, 73], ["cellular blood", "ANATOMY", 77, 91], ["CMV", "ORGANISM", 0, 3], ["recipients", "ORGANISM", 37, 47], ["organs", "ORGAN", 67, 73], ["cellular blood products", "ORGANISM_SUBSTANCE", 77, 100], ["CMV", "SPECIES", 0, 3], ["CMV", "PROBLEM", 0, 3], ["transplant recipients", "TREATMENT", 26, 47], ["infected donor organs", "PROBLEM", 52, 73], ["cellular blood products", "TREATMENT", 77, 100], ["infected", "OBSERVATION", 52, 60], ["cellular blood products", "OBSERVATION", 77, 100]]], ["Three major patterns of CMV transmission are observed in solid organ transplantation recipients: (1) primary infection develops when a CMVseronegative individual receives cells latently infected with the virus from a seropositive donor, (2) secondary infection or reactivation infection develops when endogenous latent virus is reactivated in a CMV-seropositive individual posttransplantation, and (3) superinfection or reinfection occurs when a seropositive recipient receives latently infected cells from a seropositive donor and the virus that reactivates posttransplantation is of donor origin [1] .", [["organ", "ANATOMY", 63, 68], ["cells", "ANATOMY", 171, 176], ["cells", "ANATOMY", 496, 501], ["primary infection", "DISEASE", 101, 118], ["infection", "DISEASE", 251, 260], ["infection", "DISEASE", 277, 286], ["superinfection", "DISEASE", 402, 416], ["reinfection", "DISEASE", 420, 431], ["latently infected", "DISEASE", 478, 495], ["CMV", "ORGANISM", 24, 27], ["organ", "ORGAN", 63, 68], ["cells", "CELL", 171, 176], ["CMV", "ORGANISM", 345, 348], ["cells", "CELL", 496, 501], ["latently infected cells", "CELL_TYPE", 478, 501], ["CMV", "SPECIES", 24, 27], ["CMV", "SPECIES", 345, 348], ["CMV transmission", "PROBLEM", 24, 40], ["solid organ transplantation recipients", "TREATMENT", 57, 95], ["primary infection", "PROBLEM", 101, 118], ["a CMVseronegative individual receives cells", "TREATMENT", 133, 176], ["the virus", "PROBLEM", 200, 209], ["a seropositive donor", "TREATMENT", 215, 235], ["secondary infection", "PROBLEM", 241, 260], ["reactivation infection", "PROBLEM", 264, 286], ["endogenous latent virus", "PROBLEM", 301, 324], ["a CMV", "TEST", 343, 348], ["superinfection", "PROBLEM", 402, 416], ["reinfection", "PROBLEM", 420, 431], ["a seropositive recipient", "TREATMENT", 444, 468], ["latently infected cells", "PROBLEM", 478, 501], ["a seropositive donor", "TREATMENT", 507, 527], ["the virus", "PROBLEM", 532, 541], ["CMV", "OBSERVATION", 24, 27], ["solid organ", "OBSERVATION", 57, 68], ["transplantation", "OBSERVATION", 69, 84], ["infection", "OBSERVATION", 109, 118], ["infection", "OBSERVATION", 251, 260], ["reactivation", "OBSERVATION_MODIFIER", 264, 276], ["infection", "OBSERVATION", 277, 286], ["infected cells", "OBSERVATION", 487, 501]]], ["The seronegative recipient of an organ from a seropositive donor is at highest risk (without prophylaxis CMV infections hve been reported to occur in 65-88% recipients, 48-60% of wich develop CMV disease) [9, 28, 29] .CytomegalovirusStudies of the effects of CMV disease or asymptomatic infection on graft function and the risk of acute rejection have had conflict results.", [["organ", "ANATOMY", 33, 38], ["graft", "ANATOMY", 300, 305], ["infections", "DISEASE", 109, 119], ["CMV disease", "DISEASE", 192, 203], ["CMV disease", "DISEASE", 259, 270], ["infection", "DISEASE", 287, 296], ["organ", "ORGAN", 33, 38], ["CMV", "ORGANISM", 105, 108], ["recipients", "ORGANISM", 157, 167], ["CMV", "ORGANISM", 192, 195], ["CMV", "ORGANISM", 259, 262], ["graft", "TISSUE", 300, 305], ["CMV", "SPECIES", 105, 108], ["CMV", "SPECIES", 192, 195], ["CMV", "SPECIES", 259, 262], ["a seropositive donor", "TREATMENT", 44, 64], ["prophylaxis CMV infections", "PROBLEM", 93, 119], ["CMV disease)", "PROBLEM", 192, 204], ["CMV disease", "PROBLEM", 259, 270], ["asymptomatic infection", "PROBLEM", 274, 296], ["graft function", "TREATMENT", 300, 314], ["acute rejection", "PROBLEM", 331, 346], ["seronegative recipient", "OBSERVATION", 4, 26], ["organ", "ANATOMY", 33, 38], ["without", "UNCERTAINTY", 85, 92], ["CMV disease", "OBSERVATION", 192, 203], ["CMV disease", "OBSERVATION", 259, 270], ["asymptomatic", "OBSERVATION_MODIFIER", 274, 286], ["infection", "OBSERVATION", 287, 296], ["graft", "OBSERVATION", 300, 305], ["acute", "OBSERVATION_MODIFIER", 331, 336], ["rejection", "OBSERVATION", 337, 346]]], ["Some studies have shown an association of CMV disease or CMV infection with an increased graft loss [31, 32] , while others failed to shown this effect [33, 34] .", [["graft", "ANATOMY", 89, 94], ["CMV disease", "DISEASE", 42, 53], ["CMV infection", "DISEASE", 57, 70], ["CMV", "ORGANISM", 42, 45], ["CMV", "ORGANISM", 57, 60], ["graft", "TISSUE", 89, 94], ["CMV", "SPECIES", 42, 45], ["CMV", "SPECIES", 57, 60], ["Some studies", "TEST", 0, 12], ["CMV disease", "PROBLEM", 42, 53], ["CMV infection", "PROBLEM", 57, 70], ["an increased graft loss", "PROBLEM", 76, 99], ["CMV disease", "OBSERVATION", 42, 53], ["CMV infection", "OBSERVATION", 57, 70], ["increased", "OBSERVATION_MODIFIER", 79, 88], ["graft loss", "OBSERVATION", 89, 99]]], ["Sagedal et al. showed that both CMV disease and surprisingly, even asymptomatic CMV infection were independent risk factors for overall mortality beyond 100 days posttransplantation and reduced graft survival [35] .", [["graft", "ANATOMY", 194, 199], ["CMV disease", "DISEASE", 32, 43], ["CMV infection", "DISEASE", 80, 93], ["CMV", "ORGANISM", 32, 35], ["CMV", "ORGANISM", 80, 83], ["graft", "TISSUE", 194, 199], ["CMV", "SPECIES", 32, 35], ["CMV", "SPECIES", 80, 83], ["both CMV disease", "PROBLEM", 27, 43], ["asymptomatic CMV infection", "PROBLEM", 67, 93], ["reduced graft survival", "TREATMENT", 186, 208], ["et al", "OBSERVATION", 8, 13], ["both", "OBSERVATION_MODIFIER", 27, 31], ["CMV disease", "OBSERVATION", 32, 43], ["asymptomatic", "OBSERVATION_MODIFIER", 67, 79], ["CMV infection", "OBSERVATION", 80, 93], ["graft survival", "OBSERVATION", 194, 208]]], ["On a pathological level, CMV can replicate in the kidney tissues and cause acute allograft dysfunction which usually improves with ganciclovir treatment and reduction of immunosuppression [36, 37] .", [["kidney tissues", "ANATOMY", 50, 64], ["allograft", "ANATOMY", 81, 90], ["acute allograft dysfunction", "DISEASE", 75, 102], ["ganciclovir", "CHEMICAL", 131, 142], ["ganciclovir", "CHEMICAL", 131, 142], ["CMV", "ORGANISM", 25, 28], ["kidney tissues", "TISSUE", 50, 64], ["allograft", "ORGAN", 81, 90], ["ganciclovir", "SIMPLE_CHEMICAL", 131, 142], ["CMV", "SPECIES", 25, 28], ["a pathological level", "TEST", 3, 23], ["CMV", "PROBLEM", 25, 28], ["acute allograft dysfunction", "PROBLEM", 75, 102], ["ganciclovir treatment", "TREATMENT", 131, 152], ["immunosuppression", "TREATMENT", 170, 187], ["CMV", "OBSERVATION", 25, 28], ["kidney", "ANATOMY", 50, 56], ["acute", "OBSERVATION_MODIFIER", 75, 80], ["allograft", "OBSERVATION", 81, 90]]], ["Infection with CMV has also been implicated in chronic allograft nephropathy which is the major reason for the loss of renal allografts after the first year after transplantation [38] .", [["allograft", "ANATOMY", 55, 64], ["renal allografts", "ANATOMY", 119, 135], ["nephropathy", "DISEASE", 65, 76], ["CMV", "ORGANISM", 15, 18], ["renal allografts", "TISSUE", 119, 135], ["CMV", "SPECIES", 15, 18], ["Infection", "PROBLEM", 0, 9], ["CMV", "PROBLEM", 15, 18], ["chronic allograft nephropathy", "PROBLEM", 47, 76], ["renal allografts", "TREATMENT", 119, 135], ["transplantation", "TREATMENT", 163, 178], ["CMV", "OBSERVATION", 15, 18], ["chronic", "OBSERVATION_MODIFIER", 47, 54], ["allograft nephropathy", "OBSERVATION", 55, 76], ["renal", "ANATOMY", 119, 124], ["allografts", "OBSERVATION", 125, 135]]], ["CMV disease has been linked to chronic rejection with arterial myointimal thickening, similar to atherosclerotic coronary disease [28, 39] .", [["arterial", "ANATOMY", 54, 62], ["atherosclerotic coronary", "ANATOMY", 97, 121], ["CMV disease", "DISEASE", 0, 11], ["atherosclerotic coronary disease", "DISEASE", 97, 129], ["CMV", "ORGANISM", 0, 3], ["arterial myointimal", "PATHOLOGICAL_FORMATION", 54, 73], ["coronary", "MULTI-TISSUE_STRUCTURE", 113, 121], ["CMV", "SPECIES", 0, 3], ["CMV disease", "PROBLEM", 0, 11], ["chronic rejection", "PROBLEM", 31, 48], ["arterial myointimal thickening", "PROBLEM", 54, 84], ["atherosclerotic coronary disease", "PROBLEM", 97, 129], ["disease", "OBSERVATION", 4, 11], ["chronic", "OBSERVATION_MODIFIER", 31, 38], ["rejection", "OBSERVATION", 39, 48], ["arterial", "ANATOMY_MODIFIER", 54, 62], ["myointimal", "OBSERVATION_MODIFIER", 63, 73], ["thickening", "OBSERVATION", 74, 84], ["atherosclerotic", "OBSERVATION_MODIFIER", 97, 112], ["coronary", "ANATOMY", 113, 121], ["disease", "OBSERVATION", 122, 129]]], ["However, it is still unclear whether the virus itself leads directly to this glomerulonephropathy.CytomegalovirusThe Scientific World Journal 3 The Scientific World Journal The presentation of CMV may be variable, ranging from asymptomatic infection (as defined by the presence of active viral replication) to end organ or disseminated involvement.", [["organ", "ANATOMY", 314, 319], ["glomerulonephropathy", "DISEASE", 77, 97], ["infection", "DISEASE", 240, 249], ["glomerulonephropathy", "CANCER", 77, 97], ["Cytomegalovirus", "ORGANISM", 98, 113], ["CMV", "ORGANISM", 193, 196], ["organ", "ORGAN", 314, 319], ["CMV", "SPECIES", 193, 196], ["the virus", "PROBLEM", 37, 46], ["this glomerulonephropathy", "PROBLEM", 72, 97], ["Cytomegalovirus", "PROBLEM", 98, 113], ["CMV", "PROBLEM", 193, 196], ["asymptomatic infection", "PROBLEM", 227, 249], ["active viral replication", "TREATMENT", 281, 305], ["disseminated involvement", "PROBLEM", 323, 347], ["virus", "OBSERVATION", 41, 46], ["CMV", "OBSERVATION", 193, 196], ["may be", "UNCERTAINTY", 197, 203], ["variable", "OBSERVATION_MODIFIER", 204, 212], ["asymptomatic", "OBSERVATION_MODIFIER", 227, 239], ["infection", "OBSERVATION", 240, 249], ["active", "OBSERVATION_MODIFIER", 281, 287], ["viral replication", "OBSERVATION", 288, 305], ["disseminated", "OBSERVATION_MODIFIER", 323, 335]]], ["Commonly patients present with symptoms of fever and malaise sometimes associated with leukopenia, thrombocytopenia, gastroenteritis, pneumonitis, hepatitis, or more rarely retinal or central nervous system involvement [30] .", [["retinal", "ANATOMY", 173, 180], ["central nervous system", "ANATOMY", 184, 206], ["fever", "DISEASE", 43, 48], ["leukopenia", "DISEASE", 87, 97], ["thrombocytopenia", "DISEASE", 99, 115], ["gastroenteritis", "DISEASE", 117, 132], ["pneumonitis", "DISEASE", 134, 145], ["hepatitis", "DISEASE", 147, 156], ["retinal or central nervous system involvement", "DISEASE", 173, 218], ["patients", "ORGANISM", 9, 17], ["retinal", "MULTI-TISSUE_STRUCTURE", 173, 180], ["central nervous system", "ANATOMICAL_SYSTEM", 184, 206], ["patients", "SPECIES", 9, 17], ["symptoms", "PROBLEM", 31, 39], ["fever", "PROBLEM", 43, 48], ["malaise", "PROBLEM", 53, 60], ["leukopenia", "PROBLEM", 87, 97], ["thrombocytopenia", "PROBLEM", 99, 115], ["gastroenteritis", "PROBLEM", 117, 132], ["pneumonitis", "PROBLEM", 134, 145], ["hepatitis", "PROBLEM", 147, 156], ["central nervous system involvement", "PROBLEM", 184, 218], ["leukopenia", "OBSERVATION", 87, 97], ["thrombocytopenia", "OBSERVATION", 99, 115], ["gastroenteritis", "OBSERVATION", 117, 132], ["pneumonitis", "OBSERVATION", 134, 145], ["hepatitis", "OBSERVATION", 147, 156], ["retinal", "ANATOMY", 173, 180], ["central", "ANATOMY_MODIFIER", 184, 191], ["nervous system", "ANATOMY", 192, 206]]], ["The type of immunosuppression can affect the presentation and severity of illness [40, 41] .CMV Prevention.Serologic screening for antibody to CMV should be performed on both donor and recipient before transplant to identify patients at risk for after transplant infection who might benefit from preventive strategies [23] .", [["illness", "DISEASE", 74, 81], ["infection", "DISEASE", 263, 272], ["CMV", "ORGANISM", 143, 146], ["patients", "ORGANISM", 225, 233], ["patients", "SPECIES", 225, 233], ["CMV", "SPECIES", 143, 146], ["immunosuppression", "TREATMENT", 12, 29], ["illness", "PROBLEM", 74, 81], ["Serologic screening", "TEST", 107, 126], ["antibody", "TEST", 131, 139], ["CMV", "TEST", 143, 146], ["transplant", "TREATMENT", 202, 212], ["transplant infection", "PROBLEM", 252, 272], ["preventive strategies", "TREATMENT", 296, 317], ["immunosuppression", "OBSERVATION", 12, 29]]], ["Two strategies are commonly used for CMV prevention: (1) universal prophylaxis and (2) preemptive therapy.", [["CMV", "ORGANISM", 37, 40], ["CMV", "SPECIES", 37, 40], ["Two strategies", "TREATMENT", 0, 14], ["CMV prevention", "TREATMENT", 37, 51], ["universal prophylaxis", "TREATMENT", 57, 78], ["preemptive therapy", "TREATMENT", 87, 105]]], ["Universal prophylaxis involves giving antiviral therapy to all \"atrisk\" patients beginning at or immediately after transplant for a defined time period.", [["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["Universal prophylaxis", "TREATMENT", 0, 21], ["antiviral therapy", "TREATMENT", 38, 55], ["transplant", "TREATMENT", 115, 125]]], ["In preemptive therapy, patients are monitored at regular intervals for early evidence of CMV replication prior to the onset of clinical symptoms by use of a laboratory assay [42] .", [["patients", "ORGANISM", 23, 31], ["CMV", "ORGANISM", 89, 92], ["patients", "SPECIES", 23, 31], ["CMV", "SPECIES", 89, 92], ["preemptive therapy", "TREATMENT", 3, 21], ["CMV replication", "PROBLEM", 89, 104], ["clinical symptoms", "PROBLEM", 127, 144], ["a laboratory assay", "TEST", 155, 173], ["CMV replication", "OBSERVATION", 89, 104]]], ["Patients with early replication are then treated with antiviral therapy to prevent symptomatic disease.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["antiviral therapy", "TREATMENT", 54, 71], ["symptomatic disease", "PROBLEM", 83, 102], ["symptomatic", "OBSERVATION_MODIFIER", 83, 94], ["disease", "OBSERVATION", 95, 102]]], ["Each approach has advantages and disadvantages that must be considered in the context of the patient and the allograft [43] .", [["allograft", "ANATOMY", 109, 118], ["patient", "ORGANISM", 93, 100], ["patient", "SPECIES", 93, 100], ["disadvantages", "TREATMENT", 33, 46], ["allograft", "OBSERVATION", 109, 118]]], ["Preemptive therapy may decrease drug costs and toxicity.", [["toxicity", "DISEASE", 47, 55], ["Preemptive therapy", "TREATMENT", 0, 18], ["toxicity", "PROBLEM", 47, 55]]], ["However, it requires excellent logistic coordination in order to obtain, receive, and act on results in a timely fashion; this can be difficult if patients live quite some distance from the transplant center.", [["patients", "ORGANISM", 147, 155], ["patients", "SPECIES", 147, 155]]], ["Prophylaxis might have the theoretical advantage of preventing reactivation of other viruses such as HHV 6, and theoretically may be more likely to prevent indirect effects of CMV.", [["HHV 6", "ORGANISM", 101, 106], ["CMV", "ORGANISM", 176, 179], ["HHV", "SPECIES", 101, 104], ["CMV", "SPECIES", 176, 179], ["Prophylaxis", "TREATMENT", 0, 11], ["other viruses", "PROBLEM", 79, 92], ["HHV", "PROBLEM", 101, 104], ["CMV", "TREATMENT", 176, 179], ["viruses", "OBSERVATION", 85, 92], ["may be more likely", "UNCERTAINTY", 126, 144], ["CMV", "OBSERVATION", 176, 179]]], ["CMV resistance has been observed with both strategies.", [["CMV", "ORGANISM", 0, 3], ["CMV", "SPECIES", 0, 3], ["CMV resistance", "PROBLEM", 0, 14]]], ["Drugs that have been evaluated for universal prophylaxis include acyclovir, ganciclovir, valacyclovir, valganciclovir, and immune globulin preparations.", [["acyclovir", "CHEMICAL", 65, 74], ["ganciclovir", "CHEMICAL", 76, 87], ["valacyclovir", "CHEMICAL", 89, 101], ["valganciclovir", "CHEMICAL", 103, 117], ["acyclovir", "CHEMICAL", 65, 74], ["ganciclovir", "CHEMICAL", 76, 87], ["valacyclovir", "CHEMICAL", 89, 101], ["valganciclovir", "CHEMICAL", 103, 117], ["acyclovir", "SIMPLE_CHEMICAL", 65, 74], ["ganciclovir", "SIMPLE_CHEMICAL", 76, 87], ["valacyclovir", "SIMPLE_CHEMICAL", 89, 101], ["valganciclovir", "SIMPLE_CHEMICAL", 103, 117], ["Drugs", "TREATMENT", 0, 5], ["universal prophylaxis", "TREATMENT", 35, 56], ["acyclovir", "TREATMENT", 65, 74], ["ganciclovir", "TREATMENT", 76, 87], ["valacyclovir", "TREATMENT", 89, 101], ["valganciclovir", "TREATMENT", 103, 117], ["immune globulin preparations", "TREATMENT", 123, 151]]], ["Preemptive therapy is well suited for transplant recipients at low or intermediate risk of CMV disease, while prophylaxis may be better suited for those at high risk [44, 45] .", [["CMV disease", "DISEASE", 91, 102], ["recipients", "ORGANISM", 49, 59], ["CMV", "ORGANISM", 91, 94], ["CMV", "SPECIES", 91, 94], ["Preemptive therapy", "TREATMENT", 0, 18], ["transplant recipients", "TREATMENT", 38, 59], ["CMV disease", "PROBLEM", 91, 102], ["prophylaxis", "TREATMENT", 110, 121], ["CMV disease", "OBSERVATION", 91, 102]]], ["Some studies have concluded that preemptive valganciclovir therapy and valacyclovir prophylaxis are equally effective in the prevention of CMV disease after renal transplantation and there was no difference in overall costs [46, 47] .", [["renal", "ANATOMY", 157, 162], ["valganciclovir", "CHEMICAL", 44, 58], ["valacyclovir", "CHEMICAL", 71, 83], ["CMV disease", "DISEASE", 139, 150], ["valganciclovir", "CHEMICAL", 44, 58], ["valacyclovir", "CHEMICAL", 71, 83], ["valganciclovir", "SIMPLE_CHEMICAL", 44, 58], ["valacyclovir", "SIMPLE_CHEMICAL", 71, 83], ["CMV", "ORGANISM", 139, 142], ["renal", "ORGAN", 157, 162], ["CMV", "SPECIES", 139, 142], ["Some studies", "TEST", 0, 12], ["preemptive valganciclovir therapy", "TREATMENT", 33, 66], ["valacyclovir prophylaxis", "TREATMENT", 71, 95], ["CMV disease", "PROBLEM", 139, 150], ["renal transplantation", "TREATMENT", 157, 178], ["CMV disease", "OBSERVATION", 139, 150], ["renal", "ANATOMY", 157, 162], ["transplantation", "OBSERVATION", 163, 178], ["no", "UNCERTAINTY", 193, 195]]], ["Same conclusions were obtained in studies that used the ganciclovir as antiviral therapy [48] .", [["ganciclovir", "CHEMICAL", 56, 67], ["ganciclovir", "CHEMICAL", 56, 67], ["ganciclovir", "SIMPLE_CHEMICAL", 56, 67], ["the ganciclovir", "TREATMENT", 52, 67], ["antiviral therapy", "TREATMENT", 71, 88]]], ["A metaanalysis of 32 trials (3737 patients) performed to compare outcomes for various prophylactic antivirals for transplant patients at risk for CMV disease demonstrated that prophylaxis decreased CMV disease, CMV infection, and all-cause mortality [49] .", [["CMV disease", "DISEASE", 146, 157], ["CMV disease", "DISEASE", 198, 209], ["CMV infection", "DISEASE", 211, 224], ["patients", "ORGANISM", 34, 42], ["patients", "ORGANISM", 125, 133], ["CMV", "ORGANISM", 146, 149], ["CMV", "ORGANISM", 198, 201], ["CMV", "ORGANISM", 211, 214], ["patients", "SPECIES", 34, 42], ["patients", "SPECIES", 125, 133], ["CMV", "SPECIES", 146, 149], ["CMV", "SPECIES", 198, 201], ["CMV", "SPECIES", 211, 214], ["A metaanalysis", "TEST", 0, 14], ["various prophylactic antivirals", "TREATMENT", 78, 109], ["transplant", "TREATMENT", 114, 124], ["CMV disease", "PROBLEM", 146, 157], ["prophylaxis", "TREATMENT", 176, 187], ["CMV disease", "PROBLEM", 198, 209], ["CMV infection", "PROBLEM", 211, 224], ["CMV disease", "OBSERVATION", 146, 157], ["CMV disease", "OBSERVATION", 198, 209], ["CMV infection", "OBSERVATION", 211, 224]]], ["This meta-analysis showed that ganciclovir was more effective than acyclovir in preventing CMV disease.", [["ganciclovir", "CHEMICAL", 31, 42], ["acyclovir", "CHEMICAL", 67, 76], ["CMV disease", "DISEASE", 91, 102], ["ganciclovir", "CHEMICAL", 31, 42], ["acyclovir", "CHEMICAL", 67, 76], ["ganciclovir", "SIMPLE_CHEMICAL", 31, 42], ["acyclovir", "SIMPLE_CHEMICAL", 67, 76], ["CMV", "ORGANISM", 91, 94], ["CMV", "SPECIES", 91, 94], ["This meta-analysis", "TEST", 0, 18], ["ganciclovir", "TREATMENT", 31, 42], ["acyclovir", "TREATMENT", 67, 76], ["CMV disease", "PROBLEM", 91, 102], ["ganciclovir", "OBSERVATION", 31, 42], ["CMV disease", "OBSERVATION", 91, 102]]], ["Valganciclovir and intravenous ganciclovir were found to be as effective as oral ganciclovir for prophylaxis.", [["intravenous", "ANATOMY", 19, 30], ["oral", "ANATOMY", 76, 80], ["Valganciclovir", "CHEMICAL", 0, 14], ["ganciclovir", "CHEMICAL", 31, 42], ["ganciclovir", "CHEMICAL", 81, 92], ["Valganciclovir", "CHEMICAL", 0, 14], ["ganciclovir", "CHEMICAL", 31, 42], ["ganciclovir", "CHEMICAL", 81, 92], ["Valganciclovir", "SIMPLE_CHEMICAL", 0, 14], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 19, 30], ["ganciclovir", "SIMPLE_CHEMICAL", 31, 42], ["oral", "ORGANISM_SUBDIVISION", 76, 80], ["ganciclovir", "SIMPLE_CHEMICAL", 81, 92], ["Valganciclovir", "TREATMENT", 0, 14], ["intravenous ganciclovir", "TREATMENT", 19, 42], ["oral ganciclovir", "TREATMENT", 76, 92], ["prophylaxis", "TREATMENT", 97, 108]]], ["However, the use of ganciclovir may be associated with a greater rate of CMV resistance when compared with valganciclovir, at least in the highest risk recipients [50, 51] .", [["ganciclovir", "CHEMICAL", 20, 31], ["valganciclovir", "CHEMICAL", 107, 121], ["ganciclovir", "CHEMICAL", 20, 31], ["valganciclovir", "CHEMICAL", 107, 121], ["ganciclovir", "SIMPLE_CHEMICAL", 20, 31], ["CMV", "ORGANISM", 73, 76], ["valganciclovir", "SIMPLE_CHEMICAL", 107, 121], ["CMV", "SPECIES", 73, 76], ["ganciclovir", "TREATMENT", 20, 31], ["CMV resistance", "PROBLEM", 73, 87], ["valganciclovir", "TREATMENT", 107, 121], ["CMV resistance", "OBSERVATION", 73, 87]]], ["The length of prophylactic treatment varies by institution, but generally lasts for a minimum of 3 months.CMV Diagnosis.Many techniques are currently available to aid in the diagnosis of CMV disease.", [["CMV disease", "DISEASE", 187, 198], ["CMV", "ORGANISM", 106, 109], ["CMV", "ORGANISM", 187, 190], ["CMV", "SPECIES", 106, 109], ["CMV", "SPECIES", 187, 190], ["prophylactic treatment", "TREATMENT", 14, 36], ["CMV disease", "PROBLEM", 187, 198], ["length", "OBSERVATION_MODIFIER", 4, 10], ["CMV disease", "OBSERVATION", 187, 198]]], ["These include serology, viral culture, shell vial culture, pp65 antigenemia test, and qualitative and quantitative nucleic acid detection assays [52] .", [["nucleic acid", "CHEMICAL", 115, 127], ["pp65", "ORGANISM", 59, 63], ["pp65", "PROTEIN", 59, 63], ["serology", "TEST", 14, 22], ["viral culture", "TEST", 24, 37], ["shell vial culture", "TEST", 39, 57], ["pp65 antigenemia test", "TEST", 59, 80], ["quantitative nucleic acid detection assays", "TEST", 102, 144]]], ["Although histopathologic diagnosis remains the gold standard, noninvasive measures of viremia are used more commonly to determine the presence or absence of CMV.", [["viremia", "DISEASE", 86, 93], ["CMV", "ORGANISM", 157, 160], ["CMV", "SPECIES", 157, 160], ["viremia", "PROBLEM", 86, 93], ["CMV", "PROBLEM", 157, 160], ["viremia", "OBSERVATION", 86, 93], ["CMV", "OBSERVATION", 157, 160]]], ["The antigenemia assay (detection of lower matrix phosphoprotein pp65 in leukocytes) and nucleic acid testing including CMV-PCR and hybrid-capture DNA are typically used with the choice of methodology varying among centers [20, 28] .", [["leukocytes", "ANATOMY", 72, 82], ["nucleic acid", "CHEMICAL", 88, 100], ["pp65", "GENE_OR_GENE_PRODUCT", 64, 68], ["leukocytes", "CELL", 72, 82], ["CMV", "ORGANISM", 119, 122], ["DNA", "CELLULAR_COMPONENT", 146, 149], ["matrix phosphoprotein pp65", "PROTEIN", 42, 68], ["leukocytes", "CELL_TYPE", 72, 82], ["CMV-PCR and hybrid-capture DNA", "DNA", 119, 149], ["The antigenemia assay", "TEST", 0, 21], ["lower matrix phosphoprotein pp65", "TEST", 36, 68], ["leukocytes", "TEST", 72, 82], ["nucleic acid testing", "TEST", 88, 108], ["CMV", "TEST", 119, 122], ["PCR", "TEST", 123, 126], ["hybrid-capture DNA", "PROBLEM", 131, 149], ["antigenemia", "OBSERVATION", 4, 15]]], ["A clinically useful test should ideally have good sensitivity and specificity, be able to detect asymptomatic CMV infection and predict CMV disease thus helping in treatment decisions, and be technically easy to perform.", [["CMV infection", "DISEASE", 110, 123], ["CMV disease", "DISEASE", 136, 147], ["CMV", "ORGANISM", 110, 113], ["CMV", "ORGANISM", 136, 139], ["CMV", "SPECIES", 110, 113], ["CMV", "SPECIES", 136, 139], ["asymptomatic CMV infection", "PROBLEM", 97, 123], ["CMV disease", "PROBLEM", 136, 147], ["infection", "OBSERVATION", 114, 123]]], ["Although generally accepted as the most sensitive methodology for CMV detection, nucleic acid testing has not been well-standardized and recent studies have demonstrated substantial interlaboratory variability [53, 54] .", [["nucleic acid", "CHEMICAL", 81, 93], ["CMV", "ORGANISM", 66, 69], ["CMV", "SPECIES", 66, 69], ["CMV detection", "TEST", 66, 79], ["nucleic acid testing", "TEST", 81, 101], ["recent studies", "TEST", 137, 151], ["substantial interlaboratory variability", "PROBLEM", 170, 209], ["substantial", "OBSERVATION_MODIFIER", 170, 181], ["interlaboratory variability", "OBSERVATION", 182, 209]]], ["Quantitative CMV assays have two prominent gaps: neurologic disease, including chorioretinitis, and gastrointestinal disease, including invasive colitis and gastritis.", [["neurologic", "ANATOMY", 49, 59], ["gastrointestinal", "ANATOMY", 100, 116], ["neurologic disease", "DISEASE", 49, 67], ["chorioretinitis", "DISEASE", 79, 94], ["gastrointestinal disease", "DISEASE", 100, 124], ["invasive colitis", "DISEASE", 136, 152], ["gastritis", "DISEASE", 157, 166], ["CMV", "ORGANISM", 13, 16], ["gastrointestinal", "ORGAN", 100, 116], ["colitis", "PATHOLOGICAL_FORMATION", 145, 152], ["gastritis", "PATHOLOGICAL_FORMATION", 157, 166], ["CMV", "SPECIES", 13, 16], ["Quantitative CMV assays", "TEST", 0, 23], ["neurologic disease", "PROBLEM", 49, 67], ["chorioretinitis", "PROBLEM", 79, 94], ["gastrointestinal disease", "PROBLEM", 100, 124], ["invasive colitis", "PROBLEM", 136, 152], ["gastritis", "PROBLEM", 157, 166], ["CMV", "OBSERVATION", 13, 16], ["prominent", "OBSERVATION_MODIFIER", 33, 42], ["gaps", "OBSERVATION_MODIFIER", 43, 47], ["neurologic disease", "OBSERVATION", 49, 67], ["chorioretinitis", "OBSERVATION", 79, 94], ["gastrointestinal", "ANATOMY", 100, 116], ["disease", "OBSERVATION", 117, 124], ["invasive", "OBSERVATION_MODIFIER", 136, 144], ["colitis", "OBSERVATION", 145, 152], ["gastritis", "OBSERVATION", 157, 166]]], ["In these syndromes, the CMV assays are often negative and invasive (biopsy) diagnoses are often necessary.CMV Diagnosis.The schedule for screening should be linked to the individual's risk for infection.", [["infection", "DISEASE", 193, 202], ["CMV", "ORGANISM", 24, 27], ["CMV", "ORGANISM", 106, 109], ["CMV", "SPECIES", 24, 27], ["CMV", "SPECIES", 106, 109], ["these syndromes", "PROBLEM", 3, 18], ["the CMV assays", "TEST", 20, 34], ["screening", "TEST", 137, 146], ["infection", "PROBLEM", 193, 202], ["syndromes", "OBSERVATION", 9, 18], ["CMV", "OBSERVATION", 24, 27], ["infection", "OBSERVATION", 193, 202]]], ["In the patient being treated for CMV infection, the assays provide an endpoint (a negative assay) for therapy and the reinitiation of prophylaxis.", [["CMV infection", "DISEASE", 33, 46], ["patient", "ORGANISM", 7, 14], ["CMV", "ORGANISM", 33, 36], ["patient", "SPECIES", 7, 14], ["CMV", "SPECIES", 33, 36], ["CMV infection", "PROBLEM", 33, 46], ["the assays", "TEST", 48, 58], ["therapy", "TREATMENT", 102, 109], ["prophylaxis", "TREATMENT", 134, 145], ["infection", "OBSERVATION", 37, 46]]], ["In the patient at high risk after the completion of prophylaxis, weekly to biweekly screening should be considered to assure the absence of infection for 3 to 6 months [2].CMV Therapy.Treatment of active CMV disease requires a combination of immunomodulation, antiviral therapy, and reduction of immunosuppression, if possible [30] .", [["infection", "DISEASE", 140, 149], ["CMV disease", "DISEASE", 204, 215], ["patient", "ORGANISM", 7, 14], ["CMV", "ORGANISM", 172, 175], ["CMV", "ORGANISM", 204, 207], ["patient", "SPECIES", 7, 14], ["CMV", "SPECIES", 172, 175], ["CMV", "SPECIES", 204, 207], ["prophylaxis", "TREATMENT", 52, 63], ["biweekly screening", "TEST", 75, 93], ["infection", "PROBLEM", 140, 149], ["CMV Therapy", "TREATMENT", 172, 183], ["active CMV disease", "PROBLEM", 197, 215], ["immunomodulation", "TREATMENT", 242, 258], ["antiviral therapy", "TREATMENT", 260, 277], ["immunosuppression", "TREATMENT", 296, 313], ["infection", "OBSERVATION", 140, 149], ["active", "OBSERVATION_MODIFIER", 197, 203], ["CMV disease", "OBSERVATION", 204, 215]]], ["The standard of care for treating CMV disease is 2 to 3 weeks of intravenous ganciclovir (5 mg/kg twice daily, dose adjustments for renal dysfunction) with demonstration of clinical and virological responses to therapy [30] .", [["intravenous", "ANATOMY", 65, 76], ["renal", "ANATOMY", 132, 137], ["CMV disease", "DISEASE", 34, 45], ["ganciclovir", "CHEMICAL", 77, 88], ["renal dysfunction", "DISEASE", 132, 149], ["ganciclovir", "CHEMICAL", 77, 88], ["CMV", "ORGANISM", 34, 37], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 65, 76], ["ganciclovir", "SIMPLE_CHEMICAL", 77, 88], ["renal", "ORGAN", 132, 137], ["CMV", "SPECIES", 34, 37], ["treating CMV disease", "PROBLEM", 25, 45], ["intravenous ganciclovir", "TREATMENT", 65, 88], ["renal dysfunction", "PROBLEM", 132, 149], ["renal", "ANATOMY", 132, 137], ["dysfunction", "OBSERVATION", 138, 149]]], ["In contrast, oral ganciclovir should not be used for the treatment of CMV disease because of the limited absorption and poor bioavailability.", [["oral", "ANATOMY", 13, 17], ["ganciclovir", "CHEMICAL", 18, 29], ["CMV disease", "DISEASE", 70, 81], ["ganciclovir", "CHEMICAL", 18, 29], ["oral", "ORGANISM_SUBDIVISION", 13, 17], ["ganciclovir", "SIMPLE_CHEMICAL", 18, 29], ["CMV", "ORGANISM", 70, 73], ["CMV", "SPECIES", 70, 73], ["oral ganciclovir", "TREATMENT", 13, 29], ["CMV disease", "PROBLEM", 70, 81], ["CMV", "OBSERVATION", 70, 73]]], ["In seronegative patients and those slow to respond to therapy, the addition of CMV hyperimmune globulin (100 to 150 mg/kg per dose intravenously, given monthly) may be useful [2] .", [["patients", "ORGANISM", 16, 24], ["CMV", "ORGANISM", 79, 82], ["hyperimmune", "ORGANISM", 83, 94], ["globulin", "GENE_OR_GENE_PRODUCT", 95, 103], ["patients", "SPECIES", 16, 24], ["CMV", "SPECIES", 79, 82], ["therapy", "TREATMENT", 54, 61], ["CMV hyperimmune globulin", "TREATMENT", 79, 103], ["seronegative", "OBSERVATION", 3, 15]]], ["More recently, the introduction of valganciclovir has allowed for the oral treatment of CMV disease in SOT recipients.", [["oral", "ANATOMY", 70, 74], ["valganciclovir", "CHEMICAL", 35, 49], ["CMV disease", "DISEASE", 88, 99], ["valganciclovir", "CHEMICAL", 35, 49], ["valganciclovir", "SIMPLE_CHEMICAL", 35, 49], ["oral", "ORGANISM_SUBDIVISION", 70, 74], ["CMV", "ORGANISM", 88, 91], ["SOT recipients", "ORGANISM", 103, 117], ["CMV", "SPECIES", 88, 91], ["valganciclovir", "TREATMENT", 35, 49], ["the oral treatment", "TREATMENT", 66, 84], ["CMV disease", "PROBLEM", 88, 99], ["CMV disease", "OBSERVATION", 88, 99]]], ["In a trial of 21 renal transplant recipients with symptomatic CMV disease and viremia who were treated with valganciclovir, all cleared their infection and none experienced relapse during a mean follow-up of 5.5 months [55] .", [["renal", "ANATOMY", 17, 22], ["CMV disease", "DISEASE", 62, 73], ["viremia", "DISEASE", 78, 85], ["valganciclovir", "CHEMICAL", 108, 122], ["infection", "DISEASE", 142, 151], ["valganciclovir", "CHEMICAL", 108, 122], ["renal", "ORGAN", 17, 22], ["recipients", "ORGANISM", 34, 44], ["CMV", "ORGANISM", 62, 65], ["valganciclovir", "SIMPLE_CHEMICAL", 108, 122], ["CMV", "SPECIES", 62, 65], ["21 renal transplant recipients", "TREATMENT", 14, 44], ["symptomatic CMV disease", "PROBLEM", 50, 73], ["viremia", "PROBLEM", 78, 85], ["valganciclovir", "TREATMENT", 108, 122], ["their infection", "PROBLEM", 136, 151], ["renal", "ANATOMY", 17, 22], ["transplant", "OBSERVATION", 23, 33], ["symptomatic", "OBSERVATION_MODIFIER", 50, 61], ["CMV disease", "OBSERVATION", 62, 73], ["viremia", "OBSERVATION", 78, 85], ["infection", "OBSERVATION", 142, 151]]], ["Recently, a multicenter randomized control trial was performed with 321 solid organ transplant recipients which demonstrated oral valganciclovir was not inferior to intravenously ganciclovir for the initial treatment of CMV viremia [56] .", [["organ", "ANATOMY", 78, 83], ["oral", "ANATOMY", 125, 129], ["intravenously", "ANATOMY", 165, 178], ["valganciclovir", "CHEMICAL", 130, 144], ["ganciclovir", "CHEMICAL", 179, 190], ["CMV viremia", "DISEASE", 220, 231], ["valganciclovir", "CHEMICAL", 130, 144], ["ganciclovir", "CHEMICAL", 179, 190], ["organ", "ORGAN", 78, 83], ["recipients", "ORGANISM", 95, 105], ["oral", "ORGANISM_SUBDIVISION", 125, 129], ["valganciclovir", "SIMPLE_CHEMICAL", 130, 144], ["intravenously", "IMMATERIAL_ANATOMICAL_ENTITY", 165, 178], ["ganciclovir", "SIMPLE_CHEMICAL", 179, 190], ["CMV", "ORGANISM", 220, 223], ["CMV", "SPECIES", 220, 223], ["a multicenter randomized control trial", "TREATMENT", 10, 48], ["solid organ transplant recipients", "TREATMENT", 72, 105], ["oral valganciclovir", "TREATMENT", 125, 144], ["intravenously ganciclovir", "TREATMENT", 165, 190], ["the initial treatment", "TREATMENT", 195, 216], ["CMV viremia", "PROBLEM", 220, 231], ["CMV viremia", "OBSERVATION", 220, 231]]], ["Indeed, valganciclovir was recently shown to be as effective as intravenous ganciclovir in the treatment of mild-to-moderate (i.e., nonsevere) CMV disease [57] .", [["intravenous", "ANATOMY", 64, 75], ["valganciclovir", "CHEMICAL", 8, 22], ["ganciclovir", "CHEMICAL", 76, 87], ["CMV disease", "DISEASE", 143, 154], ["valganciclovir", "CHEMICAL", 8, 22], ["ganciclovir", "CHEMICAL", 76, 87], ["valganciclovir", "SIMPLE_CHEMICAL", 8, 22], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 64, 75], ["ganciclovir", "SIMPLE_CHEMICAL", 76, 87], ["CMV", "ORGANISM", 143, 146], ["valganciclovir", "TREATMENT", 8, 22], ["intravenous ganciclovir", "TREATMENT", 64, 87], ["the treatment", "TREATMENT", 91, 104], ["mild-to-moderate (i.e., nonsevere) CMV disease", "PROBLEM", 108, 154], ["mild", "OBSERVATION_MODIFIER", 108, 112], ["-to-moderate", "OBSERVATION_MODIFIER", 112, 124], ["CMV disease", "OBSERVATION", 143, 154]]], ["The duration of treatment for CMV disease should be individualized and guided by virological and clinical surveillance.", [["CMV disease", "DISEASE", 30, 41], ["CMV", "ORGANISM", 30, 33], ["CMV", "SPECIES", 30, 33], ["treatment", "TREATMENT", 16, 25], ["CMV disease", "PROBLEM", 30, 41], ["clinical surveillance", "TEST", 97, 118]]], ["Undetectable viraemia should be achieved prior 6 The Scientific World Journal to discontinuation of therapy in order to reduce the risk of clinical relapse.", [["viraemia", "DISEASE", 13, 21], ["Undetectable viraemia", "PROBLEM", 0, 21], ["therapy", "TREATMENT", 100, 107], ["clinical relapse", "PROBLEM", 139, 155], ["viraemia", "OBSERVATION", 13, 21]]], ["Previous studies have shown that persistent viraemia at the end of therapy is associated with a higher risk of disease relapse [58] .", [["viraemia", "DISEASE", 44, 52], ["Previous studies", "TEST", 0, 16], ["persistent viraemia", "PROBLEM", 33, 52], ["therapy", "TREATMENT", 67, 74], ["disease relapse", "PROBLEM", 111, 126], ["persistent", "OBSERVATION_MODIFIER", 33, 43], ["viraemia", "OBSERVATION", 44, 52], ["disease", "OBSERVATION", 111, 118]]], ["Alternative therapies (not Food and Drug Administration-approved for use in solid organ transplant recipients) include foscarnet, cidofovir, and leflunomide; these are reserved for treatment of antiviral resistance.", [["organ", "ANATOMY", 82, 87], ["foscarnet", "CHEMICAL", 119, 128], ["cidofovir", "CHEMICAL", 130, 139], ["leflunomide", "CHEMICAL", 145, 156], ["foscarnet", "CHEMICAL", 119, 128], ["cidofovir", "CHEMICAL", 130, 139], ["leflunomide", "CHEMICAL", 145, 156], ["organ", "ORGAN", 82, 87], ["foscarnet", "SIMPLE_CHEMICAL", 119, 128], ["cidofovir", "SIMPLE_CHEMICAL", 130, 139], ["leflunomide", "SIMPLE_CHEMICAL", 145, 156], ["Alternative therapies", "TREATMENT", 0, 21], ["Drug Administration", "TREATMENT", 36, 55], ["solid organ transplant recipients", "TREATMENT", 76, 109], ["foscarnet", "TREATMENT", 119, 128], ["cidofovir", "TREATMENT", 130, 139], ["leflunomide", "TREATMENT", 145, 156], ["antiviral resistance", "PROBLEM", 194, 214], ["antiviral resistance", "OBSERVATION", 194, 214]]], ["Foscarnet is active against most ganciclovir-resistant strains of CMV but has neurotoxicity and renal toxicity with severe magnesium wasting.", [["renal", "ANATOMY", 96, 101], ["Foscarnet", "CHEMICAL", 0, 9], ["ganciclovir", "CHEMICAL", 33, 44], ["neurotoxicity", "DISEASE", 78, 91], ["renal toxicity", "DISEASE", 96, 110], ["magnesium", "CHEMICAL", 123, 132], ["wasting", "DISEASE", 133, 140], ["Foscarnet", "CHEMICAL", 0, 9], ["ganciclovir", "CHEMICAL", 33, 44], ["magnesium", "CHEMICAL", 123, 132], ["Foscarnet", "SIMPLE_CHEMICAL", 0, 9], ["ganciclovir", "SIMPLE_CHEMICAL", 33, 44], ["CMV", "ORGANISM", 66, 69], ["renal", "ORGAN", 96, 101], ["magnesium", "SIMPLE_CHEMICAL", 123, 132], ["CMV", "SPECIES", 66, 69], ["Foscarnet", "TREATMENT", 0, 9], ["most ganciclovir", "TREATMENT", 28, 44], ["resistant strains of CMV", "PROBLEM", 45, 69], ["neurotoxicity", "PROBLEM", 78, 91], ["renal toxicity", "PROBLEM", 96, 110], ["severe magnesium wasting", "PROBLEM", 116, 140], ["active", "OBSERVATION_MODIFIER", 13, 19], ["against most ganciclovir", "OBSERVATION_MODIFIER", 20, 44], ["CMV", "OBSERVATION", 66, 69], ["renal", "ANATOMY", 96, 101], ["toxicity", "OBSERVATION", 102, 110], ["severe", "OBSERVATION_MODIFIER", 116, 122], ["magnesium wasting", "OBSERVATION", 123, 140]]], ["Cidofovir has been used in renal transplant recipients, however often with nephrotoxicity.", [["renal transplant", "ANATOMY", 27, 43], ["Cidofovir", "CHEMICAL", 0, 9], ["nephrotoxicity", "DISEASE", 75, 89], ["Cidofovir", "CHEMICAL", 0, 9], ["Cidofovir", "SIMPLE_CHEMICAL", 0, 9], ["renal", "ORGAN", 27, 32], ["Cidofovir", "TREATMENT", 0, 9], ["renal transplant recipients", "TREATMENT", 27, 54], ["nephrotoxicity", "PROBLEM", 75, 89], ["renal", "ANATOMY", 27, 32], ["transplant recipients", "OBSERVATION", 33, 54], ["nephrotoxicity", "OBSERVATION", 75, 89]]], ["Both foscarnet and cidofovir may exhibit synergistic nephrotoxicity with calcineurin inhibitors [2] .", [["foscarnet", "CHEMICAL", 5, 14], ["cidofovir", "CHEMICAL", 19, 28], ["nephrotoxicity", "DISEASE", 53, 67], ["foscarnet", "CHEMICAL", 5, 14], ["cidofovir", "CHEMICAL", 19, 28], ["foscarnet", "SIMPLE_CHEMICAL", 5, 14], ["cidofovir", "SIMPLE_CHEMICAL", 19, 28], ["calcineurin", "GENE_OR_GENE_PRODUCT", 73, 84], ["calcineurin", "PROTEIN", 73, 84], ["Both foscarnet", "TREATMENT", 0, 14], ["cidofovir", "TREATMENT", 19, 28], ["synergistic nephrotoxicity", "PROBLEM", 41, 67], ["calcineurin inhibitors", "TREATMENT", 73, 95], ["foscarnet", "OBSERVATION", 5, 14]]], ["One of the biggest challenges regarding the treatment of CMV is the emergence of antiviral resistance.", [["CMV", "ORGANISM", 57, 60], ["CMV", "SPECIES", 57, 60], ["CMV", "PROBLEM", 57, 60], ["antiviral resistance", "TREATMENT", 81, 101], ["biggest", "OBSERVATION_MODIFIER", 11, 18], ["CMV", "OBSERVATION", 57, 60], ["antiviral resistance", "OBSERVATION", 81, 101]]], ["Although this is more commonly noted in lung and pancreas transplant recipients, CMV resistance to ganciclovir has been observed in renal transplant recipients.", [["lung", "ANATOMY", 40, 44], ["pancreas transplant", "ANATOMY", 49, 68], ["renal transplant", "ANATOMY", 132, 148], ["ganciclovir", "CHEMICAL", 99, 110], ["ganciclovir", "CHEMICAL", 99, 110], ["lung", "ORGAN", 40, 44], ["pancreas", "ORGAN", 49, 57], ["CMV", "ORGANISM", 81, 84], ["ganciclovir", "SIMPLE_CHEMICAL", 99, 110], ["renal", "ORGAN", 132, 137], ["CMV", "SPECIES", 81, 84], ["pancreas transplant recipients", "TREATMENT", 49, 79], ["CMV resistance", "PROBLEM", 81, 95], ["ganciclovir", "TREATMENT", 99, 110], ["renal transplant recipients", "TREATMENT", 132, 159], ["lung", "ANATOMY", 40, 44], ["pancreas", "ANATOMY", 49, 57], ["transplant", "OBSERVATION", 58, 68], ["CMV resistance", "OBSERVATION", 81, 95], ["renal", "ANATOMY", 132, 137], ["transplant recipients", "OBSERVATION", 138, 159]]], ["Ganciclovir resistance should be suspected when patients have persistent, unchanged viremia and/or symptoms at 2 weeks into therapy and in such cases, genotypic assays for the detection of the mutations associated with antiviral resistance should be performed.", [["Ganciclovir", "CHEMICAL", 0, 11], ["viremia", "DISEASE", 84, 91], ["Ganciclovir", "CHEMICAL", 0, 11], ["Ganciclovir", "SIMPLE_CHEMICAL", 0, 11], ["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56], ["Ganciclovir resistance", "TREATMENT", 0, 22], ["persistent, unchanged viremia", "PROBLEM", 62, 91], ["symptoms", "PROBLEM", 99, 107], ["therapy", "TREATMENT", 124, 131], ["genotypic assays", "TEST", 151, 167], ["the mutations", "PROBLEM", 189, 202], ["antiviral resistance", "TREATMENT", 219, 239], ["persistent", "OBSERVATION_MODIFIER", 62, 72], ["unchanged", "OBSERVATION_MODIFIER", 74, 83], ["viremia", "OBSERVATION", 84, 91]]], ["Treatment of resistant isolates may include the use of foscarnet with or without ganciclovir, or cidofovir [30] .", [["foscarnet", "CHEMICAL", 55, 64], ["ganciclovir", "CHEMICAL", 81, 92], ["cidofovir", "CHEMICAL", 97, 106], ["foscarnet", "CHEMICAL", 55, 64], ["ganciclovir", "CHEMICAL", 81, 92], ["cidofovir", "CHEMICAL", 97, 106], ["foscarnet", "SIMPLE_CHEMICAL", 55, 64], ["ganciclovir", "SIMPLE_CHEMICAL", 81, 92], ["cidofovir", "SIMPLE_CHEMICAL", 97, 106], ["resistant isolates", "PROBLEM", 13, 31], ["foscarnet", "TREATMENT", 55, 64], ["ganciclovir", "TREATMENT", 81, 92], ["cidofovir", "TREATMENT", 97, 106]]], ["Small case studies have demonstrated some efficacy of leflunomide to treat CMV disease in renal transplant patients.", [["renal transplant", "ANATOMY", 90, 106], ["leflunomide", "CHEMICAL", 54, 65], ["CMV disease", "DISEASE", 75, 86], ["leflunomide", "CHEMICAL", 54, 65], ["leflunomide", "SIMPLE_CHEMICAL", 54, 65], ["CMV", "ORGANISM", 75, 78], ["renal", "ORGAN", 90, 95], ["patients", "ORGANISM", 107, 115], ["patients", "SPECIES", 107, 115], ["CMV", "SPECIES", 75, 78], ["Small case studies", "TEST", 0, 18], ["leflunomide", "TREATMENT", 54, 65], ["CMV disease", "PROBLEM", 75, 86], ["renal transplant patients", "TREATMENT", 90, 115], ["leflunomide", "OBSERVATION", 54, 65], ["CMV disease", "OBSERVATION", 75, 86], ["renal", "ANATOMY", 90, 95], ["transplant", "OBSERVATION", 96, 106]]], ["A prospective study of 17 patients treated with leflunomide for CMV demonstrated viral clearance and healing of infected organs in 15 patients (88%) [58] .", [["organs", "ANATOMY", 121, 127], ["leflunomide", "CHEMICAL", 48, 59], ["leflunomide", "CHEMICAL", 48, 59], ["patients", "ORGANISM", 26, 34], ["leflunomide", "SIMPLE_CHEMICAL", 48, 59], ["CMV", "ORGANISM", 64, 67], ["organs", "ORGAN", 121, 127], ["patients", "ORGANISM", 134, 142], ["patients", "SPECIES", 26, 34], ["patients", "SPECIES", 134, 142], ["CMV", "SPECIES", 64, 67], ["A prospective study", "TEST", 0, 19], ["leflunomide", "TREATMENT", 48, 59], ["CMV", "PROBLEM", 64, 67], ["viral clearance", "PROBLEM", 81, 96], ["infected organs", "PROBLEM", 112, 127], ["healing", "OBSERVATION_MODIFIER", 101, 108], ["infected", "OBSERVATION", 112, 120]]], ["Other potential therapeutic agents for multidrug-resistant CMV include immunoglobulins, leflunomide and artesunate although data supporting their use remains anecdotal [59] [60] [61] .", [["leflunomide", "CHEMICAL", 88, 99], ["artesunate", "CHEMICAL", 104, 114], ["leflunomide", "CHEMICAL", 88, 99], ["artesunate", "CHEMICAL", 104, 114], ["CMV", "ORGANISM", 59, 62], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 71, 86], ["leflunomide", "SIMPLE_CHEMICAL", 88, 99], ["artesunate", "SIMPLE_CHEMICAL", 104, 114], ["[59] [60", "SIMPLE_CHEMICAL", 168, 176], ["CMV", "SPECIES", 59, 62], ["therapeutic agents", "TREATMENT", 16, 34], ["multidrug-resistant CMV", "TREATMENT", 39, 62], ["immunoglobulins", "TREATMENT", 71, 86], ["leflunomide", "TREATMENT", 88, 99], ["artesunate", "TREATMENT", 104, 114]]], ["Hence, there is a need to identify novel agents and strategies for the management of CMV infection and disease.Herpes Simplex VirusHuman herpesvirus 1-herpes simplex virus 1 (HSV) belongs to subfamily Alphaherpesvirinae, genus Simplexvirus, species Human herpesvirus 1.", [["CMV infection", "DISEASE", 85, 98], ["herpes simplex virus", "DISEASE", 151, 171], ["CMV", "ORGANISM", 85, 88], ["Herpes Simplex VirusHuman herpesvirus 1-herpes simplex virus 1", "ORGANISM", 111, 173], ["HSV", "ORGANISM", 175, 178], ["Alphaherpesvirinae", "GENE_OR_GENE_PRODUCT", 201, 219], ["genus Simplexvirus", "ORGANISM", 221, 239], ["Human herpesvirus 1", "ORGANISM", 249, 268], ["Herpes Simplex", "SPECIES", 111, 125], ["VirusHuman herpesvirus 1-herpes simplex virus 1", "SPECIES", 126, 173], ["Human", "SPECIES", 249, 254], ["herpesvirus", "SPECIES", 255, 266], ["CMV", "SPECIES", 85, 88], ["herpes simplex virus 1", "SPECIES", 151, 173], ["HSV", "SPECIES", 175, 178], ["Human herpesvirus 1", "SPECIES", 249, 268], ["novel agents", "TREATMENT", 35, 47], ["strategies", "TREATMENT", 52, 62], ["the management", "TREATMENT", 67, 81], ["CMV infection", "PROBLEM", 85, 98], ["disease", "PROBLEM", 103, 110], ["Herpes Simplex VirusHuman herpesvirus", "TEST", 111, 148], ["herpes simplex virus", "PROBLEM", 151, 171], ["Alphaherpesvirinae", "TEST", 201, 219], ["CMV infection", "OBSERVATION", 85, 98]]], ["Seroprevalence for HSV-1 in the adult population is 60%, while the incidence of HSV in renal transplant recipients is estimated to be approximately 53% [1, 30] .", [["renal transplant", "ANATOMY", 87, 103], ["HSV", "DISEASE", 80, 83], ["HSV-1", "ORGANISM", 19, 24], ["HSV", "ORGANISM", 80, 83], ["renal", "ORGAN", 87, 92], ["HSV-1", "SPECIES", 19, 24], ["HSV-1", "SPECIES", 19, 24], ["HSV", "SPECIES", 80, 83], ["HSV", "PROBLEM", 19, 22], ["HSV", "PROBLEM", 80, 83], ["renal transplant recipients", "TREATMENT", 87, 114], ["HSV", "OBSERVATION", 80, 83], ["renal", "ANATOMY", 87, 92], ["transplant", "OBSERVATION", 93, 103]]], ["HSV most commonly causes reactivation infection but may cause primary infection, transmitted by personto-person contact or via the allograft.", [["allograft", "ANATOMY", 131, 140], ["infection", "DISEASE", 38, 47], ["primary infection", "DISEASE", 62, 79], ["HSV", "ORGANISM", 0, 3], ["allograft", "TISSUE", 131, 140], ["person", "SPECIES", 105, 111], ["HSV", "SPECIES", 0, 3], ["HSV", "PROBLEM", 0, 3], ["reactivation infection", "PROBLEM", 25, 47], ["primary infection", "PROBLEM", 62, 79], ["reactivation", "OBSERVATION_MODIFIER", 25, 37], ["infection", "OBSERVATION", 38, 47], ["may cause", "UNCERTAINTY", 52, 61], ["primary", "OBSERVATION_MODIFIER", 62, 69], ["infection", "OBSERVATION", 70, 79], ["allograft", "OBSERVATION", 131, 140]]], ["Following primary infection, the virus remains latent in the sensory nerve ganglia.", [["sensory nerve ganglia", "ANATOMY", 61, 82], ["primary infection", "DISEASE", 10, 27], ["sensory nerve ganglia", "MULTI-TISSUE_STRUCTURE", 61, 82], ["primary infection", "PROBLEM", 10, 27], ["the virus", "PROBLEM", 29, 38], ["primary", "OBSERVATION_MODIFIER", 10, 17], ["infection", "OBSERVATION", 18, 27], ["virus", "OBSERVATION", 33, 38], ["latent", "OBSERVATION_MODIFIER", 47, 53], ["sensory", "ANATOMY_MODIFIER", 61, 68], ["nerve ganglia", "ANATOMY", 69, 82]]], ["In the absence of prophylaxis, HSV may be seen early, in the first posttransplant month.", [["HSV", "ORGANISM", 31, 34], ["HSV", "SPECIES", 31, 34], ["prophylaxis", "TREATMENT", 18, 29], ["HSV", "PROBLEM", 31, 34], ["prophylaxis", "OBSERVATION", 18, 29], ["may be seen", "UNCERTAINTY", 35, 46]]], ["Reactivation or primary HSV infection results in oral or genital mucocutaneous lesions, occasionally causes pneumonitis, tracheobronchitis, esophagitis, hepatitis, or disseminated infection [1, 30] .", [["oral", "ANATOMY", 49, 53], ["genital mucocutaneous lesions", "ANATOMY", 57, 86], ["primary HSV infection", "DISEASE", 16, 37], ["mucocutaneous lesions", "DISEASE", 65, 86], ["pneumonitis", "DISEASE", 108, 119], ["tracheobronchitis", "DISEASE", 121, 138], ["esophagitis", "DISEASE", 140, 151], ["hepatitis", "DISEASE", 153, 162], ["disseminated infection", "DISEASE", 167, 189], ["HSV", "ORGANISM", 24, 27], ["oral", "ORGANISM_SUBDIVISION", 49, 53], ["genital mucocutaneous lesions", "PATHOLOGICAL_FORMATION", 57, 86], ["HSV", "SPECIES", 24, 27], ["primary HSV infection", "PROBLEM", 16, 37], ["oral or genital mucocutaneous lesions", "PROBLEM", 49, 86], ["pneumonitis", "PROBLEM", 108, 119], ["tracheobronchitis", "PROBLEM", 121, 138], ["esophagitis", "PROBLEM", 140, 151], ["hepatitis", "PROBLEM", 153, 162], ["disseminated infection", "PROBLEM", 167, 189], ["primary", "OBSERVATION_MODIFIER", 16, 23], ["HSV", "OBSERVATION_MODIFIER", 24, 27], ["infection", "OBSERVATION", 28, 37], ["genital", "ANATOMY", 57, 64], ["mucocutaneous lesions", "OBSERVATION", 65, 86], ["pneumonitis", "OBSERVATION", 108, 119], ["tracheobronchitis", "OBSERVATION", 121, 138], ["esophagitis", "OBSERVATION", 140, 151], ["hepatitis", "OBSERVATION", 153, 162], ["disseminated", "OBSERVATION_MODIFIER", 167, 179], ["infection", "OBSERVATION", 180, 189]]], ["Disease may be more severe, invasive, and prolonged in transplant recipients.", [["recipients", "ORGANISM", 66, 76], ["Disease", "PROBLEM", 0, 7], ["transplant recipients", "TREATMENT", 55, 76], ["may be", "UNCERTAINTY", 8, 14], ["more severe", "OBSERVATION_MODIFIER", 15, 26], ["invasive", "OBSERVATION_MODIFIER", 28, 36], ["prolonged", "OBSERVATION_MODIFIER", 42, 51]]], ["HSV esophagitis may present with superficial, punched-out lesions that may be superinfected with Candida.", [["lesions", "ANATOMY", 58, 65], ["HSV esophagitis", "DISEASE", 0, 15], ["HSV", "ORGANISM", 0, 3], ["lesions", "PATHOLOGICAL_FORMATION", 58, 65], ["HSV", "SPECIES", 0, 3], ["HSV esophagitis", "PROBLEM", 0, 15], ["superficial, punched-out lesions", "PROBLEM", 33, 65], ["Candida", "PROBLEM", 97, 104], ["esophagitis", "OBSERVATION", 4, 15], ["superficial", "OBSERVATION_MODIFIER", 33, 44], ["lesions", "OBSERVATION", 58, 65], ["may be", "UNCERTAINTY", 71, 77], ["superinfected", "OBSERVATION_MODIFIER", 78, 91], ["Candida", "OBSERVATION", 97, 104]]], ["HSV is the most common form of encephalitis in transplant recipients.", [["encephalitis", "DISEASE", 31, 43], ["HSV", "ORGANISM", 0, 3], ["recipients", "ORGANISM", 58, 68], ["HSV", "SPECIES", 0, 3], ["HSV", "PROBLEM", 0, 3], ["encephalitis", "PROBLEM", 31, 43], ["transplant recipients", "TREATMENT", 47, 68], ["most common", "OBSERVATION_MODIFIER", 11, 22], ["encephalitis", "OBSERVATION", 31, 43], ["transplant recipients", "OBSERVATION", 47, 68]]], ["HSV PCR and cultures from cerebrospinal fluid can assist diagnosis.", [["cerebrospinal fluid", "ANATOMY", 26, 45], ["HSV", "ORGANISM", 0, 3], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 26, 45], ["HSV", "SPECIES", 0, 3], ["HSV PCR", "TEST", 0, 7], ["cultures", "TEST", 12, 20], ["cerebrospinal fluid", "TEST", 26, 45]]], ["Diffuse interstitial pneumonitis may complicate disseminated disease.", [["interstitial", "ANATOMY", 8, 20], ["interstitial pneumonitis", "DISEASE", 8, 32], ["Diffuse interstitial pneumonitis", "PROBLEM", 0, 32], ["disseminated disease", "PROBLEM", 48, 68], ["interstitial", "ANATOMY_MODIFIER", 8, 20], ["pneumonitis", "OBSERVATION", 21, 32], ["may complicate", "UNCERTAINTY", 33, 47], ["disseminated", "OBSERVATION_MODIFIER", 48, 60], ["disease", "OBSERVATION", 61, 68]]], ["Multivisceral involvement with HSV infection is often fatal [62] [63] [64] .Herpes Simplex VirusDiagnosis may be made with the aid of direct fluorescence antibody for HSV from vesicular lesions or PCR from cerebrospinal fluid or visceral tissue samples.", [["vesicular lesions", "ANATOMY", 176, 193], ["cerebrospinal fluid", "ANATOMY", 206, 225], ["visceral tissue samples", "ANATOMY", 229, 252], ["HSV infection", "DISEASE", 31, 44], ["Herpes Simplex VirusDiagnosis", "DISEASE", 76, 105], ["HSV", "ORGANISM", 31, 34], ["Herpes", "ORGANISM", 76, 82], ["HSV", "ORGANISM", 167, 170], ["vesicular lesions", "PATHOLOGICAL_FORMATION", 176, 193], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 206, 225], ["visceral tissue samples", "TISSUE", 229, 252], ["direct fluorescence antibody", "PROTEIN", 134, 162], ["HSV", "SPECIES", 31, 34], ["HSV", "SPECIES", 167, 170], ["Multivisceral involvement", "PROBLEM", 0, 25], ["HSV infection", "PROBLEM", 31, 44], ["Herpes Simplex VirusDiagnosis", "PROBLEM", 76, 105], ["direct fluorescence antibody", "TEST", 134, 162], ["HSV", "PROBLEM", 167, 170], ["vesicular lesions", "PROBLEM", 176, 193], ["PCR from cerebrospinal fluid", "TEST", 197, 225], ["visceral tissue samples", "TEST", 229, 252], ["HSV", "OBSERVATION_MODIFIER", 31, 34], ["infection", "OBSERVATION", 35, 44], ["vesicular", "OBSERVATION_MODIFIER", 176, 185], ["lesions", "OBSERVATION", 186, 193], ["cerebrospinal", "ANATOMY", 206, 219], ["fluid", "OBSERVATION", 220, 225], ["visceral tissue", "ANATOMY", 229, 244]]], ["Due to high seroprevalence in the adult population, serologies are rarely helpful in the setting of active infection [20] .Herpes Simplex VirusTreatment of HSV infection with acyclovir has been shown to be effective.", [["infection", "DISEASE", 107, 116], ["Herpes Simplex VirusTreatment", "DISEASE", 123, 152], ["HSV infection", "DISEASE", 156, 169], ["acyclovir", "CHEMICAL", 175, 184], ["acyclovir", "CHEMICAL", 175, 184], ["Herpes Simplex VirusTreatment", "ORGANISM", 123, 152], ["HSV", "ORGANISM", 156, 159], ["acyclovir", "SIMPLE_CHEMICAL", 175, 184], ["HSV", "SPECIES", 156, 159], ["serologies", "TEST", 52, 62], ["active infection", "PROBLEM", 100, 116], ["Herpes", "PROBLEM", 123, 129], ["HSV infection", "PROBLEM", 156, 169], ["acyclovir", "TREATMENT", 175, 184], ["high", "OBSERVATION_MODIFIER", 7, 11], ["seroprevalence", "OBSERVATION", 12, 26], ["active", "OBSERVATION_MODIFIER", 100, 106], ["infection", "OBSERVATION", 107, 116], ["HSV", "OBSERVATION_MODIFIER", 156, 159], ["infection", "OBSERVATION", 160, 169]]], ["Mucocutaneous HSV infection in solid-organ transplant recipients should be treated with oral acyclovir while disseminated or deep HSV infection should always be treated with intravenous acyclovir [1, 30] .", [["solid-organ", "ANATOMY", 31, 42], ["oral", "ANATOMY", 88, 92], ["intravenous", "ANATOMY", 174, 185], ["HSV infection", "DISEASE", 14, 27], ["acyclovir", "CHEMICAL", 93, 102], ["HSV infection", "DISEASE", 130, 143], ["acyclovir", "CHEMICAL", 186, 195], ["acyclovir", "CHEMICAL", 93, 102], ["acyclovir", "CHEMICAL", 186, 195], ["Mucocutaneous HSV", "ORGANISM", 0, 17], ["solid-", "CANCER", 31, 37], ["organ", "ORGAN", 37, 42], ["recipients", "ORGANISM", 54, 64], ["oral", "ORGANISM_SUBDIVISION", 88, 92], ["acyclovir", "SIMPLE_CHEMICAL", 93, 102], ["HSV", "ORGANISM", 130, 133], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 174, 185], ["acyclovir", "SIMPLE_CHEMICAL", 186, 195], ["HSV", "SPECIES", 14, 17], ["HSV", "SPECIES", 130, 133], ["Mucocutaneous HSV infection", "PROBLEM", 0, 27], ["solid-organ transplant recipients", "TREATMENT", 31, 64], ["oral acyclovir", "TREATMENT", 88, 102], ["deep HSV infection", "PROBLEM", 125, 143], ["intravenous acyclovir", "TREATMENT", 174, 195], ["HSV", "OBSERVATION_MODIFIER", 14, 17], ["infection", "OBSERVATION", 18, 27], ["solid", "OBSERVATION_MODIFIER", 31, 36], ["organ", "ANATOMY", 37, 42], ["transplant", "OBSERVATION", 43, 53], ["deep", "OBSERVATION_MODIFIER", 125, 129], ["HSV", "OBSERVATION", 130, 133]]], ["The dose should be adjusted in patients with renal failure.", [["renal", "ANATOMY", 45, 50], ["renal failure", "DISEASE", 45, 58], ["patients", "ORGANISM", 31, 39], ["renal", "ORGAN", 45, 50], ["patients", "SPECIES", 31, 39], ["The dose", "TREATMENT", 0, 8], ["renal failure", "PROBLEM", 45, 58], ["renal", "ANATOMY", 45, 50], ["failure", "OBSERVATION", 51, 58]]], ["Although more toxic than acyclovir, ganciclovir and foscarnet are also effective against HSV.", [["acyclovir", "CHEMICAL", 25, 34], ["ganciclovir", "CHEMICAL", 36, 47], ["foscarnet", "CHEMICAL", 52, 61], ["acyclovir", "CHEMICAL", 25, 34], ["ganciclovir", "CHEMICAL", 36, 47], ["foscarnet", "CHEMICAL", 52, 61], ["acyclovir", "SIMPLE_CHEMICAL", 25, 34], ["ganciclovir", "SIMPLE_CHEMICAL", 36, 47], ["foscarnet", "SIMPLE_CHEMICAL", 52, 61], ["HSV", "ORGANISM", 89, 92], ["HSV", "SPECIES", 89, 92], ["acyclovir", "TREATMENT", 25, 34], ["ganciclovir", "TREATMENT", 36, 47], ["foscarnet", "TREATMENT", 52, 61], ["HSV", "PROBLEM", 89, 92], ["toxic", "OBSERVATION_MODIFIER", 14, 19]]], ["A concern with respect to chronic acyclovir use is the development of resistant mutants of HSV.", [["acyclovir", "CHEMICAL", 34, 43], ["HSV", "DISEASE", 91, 94], ["acyclovir", "CHEMICAL", 34, 43], ["acyclovir", "SIMPLE_CHEMICAL", 34, 43], ["HSV", "ORGANISM", 91, 94], ["HSV", "SPECIES", 91, 94], ["chronic acyclovir", "TREATMENT", 26, 43], ["resistant mutants of HSV", "PROBLEM", 70, 94], ["chronic", "OBSERVATION_MODIFIER", 26, 33], ["acyclovir", "OBSERVATION", 34, 43], ["resistant mutants", "OBSERVATION", 70, 87]]], ["Acyclovir resistance may arise from mutations in the genes for thymidine kinase or DNA polymerase.", [["Acyclovir", "CHEMICAL", 0, 9], ["thymidine", "CHEMICAL", 63, 72], ["Acyclovir", "CHEMICAL", 0, 9], ["thymidine", "CHEMICAL", 63, 72], ["Acyclovir", "SIMPLE_CHEMICAL", 0, 9], ["thymidine kinase", "GENE_OR_GENE_PRODUCT", 63, 79], ["DNA", "CELLULAR_COMPONENT", 83, 86], ["thymidine kinase", "PROTEIN", 63, 79], ["DNA polymerase", "PROTEIN", 83, 97], ["Acyclovir resistance", "TREATMENT", 0, 20], ["mutations", "PROBLEM", 36, 45], ["thymidine kinase", "TREATMENT", 63, 79], ["DNA polymerase", "PROBLEM", 83, 97]]], ["Acyclovir resistance has been rarely reported in some strains; foscarnet, cidofovir, and topical trifluridine may be considered for treatment of resistant virus, although careful monitoring of renal function is required [1, 2, 20, 65 ].Varicella Zoster VirusHuman herpesvirus 3-Varicella zoster (VZV) belongs to subfamily Alphaherpesvirinae, genus Varicellovirus, species Human herpesvirus 3.", [["renal", "ANATOMY", 193, 198], ["Acyclovir", "CHEMICAL", 0, 9], ["foscarnet", "CHEMICAL", 63, 72], ["cidofovir", "CHEMICAL", 74, 83], ["trifluridine", "CHEMICAL", 97, 109], ["Varicella zoster", "DISEASE", 278, 294], ["Acyclovir", "CHEMICAL", 0, 9], ["foscarnet", "CHEMICAL", 63, 72], ["cidofovir", "CHEMICAL", 74, 83], ["trifluridine", "CHEMICAL", 97, 109], ["Acyclovir", "SIMPLE_CHEMICAL", 0, 9], ["foscarnet", "SIMPLE_CHEMICAL", 63, 72], ["cidofovir", "SIMPLE_CHEMICAL", 74, 83], ["trifluridine", "SIMPLE_CHEMICAL", 97, 109], ["renal", "ORGAN", 193, 198], ["Varicella Zoster VirusHuman herpesvirus 3-Varicella zoster", "ORGANISM", 236, 294], ["VZV", "ORGANISM", 296, 299], ["Human herpesvirus 3", "ORGANISM", 372, 391], ["Varicella", "SPECIES", 236, 245], ["Zoster VirusHuman herpesvirus", "SPECIES", 246, 275], ["Varicella zoster", "SPECIES", 278, 294], ["Human", "SPECIES", 372, 377], ["herpesvirus", "SPECIES", 378, 389], ["Varicella Zoster VirusHuman herpesvirus", "SPECIES", 236, 275], ["VZV", "SPECIES", 296, 299], ["Human herpesvirus", "SPECIES", 372, 389], ["Acyclovir resistance", "TREATMENT", 0, 20], ["some strains", "PROBLEM", 49, 61], ["foscarnet", "TREATMENT", 63, 72], ["cidofovir", "TREATMENT", 74, 83], ["topical trifluridine", "TREATMENT", 89, 109], ["resistant virus", "PROBLEM", 145, 160], ["careful monitoring of renal function", "TEST", 171, 207], ["Varicella Zoster VirusHuman herpesvirus", "PROBLEM", 236, 275], ["Varicella zoster", "PROBLEM", 278, 294], ["VZV", "PROBLEM", 296, 299], ["Alphaherpesvirinae", "TEST", 322, 340], ["renal", "ANATOMY", 193, 198], ["Zoster", "OBSERVATION", 246, 252], ["Varicella zoster", "OBSERVATION", 278, 294]]], ["VZV causes two distinct clinical diseases following transplantation.", [["VZV", "DISEASE", 0, 3], ["VZV", "ORGANISM", 0, 3], ["VZV", "SPECIES", 0, 3], ["VZV", "PROBLEM", 0, 3], ["two distinct clinical diseases", "PROBLEM", 11, 41], ["transplantation", "TREATMENT", 52, 67], ["two", "OBSERVATION_MODIFIER", 11, 14], ["distinct", "OBSERVATION_MODIFIER", 15, 23], ["clinical diseases", "OBSERVATION", 24, 41]]], ["Ninety percent of adult solidorgan transplant recipients are VZV seropositive pretransplantation, and thus VZV reactivation in this group will cause herpes zoster.", [["herpes zoster", "DISEASE", 149, 162], ["solidorgan", "ORGANISM", 24, 34], ["recipients", "ORGANISM", 46, 56], ["VZV", "ORGANISM", 61, 64], ["VZV", "ORGANISM", 107, 110], ["herpes zoster", "ORGANISM", 149, 162], ["herpes zoster", "SPECIES", 149, 162], ["VZV", "SPECIES", 61, 64], ["VZV", "SPECIES", 107, 110], ["adult solidorgan transplant recipients", "TREATMENT", 18, 56], ["VZV seropositive pretransplantation", "TREATMENT", 61, 96], ["VZV reactivation", "PROBLEM", 107, 123], ["herpes zoster", "PROBLEM", 149, 162], ["adult", "OBSERVATION_MODIFIER", 18, 23], ["solidorgan", "OBSERVATION_MODIFIER", 24, 34], ["transplant", "OBSERVATION", 35, 45], ["VZV", "OBSERVATION_MODIFIER", 61, 64], ["seropositive pretransplantation", "OBSERVATION", 65, 96], ["VZV reactivation", "OBSERVATION", 107, 123], ["herpes zoster", "OBSERVATION", 149, 162]]], ["The remaining 10% are VZV seronegative and are thus at risk of primary infection.", [["primary infection", "DISEASE", 63, 80], ["VZV", "ORGANISM", 22, 25], ["VZV", "SPECIES", 22, 25], ["VZV seronegative", "PROBLEM", 22, 38], ["primary infection", "PROBLEM", 63, 80], ["VZV", "OBSERVATION_MODIFIER", 22, 25], ["seronegative", "OBSERVATION", 26, 38], ["primary", "OBSERVATION_MODIFIER", 63, 70], ["infection", "OBSERVATION", 71, 80]]], ["The incidence of VZV in renal transplant recipients is lower than HSV and is approximately 4 to 12% [1] .", [["renal transplant", "ANATOMY", 24, 40], ["VZV", "DISEASE", 17, 20], ["VZV", "ORGANISM", 17, 20], ["renal", "ORGAN", 24, 29], ["HSV", "ORGANISM", 66, 69], ["VZV", "SPECIES", 17, 20], ["HSV", "SPECIES", 66, 69], ["VZV in renal transplant recipients", "TREATMENT", 17, 51], ["HSV", "TEST", 66, 69], ["VZV", "OBSERVATION", 17, 20], ["renal", "ANATOMY", 24, 29], ["transplant", "OBSERVATION", 30, 40], ["lower", "OBSERVATION_MODIFIER", 55, 60]]], ["VZV causes a spectrum of disease in solid organ transplant recipients, ranging from localized dermatomal zoster (involving a few adjoining dermatomes) to multidermatomal or disseminated zoster with or without visceral involvement.", [["solid organ transplant", "ANATOMY", 36, 58], ["dermatomes", "ANATOMY", 139, 149], ["multidermatomal", "ANATOMY", 154, 169], ["visceral", "ANATOMY", 209, 217], ["VZV", "DISEASE", 0, 3], ["dermatomal zoster", "DISEASE", 94, 111], ["zoster", "DISEASE", 186, 192], ["VZV", "ORGANISM", 0, 3], ["solid", "CANCER", 36, 41], ["organ", "ORGAN", 42, 47], ["dermatomes", "ORGAN", 139, 149], ["zoster", "ORGANISM", 186, 192], ["visceral", "ORGANISM_SUBDIVISION", 209, 217], ["VZV", "SPECIES", 0, 3], ["VZV", "PROBLEM", 0, 3], ["disease", "PROBLEM", 25, 32], ["solid organ transplant recipients", "TREATMENT", 36, 69], ["localized dermatomal zoster", "PROBLEM", 84, 111], ["multidermatomal or disseminated zoster", "PROBLEM", 154, 192], ["visceral involvement", "PROBLEM", 209, 229], ["spectrum", "OBSERVATION_MODIFIER", 13, 21], ["disease", "OBSERVATION", 25, 32], ["solid organ", "ANATOMY", 36, 47], ["transplant recipients", "OBSERVATION", 48, 69], ["ranging", "OBSERVATION_MODIFIER", 71, 78], ["localized", "OBSERVATION_MODIFIER", 84, 93], ["dermatomal", "OBSERVATION_MODIFIER", 94, 104], ["zoster", "OBSERVATION", 105, 111], ["disseminated", "OBSERVATION_MODIFIER", 173, 185], ["zoster", "OBSERVATION", 186, 192], ["without", "UNCERTAINTY", 201, 208], ["visceral", "ANATOMY", 209, 217], ["involvement", "OBSERVATION", 218, 229]]], ["In a cohort of 869 adult solid organ transplants (434 renal transplant recipients), 7.4% of the renal transplant recipients had herpes zoster with a median time to onset of 9 month [66] .", [["organ", "ANATOMY", 31, 36], ["renal", "ANATOMY", 54, 59], ["renal", "ANATOMY", 96, 101], ["herpes zoster", "DISEASE", 128, 141], ["organ", "ORGAN", 31, 36], ["renal", "ORGAN", 54, 59], ["renal", "ORGAN", 96, 101], ["recipients", "ORGANISM", 113, 123], ["herpes", "ORGANISM", 128, 134], ["herpes zoster", "SPECIES", 128, 141], ["adult solid organ transplants", "TREATMENT", 19, 48], ["renal transplant recipients", "TREATMENT", 54, 81], ["the renal transplant recipients", "TREATMENT", 92, 123], ["herpes zoster", "PROBLEM", 128, 141], ["transplants", "OBSERVATION", 37, 48], ["renal", "ANATOMY", 96, 101], ["transplant", "OBSERVATION", 102, 112]]], ["The main complications of a VZV infection in this immunosuppressed population were disseminated intravascular coagulation (DIC) and hepatitis in almost half and pneumonitis in 29% of patients.", [["intravascular", "ANATOMY", 96, 109], ["VZV infection", "DISEASE", 28, 41], ["disseminated intravascular coagulation", "DISEASE", 83, 121], ["DIC", "DISEASE", 123, 126], ["hepatitis", "DISEASE", 132, 141], ["pneumonitis", "DISEASE", 161, 172], ["VZV", "ORGANISM", 28, 31], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 96, 109], ["patients", "ORGANISM", 183, 191], ["patients", "SPECIES", 183, 191], ["VZV", "SPECIES", 28, 31], ["a VZV infection", "PROBLEM", 26, 41], ["this immunosuppressed population", "PROBLEM", 45, 77], ["disseminated intravascular coagulation", "PROBLEM", 83, 121], ["DIC)", "PROBLEM", 123, 127], ["hepatitis", "PROBLEM", 132, 141], ["pneumonitis", "PROBLEM", 161, 172], ["main", "OBSERVATION_MODIFIER", 4, 8], ["complications", "OBSERVATION", 9, 22], ["VZV", "OBSERVATION_MODIFIER", 28, 31], ["infection", "OBSERVATION", 32, 41], ["disseminated", "OBSERVATION_MODIFIER", 83, 95], ["intravascular coagulation", "OBSERVATION", 96, 121], ["hepatitis", "OBSERVATION", 132, 141], ["pneumonitis", "OBSERVATION", 161, 172]]], ["Infections of the allograft and of the CNS as well as pancreatitis were also described.", [["allograft", "ANATOMY", 18, 27], ["CNS", "ANATOMY", 39, 42], ["Infections of the allograft and of the CNS", "DISEASE", 0, 42], ["pancreatitis", "DISEASE", 54, 66], ["allograft", "TISSUE", 18, 27], ["CNS", "ANATOMICAL_SYSTEM", 39, 42], ["Infections of the allograft", "PROBLEM", 0, 27], ["the CNS", "PROBLEM", 35, 42], ["pancreatitis", "PROBLEM", 54, 66], ["allograft", "OBSERVATION", 18, 27], ["CNS", "ANATOMY", 39, 42], ["pancreatitis", "OBSERVATION", 54, 66]]], ["Concomitant bacterial or CMV infections have been reported too [67] .Varicella Zoster VirusUnilateral vesicular lesions in a dermatomal pattern are usually sufficiently characteristic of herpes zoster to enable a clinical diagnosis; however, culture of VZV in susceptible cell culture lines, demonstration of multinucleated giant cells on Tzanck smear, and/or direct immunofluorescence is recommended for confirmation.", [["vesicular lesions", "ANATOMY", 102, 119], ["dermatomal", "ANATOMY", 125, 135], ["cell culture lines", "ANATOMY", 272, 290], ["multinucleated giant cells", "ANATOMY", 309, 335], ["bacterial or CMV infections", "DISEASE", 12, 39], ["herpes zoster", "DISEASE", 187, 200], ["VZV", "DISEASE", 253, 256], ["CMV", "ORGANISM", 25, 28], ["Varicella Zoster", "ORGANISM", 69, 85], ["VirusUnilateral vesicular lesions", "PATHOLOGICAL_FORMATION", 86, 119], ["herpes zoster", "ORGANISM", 187, 200], ["VZV", "ORGANISM", 253, 256], ["cell culture lines", "CELL", 272, 290], ["multinucleated giant cells", "CELL", 309, 335], ["susceptible cell culture lines", "CELL_LINE", 260, 290], ["multinucleated giant cells", "CELL_TYPE", 309, 335], ["Varicella Zoster", "SPECIES", 69, 85], ["herpes zoster", "SPECIES", 187, 200], ["CMV", "SPECIES", 25, 28], ["VZV", "SPECIES", 253, 256], ["Concomitant bacterial", "PROBLEM", 0, 21], ["CMV infections", "PROBLEM", 25, 39], ["Varicella Zoster VirusUnilateral vesicular lesions", "PROBLEM", 69, 119], ["a dermatomal pattern", "PROBLEM", 123, 143], ["herpes zoster", "PROBLEM", 187, 200], ["culture", "TEST", 242, 249], ["VZV", "PROBLEM", 253, 256], ["susceptible cell culture lines", "TEST", 260, 290], ["multinucleated giant cells", "PROBLEM", 309, 335], ["Tzanck smear", "TEST", 339, 351], ["direct immunofluorescence", "TEST", 360, 385], ["bacterial", "OBSERVATION_MODIFIER", 12, 21], ["CMV infections", "OBSERVATION", 25, 39], ["Zoster", "OBSERVATION_MODIFIER", 79, 85], ["VirusUnilateral", "OBSERVATION_MODIFIER", 86, 101], ["vesicular", "OBSERVATION_MODIFIER", 102, 111], ["lesions", "OBSERVATION", 112, 119], ["dermatomal", "ANATOMY", 125, 135], ["herpes", "OBSERVATION", 187, 193], ["multinucleated", "OBSERVATION_MODIFIER", 309, 323], ["giant cells", "OBSERVATION", 324, 335]]], ["These techniques can also be used for diagnosis in cases of primary infection [1] .", [["primary infection", "DISEASE", 60, 77], ["primary infection", "PROBLEM", 60, 77], ["infection", "OBSERVATION", 68, 77]]], ["Pretransplant screening for previous VZV infection should be performed and na\u00efve patients should be vaccinated with live attenuated varicella vaccine before transplant whenever possible to avoid primary VZV infection after transplantation, an often severe disease with a high mortality rate [67] .", [["VZV infection", "DISEASE", 37, 50], ["VZV infection", "DISEASE", 203, 216], ["VZV", "ORGANISM", 37, 40], ["patients", "ORGANISM", 81, 89], ["VZV", "ORGANISM", 203, 206], ["patients", "SPECIES", 81, 89], ["VZV", "SPECIES", 37, 40], ["VZV", "SPECIES", 203, 206], ["Pretransplant screening", "TEST", 0, 23], ["previous VZV infection", "PROBLEM", 28, 50], ["live attenuated varicella vaccine", "TREATMENT", 116, 149], ["transplant", "TREATMENT", 157, 167], ["primary VZV infection", "PROBLEM", 195, 216], ["transplantation", "TREATMENT", 223, 238], ["an often severe disease", "PROBLEM", 240, 263], ["a high mortality rate", "PROBLEM", 269, 290], ["severe", "OBSERVATION_MODIFIER", 249, 255], ["disease", "OBSERVATION", 256, 263]]], ["However, due to the fact that the VZV vaccine is a live vaccine, the vaccineVaricella Zoster VirusThe Scientific World Journal 7 should not be given it if transplant is expected within four to six weeks to prevent active viral shedding at the time of transplant [30] .", [["Varicella Zoster Virus", "DISEASE", 76, 98], ["VZV", "ORGANISM", 34, 37], ["Varicella Zoster Virus", "ORGANISM", 76, 98], ["Varicella Zoster Virus", "SPECIES", 76, 98], ["VZV", "SPECIES", 34, 37], ["the VZV vaccine", "TREATMENT", 30, 45], ["a live vaccine", "TREATMENT", 49, 63], ["the vaccine", "TREATMENT", 65, 76], ["Varicella Zoster Virus", "PROBLEM", 76, 98], ["transplant", "TREATMENT", 155, 165], ["active viral shedding", "PROBLEM", 214, 235], ["transplant", "TREATMENT", 251, 261], ["Zoster Virus", "OBSERVATION", 86, 98], ["active", "OBSERVATION_MODIFIER", 214, 220], ["viral", "OBSERVATION", 221, 226]]], ["A VZV na\u00efve transplant patient who is exposed to someone infected with varicella should receive varicella immune globulin within 96 hours of exposure (if available).", [["varicella", "DISEASE", 71, 80], ["VZV", "ORGANISM", 2, 5], ["patient", "ORGANISM", 23, 30], ["someone", "ORGANISM", 49, 56], ["varicella", "ORGANISM", 71, 80], ["patient", "SPECIES", 23, 30], ["VZV", "SPECIES", 2, 5], ["A VZV na\u00efve transplant", "TREATMENT", 0, 22], ["varicella", "PROBLEM", 71, 80], ["varicella immune globulin", "TREATMENT", 96, 121]]], ["If VZIG is not available, or the patient presents greater than 96 hours following exposure, acyclovir may be considered for postexposure prophylaxis [30] .", [["acyclovir", "CHEMICAL", 92, 101], ["acyclovir", "CHEMICAL", 92, 101], ["VZIG", "SIMPLE_CHEMICAL", 3, 7], ["patient", "ORGANISM", 33, 40], ["acyclovir", "SIMPLE_CHEMICAL", 92, 101], ["patient", "SPECIES", 33, 40], ["VZIG", "PROBLEM", 3, 7], ["acyclovir", "TREATMENT", 92, 101], ["postexposure prophylaxis", "TREATMENT", 124, 148]]], ["Posttransplant prophylaxis against reactivation of VZV and also HSV is recommended to prevent severe recurrences and consists of ganciclovir in patients needing CMV prophylaxis.", [["VZV", "DISEASE", 51, 54], ["ganciclovir", "CHEMICAL", 129, 140], ["ganciclovir", "CHEMICAL", 129, 140], ["VZV", "ORGANISM", 51, 54], ["HSV", "ORGANISM", 64, 67], ["ganciclovir", "SIMPLE_CHEMICAL", 129, 140], ["patients", "ORGANISM", 144, 152], ["CMV", "ORGANISM", 161, 164], ["patients", "SPECIES", 144, 152], ["VZV", "SPECIES", 51, 54], ["HSV", "SPECIES", 64, 67], ["CMV", "SPECIES", 161, 164], ["Posttransplant prophylaxis", "TREATMENT", 0, 26], ["VZV", "PROBLEM", 51, 54], ["HSV", "PROBLEM", 64, 67], ["severe recurrences", "PROBLEM", 94, 112], ["ganciclovir", "TREATMENT", 129, 140], ["CMV prophylaxis", "TREATMENT", 161, 176], ["severe", "OBSERVATION_MODIFIER", 94, 100], ["recurrences", "OBSERVATION", 101, 112]]], ["Those patients who do not require CMV prophylaxis can receive valacyclovir or acyclovir for approximately one to three months posttransplant [30] .", [["valacyclovir", "CHEMICAL", 62, 74], ["acyclovir", "CHEMICAL", 78, 87], ["valacyclovir", "CHEMICAL", 62, 74], ["acyclovir", "CHEMICAL", 78, 87], ["patients", "ORGANISM", 6, 14], ["CMV", "ORGANISM", 34, 37], ["valacyclovir", "SIMPLE_CHEMICAL", 62, 74], ["acyclovir", "SIMPLE_CHEMICAL", 78, 87], ["patients", "SPECIES", 6, 14], ["CMV", "SPECIES", 34, 37], ["CMV prophylaxis", "TREATMENT", 34, 49], ["valacyclovir", "TREATMENT", 62, 74], ["acyclovir", "TREATMENT", 78, 87]]], ["After transplantation, most authorities defer vaccination with live vaccines; killed vaccine appears to be beneficial [67, 68] .", [["transplantation", "TREATMENT", 6, 21], ["vaccination", "TREATMENT", 46, 57], ["live vaccines", "TREATMENT", 63, 76], ["killed vaccine", "TREATMENT", 78, 92]]], ["VZ-immunoglobulin is recommended for immunocompromised individuals with exposures to varicella or zoster; protection is incomplete [69] .Epstein-Barr VirusEpstein-Barr virus-Human herpesvirus 4 (EBV) belongs to subfamily Gammaherpesvirinae, genus Lymphocryptovirus, species Human herpesvirus 4.", [["VZ-immunoglobulin", "CHEMICAL", 0, 17], ["varicella or zoster", "DISEASE", 85, 104], ["VZ-immunoglobulin", "GENE_OR_GENE_PRODUCT", 0, 17], ["zoster", "ORGANISM", 98, 104], ["Epstein-Barr VirusEpstein-Barr virus-", "ORGANISM", 137, 174], ["Human herpesvirus 4", "ORGANISM", 174, 193], ["EBV", "ORGANISM", 195, 198], ["Gammaherpesvirinae", "GENE_OR_GENE_PRODUCT", 221, 239], ["Human herpesvirus 4", "ORGANISM", 274, 293], ["immunoglobulin", "PROTEIN", 3, 17], ["Human herpesvirus", "SPECIES", 174, 191], ["Human", "SPECIES", 274, 279], ["herpesvirus", "SPECIES", 280, 291], ["Epstein-Barr VirusEpstein-Barr virus", "SPECIES", 137, 173], ["Human herpesvirus 4", "SPECIES", 174, 193], ["EBV", "SPECIES", 195, 198], ["Human herpesvirus", "SPECIES", 274, 291], ["VZ", "TEST", 0, 2], ["immunoglobulin", "TREATMENT", 3, 17], ["immunocompromised individuals", "PROBLEM", 37, 66], ["varicella", "PROBLEM", 85, 94], ["zoster", "PROBLEM", 98, 104], ["Epstein", "TEST", 137, 144], ["Barr VirusEpstein", "TEST", 145, 162], ["Barr virus", "PROBLEM", 163, 173], ["Human herpesvirus", "PROBLEM", 174, 191], ["zoster", "OBSERVATION", 98, 104], ["Barr VirusEpstein", "OBSERVATION", 145, 162], ["Barr virus", "OBSERVATION", 163, 173]]], ["It can infect B lymphocytes as well as malignant cells of several lineages, including T lymphocytes, epithelial cells, and smooth muscle cells.", [["B lymphocytes", "ANATOMY", 14, 27], ["malignant cells", "ANATOMY", 39, 54], ["T lymphocytes", "ANATOMY", 86, 99], ["epithelial cells", "ANATOMY", 101, 117], ["smooth muscle cells", "ANATOMY", 123, 142], ["B lymphocytes", "CELL", 14, 27], ["malignant cells", "CELL", 39, 54], ["T lymphocytes", "CELL", 86, 99], ["epithelial cells", "CELL", 101, 117], ["smooth muscle cells", "CELL", 123, 142], ["B lymphocytes", "CELL_TYPE", 14, 27], ["malignant cells", "CELL_TYPE", 39, 54], ["T lymphocytes", "CELL_TYPE", 86, 99], ["epithelial cells", "CELL_TYPE", 101, 117], ["smooth muscle cells", "CELL_TYPE", 123, 142], ["malignant cells", "PROBLEM", 39, 54], ["several lineages", "PROBLEM", 58, 74], ["T lymphocytes", "TEST", 86, 99], ["epithelial cells", "PROBLEM", 101, 117], ["smooth muscle cells", "PROBLEM", 123, 142], ["lymphocytes", "ANATOMY", 16, 27], ["malignant cells", "OBSERVATION", 39, 54], ["several", "OBSERVATION_MODIFIER", 58, 65], ["lineages", "OBSERVATION_MODIFIER", 66, 74], ["lymphocytes", "ANATOMY", 88, 99], ["epithelial cells", "OBSERVATION", 101, 117], ["smooth muscle cells", "OBSERVATION", 123, 142]]], ["EBV is associated with a wide range of malignancies, including posttransplant lymphoproliferative disorder (PTLD), Hodgkin and non-Hodgkin lymphomas, nasopharyngeal carcinoma, gastric carcinoma, and leiomyosarcoma [70] .", [["malignancies", "ANATOMY", 39, 51], ["Hodgkin", "ANATOMY", 115, 122], ["non-Hodgkin lymphomas", "ANATOMY", 127, 148], ["nasopharyngeal carcinoma", "ANATOMY", 150, 174], ["gastric carcinoma", "ANATOMY", 176, 193], ["leiomyosarcoma", "ANATOMY", 199, 213], ["malignancies", "DISEASE", 39, 51], ["posttransplant lymphoproliferative disorder", "DISEASE", 63, 106], ["PTLD", "DISEASE", 108, 112], ["Hodgkin and non-Hodgkin lymphomas", "DISEASE", 115, 148], ["nasopharyngeal carcinoma", "DISEASE", 150, 174], ["gastric carcinoma", "DISEASE", 176, 193], ["leiomyosarcoma", "DISEASE", 199, 213], ["EBV", "ORGANISM", 0, 3], ["malignancies", "CANCER", 39, 51], ["Hodgkin", "CANCER", 115, 122], ["non-Hodgkin lymphomas", "CANCER", 127, 148], ["nasopharyngeal carcinoma", "CANCER", 150, 174], ["gastric carcinoma", "CANCER", 176, 193], ["leiomyosarcoma", "CANCER", 199, 213], ["EBV", "SPECIES", 0, 3], ["EBV", "PROBLEM", 0, 3], ["a wide range of malignancies", "PROBLEM", 23, 51], ["posttransplant lymphoproliferative disorder", "PROBLEM", 63, 106], ["PTLD", "PROBLEM", 108, 112], ["Hodgkin and non-Hodgkin lymphomas", "PROBLEM", 115, 148], ["nasopharyngeal carcinoma", "PROBLEM", 150, 174], ["gastric carcinoma", "PROBLEM", 176, 193], ["leiomyosarcoma", "PROBLEM", 199, 213], ["wide range", "OBSERVATION_MODIFIER", 25, 35], ["malignancies", "OBSERVATION", 39, 51], ["posttransplant lymphoproliferative disorder", "OBSERVATION", 63, 106], ["Hodgkin", "ANATOMY", 115, 122], ["non-Hodgkin lymphomas", "OBSERVATION", 127, 148], ["nasopharyngeal", "ANATOMY", 150, 164], ["carcinoma", "OBSERVATION", 165, 174], ["gastric", "ANATOMY", 176, 183], ["carcinoma", "OBSERVATION", 184, 193], ["leiomyosarcoma", "OBSERVATION", 199, 213]]], ["Nearly every human is infected before adulthood.", [["human", "ORGANISM", 13, 18], ["human", "SPECIES", 13, 18], ["human", "SPECIES", 13, 18], ["infected", "OBSERVATION", 22, 30]]], ["Infection early in childhood is usually asymptomatic, while delayed primary infection is typically manifested through the symptoms of infectious mononucleosis.", [["primary infection", "DISEASE", 68, 85], ["infectious mononucleosis", "DISEASE", 134, 158], ["Infection", "PROBLEM", 0, 9], ["delayed primary infection", "PROBLEM", 60, 85], ["the symptoms", "PROBLEM", 118, 130], ["infectious mononucleosis", "PROBLEM", 134, 158], ["asymptomatic", "OBSERVATION_MODIFIER", 40, 52], ["infection", "OBSERVATION", 76, 85], ["infectious", "OBSERVATION_MODIFIER", 134, 144], ["mononucleosis", "OBSERVATION", 145, 158]]], ["Once infection occurs, the viral genome is maintained for life in a small fraction of B lymphocytes.", [["B lymphocytes", "ANATOMY", 86, 99], ["infection", "DISEASE", 5, 14], ["B lymphocytes", "CELL", 86, 99], ["viral genome", "DNA", 27, 39], ["B lymphocytes", "CELL_TYPE", 86, 99], ["infection", "PROBLEM", 5, 14], ["the viral genome", "PROBLEM", 23, 39], ["infection", "OBSERVATION", 5, 14], ["viral genome", "OBSERVATION", 27, 39], ["B lymphocytes", "OBSERVATION", 86, 99]]], ["In the setting of allogeneic transplantation when iatrogenic immunosuppression is used to prevent graft rejection, an unintended consequence is failure to suppress active EBV infection, which is accompanied by a heightened risk of developing PTLD [71] .", [["graft", "ANATOMY", 98, 103], ["EBV infection", "DISEASE", 171, 184], ["PTLD", "DISEASE", 242, 246], ["graft", "TISSUE", 98, 103], ["EBV", "ORGANISM", 171, 174], ["EBV", "SPECIES", 171, 174], ["allogeneic transplantation", "TREATMENT", 18, 44], ["iatrogenic immunosuppression", "TREATMENT", 50, 78], ["graft rejection", "PROBLEM", 98, 113], ["failure", "PROBLEM", 144, 151], ["active EBV infection", "PROBLEM", 164, 184], ["PTLD", "PROBLEM", 242, 246], ["allogeneic transplantation", "OBSERVATION", 18, 44], ["graft rejection", "OBSERVATION", 98, 113], ["active", "OBSERVATION_MODIFIER", 164, 170], ["EBV", "OBSERVATION_MODIFIER", 171, 174], ["infection", "OBSERVATION", 175, 184], ["PTLD", "OBSERVATION", 242, 246]]], ["PTLD is a potentially life-threatening neoplasm exhibiting a spectrum of histopathologies ranging from reactive-appearing, polyclonal lymphoid infiltrates to sheets of undifferentiated cells that are morphologically indistinguishable from malignant lymphoma or plasma cell myeloma [70] .Epstein-Barr VirusThe majority of symptomatic infections in renal transplant recipients are primary infection, likely related to reactivation of donor virus.", [["neoplasm", "ANATOMY", 39, 47], ["lymphoid infiltrates", "ANATOMY", 134, 154], ["undifferentiated cells", "ANATOMY", 168, 190], ["malignant lymphoma", "ANATOMY", 239, 257], ["plasma cell myeloma", "ANATOMY", 261, 280], ["renal", "ANATOMY", 347, 352], ["PTLD", "DISEASE", 0, 4], ["neoplasm", "DISEASE", 39, 47], ["malignant lymphoma", "DISEASE", 239, 257], ["plasma cell myeloma", "DISEASE", 261, 280], ["infections", "DISEASE", 333, 343], ["primary infection", "DISEASE", 379, 396], ["neoplasm", "CANCER", 39, 47], ["histopathologies", "CANCER", 73, 89], ["cells", "CELL", 185, 190], ["malignant lymphoma", "CANCER", 239, 257], ["plasma cell myeloma", "CANCER", 261, 280], ["Epstein-Barr Virus", "ORGANISM", 287, 305], ["renal", "ORGAN", 347, 352], ["donor virus", "ORGANISM", 432, 443], ["undifferentiated cells", "CELL_TYPE", 168, 190], ["Epstein-Barr Virus", "SPECIES", 287, 305], ["PTLD", "PROBLEM", 0, 4], ["a potentially life-threatening neoplasm", "PROBLEM", 8, 47], ["histopathologies", "PROBLEM", 73, 89], ["polyclonal lymphoid infiltrates", "PROBLEM", 123, 154], ["undifferentiated cells", "PROBLEM", 168, 190], ["malignant lymphoma", "PROBLEM", 239, 257], ["plasma cell myeloma", "PROBLEM", 261, 280], ["Barr Virus", "PROBLEM", 295, 305], ["symptomatic infections", "PROBLEM", 321, 343], ["renal transplant recipients", "TREATMENT", 347, 374], ["primary infection", "PROBLEM", 379, 396], ["donor virus", "PROBLEM", 432, 443], ["threatening", "OBSERVATION_MODIFIER", 27, 38], ["neoplasm", "OBSERVATION", 39, 47], ["reactive", "OBSERVATION_MODIFIER", 103, 111], ["polyclonal lymphoid infiltrates", "OBSERVATION", 123, 154], ["undifferentiated cells", "OBSERVATION", 168, 190], ["malignant lymphoma", "OBSERVATION", 239, 257], ["plasma cell myeloma", "OBSERVATION", 261, 280], ["Barr Virus", "OBSERVATION", 295, 305], ["majority", "OBSERVATION_MODIFIER", 309, 317], ["symptomatic", "OBSERVATION_MODIFIER", 321, 332], ["infections", "OBSERVATION", 333, 343], ["renal", "ANATOMY", 347, 352], ["transplant", "OBSERVATION", 353, 363], ["primary", "OBSERVATION_MODIFIER", 379, 386], ["infection", "OBSERVATION", 387, 396], ["likely related to", "UNCERTAINTY", 398, 415], ["donor virus", "OBSERVATION", 432, 443]]], ["Since ninety percent of adults have antibodies to EBV by age 40, symptomatic infection is most commonly seen in pediatric populations.", [["infection", "DISEASE", 77, 86], ["adults", "ORGANISM", 24, 30], ["EBV", "ORGANISM", 50, 53], ["antibodies", "PROTEIN", 36, 46], ["EBV", "SPECIES", 50, 53], ["symptomatic infection", "PROBLEM", 65, 86], ["symptomatic", "OBSERVATION_MODIFIER", 65, 76], ["infection", "OBSERVATION", 77, 86], ["most commonly", "OBSERVATION_MODIFIER", 90, 103]]], ["Renal transplants have the lowest risk of acquiring PTLD in comparison with other transplant populations (approximately 1 to 3%).", [["Renal", "ANATOMY", 0, 5], ["PTLD", "DISEASE", 52, 56], ["Renal", "ORGAN", 0, 5], ["Renal transplants", "TREATMENT", 0, 17], ["acquiring PTLD", "PROBLEM", 42, 56], ["other transplant populations", "TREATMENT", 76, 104], ["transplants", "OBSERVATION", 6, 17], ["PTLD", "OBSERVATION", 52, 56]]], ["PTLD most commonly occurs in the first year after transplant [20, 30] .", [["PTLD", "DISEASE", 0, 4], ["PTLD", "PROBLEM", 0, 4], ["transplant", "TREATMENT", 50, 60]]], ["Symptoms are often quite nonspecific, for example, fever, malaise, and anorexia, and some patients are asymptomatic.", [["fever", "DISEASE", 51, 56], ["malaise", "DISEASE", 58, 65], ["anorexia", "DISEASE", 71, 79], ["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 90, 98], ["Symptoms", "PROBLEM", 0, 8], ["fever", "PROBLEM", 51, 56], ["malaise", "PROBLEM", 58, 65], ["anorexia", "PROBLEM", 71, 79], ["asymptomatic", "PROBLEM", 103, 115], ["nonspecific", "OBSERVATION", 25, 36], ["malaise", "OBSERVATION", 58, 65], ["anorexia", "OBSERVATION", 71, 79], ["asymptomatic", "OBSERVATION_MODIFIER", 103, 115]]], ["PTLD frequently presents as a rapidly enlarging mass in the grafted organ, in lymph nodes, filling the marrow space, or in extranodal sites such as upper airway or intestine [72] .Epstein-Barr VirusNearly all transplant recipients are infected or eventually become infected by EBV, yet only a fraction will develop PTLD.", [["mass", "ANATOMY", 48, 52], ["organ", "ANATOMY", 68, 73], ["lymph nodes", "ANATOMY", 78, 89], ["marrow space", "ANATOMY", 103, 115], ["extranodal sites", "ANATOMY", 123, 139], ["upper airway", "ANATOMY", 148, 160], ["intestine", "ANATOMY", 164, 173], ["PTLD", "DISEASE", 0, 4], ["PTLD", "DISEASE", 315, 319], ["organ", "ORGAN", 68, 73], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 78, 89], ["marrow space", "MULTI-TISSUE_STRUCTURE", 103, 115], ["extranodal sites", "MULTI-TISSUE_STRUCTURE", 123, 139], ["upper airway", "MULTI-TISSUE_STRUCTURE", 148, 160], ["intestine", "ORGAN", 164, 173], ["Epstein-Barr VirusNearly", "ORGANISM", 180, 204], ["recipients", "ORGANISM", 220, 230], ["EBV", "ORGANISM", 277, 280], ["EBV", "SPECIES", 277, 280], ["PTLD", "PROBLEM", 0, 4], ["a rapidly enlarging mass in the grafted organ", "PROBLEM", 28, 73], ["lymph nodes", "PROBLEM", 78, 89], ["filling the marrow space", "PROBLEM", 91, 115], ["Barr VirusNearly all transplant recipients", "TREATMENT", 188, 230], ["infected", "PROBLEM", 235, 243], ["PTLD", "PROBLEM", 315, 319], ["rapidly", "OBSERVATION_MODIFIER", 30, 37], ["enlarging", "OBSERVATION_MODIFIER", 38, 47], ["mass", "OBSERVATION", 48, 52], ["grafted", "ANATOMY_MODIFIER", 60, 67], ["organ", "ANATOMY", 68, 73], ["lymph nodes", "OBSERVATION", 78, 89], ["marrow space", "OBSERVATION", 103, 115], ["extranodal sites", "OBSERVATION", 123, 139], ["upper", "ANATOMY_MODIFIER", 148, 153], ["airway", "ANATOMY", 154, 160], ["intestine", "ANATOMY", 164, 173], ["infected", "OBSERVATION", 235, 243], ["infected", "OBSERVATION", 265, 273], ["PTLD", "OBSERVATION", 315, 319]]], ["Risk factors for PTLD are as follows: EBV seronegativity at the time of transplant, active primary EBV infection at the time of transplant, underlying disease leading to transplantation, prior splenectomy, second transplant, patient age (children and older adults), coinfection by cytomegalovirus and other viruses, acute or chronic graft-versus-host disease, immunosuppressive drug regimen and intensity, cytokine polymorphisms, HLA type and extent of HLA mismatch, or the presence of multiple risk factors [70] .", [["graft", "ANATOMY", 333, 338], ["PTLD", "DISEASE", 17, 21], ["primary EBV infection", "DISEASE", 91, 112], ["coinfection", "DISEASE", 266, 277], ["cytomegalovirus", "DISEASE", 281, 296], ["chronic graft-versus-host disease", "DISEASE", 325, 358], ["EBV", "ORGANISM", 38, 41], ["EBV", "ORGANISM", 99, 102], ["patient", "ORGANISM", 225, 232], ["children", "ORGANISM", 238, 246], ["cytomegalovirus", "ORGANISM", 281, 296], ["cytokine", "PROTEIN", 406, 414], ["patient", "SPECIES", 225, 232], ["children", "SPECIES", 238, 246], ["EBV", "SPECIES", 99, 102], ["Risk factors", "PROBLEM", 0, 12], ["PTLD", "PROBLEM", 17, 21], ["EBV seronegativity", "PROBLEM", 38, 56], ["transplant", "TREATMENT", 72, 82], ["active primary EBV infection", "PROBLEM", 84, 112], ["transplant", "TREATMENT", 128, 138], ["underlying disease", "PROBLEM", 140, 158], ["transplantation", "TREATMENT", 170, 185], ["prior splenectomy", "TREATMENT", 187, 204], ["second transplant", "TREATMENT", 206, 223], ["coinfection", "PROBLEM", 266, 277], ["cytomegalovirus", "PROBLEM", 281, 296], ["other viruses", "PROBLEM", 301, 314], ["acute or chronic graft-versus-host disease", "PROBLEM", 316, 358], ["immunosuppressive drug regimen", "TREATMENT", 360, 390], ["cytokine polymorphisms", "PROBLEM", 406, 428], ["HLA type", "PROBLEM", 430, 438], ["HLA mismatch", "PROBLEM", 453, 465], ["multiple risk factors", "PROBLEM", 486, 507], ["transplant", "OBSERVATION", 72, 82], ["active", "OBSERVATION_MODIFIER", 84, 90], ["primary", "OBSERVATION_MODIFIER", 91, 98], ["EBV infection", "OBSERVATION", 99, 112], ["transplant", "OBSERVATION", 128, 138], ["disease", "OBSERVATION", 151, 158], ["transplantation", "OBSERVATION", 170, 185], ["splenectomy", "OBSERVATION", 193, 204], ["cytomegalovirus", "OBSERVATION", 281, 296], ["acute", "OBSERVATION_MODIFIER", 316, 321], ["chronic", "OBSERVATION_MODIFIER", 325, 332], ["graft", "OBSERVATION", 333, 338], ["host disease", "OBSERVATION", 346, 358], ["HLA mismatch", "OBSERVATION", 453, 465]]], ["Active primary EBV infection is a contraindication to transplantation [73] .", [["primary EBV infection", "DISEASE", 7, 28], ["EBV", "ORGANISM", 15, 18], ["EBV", "SPECIES", 15, 18], ["Active primary EBV infection", "PROBLEM", 0, 28], ["transplantation", "TREATMENT", 54, 69], ["primary", "OBSERVATION_MODIFIER", 7, 14], ["EBV", "OBSERVATION_MODIFIER", 15, 18], ["infection", "OBSERVATION", 19, 28]]], ["The type of immunosuppression can alter the risk of development of PTLD, with higher incidence rates observed in patients receiving cytolytic therapies, including antithymocyte globulin and OKT3 [74] .", [["PTLD", "DISEASE", 67, 71], ["antithymocyte globulin", "CHEMICAL", 163, 185], ["OKT3", "CHEMICAL", 190, 194], ["patients", "ORGANISM", 113, 121], ["antithymocyte globulin", "SIMPLE_CHEMICAL", 163, 185], ["OKT3", "GENE_OR_GENE_PRODUCT", 190, 194], ["antithymocyte globulin", "PROTEIN", 163, 185], ["OKT3", "PROTEIN", 190, 194], ["patients", "SPECIES", 113, 121], ["immunosuppression", "TREATMENT", 12, 29], ["PTLD", "PROBLEM", 67, 71], ["higher incidence rates", "PROBLEM", 78, 100], ["cytolytic therapies", "TREATMENT", 132, 151], ["antithymocyte globulin", "TREATMENT", 163, 185], ["OKT3", "TREATMENT", 190, 194], ["immunosuppression", "OBSERVATION", 12, 29], ["PTLD", "OBSERVATION", 67, 71]]], ["Fludarabine, azathioprine, and other agents causing profound T-cell suppression or mutagenicity are also implicated in PTLD pathogenesis [75, 76] .Epstein-Barr VirusPTLD is divided into four major histopathologic subtypes with corresponding clinical and biologic features, as described in the World Health Organization (WHO) subclassification scheme [77] .", [["T-cell", "ANATOMY", 61, 67], ["Fludarabine", "CHEMICAL", 0, 11], ["azathioprine", "CHEMICAL", 13, 25], ["PTLD", "DISEASE", 119, 123], ["Fludarabine", "CHEMICAL", 0, 11], ["azathioprine", "CHEMICAL", 13, 25], ["Fludarabine", "SIMPLE_CHEMICAL", 0, 11], ["azathioprine", "SIMPLE_CHEMICAL", 13, 25], ["T-cell", "CELL", 61, 67], ["PTLD", "CANCER", 119, 123], ["Epstein-Barr VirusPTLD", "ORGANISM", 147, 169], ["Epstein-Barr VirusPTLD", "PROTEIN", 147, 169], ["Epstein-Barr VirusPTLD", "SPECIES", 147, 169], ["Fludarabine", "TREATMENT", 0, 11], ["azathioprine", "TREATMENT", 13, 25], ["other agents", "TREATMENT", 31, 43], ["profound T-cell suppression", "PROBLEM", 52, 79], ["corresponding clinical and biologic features", "PROBLEM", 227, 271], ["cell suppression", "OBSERVATION", 63, 79], ["Barr VirusPTLD", "OBSERVATION", 155, 169]]], ["These include early lesions, polymorphic PTLD, monomorphic PTLD, and classical Hodgkin lymphoma type PTLD.", [["early lesions", "ANATOMY", 14, 27], ["Hodgkin lymphoma", "ANATOMY", 79, 95], ["PTLD", "DISEASE", 41, 45], ["PTLD", "DISEASE", 59, 63], ["Hodgkin lymphoma", "DISEASE", 79, 95], ["PTLD", "DISEASE", 101, 105], ["lesions", "CANCER", 20, 27], ["Hodgkin lymphoma type PTLD", "CANCER", 79, 105], ["early lesions", "PROBLEM", 14, 27], ["polymorphic PTLD", "PROBLEM", 29, 45], ["monomorphic PTLD", "PROBLEM", 47, 63], ["classical Hodgkin lymphoma type PTLD", "PROBLEM", 69, 105], ["early", "OBSERVATION_MODIFIER", 14, 19], ["lesions", "OBSERVATION", 20, 27], ["polymorphic PTLD", "OBSERVATION", 29, 45], ["monomorphic", "OBSERVATION_MODIFIER", 47, 58], ["PTLD", "OBSERVATION", 59, 63], ["Hodgkin lymphoma", "OBSERVATION", 79, 95]]], ["Although these lesions may bear microscopic resemblance to diseases arising sporadically in otherwise healthy individuals (e.g., infectious mononucleosis, diffuse large B-cell lymphoma, myeloma, Hodgkin lymphoma, and age-related B-cell lymphoproliferative disorder), their occurrence in the setting of transplantation warrants a diagnosis of PTLD given that the natural history and recommended therapy for PTLD differ from those for lesions having similar histologic features in nonimmunocompromised hosts.", [["lesions", "ANATOMY", 15, 22], ["diffuse large B-cell lymphoma", "ANATOMY", 155, 184], ["myeloma", "ANATOMY", 186, 193], ["Hodgkin lymphoma", "ANATOMY", 195, 211], ["B-cell", "ANATOMY", 229, 235], ["lesions", "ANATOMY", 433, 440], ["infectious mononucleosis", "DISEASE", 129, 153], ["large B-cell lymphoma", "DISEASE", 163, 184], ["myeloma", "DISEASE", 186, 193], ["Hodgkin lymphoma", "DISEASE", 195, 211], ["B-cell lymphoproliferative disorder", "DISEASE", 229, 264], ["PTLD", "DISEASE", 342, 346], ["PTLD", "DISEASE", 406, 410], ["lesions", "CANCER", 15, 22], ["diffuse large B-cell lymphoma", "CANCER", 155, 184], ["myeloma", "CANCER", 186, 193], ["Hodgkin lymphoma", "CANCER", 195, 211], ["B-cell", "CELL", 229, 235], ["PTLD", "CANCER", 342, 346], ["lesions", "PATHOLOGICAL_FORMATION", 433, 440], ["these lesions", "PROBLEM", 9, 22], ["diseases", "PROBLEM", 59, 67], ["infectious mononucleosis", "PROBLEM", 129, 153], ["diffuse large B-cell lymphoma", "PROBLEM", 155, 184], ["myeloma", "PROBLEM", 186, 193], ["Hodgkin lymphoma", "PROBLEM", 195, 211], ["B-cell lymphoproliferative disorder", "PROBLEM", 229, 264], ["transplantation", "TREATMENT", 302, 317], ["PTLD", "PROBLEM", 342, 346], ["therapy", "TREATMENT", 394, 401], ["PTLD", "PROBLEM", 406, 410], ["lesions", "PROBLEM", 433, 440], ["similar histologic features in nonimmunocompromised hosts", "PROBLEM", 448, 505], ["lesions", "OBSERVATION", 15, 22], ["infectious", "OBSERVATION_MODIFIER", 129, 139], ["diffuse", "OBSERVATION_MODIFIER", 155, 162], ["large", "OBSERVATION_MODIFIER", 163, 168], ["B-cell lymphoma", "OBSERVATION", 169, 184], ["myeloma", "OBSERVATION", 186, 193], ["Hodgkin lymphoma", "OBSERVATION", 195, 211], ["cell lymphoproliferative disorder", "OBSERVATION", 231, 264], ["transplantation", "OBSERVATION", 302, 317]]], ["In terms of natural history, PTLD almost always progresses quite rapidly to a fatal conclusion unless promptly recognized and treated [70] .", [["PTLD", "DISEASE", 29, 33], ["PTLD", "PROBLEM", 29, 33]]], ["The ability to reduce or eliminate immunosuppressive drugs is a helpful strategy for restoring natural antiviral and antineoplastic immunity.Epstein-Barr VirusBiopsy is necessary to confirm a diagnosis of PTLD and to rule out other neoplastic or infectious lesions [73] .", [["antineoplastic", "ANATOMY", 117, 131], ["neoplastic", "ANATOMY", 232, 242], ["lesions", "ANATOMY", 257, 264], ["PTLD", "DISEASE", 205, 209], ["antineoplastic", "CANCER", 117, 131], ["Epstein-Barr VirusBiopsy", "ORGANISM", 141, 165], ["PTLD", "CANCER", 205, 209], ["immunosuppressive drugs", "TREATMENT", 35, 58], ["restoring natural antiviral", "TREATMENT", 85, 112], ["antineoplastic immunity", "TREATMENT", 117, 140], ["PTLD", "PROBLEM", 205, 209], ["other neoplastic or infectious lesions", "PROBLEM", 226, 264], ["PTLD", "OBSERVATION", 205, 209], ["neoplastic", "OBSERVATION", 232, 242], ["infectious", "OBSERVATION_MODIFIER", 246, 256]]], ["Histochemical stains are helpful in narrowing the differential diagnosis.", [["Histochemical stains", "TEST", 0, 20], ["narrowing", "OBSERVATION", 36, 45]]], ["Immunohistochemistry is somewhat less reliable, since viral proteins such as LMP1, LMP2, EBNA1, and EBNA2 may be expressed focally or inconsistently in PTLD cases with EBV infection [78] .Epstein-Barr VirusEBV load testing is commonly used to assist in diagnosis and monitoring of transplant recipients, despite a paucity of clinical trials demonstrating the utility of EBV DNA measurement in such settings.", [["PTLD", "DISEASE", 152, 156], ["EBV infection", "DISEASE", 168, 181], ["LMP1", "GENE_OR_GENE_PRODUCT", 77, 81], ["LMP2", "GENE_OR_GENE_PRODUCT", 83, 87], ["EBNA1", "GENE_OR_GENE_PRODUCT", 89, 94], ["EBNA2", "GENE_OR_GENE_PRODUCT", 100, 105], ["PTLD", "CANCER", 152, 156], ["EBV", "ORGANISM", 168, 171], ["Epstein-Barr VirusEBV", "ORGANISM", 188, 209], ["EBV", "ORGANISM", 370, 373], ["DNA", "CELLULAR_COMPONENT", 374, 377], ["viral proteins", "PROTEIN", 54, 68], ["LMP1", "PROTEIN", 77, 81], ["LMP2", "PROTEIN", 83, 87], ["EBNA1", "PROTEIN", 89, 94], ["EBNA2", "PROTEIN", 100, 105], ["EBV", "SPECIES", 168, 171], ["EBV", "SPECIES", 370, 373], ["Immunohistochemistry", "TEST", 0, 20], ["viral proteins", "TEST", 54, 68], ["LMP1", "TEST", 77, 81], ["LMP2", "TEST", 83, 87], ["EBNA1", "TEST", 89, 94], ["EBNA2", "TEST", 100, 105], ["EBV infection", "PROBLEM", 168, 181], ["Barr VirusEBV load testing", "TEST", 196, 222], ["transplant recipients", "TREATMENT", 281, 302], ["EBV DNA measurement", "TEST", 370, 389], ["less reliable", "OBSERVATION_MODIFIER", 33, 46]]], ["Indications for EBV load testing in an immunosuppressed transplant recipient typically include lymphadenopathy or other mass lesion, organ dysfunction, fever, malaise, or other signs and symptoms suggestive of PTLD.", [["mass lesion", "ANATOMY", 120, 131], ["organ", "ANATOMY", 133, 138], ["lymphadenopathy", "DISEASE", 95, 110], ["organ dysfunction", "DISEASE", 133, 150], ["fever", "DISEASE", 152, 157], ["malaise", "DISEASE", 159, 166], ["PTLD", "DISEASE", 210, 214], ["EBV", "ORGANISM", 16, 19], ["organ", "ORGAN", 133, 138], ["EBV load testing", "TEST", 16, 32], ["an immunosuppressed transplant recipient", "TREATMENT", 36, 76], ["lymphadenopathy", "PROBLEM", 95, 110], ["other mass lesion", "PROBLEM", 114, 131], ["organ dysfunction", "PROBLEM", 133, 150], ["fever", "PROBLEM", 152, 157], ["malaise", "PROBLEM", 159, 166], ["other signs and symptoms", "PROBLEM", 171, 195], ["PTLD", "PROBLEM", 210, 214], ["EBV load", "OBSERVATION", 16, 24], ["lymphadenopathy", "OBSERVATION", 95, 110], ["mass", "OBSERVATION", 120, 124], ["organ", "ANATOMY", 133, 138], ["dysfunction", "OBSERVATION", 139, 150], ["PTLD", "OBSERVATION", 210, 214]]], ["In addition, routine monitoring of EBV load in highrisk patients can help identify PTLD before signs and symptoms appear [79, 80] .", [["PTLD", "DISEASE", 83, 87], ["EBV", "ORGANISM", 35, 38], ["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64], ["EBV", "SPECIES", 35, 38], ["routine monitoring", "TEST", 13, 31], ["EBV load", "PROBLEM", 35, 43], ["PTLD", "PROBLEM", 83, 87], ["symptoms", "PROBLEM", 105, 113]]], ["An EBV load above the laboratory's established threshold for PTLD should be conveyed to the clinician immediately so it may trigger a search for putative sites of disease followed by biopsy, when reasonable, to establish a histopathologic diagnosis.", [["sites", "ANATOMY", 154, 159], ["PTLD", "DISEASE", 61, 65], ["EBV", "ORGANISM", 3, 6], ["An EBV load", "TEST", 0, 11], ["PTLD", "PROBLEM", 61, 65], ["putative sites of disease", "PROBLEM", 145, 170], ["biopsy", "TEST", 183, 189], ["a histopathologic diagnosis", "TEST", 221, 248], ["EBV load", "OBSERVATION", 3, 11]]], ["Even in the absence of biopsy-diagnosed PTLD, preemptive intervention may be 8Epstein-Barr VirusThe Scientific World Journal used to resolve laboratory-detected disease [71] .", [["PTLD", "DISEASE", 40, 44], ["8Epstein-Barr Virus", "ORGANISM", 77, 96], ["biopsy", "TEST", 23, 29], ["PTLD", "PROBLEM", 40, 44], ["preemptive intervention", "TREATMENT", 46, 69], ["Barr Virus", "PROBLEM", 86, 96], ["disease", "PROBLEM", 161, 168], ["biopsy", "OBSERVATION", 23, 29]]], ["Preemptive therapy may include reducing immunosuppression and infusing anti-CD20 antibody or donor T cells.", [["donor T cells", "ANATOMY", 93, 106], ["anti-CD20 antibody", "GENE_OR_GENE_PRODUCT", 71, 89], ["donor T cells", "CELL", 93, 106], ["anti-CD20 antibody", "PROTEIN", 71, 89], ["donor T cells", "CELL_TYPE", 93, 106], ["Preemptive therapy", "TREATMENT", 0, 18], ["reducing immunosuppression", "TREATMENT", 31, 57], ["infusing anti-CD20 antibody", "TREATMENT", 62, 89], ["donor T cells", "PROBLEM", 93, 106]]], ["Patients at high risk for PTLD (e.g., those who are intensely immunosuppressed and who were seronegative at the time of transplant) tend to be monitored frequently (e.g., weekly in the first few months after transplant and then monthly) so that preemptive therapy may be considered [71, 81] .", [["PTLD", "DISEASE", 26, 30], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["PTLD", "PROBLEM", 26, 30], ["transplant", "TREATMENT", 120, 130], ["transplant", "TREATMENT", 208, 218], ["preemptive therapy", "TREATMENT", 245, 263]]], ["Optimally designed trials should measure EBV load once monthly during the first year, with some patients continuing to be frequently monitored beyond the first year if they have a history of high EBV loads, if their drug regimen is particularly immunosuppressive, or in the aftermath of discontinuing antiviral prophylaxis.", [["EBV", "ORGANISM", 41, 44], ["patients", "ORGANISM", 96, 104], ["EBV", "ORGANISM", 196, 199], ["patients", "SPECIES", 96, 104], ["EBV load", "PROBLEM", 41, 49], ["high EBV loads", "PROBLEM", 191, 205], ["their drug regimen", "TREATMENT", 210, 228], ["antiviral prophylaxis", "TREATMENT", 301, 322]]], ["The European Best Practice Guidelines for Renal Transplantation recommend using EBV load to gauge intervention [73] .", [["Renal", "ANATOMY", 42, 47], ["Renal", "ORGAN", 42, 47], ["EBV", "ORGANISM", 80, 83], ["Renal Transplantation", "TREATMENT", 42, 63], ["EBV load to gauge intervention", "TREATMENT", 80, 110], ["Renal", "ANATOMY", 42, 47], ["Transplantation", "OBSERVATION", 48, 63]]], ["In its practice guidelines, the \"Kidney Disease: Improving Global Outcomes\" Transplant Work Group recommends that high-risk renal transplant patients be tested for EBV nucleic acid once within the first week after transplant, then at least monthly for 3 to 6 months, and then every 3 months for the rest of the first year.", [["Kidney", "ANATOMY", 33, 39], ["renal", "ANATOMY", 124, 129], ["Kidney Disease", "DISEASE", 33, 47], ["nucleic acid", "CHEMICAL", 168, 180], ["Kidney", "ORGAN", 33, 39], ["renal", "ORGAN", 124, 129], ["patients", "ORGANISM", 141, 149], ["EBV", "ORGANISM", 164, 167], ["patients", "SPECIES", 141, 149], ["EBV", "SPECIES", 164, 167], ["the \"Kidney Disease", "PROBLEM", 28, 47], ["high-risk renal transplant", "TREATMENT", 114, 140], ["EBV nucleic acid", "PROBLEM", 164, 180], ["transplant", "TREATMENT", 214, 224], ["Kidney", "ANATOMY", 33, 39], ["Disease", "OBSERVATION", 40, 47], ["renal", "ANATOMY", 124, 129], ["transplant", "OBSERVATION", 130, 140]]], ["Additional EBV testing is recommended after treatment for acute rejection [82] .Epstein-Barr VirusClinical management of PTLD typically involves reducing iatrogenic immunosuppression so that natural immunity against EBV and the neoplastic clone is restored [71, 82] .", [["neoplastic clone", "ANATOMY", 228, 244], ["PTLD", "DISEASE", 121, 125], ["EBV", "ORGANISM", 11, 14], ["Epstein-Barr VirusClinical", "ORGANISM", 80, 106], ["EBV", "ORGANISM", 216, 219], ["neoplastic clone", "CELL", 228, 244], ["EBV", "SPECIES", 11, 14], ["EBV", "SPECIES", 216, 219], ["Additional EBV testing", "TEST", 0, 22], ["treatment", "TREATMENT", 44, 53], ["acute rejection", "PROBLEM", 58, 73], ["Barr VirusClinical management", "TREATMENT", 88, 117], ["PTLD", "PROBLEM", 121, 125], ["iatrogenic immunosuppression", "TREATMENT", 154, 182], ["EBV", "PROBLEM", 216, 219], ["the neoplastic clone", "PROBLEM", 224, 244], ["acute", "OBSERVATION_MODIFIER", 58, 63], ["rejection", "OBSERVATION", 64, 73], ["PTLD", "OBSERVATION", 121, 125]]], ["Complementary interventions include infusing donor lymphocytes, infusing EBV-specific cytotoxic T cells that are grown ex vivo by exposing HLA-matched T cells to EBV antigens [83] [84] [85] and infusing anti-CD20 monoclonal antibody (e.g., rituximab) [86] [87] [88] .", [["lymphocytes", "ANATOMY", 51, 62], ["cytotoxic T cells", "ANATOMY", 86, 103], ["T cells", "ANATOMY", 151, 158], ["rituximab", "CHEMICAL", 240, 249], ["lymphocytes", "CELL", 51, 62], ["EBV", "ORGANISM", 73, 76], ["cytotoxic T cells", "CELL", 86, 103], ["T cells", "CELL", 151, 158], ["EBV", "ORGANISM", 162, 165], ["anti-CD20", "GENE_OR_GENE_PRODUCT", 203, 212], ["rituximab", "SIMPLE_CHEMICAL", 240, 249], ["donor lymphocytes", "CELL_TYPE", 45, 62], ["cytotoxic T cells", "CELL_TYPE", 86, 103], ["T cells", "CELL_TYPE", 151, 158], ["anti-CD20 monoclonal antibody", "PROTEIN", 203, 232], ["Complementary interventions", "TREATMENT", 0, 27], ["infusing donor lymphocytes", "TREATMENT", 36, 62], ["infusing EBV", "TREATMENT", 64, 76], ["specific cytotoxic T cells", "PROBLEM", 77, 103], ["HLA", "TEST", 139, 142], ["EBV antigens", "TEST", 162, 174], ["anti-CD20 monoclonal antibody", "TEST", 203, 232], ["rituximab", "TEST", 240, 249]]], ["If initial intervention is insufficient, more traditional cancer treatment with radiation and multidrug chemotherapy is used [72] .", [["cancer", "ANATOMY", 58, 64], ["cancer", "DISEASE", 58, 64], ["cancer", "CANCER", 58, 64], ["initial intervention", "TREATMENT", 3, 23], ["traditional cancer treatment", "TREATMENT", 46, 74], ["radiation and multidrug chemotherapy", "TREATMENT", 80, 116], ["cancer", "OBSERVATION", 58, 64]]], ["Antiviral therapy with acyclovir or ganciclovir remains controversial as these agents are not active against the latent form of EBV found in PTLD.", [["acyclovir", "CHEMICAL", 23, 32], ["ganciclovir", "CHEMICAL", 36, 47], ["PTLD", "DISEASE", 141, 145], ["acyclovir", "CHEMICAL", 23, 32], ["ganciclovir", "CHEMICAL", 36, 47], ["acyclovir", "SIMPLE_CHEMICAL", 23, 32], ["ganciclovir", "SIMPLE_CHEMICAL", 36, 47], ["EBV", "ORGANISM", 128, 131], ["PTLD", "CANCER", 141, 145], ["EBV", "SPECIES", 128, 131], ["Antiviral therapy", "TREATMENT", 0, 17], ["acyclovir", "TREATMENT", 23, 32], ["ganciclovir", "TREATMENT", 36, 47], ["EBV", "PROBLEM", 128, 131], ["PTLD", "PROBLEM", 141, 145], ["EBV", "OBSERVATION", 128, 131]]], ["Outcomes with PTLD in renal transplant recipients vary depending on the site of involvement.", [["renal", "ANATOMY", 22, 27], ["PTLD", "DISEASE", 14, 18], ["renal", "ORGAN", 22, 27], ["PTLD", "PROBLEM", 14, 18], ["renal transplant recipients", "TREATMENT", 22, 49], ["PTLD", "OBSERVATION", 14, 18], ["renal", "ANATOMY", 22, 27], ["transplant", "OBSERVATION", 28, 38]]], ["Patients with isolated allograft involvement have a five-year survival of approximately 68% compared with those patients with PTLD extending beyond the transplanted kidney whose five-year survival varied between 36 and 38 percent [89] .Human Herpesvirus 6, Human Herpesvirus 7, and Human Herpesvirus 8Human herpesvirus 6 and human herpesvirus 7 (HHV 6 and HHV 7) belong to subfamily Betaherpesvirinae, genus Roseolovirus, species Human herpesvirus 6 and human herpesvirus 7.", [["allograft", "ANATOMY", 23, 32], ["kidney", "ANATOMY", 165, 171], ["PTLD", "DISEASE", 126, 130], ["Patients", "ORGANISM", 0, 8], ["allograft", "ORGAN", 23, 32], ["patients", "ORGANISM", 112, 120], ["kidney", "ORGAN", 165, 171], ["Human Herpesvirus 6", "ORGANISM", 236, 255], ["Human Herpesvirus 7", "ORGANISM", 257, 276], ["Human Herpesvirus 8Human herpesvirus 6", "ORGANISM", 282, 320], ["human herpesvirus 7", "ORGANISM", 325, 344], ["HHV 6", "ORGANISM", 346, 351], ["HHV 7", "ORGANISM", 356, 361], ["Betaherpesvirinae", "GENE_OR_GENE_PRODUCT", 383, 400], ["species", "ORGANISM", 422, 429], ["Human herpesvirus 6", "ORGANISM", 430, 449], ["human herpesvirus 7", "ORGANISM", 454, 473], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 112, 120], ["Human", "SPECIES", 236, 241], ["Human", "SPECIES", 257, 262], ["Herpesvirus", "SPECIES", 263, 274], ["Human", "SPECIES", 282, 287], ["Herpesvirus 8Human herpesvirus", "SPECIES", 288, 318], ["human", "SPECIES", 325, 330], ["herpesvirus", "SPECIES", 331, 342], ["Human herpesvirus", "SPECIES", 430, 447], ["human", "SPECIES", 454, 459], ["herpesvirus", "SPECIES", 460, 471], ["Human Herpesvirus 6", "SPECIES", 236, 255], ["Human Herpesvirus 7", "SPECIES", 257, 276], ["Human Herpesvirus 8Human herpesvirus 6", "SPECIES", 282, 320], ["human herpesvirus 7", "SPECIES", 325, 344], ["HHV", "SPECIES", 346, 349], ["HHV", "SPECIES", 356, 359], ["Human herpesvirus 6", "SPECIES", 430, 449], ["human herpesvirus 7", "SPECIES", 454, 473], ["isolated allograft involvement", "PROBLEM", 14, 44], ["PTLD", "PROBLEM", 126, 130], ["Human Herpesvirus", "TEST", 236, 253], ["Human Herpesvirus", "TEST", 257, 274], ["Human Herpesvirus 8Human herpesvirus", "TREATMENT", 282, 318], ["human herpesvirus", "TEST", 325, 342], ["HHV", "PROBLEM", 356, 359], ["allograft", "OBSERVATION", 23, 32], ["PTLD", "OBSERVATION", 126, 130], ["transplanted", "ANATOMY_MODIFIER", 152, 164], ["kidney", "ANATOMY", 165, 171]]], ["Both viruses are ubiquitous with a high seroprevalence in adults.", [["viruses", "OBSERVATION", 5, 12]]], ["After primary infection, these viruses establish a latent or persistent infection that remains for the lifetime of the host.", [["primary infection", "DISEASE", 6, 23], ["infection", "DISEASE", 72, 81], ["primary infection", "PROBLEM", 6, 23], ["these viruses", "PROBLEM", 25, 38], ["persistent infection", "PROBLEM", 61, 81], ["infection", "OBSERVATION", 14, 23], ["latent", "OBSERVATION_MODIFIER", 51, 57], ["persistent", "OBSERVATION_MODIFIER", 61, 71], ["infection", "OBSERVATION", 72, 81]]], ["The viruses are lymphotropic, but HHV 6 in particular, which uses the CD46 molecule as its receptor, may also infect other cell types, such as monocytes and epithelial and endothelial cells.", [["cell", "ANATOMY", 123, 127], ["monocytes", "ANATOMY", 143, 152], ["epithelial", "ANATOMY", 157, 167], ["endothelial cells", "ANATOMY", 172, 189], ["lymphotropic", "DISEASE", 16, 28], ["HHV 6", "ORGANISM", 34, 39], ["CD46", "GENE_OR_GENE_PRODUCT", 70, 74], ["cell", "CELL", 123, 127], ["monocytes", "CELL", 143, 152], ["epithelial", "CELL", 157, 167], ["endothelial cells", "CELL", 172, 189], ["CD46 molecule", "PROTEIN", 70, 83], ["monocytes", "CELL_TYPE", 143, 152], ["epithelial and endothelial cells", "CELL_TYPE", 157, 189], ["HHV", "SPECIES", 34, 37], ["lymphotropic", "PROBLEM", 16, 28], ["HHV", "PROBLEM", 34, 37], ["the CD46 molecule", "TREATMENT", 66, 83], ["monocytes", "TEST", 143, 152], ["epithelial and endothelial cells", "PROBLEM", 157, 189], ["viruses", "OBSERVATION", 4, 11], ["lymphotropic", "OBSERVATION", 16, 28], ["cell types", "OBSERVATION", 123, 133], ["epithelial", "ANATOMY_MODIFIER", 157, 167], ["endothelial cells", "OBSERVATION", 172, 189]]], ["HHV-6 isolates are classified into two variants (termed HHV 6A and HHV 6B) on the basis of distinct genetic, antigenic, and biological characteristics.", [["HHV-6 isolates", "ORGANISM", 0, 14], ["HHV 6A", "ORGANISM", 56, 62], ["HHV 6B", "ORGANISM", 67, 73], ["HHV-", "SPECIES", 0, 4], ["HHV-6", "SPECIES", 0, 5], ["HHV", "SPECIES", 56, 59], ["HHV", "SPECIES", 67, 70], ["HHV", "TEST", 0, 3], ["distinct", "OBSERVATION_MODIFIER", 91, 99], ["genetic", "OBSERVATION", 100, 107]]], ["Most infections in renal transplant recipients are due to HHV 6B.", [["renal transplant", "ANATOMY", 19, 35], ["infections", "DISEASE", 5, 15], ["renal", "ORGAN", 19, 24], ["HHV 6B", "ORGANISM", 58, 64], ["HHV", "SPECIES", 58, 61], ["Most infections", "PROBLEM", 0, 15], ["renal transplant recipients", "TREATMENT", 19, 46], ["HHV 6B", "PROBLEM", 58, 64], ["infections", "OBSERVATION", 5, 15], ["renal", "ANATOMY", 19, 24], ["transplant", "OBSERVATION", 25, 35]]], ["HHV7 uses the CD4 molecule as its receptor and is more strictly lymphotropic.The stimulus for reactivation of beta-herpesviruses in renal transplant recipients is an immunosuppressive regimen.", [["renal transplant", "ANATOMY", 132, 148], ["lymphotropic", "DISEASE", 64, 76], ["HHV7", "GENE_OR_GENE_PRODUCT", 0, 4], ["CD4", "GENE_OR_GENE_PRODUCT", 14, 17], ["beta", "GENE_OR_GENE_PRODUCT", 110, 114], ["renal", "ORGAN", 132, 137], ["HHV7", "PROTEIN", 0, 4], ["CD4 molecule", "PROTEIN", 14, 26], ["beta-herpesviruses", "PROTEIN", 110, 128], ["HHV7", "SPECIES", 0, 4], ["the CD4 molecule", "TREATMENT", 10, 26], ["The stimulus", "TREATMENT", 77, 89], ["beta-herpesviruses", "TREATMENT", 110, 128], ["renal transplant recipients", "TREATMENT", 132, 159], ["an immunosuppressive regimen", "TREATMENT", 163, 191], ["CD4 molecule", "OBSERVATION", 14, 26], ["more strictly", "OBSERVATION_MODIFIER", 50, 63], ["lymphotropic", "OBSERVATION", 64, 76], ["renal", "ANATOMY", 132, 137], ["transplant", "OBSERVATION", 138, 148], ["immunosuppressive regimen", "OBSERVATION", 166, 191]]], ["In addition, these viruses possess immunomodulating properties, including the ability to alter the expression of immune activation molecules, modulate expression of several cytokines and chemokines and induce apoptosis in lymphocytes, which may contribute to immunosuppression.", [["lymphocytes", "ANATOMY", 222, 233], ["lymphocytes", "CELL", 222, 233], ["immune activation molecules", "PROTEIN", 113, 140], ["cytokines", "PROTEIN", 173, 182], ["chemokines", "PROTEIN", 187, 197], ["lymphocytes", "CELL_TYPE", 222, 233], ["immunomodulating properties", "TREATMENT", 35, 62], ["immune activation molecules", "PROBLEM", 113, 140], ["several cytokines", "TREATMENT", 165, 182], ["chemokines", "TREATMENT", 187, 197], ["apoptosis in lymphocytes", "PROBLEM", 209, 233], ["immunosuppression", "TREATMENT", 259, 276], ["viruses", "OBSERVATION", 19, 26], ["may contribute to", "UNCERTAINTY", 241, 258], ["immunosuppression", "OBSERVATION", 259, 276]]], ["Productive infection of CD4 T cells results in cytopathic effects and cell destruction [92] .", [["CD4 T cells", "ANATOMY", 24, 35], ["cell", "ANATOMY", 70, 74], ["infection", "DISEASE", 11, 20], ["CD4 T cells", "CELL", 24, 35], ["cell", "CELL", 70, 74], ["CD4 T cells", "CELL_TYPE", 24, 35], ["Productive infection of CD4 T cells", "PROBLEM", 0, 35], ["cytopathic effects", "PROBLEM", 47, 65], ["cell destruction", "PROBLEM", 70, 86], ["infection", "OBSERVATION", 11, 20], ["cytopathic", "OBSERVATION_MODIFIER", 47, 57], ["cell destruction", "OBSERVATION", 70, 86]]], ["The ubiquitous nature of HHV 6 and HHV 7 creates conditions for the development of concurrent infection and interaction between these viruses.", [["infection", "DISEASE", 94, 103], ["HHV 6", "ORGANISM", 25, 30], ["HHV 7", "ORGANISM", 35, 40], ["HHV", "SPECIES", 25, 28], ["HHV", "SPECIES", 35, 38], ["HHV", "PROBLEM", 25, 28], ["HHV", "PROBLEM", 35, 38], ["concurrent infection", "PROBLEM", 83, 103], ["these viruses", "PROBLEM", 128, 141], ["infection", "OBSERVATION", 94, 103]]], ["The kinetics of the activation of these viruses during the posttransplantation period suggest that HHV 7 may act as a cofactor for HHV 6 and CMV reactivation, while both HHV 6 and HHV 7 may act as cofactors in the pathogenesis of CMV disease and acute rejection [4, 5, 11] HHV 6 has been associated with fever, rash, encephalitis, hepatitis, myelosuppression, and interstitial pneumonitis [93] .", [["interstitial", "ANATOMY", 364, 376], ["CMV disease", "DISEASE", 230, 241], ["fever", "DISEASE", 304, 309], ["rash", "DISEASE", 311, 315], ["encephalitis", "DISEASE", 317, 329], ["hepatitis", "DISEASE", 331, 340], ["myelosuppression", "DISEASE", 342, 358], ["interstitial pneumonitis", "DISEASE", 364, 388], ["HHV 7", "ORGANISM", 99, 104], ["HHV 6", "ORGANISM", 131, 136], ["CMV", "ORGANISM", 141, 144], ["HHV 6", "ORGANISM", 170, 175], ["HHV 7", "ORGANISM", 180, 185], ["CMV", "ORGANISM", 230, 233], ["HHV", "SPECIES", 99, 102], ["HHV", "SPECIES", 131, 134], ["CMV", "SPECIES", 141, 144], ["HHV", "SPECIES", 170, 173], ["HHV", "SPECIES", 180, 183], ["CMV", "SPECIES", 230, 233], ["HHV", "SPECIES", 273, 276], ["HHV", "PROBLEM", 99, 102], ["HHV", "PROBLEM", 131, 134], ["CMV reactivation", "PROBLEM", 141, 157], ["HHV", "PROBLEM", 180, 183], ["CMV disease", "PROBLEM", 230, 241], ["acute rejection", "PROBLEM", 246, 261], ["fever", "PROBLEM", 304, 309], ["rash", "PROBLEM", 311, 315], ["encephalitis", "PROBLEM", 317, 329], ["hepatitis", "PROBLEM", 331, 340], ["myelosuppression", "PROBLEM", 342, 358], ["interstitial pneumonitis", "PROBLEM", 364, 388], ["viruses", "OBSERVATION", 40, 47], ["CMV disease", "OBSERVATION", 230, 241], ["acute", "OBSERVATION_MODIFIER", 246, 251], ["rejection", "OBSERVATION", 252, 261], ["associated with", "UNCERTAINTY", 288, 303], ["fever", "OBSERVATION", 304, 309], ["rash", "OBSERVATION", 311, 315], ["encephalitis", "OBSERVATION", 317, 329], ["hepatitis", "OBSERVATION", 331, 340], ["myelosuppression", "OBSERVATION", 342, 358], ["interstitial", "ANATOMY_MODIFIER", 364, 376], ["pneumonitis", "OBSERVATION", 377, 388]]], ["Diagnoses of HHV 6 and HHV 7 infections are made by qualitative and quantitative molecular assays, by tissue immunohistochemistry, and/or peripheral blood mononuclear cell culture.", [["tissue", "ANATOMY", 102, 108], ["peripheral blood mononuclear cell", "ANATOMY", 138, 171], ["infections", "DISEASE", 29, 39], ["HHV 6", "ORGANISM", 13, 18], ["HHV 7", "ORGANISM", 23, 28], ["tissue", "TISSUE", 102, 108], ["peripheral blood mononuclear cell culture", "CELL", 138, 179], ["peripheral blood mononuclear cell culture", "CELL_LINE", 138, 179], ["HHV", "SPECIES", 13, 16], ["HHV", "SPECIES", 23, 26], ["HHV", "PROBLEM", 13, 16], ["HHV 7 infections", "PROBLEM", 23, 39], ["quantitative molecular assays", "TEST", 68, 97], ["tissue immunohistochemistry", "TEST", 102, 129], ["peripheral blood mononuclear cell culture", "TEST", 138, 179], ["peripheral", "ANATOMY_MODIFIER", 138, 148], ["blood", "ANATOMY", 149, 154], ["mononuclear cell", "OBSERVATION", 155, 171]]], ["Treatment is similar to CMV and should involve reduction of immunosuppression and ganciclovir, but cidofovir and foscarnet have also been utilized [11] .Human Herpesvirus 6, Human Herpesvirus 7, and Human Herpesvirus 8Human herpesvirus 8 (HHV 8) belongs to subfamily Gammaherpesvirinae, genus Rhadinovirus, species Human herpesvirus 8.", [["ganciclovir", "CHEMICAL", 82, 93], ["cidofovir", "CHEMICAL", 99, 108], ["foscarnet", "CHEMICAL", 113, 122], ["ganciclovir", "CHEMICAL", 82, 93], ["cidofovir", "CHEMICAL", 99, 108], ["foscarnet", "CHEMICAL", 113, 122], ["CMV", "ORGANISM", 24, 27], ["ganciclovir", "SIMPLE_CHEMICAL", 82, 93], ["cidofovir", "SIMPLE_CHEMICAL", 99, 108], ["foscarnet", "SIMPLE_CHEMICAL", 113, 122], ["Human Herpesvirus 6", "ORGANISM", 153, 172], ["Human Herpesvirus 7", "ORGANISM", 174, 193], ["Human Herpesvirus 8Human herpesvirus 8", "ORGANISM", 199, 237], ["HHV 8", "ORGANISM", 239, 244], ["Gammaherpesvirinae", "GENE_OR_GENE_PRODUCT", 267, 285], ["Human herpesvirus 8", "ORGANISM", 315, 334], ["Human", "SPECIES", 153, 158], ["Human", "SPECIES", 174, 179], ["Herpesvirus", "SPECIES", 180, 191], ["Human", "SPECIES", 199, 204], ["Herpesvirus 8Human herpesvirus", "SPECIES", 205, 235], ["Human", "SPECIES", 315, 320], ["herpesvirus", "SPECIES", 321, 332], ["CMV", "SPECIES", 24, 27], ["Human Herpesvirus 6", "SPECIES", 153, 172], ["Human Herpesvirus 7", "SPECIES", 174, 193], ["Human Herpesvirus 8Human herpesvirus", "SPECIES", 199, 235], ["HHV", "SPECIES", 239, 242], ["Human herpesvirus", "SPECIES", 315, 332], ["Treatment", "TREATMENT", 0, 9], ["CMV", "PROBLEM", 24, 27], ["immunosuppression", "TREATMENT", 60, 77], ["ganciclovir", "TREATMENT", 82, 93], ["cidofovir", "TREATMENT", 99, 108], ["foscarnet", "TREATMENT", 113, 122], ["Human Herpesvirus", "TEST", 153, 170], ["Human Herpesvirus", "TREATMENT", 174, 191], ["Human Herpesvirus 8Human herpesvirus", "TREATMENT", 199, 235], ["CMV", "OBSERVATION", 24, 27]]], ["HHV 8 has been associated with Kaposi's Sarcoma, primary effusive lymphoma, and Multicentric Castleman's Disease (lymphoproliferative disorder).", [["Kaposi's Sarcoma", "ANATOMY", 31, 47], ["primary effusive lymphoma", "ANATOMY", 49, 74], ["Kaposi's Sarcoma", "DISEASE", 31, 47], ["primary effusive lymphoma", "DISEASE", 49, 74], ["Castleman's Disease", "DISEASE", 93, 112], ["lymphoproliferative disorder", "DISEASE", 114, 142], ["HHV 8", "ORGANISM", 0, 5], ["Kaposi's Sarcoma", "CANCER", 31, 47], ["primary effusive lymphoma", "CANCER", 49, 74], ["HHV", "SPECIES", 0, 3], ["HHV", "PROBLEM", 0, 3], ["Kaposi's Sarcoma", "PROBLEM", 31, 47], ["primary effusive lymphoma", "PROBLEM", 49, 74], ["Multicentric Castleman's Disease", "PROBLEM", 80, 112], ["lymphoproliferative disorder", "PROBLEM", 114, 142], ["associated with", "UNCERTAINTY", 15, 30], ["Kaposi", "OBSERVATION", 31, 37], ["Sarcoma", "OBSERVATION", 40, 47], ["effusive lymphoma", "OBSERVATION", 57, 74], ["Multicentric", "OBSERVATION_MODIFIER", 80, 92], ["Castleman", "OBSERVATION", 93, 102], ["lymphoproliferative disorder", "OBSERVATION", 114, 142]]], ["Infection in the renal transplant population is thought to most commonly happen through reactivation of latent virus, although primary infection after transplant can occur and can be acquired through the allograft itself [94] .", [["renal transplant", "ANATOMY", 17, 33], ["allograft", "ANATOMY", 204, 213], ["Infection", "DISEASE", 0, 9], ["primary infection", "DISEASE", 127, 144], ["renal", "ORGAN", 17, 22], ["latent virus", "ORGANISM", 104, 116], ["allograft", "TISSUE", 204, 213], ["Infection in the renal transplant population", "PROBLEM", 0, 44], ["latent virus", "PROBLEM", 104, 116], ["primary infection", "PROBLEM", 127, 144], ["transplant", "TREATMENT", 151, 161], ["renal", "ANATOMY", 17, 22], ["transplant", "OBSERVATION", 23, 33], ["latent", "OBSERVATION_MODIFIER", 104, 110], ["virus", "OBSERVATION", 111, 116], ["primary", "OBSERVATION_MODIFIER", 127, 134], ["infection", "OBSERVATION", 135, 144], ["allograft", "OBSERVATION", 204, 213]]], ["Transplantationassociated Kaposi's Sarcoma occurs in 0.2 to 5% of renal transplant recipients, varying by ethnic group and immunosuppressive regimen [95] [96] [97] .", [["Kaposi's Sarcoma", "ANATOMY", 26, 42], ["renal transplant", "ANATOMY", 66, 82], ["Kaposi's Sarcoma", "DISEASE", 26, 42], ["Kaposi's Sarcoma", "CANCER", 26, 42], ["renal", "ORGAN", 66, 71], ["Transplantationassociated Kaposi's Sarcoma", "PROBLEM", 0, 42], ["renal transplant recipients", "TREATMENT", 66, 93], ["immunosuppressive regimen", "TREATMENT", 123, 148], ["Kaposi", "OBSERVATION", 26, 32], ["Sarcoma", "OBSERVATION", 35, 42], ["renal", "ANATOMY", 66, 71], ["transplant", "OBSERVATION", 72, 82], ["varying", "OBSERVATION_MODIFIER", 95, 102]]], ["Of all of the tumors in solid-organ transplantation, Kaposi's Sarcoma occurs at the shortest interval after transplant.", [["tumors", "ANATOMY", 14, 20], ["solid-organ", "ANATOMY", 24, 35], ["Kaposi's Sarcoma", "ANATOMY", 53, 69], ["tumors", "DISEASE", 14, 20], ["Kaposi's Sarcoma", "DISEASE", 53, 69], ["tumors", "CANCER", 14, 20], ["solid-", "CANCER", 24, 30], ["organ", "ORGAN", 30, 35], ["Kaposi's Sarcoma", "CANCER", 53, 69], ["the tumors", "PROBLEM", 10, 20], ["solid-organ transplantation", "TREATMENT", 24, 51], ["Kaposi's Sarcoma", "PROBLEM", 53, 69], ["transplant", "TREATMENT", 108, 118], ["tumors", "OBSERVATION", 14, 20], ["solid", "OBSERVATION_MODIFIER", 24, 29], ["organ", "ANATOMY", 30, 35], ["transplantation", "OBSERVATION", 36, 51], ["Kaposi", "OBSERVATION", 53, 59], ["Sarcoma", "OBSERVATION", 62, 69], ["transplant", "OBSERVATION", 108, 118]]], ["HHV 8 is thought to lead to Kaposi's Sarcoma through upregulation of vascular endothelial growth factor (VEGF) receptor Flk1/KDR in endothelial cells [98] .", [["Kaposi's Sarcoma", "ANATOMY", 28, 44], ["endothelial cells", "ANATOMY", 132, 149], ["Kaposi's Sarcoma", "DISEASE", 28, 44], ["HHV 8", "ORGANISM", 0, 5], ["Kaposi's Sarcoma", "CANCER", 28, 44], ["vascular endothelial growth factor (VEGF) receptor", "GENE_OR_GENE_PRODUCT", 69, 119], ["Flk1", "GENE_OR_GENE_PRODUCT", 120, 124], ["KDR", "GENE_OR_GENE_PRODUCT", 125, 128], ["endothelial cells", "CELL", 132, 149], ["vascular endothelial growth factor (VEGF) receptor", "PROTEIN", 69, 119], ["Flk1", "PROTEIN", 120, 124], ["KDR", "PROTEIN", 125, 128], ["endothelial cells", "CELL_TYPE", 132, 149], ["HHV", "SPECIES", 0, 3], ["HHV", "PROBLEM", 0, 3], ["Kaposi's Sarcoma", "PROBLEM", 28, 44], ["vascular endothelial growth factor", "PROBLEM", 69, 103], ["receptor Flk1", "TEST", 111, 124], ["KDR", "PROBLEM", 125, 128], ["endothelial cells", "TEST", 132, 149], ["thought to lead to", "UNCERTAINTY", 9, 27], ["Kaposi", "OBSERVATION", 28, 34], ["Sarcoma", "OBSERVATION", 37, 44], ["vascular endothelial", "ANATOMY", 69, 89], ["endothelial", "ANATOMY", 132, 143]]], ["Therapy for Kaposi's Sarcoma includes reduction of immunosuppression and cytotoxic chemotherapy.", [["Kaposi's Sarcoma", "ANATOMY", 12, 28], ["Kaposi's Sarcoma", "DISEASE", 12, 28], ["Kaposi's Sarcoma", "CANCER", 12, 28], ["Therapy", "TREATMENT", 0, 7], ["Kaposi's Sarcoma", "PROBLEM", 12, 28], ["immunosuppression", "TREATMENT", 51, 68], ["cytotoxic chemotherapy", "TREATMENT", 73, 95], ["Kaposi", "OBSERVATION", 12, 18], ["Sarcoma", "OBSERVATION", 21, 28], ["immunosuppression", "OBSERVATION", 51, 68], ["cytotoxic chemotherapy", "OBSERVATION", 73, 95]]], ["Sirolimus (rapamycin), an immunosuppressive drug used in kidney-transplant recipients, probably has antineoplastic effects.", [["kidney", "ANATOMY", 57, 63], ["Sirolimus", "CHEMICAL", 0, 9], ["rapamycin", "CHEMICAL", 11, 20], ["Sirolimus", "CHEMICAL", 0, 9], ["rapamycin", "CHEMICAL", 11, 20], ["Sirolimus", "SIMPLE_CHEMICAL", 0, 9], ["rapamycin", "SIMPLE_CHEMICAL", 11, 20], ["kidney", "ORGAN", 57, 63], ["recipients", "ORGANISM", 75, 85], ["Sirolimus (rapamycin)", "TREATMENT", 0, 21], ["an immunosuppressive drug", "TREATMENT", 23, 48], ["transplant recipients", "TREATMENT", 64, 85], ["antineoplastic effects", "TREATMENT", 100, 122], ["kidney", "ANATOMY", 57, 63], ["transplant recipients", "OBSERVATION", 64, 85], ["antineoplastic effects", "OBSERVATION", 100, 122]]], ["The immunosuppressive and antineoplastic effects of sirolimus may be due to a common mechanism [98] [99] [100] [101] .", [["antineoplastic", "ANATOMY", 26, 40], ["sirolimus", "CHEMICAL", 52, 61], ["sirolimus", "CHEMICAL", 52, 61], ["sirolimus", "SIMPLE_CHEMICAL", 52, 61], ["The immunosuppressive and antineoplastic effects of sirolimus", "TREATMENT", 0, 61]]], ["It is thought that sirolimus inhibits not only production of VEGF but also dampens its effects on endothelial cells, and it has been suggested that sirolimus inhibits the progression of Kaposi's sarcoma in kidney-transplant recipients while exerting an antirejection effect on organ allografts [98] .Human Herpesvirus 6, Human Herpesvirus 7, and Human Herpesvirus 8The Scientific World Journal 9BK and JC VirusBK polyomavirus (BKV), JC polyomavirus (JCV), and Simian virus belong to family Polyomaviridae, genus Polyomavirus.", [["endothelial cells", "ANATOMY", 98, 115], ["Kaposi's sarcoma", "ANATOMY", 186, 202], ["kidney", "ANATOMY", 206, 212], ["organ allografts", "ANATOMY", 277, 293], ["sirolimus", "CHEMICAL", 19, 28], ["sirolimus", "CHEMICAL", 148, 157], ["Kaposi's sarcoma", "DISEASE", 186, 202], ["VirusBK polyomavirus (BKV), JC polyomavirus (JCV)", "DISEASE", 405, 454], ["Simian virus", "DISEASE", 460, 472], ["sirolimus", "CHEMICAL", 19, 28], ["sirolimus", "CHEMICAL", 148, 157], ["sirolimus", "SIMPLE_CHEMICAL", 19, 28], ["VEGF", "GENE_OR_GENE_PRODUCT", 61, 65], ["endothelial cells", "CELL", 98, 115], ["sirolimus", "SIMPLE_CHEMICAL", 148, 157], ["Kaposi's sarcoma", "CANCER", 186, 202], ["kidney", "ORGAN", 206, 212], ["recipients", "ORGANISM", 224, 234], ["organ", "ORGAN", 277, 282], ["Human Herpesvirus 6", "ORGANISM", 300, 319], ["Human Herpesvirus 7", "ORGANISM", 321, 340], ["Human Herpesvirus 8", "ORGANISM", 346, 365], ["JC VirusBK polyomavirus", "ORGANISM", 402, 425], ["BKV", "ORGANISM", 427, 430], ["JC polyomavirus", "ORGANISM", 433, 448], ["JCV", "ORGANISM", 450, 453], ["Simian virus", "ORGANISM", 460, 472], ["VEGF", "PROTEIN", 61, 65], ["endothelial cells", "CELL_TYPE", 98, 115], ["Human", "SPECIES", 300, 305], ["Human", "SPECIES", 321, 326], ["Human", "SPECIES", 346, 351], ["JC polyomavirus", "SPECIES", 433, 448], ["Simian virus", "SPECIES", 460, 472], ["Human Herpesvirus 6", "SPECIES", 300, 319], ["Human Herpesvirus 7", "SPECIES", 321, 340], ["Human Herpesvirus", "SPECIES", 346, 363], ["JC VirusBK polyomavirus", "SPECIES", 402, 425], ["BKV", "SPECIES", 427, 430], ["JC polyomavirus", "SPECIES", 433, 448], ["JCV", "SPECIES", 450, 453], ["Simian virus", "SPECIES", 460, 472], ["sirolimus inhibits", "PROBLEM", 19, 37], ["VEGF", "PROBLEM", 61, 65], ["endothelial cells", "PROBLEM", 98, 115], ["sirolimus", "TREATMENT", 148, 157], ["Kaposi's sarcoma", "PROBLEM", 186, 202], ["transplant recipients", "TREATMENT", 213, 234], ["an antirejection effect", "TREATMENT", 250, 273], ["organ allografts", "TREATMENT", 277, 293], ["Human Herpesvirus", "TEST", 300, 317], ["Human Herpesvirus", "TEST", 321, 338], ["Human Herpesvirus", "TEST", 346, 363], ["JC VirusBK polyomavirus (BKV", "PROBLEM", 402, 430], ["JC polyomavirus (JCV)", "PROBLEM", 433, 454], ["Simian virus", "PROBLEM", 460, 472], ["Polyomaviridae", "TREATMENT", 490, 504], ["genus Polyomavirus", "PROBLEM", 506, 524], ["sirolimus", "OBSERVATION", 19, 28], ["VEGF", "OBSERVATION", 61, 65], ["endothelial cells", "OBSERVATION", 98, 115], ["progression", "OBSERVATION_MODIFIER", 171, 182], ["Kaposi", "OBSERVATION", 186, 192], ["sarcoma", "OBSERVATION", 195, 202], ["kidney", "ANATOMY", 206, 212], ["transplant", "OBSERVATION", 213, 223], ["antirejection", "OBSERVATION", 253, 266], ["genus Polyomavirus", "OBSERVATION", 506, 524]]], ["In the last 10 years, improved immunosuppression drugs have decreased the rates of acute rejection in kidney transplantation but have also led to the emergence of polyomavirus-associated nephropathy (PVAN).", [["kidney", "ANATOMY", 102, 108], ["nephropathy", "DISEASE", 187, 198], ["PVAN", "DISEASE", 200, 204], ["kidney", "ORGAN", 102, 108], ["polyomavirus", "ORGANISM", 163, 175], ["PVAN", "CANCER", 200, 204], ["improved immunosuppression drugs", "TREATMENT", 22, 54], ["acute rejection", "PROBLEM", 83, 98], ["kidney transplantation", "TREATMENT", 102, 124], ["polyomavirus", "PROBLEM", 163, 175], ["associated nephropathy", "PROBLEM", 176, 198], ["acute", "OBSERVATION_MODIFIER", 83, 88], ["rejection", "OBSERVATION", 89, 98], ["kidney", "ANATOMY", 102, 108], ["transplantation", "OBSERVATION", 109, 124], ["polyomavirus", "OBSERVATION", 163, 175], ["nephropathy", "OBSERVATION", 187, 198]]], ["This occurs in 1% to 10% of patients with kidney transplantation and is caused by BK virus in more than 95% of cases.", [["kidney", "ANATOMY", 42, 48], ["patients", "ORGANISM", 28, 36], ["kidney", "ORGAN", 42, 48], ["BK virus", "ORGANISM", 82, 90], ["patients", "SPECIES", 28, 36], ["BK virus", "SPECIES", 82, 90], ["kidney transplantation", "TREATMENT", 42, 64], ["BK virus", "PROBLEM", 82, 90], ["kidney", "ANATOMY", 42, 48], ["transplantation", "OBSERVATION", 49, 64]]], ["Less than 5% of cases are attributed to the JC virus.", [["JC", "DISEASE", 44, 46], ["JC virus", "ORGANISM", 44, 52], ["JC virus", "SPECIES", 44, 52], ["the JC virus", "PROBLEM", 40, 52], ["JC virus", "OBSERVATION", 44, 52]]], ["Initially, lack of recognition or late diagnosis of PVAN resulted in rapid loss of graft function in more than 50% of patients [102, 103] .BK and JC VirusSerological evidence of past BKV exposure has been seen to reach 90% in adolescents and adults around the world and seems not to have changed since the first discovery of BKV in the 1970s.", [["graft", "ANATOMY", 83, 88], ["PVAN", "DISEASE", 52, 56], ["PVAN", "CANCER", 52, 56], ["graft", "TISSUE", 83, 88], ["patients", "ORGANISM", 118, 126], ["BK", "CELL", 139, 141], ["BKV", "ORGANISM", 183, 186], ["BKV", "ORGANISM", 325, 328], ["patients", "SPECIES", 118, 126], ["adolescents", "SPECIES", 226, 237], ["BKV", "SPECIES", 183, 186], ["BKV", "SPECIES", 325, 328], ["PVAN", "TREATMENT", 52, 56], ["rapid loss of graft function", "PROBLEM", 69, 97], ["BK", "PROBLEM", 139, 141], ["past BKV exposure", "PROBLEM", 178, 195], ["BKV", "TEST", 325, 328], ["rapid", "OBSERVATION_MODIFIER", 69, 74], ["loss", "OBSERVATION_MODIFIER", 75, 79], ["graft", "OBSERVATION", 83, 88], ["JC VirusSerological", "OBSERVATION_MODIFIER", 146, 165], ["BKV", "OBSERVATION", 183, 186], ["BKV", "OBSERVATION", 325, 328]]], ["Similar to earlier studies, Hirsch et al. [104] found 80% seropositivity in a prospective study of patients with kidney transplantation.", [["kidney", "ANATOMY", 113, 119], ["patients", "ORGANISM", 99, 107], ["kidney", "ORGAN", 113, 119], ["patients", "SPECIES", 99, 107], ["earlier studies", "TEST", 11, 26], ["a prospective study", "TEST", 76, 95], ["kidney transplantation", "TREATMENT", 113, 135], ["kidney", "ANATOMY", 113, 119], ["transplantation", "OBSERVATION", 120, 135]]], ["Accordingly, mismatched BKV serostatus between donor graft and recipient is significantly less frequent than cytomegalovirus mismatches and, in the absence of change, cannot explain the emergence of PVAN in the last decade.", [["graft", "ANATOMY", 53, 58], ["PVAN", "DISEASE", 199, 203], ["BKV", "ORGANISM", 24, 27], ["graft", "TISSUE", 53, 58], ["cytomegalovirus", "ORGANISM", 109, 124], ["BKV", "SPECIES", 24, 27], ["mismatched BKV serostatus between donor graft", "TREATMENT", 13, 58], ["cytomegalovirus mismatches", "PROBLEM", 109, 135], ["PVAN", "TREATMENT", 199, 203], ["BKV", "OBSERVATION", 24, 27], ["graft", "OBSERVATION", 53, 58], ["significantly", "OBSERVATION_MODIFIER", 76, 89], ["less", "OBSERVATION_MODIFIER", 90, 94], ["mismatches", "OBSERVATION", 125, 135]]], ["However, higher BKV antibody titers in kidney donors and lower titers in recipients have been identified as risk factors for BKV replication and viremia posttransplantation [102] .", [["kidney", "ANATOMY", 39, 45], ["viremia", "DISEASE", 145, 152], ["BKV", "ORGANISM", 16, 19], ["kidney", "ORGAN", 39, 45], ["donors", "ORGANISM", 46, 52], ["recipients", "ORGANISM", 73, 83], ["BKV", "ORGANISM", 125, 128], ["BKV antibody", "PROTEIN", 16, 28], ["BKV", "SPECIES", 16, 19], ["BKV", "SPECIES", 125, 128], ["higher BKV antibody titers", "TEST", 9, 35], ["kidney donors", "PROBLEM", 39, 52], ["lower titers in recipients", "PROBLEM", 57, 83], ["BKV replication", "TREATMENT", 125, 140], ["viremia posttransplantation", "TREATMENT", 145, 172], ["higher", "OBSERVATION_MODIFIER", 9, 15], ["BKV", "OBSERVATION", 16, 19], ["kidney", "ANATOMY", 39, 45], ["lower titers", "OBSERVATION_MODIFIER", 57, 69]]], ["The recent increase in BK infections has been attributed, in part, to the use of more potent immunosuppressive regimens.", [["infections", "DISEASE", 26, 36], ["BK", "ORGANISM", 23, 25], ["BK infections", "PROBLEM", 23, 36], ["more potent immunosuppressive regimens", "TREATMENT", 81, 119], ["increase", "OBSERVATION_MODIFIER", 11, 19], ["BK infections", "OBSERVATION", 23, 36]]], ["However, no specific immunosuppressant medication or combination has been demonstrated to increase the risk of nephropathy.", [["nephropathy", "DISEASE", 111, 122], ["specific immunosuppressant medication", "TREATMENT", 12, 49], ["nephropathy", "PROBLEM", 111, 122], ["no", "UNCERTAINTY", 9, 11], ["nephropathy", "OBSERVATION", 111, 122]]], ["Caucasian race, cadaveric renal transplant, older age, presence of diabetes, and combined kidney and pancreas transplants have all been shown to be associated with BK virus nephropathy [105] .BK and JC VirusPrimary infections with BKV and JCV are typically subclinical or linked to mild respiratory illness and are followed by viral dissemination to the sites of lifelong persistent infection.", [["renal", "ANATOMY", 26, 31], ["kidney", "ANATOMY", 90, 96], ["pancreas", "ANATOMY", 101, 109], ["respiratory", "ANATOMY", 287, 298], ["sites", "ANATOMY", 354, 359], ["diabetes", "DISEASE", 67, 75], ["nephropathy", "DISEASE", 173, 184], ["infections", "DISEASE", 215, 225], ["respiratory illness", "DISEASE", 287, 306], ["infection", "DISEASE", 383, 392], ["renal", "ORGAN", 26, 31], ["kidney", "ORGAN", 90, 96], ["pancreas", "ORGAN", 101, 109], ["BK virus", "ORGANISM", 164, 172], ["JC VirusPrimary", "ORGANISM", 199, 214], ["BKV", "ORGANISM", 231, 234], ["JCV", "ORGANISM", 239, 242], ["BKV", "SPECIES", 231, 234], ["JCV", "SPECIES", 239, 242], ["cadaveric renal transplant", "TREATMENT", 16, 42], ["diabetes", "PROBLEM", 67, 75], ["combined kidney and pancreas transplants", "TREATMENT", 81, 121], ["BK virus nephropathy", "PROBLEM", 164, 184], ["JC VirusPrimary infections", "PROBLEM", 199, 225], ["BKV and JCV", "PROBLEM", 231, 242], ["mild respiratory illness", "PROBLEM", 282, 306], ["viral dissemination", "PROBLEM", 327, 346], ["lifelong persistent infection", "PROBLEM", 363, 392], ["renal", "ANATOMY", 26, 31], ["transplant", "OBSERVATION", 32, 42], ["diabetes", "OBSERVATION", 67, 75], ["kidney", "ANATOMY", 90, 96], ["pancreas", "ANATOMY", 101, 109], ["transplants", "OBSERVATION", 110, 121], ["infections", "OBSERVATION", 215, 225], ["BKV", "OBSERVATION", 231, 234], ["mild", "OBSERVATION_MODIFIER", 282, 286], ["respiratory illness", "OBSERVATION", 287, 306], ["lifelong", "OBSERVATION_MODIFIER", 363, 371], ["persistent", "OBSERVATION_MODIFIER", 372, 382], ["infection", "OBSERVATION", 383, 392]]], ["The major sites of persistence for both BKV and JCV are the cells of the kidney and urinary tract [106] .", [["sites", "ANATOMY", 10, 15], ["cells", "ANATOMY", 60, 65], ["kidney", "ANATOMY", 73, 79], ["urinary tract", "ANATOMY", 84, 97], ["BKV", "ORGANISM", 40, 43], ["JCV", "ORGANISM", 48, 51], ["cells", "CELL", 60, 65], ["kidney", "ORGAN", 73, 79], ["urinary tract", "ORGANISM_SUBDIVISION", 84, 97], ["BKV", "SPECIES", 40, 43], ["JCV", "SPECIES", 48, 51], ["urinary tract", "TEST", 84, 97], ["persistence", "OBSERVATION", 19, 30], ["BKV", "OBSERVATION", 40, 43], ["JCV", "OBSERVATION", 48, 51], ["kidney", "ANATOMY", 73, 79], ["urinary tract", "ANATOMY", 84, 97]]], ["BKV DNA has been found in 30 to 50% of normal kidney tissues, with distribution patterns of small foci throughout the cortex and medulla, and in 40% of ureters.", [["kidney tissues", "ANATOMY", 46, 60], ["foci", "ANATOMY", 98, 102], ["cortex", "ANATOMY", 118, 124], ["medulla", "ANATOMY", 129, 136], ["ureters", "ANATOMY", 152, 159], ["BKV", "ORGANISM", 0, 3], ["DNA", "CELLULAR_COMPONENT", 4, 7], ["kidney tissues", "TISSUE", 46, 60], ["cortex", "CANCER", 118, 124], ["medulla", "ORGAN", 129, 136], ["ureters", "ORGAN", 152, 159], ["BKV DNA", "DNA", 0, 7], ["BKV", "SPECIES", 0, 3], ["BKV DNA", "TEST", 0, 7], ["small foci throughout the cortex and medulla", "PROBLEM", 92, 136], ["30 to 50", "OBSERVATION_MODIFIER", 26, 34], ["normal", "OBSERVATION", 39, 45], ["kidney tissues", "ANATOMY", 46, 60], ["distribution", "OBSERVATION_MODIFIER", 67, 79], ["small", "OBSERVATION_MODIFIER", 92, 97], ["foci", "OBSERVATION", 98, 102], ["cortex", "ANATOMY_MODIFIER", 118, 124], ["medulla", "ANATOMY", 129, 136], ["ureters", "ANATOMY", 152, 159]]], ["JCV DNA can be detected in approximately 10 to 50% of normal kidney samples [106] .", [["kidney samples", "ANATOMY", 61, 75], ["JCV", "ORGANISM", 0, 3], ["DNA", "CELLULAR_COMPONENT", 4, 7], ["kidney", "ORGAN", 61, 67], ["JCV DNA", "DNA", 0, 7], ["JCV", "SPECIES", 0, 3], ["JCV DNA", "PROBLEM", 0, 7], ["normal", "OBSERVATION", 54, 60], ["kidney", "ANATOMY", 61, 67]]], ["Reactivation of latent virus has been reported in old age, pregnancy, and diabetes mellitus, and immunosuppression associated with congenital immunodeficiency, organ transplantation, or HIV infection.", [["organ", "ANATOMY", 160, 165], ["diabetes mellitus", "DISEASE", 74, 91], ["congenital immunodeficiency", "DISEASE", 131, 158], ["HIV infection", "DISEASE", 186, 199], ["organ", "ORGAN", 160, 165], ["HIV", "SPECIES", 186, 189], ["HIV", "SPECIES", 186, 189], ["latent virus", "PROBLEM", 16, 28], ["diabetes mellitus", "PROBLEM", 74, 91], ["immunosuppression", "TREATMENT", 97, 114], ["congenital immunodeficiency", "PROBLEM", 131, 158], ["organ transplantation", "TREATMENT", 160, 181], ["HIV infection", "PROBLEM", 186, 199], ["latent", "OBSERVATION_MODIFIER", 16, 22], ["virus", "OBSERVATION", 23, 28], ["diabetes mellitus", "OBSERVATION", 74, 91], ["congenital", "OBSERVATION_MODIFIER", 131, 141], ["immunodeficiency", "OBSERVATION", 142, 158], ["HIV", "OBSERVATION_MODIFIER", 186, 189], ["infection", "OBSERVATION", 190, 199]]], ["The most striking feature of BK infection in kidney transplant recipients is the lack of fever, malaise, myalgias, leukopenia, anemia, thrombocytopenia, or other symptoms or signs typical of viral infection, despite viral loads exceeding a billion copies/mL in the urine or 100 000 copies/mL in the blood [107] .", [["kidney transplant", "ANATOMY", 45, 62], ["urine", "ANATOMY", 265, 270], ["blood", "ANATOMY", 299, 304], ["BK", "CHEMICAL", 29, 31], ["infection", "DISEASE", 32, 41], ["fever", "DISEASE", 89, 94], ["myalgias", "DISEASE", 105, 113], ["leukopenia", "DISEASE", 115, 125], ["anemia", "DISEASE", 127, 133], ["thrombocytopenia", "DISEASE", 135, 151], ["viral infection", "DISEASE", 191, 206], ["BK", "CELL", 29, 31], ["kidney", "ORGAN", 45, 51], ["urine", "ORGANISM_SUBSTANCE", 265, 270], ["blood", "ORGANISM_SUBSTANCE", 299, 304], ["BK infection", "PROBLEM", 29, 41], ["kidney transplant recipients", "TREATMENT", 45, 73], ["fever", "PROBLEM", 89, 94], ["malaise", "PROBLEM", 96, 103], ["myalgias", "PROBLEM", 105, 113], ["leukopenia", "PROBLEM", 115, 125], ["anemia", "PROBLEM", 127, 133], ["thrombocytopenia", "PROBLEM", 135, 151], ["other symptoms", "PROBLEM", 156, 170], ["viral infection", "PROBLEM", 191, 206], ["viral loads", "PROBLEM", 216, 227], ["the urine", "TEST", 261, 270], ["the blood", "TEST", 295, 304], ["most striking", "OBSERVATION_MODIFIER", 4, 17], ["BK", "OBSERVATION_MODIFIER", 29, 31], ["infection", "OBSERVATION", 32, 41], ["kidney", "ANATOMY", 45, 51], ["transplant", "OBSERVATION", 52, 62], ["anemia", "OBSERVATION", 127, 133], ["thrombocytopenia", "OBSERVATION", 135, 151], ["viral", "OBSERVATION_MODIFIER", 191, 196], ["infection", "OBSERVATION", 197, 206]]], ["BKV nephropathy presents with renal dysfunction without other clinical signs or symptoms.BK and JC VirusAlthough JC virus has been rarely implicated as a cause of nephropathy either alone or in combination with BK, it is more commonly seen as a cause of Progressive Multifocal Leukoencephalopathy, a demyelinating process involving the cerebral white matter.", [["renal", "ANATOMY", 30, 35], ["cerebral white matter", "ANATOMY", 336, 357], ["BKV nephropathy", "DISEASE", 0, 15], ["renal dysfunction", "DISEASE", 30, 47], ["BK", "CHEMICAL", 89, 91], ["nephropathy", "DISEASE", 163, 174], ["Leukoencephalopathy", "DISEASE", 277, 296], ["BKV", "ORGANISM", 0, 3], ["renal", "ORGAN", 30, 35], ["BK", "ORGANISM", 89, 91], ["JC VirusAlthough JC virus", "ORGANISM", 96, 121], ["cerebral", "ORGAN", 336, 344], ["BKV", "SPECIES", 0, 3], ["JC VirusAlthough JC virus", "SPECIES", 96, 121], ["BKV nephropathy", "PROBLEM", 0, 15], ["renal dysfunction", "PROBLEM", 30, 47], ["symptoms", "PROBLEM", 80, 88], ["BK", "PROBLEM", 89, 91], ["JC VirusAlthough JC virus", "PROBLEM", 96, 121], ["nephropathy", "PROBLEM", 163, 174], ["BK", "PROBLEM", 211, 213], ["Progressive Multifocal Leukoencephalopathy", "PROBLEM", 254, 296], ["a demyelinating process involving the cerebral white matter", "PROBLEM", 298, 357], ["nephropathy", "OBSERVATION", 4, 15], ["renal", "ANATOMY", 30, 35], ["dysfunction", "OBSERVATION", 36, 47], ["JC VirusAlthough", "OBSERVATION_MODIFIER", 96, 112], ["JC virus", "OBSERVATION", 113, 121], ["nephropathy", "OBSERVATION", 163, 174], ["Progressive", "OBSERVATION_MODIFIER", 254, 265], ["Multifocal", "OBSERVATION_MODIFIER", 266, 276], ["Leukoencephalopathy", "OBSERVATION", 277, 296], ["demyelinating process", "OBSERVATION", 300, 321], ["cerebral white matter", "ANATOMY", 336, 357]]], ["Presenting symptoms include progressive neurologic impairment, which can progress to dementia [108] .BK and JC VirusLaboratory monitoring strategies for BKV are still evolving.", [["neurologic", "ANATOMY", 40, 50], ["neurologic impairment", "DISEASE", 40, 61], ["dementia", "DISEASE", 85, 93], ["BK", "CELL", 101, 103], ["BKV", "ORGANISM", 153, 156], ["BKV", "SPECIES", 153, 156], ["Presenting symptoms", "PROBLEM", 0, 19], ["progressive neurologic impairment", "PROBLEM", 28, 61], ["dementia", "PROBLEM", 85, 93], ["BK", "TEST", 101, 103], ["JC VirusLaboratory monitoring", "TEST", 108, 137], ["BKV", "PROBLEM", 153, 156], ["progressive", "OBSERVATION_MODIFIER", 28, 39], ["neurologic impairment", "OBSERVATION", 40, 61]]], ["Quantitative nucleic acid-based viral load assay of urine or blood are becoming widely used for BKV screening [107] .", [["urine", "ANATOMY", 52, 57], ["blood", "ANATOMY", 61, 66], ["nucleic acid", "CHEMICAL", 13, 25], ["urine", "ORGANISM_SUBSTANCE", 52, 57], ["blood", "ORGANISM_SUBSTANCE", 61, 66], ["BKV", "ORGANISM", 96, 99], ["BKV", "SPECIES", 96, 99], ["Quantitative nucleic acid", "TEST", 0, 25], ["based viral load assay", "TEST", 26, 48], ["BKV screening", "TEST", 96, 109]]], ["Detectable virus in the blood is more predictive of BKVN than viruria alone.", [["blood", "ANATOMY", 24, 29], ["viruria", "DISEASE", 62, 69], ["blood", "ORGANISM_SUBSTANCE", 24, 29], ["BKVN", "CANCER", 52, 56], ["viruria", "CANCER", 62, 69], ["BKVN", "SPECIES", 52, 56], ["Detectable virus in the blood", "PROBLEM", 0, 29], ["BKVN", "PROBLEM", 52, 56], ["viruria", "PROBLEM", 62, 69], ["virus", "OBSERVATION", 11, 16], ["blood", "ANATOMY", 24, 29]]], ["Some medical centers prefer urine cytology as the primary screening technique [109] .", [["urine", "ANATOMY", 28, 33], ["urine", "ORGANISM_SUBSTANCE", 28, 33], ["urine cytology", "TEST", 28, 42], ["the primary screening technique", "TEST", 46, 77]]], ["While urinary \"decoy cells\" have excellent sensitivity for the detection of overt BKVN, polymerase chain reaction (PCR) is four times more sensitive than urine cytology for monitoring asymptomatic viruria [110] .", [["urinary \"decoy cells", "ANATOMY", 6, 26], ["urine", "ANATOMY", 154, 159], ["urinary", "ORGANISM_SUBSTANCE", 6, 13], ["cells", "CELL", 21, 26], ["urine", "ORGANISM_SUBSTANCE", 154, 159], ["decoy cells", "CELL_TYPE", 15, 26], ["BKVN", "SPECIES", 82, 86], ["urinary \"decoy cells", "PROBLEM", 6, 26], ["overt BKVN", "PROBLEM", 76, 86], ["polymerase chain reaction", "PROBLEM", 88, 113], ["PCR", "TEST", 115, 118], ["urine cytology", "TEST", 154, 168], ["asymptomatic viruria", "PROBLEM", 184, 204]]], ["Additionally, PCR provides a more objective estimate of true viral load and can distinguish BK viruria from JC viruria.", [["viruria", "DISEASE", 95, 102], ["JC viruria", "DISEASE", 108, 118], ["BK viruria", "CANCER", 92, 102], ["BK viruria", "SPECIES", 92, 102], ["JC viruria", "SPECIES", 108, 118], ["PCR", "TEST", 14, 17], ["true viral load", "PROBLEM", 56, 71], ["BK viruria", "PROBLEM", 92, 102], ["JC viruria", "PROBLEM", 108, 118], ["viral load", "OBSERVATION", 61, 71], ["viruria", "OBSERVATION", 95, 102], ["JC viruria", "OBSERVATION", 108, 118]]], ["JCV excretion in the urine is usually insignificant, although very rare cases of JCV associated interstitial nephritis are on record.", [["urine", "ANATOMY", 21, 26], ["interstitial", "ANATOMY", 96, 108], ["JCV", "DISEASE", 81, 84], ["interstitial nephritis", "DISEASE", 96, 118], ["JCV", "ORGANISM", 0, 3], ["urine", "ORGANISM_SUBSTANCE", 21, 26], ["JCV", "ORGANISM", 81, 84], ["JCV", "SPECIES", 0, 3], ["JCV excretion in the urine", "TEST", 0, 26], ["JCV associated interstitial nephritis", "PROBLEM", 81, 118], ["excretion", "OBSERVATION", 4, 13], ["urine", "ANATOMY", 21, 26], ["insignificant", "OBSERVATION_MODIFIER", 38, 51], ["JCV", "OBSERVATION", 81, 84], ["interstitial", "ANATOMY_MODIFIER", 96, 108], ["nephritis", "OBSERVATION", 109, 118]]], ["Decoy cells are not stable, whereas DNA is, and PCR may be used for monitoring of patients at a distance from the transplant center.", [["Decoy cells", "ANATOMY", 0, 11], ["Decoy cells", "CELL", 0, 11], ["DNA", "CELLULAR_COMPONENT", 36, 39], ["patients", "ORGANISM", 82, 90], ["Decoy cells", "CELL_TYPE", 0, 11], ["patients", "SPECIES", 82, 90], ["Decoy cells", "PROBLEM", 0, 11], ["PCR", "TEST", 48, 51], ["not", "UNCERTAINTY", 16, 19], ["stable", "OBSERVATION_MODIFIER", 20, 26], ["transplant", "ANATOMY", 114, 124]]], ["The relative costs of PCR versus cytology are a center-dependent variable.", [["PCR", "TEST", 22, 25], ["cytology", "TEST", 33, 41], ["dependent", "OBSERVATION_MODIFIER", 55, 64], ["variable", "OBSERVATION_MODIFIER", 65, 73]]], ["Laboratory screening for BKV should certainly be done for any unexplained rise in serum creatinine [107] .", [["serum", "ANATOMY", 82, 87], ["creatinine", "CHEMICAL", 88, 98], ["creatinine", "CHEMICAL", 88, 98], ["BKV", "ORGANISM", 25, 28], ["serum", "ORGANISM_SUBSTANCE", 82, 87], ["creatinine", "SIMPLE_CHEMICAL", 88, 98], ["BKV", "SPECIES", 25, 28], ["Laboratory screening", "TEST", 0, 20], ["BKV", "TEST", 25, 28], ["any unexplained rise", "PROBLEM", 58, 78], ["serum creatinine", "TEST", 82, 98]]], ["The cost of screening was found to be substantially offset by the savings related to reductions in immunosuppression following diagnosis of BKVN.", [["BKVN", "DISEASE", 140, 144], ["screening", "TEST", 12, 21], ["immunosuppression", "TREATMENT", 99, 116], ["BKVN", "PROBLEM", 140, 144], ["immunosuppression", "OBSERVATION", 99, 116]]], ["No anti-viral agents were administered.", [["anti-viral agents", "TREATMENT", 3, 20], ["anti-viral agents", "OBSERVATION", 3, 20]]], ["Definitive diagnosis of BKVN requires a biopsy and demonstration of BKV inclusions in tubular epithelial or Bowman's capsular epithelial cells.", [["tubular epithelial", "ANATOMY", 86, 104], ["Bowman's capsular epithelial cells", "ANATOMY", 108, 142], ["BKVN", "DISEASE", 24, 28], ["BKVN", "CANCER", 24, 28], ["BKV", "ORGANISM", 68, 71], ["tubular epithelial", "CELL", 86, 104], ["Bowman's capsular epithelial cells", "CELL", 108, 142], ["tubular epithelial or Bowman's capsular epithelial cells", "CELL_TYPE", 86, 142], ["BKV", "SPECIES", 68, 71], ["a biopsy", "TEST", 38, 46], ["BKV inclusions", "PROBLEM", 68, 82], ["tubular epithelial", "PROBLEM", 86, 104], ["BKV", "OBSERVATION", 68, 71], ["tubular", "ANATOMY_MODIFIER", 86, 93], ["epithelial", "ANATOMY_MODIFIER", 94, 104], ["Bowman", "ANATOMY", 108, 114], ["capsular epithelial cells", "OBSERVATION", 117, 142]]], ["Viral infection is accompanied by varying degrees of inflammatory cell infiltrates, tubular atrophy, and fibrosis.", [["inflammatory cell", "ANATOMY", 53, 70], ["tubular", "ANATOMY", 84, 91], ["Viral infection", "DISEASE", 0, 15], ["tubular atrophy", "DISEASE", 84, 99], ["fibrosis", "DISEASE", 105, 113], ["inflammatory cell", "CELL", 53, 70], ["tubular", "TISSUE", 84, 91], ["Viral infection", "PROBLEM", 0, 15], ["inflammatory cell infiltrates", "PROBLEM", 53, 82], ["tubular atrophy", "PROBLEM", 84, 99], ["fibrosis", "PROBLEM", 105, 113], ["infection", "OBSERVATION", 6, 15], ["varying degrees", "OBSERVATION_MODIFIER", 34, 49], ["inflammatory cell infiltrates", "OBSERVATION", 53, 82], ["tubular", "ANATOMY_MODIFIER", 84, 91], ["atrophy", "OBSERVATION", 92, 99], ["fibrosis", "OBSERVATION", 105, 113]]], ["The cytopathic effect seen by light microscopy is typical, but not pathognomonic for BKVN.", [["BKVN", "CANCER", 85, 89], ["The cytopathic effect", "PROBLEM", 0, 21], ["light microscopy", "TEST", 30, 46], ["BKVN", "PROBLEM", 85, 89], ["cytopathic", "OBSERVATION_MODIFIER", 4, 14]]], ["Confirmatory immunohistochemistry or in situ hybridization studies are usually performed using antibodies against specific for BKV proteins or probes complementary to viral DNA [103, 105, 107] .", [["BKV", "ORGANISM", 127, 130], ["DNA", "CELLULAR_COMPONENT", 173, 176], ["antibodies", "PROTEIN", 95, 105], ["BKV proteins", "PROTEIN", 127, 139], ["viral DNA", "DNA", 167, 176], ["BKV", "SPECIES", 127, 130], ["Confirmatory immunohistochemistry", "TEST", 0, 33], ["situ hybridization studies", "TEST", 40, 66], ["antibodies", "TEST", 95, 105], ["BKV proteins", "PROBLEM", 127, 139], ["viral DNA", "TEST", 167, 176]]], ["Electron microscopy can be used to demonstrate unenveloped, viral particles, approximately 40 nm in diameter.", [["Electron microscopy", "TEST", 0, 19], ["viral particles", "PROBLEM", 60, 75], ["viral particles", "OBSERVATION", 60, 75], ["40 nm", "OBSERVATION_MODIFIER", 91, 96]]], ["Since BKVN can be focal in distribution, ideally two biopsy cores should be examined.", [["BKVN", "GENE_OR_GENE_PRODUCT", 6, 10], ["biopsy cores", "CANCER", 53, 65], ["two biopsy cores", "TEST", 49, 65], ["can be", "UNCERTAINTY", 11, 17], ["focal", "OBSERVATION_MODIFIER", 18, 23], ["distribution", "OBSERVATION_MODIFIER", 27, 39]]], ["The availability of medullary parenchyma increases the diagnostic sensitivity.", [["medullary parenchyma", "ANATOMY", 20, 40], ["medullary parenchyma", "MULTI-TISSUE_STRUCTURE", 20, 40], ["medullary", "ANATOMY", 20, 29], ["parenchyma", "ANATOMY_MODIFIER", 30, 40]]], ["Negative biopsy results cannot rule out BKVN with certainty, and a diagnosis of \"presumptive BKVN\" can be made if there is renal allograft dysfunction associated with BK viremia [107] .", [["renal allograft", "ANATOMY", 123, 138], ["BKVN", "DISEASE", 93, 97], ["renal allograft dysfunction", "DISEASE", 123, 150], ["viremia", "DISEASE", 170, 177], ["BKVN", "CANCER", 40, 44], ["BKVN", "CANCER", 93, 97], ["renal allograft", "TISSUE", 123, 138], ["biopsy", "TEST", 9, 15], ["renal allograft dysfunction", "PROBLEM", 123, 150], ["BK viremia", "PROBLEM", 167, 177], ["biopsy", "OBSERVATION", 9, 15], ["renal", "ANATOMY", 123, 128], ["allograft", "OBSERVATION", 129, 138]]], ["A definitive diagnosis of rejection concurrent with viral nephropathy should only be made if there is endarteritis, fibrinoid arterial necrosis, glomerulitis, or accumulation of the complement degradation product C4d along peritubular capillaries.BK and JC VirusBK and JC shedding have been reported to coexist in 16% of patients with decoy cells with the long-term prognosis of this finding being similar to that of patients with pure BK shedding.", [["fibrinoid arterial", "ANATOMY", 116, 134], ["peritubular capillaries", "ANATOMY", 223, 246], ["cells", "ANATOMY", 341, 346], ["viral nephropathy", "DISEASE", 52, 69], ["endarteritis", "DISEASE", 102, 114], ["arterial necrosis", "DISEASE", 126, 143], ["glomerulitis", "DISEASE", 145, 157], ["fibrinoid arterial", "PATHOLOGICAL_FORMATION", 116, 134], ["C4d", "GENE_OR_GENE_PRODUCT", 213, 216], ["peritubular capillaries", "TISSUE", 223, 246], ["BK", "CELL", 247, 249], ["JC VirusBK", "ORGANISM", 254, 264], ["JC", "ORGANISM", 269, 271], ["patients", "ORGANISM", 321, 329], ["cells", "CELL", 341, 346], ["patients", "ORGANISM", 417, 425], ["complement degradation product", "PROTEIN", 182, 212], ["C4d", "PROTEIN", 213, 216], ["decoy cells", "CELL_TYPE", 335, 346], ["patients", "SPECIES", 321, 329], ["patients", "SPECIES", 417, 425], ["rejection", "PROBLEM", 26, 35], ["viral nephropathy", "PROBLEM", 52, 69], ["endarteritis", "PROBLEM", 102, 114], ["fibrinoid arterial necrosis", "PROBLEM", 116, 143], ["glomerulitis", "PROBLEM", 145, 157], ["the complement degradation", "PROBLEM", 178, 204], ["BK", "TEST", 247, 249], ["JC VirusBK", "TEST", 254, 264], ["JC shedding", "PROBLEM", 269, 280], ["decoy cells", "PROBLEM", 335, 346], ["pure BK shedding", "PROBLEM", 431, 447], ["rejection", "OBSERVATION", 26, 35], ["viral nephropathy", "OBSERVATION", 52, 69], ["endarteritis", "OBSERVATION", 102, 114], ["fibrinoid", "OBSERVATION_MODIFIER", 116, 125], ["arterial", "ANATOMY", 126, 134], ["necrosis", "OBSERVATION", 135, 143], ["degradation", "OBSERVATION_MODIFIER", 193, 204], ["product", "OBSERVATION_MODIFIER", 205, 212], ["C4d", "OBSERVATION", 213, 216], ["peritubular", "ANATOMY_MODIFIER", 223, 234], ["capillaries", "ANATOMY", 235, 246], ["JC VirusBK", "OBSERVATION", 254, 264], ["long-term", "OBSERVATION_MODIFIER", 356, 365]]], ["Only a few published cases of PVAN have been attributed to JC virus.", [["PVAN", "DISEASE", 30, 34], ["JC", "DISEASE", 59, 61], ["PVAN", "CANCER", 30, 34], ["JC virus", "ORGANISM", 59, 67], ["JC virus", "SPECIES", 59, 67], ["PVAN", "TREATMENT", 30, 34], ["JC virus", "PROBLEM", 59, 67], ["few", "OBSERVATION_MODIFIER", 7, 10], ["attributed to", "UNCERTAINTY", 45, 58], ["JC virus", "OBSERVATION", 59, 67]]], ["In a cohort of patients screened for decoy cells, 27% were found to have JC (only) shedding in the urine.", [["cells", "ANATOMY", 43, 48], ["urine", "ANATOMY", 99, 104], ["JC", "DISEASE", 73, 75], ["patients", "ORGANISM", 15, 23], ["cells", "CELL", 43, 48], ["urine", "ORGANISM_SUBSTANCE", 99, 104], ["decoy cells", "CELL_TYPE", 37, 48], ["patients", "SPECIES", 15, 23], ["decoy cells", "TEST", 37, 48], ["JC", "PROBLEM", 73, 75], ["shedding in the urine", "PROBLEM", 83, 104], ["urine", "ANATOMY", 99, 104]]], ["These patients were older and showed decoy cells appearing later compared with patients with pure BK shedding [111] .", [["cells", "ANATOMY", 43, 48], ["BK", "CHEMICAL", 98, 100], ["patients", "ORGANISM", 6, 14], ["cells", "CELL", 43, 48], ["patients", "ORGANISM", 79, 87], ["decoy cells", "CELL_TYPE", 37, 48], ["patients", "SPECIES", 6, 14], ["patients", "SPECIES", 79, 87], ["decoy cells", "PROBLEM", 37, 48]]], ["Among these were six patients with JCV-associated nephropathy, documented by positive cytology, positive plasma quantitative PCR, and positive SV40 staining.", [["plasma", "ANATOMY", 105, 111], ["nephropathy", "DISEASE", 50, 61], ["patients", "ORGANISM", 21, 29], ["JCV", "ORGANISM", 35, 38], ["plasma", "ORGANISM_SUBSTANCE", 105, 111], ["SV40", "ORGANISM", 143, 147], ["patients", "SPECIES", 21, 29], ["JCV-associated nephropathy", "PROBLEM", 35, 61], ["positive plasma quantitative PCR", "PROBLEM", 96, 128], ["positive SV40 staining", "PROBLEM", 134, 156], ["nephropathy", "OBSERVATION", 50, 61], ["SV40 staining", "OBSERVATION", 143, 156]]], ["With decreased immunosuppression, many of these patients continued to shed JCV.", [["patients", "ORGANISM", 48, 56], ["JCV", "ORGANISM", 75, 78], ["patients", "SPECIES", 48, 56], ["decreased immunosuppression", "TREATMENT", 5, 32], ["decreased", "OBSERVATION_MODIFIER", 5, 14], ["immunosuppression", "OBSERVATION", 15, 32], ["JCV", "OBSERVATION", 75, 78]]], ["They all had stable serum creatinin, and the only indication for biopsy was the presence of \"decoy\" cells in the urine.", [["serum", "ANATOMY", 20, 25], ["cells", "ANATOMY", 100, 105], ["urine", "ANATOMY", 113, 118], ["creatinin", "CHEMICAL", 26, 35], ["creatinin", "CHEMICAL", 26, 35], ["serum", "ORGANISM_SUBSTANCE", 20, 25], ["creatinin", "SIMPLE_CHEMICAL", 26, 35], ["cells", "CELL", 100, 105], ["urine", "ORGANISM_SUBSTANCE", 113, 118], ["biopsy", "TEST", 65, 71], ["\"decoy\" cells in the urine", "PROBLEM", 92, 118], ["stable", "OBSERVATION_MODIFIER", 13, 19]]], ["These patients did not have graft dysfunction or loss.", [["graft", "ANATOMY", 28, 33], ["patients", "ORGANISM", 6, 14], ["graft", "TISSUE", 28, 33], ["patients", "SPECIES", 6, 14], ["graft dysfunction", "PROBLEM", 28, 45], ["loss", "PROBLEM", 49, 53], ["graft", "OBSERVATION", 28, 33], ["loss", "OBSERVATION", 49, 53]]], ["Progressive multifocal leukoencephalopathy, a complication of JCV infection typically found in patients with HIV infection, has rarely been reported in renal transplant recipients [109] .BK and JC VirusReduction/adjustment in immunosuppression remains the cornerstone for the treatment or prevention of PVAN [102] [103] [104] [105] .", [["renal transplant", "ANATOMY", 152, 168], ["leukoencephalopathy", "DISEASE", 23, 42], ["JCV infection", "DISEASE", 62, 75], ["HIV infection", "DISEASE", 109, 122], ["BK", "CHEMICAL", 187, 189], ["PVAN", "CHEMICAL", 303, 307], ["PVAN", "CHEMICAL", 303, 307], ["JCV", "ORGANISM", 62, 65], ["patients", "ORGANISM", 95, 103], ["HIV", "ORGANISM", 109, 112], ["renal", "ORGAN", 152, 157], ["BK", "CELL", 187, 189], ["patients", "SPECIES", 95, 103], ["HIV", "SPECIES", 109, 112], ["JCV", "SPECIES", 62, 65], ["HIV", "SPECIES", 109, 112], ["Progressive multifocal leukoencephalopathy", "PROBLEM", 0, 42], ["JCV infection", "PROBLEM", 62, 75], ["HIV infection", "PROBLEM", 109, 122], ["renal transplant recipients", "TREATMENT", 152, 179], ["BK", "PROBLEM", 187, 189], ["JC VirusReduction", "TREATMENT", 194, 211], ["immunosuppression", "TREATMENT", 226, 243], ["the treatment", "TREATMENT", 272, 285], ["multifocal", "OBSERVATION_MODIFIER", 12, 22], ["leukoencephalopathy", "OBSERVATION", 23, 42], ["JCV infection", "OBSERVATION", 62, 75], ["HIV", "OBSERVATION_MODIFIER", 109, 112], ["infection", "OBSERVATION", 113, 122], ["renal", "ANATOMY", 152, 157], ["transplant", "OBSERVATION", 158, 168]]], ["Because the reconstitution of the immune system with control of the infection takes 4 to 12 weeks, it is imperative to start treatment as early as possible [112] .", [["infection", "DISEASE", 68, 77], ["the immune system", "TREATMENT", 30, 47], ["the infection", "PROBLEM", 64, 77], ["treatment", "TREATMENT", 125, 134], ["reconstitution", "OBSERVATION", 12, 26], ["infection", "OBSERVATION", 68, 77]]], ["The one risk encountered with reduction in immunosuppression is the development of acute rejection.", [["reduction", "TREATMENT", 30, 39], ["immunosuppression", "TREATMENT", 43, 60], ["acute rejection", "PROBLEM", 83, 98], ["one risk", "OBSERVATION_MODIFIER", 4, 12], ["reduction", "OBSERVATION_MODIFIER", 30, 39], ["immunosuppression", "OBSERVATION", 43, 60], ["acute", "OBSERVATION_MODIFIER", 83, 88], ["rejection", "OBSERVATION", 89, 98]]], ["The preliminary results of Wali et al. [113] reflect the protocol used at the University of Maryland, which consists of intensive screening with subsequent stepwise decrease in immunosuppression.", [["the protocol", "TREATMENT", 53, 65], ["intensive screening", "TEST", 120, 139], ["subsequent stepwise decrease in immunosuppression", "TREATMENT", 145, 194], ["decrease", "OBSERVATION_MODIFIER", 165, 173], ["immunosuppression", "OBSERVATION", 177, 194]]], ["This protocol has resulted in clearance of Vm with no graft loss or significant rejection diagnosed.", [["graft", "ANATOMY", 54, 59], ["graft", "TISSUE", 54, 59], ["This protocol", "TREATMENT", 0, 13], ["Vm", "PROBLEM", 43, 45], ["graft loss", "PROBLEM", 54, 64], ["significant rejection", "PROBLEM", 68, 89], ["Vm", "ANATOMY", 43, 45], ["no", "UNCERTAINTY", 51, 53], ["graft loss", "OBSERVATION", 54, 64], ["significant", "OBSERVATION_MODIFIER", 68, 79], ["rejection", "OBSERVATION", 80, 89]]], ["Specifically immunosuppression reduction is as follows: step 1, decrease in the dose of MMF by 50% immediately after diagnosis; step 2, 50% decrease in the target trough level of tacrolimus at 3 months if decoy cells persisted; and step 3, elimination of MMF at 6 months if decoy cells persisted.", [["cells", "ANATOMY", 211, 216], ["cells", "ANATOMY", 280, 285], ["MMF", "CHEMICAL", 88, 91], ["tacrolimus", "CHEMICAL", 179, 189], ["MMF", "CHEMICAL", 255, 258], ["MMF", "CHEMICAL", 88, 91], ["tacrolimus", "CHEMICAL", 179, 189], ["MMF", "CHEMICAL", 255, 258], ["MMF", "SIMPLE_CHEMICAL", 88, 91], ["tacrolimus", "SIMPLE_CHEMICAL", 179, 189], ["cells", "CELL", 211, 216], ["MMF", "SIMPLE_CHEMICAL", 255, 258], ["cells", "CELL", 280, 285], ["decoy cells", "CELL_TYPE", 205, 216], ["decoy cells", "CELL_TYPE", 274, 285], ["immunosuppression reduction", "TREATMENT", 13, 40], ["MMF", "TREATMENT", 88, 91], ["tacrolimus", "TREATMENT", 179, 189], ["decoy cells", "PROBLEM", 205, 216], ["MMF", "TREATMENT", 255, 258], ["decoy cells", "PROBLEM", 274, 285], ["immunosuppression", "OBSERVATION", 13, 30]]], ["Maintenance dual therapy consisted of the modified dose of tacrolimus and maintenance dose of prednisone (not exceeding 7.5 to 15 mg per week).", [["tacrolimus", "CHEMICAL", 59, 69], ["prednisone", "CHEMICAL", 94, 104], ["tacrolimus", "CHEMICAL", 59, 69], ["prednisone", "CHEMICAL", 94, 104], ["tacrolimus", "SIMPLE_CHEMICAL", 59, 69], ["prednisone", "SIMPLE_CHEMICAL", 94, 104], ["Maintenance dual therapy", "TREATMENT", 0, 24], ["tacrolimus", "TREATMENT", 59, 69], ["prednisone", "TREATMENT", 94, 104], ["dual therapy", "OBSERVATION", 12, 24]]], ["In addition to decrease in immunosuppression, several centers have reported the use of several antipolyomaviral agents, with anti-BKV activity in vitro.", [["anti-BKV", "SIMPLE_CHEMICAL", 125, 133], ["immunosuppression", "TREATMENT", 27, 44], ["several antipolyomaviral agents", "TREATMENT", 87, 118], ["anti-BKV activity", "TREATMENT", 125, 142], ["decrease", "OBSERVATION_MODIFIER", 15, 23], ["immunosuppression", "OBSERVATION", 27, 44]]], ["These include cidofovir, leflunomide, quinolones, and intravenous immunoglobulin [102, 105, 114] .", [["intravenous", "ANATOMY", 54, 65], ["cidofovir", "CHEMICAL", 14, 23], ["leflunomide", "CHEMICAL", 25, 36], ["quinolones", "CHEMICAL", 38, 48], ["cidofovir", "CHEMICAL", 14, 23], ["leflunomide", "CHEMICAL", 25, 36], ["quinolones", "CHEMICAL", 38, 48], ["cidofovir", "SIMPLE_CHEMICAL", 14, 23], ["leflunomide", "SIMPLE_CHEMICAL", 25, 36], ["quinolones", "SIMPLE_CHEMICAL", 38, 48], ["intravenous immunoglobulin", "SIMPLE_CHEMICAL", 54, 80], ["cidofovir", "TREATMENT", 14, 23], ["leflunomide", "TREATMENT", 25, 36], ["quinolones", "TREATMENT", 38, 48], ["intravenous immunoglobulin", "TREATMENT", 54, 80]]], ["None of these agents have been approved by the Food and Drug Administration for PVAN treatment.", [["PVAN", "CHEMICAL", 80, 84], ["PVAN", "SIMPLE_CHEMICAL", 80, 84], ["Drug Administration", "TREATMENT", 56, 75], ["PVAN treatment", "TREATMENT", 80, 94]]], ["However, they have been used empirically, and in many cases at advanced stages of the disease when graft dysfunction persists or worsens.", [["graft", "ANATOMY", 99, 104], ["graft dysfunction", "DISEASE", 99, 116], ["graft", "TISSUE", 99, 104], ["the disease", "PROBLEM", 82, 93], ["graft dysfunction", "PROBLEM", 99, 116], ["disease", "OBSERVATION", 86, 93], ["graft dysfunction", "OBSERVATION", 99, 116]]], ["The efficacy of these antiviral agents is difficult to determine, as they have been used in combination with reduction in immunosuppression, and even, in certain cases, in combination with each other.", [["these antiviral agents", "TREATMENT", 16, 38], ["immunosuppression", "TREATMENT", 122, 139], ["antiviral agents", "OBSERVATION", 22, 38], ["immunosuppression", "OBSERVATION", 122, 139]]], ["In addition, no prospective, randomized control trials have been conducted.", [["randomized control trials", "TREATMENT", 29, 54], ["no", "UNCERTAINTY", 13, 15]]], ["In summary, examination of the available literature demonstrates that none of the ancillary treatments described has been conclusively proven to be efficacious.", [["examination", "TEST", 12, 23], ["the ancillary treatments", "TREATMENT", 78, 102]]], ["Most studies were neither randomized nor double-blinded, and histologic grading of PVAN was often missing.", [["PVAN", "DISEASE", 83, 87], ["PVAN", "CANCER", 83, 87], ["Most studies", "TEST", 0, 12], ["histologic grading", "TEST", 61, 79]]], ["In addition, in many cases, renal dysfunction was present at the time of diagnosis.", [["renal", "ANATOMY", 28, 33], ["renal dysfunction", "DISEASE", 28, 45], ["renal", "ORGAN", 28, 33], ["renal dysfunction", "PROBLEM", 28, 45], ["renal", "ANATOMY", 28, 33], ["dysfunction", "OBSERVATION", 34, 45]]], ["Multicenter prospective studies are needed to clarify this important issue stratifying histologic grading, renal function, viral load diagnosis, and most importantly, an evaluation of different strategies assessed independently.BK and JC VirusEarly diagnosis with close monitoring of renal function andserial determinations of Vm continue to represent the most efficacious tool to control PVAN.", [["renal", "ANATOMY", 107, 112], ["renal", "ANATOMY", 284, 289], ["PVAN", "DISEASE", 389, 393], ["renal", "ORGAN", 107, 112], ["BK", "CELL", 228, 230], ["renal", "ORGAN", 284, 289], ["Vm", "GENE_OR_GENE_PRODUCT", 327, 329], ["Multicenter prospective studies", "TEST", 0, 31], ["histologic grading", "TEST", 87, 105], ["viral load diagnosis", "TEST", 123, 143], ["an evaluation", "TEST", 167, 180], ["close monitoring", "TEST", 264, 280], ["renal function", "TEST", 284, 298], ["PVAN", "TREATMENT", 389, 393], ["renal", "ANATOMY", 107, 112], ["viral load", "OBSERVATION", 123, 133], ["renal", "ANATOMY", 284, 289]]], ["Systematic reduction in immunosuppression has not been associated with clear evidence of increased chronic rejection but longer times of followup and more stringent studies are necessary to determine the longterm impact of the interventions for PVAN on long-term graft outcomes.Hepatitis B and C VirusHepatitis B virus (HBV) belong to family Hepadnaviridae, genus Orthohepadnavirus,species Hepatitis B virus.", [["graft", "ANATOMY", 263, 268], ["PVAN", "DISEASE", 245, 249], ["Hepatitis B", "DISEASE", 278, 289], ["Hepatitis B", "DISEASE", 390, 401], ["PVAN", "SIMPLE_CHEMICAL", 245, 249], ["graft", "TISSUE", 263, 268], ["Hepatitis B and C VirusHepatitis B virus", "ORGANISM", 278, 318], ["HBV", "ORGANISM", 320, 323], ["Hepadnaviridae", "GENE_OR_GENE_PRODUCT", 342, 356], ["genus Orthohepadnavirus", "ORGANISM", 358, 381], ["species", "ORGANISM", 382, 389], ["Hepatitis B virus", "ORGANISM", 390, 407], ["C VirusHepatitis B virus", "SPECIES", 294, 318], ["Hepatitis B virus", "SPECIES", 390, 407], ["Hepatitis B", "SPECIES", 278, 289], ["C VirusHepatitis B virus", "SPECIES", 294, 318], ["HBV", "SPECIES", 320, 323], ["Hepatitis B virus", "SPECIES", 390, 407], ["Systematic reduction", "PROBLEM", 0, 20], ["immunosuppression", "TREATMENT", 24, 41], ["increased chronic rejection", "PROBLEM", 89, 116], ["more stringent studies", "TEST", 150, 172], ["the interventions", "TREATMENT", 223, 240], ["PVAN", "TREATMENT", 245, 249], ["long-term graft outcomes", "TREATMENT", 253, 277], ["Hepatitis B and C VirusHepatitis B virus (HBV)", "PROBLEM", 278, 324], ["Hepadnaviridae", "TREATMENT", 342, 356], ["species Hepatitis B virus", "PROBLEM", 382, 407], ["reduction", "OBSERVATION_MODIFIER", 11, 20], ["immunosuppression", "OBSERVATION", 24, 41], ["evidence of", "UNCERTAINTY", 77, 88], ["increased", "OBSERVATION_MODIFIER", 89, 98], ["chronic", "OBSERVATION_MODIFIER", 99, 106], ["rejection", "OBSERVATION", 107, 116]]], ["In patients with chronic kidney disease undergoing renal transplantation, despite improved outcomes, liver disease has persisted as an important cause of morbidity and mortality.", [["kidney", "ANATOMY", 25, 31], ["renal", "ANATOMY", 51, 56], ["liver", "ANATOMY", 101, 106], ["chronic kidney disease", "DISEASE", 17, 39], ["liver disease", "DISEASE", 101, 114], ["patients", "ORGANISM", 3, 11], ["kidney", "ORGAN", 25, 31], ["renal", "ORGAN", 51, 56], ["liver", "ORGAN", 101, 106], ["patients", "SPECIES", 3, 11], ["chronic kidney disease", "PROBLEM", 17, 39], ["renal transplantation", "TREATMENT", 51, 72], ["liver disease", "PROBLEM", 101, 114], ["morbidity", "PROBLEM", 154, 163], ["chronic", "OBSERVATION_MODIFIER", 17, 24], ["kidney", "ANATOMY", 25, 31], ["disease", "OBSERVATION", 32, 39], ["renal", "ANATOMY", 51, 56], ["transplantation", "OBSERVATION", 57, 72], ["improved", "OBSERVATION_MODIFIER", 82, 90], ["liver", "ANATOMY", 101, 106], ["disease", "OBSERVATION", 107, 114], ["morbidity", "OBSERVATION", 154, 163]]], ["The prevalence of hepatitis B virus infection among patients on renal replacement therapy has decreased because of the implementation of preventive strategies in the dialysis population [115, 116] .", [["renal", "ANATOMY", 64, 69], ["hepatitis B virus infection", "DISEASE", 18, 45], ["hepatitis B virus", "ORGANISM", 18, 35], ["patients", "ORGANISM", 52, 60], ["renal", "ORGAN", 64, 69], ["hepatitis B virus", "SPECIES", 18, 35], ["patients", "SPECIES", 52, 60], ["hepatitis B virus", "SPECIES", 18, 35], ["hepatitis B virus infection", "PROBLEM", 18, 45], ["renal replacement therapy", "TREATMENT", 64, 89], ["preventive strategies", "TREATMENT", 137, 158], ["the dialysis population", "TREATMENT", 162, 185], ["hepatitis", "OBSERVATION", 18, 27], ["renal", "ANATOMY", 64, 69], ["replacement", "OBSERVATION", 70, 81]]], ["Currently, it is estimated the prevalence in the hepatitis disease population ranges from 0.1 to 0.4 percent [30] .", [["hepatitis disease", "DISEASE", 49, 66], ["the hepatitis disease population", "PROBLEM", 45, 77], ["hepatitis disease", "OBSERVATION", 49, 66]]], ["Approximately 2 to 10 percent of patients with a history of Hepatitis B before transplantation will reactivate posttransplant.", [["Hepatitis B", "DISEASE", 60, 71], ["patients", "ORGANISM", 33, 41], ["Hepatitis B", "ORGANISM", 60, 71], ["patients", "SPECIES", 33, 41], ["Hepatitis B", "SPECIES", 60, 71], ["Hepatitis B", "TREATMENT", 60, 71], ["transplantation", "TREATMENT", 79, 94], ["Hepatitis", "OBSERVATION", 60, 69]]], ["The most important factor influencing HBsAg seropositive status in recipients is the acquisition of HBV infection before renal transplantation and not via an infected graft or the surgery itself [117] .", [["renal", "ANATOMY", 121, 126], ["graft", "ANATOMY", 167, 172], ["HBsAg", "CHEMICAL", 38, 43], ["HBV infection", "DISEASE", 100, 113], ["HBsAg", "GENE_OR_GENE_PRODUCT", 38, 43], ["recipients", "ORGANISM", 67, 77], ["HBV", "ORGANISM", 100, 103], ["renal", "ORGAN", 121, 126], ["graft", "TISSUE", 167, 172], ["HBsAg", "PROTEIN", 38, 43], ["HBV", "SPECIES", 100, 103], ["HBsAg seropositive status", "PROBLEM", 38, 63], ["HBV infection", "PROBLEM", 100, 113], ["renal transplantation", "TREATMENT", 121, 142], ["an infected graft", "TREATMENT", 155, 172], ["the surgery", "TREATMENT", 176, 187], ["infection", "OBSERVATION", 104, 113], ["renal", "ANATOMY", 121, 126], ["transplantation", "OBSERVATION", 127, 142], ["infected", "OBSERVATION_MODIFIER", 158, 166], ["graft", "OBSERVATION", 167, 172]]], ["In the era of increasing emigration of people from high endemic area to industrialized countries, HBV infection will remain a persistent concern for public health authorities.Hepatitis B and C VirusThe impact of HBsAg seropositive status on patient survival after renal transplantation has been controversial [117] .", [["renal", "ANATOMY", 264, 269], ["HBV infection", "DISEASE", 98, 111], ["Hepatitis B", "DISEASE", 175, 186], ["HBsAg", "CHEMICAL", 212, 217], ["people", "ORGANISM", 39, 45], ["HBV", "ORGANISM", 98, 101], ["Hepatitis B and C Virus", "ORGANISM", 175, 198], ["HBsAg", "GENE_OR_GENE_PRODUCT", 212, 217], ["patient", "ORGANISM", 241, 248], ["renal", "ORGAN", 264, 269], ["people", "SPECIES", 39, 45], ["patient", "SPECIES", 241, 248], ["HBV", "SPECIES", 98, 101], ["high endemic area", "PROBLEM", 51, 68], ["HBV infection", "PROBLEM", 98, 111], ["Hepatitis B", "PROBLEM", 175, 186], ["C Virus", "PROBLEM", 191, 198], ["HBsAg seropositive status", "PROBLEM", 212, 237], ["renal transplantation", "TREATMENT", 264, 285], ["increasing", "OBSERVATION_MODIFIER", 14, 24], ["emigration", "OBSERVATION", 25, 35], ["high", "OBSERVATION_MODIFIER", 51, 55], ["endemic", "OBSERVATION_MODIFIER", 56, 63], ["HBV", "OBSERVATION_MODIFIER", 98, 101], ["infection", "OBSERVATION", 102, 111], ["renal", "ANATOMY", 264, 269], ["transplantation", "OBSERVATION", 270, 285]]], ["Initial reports mostly focused on 5-year survival rates and generally failed to show a difference between HBsAg-positive and -negative renal transplant patients.", [["renal", "ANATOMY", 135, 140], ["HBsAg", "CHEMICAL", 106, 111], ["HBsAg", "GENE_OR_GENE_PRODUCT", 106, 111], ["renal", "ORGAN", 135, 140], ["patients", "ORGANISM", 152, 160], ["HBsAg", "PROTEIN", 106, 111], ["patients", "SPECIES", 152, 160], ["survival rates", "TEST", 41, 55], ["HBsAg", "TEST", 106, 111], ["renal", "ANATOMY", 135, 140], ["transplant", "OBSERVATION", 141, 151]]], ["In contrast, other studies of appropriate size and longer followup have found an unfavorable effect of HBsAg [116] .", [["HBsAg", "CHEMICAL", 103, 108], ["HBsAg", "PROTEIN", 103, 108], ["other studies", "TEST", 13, 26], ["longer followup", "TEST", 51, 66], ["HBsAg", "TEST", 103, 108], ["size", "OBSERVATION_MODIFIER", 42, 46]]], ["Mathurin and colleagues reported that 10-year patient survival was significantly higher in noninfected (80% \u00b1 3%) than in HBsAgpositive recipients (55% \u00b1 6%) or in recipients who were anti-hepatitis C virus (HCV) positive (65% \u00b1 5%) [118] .", [["anti-hepatitis C virus (HCV) positive", "DISEASE", 184, 221], ["patient", "ORGANISM", 46, 53], ["recipients", "ORGANISM", 164, 174], ["anti-hepatitis C virus", "ORGANISM", 184, 206], ["HCV", "ORGANISM", 208, 211], ["patient", "SPECIES", 46, 53], ["anti-hepatitis C virus", "SPECIES", 184, 206], ["anti-hepatitis C virus", "SPECIES", 184, 206], ["HCV", "SPECIES", 208, 211], ["HBsAgpositive recipients", "TEST", 122, 146], ["anti-hepatitis C virus (HCV) positive", "PROBLEM", 184, 221], ["higher", "OBSERVATION_MODIFIER", 81, 87]]], ["Multivariate analysis demonstrated that HBsAg was an independent factor associated with inferior patient survival at 10 years (P b.0001).", [["HBsAg", "CHEMICAL", 40, 45], ["HBsAg", "GENE_OR_GENE_PRODUCT", 40, 45], ["patient", "ORGANISM", 97, 104], ["HBsAg", "PROTEIN", 40, 45], ["patient", "SPECIES", 97, 104], ["Multivariate analysis", "TEST", 0, 21], ["HBsAg", "TEST", 40, 45], ["HBsAg", "OBSERVATION", 40, 45]]], ["Fabrizi and colleagues, in a subsequent meta-analysis, showed that HBsAg seropositive status was an independent risk factor for death [119] .Hepatitis B and C VirusA more recent study by Matos and colleagues attempted to identify factors that increase liver fibrosis formation in renal transplanted patients with HBV infection [120] .", [["liver", "ANATOMY", 252, 257], ["renal", "ANATOMY", 280, 285], ["HBsAg", "CHEMICAL", 67, 72], ["death", "DISEASE", 128, 133], ["Hepatitis B", "DISEASE", 141, 152], ["liver fibrosis", "DISEASE", 252, 266], ["HBV infection", "DISEASE", 313, 326], ["HBsAg", "GENE_OR_GENE_PRODUCT", 67, 72], ["Hepatitis B", "ORGANISM", 141, 152], ["C VirusA", "ORGANISM", 157, 165], ["liver", "ORGAN", 252, 257], ["renal", "ORGAN", 280, 285], ["patients", "ORGANISM", 299, 307], ["HBV", "ORGANISM", 313, 316], ["HBsAg", "PROTEIN", 67, 72], ["patients", "SPECIES", 299, 307], ["HBV", "SPECIES", 313, 316], ["a subsequent meta-analysis", "TEST", 27, 53], ["HBsAg seropositive status", "PROBLEM", 67, 92], ["death", "PROBLEM", 128, 133], ["Hepatitis B", "PROBLEM", 141, 152], ["liver fibrosis formation", "PROBLEM", 252, 276], ["HBV infection", "PROBLEM", 313, 326], ["liver", "ANATOMY", 252, 257], ["fibrosis", "OBSERVATION", 258, 266], ["renal", "ANATOMY", 280, 285], ["HBV", "OBSERVATION", 313, 316]]], ["They followed 55 patients for a mean time of 5 \u00b1 4 years posttransplant.", [["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25]]], ["Liver biopsies of post-renal transplantation with advanced fibrosis were compared with those with mild fibrosis.", [["Liver biopsies", "ANATOMY", 0, 14], ["post-renal", "ANATOMY", 18, 28], ["fibrosis", "DISEASE", 59, 67], ["fibrosis", "DISEASE", 103, 111], ["Liver biopsies", "MULTI-TISSUE_STRUCTURE", 0, 14], ["Liver biopsies", "TEST", 0, 14], ["post-renal transplantation", "TREATMENT", 18, 44], ["advanced fibrosis", "PROBLEM", 50, 67], ["mild fibrosis", "PROBLEM", 98, 111], ["biopsies", "OBSERVATION", 6, 14], ["post-renal", "ANATOMY", 18, 28], ["transplantation", "OBSERVATION", 29, 44], ["advanced", "OBSERVATION_MODIFIER", 50, 58], ["fibrosis", "OBSERVATION", 59, 67], ["mild", "OBSERVATION_MODIFIER", 98, 102], ["fibrosis", "OBSERVATION", 103, 111]]], ["Logistic regression analysis was applied to variables (age, sex, estimated time since infection, history of renal transplantation, donor type, ALT index, HBeAg, anti-HCV or quantitative HBV DNA, post-RT time, and HBV-HCV coinfection).", [["renal", "ANATOMY", 108, 113], ["infection", "DISEASE", 86, 95], ["HBeAg", "CHEMICAL", 154, 159], ["HBV-HCV coinfection", "DISEASE", 213, 232], ["renal", "ORGAN", 108, 113], ["ALT", "GENE_OR_GENE_PRODUCT", 143, 146], ["HBeAg", "GENE_OR_GENE_PRODUCT", 154, 159], ["HBV", "ORGANISM", 186, 189], ["DNA", "CELLULAR_COMPONENT", 190, 193], ["HBV-HCV", "ORGANISM", 213, 220], ["HBV", "SPECIES", 186, 189], ["HBV", "SPECIES", 213, 216], ["HCV", "SPECIES", 217, 220], ["Logistic regression analysis", "TEST", 0, 28], ["infection", "PROBLEM", 86, 95], ["renal transplantation", "TREATMENT", 108, 129], ["donor type", "TEST", 131, 141], ["ALT index", "TEST", 143, 152], ["HBeAg", "PROBLEM", 154, 159], ["anti-HCV", "PROBLEM", 161, 169], ["quantitative HBV DNA", "PROBLEM", 173, 193], ["HBV", "PROBLEM", 213, 216], ["HCV coinfection", "PROBLEM", 217, 232], ["infection", "OBSERVATION", 86, 95], ["renal", "ANATOMY", 108, 113], ["transplantation", "OBSERVATION", 114, 129], ["HCV coinfection", "OBSERVATION", 217, 232]]], ["Sixty-six percent of patients were on a cyclosporinebased regimen.", [["cyclosporinebased", "CHEMICAL", 40, 57], ["cyclosporinebased", "CHEMICAL", 40, 57], ["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29], ["a cyclosporinebased regimen", "TREATMENT", 38, 65]]], ["The only independent factor associated with more advanced fibrosis was increased length of time after transplant.", [["fibrosis", "DISEASE", 58, 66], ["more advanced fibrosis", "PROBLEM", 44, 66], ["transplant", "TREATMENT", 102, 112], ["advanced", "OBSERVATION_MODIFIER", 49, 57], ["fibrosis", "OBSERVATION", 58, 66], ["increased", "OBSERVATION_MODIFIER", 71, 80], ["length", "OBSERVATION_MODIFIER", 81, 87]]], ["Immunosuppression postrenal transplantation may augment HBV replication by a variety of mechanisms including by diminishing activity of cytotoxic T lymphocytes.", [["postrenal", "ANATOMY", 18, 27], ["cytotoxic T lymphocytes", "ANATOMY", 136, 159], ["HBV", "ORGANISM", 56, 59], ["cytotoxic T lymphocytes", "CELL", 136, 159], ["cytotoxic T lymphocytes", "CELL_TYPE", 136, 159], ["HBV", "SPECIES", 56, 59], ["Immunosuppression postrenal transplantation", "TREATMENT", 0, 43], ["HBV replication", "TREATMENT", 56, 71], ["cytotoxic T lymphocytes", "PROBLEM", 136, 159], ["transplantation", "OBSERVATION", 28, 43], ["HBV", "OBSERVATION", 56, 59]]], ["Azathioprine may stimulate intracellular HBV synthesis.", [["intracellular", "ANATOMY", 27, 40], ["Azathioprine", "CHEMICAL", 0, 12], ["Azathioprine", "CHEMICAL", 0, 12], ["Azathioprine", "SIMPLE_CHEMICAL", 0, 12], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 27, 40], ["HBV", "ORGANISM", 41, 44], ["HBV", "SPECIES", 41, 44], ["Azathioprine", "TREATMENT", 0, 12], ["intracellular HBV synthesis", "PROBLEM", 27, 54], ["intracellular HBV", "OBSERVATION", 27, 44]]], ["Furthermore, calcineurin inhibitors (CNIs) may have direct effects on HBV replication [116] .", [["calcineurin", "GENE_OR_GENE_PRODUCT", 13, 24], ["CNIs", "SIMPLE_CHEMICAL", 37, 41], ["HBV", "ORGANISM", 70, 73], ["calcineurin", "PROTEIN", 13, 24], ["HBV", "SPECIES", 70, 73], ["calcineurin inhibitors (CNIs", "TREATMENT", 13, 41], ["HBV replication", "TREATMENT", 70, 85]]], ["Reactivation of HBV infection even in HBs Agseronegative individuals whose serological profile indicates remote, resolved HBV infection is recognized after transplantation with reappearance of The Scientific World Journal 11 HBsAg in serum [117] .", [["serum", "ANATOMY", 234, 239], ["HBV infection", "DISEASE", 16, 29], ["HBV infection", "DISEASE", 122, 135], ["HBsAg", "CHEMICAL", 225, 230], ["HBV", "ORGANISM", 16, 19], ["HBs Agseronegative individuals", "ORGANISM", 38, 68], ["HBV", "ORGANISM", 122, 125], ["serum", "ORGANISM_SUBSTANCE", 234, 239], ["HBsAg", "PROTEIN", 225, 230], ["HBV", "SPECIES", 16, 19], ["HBV", "SPECIES", 122, 125], ["HBV infection", "PROBLEM", 16, 29], ["serological profile", "TEST", 75, 94], ["HBV infection", "PROBLEM", 122, 135], ["transplantation", "TREATMENT", 156, 171], ["HBsAg in serum", "TEST", 225, 239], ["HBV", "OBSERVATION_MODIFIER", 16, 19], ["infection", "OBSERVATION", 20, 29], ["HBV", "OBSERVATION_MODIFIER", 122, 125], ["infection", "OBSERVATION", 126, 135]]], ["Newly recognized HBV infection after renal transplantation can reflect de novo infection or reactivation of prior resolved infection.", [["renal", "ANATOMY", 37, 42], ["HBV infection", "DISEASE", 17, 30], ["infection", "DISEASE", 79, 88], ["infection", "DISEASE", 123, 132], ["HBV", "ORGANISM", 17, 20], ["renal", "ORGAN", 37, 42], ["HBV", "SPECIES", 17, 20], ["Newly recognized HBV infection", "PROBLEM", 0, 30], ["renal transplantation", "TREATMENT", 37, 58], ["de novo infection", "PROBLEM", 71, 88], ["prior resolved infection", "PROBLEM", 108, 132], ["HBV", "OBSERVATION_MODIFIER", 17, 20], ["infection", "OBSERVATION", 21, 30], ["renal", "ANATOMY", 37, 42], ["transplantation", "OBSERVATION", 43, 58], ["novo", "OBSERVATION_MODIFIER", 74, 78], ["infection", "OBSERVATION", 79, 88], ["resolved", "OBSERVATION_MODIFIER", 114, 122], ["infection", "OBSERVATION", 123, 132]]], ["Some investigators observed in renal transplanted recipients after transplantation an increased replication with reappearance or increase in serum HBV DNA levels and HBeAg as well as reappearance of serum HBsAg following apparent clearance of prior HBV infection.", [["renal", "ANATOMY", 31, 36], ["serum", "ANATOMY", 141, 146], ["serum", "ANATOMY", 199, 204], ["HBeAg", "CHEMICAL", 166, 171], ["HBsAg", "CHEMICAL", 205, 210], ["HBV infection", "DISEASE", 249, 262], ["renal", "ORGAN", 31, 36], ["recipients", "ORGANISM", 50, 60], ["serum", "ORGANISM_SUBSTANCE", 141, 146], ["HBV", "ORGANISM", 147, 150], ["DNA", "CELLULAR_COMPONENT", 151, 154], ["HBeAg", "GENE_OR_GENE_PRODUCT", 166, 171], ["serum", "ORGANISM_SUBSTANCE", 199, 204], ["HBsAg", "GENE_OR_GENE_PRODUCT", 205, 210], ["HBV", "ORGANISM", 249, 252], ["serum HBsAg", "PROTEIN", 199, 210], ["HBV", "SPECIES", 147, 150], ["HBV", "SPECIES", 249, 252], ["renal transplanted recipients", "TREATMENT", 31, 60], ["transplantation", "TREATMENT", 67, 82], ["an increased replication", "TREATMENT", 83, 107], ["serum HBV DNA levels", "TEST", 141, 161], ["HBeAg", "PROBLEM", 166, 171], ["serum HBsAg", "TEST", 199, 210], ["prior HBV infection", "PROBLEM", 243, 262], ["renal", "ANATOMY", 31, 36], ["transplanted recipients", "OBSERVATION", 37, 60], ["increase", "OBSERVATION_MODIFIER", 129, 137], ["HBV", "OBSERVATION_MODIFIER", 249, 252], ["infection", "OBSERVATION", 253, 262]]], ["Reactivation may cause necroinflammatory liver injury with biochemical dysfunction.", [["liver", "ANATOMY", 41, 46], ["liver injury", "DISEASE", 41, 53], ["liver", "ORGAN", 41, 46], ["necroinflammatory liver injury", "PROBLEM", 23, 53], ["biochemical dysfunction", "PROBLEM", 59, 82], ["may cause", "UNCERTAINTY", 13, 22], ["necroinflammatory", "OBSERVATION_MODIFIER", 23, 40], ["liver", "ANATOMY", 41, 46], ["injury", "OBSERVATION", 47, 53], ["biochemical dysfunction", "OBSERVATION", 59, 82]]], ["Recent cases of reactivation of HBV after RT have been reported [121, 122] , and fulminant hepatic failure due to HBV reactivation has been already noted after renal transplantation [123] .", [["hepatic", "ANATOMY", 91, 98], ["renal", "ANATOMY", 160, 165], ["fulminant hepatic failure", "DISEASE", 81, 106], ["HBV", "ORGANISM", 32, 35], ["hepatic", "ORGAN", 91, 98], ["HBV", "ORGANISM", 114, 117], ["renal", "ORGAN", 160, 165], ["HBV", "SPECIES", 32, 35], ["HBV", "SPECIES", 114, 117], ["reactivation of HBV", "PROBLEM", 16, 35], ["fulminant hepatic failure", "PROBLEM", 81, 106], ["HBV reactivation", "PROBLEM", 114, 130], ["renal transplantation", "TREATMENT", 160, 181], ["fulminant", "OBSERVATION_MODIFIER", 81, 90], ["hepatic", "ANATOMY", 91, 98], ["failure", "OBSERVATION", 99, 106], ["HBV", "OBSERVATION", 114, 117], ["renal", "ANATOMY", 160, 165], ["transplantation", "OBSERVATION", 166, 181]]], ["The 2 proposed theories for viral reactivation after RT are as follows: the first hypothesis include \"occult HBV infection\" in the RT candidate before transplant and viral replication of HBV under the influence of immunosuppression.", [["HBV infection", "DISEASE", 109, 122], ["HBV", "ORGANISM", 109, 112], ["HBV", "ORGANISM", 187, 190], ["HBV", "SPECIES", 109, 112], ["HBV", "SPECIES", 187, 190], ["viral reactivation", "PROBLEM", 28, 46], ["occult HBV infection", "PROBLEM", 102, 122], ["transplant", "TREATMENT", 151, 161], ["viral replication", "TREATMENT", 166, 183], ["HBV", "PROBLEM", 187, 190], ["immunosuppression", "TREATMENT", 214, 231], ["viral reactivation", "OBSERVATION", 28, 46], ["HBV", "OBSERVATION_MODIFIER", 109, 112], ["infection", "OBSERVATION", 113, 122], ["viral replication", "OBSERVATION", 166, 183], ["HBV", "OBSERVATION", 187, 190]]], ["Another theory is the loss of protective immunity and infection by a mutated strain.", [["infection", "DISEASE", 54, 63], ["the loss of protective immunity", "PROBLEM", 18, 49], ["infection", "PROBLEM", 54, 63], ["a mutated strain", "PROBLEM", 67, 83], ["infection", "OBSERVATION", 54, 63]]], ["Naturally occurring mutations in the preC region and core promoter region are found in patients with long-standing chronic HBV infection [124] .", [["HBV infection", "DISEASE", 123, 136], ["preC", "GENE_OR_GENE_PRODUCT", 37, 41], ["patients", "ORGANISM", 87, 95], ["HBV", "ORGANISM", 123, 126], ["preC region", "DNA", 37, 48], ["core promoter region", "DNA", 53, 73], ["patients", "SPECIES", 87, 95], ["HBV", "SPECIES", 123, 126], ["Naturally occurring mutations in the preC region", "PROBLEM", 0, 48], ["long-standing chronic HBV infection", "PROBLEM", 101, 136], ["mutations", "OBSERVATION", 20, 29], ["preC", "ANATOMY", 37, 41], ["region", "ANATOMY_MODIFIER", 42, 48], ["chronic", "OBSERVATION_MODIFIER", 115, 122], ["HBV", "OBSERVATION_MODIFIER", 123, 126], ["infection", "OBSERVATION", 127, 136]]], ["Renal transplant recipients are at increased risk of developing a variety of cancers.", [["Renal", "ANATOMY", 0, 5], ["cancers", "ANATOMY", 77, 84], ["cancers", "DISEASE", 77, 84], ["Renal", "ORGAN", 0, 5], ["cancers", "CANCER", 77, 84], ["Renal transplant recipients", "TREATMENT", 0, 27], ["cancers", "PROBLEM", 77, 84], ["transplant", "OBSERVATION", 6, 16], ["increased", "OBSERVATION_MODIFIER", 35, 44], ["variety", "OBSERVATION_MODIFIER", 66, 73], ["cancers", "OBSERVATION", 77, 84]]], ["Hepatocellular carcinoma is usually associated with viral hepatitis (HBV and HCV) but has been reported in postrenal transplanted recipients without overt evidence of viral hepatitis, cirrhosis, or metabolic liver disease [125] .Hepatitis B and C VirusEffective and safe vaccines that contain HBsAg, initially plasma derived and more recently manufactured by recombinant DNA technology, have been available since the early 1980s [126] .", [["Hepatocellular carcinoma", "ANATOMY", 0, 24], ["liver", "ANATOMY", 208, 213], ["plasma", "ANATOMY", 310, 316], ["Hepatocellular carcinoma", "DISEASE", 0, 24], ["viral hepatitis (HBV and HCV)", "DISEASE", 52, 81], ["viral hepatitis", "DISEASE", 167, 182], ["cirrhosis", "DISEASE", 184, 193], ["metabolic liver disease", "DISEASE", 198, 221], ["Hepatitis B", "DISEASE", 229, 240], ["HBsAg", "CHEMICAL", 293, 298], ["Hepatocellular carcinoma", "CANCER", 0, 24], ["HBV", "ORGANISM", 69, 72], ["recipients", "ORGANISM", 130, 140], ["liver", "ORGAN", 208, 213], ["Hepatitis B", "ORGANISM", 229, 240], ["C VirusEffective", "ORGANISM", 245, 261], ["HBsAg", "GENE_OR_GENE_PRODUCT", 293, 298], ["plasma", "ORGANISM_SUBSTANCE", 310, 316], ["DNA", "CELLULAR_COMPONENT", 371, 374], ["HBsAg", "PROTEIN", 293, 298], ["HBV", "SPECIES", 69, 72], ["HCV", "SPECIES", 77, 80], ["Hepatocellular carcinoma", "PROBLEM", 0, 24], ["viral hepatitis", "PROBLEM", 52, 67], ["HBV", "PROBLEM", 69, 72], ["HCV", "PROBLEM", 77, 80], ["viral hepatitis", "PROBLEM", 167, 182], ["cirrhosis", "PROBLEM", 184, 193], ["metabolic liver disease", "PROBLEM", 198, 221], ["Hepatitis B", "PROBLEM", 229, 240], ["C VirusEffective", "TREATMENT", 245, 261], ["safe vaccines", "TREATMENT", 266, 279], ["HBsAg", "TEST", 293, 298], ["carcinoma", "OBSERVATION", 15, 24], ["usually associated with", "UNCERTAINTY", 28, 51], ["viral", "OBSERVATION_MODIFIER", 52, 57], ["hepatitis", "OBSERVATION", 58, 67], ["HBV", "OBSERVATION", 69, 72], ["HCV", "OBSERVATION", 77, 80], ["postrenal", "OBSERVATION_MODIFIER", 107, 116], ["transplanted recipients", "OBSERVATION", 117, 140], ["without overt evidence of", "UNCERTAINTY", 141, 166], ["viral", "OBSERVATION_MODIFIER", 167, 172], ["hepatitis", "OBSERVATION", 173, 182], ["cirrhosis", "OBSERVATION", 184, 193], ["metabolic", "OBSERVATION_MODIFIER", 198, 207], ["liver", "ANATOMY", 208, 213], ["HBsAg", "OBSERVATION", 293, 298]]], ["Vaccination against HBV is recommended for all susceptible patients on dialysis (i.e., those having antihepatitis B surface titers b10 IU/mL).", [["HBV", "ORGANISM", 20, 23], ["patients", "ORGANISM", 59, 67], ["antihepatitis B surface", "GENE_OR_GENE_PRODUCT", 100, 123], ["patients", "SPECIES", 59, 67], ["HBV", "SPECIES", 20, 23], ["Vaccination", "TREATMENT", 0, 11], ["HBV", "PROBLEM", 20, 23], ["dialysis", "TREATMENT", 71, 79], ["antihepatitis B surface titers", "TREATMENT", 100, 130]]], ["Patients on maintenance dialysis have a suboptimal response (40%-50%) to HBV vaccine compared with the general population (N95% response).", [["Patients", "ORGANISM", 0, 8], ["HBV", "ORGANISM", 73, 76], ["Patients", "SPECIES", 0, 8], ["HBV", "SPECIES", 73, 76], ["maintenance dialysis", "TREATMENT", 12, 32], ["HBV vaccine", "TREATMENT", 73, 84]]], ["Several approaches have been tried to enhance response rates to HBV vaccine in these patients.", [["HBV", "ORGANISM", 64, 67], ["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["HBV", "SPECIES", 64, 67], ["HBV vaccine", "TREATMENT", 64, 75]]], ["These have included the administration of double or multiple doses of HBV vaccine, intradermal administration of vaccine, and vaccination with the simultaneous use of adjuvants (granulocyte macrophage-stimulating factor, thymopentin, erythropoietin, zinc supplements, etc.).", [["zinc", "CHEMICAL", 250, 254], ["zinc", "CHEMICAL", 250, 254], ["HBV", "ORGANISM", 70, 73], ["granulocyte macrophage-stimulating factor", "GENE_OR_GENE_PRODUCT", 178, 219], ["thymopentin", "SIMPLE_CHEMICAL", 221, 232], ["erythropoietin", "GENE_OR_GENE_PRODUCT", 234, 248], ["zinc", "SIMPLE_CHEMICAL", 250, 254], ["granulocyte macrophage-stimulating factor", "PROTEIN", 178, 219], ["thymopentin", "PROTEIN", 221, 232], ["erythropoietin", "PROTEIN", 234, 248], ["HBV", "SPECIES", 70, 73], ["double", "TREATMENT", 42, 48], ["HBV vaccine", "TREATMENT", 70, 81], ["intradermal administration of vaccine", "TREATMENT", 83, 120], ["vaccination", "TREATMENT", 126, 137], ["adjuvants (granulocyte macrophage", "TREATMENT", 167, 200], ["stimulating factor", "TREATMENT", 201, 219], ["thymopentin", "TREATMENT", 221, 232], ["erythropoietin", "TREATMENT", 234, 248], ["zinc supplements", "TREATMENT", 250, 266]]], ["Current recommendations for HBV vaccination in susceptible dialysis patients are administration of 4 double doses (40 \u03bcg each dose) by intramuscular route at 0, 1, 2, and 6 months [126] .Hepatitis B and C VirusEvaluation of the donor includes testing with suspected HBV infection including HBsAg, HBsAb, and anti-HBc.", [["intramuscular", "ANATOMY", 135, 148], ["Hepatitis B", "DISEASE", 187, 198], ["HBV infection", "DISEASE", 266, 279], ["HBsAg", "CHEMICAL", 290, 295], ["HBV", "ORGANISM", 28, 31], ["patients", "ORGANISM", 68, 76], ["Hepatitis B", "ORGANISM", 187, 198], ["HBV", "ORGANISM", 266, 269], ["HBsAg", "GENE_OR_GENE_PRODUCT", 290, 295], ["HBsAb", "GENE_OR_GENE_PRODUCT", 297, 302], ["HBsAg", "PROTEIN", 290, 295], ["HBsAb", "PROTEIN", 297, 302], ["anti-HBc", "PROTEIN", 308, 316], ["patients", "SPECIES", 68, 76], ["HBV", "SPECIES", 28, 31], ["HBV", "SPECIES", 266, 269], ["HBV vaccination", "TREATMENT", 28, 43], ["susceptible dialysis patients", "TREATMENT", 47, 76], ["Hepatitis B", "PROBLEM", 187, 198], ["testing", "TEST", 243, 250], ["HBV infection", "PROBLEM", 266, 279], ["HBsAg", "TEST", 290, 295], ["HBsAb", "TEST", 297, 302], ["anti-HBc", "TEST", 308, 316], ["HBV", "OBSERVATION_MODIFIER", 266, 269], ["infection", "OBSERVATION", 270, 279]]], ["The risk of HBV transmission to the renal transplanted recipient is a function of serologic status of both donor and recipient.", [["renal", "ANATOMY", 36, 41], ["HBV", "ORGANISM", 12, 15], ["renal", "ORGAN", 36, 41], ["HBV", "SPECIES", 12, 15], ["HBV transmission", "PROBLEM", 12, 28], ["the renal transplanted recipient", "TREATMENT", 32, 64], ["HBV", "OBSERVATION", 12, 15], ["renal", "ANATOMY", 36, 41], ["transplanted", "OBSERVATION", 42, 54]]], ["A donor with HBsAb-positive serology due to vaccination will not transmit HBV infection.", [["HBV infection", "DISEASE", 74, 87], ["HBsAb", "GENE_OR_GENE_PRODUCT", 13, 18], ["HBV", "ORGANISM", 74, 77], ["HBV", "SPECIES", 74, 77], ["A donor with HBsAb", "TEST", 0, 18], ["positive serology", "PROBLEM", 19, 36], ["vaccination", "TREATMENT", 44, 55], ["transmit HBV infection", "PROBLEM", 65, 87], ["infection", "OBSERVATION", 78, 87]]], ["A donor with isolated anti-HBc-positive serology should have further serologic testing done to differentiate acute infection or remote exposure.", [["infection", "DISEASE", 115, 124], ["anti-HBc", "GENE_OR_GENE_PRODUCT", 22, 30], ["isolated anti-HBc", "TEST", 13, 30], ["positive serology", "PROBLEM", 31, 48], ["further serologic testing", "TEST", 61, 86], ["acute infection", "PROBLEM", 109, 124], ["anti-HBc", "OBSERVATION", 22, 30], ["acute", "OBSERVATION_MODIFIER", 109, 114], ["infection", "OBSERVATION", 115, 124]]], ["If an IgM anticore is detected, the patient may have a recent acute HBV infection and should not be used in an HBV naive recipient without antiviral prophylaxis.", [["HBV infection", "DISEASE", 68, 81], ["IgM", "GENE_OR_GENE_PRODUCT", 6, 9], ["patient", "ORGANISM", 36, 43], ["HBV", "ORGANISM", 68, 71], ["HBV", "ORGANISM", 111, 114], ["IgM", "PROTEIN", 6, 9], ["patient", "SPECIES", 36, 43], ["HBV", "SPECIES", 68, 71], ["HBV", "SPECIES", 111, 114], ["an IgM anticore", "TEST", 3, 18], ["a recent acute HBV infection", "PROBLEM", 53, 81], ["an HBV naive recipient", "TREATMENT", 108, 130], ["antiviral prophylaxis", "TREATMENT", 139, 160], ["acute", "OBSERVATION_MODIFIER", 62, 67], ["HBV", "OBSERVATION", 68, 71], ["infection", "OBSERVATION", 72, 81], ["antiviral prophylaxis", "OBSERVATION", 139, 160]]], ["Although livers harvested from isolated anti-HBc positive donors have a considerable risk of HBV transmission to recipients of liver grafts, kidneys from the same donors carry a low risk of transmission [127] .", [["livers", "ANATOMY", 9, 15], ["liver grafts", "ANATOMY", 127, 139], ["kidneys", "ANATOMY", 141, 148], ["livers", "ORGAN", 9, 15], ["HBc", "GENE_OR_GENE_PRODUCT", 45, 48], ["HBV", "ORGANISM", 93, 96], ["recipients", "ORGANISM", 113, 123], ["liver grafts", "MULTI-TISSUE_STRUCTURE", 127, 139], ["kidneys", "ORGAN", 141, 148], ["donors", "ORGANISM", 163, 169], ["HBV", "SPECIES", 93, 96], ["isolated anti-HBc positive donors", "TREATMENT", 31, 64], ["HBV transmission", "TREATMENT", 93, 109], ["liver grafts", "TREATMENT", 127, 139], ["livers", "ANATOMY", 9, 15], ["harvested", "OBSERVATION", 16, 25], ["HBV", "OBSERVATION", 93, 96], ["liver", "ANATOMY", 127, 132], ["grafts", "OBSERVATION", 133, 139], ["kidneys", "ANATOMY", 141, 148]]], ["Kidneys from HBsAg-positive donors have a higher risk of transmitting HBV infection to their recipients, and the risk of transmission is greater if the donor status is HBsAg positive along with being HBeAg positive.", [["Kidneys", "ANATOMY", 0, 7], ["HBsAg", "CHEMICAL", 13, 18], ["HBV infection", "DISEASE", 70, 83], ["HBsAg", "CHEMICAL", 168, 173], ["HBeAg", "CHEMICAL", 200, 205], ["Kidneys", "ORGAN", 0, 7], ["HBsAg", "GENE_OR_GENE_PRODUCT", 13, 18], ["donors", "ORGANISM", 28, 34], ["HBV", "ORGANISM", 70, 73], ["recipients", "ORGANISM", 93, 103], ["HBsAg", "GENE_OR_GENE_PRODUCT", 168, 173], ["HBeAg", "GENE_OR_GENE_PRODUCT", 200, 205], ["HBsAg", "PROTEIN", 13, 18], ["HBsAg", "PROTEIN", 168, 173], ["HBV", "SPECIES", 70, 73], ["Kidneys", "TEST", 0, 7], ["HBsAg", "TEST", 13, 18], ["transmitting HBV infection", "PROBLEM", 57, 83], ["HBsAg positive", "PROBLEM", 168, 182], ["HBeAg positive", "PROBLEM", 200, 214], ["HBsAg", "OBSERVATION", 13, 18], ["positive donors", "OBSERVATION", 19, 34], ["HBV", "OBSERVATION_MODIFIER", 70, 73], ["infection", "OBSERVATION", 74, 83]]], ["HBsAbpositive recipients should not require prophylaxis [116] .", [["recipients", "ORGANISM", 14, 24], ["HBsAbpositive recipients", "TREATMENT", 0, 24], ["prophylaxis", "TREATMENT", 44, 55]]], ["On the other hand, organs from HBsAg-positive donors can be used in HBcAb-positive/HBsAb-positive recipients while requiring lamivudine prophylaxis (1 year).", [["organs", "ANATOMY", 19, 25], ["HBsAg", "CHEMICAL", 31, 36], ["lamivudine", "CHEMICAL", 125, 135], ["lamivudine", "CHEMICAL", 125, 135], ["organs", "ORGAN", 19, 25], ["HBsAg", "GENE_OR_GENE_PRODUCT", 31, 36], ["donors", "ORGANISM", 46, 52], ["HBcAb", "GENE_OR_GENE_PRODUCT", 68, 73], ["HBsAb", "ORGANISM", 83, 88], ["recipients", "ORGANISM", 98, 108], ["lamivudine", "SIMPLE_CHEMICAL", 125, 135], ["HBsAg", "PROTEIN", 31, 36], ["HBsAg", "TEST", 31, 36], ["HBcAb", "TEST", 68, 73], ["HBsAb", "TEST", 83, 88], ["lamivudine prophylaxis", "TREATMENT", 125, 147], ["organs", "ANATOMY", 19, 25]]], ["There are 6 licensed drugs available for the treatment of chronic HBV (interferon, lamivudine, adefovir, entecavir, telbivudine, and tenofovir).", [["lamivudine", "CHEMICAL", 83, 93], ["adefovir", "CHEMICAL", 95, 103], ["entecavir", "CHEMICAL", 105, 114], ["telbivudine", "CHEMICAL", 116, 127], ["tenofovir", "CHEMICAL", 133, 142], ["lamivudine", "CHEMICAL", 83, 93], ["adefovir", "CHEMICAL", 95, 103], ["entecavir", "CHEMICAL", 105, 114], ["telbivudine", "CHEMICAL", 116, 127], ["tenofovir", "CHEMICAL", 133, 142], ["HBV", "ORGANISM", 66, 69], ["lamivudine", "SIMPLE_CHEMICAL", 83, 93], ["adefovir", "SIMPLE_CHEMICAL", 95, 103], ["entecavir", "SIMPLE_CHEMICAL", 105, 114], ["telbivudine", "SIMPLE_CHEMICAL", 116, 127], ["tenofovir", "SIMPLE_CHEMICAL", 133, 142], ["HBV", "SPECIES", 66, 69], ["6 licensed drugs", "TREATMENT", 10, 26], ["the treatment", "TREATMENT", 41, 54], ["chronic HBV", "PROBLEM", 58, 69], ["interferon", "TREATMENT", 71, 81], ["lamivudine", "TREATMENT", 83, 93], ["adefovir", "TREATMENT", 95, 103], ["entecavir", "TREATMENT", 105, 114], ["telbivudine", "TREATMENT", 116, 127], ["tenofovir", "TREATMENT", 133, 142], ["chronic", "OBSERVATION_MODIFIER", 58, 65], ["HBV", "OBSERVATION", 66, 69]]], ["To date, interferon has not been promising in the management of HBV in renal transplanted recipients.", [["renal", "ANATOMY", 71, 76], ["interferon", "CHEMICAL", 9, 19], ["interferon", "GENE_OR_GENE_PRODUCT", 9, 19], ["HBV", "ORGANISM", 64, 67], ["renal", "ORGAN", 71, 76], ["interferon", "PROTEIN", 9, 19], ["HBV", "SPECIES", 64, 67], ["interferon", "TREATMENT", 9, 19], ["HBV", "PROBLEM", 64, 67], ["renal transplanted recipients", "TREATMENT", 71, 100], ["HBV", "OBSERVATION", 64, 67], ["renal", "ANATOMY", 71, 76], ["transplanted recipients", "OBSERVATION", 77, 100]]], ["There have been no studies regarding the use of telbivudine and tenofovir after renal transplantation.", [["renal", "ANATOMY", 80, 85], ["telbivudine", "CHEMICAL", 48, 59], ["tenofovir", "CHEMICAL", 64, 73], ["telbivudine", "CHEMICAL", 48, 59], ["tenofovir", "CHEMICAL", 64, 73], ["telbivudine", "SIMPLE_CHEMICAL", 48, 59], ["tenofovir", "SIMPLE_CHEMICAL", 64, 73], ["renal", "ORGAN", 80, 85], ["studies", "TEST", 19, 26], ["telbivudine", "TREATMENT", 48, 59], ["tenofovir", "TREATMENT", 64, 73], ["renal transplantation", "TREATMENT", 80, 101], ["renal", "ANATOMY", 80, 85], ["transplantation", "OBSERVATION", 86, 101]]], ["However, the management of HBV after renal transplantation has given encouraging results with lamivudine, adefovir, and entecavir [116] .Hepatitis B and C VirusThe role of liver biopsy in the evaluation of RT candidates with HBsAg is important because it is difficult, on clinical grounds alone, to estimate the severity of liver disease in CKD population.", [["renal", "ANATOMY", 37, 42], ["liver biopsy", "ANATOMY", 172, 184], ["liver", "ANATOMY", 324, 329], ["lamivudine", "CHEMICAL", 94, 104], ["adefovir", "CHEMICAL", 106, 114], ["entecavir", "CHEMICAL", 120, 129], ["Hepatitis B", "DISEASE", 137, 148], ["HBsAg", "CHEMICAL", 225, 230], ["liver disease", "DISEASE", 324, 337], ["CKD", "DISEASE", 341, 344], ["lamivudine", "CHEMICAL", 94, 104], ["adefovir", "CHEMICAL", 106, 114], ["entecavir", "CHEMICAL", 120, 129], ["HBV", "ORGANISM", 27, 30], ["renal", "ORGAN", 37, 42], ["lamivudine", "SIMPLE_CHEMICAL", 94, 104], ["adefovir", "SIMPLE_CHEMICAL", 106, 114], ["entecavir", "SIMPLE_CHEMICAL", 120, 129], ["Hepatitis B", "ORGANISM", 137, 148], ["C Virus", "ORGANISM", 153, 160], ["liver biopsy", "MULTI-TISSUE_STRUCTURE", 172, 184], ["HBsAg", "GENE_OR_GENE_PRODUCT", 225, 230], ["liver", "ORGAN", 324, 329], ["HBsAg", "PROTEIN", 225, 230], ["HBV", "SPECIES", 27, 30], ["Hepatitis B", "SPECIES", 137, 148], ["HBV", "PROBLEM", 27, 30], ["renal transplantation", "TREATMENT", 37, 58], ["lamivudine", "TREATMENT", 94, 104], ["adefovir", "TREATMENT", 106, 114], ["entecavir", "TREATMENT", 120, 129], ["Hepatitis B and C Virus", "PROBLEM", 137, 160], ["liver biopsy", "TEST", 172, 184], ["the evaluation", "TEST", 188, 202], ["RT candidates", "TREATMENT", 206, 219], ["HBsAg", "TREATMENT", 225, 230], ["liver disease", "PROBLEM", 324, 337], ["CKD population", "PROBLEM", 341, 355], ["renal", "ANATOMY", 37, 42], ["transplantation", "OBSERVATION", 43, 58], ["liver", "ANATOMY", 172, 177], ["biopsy", "OBSERVATION", 178, 184], ["liver", "ANATOMY", 324, 329], ["disease", "OBSERVATION", 330, 337], ["CKD", "OBSERVATION", 341, 344]]], ["Patients with established cirrhosis on liver biopsy are at risk for hepatic decompensation after isolated RT, and kidney transplantation alone is contraindicated.", [["liver biopsy", "ANATOMY", 39, 51], ["hepatic", "ANATOMY", 68, 75], ["kidney", "ANATOMY", 114, 120], ["cirrhosis", "DISEASE", 26, 35], ["hepatic decompensation", "DISEASE", 68, 90], ["Patients", "ORGANISM", 0, 8], ["liver biopsy", "MULTI-TISSUE_STRUCTURE", 39, 51], ["hepatic", "ORGAN", 68, 75], ["kidney", "ORGAN", 114, 120], ["Patients", "SPECIES", 0, 8], ["established cirrhosis", "PROBLEM", 14, 35], ["liver biopsy", "TEST", 39, 51], ["hepatic decompensation", "PROBLEM", 68, 90], ["isolated RT", "TREATMENT", 97, 108], ["kidney transplantation", "TREATMENT", 114, 136], ["cirrhosis", "OBSERVATION", 26, 35], ["liver", "ANATOMY", 39, 44], ["biopsy", "OBSERVATION", 45, 51], ["hepatic", "ANATOMY", 68, 75], ["decompensation", "OBSERVATION", 76, 90], ["kidney", "ANATOMY", 114, 120], ["transplantation", "OBSERVATION", 121, 136]]], ["In patients with normal renal function, antiviral therapy has been reported to lead to regression of advanced histologic lesions.Hepatitis B and C VirusSimilar to hepatitis B, hepatitis C is a complex problem for the renal transplant recipient.", [["renal", "ANATOMY", 24, 29], ["histologic lesions", "ANATOMY", 110, 128], ["renal transplant", "ANATOMY", 217, 233], ["Hepatitis B", "DISEASE", 129, 140], ["hepatitis B", "DISEASE", 163, 174], ["hepatitis C", "DISEASE", 176, 187], ["patients", "ORGANISM", 3, 11], ["renal", "ORGAN", 24, 29], ["histologic lesions", "CANCER", 110, 128], ["Hepatitis B", "ORGANISM", 129, 140], ["C VirusSimilar", "ORGANISM", 145, 159], ["hepatitis B", "ORGANISM", 163, 174], ["hepatitis C", "ORGANISM", 176, 187], ["renal", "ORGAN", 217, 222], ["patients", "SPECIES", 3, 11], ["Hepatitis B", "SPECIES", 129, 140], ["hepatitis B", "SPECIES", 163, 174], ["antiviral therapy", "TREATMENT", 40, 57], ["advanced histologic lesions", "PROBLEM", 101, 128], ["Hepatitis B", "PROBLEM", 129, 140], ["C VirusSimilar", "PROBLEM", 145, 159], ["hepatitis B", "PROBLEM", 163, 174], ["hepatitis C", "PROBLEM", 176, 187], ["a complex problem", "PROBLEM", 191, 208], ["the renal transplant recipient", "TREATMENT", 213, 243], ["normal", "OBSERVATION", 17, 23], ["renal", "ANATOMY", 24, 29], ["function", "OBSERVATION", 30, 38], ["antiviral therapy", "OBSERVATION", 40, 57], ["advanced", "OBSERVATION_MODIFIER", 101, 109], ["histologic", "OBSERVATION_MODIFIER", 110, 120], ["lesions", "OBSERVATION", 121, 128], ["hepatitis", "OBSERVATION", 163, 172], ["hepatitis", "OBSERVATION", 176, 185], ["renal", "ANATOMY", 217, 222], ["transplant", "OBSERVATION", 223, 233]]], ["Hepatitis C virus belongs to family Flaviviridae, genus Hepacivirus, species Hepatitis C virus Incidence rates in the chronic disease population have decreased, averaging 0.7 to 3 percent per year [30] .", [["Hepatitis C", "DISEASE", 0, 11], ["Hepatitis C", "DISEASE", 77, 88], ["chronic disease", "DISEASE", 118, 133], ["Hepatitis C virus", "ORGANISM", 0, 17], ["genus Hepacivirus", "ORGANISM", 50, 67], ["species", "ORGANISM", 69, 76], ["Hepatitis C virus", "ORGANISM", 77, 94], ["Hepatitis C virus", "SPECIES", 0, 17], ["Hepatitis C virus", "SPECIES", 77, 94], ["Hepatitis C virus", "SPECIES", 0, 17], ["Hepatitis C virus", "SPECIES", 77, 94], ["Hepatitis C virus", "PROBLEM", 0, 17], ["Flaviviridae", "TREATMENT", 36, 48], ["genus Hepacivirus", "PROBLEM", 50, 67], ["species Hepatitis C virus", "PROBLEM", 69, 94], ["the chronic disease population", "PROBLEM", 114, 144], ["chronic", "OBSERVATION_MODIFIER", 118, 125], ["disease", "OBSERVATION", 126, 133], ["decreased", "OBSERVATION_MODIFIER", 150, 159]]], ["Recognition of hepatitis C in patients with chronic renal failure may be confounded by the limited sensitivity of serologic diagnosis in this population.", [["renal", "ANATOMY", 52, 57], ["hepatitis C", "DISEASE", 15, 26], ["chronic renal failure", "DISEASE", 44, 65], ["hepatitis C", "ORGANISM", 15, 26], ["patients", "ORGANISM", 30, 38], ["renal", "ORGAN", 52, 57], ["patients", "SPECIES", 30, 38], ["hepatitis C", "PROBLEM", 15, 26], ["chronic renal failure", "PROBLEM", 44, 65], ["serologic diagnosis", "TEST", 114, 133], ["hepatitis", "OBSERVATION", 15, 24], ["chronic", "OBSERVATION_MODIFIER", 44, 51], ["renal", "ANATOMY", 52, 57], ["failure", "OBSERVATION", 58, 65]]], ["All hepatitis C seronegative transplant candidates who have abnormal transaminases and/or risk factors for hepatitis C should undergo nucleic acid testing.", [["hepatitis C", "DISEASE", 4, 15], ["abnormal transaminases", "DISEASE", 60, 82], ["hepatitis C", "DISEASE", 107, 118], ["nucleic acid", "CHEMICAL", 134, 146], ["hepatitis C", "ORGANISM", 4, 15], ["hepatitis C", "ORGANISM", 107, 118], ["All hepatitis C seronegative transplant", "TREATMENT", 0, 39], ["abnormal transaminases", "PROBLEM", 60, 82], ["risk factors", "PROBLEM", 90, 102], ["hepatitis C", "PROBLEM", 107, 118], ["nucleic acid testing", "TEST", 134, 154], ["hepatitis", "OBSERVATION", 4, 13]]], ["Because of the increased risk of progressive liver disease following transplantation, patients with hepatitis C should undergo liver biopsy to exclude advanced liver disease, which in some cases may necessitate a combined liver-kidney transplant [128] .", [["liver", "ANATOMY", 45, 50], ["liver", "ANATOMY", 127, 132], ["liver", "ANATOMY", 160, 165], ["liver", "ANATOMY", 222, 227], ["kidney", "ANATOMY", 228, 234], ["liver disease", "DISEASE", 45, 58], ["hepatitis C", "DISEASE", 100, 111], ["liver disease", "DISEASE", 160, 173], ["liver", "ORGAN", 45, 50], ["patients", "ORGANISM", 86, 94], ["hepatitis C", "ORGANISM", 100, 111], ["liver", "ORGAN", 127, 132], ["liver", "ORGAN", 160, 165], ["liver", "ORGAN", 222, 227], ["kidney", "ORGAN", 228, 234], ["patients", "SPECIES", 86, 94], ["progressive liver disease", "PROBLEM", 33, 58], ["transplantation", "TREATMENT", 69, 84], ["hepatitis C", "PROBLEM", 100, 111], ["liver biopsy", "TEST", 127, 139], ["advanced liver disease", "PROBLEM", 151, 173], ["a combined liver-kidney transplant", "TREATMENT", 211, 245], ["increased", "OBSERVATION_MODIFIER", 15, 24], ["progressive", "OBSERVATION_MODIFIER", 33, 44], ["liver", "ANATOMY", 45, 50], ["disease", "OBSERVATION", 51, 58], ["liver", "ANATOMY", 127, 132], ["liver", "ANATOMY", 160, 165], ["disease", "OBSERVATION", 166, 173], ["liver", "ANATOMY", 222, 227], ["kidney", "ANATOMY", 228, 234], ["transplant", "OBSERVATION", 235, 245]]], ["Hepatitis-C-positive patients usually have a marked rise in viral load with initiation of immunosuppression immediately after transplant.", [["Hepatitis-C-positive", "DISEASE", 0, 20], ["Hepatitis-C", "ORGANISM", 0, 11], ["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29], ["Hepatitis", "TEST", 0, 9], ["a marked rise in viral load", "PROBLEM", 43, 70], ["immunosuppression", "TREATMENT", 90, 107], ["transplant", "TREATMENT", 126, 136], ["marked", "OBSERVATION_MODIFIER", 45, 51], ["rise", "OBSERVATION_MODIFIER", 52, 56], ["viral load", "OBSERVATION", 60, 70]]], ["Chronic immunosuppression used in transplant recipients also leads to higher circulating levels of virus and intrahepatic virus due to the decreased T-cell response to the NS3 region of hepatitis C virus [30] .", [["T-cell", "ANATOMY", 149, 155], ["hepatitis C", "DISEASE", 186, 197], ["recipients", "ORGANISM", 45, 55], ["intrahepatic virus", "ORGANISM", 109, 127], ["T-cell", "CELL", 149, 155], ["hepatitis C virus", "ORGANISM", 186, 203], ["NS3 region", "PROTEIN", 172, 182], ["hepatitis C virus", "SPECIES", 186, 203], ["hepatitis C virus", "SPECIES", 186, 203], ["Chronic immunosuppression", "TREATMENT", 0, 25], ["transplant recipients", "TREATMENT", 34, 55], ["higher circulating levels of virus", "PROBLEM", 70, 104], ["intrahepatic virus", "PROBLEM", 109, 127], ["the decreased T-cell response", "PROBLEM", 135, 164], ["hepatitis C virus", "PROBLEM", 186, 203], ["immunosuppression", "OBSERVATION", 8, 25], ["intrahepatic", "ANATOMY", 109, 121], ["virus", "OBSERVATION", 122, 127], ["hepatitis", "OBSERVATION", 186, 195]]], ["Consequently patients with hepatitis C are at increased risk for progressive liver disease and the development of cirrhosis following transplantation.Hepatitis B and C VirusBecause of the large demand for organs, consideration has been given to the use of hepatitis-C-positive donors.", [["liver", "ANATOMY", 77, 82], ["organs", "ANATOMY", 205, 211], ["hepatitis C", "DISEASE", 27, 38], ["liver disease", "DISEASE", 77, 90], ["cirrhosis", "DISEASE", 114, 123], ["Hepatitis B", "DISEASE", 150, 161], ["hepatitis-C", "CHEMICAL", 256, 267], ["patients", "ORGANISM", 13, 21], ["hepatitis C", "ORGANISM", 27, 38], ["liver", "ORGAN", 77, 82], ["Hepatitis B", "ORGANISM", 150, 161], ["organs", "ORGAN", 205, 211], ["hepatitis-C", "ORGANISM", 256, 267], ["donors", "ORGANISM", 277, 283], ["patients", "SPECIES", 13, 21], ["hepatitis C", "PROBLEM", 27, 38], ["progressive liver disease", "PROBLEM", 65, 90], ["cirrhosis", "PROBLEM", 114, 123], ["transplantation", "TREATMENT", 134, 149], ["Hepatitis B", "PROBLEM", 150, 161], ["hepatitis", "PROBLEM", 256, 265], ["positive donors", "PROBLEM", 268, 283], ["hepatitis", "OBSERVATION", 27, 36], ["progressive", "OBSERVATION_MODIFIER", 65, 76], ["liver", "ANATOMY", 77, 82], ["disease", "OBSERVATION", 83, 90], ["cirrhosis", "OBSERVATION", 114, 123], ["large", "OBSERVATION_MODIFIER", 188, 193], ["demand", "OBSERVATION", 194, 200]]], ["Transplant recipients may acquire hepatitis C through transplantation itself, which may lead to severe hepatitis.", [["hepatitis C", "DISEASE", 34, 45], ["hepatitis", "DISEASE", 103, 112], ["recipients", "ORGANISM", 11, 21], ["hepatitis C", "ORGANISM", 34, 45], ["Transplant recipients", "TREATMENT", 0, 21], ["hepatitis C through transplantation", "TREATMENT", 34, 69], ["severe hepatitis", "PROBLEM", 96, 112], ["recipients", "OBSERVATION", 11, 21], ["hepatitis", "OBSERVATION", 34, 43], ["may lead to", "UNCERTAINTY", 84, 95], ["severe", "OBSERVATION_MODIFIER", 96, 102], ["hepatitis", "OBSERVATION", 103, 112]]], ["Although recipients of HCV positive kidneys have diminished patient and graft survival as compared with recipients of HCV-negative kidneys, survival may be improved when compared with survival on dialysis [129] .Hepatitis B and C VirusThe problem of anti-HCV therapy is that interferon (IFN) has been associated with an increased risk of allograft rejection not only in the functioning grafts but also in the already failed grafts [130] .", [["kidneys", "ANATOMY", 36, 43], ["graft", "ANATOMY", 72, 77], ["kidneys", "ANATOMY", 131, 138], ["allograft", "ANATOMY", 338, 347], ["grafts", "ANATOMY", 386, 392], ["grafts", "ANATOMY", 424, 430], ["Hepatitis B", "DISEASE", 212, 223], ["recipients", "ORGANISM", 9, 19], ["HCV", "ORGANISM", 23, 26], ["kidneys", "ORGAN", 36, 43], ["patient", "ORGANISM", 60, 67], ["graft", "TISSUE", 72, 77], ["recipients", "ORGANISM", 104, 114], ["HCV", "ORGANISM", 118, 121], ["kidneys", "ORGAN", 131, 138], ["Hepatitis B", "ORGANISM", 212, 223], ["C Virus", "ORGANISM", 228, 235], ["interferon", "GENE_OR_GENE_PRODUCT", 275, 285], ["IFN", "GENE_OR_GENE_PRODUCT", 287, 290], ["allograft", "TISSUE", 338, 347], ["grafts", "TISSUE", 386, 392], ["grafts", "TISSUE", 424, 430], ["interferon", "PROTEIN", 275, 285], ["IFN", "PROTEIN", 287, 290], ["patient", "SPECIES", 60, 67], ["HCV", "SPECIES", 23, 26], ["HCV", "SPECIES", 118, 121], ["Hepatitis B", "SPECIES", 212, 223], ["HCV positive kidneys", "PROBLEM", 23, 43], ["graft survival", "TREATMENT", 72, 86], ["HCV", "PROBLEM", 118, 121], ["dialysis", "TREATMENT", 196, 204], ["Hepatitis B", "PROBLEM", 212, 223], ["C Virus", "PROBLEM", 228, 235], ["anti-HCV therapy", "TREATMENT", 250, 266], ["interferon (IFN", "TREATMENT", 275, 290], ["allograft rejection", "PROBLEM", 338, 357], ["the functioning grafts", "TREATMENT", 370, 392], ["HCV", "OBSERVATION", 23, 26], ["kidneys", "ANATOMY", 36, 43], ["diminished", "OBSERVATION_MODIFIER", 49, 59], ["graft survival", "OBSERVATION", 72, 86], ["HCV", "OBSERVATION", 118, 121], ["negative", "OBSERVATION", 122, 130], ["kidneys", "ANATOMY", 131, 138], ["anti-HCV therapy", "OBSERVATION", 250, 266], ["increased", "OBSERVATION_MODIFIER", 320, 329], ["allograft rejection", "OBSERVATION", 338, 357], ["grafts", "OBSERVATION", 386, 392], ["grafts", "OBSERVATION", 424, 430]]], ["Therefore this may explain the major hesitancy to the use of IFNa in renal transplant recipients.", [["renal transplant", "ANATOMY", 69, 85], ["IFNa", "CHEMICAL", 61, 65], ["IFNa", "GENE_OR_GENE_PRODUCT", 61, 65], ["renal", "ORGAN", 69, 74], ["IFNa", "PROTEIN", 61, 65], ["renal transplant recipients", "TREATMENT", 69, 96], ["renal", "ANATOMY", 69, 74], ["transplant", "OBSERVATION", 75, 85]]], ["It increases rejection possibly by cytokine gene expression, increased cell surface expression of HLA antigens, and enhanced function of natural killer cells, cytotoxic T cells, and monocytes.", [["cell surface", "ANATOMY", 71, 83], ["natural killer cells", "ANATOMY", 137, 157], ["cytotoxic T cells", "ANATOMY", 159, 176], ["monocytes", "ANATOMY", 182, 191], ["cell", "CELL", 71, 75], ["HLA antigens", "GENE_OR_GENE_PRODUCT", 98, 110], ["natural killer cells", "CELL", 137, 157], ["cytotoxic T cells", "CELL", 159, 176], ["monocytes", "CELL", 182, 191], ["cytokine gene", "DNA", 35, 48], ["HLA antigens", "PROTEIN", 98, 110], ["natural killer cells", "CELL_TYPE", 137, 157], ["cytotoxic T cells", "CELL_TYPE", 159, 176], ["monocytes", "CELL_TYPE", 182, 191], ["rejection", "PROBLEM", 13, 22], ["cytokine gene expression", "PROBLEM", 35, 59], ["increased cell surface expression of HLA antigens", "PROBLEM", 61, 110], ["natural killer cells", "PROBLEM", 137, 157], ["cytotoxic T cells", "TEST", 159, 176], ["monocytes", "TEST", 182, 191], ["increases", "OBSERVATION_MODIFIER", 3, 12], ["rejection", "OBSERVATION", 13, 22], ["cytokine gene expression", "OBSERVATION", 35, 59], ["increased", "OBSERVATION_MODIFIER", 61, 70], ["cell", "OBSERVATION", 71, 75], ["surface", "OBSERVATION_MODIFIER", 76, 83], ["natural killer cells", "OBSERVATION", 137, 157], ["monocytes", "ANATOMY", 182, 191]]], ["These immune-stimulant effects can result in enhanced allograft rejection-which may be irreversible-even in patients with stable grafts.", [["allograft", "ANATOMY", 54, 63], ["grafts", "ANATOMY", 129, 135], ["allograft", "ORGAN", 54, 63], ["patients", "ORGANISM", 108, 116], ["grafts", "TISSUE", 129, 135], ["patients", "SPECIES", 108, 116], ["stimulant effects", "PROBLEM", 13, 30], ["enhanced allograft rejection", "PROBLEM", 45, 73], ["stable grafts", "TREATMENT", 122, 135], ["allograft rejection", "OBSERVATION", 54, 73], ["may be", "UNCERTAINTY", 80, 86], ["irreversible", "OBSERVATION_MODIFIER", 87, 99], ["stable", "OBSERVATION_MODIFIER", 122, 128], ["grafts", "OBSERVATION", 129, 135]]], ["So it has been indicated only in patients with fibrosing cholestatic hepatitis or other conditions in which the benefits of treatment outweigh the risk of allograft loss [131] .", [["allograft", "ANATOMY", 155, 164], ["fibrosing cholestatic hepatitis", "DISEASE", 47, 78], ["patients", "ORGANISM", 33, 41], ["allograft", "TISSUE", 155, 164], ["patients", "SPECIES", 33, 41], ["fibrosing cholestatic hepatitis", "PROBLEM", 47, 78], ["other conditions", "PROBLEM", 82, 98], ["treatment", "TREATMENT", 124, 133], ["allograft loss", "PROBLEM", 155, 169], ["fibrosing", "OBSERVATION_MODIFIER", 47, 56], ["cholestatic", "OBSERVATION_MODIFIER", 57, 68], ["hepatitis", "OBSERVATION", 69, 78], ["allograft", "OBSERVATION", 155, 164]]], ["There are extremely limited data evaluating the efficacy and complications of IFNa therapy in the treatment of possible HCV-related cryoglobulinemia or de novo or recurrent glomerular disease in renal transplant recipients.", [["glomerular", "ANATOMY", 173, 183], ["renal transplant", "ANATOMY", 195, 211], ["IFNa", "CHEMICAL", 78, 82], ["cryoglobulinemia", "DISEASE", 132, 148], ["glomerular disease", "DISEASE", 173, 191], ["IFNa", "SIMPLE_CHEMICAL", 78, 82], ["HCV", "ORGANISM", 120, 123], ["glomerular", "TISSUE", 173, 183], ["renal", "ORGAN", 195, 200], ["HCV", "SPECIES", 120, 123], ["IFNa therapy", "TREATMENT", 78, 90], ["the treatment", "TREATMENT", 94, 107], ["HCV", "PROBLEM", 120, 123], ["related cryoglobulinemia", "PROBLEM", 124, 148], ["recurrent glomerular disease", "PROBLEM", 163, 191], ["renal transplant recipients", "TREATMENT", 195, 222], ["possible", "UNCERTAINTY", 111, 119], ["HCV", "OBSERVATION", 120, 123], ["cryoglobulinemia", "OBSERVATION", 132, 148], ["recurrent", "OBSERVATION_MODIFIER", 163, 172], ["glomerular disease", "OBSERVATION", 173, 191], ["renal", "ANATOMY", 195, 200], ["transplant recipients", "OBSERVATION", 201, 222]]], ["Pageaux et al. [132] showed that treatment of HCV with IFN after transplantation might not be as risky as initially shown.", [["HCV", "DISEASE", 46, 49], ["IFN", "CHEMICAL", 55, 58], ["HCV", "ORGANISM", 46, 49], ["IFN", "PROTEIN", 55, 58], ["HCV", "SPECIES", 46, 49], ["HCV", "PROBLEM", 46, 49], ["IFN", "TREATMENT", 55, 58], ["transplantation", "TREATMENT", 65, 80]]], ["Posttransplant monotherapies with ribavirin and/or amantadine have no apparent impact on HCV viremia or liver histology [133] .", [["liver", "ANATOMY", 104, 109], ["ribavirin", "CHEMICAL", 34, 43], ["amantadine", "CHEMICAL", 51, 61], ["viremia", "DISEASE", 93, 100], ["ribavirin", "CHEMICAL", 34, 43], ["amantadine", "CHEMICAL", 51, 61], ["ribavirin", "SIMPLE_CHEMICAL", 34, 43], ["amantadine", "SIMPLE_CHEMICAL", 51, 61], ["HCV", "ORGANISM", 89, 92], ["liver", "ORGAN", 104, 109], ["HCV", "SPECIES", 89, 92], ["Posttransplant monotherapies", "TREATMENT", 0, 28], ["ribavirin", "TREATMENT", 34, 43], ["amantadine", "TREATMENT", 51, 61], ["HCV viremia", "PROBLEM", 89, 100], ["liver histology", "TEST", 104, 119], ["ribavirin", "OBSERVATION", 34, 43], ["no apparent", "UNCERTAINTY", 67, 78], ["HCV", "OBSERVATION", 89, 92], ["liver", "ANATOMY", 104, 109]]], ["So the best strategy is to treat HCV infection in patients on dialysis before transplantation after excluding cirrhosis by liver biopsy and if present patients should be considered for combined kidneyliver transplantation [128, 132, 133] .", [["liver", "ANATOMY", 123, 128], ["HCV infection", "DISEASE", 33, 46], ["cirrhosis", "DISEASE", 110, 119], ["HCV", "ORGANISM", 33, 36], ["patients", "ORGANISM", 50, 58], ["liver", "ORGAN", 123, 128], ["patients", "ORGANISM", 151, 159], ["patients", "SPECIES", 50, 58], ["patients", "SPECIES", 151, 159], ["HCV", "SPECIES", 33, 36], ["HCV infection", "PROBLEM", 33, 46], ["dialysis", "TREATMENT", 62, 70], ["transplantation", "TREATMENT", 78, 93], ["cirrhosis", "PROBLEM", 110, 119], ["liver biopsy", "TEST", 123, 135], ["combined kidneyliver transplantation", "TREATMENT", 185, 221], ["infection", "OBSERVATION", 37, 46], ["cirrhosis", "OBSERVATION", 110, 119], ["liver", "ANATOMY", 123, 128], ["biopsy", "OBSERVATION", 129, 135]]], ["Such strategy could prevent liver disease progression and even HCV-related morbidities such as glomerulonephritis and posttransplant diabetes mellitus.Human Immunodeficiency VirusHuman immunodeficiency virus (HIV) belong to family Retroviridae, genus Lentivirus, species Human immunodeficiency virus.", [["liver", "ANATOMY", 28, 33], ["liver disease", "DISEASE", 28, 41], ["glomerulonephritis", "DISEASE", 95, 113], ["posttransplant diabetes mellitus", "DISEASE", 118, 150], ["Human Immunodeficiency VirusHuman immunodeficiency virus (HIV)", "DISEASE", 151, 213], ["Human immunodeficiency virus", "DISEASE", 271, 299], ["liver", "ORGAN", 28, 33], ["Human Immunodeficiency VirusHuman immunodeficiency virus", "ORGANISM", 151, 207], ["HIV", "ORGANISM", 209, 212], ["Retroviridae", "GENE_OR_GENE_PRODUCT", 231, 243], ["Lentivirus", "ORGANISM", 251, 261], ["species", "ORGANISM", 263, 270], ["Human immunodeficiency virus", "ORGANISM", 271, 299], ["Human", "SPECIES", 151, 156], ["VirusHuman immunodeficiency virus (HIV", "SPECIES", 174, 212], ["Human immunodeficiency virus", "SPECIES", 271, 299], ["HCV", "SPECIES", 63, 66], ["Human Immunodeficiency VirusHuman immunodeficiency virus", "SPECIES", 151, 207], ["HIV", "SPECIES", 209, 212], ["Human immunodeficiency virus", "SPECIES", 271, 299], ["liver disease progression", "PROBLEM", 28, 53], ["HCV", "PROBLEM", 63, 66], ["related morbidities", "PROBLEM", 67, 86], ["glomerulonephritis", "PROBLEM", 95, 113], ["posttransplant diabetes mellitus", "PROBLEM", 118, 150], ["Human Immunodeficiency VirusHuman immunodeficiency virus", "PROBLEM", 151, 207], ["Retroviridae", "TREATMENT", 231, 243], ["genus Lentivirus", "TREATMENT", 245, 261], ["Human immunodeficiency virus", "PROBLEM", 271, 299], ["liver", "ANATOMY", 28, 33], ["disease", "OBSERVATION", 34, 41], ["HCV", "OBSERVATION", 63, 66], ["glomerulonephritis", "OBSERVATION", 95, 113], ["posttransplant", "OBSERVATION_MODIFIER", 118, 132], ["diabetes mellitus", "OBSERVATION", 133, 150], ["genus Lentivirus", "ANATOMY", 245, 261], ["immunodeficiency virus", "OBSERVATION", 277, 299]]], ["HIV infection has been a major global health problem for almost three decades.", [["HIV infection", "DISEASE", 0, 13], ["HIV", "ORGANISM", 0, 3], ["HIV", "SPECIES", 0, 3], ["HIV", "SPECIES", 0, 3], ["HIV infection", "PROBLEM", 0, 13], ["infection", "OBSERVATION", 4, 13], ["major", "OBSERVATION_MODIFIER", 25, 30], ["global", "OBSERVATION_MODIFIER", 31, 37], ["health", "OBSERVATION", 38, 44]]], ["With the introduction of highly active antiretroviral therapy (HAART) in 1996, and the advent of effective prophylaxis and management of opportunistic infections, AIDS mortality has decreased markedly.", [["opportunistic infections", "DISEASE", 137, 161], ["AIDS", "DISEASE", 163, 167], ["highly active antiretroviral therapy", "TREATMENT", 25, 61], ["HAART", "TREATMENT", 63, 68], ["effective prophylaxis", "TREATMENT", 97, 118], ["management", "TREATMENT", 123, 133], ["opportunistic infections", "PROBLEM", 137, 161], ["AIDS mortality", "PROBLEM", 163, 177], ["antiretroviral therapy", "OBSERVATION", 39, 61], ["opportunistic", "OBSERVATION_MODIFIER", 137, 150], ["infections", "OBSERVATION", 151, 161], ["decreased", "OBSERVATION_MODIFIER", 182, 191], ["markedly", "OBSERVATION_MODIFIER", 192, 200]]], ["In developed countries, this once fatal infection is now being treated as a chronic condition.", [["infection", "DISEASE", 40, 49], ["fatal infection", "PROBLEM", 34, 49], ["a chronic condition", "PROBLEM", 74, 93], ["infection", "OBSERVATION", 40, 49], ["chronic", "OBSERVATION_MODIFIER", 76, 83]]], ["As a result, rate of morbidity and mortality from other medical conditions leading to end-stage liver, kidney, and heart disease is steadily increasing in individuals with HIV.", [["liver", "ANATOMY", 96, 101], ["kidney", "ANATOMY", 103, 109], ["heart", "ANATOMY", 115, 120], ["end-stage liver, kidney, and heart disease", "DISEASE", 86, 128], ["liver", "ORGAN", 96, 101], ["kidney", "ORGAN", 103, 109], ["heart", "ORGAN", 115, 120], ["HIV", "SPECIES", 172, 175], ["HIV", "SPECIES", 172, 175], ["morbidity", "PROBLEM", 21, 30], ["other medical conditions", "PROBLEM", 50, 74], ["end-stage liver, kidney", "PROBLEM", 86, 109], ["heart disease", "PROBLEM", 115, 128], ["HIV", "PROBLEM", 172, 175], ["liver", "ANATOMY", 96, 101], ["kidney", "ANATOMY", 103, 109], ["heart", "ANATOMY", 115, 120], ["disease", "OBSERVATION", 121, 128], ["steadily", "OBSERVATION_MODIFIER", 132, 140], ["increasing", "OBSERVATION_MODIFIER", 141, 151]]], ["Renal diseases directly related to HIV infection include HIV-associated nephropathy (HIVAN), immune complex diseases, and thrombotic microangiopathy [134] .", [["Renal", "ANATOMY", 0, 5], ["Renal diseases", "DISEASE", 0, 14], ["HIV infection", "DISEASE", 35, 48], ["HIV-associated nephropathy", "DISEASE", 57, 83], ["HIVAN", "DISEASE", 85, 90], ["immune complex diseases", "DISEASE", 93, 116], ["thrombotic microangiopathy", "DISEASE", 122, 148], ["Renal", "ORGAN", 0, 5], ["HIV", "ORGANISM", 35, 38], ["HIV", "ORGANISM", 57, 60], ["HIV", "SPECIES", 35, 38], ["HIV", "SPECIES", 57, 60], ["HIV", "SPECIES", 35, 38], ["Renal diseases", "PROBLEM", 0, 14], ["HIV infection", "PROBLEM", 35, 48], ["HIV", "PROBLEM", 57, 60], ["associated nephropathy", "PROBLEM", 61, 83], ["HIVAN)", "PROBLEM", 85, 91], ["immune complex diseases", "PROBLEM", 93, 116], ["thrombotic microangiopathy", "PROBLEM", 122, 148], ["diseases", "OBSERVATION", 6, 14], ["HIV", "OBSERVATION_MODIFIER", 35, 38], ["infection", "OBSERVATION", 39, 48], ["nephropathy", "OBSERVATION", 72, 83], ["complex diseases", "OBSERVATION", 100, 116], ["thrombotic", "OBSERVATION_MODIFIER", 122, 132], ["microangiopathy", "OBSERVATION", 133, 148]]], ["Although the widespread use of HAART has decreased the incidence of HIV-related renal disease, the overall prevalence of renal disease continues to increase among patients with HIV.", [["renal", "ANATOMY", 80, 85], ["renal", "ANATOMY", 121, 126], ["HIV-related renal disease", "DISEASE", 68, 93], ["renal disease", "DISEASE", 121, 134], ["HIV", "DISEASE", 177, 180], ["renal", "ORGAN", 80, 85], ["renal", "ORGAN", 121, 126], ["patients", "ORGANISM", 163, 171], ["HIV", "SPECIES", 68, 71], ["patients", "SPECIES", 163, 171], ["HIV", "SPECIES", 177, 180], ["HIV", "SPECIES", 68, 71], ["HIV", "SPECIES", 177, 180], ["HAART", "TREATMENT", 31, 36], ["HIV-related renal disease", "PROBLEM", 68, 93], ["renal disease", "PROBLEM", 121, 134], ["HIV", "PROBLEM", 177, 180], ["widespread", "OBSERVATION_MODIFIER", 13, 23], ["HIV", "OBSERVATION", 68, 71], ["renal", "ANATOMY", 80, 85], ["disease", "OBSERVATION", 86, 93], ["renal", "ANATOMY", 121, 126], ["disease", "OBSERVATION", 127, 134]]], ["The most aggressive HIVrelated renal disease is HIVAN, which occurs in approximately 10% of patients with HIV [135] .", [["renal", "ANATOMY", 31, 36], ["HIVrelated renal disease", "DISEASE", 20, 44], ["HIVAN", "DISEASE", 48, 53], ["HIVrelated renal", "CANCER", 20, 36], ["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 92, 100], ["HIV", "SPECIES", 106, 109], ["HIV", "SPECIES", 106, 109], ["The most aggressive HIVrelated renal disease", "PROBLEM", 0, 44], ["HIVAN", "PROBLEM", 48, 53], ["HIV", "PROBLEM", 106, 109], ["most", "OBSERVATION_MODIFIER", 4, 8], ["aggressive", "OBSERVATION_MODIFIER", 9, 19], ["renal", "ANATOMY", 31, 36], ["disease", "OBSERVATION", 37, 44], ["HIVAN", "OBSERVATION", 48, 53]]], ["These patients can progress to end-stage renal disease (ESRD) within weeks to months.Human Immunodeficiency VirusRecent studies confirm that outcome of renal transplantation in adequately selected HIV-infected patients receiving kidneys from HIV-negative donors is similar to that of HIVnegative RT recipients [136] .", [["renal", "ANATOMY", 41, 46], ["renal", "ANATOMY", 152, 157], ["kidneys", "ANATOMY", 229, 236], ["end-stage renal disease", "DISEASE", 31, 54], ["ESRD", "DISEASE", 56, 60], ["HIV-infected", "DISEASE", 197, 209], ["patients", "ORGANISM", 6, 14], ["renal", "ORGAN", 41, 46], ["Human", "ORGANISM", 85, 90], ["renal", "ORGAN", 152, 157], ["HIV", "ORGANISM", 197, 200], ["patients", "ORGANISM", 210, 218], ["kidneys", "ORGAN", 229, 236], ["HIV", "ORGANISM", 242, 245], ["donors", "ORGANISM", 255, 261], ["HIVnegative RT recipients", "ORGANISM", 284, 309], ["patients", "SPECIES", 6, 14], ["Human", "SPECIES", 85, 90], ["HIV", "SPECIES", 197, 200], ["patients", "SPECIES", 210, 218], ["HIV", "SPECIES", 197, 200], ["HIV", "SPECIES", 242, 245], ["end-stage renal disease", "PROBLEM", 31, 54], ["ESRD", "PROBLEM", 56, 60], ["Human Immunodeficiency VirusRecent studies", "TEST", 85, 127], ["renal transplantation", "TREATMENT", 152, 173], ["kidneys", "TREATMENT", 229, 236], ["HIV", "PROBLEM", 242, 245], ["HIVnegative RT recipients", "TREATMENT", 284, 309], ["stage", "OBSERVATION_MODIFIER", 35, 40], ["renal", "ANATOMY", 41, 46], ["disease", "OBSERVATION", 47, 54], ["renal", "ANATOMY", 152, 157], ["transplantation", "OBSERVATION", 158, 173], ["kidneys", "ANATOMY", 229, 236]]], ["Main challenges in the clinical management of HIV-infected RT recipients are the pharmacologic interactions between immunosuppressive agents and some classes of antiretroviral drugs and a higher rate of acute rejection in comparison with HIV-negative RT recipients.", [["HIV-infected", "DISEASE", 46, 58], ["HIV", "ORGANISM", 46, 49], ["RT recipients", "ORGANISM", 59, 72], ["HIV", "ORGANISM", 238, 241], ["RT recipients", "ORGANISM", 251, 264], ["HIV", "SPECIES", 46, 49], ["HIV", "SPECIES", 238, 241], ["HIV", "SPECIES", 46, 49], ["HIV", "SPECIES", 238, 241], ["the clinical management", "TREATMENT", 19, 42], ["HIV", "PROBLEM", 46, 49], ["infected RT recipients", "TREATMENT", 50, 72], ["immunosuppressive agents", "TREATMENT", 116, 140], ["antiretroviral drugs", "TREATMENT", 161, 181], ["acute rejection", "PROBLEM", 203, 218], ["antiretroviral drugs", "OBSERVATION", 161, 181], ["acute", "OBSERVATION_MODIFIER", 203, 208], ["rejection", "OBSERVATION", 209, 218]]], ["Currently, organ transplantation from HIV-infected donors is an absolute contraindication in Western countries but its potential utility is under consideration [137] Recently, Muller et al. [138] reported the outcome of four HIV-infected RT recipients who received their grafts from two HIVinfected donors in South Africa, being the first clinical experience published involving this type of transplants.", [["organ", "ANATOMY", 11, 16], ["grafts", "ANATOMY", 271, 277], ["HIV-infected", "DISEASE", 38, 50], ["HIV-infected", "DISEASE", 225, 237], ["organ", "ORGAN", 11, 16], ["HIV", "ORGANISM", 38, 41], ["donors", "ORGANISM", 51, 57], ["HIV", "ORGANISM", 225, 228], ["RT", "ORGANISM", 238, 240], ["recipients", "ORGANISM", 241, 251], ["grafts", "TISSUE", 271, 277], ["donors", "ORGANISM", 299, 305], ["HIV", "SPECIES", 38, 41], ["HIV", "SPECIES", 38, 41], ["HIV", "SPECIES", 225, 228], ["organ transplantation", "TREATMENT", 11, 32], ["HIV", "PROBLEM", 38, 41], ["infected donors", "TREATMENT", 42, 57], ["infected RT recipients", "TREATMENT", 229, 251], ["their grafts", "TREATMENT", 265, 277], ["transplants", "TREATMENT", 392, 403], ["organ", "ANATOMY", 11, 16], ["transplantation", "OBSERVATION", 17, 32], ["grafts", "OBSERVATION", 271, 277], ["transplants", "OBSERVATION", 392, 403]]], ["After 12 months of followup, all recipients had a functioning renal allograft with a good renal function, and HIV infection was controlled under different antiretroviral regimens.", [["renal allograft", "ANATOMY", 62, 77], ["renal", "ANATOMY", 90, 95], ["HIV infection", "DISEASE", 110, 123], ["recipients", "ORGANISM", 33, 43], ["renal", "ORGAN", 62, 67], ["renal", "ORGAN", 90, 95], ["HIV", "ORGANISM", 110, 113], ["HIV", "SPECIES", 110, 113], ["a functioning renal allograft", "TREATMENT", 48, 77], ["HIV infection", "PROBLEM", 110, 123], ["different antiretroviral regimens", "TREATMENT", 145, 178], ["renal", "ANATOMY", 62, 67], ["allograft", "OBSERVATION", 68, 77], ["renal", "ANATOMY", 90, 95], ["function", "OBSERVATION", 96, 104], ["infection", "OBSERVATION", 114, 123], ["antiretroviral regimens", "OBSERVATION", 155, 178]]], ["South Africa is a country with a high HIV prevalence in the general population, and HIV infection is an absolute exclusion criterion for access to dialysis or RT.", [["HIV infection", "DISEASE", 84, 97], ["HIV", "ORGANISM", 84, 87], ["HIV", "SPECIES", 84, 87], ["HIV", "SPECIES", 38, 41], ["HIV", "SPECIES", 84, 87], ["a high HIV prevalence", "PROBLEM", 31, 52], ["HIV infection", "PROBLEM", 84, 97], ["dialysis", "TREATMENT", 147, 155], ["RT", "TREATMENT", 159, 161], ["infection", "OBSERVATION", 88, 97]]], ["Muller et al. [138] suggested that the use of HIV-infected donors would increase the donor pool, providing renal allografts to HIV-infected patients otherwise sentenced to death as a consequence of endstage renal disease.", [["renal allografts", "ANATOMY", 107, 123], ["renal", "ANATOMY", 207, 212], ["HIV-infected", "DISEASE", 46, 58], ["HIV-infected", "DISEASE", 127, 139], ["death", "DISEASE", 172, 177], ["endstage renal disease", "DISEASE", 198, 220], ["HIV", "ORGANISM", 46, 49], ["donors", "ORGANISM", 59, 65], ["renal allografts", "TISSUE", 107, 123], ["HIV", "ORGANISM", 127, 130], ["patients", "ORGANISM", 140, 148], ["renal", "ORGAN", 207, 212], ["patients", "SPECIES", 140, 148], ["HIV", "SPECIES", 46, 49], ["HIV", "SPECIES", 127, 130], ["HIV-infected donors", "TREATMENT", 46, 65], ["the donor pool", "TREATMENT", 81, 95], ["renal allografts", "TREATMENT", 107, 123], ["endstage renal disease", "PROBLEM", 198, 220], ["renal", "ANATOMY", 107, 112], ["allografts", "OBSERVATION", 113, 123], ["endstage", "OBSERVATION_MODIFIER", 198, 206], ["renal", "ANATOMY", 207, 212], ["disease", "OBSERVATION", 213, 220]]], ["Deceased HIV-infected patients represent a potential of approximately 500-600 donors per year for HIV-infected transplant candidates.", [["HIV-infected", "DISEASE", 9, 21], ["HIV-infected", "DISEASE", 98, 110], ["HIV", "ORGANISM", 9, 12], ["patients", "ORGANISM", 22, 30], ["donors", "ORGANISM", 78, 84], ["HIV", "ORGANISM", 98, 101], ["HIV-", "SPECIES", 9, 13], ["patients", "SPECIES", 22, 30], ["HIV", "SPECIES", 9, 12], ["HIV", "SPECIES", 98, 101], ["HIV", "PROBLEM", 98, 101], ["infected transplant candidates", "TREATMENT", 102, 132], ["infected", "OBSERVATION_MODIFIER", 102, 110], ["transplant", "OBSERVATION", 111, 121]]], ["In the current era of HIV management, a legal ban on the use of these organs seems unwarranted and likely harmful [139] .Human Immunodeficiency VirusHIV-infected patients receiving renal transplants may be at higher risk of acute rejection (up to 25%) and the optimal management of immunosuppression in HIV-infected individuals remains unknown [140] .", [["organs", "ANATOMY", 70, 76], ["renal", "ANATOMY", 181, 186], ["Human Immunodeficiency VirusHIV-infected", "DISEASE", 121, 161], ["HIV-infected", "DISEASE", 303, 315], ["HIV", "ORGANISM", 22, 25], ["organs", "ORGAN", 70, 76], ["Human Immunodeficiency VirusHIV", "ORGANISM", 121, 152], ["patients", "ORGANISM", 162, 170], ["renal", "ORGAN", 181, 186], ["HIV", "ORGANISM", 303, 306], ["Human", "SPECIES", 121, 126], ["patients", "SPECIES", 162, 170], ["HIV", "SPECIES", 303, 306], ["HIV", "SPECIES", 22, 25], ["Human Immunodeficiency VirusHIV", "SPECIES", 121, 152], ["HIV", "SPECIES", 303, 306], ["HIV management", "TREATMENT", 22, 36], ["Human Immunodeficiency VirusHIV", "PROBLEM", 121, 152], ["renal transplants", "TREATMENT", 181, 198], ["acute rejection", "PROBLEM", 224, 239], ["immunosuppression", "TREATMENT", 282, 299], ["HIV", "PROBLEM", 303, 306], ["infected individuals", "PROBLEM", 307, 327], ["Immunodeficiency VirusHIV", "OBSERVATION", 127, 152], ["infected", "OBSERVATION_MODIFIER", 153, 161], ["renal", "ANATOMY", 181, 186], ["transplants", "OBSERVATION", 187, 198], ["acute", "OBSERVATION_MODIFIER", 224, 229], ["rejection", "OBSERVATION", 230, 239]]], ["Treatment of rejection with cytolytic agents such as thymoglobulin may result in prolonged depression of CD4 counts and significant infection-related morbidity [141] .", [["CD4", "ANATOMY", 105, 108], ["thymoglobulin", "CHEMICAL", 53, 66], ["depression", "DISEASE", 91, 101], ["infection", "DISEASE", 132, 141], ["thymoglobulin", "CHEMICAL", 53, 66], ["thymoglobulin", "SIMPLE_CHEMICAL", 53, 66], ["CD4", "GENE_OR_GENE_PRODUCT", 105, 108], ["CD4", "PROTEIN", 105, 108], ["rejection", "PROBLEM", 13, 22], ["cytolytic agents", "TREATMENT", 28, 44], ["thymoglobulin", "TREATMENT", 53, 66], ["prolonged depression of CD4 counts", "PROBLEM", 81, 115], ["significant infection", "PROBLEM", 120, 141], ["rejection", "OBSERVATION", 13, 22], ["significant", "OBSERVATION_MODIFIER", 120, 131], ["infection", "OBSERVATION", 132, 141]]], ["The risks of antilymphocyte therapy should be balanced with the risks for rejection in HIV-infected recipients.Respiratory VirusesVarious viruses can cause respiratory disease in the renal transplant population, including adenovirus, respiratory syncytial virus, influenza, parainfluenza, human metapneumovirus, rhinovirus, and coronavirus [30] .", [["antilymphocyte", "ANATOMY", 13, 27], ["respiratory", "ANATOMY", 156, 167], ["renal transplant", "ANATOMY", 183, 199], ["HIV-infected", "DISEASE", 87, 99], ["Respiratory VirusesVarious viruses", "DISEASE", 111, 145], ["respiratory disease", "DISEASE", 156, 175], ["respiratory syncytial virus", "DISEASE", 234, 261], ["influenza", "DISEASE", 263, 272], ["parainfluenza, human metapneumovirus, rhinovirus", "DISEASE", 274, 322], ["coronavirus", "DISEASE", 328, 339], ["antilymphocyte", "ORGANISM", 13, 27], ["HIV", "ORGANISM", 87, 90], ["recipients", "ORGANISM", 100, 110], ["Respiratory VirusesVarious viruses", "ORGANISM", 111, 145], ["renal", "ORGAN", 183, 188], ["adenovirus", "ORGANISM", 222, 232], ["respiratory syncytial virus", "ORGANISM", 234, 261], ["parainfluenza", "ORGANISM", 274, 287], ["human", "ORGANISM", 289, 294], ["metapneumovirus", "ORGANISM", 295, 310], ["rhinovirus", "ORGANISM", 312, 322], ["HIV", "SPECIES", 87, 90], ["respiratory syncytial virus", "SPECIES", 234, 261], ["parainfluenza", "SPECIES", 274, 287], ["human", "SPECIES", 289, 294], ["metapneumovirus", "SPECIES", 295, 310], ["HIV", "SPECIES", 87, 90], ["Respiratory VirusesVarious viruses", "SPECIES", 111, 145], ["respiratory syncytial virus", "SPECIES", 234, 261], ["human metapneumovirus", "SPECIES", 289, 310], ["antilymphocyte therapy", "TREATMENT", 13, 35], ["rejection", "PROBLEM", 74, 83], ["HIV", "PROBLEM", 87, 90], ["infected recipients", "TREATMENT", 91, 110], ["Respiratory VirusesVarious viruses", "PROBLEM", 111, 145], ["respiratory disease", "PROBLEM", 156, 175], ["the renal transplant population", "PROBLEM", 179, 210], ["adenovirus", "PROBLEM", 222, 232], ["respiratory syncytial virus", "PROBLEM", 234, 261], ["influenza", "PROBLEM", 263, 272], ["parainfluenza", "PROBLEM", 274, 287], ["human metapneumovirus", "PROBLEM", 289, 310], ["rhinovirus", "PROBLEM", 312, 322], ["coronavirus", "PROBLEM", 328, 339], ["rejection", "OBSERVATION", 74, 83], ["viruses", "OBSERVATION", 138, 145], ["respiratory disease", "OBSERVATION", 156, 175], ["renal", "ANATOMY", 183, 188], ["transplant", "OBSERVATION", 189, 199], ["respiratory", "ANATOMY", 234, 245], ["syncytial virus", "OBSERVATION", 246, 261]]], ["These viruses can lead to upper respiratory tract disease, as well as bronchitis, pneumonitis, and pneumonia.", [["upper respiratory tract", "ANATOMY", 26, 49], ["upper respiratory tract disease", "DISEASE", 26, 57], ["bronchitis", "DISEASE", 70, 80], ["pneumonitis", "DISEASE", 82, 93], ["pneumonia", "DISEASE", 99, 108], ["upper", "ORGANISM_SUBDIVISION", 26, 31], ["respiratory tract", "ORGANISM_SUBDIVISION", 32, 49], ["These viruses", "PROBLEM", 0, 13], ["upper respiratory tract disease", "PROBLEM", 26, 57], ["bronchitis", "PROBLEM", 70, 80], ["pneumonitis", "PROBLEM", 82, 93], ["pneumonia", "PROBLEM", 99, 108], ["viruses", "OBSERVATION", 6, 13], ["upper", "ANATOMY_MODIFIER", 26, 31], ["respiratory tract", "ANATOMY", 32, 49], ["disease", "OBSERVATION", 50, 57], ["bronchitis", "OBSERVATION", 70, 80], ["pneumonitis", "OBSERVATION", 82, 93], ["pneumonia", "OBSERVATION", 99, 108]]], ["Adenovirus can cause a multitude of complications including gastroenteritis, cystitis, and necrotizing hepatitis in addition to respiratory illness.", [["respiratory", "ANATOMY", 128, 139], ["Adenovirus", "DISEASE", 0, 10], ["gastroenteritis", "DISEASE", 60, 75], ["cystitis", "DISEASE", 77, 85], ["necrotizing hepatitis", "DISEASE", 91, 112], ["respiratory illness", "DISEASE", 128, 147], ["Adenovirus", "ORGANISM", 0, 10], ["Adenovirus", "SPECIES", 0, 10], ["Adenovirus", "PROBLEM", 0, 10], ["complications", "PROBLEM", 36, 49], ["gastroenteritis", "PROBLEM", 60, 75], ["cystitis", "PROBLEM", 77, 85], ["necrotizing hepatitis", "PROBLEM", 91, 112], ["respiratory illness", "PROBLEM", 128, 147], ["multitude", "OBSERVATION_MODIFIER", 23, 32], ["complications", "OBSERVATION", 36, 49], ["gastroenteritis", "OBSERVATION", 60, 75], ["cystitis", "OBSERVATION", 77, 85], ["necrotizing", "OBSERVATION_MODIFIER", 91, 102], ["hepatitis", "OBSERVATION", 103, 112], ["respiratory", "ANATOMY", 128, 139], ["illness", "OBSERVATION", 140, 147]]], ["In immunocompromised patients, adenovirus infections tend to be more prolonged, more severe, and sometimes fatal.", [["adenovirus infections", "DISEASE", 31, 52], ["patients", "ORGANISM", 21, 29], ["adenovirus", "ORGANISM", 31, 41], ["patients", "SPECIES", 21, 29], ["adenovirus", "SPECIES", 31, 41], ["adenovirus infections", "PROBLEM", 31, 52], ["immunocompromised", "OBSERVATION", 3, 20], ["adenovirus infections", "OBSERVATION", 31, 52], ["more prolonged", "OBSERVATION_MODIFIER", 64, 78], ["more severe", "OBSERVATION_MODIFIER", 80, 91], ["fatal", "OBSERVATION_MODIFIER", 107, 112]]], ["They may occur due to endogenous reactivation or primary infection.", [["primary infection", "DISEASE", 49, 66], ["endogenous reactivation", "PROBLEM", 22, 45], ["primary infection", "PROBLEM", 49, 66], ["may occur due to", "UNCERTAINTY", 5, 21], ["endogenous", "OBSERVATION_MODIFIER", 22, 32], ["reactivation", "OBSERVATION", 33, 45], ["primary", "OBSERVATION_MODIFIER", 49, 56], ["infection", "OBSERVATION", 57, 66]]], ["Coinfection with more than one adenovirus serotype per clinical event was more frequent in immunocompromised patients (30%) than in immunocompetent patients (5%) [142] .", [["Coinfection", "DISEASE", 0, 11], ["immunocompetent", "DISEASE", 132, 147], ["adenovirus", "ORGANISM", 31, 41], ["patients", "ORGANISM", 109, 117], ["patients", "ORGANISM", 148, 156], ["patients", "SPECIES", 109, 117], ["patients", "SPECIES", 148, 156], ["Coinfection", "PROBLEM", 0, 11], ["one adenovirus serotype", "PROBLEM", 27, 50]]], ["Clinical manifestations in immunocompromised patients include pneumonia, hepatitis, hemorrhagic cystitis, colitis, pancreatitis, meningoencephalitis, and disseminated disease, depending on the underlying disease, affected organ system, patient age, and virus serotype.", [["organ system", "ANATOMY", 222, 234], ["pneumonia", "DISEASE", 62, 71], ["hepatitis", "DISEASE", 73, 82], ["hemorrhagic cystitis", "DISEASE", 84, 104], ["colitis", "DISEASE", 106, 113], ["pancreatitis", "DISEASE", 115, 127], ["meningoencephalitis", "DISEASE", 129, 148], ["disseminated disease", "DISEASE", 154, 174], ["patients", "ORGANISM", 45, 53], ["organ", "ORGAN", 222, 227], ["patient", "ORGANISM", 236, 243], ["patients", "SPECIES", 45, 53], ["patient", "SPECIES", 236, 243], ["Clinical manifestations in immunocompromised patients", "PROBLEM", 0, 53], ["pneumonia", "PROBLEM", 62, 71], ["hepatitis", "PROBLEM", 73, 82], ["hemorrhagic cystitis", "PROBLEM", 84, 104], ["colitis", "PROBLEM", 106, 113], ["pancreatitis", "PROBLEM", 115, 127], ["meningoencephalitis", "PROBLEM", 129, 148], ["disseminated disease", "PROBLEM", 154, 174], ["the underlying disease", "PROBLEM", 189, 211], ["affected organ system", "PROBLEM", 213, 234], ["virus serotype", "PROBLEM", 253, 267], ["immunocompromised", "OBSERVATION", 27, 44], ["pneumonia", "OBSERVATION", 62, 71], ["hepatitis", "OBSERVATION", 73, 82], ["hemorrhagic", "OBSERVATION_MODIFIER", 84, 95], ["cystitis", "OBSERVATION", 96, 104], ["colitis", "OBSERVATION", 106, 113], ["pancreatitis", "OBSERVATION", 115, 127], ["meningoencephalitis", "OBSERVATION", 129, 148], ["disseminated", "OBSERVATION_MODIFIER", 154, 166], ["disease", "OBSERVATION", 167, 174], ["disease", "OBSERVATION", 204, 211]]], ["In the renal transplant recipient, adenovirus can also cause nephritis, which presents with fever, renal dysfunction and liver function test abnormalities [143, 144] .", [["renal transplant", "ANATOMY", 7, 23], ["renal", "ANATOMY", 99, 104], ["liver", "ANATOMY", 121, 126], ["nephritis", "DISEASE", 61, 70], ["fever", "DISEASE", 92, 97], ["renal dysfunction", "DISEASE", 99, 116], ["renal", "ORGAN", 7, 12], ["adenovirus", "ORGANISM", 35, 45], ["renal", "ORGAN", 99, 104], ["liver", "ORGAN", 121, 126], ["adenovirus", "SPECIES", 35, 45], ["the renal transplant recipient", "TREATMENT", 3, 33], ["adenovirus", "PROBLEM", 35, 45], ["nephritis", "PROBLEM", 61, 70], ["fever", "PROBLEM", 92, 97], ["renal dysfunction", "PROBLEM", 99, 116], ["liver function test abnormalities", "PROBLEM", 121, 154], ["renal", "ANATOMY", 7, 12], ["transplant", "OBSERVATION", 13, 23], ["adenovirus", "OBSERVATION", 35, 45], ["nephritis", "OBSERVATION", 61, 70], ["fever", "OBSERVATION", 92, 97], ["renal", "ANATOMY", 99, 104], ["dysfunction", "OBSERVATION", 105, 116], ["liver", "ANATOMY", 121, 126]]], ["Infection with respiratory viruses may also be associated with rejection.", [["respiratory viruses", "DISEASE", 15, 34], ["Infection", "PROBLEM", 0, 9], ["respiratory viruses", "PROBLEM", 15, 34], ["rejection", "PROBLEM", 63, 72], ["respiratory viruses", "OBSERVATION", 15, 34], ["may also be associated with", "UNCERTAINTY", 35, 62], ["rejection", "OBSERVATION", 63, 72]]], ["Severity of disease is greatest in those who have been more recently transplanted or are more immunosuppressed.Respiratory VirusesClinicians and pathologists should be vigilant and aware of AV nephritis in renal allografts.", [["renal allografts", "ANATOMY", 206, 222], ["AV nephritis", "DISEASE", 190, 202], ["renal allografts", "TISSUE", 206, 222], ["Severity of disease", "PROBLEM", 0, 19], ["AV nephritis", "PROBLEM", 190, 202], ["renal allografts", "TREATMENT", 206, 222], ["disease", "OBSERVATION", 12, 19], ["greatest", "OBSERVATION_MODIFIER", 23, 31], ["AV", "ANATOMY", 190, 192], ["nephritis", "OBSERVATION", 193, 202], ["renal", "ANATOMY", 206, 211], ["allografts", "OBSERVATION", 212, 222]]], ["Few laboratories perform immunohistochemistry for AV.Respiratory VirusesMultiple diagnostic modalities, including immunohistochemistry of biopsy material, serology, viral cultures, and viral gene PCR may be required to make the diagnosis.", [["Few laboratories", "TEST", 0, 16], ["immunohistochemistry", "TEST", 25, 45], ["AV", "PROBLEM", 50, 52], ["immunohistochemistry of biopsy material", "TEST", 114, 153], ["serology", "TEST", 155, 163], ["viral cultures", "TEST", 165, 179], ["viral gene PCR", "TEST", 185, 199]]], ["Pathological clues to the diagnosis of AV infection include gross haematuria, often severe, with haemorrhagic cystitis and fever with or without pneumonitis.", [["AV infection", "DISEASE", 39, 51], ["haematuria", "DISEASE", 66, 76], ["haemorrhagic cystitis", "DISEASE", 97, 118], ["fever", "DISEASE", 123, 128], ["pneumonitis", "DISEASE", 145, 156], ["AV infection", "PROBLEM", 39, 51], ["gross haematuria", "PROBLEM", 60, 76], ["haemorrhagic cystitis", "PROBLEM", 97, 118], ["fever", "PROBLEM", 123, 128], ["pneumonitis", "PROBLEM", 145, 156], ["AV", "ANATOMY", 39, 41], ["infection", "OBSERVATION", 42, 51], ["gross", "OBSERVATION_MODIFIER", 60, 65], ["haematuria", "OBSERVATION", 66, 76], ["severe", "OBSERVATION_MODIFIER", 84, 90], ["haemorrhagic", "OBSERVATION_MODIFIER", 97, 109], ["cystitis", "OBSERVATION", 110, 118], ["fever", "OBSERVATION", 123, 128], ["without", "UNCERTAINTY", 137, 144], ["pneumonitis", "OBSERVATION", 145, 156]]], ["On renal biopsy, the presence of tubulointerstitial necrosis, haemorrhage, and atypical \"smudged\" epithelial cells can be helpful in recognizing the lesion.", [["renal", "ANATOMY", 3, 8], ["tubulointerstitial", "ANATOMY", 33, 51], ["smudged\" epithelial cells", "ANATOMY", 89, 114], ["lesion", "ANATOMY", 149, 155], ["tubulointerstitial necrosis", "DISEASE", 33, 60], ["haemorrhage", "DISEASE", 62, 73], ["renal biopsy", "MULTI-TISSUE_STRUCTURE", 3, 15], ["epithelial cells", "CELL", 98, 114], ["lesion", "CANCER", 149, 155], ["atypical \"smudged\" epithelial cells", "CELL_TYPE", 79, 114], ["renal biopsy", "TEST", 3, 15], ["tubulointerstitial necrosis", "PROBLEM", 33, 60], ["haemorrhage", "PROBLEM", 62, 73], ["atypical \"smudged\" epithelial cells", "PROBLEM", 79, 114], ["the lesion", "PROBLEM", 145, 155], ["renal", "ANATOMY", 3, 8], ["biopsy", "OBSERVATION", 9, 15], ["tubulointerstitial", "OBSERVATION_MODIFIER", 33, 51], ["necrosis", "OBSERVATION", 52, 60], ["haemorrhage", "OBSERVATION", 62, 73], ["atypical", "OBSERVATION_MODIFIER", 79, 87], ["epithelial cells", "OBSERVATION", 98, 114], ["lesion", "OBSERVATION", 149, 155]]], ["Although most AV infections occur within weeks or months of transplantation due to activation of a latent infection, AV infection can also uncommonly occur years later.", [["AV infections", "DISEASE", 14, 27], ["infection", "DISEASE", 106, 115], ["AV infection", "DISEASE", 117, 129], ["most AV infections", "PROBLEM", 9, 27], ["transplantation", "TREATMENT", 60, 75], ["a latent infection", "PROBLEM", 97, 115], ["AV infection", "PROBLEM", 117, 129], ["infections", "OBSERVATION", 17, 27], ["latent", "OBSERVATION_MODIFIER", 99, 105], ["infection", "OBSERVATION", 106, 115], ["infection", "OBSERVATION", 120, 129]]], ["This may be due to a de novo AV infection [144] .Respiratory VirusesPrevention involves avoidance of other individuals who have signs or symptoms of infection, hand hygiene, and use of droplet precautions for those suspected of having infection.", [["hand", "ANATOMY", 160, 164], ["AV infection", "DISEASE", 29, 41], ["Respiratory Viruses", "DISEASE", 49, 68], ["infection", "DISEASE", 149, 158], ["infection", "DISEASE", 235, 244], ["hand", "ORGANISM_SUBDIVISION", 160, 164], ["a de novo AV infection", "PROBLEM", 19, 41], ["Respiratory Viruses", "PROBLEM", 49, 68], ["symptoms", "PROBLEM", 137, 145], ["infection", "PROBLEM", 149, 158], ["hand hygiene", "TREATMENT", 160, 172], ["droplet precautions", "TREATMENT", 185, 204], ["infection", "PROBLEM", 235, 244], ["may be due to", "UNCERTAINTY", 5, 18], ["infection", "OBSERVATION", 32, 41], ["Viruses", "OBSERVATION", 61, 68], ["infection", "OBSERVATION", 149, 158], ["infection", "OBSERVATION", 235, 244]]], ["Influenza vaccine should be administered before transplant and every year after transplant, although administration should not be given in the early posttransplant period because of especially reduced vaccine responses [30] .", [["Influenza", "DISEASE", 0, 9], ["Influenza vaccine", "TREATMENT", 0, 17], ["transplant", "TREATMENT", 48, 58], ["transplant", "TREATMENT", 80, 90], ["administration", "TREATMENT", 101, 115], ["reduced vaccine responses", "PROBLEM", 193, 218]]], ["Because the vaccine may be insufficiently protective in the patient after transplant, the influenza vaccine should also be administered to the patient's family members and to health care providers to decrease possible risk of transmission.", [["patient", "ORGANISM", 60, 67], ["patient", "ORGANISM", 143, 150], ["patient", "SPECIES", 60, 67], ["patient", "SPECIES", 143, 150], ["the vaccine", "TREATMENT", 8, 19], ["transplant", "TREATMENT", 74, 84], ["the influenza vaccine", "TREATMENT", 86, 107]]], ["Intranasal influenza vaccine should not be used, as it is utilizes live virus [20] .", [["live virus", "ORGANISM", 67, 77], ["Intranasal influenza vaccine", "TREATMENT", 0, 28]]], ["Morelon et al. [145] suggest that intradermal influenza vaccination may offer enhanced immunogenicity and protection in persons who do not respond well to conventional trivalent inactivated influenza vaccine.", [["influenza", "DISEASE", 190, 199], ["intradermal influenza", "ORGANISM", 34, 55], ["persons", "ORGANISM", 120, 127], ["persons", "SPECIES", 120, 127], ["intradermal influenza vaccination", "TREATMENT", 34, 67], ["conventional trivalent inactivated influenza vaccine", "TREATMENT", 155, 207]]], ["Further studies should be conducted in immunocompromised populations to validate the trends for higher efficacy of ID versus conventional route of immunization against influenza.Respiratory VirusesTreatment of respiratory viral infections involves supportive care and, in some cases, the use of antiviral medications.", [["influenza", "DISEASE", 168, 177], ["Respiratory Viruses", "DISEASE", 178, 197], ["respiratory viral infections", "DISEASE", 210, 238], ["Further studies", "TEST", 0, 15], ["immunocompromised populations", "PROBLEM", 39, 68], ["immunization", "TREATMENT", 147, 159], ["influenza", "PROBLEM", 168, 177], ["Respiratory Viruses", "PROBLEM", 178, 197], ["respiratory viral infections", "PROBLEM", 210, 238], ["supportive care", "TREATMENT", 248, 263], ["antiviral medications", "TREATMENT", 295, 316], ["Viruses", "OBSERVATION", 190, 197], ["respiratory viral infections", "OBSERVATION", 210, 238]]], ["Influenza can be treated with oseltamivir or zanamavir, which will treat both influenza A and B. Amantadine is not recommended because it treats influenza A only and increasing rates of resistance have been seen in influenza A. Ribavirin is approved to treat lower respiratory infection with respiratory syncytial virus; however actual clinical efficacy has not been proven.", [["respiratory", "ANATOMY", 265, 276], ["Influenza", "DISEASE", 0, 9], ["oseltamivir", "CHEMICAL", 30, 41], ["zanamavir", "CHEMICAL", 45, 54], ["influenza A", "DISEASE", 78, 89], ["Amantadine", "CHEMICAL", 97, 107], ["influenza A", "DISEASE", 145, 156], ["Ribavirin", "CHEMICAL", 228, 237], ["respiratory infection", "DISEASE", 265, 286], ["respiratory syncytial virus", "DISEASE", 292, 319], ["oseltamivir", "CHEMICAL", 30, 41], ["zanamavir", "CHEMICAL", 45, 54], ["Amantadine", "CHEMICAL", 97, 107], ["Ribavirin", "CHEMICAL", 228, 237], ["Influenza", "ORGANISM", 0, 9], ["oseltamivir", "SIMPLE_CHEMICAL", 30, 41], ["zanamavir", "SIMPLE_CHEMICAL", 45, 54], ["B. Amantadine", "ORGANISM", 94, 107], ["influenza A. Ribavirin", "ORGANISM", 215, 237], ["respiratory syncytial virus", "ORGANISM", 292, 319], ["respiratory syncytial virus", "SPECIES", 292, 319], ["Influenza", "PROBLEM", 0, 9], ["oseltamivir", "TREATMENT", 30, 41], ["zanamavir", "TREATMENT", 45, 54], ["influenza A and B. Amantadine", "TREATMENT", 78, 107], ["influenza A", "PROBLEM", 145, 156], ["influenza", "PROBLEM", 215, 224], ["Ribavirin", "TREATMENT", 228, 237], ["lower respiratory infection", "PROBLEM", 259, 286], ["respiratory syncytial virus", "PROBLEM", 292, 319], ["Ribavirin", "OBSERVATION", 228, 237], ["respiratory", "ANATOMY", 265, 276], ["infection", "OBSERVATION", 277, 286], ["syncytial virus", "OBSERVATION", 304, 319]]], ["Severe adenovirus infections are usually treated with reduction of immunosuppression.", [["adenovirus infections", "DISEASE", 7, 28], ["adenovirus", "ORGANISM", 7, 17], ["Severe adenovirus infections", "PROBLEM", 0, 28], ["immunosuppression", "TREATMENT", 67, 84], ["adenovirus", "OBSERVATION_MODIFIER", 7, 17], ["infections", "OBSERVATION", 18, 28], ["immunosuppression", "OBSERVATION", 67, 84]]], ["Anecdotal reports suggest that cidofovir may have activity against adenovirus, but its use must be balanced with the associated risk of nephrotoxicity [146, 147] .West Nile VirusWest Nile virus (WNV) belong to family Flaviviridae, genus Flavivirus, species West Nile virus.", [["cidofovir", "CHEMICAL", 31, 40], ["nephrotoxicity", "DISEASE", 136, 150], ["cidofovir", "CHEMICAL", 31, 40], ["cidofovir", "SIMPLE_CHEMICAL", 31, 40], ["adenovirus", "ORGANISM", 67, 77], ["West Nile VirusWest Nile virus", "ORGANISM", 163, 193], ["WNV", "ORGANISM", 195, 198], ["genus Flavivirus", "ORGANISM", 231, 247], ["species", "ORGANISM", 249, 256], ["West Nile virus", "ORGANISM", 257, 272], ["Nile VirusWest Nile virus", "SPECIES", 168, 193], ["Nile virus", "SPECIES", 262, 272], ["adenovirus", "SPECIES", 67, 77], ["West Nile VirusWest Nile virus", "SPECIES", 163, 193], ["WNV", "SPECIES", 195, 198], ["West Nile virus", "SPECIES", 257, 272], ["cidofovir", "TREATMENT", 31, 40], ["adenovirus", "PROBLEM", 67, 77], ["nephrotoxicity", "PROBLEM", 136, 150], ["Flaviviridae", "TREATMENT", 217, 229], ["genus Flavivirus", "PROBLEM", 231, 247], ["nephrotoxicity", "OBSERVATION", 136, 150], ["genus Flavivirus", "ANATOMY", 231, 247]]], ["Since its isolation in Uganda in 1937, WNV has been responsible for thousands of cases of morbidity and mortality in birds, horses, and humans.", [["WNV", "DISEASE", 39, 42], ["WNV", "ORGANISM", 39, 42], ["horses", "ORGANISM_SUBDIVISION", 124, 130], ["humans", "ORGANISM", 136, 142], ["humans", "SPECIES", 136, 142], ["WNV", "SPECIES", 39, 42], ["humans", "SPECIES", 136, 142], ["morbidity", "PROBLEM", 90, 99], ["isolation", "OBSERVATION_MODIFIER", 10, 19], ["morbidity", "OBSERVATION", 90, 99]]], ["Historically, epidemics were localized to Europe, Africa, the Middle East, and parts of Asia, and primarily caused a mild febrile illness in humans.", [["febrile illness", "DISEASE", 122, 137], ["humans", "ORGANISM", 141, 147], ["humans", "SPECIES", 141, 147], ["humans", "SPECIES", 141, 147], ["epidemics", "PROBLEM", 14, 23], ["a mild febrile illness in humans", "PROBLEM", 115, 147], ["Middle", "ANATOMY_MODIFIER", 62, 68], ["mild", "OBSERVATION_MODIFIER", 117, 121], ["febrile", "OBSERVATION_MODIFIER", 122, 129], ["illness", "OBSERVATION", 130, 137]]], ["However, in the late 1990s, the virus became more virulent and expanded its geographical range to North America.", [["the virus", "PROBLEM", 28, 37], ["virulent", "PROBLEM", 50, 58], ["virulent", "OBSERVATION_MODIFIER", 50, 58]]], ["In humans, the clinical presentation ranges from asymptomatic (approximately 80% of infections) to encephalitis/paralysis and death (less than 1% of infections) [148] .West Nile VirusWNV was recently transmitted from one donor (likely related to a blood transfusion) to multiple recipients [149] .", [["blood", "ANATOMY", 248, 253], ["infections", "DISEASE", 84, 94], ["encephalitis", "DISEASE", 99, 111], ["paralysis", "DISEASE", 112, 121], ["death", "DISEASE", 126, 131], ["infections", "DISEASE", 149, 159], ["humans", "ORGANISM", 3, 9], ["West Nile VirusWNV", "ORGANISM", 168, 186], ["blood", "ORGANISM_SUBSTANCE", 248, 253], ["humans", "SPECIES", 3, 9], ["humans", "SPECIES", 3, 9], ["West Nile VirusWNV", "SPECIES", 168, 186], ["asymptomatic", "PROBLEM", 49, 61], ["infections", "PROBLEM", 84, 94], ["encephalitis", "PROBLEM", 99, 111], ["paralysis", "PROBLEM", 112, 121], ["death", "PROBLEM", 126, 131], ["infections", "PROBLEM", 149, 159], ["a blood transfusion", "TREATMENT", 246, 265], ["encephalitis", "OBSERVATION", 99, 111], ["paralysis", "OBSERVATION", 112, 121]]], ["Transplant recipients are at higher risk than the general population for meningoencephalitis after exposure.", [["meningoencephalitis", "DISEASE", 73, 92], ["recipients", "ORGANISM", 11, 21], ["Transplant recipients", "TREATMENT", 0, 21], ["meningoencephalitis", "PROBLEM", 73, 92], ["recipients", "OBSERVATION", 11, 21], ["higher risk", "OBSERVATION_MODIFIER", 29, 40], ["meningoencephalitis", "OBSERVATION", 73, 92]]], ["In WNV endemic regions, donors should be tested for WNV.", [["WNV", "DISEASE", 52, 55], ["donors", "ORGANISM", 24, 30], ["WNV", "ORGANISM", 52, 55], ["WNV", "SPECIES", 3, 6], ["WNV", "SPECIES", 52, 55], ["donors", "TREATMENT", 24, 30], ["WNV", "PROBLEM", 52, 55], ["WNV", "OBSERVATION", 3, 6]]], ["Virus from their donors have increased morbidity and mortality [150, 151] .", [["Virus", "ORGANISM", 0, 5], ["donors", "ORGANISM", 17, 23], ["Virus", "PROBLEM", 0, 5], ["increased morbidity", "PROBLEM", 29, 48], ["increased", "OBSERVATION_MODIFIER", 29, 38], ["morbidity", "OBSERVATION_MODIFIER", 39, 48]]], ["Recipients who acquire West Nile later in the transplant course have more variable outcomes.", [["Recipients", "ORGANISM", 0, 10], ["West Nile", "ORGANISM", 23, 32]]], ["To prevent infection, seasonal screening should be considered for donors before transplant by serologic and/or nucleic acid testing.", [["infection", "DISEASE", 11, 20], ["nucleic acid", "CHEMICAL", 111, 123], ["donors", "ORGANISM", 66, 72], ["infection", "PROBLEM", 11, 20], ["seasonal screening", "TEST", 22, 40], ["transplant", "TREATMENT", 80, 90], ["serologic", "TEST", 94, 103], ["nucleic acid testing", "TEST", 111, 131], ["infection", "OBSERVATION", 11, 20]]], ["Treatment for West Nile in transplant recipients has not been standardized but should include a reduction in immunosuppression along with supportive care [151] .", [["West Nile", "ORGANISM", 14, 23], ["recipients", "ORGANISM", 38, 48], ["West Nile in transplant recipients", "TREATMENT", 14, 48], ["a reduction in immunosuppression", "TREATMENT", 94, 126], ["supportive care", "TREATMENT", 138, 153]]], ["Whether there is a role for hyperimmune globulin in transplant recipients is currently unknown.", [["hyperimmune", "ORGANISM", 28, 39], ["globulin", "GENE_OR_GENE_PRODUCT", 40, 48], ["hyperimmune globulin", "PROTEIN", 28, 48], ["hyperimmune globulin", "TREATMENT", 28, 48], ["transplant recipients", "TREATMENT", 52, 73]]], ["Viral infections in renal transplant patients continue to have significant impact on patient outcomes.", [["renal transplant", "ANATOMY", 20, 36], ["Viral infections", "DISEASE", 0, 16], ["Viral", "ORGANISM", 0, 5], ["renal", "ORGAN", 20, 25], ["patients", "ORGANISM", 37, 45], ["patient", "ORGANISM", 85, 92], ["patients", "SPECIES", 37, 45], ["patient", "SPECIES", 85, 92], ["Viral infections", "PROBLEM", 0, 16], ["renal transplant", "TREATMENT", 20, 36], ["infections", "OBSERVATION", 6, 16], ["renal", "ANATOMY", 20, 25], ["transplant", "OBSERVATION", 26, 36]]], ["Although preventive measures have improved, the impact of newer immunosuppressive strategies continues to promote the development of severe viral infections [20] .", [["viral infections", "DISEASE", 140, 156], ["preventive measures", "TREATMENT", 9, 28], ["newer immunosuppressive strategies", "TREATMENT", 58, 92], ["severe viral infections", "PROBLEM", 133, 156], ["improved", "OBSERVATION_MODIFIER", 34, 42], ["severe", "OBSERVATION_MODIFIER", 133, 139], ["viral", "OBSERVATION_MODIFIER", 140, 145], ["infections", "OBSERVATION", 146, 156]]], ["The presence of new and emerging viral infections that may be transmitted by transplantation, such as West Nile virus, will likely present many future challenges for physician treating transplant recipients.", [["viral infections", "DISEASE", 33, 49], ["West Nile virus", "ORGANISM", 102, 117], ["recipients", "ORGANISM", 196, 206], ["West Nile virus", "SPECIES", 102, 117], ["West Nile virus", "SPECIES", 102, 117], ["new and emerging viral infections", "PROBLEM", 16, 49], ["transplantation", "TREATMENT", 77, 92], ["West Nile virus", "PROBLEM", 102, 117], ["transplant recipients", "TREATMENT", 185, 206], ["new", "OBSERVATION_MODIFIER", 16, 19], ["viral", "OBSERVATION_MODIFIER", 33, 38], ["infections", "OBSERVATION", 39, 49], ["transplantation", "OBSERVATION", 77, 92]]]], "2f6596c620508388cc722e8fa514b7d63146a8b0": [["IntroductionThe incidence of lower airway infections in immunocompromised patients is high and the course of a disease is usually more severe than that in immunocompetent hosts (Sousa et al. 2013; Bonatti et al. 2009 ).", [["lower airway", "ANATOMY", 29, 41], ["airway infections", "DISEASE", 35, 52], ["lower airway", "ORGANISM_SUBDIVISION", 29, 41], ["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 74, 82], ["lower airway infections", "PROBLEM", 29, 52], ["immunocompromised patients", "PROBLEM", 56, 82], ["a disease", "PROBLEM", 109, 118], ["lower", "ANATOMY_MODIFIER", 29, 34], ["airway", "ANATOMY", 35, 41], ["infections", "OBSERVATION", 42, 52], ["immunocompromised", "OBSERVATION", 56, 73], ["high", "OBSERVATION_MODIFIER", 86, 90], ["disease", "OBSERVATION", 111, 118], ["more severe", "OBSERVATION_MODIFIER", 130, 141]]], ["Mortality rate largely depends on the type and severity of immunosuppression, with the highest rate reported after hematopoietic stem cell transplantation (HSCT) and somewhat lower in solid organ transplant (SOT) recipients and patients with hematologic malignancies (HM) (Cervera et al. 2006; Ra\u00f1\u00f3 et al. 2001; 2002) .", [["hematopoietic stem cell", "ANATOMY", 115, 138], ["solid organ transplant", "ANATOMY", 184, 206], ["hematologic malignancies", "ANATOMY", 242, 266], ["hematologic malignancies", "DISEASE", 242, 266], ["HM", "DISEASE", 268, 270], ["hematopoietic stem cell", "CELL", 115, 138], ["solid organ", "CANCER", 184, 195], ["SOT", "CANCER", 208, 211], ["recipients", "ORGANISM", 213, 223], ["patients", "ORGANISM", 228, 236], ["hematologic malignancies", "CANCER", 242, 266], ["patients", "SPECIES", 228, 236], ["Mortality rate", "TEST", 0, 14], ["immunosuppression", "TREATMENT", 59, 76], ["hematopoietic stem cell transplantation", "TREATMENT", 115, 154], ["HSCT", "TEST", 156, 160], ["solid organ transplant", "TREATMENT", 184, 206], ["hematologic malignancies", "PROBLEM", 242, 266], ["immunosuppression", "OBSERVATION", 59, 76], ["hematopoietic stem cell transplantation", "OBSERVATION", 115, 154], ["lower", "OBSERVATION_MODIFIER", 175, 180], ["solid organ", "ANATOMY", 184, 195], ["transplant", "OBSERVATION", 196, 206]]], ["It has also been shown that the outcome of pulmonary infections is significantly affected by a delay in diagnosis of specific etiology.", [["pulmonary", "ANATOMY", 43, 52], ["pulmonary infections", "DISEASE", 43, 63], ["pulmonary", "ORGAN", 43, 52], ["pulmonary infections", "PROBLEM", 43, 63], ["pulmonary", "ANATOMY", 43, 52], ["infections", "OBSERVATION", 53, 63]]], ["An increase in mortality rate from 29 to 71 % has been reported in patients in whom the etiology of infection was ascertained within the first 7 days of onset of symptoms compared with those with later diagnosis (Ra\u00f1\u00f3 et al. 2001 ).", [["infection", "DISEASE", 100, 109], ["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75], ["mortality rate", "TEST", 15, 29], ["infection", "PROBLEM", 100, 109], ["symptoms", "PROBLEM", 162, 170], ["increase", "OBSERVATION_MODIFIER", 3, 11], ["mortality", "OBSERVATION_MODIFIER", 15, 24], ["infection", "OBSERVATION", 100, 109]]], ["The etiology of lower respiratory tract infections in immunocompromised patients is diverse.", [["lower respiratory tract", "ANATOMY", 16, 39], ["lower respiratory tract infections", "DISEASE", 16, 50], ["lower", "ORGANISM", 16, 21], ["respiratory tract", "ORGANISM_SUBDIVISION", 22, 39], ["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["lower respiratory tract infections", "PROBLEM", 16, 50], ["lower", "ANATOMY_MODIFIER", 16, 21], ["respiratory tract", "ANATOMY", 22, 39], ["infections", "OBSERVATION", 40, 50], ["immunocompromised", "OBSERVATION", 54, 71], ["diverse", "OBSERVATION_MODIFIER", 84, 91]]], ["It includes common bacteria, uncommon bacterial agents, and opportunistic pathogens such as various fungal species and viruses.", [["common bacteria", "PROBLEM", 12, 27], ["uncommon bacterial agents", "PROBLEM", 29, 54], ["opportunistic pathogens", "PROBLEM", 60, 83], ["various fungal species", "PROBLEM", 92, 114], ["viruses", "PROBLEM", 119, 126], ["common", "OBSERVATION_MODIFIER", 12, 18], ["bacteria", "OBSERVATION", 19, 27], ["uncommon", "OBSERVATION_MODIFIER", 29, 37], ["bacterial agents", "OBSERVATION", 38, 54], ["fungal species", "OBSERVATION", 100, 114]]], ["Although atypical bacteria are important causes of pulmonary infections in the general population, data on the role of these pathogens in immunocompromised patients are relatively scarce.", [["pulmonary", "ANATOMY", 51, 60], ["pulmonary infections", "DISEASE", 51, 71], ["pulmonary", "ORGAN", 51, 60], ["patients", "ORGANISM", 156, 164], ["patients", "SPECIES", 156, 164], ["atypical bacteria", "PROBLEM", 9, 26], ["pulmonary infections", "PROBLEM", 51, 71], ["these pathogens", "PROBLEM", 119, 134], ["atypical", "OBSERVATION_MODIFIER", 9, 17], ["bacteria", "OBSERVATION", 18, 26], ["important causes of", "UNCERTAINTY", 31, 50], ["pulmonary", "ANATOMY", 51, 60], ["infections", "OBSERVATION", 61, 71], ["pathogens", "OBSERVATION", 125, 134], ["immunocompromised", "OBSERVATION", 138, 155]]], ["In the immunocompetent hosts Mycoplasma pneumoniae and Chlamydophila pneumoniae are responsible for 1-36 % and 3-22 % of community acquired pneumonia (CAP) cases, respectively (Singanayagam et al. 2014; Masi\u00e1 et al. 2007; Gleason 2002) .", [["Mycoplasma pneumoniae", "DISEASE", 29, 50], ["Chlamydophila pneumoniae", "DISEASE", 55, 79], ["pneumonia", "DISEASE", 140, 149], ["CAP", "DISEASE", 151, 154], ["hosts", "ORGANISM", 23, 28], ["Mycoplasma pneumoniae", "ORGANISM", 29, 50], ["Chlamydophila pneumoniae", "ORGANISM", 55, 79], ["Mycoplasma pneumoniae", "SPECIES", 29, 50], ["Chlamydophila pneumoniae", "SPECIES", 55, 79], ["Mycoplasma pneumoniae", "SPECIES", 29, 50], ["Chlamydophila pneumoniae", "SPECIES", 55, 79], ["Mycoplasma pneumoniae", "PROBLEM", 29, 50], ["Chlamydophila pneumoniae", "PROBLEM", 55, 79], ["community acquired pneumonia (CAP) cases", "PROBLEM", 121, 161], ["immunocompetent", "OBSERVATION_MODIFIER", 7, 22], ["hosts Mycoplasma pneumoniae", "OBSERVATION", 23, 50], ["Chlamydophila pneumoniae", "OBSERVATION", 55, 79], ["pneumonia", "OBSERVATION", 140, 149]]], ["The majority of these infections affect children and young adults and present as mild, self-limiting disease (Capelastegui et al. 2012 ).", [["infections", "DISEASE", 22, 32], ["children", "ORGANISM", 40, 48], ["children", "SPECIES", 40, 48], ["self-limiting disease", "PROBLEM", 87, 108], ["infections", "OBSERVATION", 22, 32], ["mild", "OBSERVATION_MODIFIER", 81, 85], ["self-limiting", "OBSERVATION_MODIFIER", 87, 100]]], ["However, even 26 % of patients may require hospital admission and in-hospital death rate may be as high as 5 %.", [["death", "DISEASE", 78, 83], ["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30], ["death rate", "TEST", 78, 88]]], ["The prevalence of Legionella pneumophila pneumonia in the general population is slightly lower (2-16 %), but this infection is usually more severe.", [["Legionella pneumophila pneumonia", "DISEASE", 18, 50], ["infection", "DISEASE", 114, 123], ["Legionella pneumophila", "ORGANISM", 18, 40], ["Legionella pneumophila", "SPECIES", 18, 40], ["Legionella pneumophila", "SPECIES", 18, 40], ["Legionella pneumophila pneumonia", "PROBLEM", 18, 50], ["slightly lower", "PROBLEM", 80, 94], ["this infection", "PROBLEM", 109, 123], ["Legionella", "OBSERVATION_MODIFIER", 18, 28], ["pneumophila", "OBSERVATION_MODIFIER", 29, 40], ["pneumonia", "OBSERVATION", 41, 50], ["population", "OBSERVATION_MODIFIER", 66, 76], ["slightly", "OBSERVATION_MODIFIER", 80, 88], ["lower", "OBSERVATION_MODIFIER", 89, 94], ["infection", "OBSERVATION", 114, 123], ["more severe", "OBSERVATION_MODIFIER", 135, 146]]], ["In two studies, L. pneumophila was responsible for 2-9 % of CAP that required hospitalization (Yu and Stout 2008; Gleason 2002) .", [["CAP", "DISEASE", 60, 63], ["L. pneumophila", "ORGANISM", 16, 30], ["L. pneumophila", "SPECIES", 16, 30], ["L. pneumophila", "SPECIES", 16, 30], ["two studies", "TEST", 3, 14], ["L. pneumophila", "PROBLEM", 16, 30], ["CAP", "PROBLEM", 60, 63], ["L.", "OBSERVATION_MODIFIER", 16, 18], ["pneumophila", "OBSERVATION", 19, 30]]], ["On the other hand, recent data do not confirm the relation between L. pneumophila infection and increased in-hospital mortality rate (Capelastegui et al. 2012) .", [["L. pneumophila infection", "DISEASE", 67, 91], ["L. pneumophila", "ORGANISM", 67, 81], ["L. pneumophila", "SPECIES", 67, 81], ["L. pneumophila", "SPECIES", 67, 81], ["recent data", "TEST", 19, 30], ["L. pneumophila infection", "PROBLEM", 67, 91], ["pneumophila", "OBSERVATION_MODIFIER", 70, 81], ["infection", "OBSERVATION", 82, 91], ["increased", "OBSERVATION_MODIFIER", 96, 105]]], ["It might be hypothesized that the course of atypical pulmonary infections in immunocompromised patients can be more severe than that in the general population and that the co-infection with atypical pathogens can aggravate the course of pulmonary disease caused by typical bacteria or fungi.", [["pulmonary", "ANATOMY", 53, 62], ["pulmonary", "ANATOMY", 237, 246], ["pulmonary infections", "DISEASE", 53, 73], ["co-infection", "DISEASE", 172, 184], ["pulmonary disease", "DISEASE", 237, 254], ["pulmonary", "ORGAN", 53, 62], ["patients", "ORGANISM", 95, 103], ["pulmonary", "ORGAN", 237, 246], ["patients", "SPECIES", 95, 103], ["atypical pulmonary infections", "PROBLEM", 44, 73], ["the co-infection", "PROBLEM", 168, 184], ["atypical pathogens", "PROBLEM", 190, 208], ["pulmonary disease", "PROBLEM", 237, 254], ["typical bacteria", "PROBLEM", 265, 281], ["fungi", "PROBLEM", 285, 290], ["atypical", "OBSERVATION_MODIFIER", 44, 52], ["pulmonary", "ANATOMY", 53, 62], ["infections", "OBSERVATION", 63, 73], ["pulmonary", "ANATOMY", 237, 246], ["disease", "OBSERVATION", 247, 254], ["typical", "OBSERVATION_MODIFIER", 265, 272], ["bacteria", "OBSERVATION", 273, 281], ["fungi", "OBSERVATION", 285, 290]]], ["Surprisingly, there are little data on the incidence and clinical features of atypical pulmonary infections in immunocompromised patients.", [["pulmonary", "ANATOMY", 87, 96], ["pulmonary infections", "DISEASE", 87, 107], ["pulmonary", "ORGAN", 87, 96], ["patients", "ORGANISM", 129, 137], ["patients", "SPECIES", 129, 137], ["atypical pulmonary infections", "PROBLEM", 78, 107], ["little", "OBSERVATION_MODIFIER", 24, 30], ["atypical", "OBSERVATION_MODIFIER", 78, 86], ["pulmonary", "ANATOMY", 87, 96], ["infections", "OBSERVATION", 97, 107], ["immunocompromised", "OBSERVATION", 111, 128]]], ["According to the available publications, the incidence of these infections is quite low (Corti et al. 2009; Jain et al. 2004; Perez and Leigh 1991) .", [["infections", "DISEASE", 64, 74], ["these infections", "PROBLEM", 58, 74], ["infections", "OBSERVATION", 64, 74]]], ["However, a few cases of life threatening pneumonia caused by C. pneumoniae and L. pneumophila have been described (Di Stefano et al. 2007; Heinemann et al. 2000) .", [["pneumonia", "DISEASE", 41, 50], ["C. pneumoniae and L. pneumophila", "DISEASE", 61, 93], ["C. pneumoniae", "ORGANISM", 61, 74], ["L. pneumophila", "ORGANISM", 79, 93], ["C. pneumoniae", "SPECIES", 61, 74], ["L. pneumophila", "SPECIES", 79, 93], ["C. pneumoniae", "SPECIES", 61, 74], ["L. pneumophila", "SPECIES", 79, 93], ["life threatening pneumonia", "PROBLEM", 24, 50], ["C. pneumoniae", "PROBLEM", 61, 74], ["L. pneumophila", "PROBLEM", 79, 93], ["few", "OBSERVATION_MODIFIER", 11, 14], ["pneumonia", "OBSERVATION", 41, 50], ["pneumoniae", "OBSERVATION", 64, 74], ["L.", "OBSERVATION_MODIFIER", 79, 81], ["pneumophila", "OBSERVATION", 82, 93]]], ["Whether the true prevalence of atypical pathogen infections in immunocompromised hosts is low or it is underestimated due to low sensitivity of the diagnostic methods seems to be an interesting issue.", [["pathogen infections", "DISEASE", 40, 59], ["atypical pathogen infections", "PROBLEM", 31, 59], ["immunocompromised hosts", "PROBLEM", 63, 86], ["low sensitivity", "PROBLEM", 125, 140], ["atypical", "OBSERVATION_MODIFIER", 31, 39], ["pathogen", "OBSERVATION_MODIFIER", 40, 48], ["infections", "OBSERVATION", 49, 59]]], ["It must be realized that the culture of atypical bacteria is difficult and demanding and can be offered by few laboratories only.", [["the culture", "TEST", 25, 36], ["atypical bacteria", "PROBLEM", 40, 57], ["atypical", "OBSERVATION_MODIFIER", 40, 48], ["bacteria", "OBSERVATION", 49, 57]]], ["Serological methods, including specific IgM and IgG antibodies detection in the serum, have limited clinical application due to a delay in the diagnosis and suboptimal sensitivity in patients with immunoglobulin deficiency (false negative results) (Bartlett 2008; Hammerschlag 2000; Welti et al. 2003) .", [["serum", "ANATOMY", 80, 85], ["immunoglobulin deficiency", "DISEASE", 197, 222], ["IgM", "GENE_OR_GENE_PRODUCT", 40, 43], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 48, 62], ["serum", "ORGANISM_SUBSTANCE", 80, 85], ["patients", "ORGANISM", 183, 191], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 197, 211], ["IgM", "PROTEIN", 40, 43], ["IgG antibodies", "PROTEIN", 48, 62], ["immunoglobulin", "PROTEIN", 197, 211], ["patients", "SPECIES", 183, 191], ["Serological methods", "TEST", 0, 19], ["specific IgM", "TEST", 31, 43], ["IgG antibodies detection", "TEST", 48, 72], ["the serum", "TEST", 76, 85], ["a delay", "PROBLEM", 128, 135], ["suboptimal sensitivity", "PROBLEM", 157, 179], ["immunoglobulin deficiency", "PROBLEM", 197, 222]]], ["Likewise, L. pneumophila antigen detection in the urine has limited sensitivity as a negative result of this test does not exclude infection with other than serotype 1 L. pneumophila strains.", [["urine", "ANATOMY", 50, 55], ["infection", "DISEASE", 131, 140], ["L. pneumophila antigen", "GENE_OR_GENE_PRODUCT", 10, 32], ["urine", "ORGANISM_SUBSTANCE", 50, 55], ["serotype 1", "ORGANISM", 157, 167], ["L. pneumophila", "ORGANISM", 168, 182], ["strains", "ORGANISM", 183, 190], ["L. pneumophila", "SPECIES", 10, 24], ["L. pneumophila", "SPECIES", 168, 182], ["L. pneumophila", "SPECIES", 10, 24], ["L. pneumophila", "SPECIES", 168, 182], ["L. pneumophila antigen detection", "TEST", 10, 42], ["the urine", "TEST", 46, 55], ["this test", "TEST", 104, 113], ["infection", "PROBLEM", 131, 140], ["serotype 1 L. pneumophila strains", "PROBLEM", 157, 190], ["L.", "OBSERVATION_MODIFIER", 10, 12], ["pneumophila", "OBSERVATION_MODIFIER", 13, 24], ["infection", "OBSERVATION", 131, 140], ["pneumophila strains", "OBSERVATION", 171, 190]]], ["The introduction of polymerase chain reaction (PCR)-based methods that can identify specific genetic material in different biological samples, including broncholaveolar lavage fluid (BALF), throat swabs, and nasopharyngeal samples, enables a rapid, sensitive, and specific diagnosis of atypical pathogen infection even if patients are already treated with an antibiotic (Murdoch 2004; Welti et al. 2003; Murdoch 2003) .", [["samples", "ANATOMY", 134, 141], ["broncholaveolar lavage fluid", "ANATOMY", 153, 181], ["BALF", "ANATOMY", 183, 187], ["throat swabs", "ANATOMY", 190, 202], ["nasopharyngeal samples", "ANATOMY", 208, 230], ["pathogen infection", "DISEASE", 295, 313], ["broncholaveolar lavage fluid", "ORGANISM_SUBSTANCE", 153, 181], ["BALF", "ORGANISM_SUBSTANCE", 183, 187], ["nasopharyngeal samples", "CANCER", 208, 230], ["patients", "ORGANISM", 322, 330], ["patients", "SPECIES", 322, 330], ["polymerase chain reaction", "PROBLEM", 20, 45], ["PCR)", "TEST", 47, 51], ["broncholaveolar lavage fluid (BALF)", "TEST", 153, 188], ["throat swabs", "TEST", 190, 202], ["nasopharyngeal samples", "TEST", 208, 230], ["atypical pathogen infection", "PROBLEM", 286, 313], ["an antibiotic (Murdoch", "TREATMENT", 356, 378], ["throat", "ANATOMY", 190, 196], ["nasopharyngeal", "ANATOMY", 208, 222], ["atypical", "OBSERVATION_MODIFIER", 286, 294], ["pathogen", "OBSERVATION_MODIFIER", 295, 303], ["infection", "OBSERVATION", 304, 313]]], ["Therefore, the aims of this study were to evaluate the prevalence of atypical lower airway infections using nested PCR (nPCR) method in patients with various types of immunosuppression and to analyze clinical characteristics of these infections.PatientsThe study protocol was approved by an Institutional Bioethics Committee.", [["lower airway", "ANATOMY", 78, 90], ["airway infections", "DISEASE", 84, 101], ["infections", "DISEASE", 234, 244], ["lower airway", "ORGANISM_SUBDIVISION", 78, 90], ["patients", "ORGANISM", 136, 144], ["Patients", "ORGANISM", 245, 253], ["patients", "SPECIES", 136, 144], ["Patients", "SPECIES", 245, 253], ["this study", "TEST", 23, 33], ["atypical lower airway infections", "PROBLEM", 69, 101], ["nested PCR", "TEST", 108, 118], ["immunosuppression", "TREATMENT", 167, 184], ["these infections", "PROBLEM", 228, 244], ["The study protocol", "TEST", 253, 271], ["atypical", "OBSERVATION_MODIFIER", 69, 77], ["lower", "ANATOMY_MODIFIER", 78, 83], ["airway", "ANATOMY", 84, 90], ["infections", "OBSERVATION", 91, 101], ["infections", "OBSERVATION", 234, 244]]], ["The study group consisted of 80 non-HIV immunocompromised patients with different underlying diseases and clinical and radiological signs of pulmonary infection.", [["pulmonary", "ANATOMY", 141, 150], ["HIV immunocompromised", "DISEASE", 36, 57], ["pulmonary infection", "DISEASE", 141, 160], ["patients", "ORGANISM", 58, 66], ["pulmonary", "ORGAN", 141, 150], ["HIV", "SPECIES", 36, 39], ["patients", "SPECIES", 58, 66], ["HIV", "SPECIES", 36, 39], ["The study", "TEST", 0, 9], ["different underlying diseases", "PROBLEM", 72, 101], ["pulmonary infection", "PROBLEM", 141, 160], ["diseases", "OBSERVATION", 93, 101], ["pulmonary", "ANATOMY", 141, 150], ["infection", "OBSERVATION", 151, 160]]], ["Due to incomplete data on eight patients, 72 patients were eligible for final analysis (median age 58; range 16-79 years; F/M -21/51).", [["patients", "ORGANISM", 32, 40], ["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 32, 40], ["patients", "SPECIES", 45, 53], ["final analysis", "TEST", 72, 86]]], ["The patients were treated in a large multidisciplinary university hospital and in a specialized center for hematology and hematologic oncology in Warsaw, Poland.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12]]], ["All met the following inclusion criteria: (1) known immunosuppression; (2) clinical or radiological signs and symptoms of pulmonary infection; and (3) signed informed consent for diagnostic bronchoscopy.PatientsImmunosuppression was defined as: (1) hematologic diseases or malignancies (HDM); or (2) immunosuppressive chemotherapy due to any malignant disease; or (3) immunosuppressive treatment due to solid organ or hematologic stem cell transplantation (SOTR); or (4) immunosuppressive therapy due to autoimmune or other diseases; or (5) miscellaneous chronic diseases that could affect the immune state (MISC group).", [["pulmonary", "ANATOMY", 122, 131], ["hematologic", "ANATOMY", 249, 260], ["malignancies", "ANATOMY", 273, 285], ["solid organ", "ANATOMY", 403, 414], ["hematologic stem cell", "ANATOMY", 418, 439], ["pulmonary infection", "DISEASE", 122, 141], ["Immunosuppression", "DISEASE", 211, 228], ["malignancies", "DISEASE", 273, 285], ["HDM", "DISEASE", 287, 290], ["malignant disease", "DISEASE", 342, 359], ["autoimmune or other diseases", "DISEASE", 504, 532], ["pulmonary", "ORGAN", 122, 131], ["Patients", "ORGANISM", 203, 211], ["malignancies", "CANCER", 273, 285], ["malignant disease", "CANCER", 342, 359], ["organ", "ORGAN", 409, 414], ["hematologic stem cell", "CELL", 418, 439], ["Patients", "SPECIES", 203, 211], ["known immunosuppression", "PROBLEM", 46, 69], ["clinical or radiological signs and symptoms", "PROBLEM", 75, 118], ["pulmonary infection", "PROBLEM", 122, 141], ["diagnostic bronchoscopy", "TEST", 179, 202], ["hematologic diseases", "PROBLEM", 249, 269], ["malignancies (HDM)", "PROBLEM", 273, 291], ["immunosuppressive chemotherapy", "TREATMENT", 300, 330], ["any malignant disease", "PROBLEM", 338, 359], ["immunosuppressive treatment", "TREATMENT", 368, 395], ["solid organ", "PROBLEM", 403, 414], ["hematologic stem cell transplantation", "TREATMENT", 418, 455], ["immunosuppressive therapy", "TREATMENT", 471, 496], ["autoimmune", "PROBLEM", 504, 514], ["other diseases", "PROBLEM", 518, 532], ["miscellaneous chronic diseases", "PROBLEM", 541, 571], ["pulmonary", "ANATOMY", 122, 131], ["infection", "OBSERVATION", 132, 141], ["Immunosuppression", "OBSERVATION", 211, 228], ["malignancies", "OBSERVATION", 273, 285], ["malignant", "OBSERVATION", 342, 351], ["hematologic stem cell transplantation", "OBSERVATION", 418, 455], ["chronic", "OBSERVATION_MODIFIER", 555, 562], ["diseases", "OBSERVATION", 563, 571]]], ["Clinical signs and symptoms suggestive of lower airway infection included recent cough, fever, dyspnea, or auscultatory findings.", [["lower airway", "ANATOMY", 42, 54], ["airway infection", "DISEASE", 48, 64], ["cough", "DISEASE", 81, 86], ["fever", "DISEASE", 88, 93], ["dyspnea", "DISEASE", 95, 102], ["lower airway", "ORGANISM_SUBDIVISION", 42, 54], ["Clinical signs", "TEST", 0, 14], ["symptoms", "PROBLEM", 19, 27], ["lower airway infection", "PROBLEM", 42, 64], ["recent cough", "PROBLEM", 74, 86], ["fever", "PROBLEM", 88, 93], ["dyspnea", "PROBLEM", 95, 102], ["auscultatory findings", "PROBLEM", 107, 128], ["lower", "ANATOMY_MODIFIER", 42, 47], ["airway", "ANATOMY", 48, 54], ["infection", "OBSERVATION", 55, 64], ["cough", "OBSERVATION", 81, 86]]], ["Radiological findings consistent with pulmonary infection were defined as the presence of the following pulmonary abnormalities: single or multifocal consolidations, areas of ground glass opacity, pulmonary nodules, interstitial pattern which could not have been explained by other causes, such as e.g. progression of lung tumors or new lung metastases.", [["pulmonary", "ANATOMY", 38, 47], ["pulmonary", "ANATOMY", 104, 113], ["pulmonary nodules", "ANATOMY", 197, 214], ["interstitial", "ANATOMY", 216, 228], ["lung tumors", "ANATOMY", 318, 329], ["lung metastases", "ANATOMY", 337, 352], ["pulmonary infection", "DISEASE", 38, 57], ["pulmonary abnormalities", "DISEASE", 104, 127], ["lung tumors", "DISEASE", 318, 329], ["lung metastases", "DISEASE", 337, 352], ["pulmonary", "ORGAN", 38, 47], ["pulmonary", "ORGAN", 104, 113], ["pulmonary nodules", "PATHOLOGICAL_FORMATION", 197, 214], ["lung tumors", "CANCER", 318, 329], ["lung", "ORGAN", 337, 341], ["Radiological findings", "TEST", 0, 21], ["pulmonary infection", "PROBLEM", 38, 57], ["the following pulmonary abnormalities", "PROBLEM", 90, 127], ["single or multifocal consolidations", "PROBLEM", 129, 164], ["ground glass opacity", "PROBLEM", 175, 195], ["pulmonary nodules", "PROBLEM", 197, 214], ["interstitial pattern", "PROBLEM", 216, 236], ["lung tumors", "PROBLEM", 318, 329], ["new lung metastases", "PROBLEM", 333, 352], ["consistent with", "UNCERTAINTY", 22, 37], ["pulmonary", "ANATOMY", 38, 47], ["infection", "OBSERVATION", 48, 57], ["pulmonary", "ANATOMY", 104, 113], ["abnormalities", "OBSERVATION", 114, 127], ["single", "OBSERVATION_MODIFIER", 129, 135], ["multifocal", "OBSERVATION_MODIFIER", 139, 149], ["consolidations", "OBSERVATION", 150, 164], ["areas", "OBSERVATION_MODIFIER", 166, 171], ["ground glass opacity", "OBSERVATION", 175, 195], ["pulmonary", "ANATOMY", 197, 206], ["nodules", "OBSERVATION", 207, 214], ["interstitial", "ANATOMY_MODIFIER", 216, 228], ["progression", "OBSERVATION_MODIFIER", 303, 314], ["lung", "ANATOMY", 318, 322], ["tumors", "OBSERVATION", 323, 329], ["new", "OBSERVATION_MODIFIER", 333, 336], ["lung", "ANATOMY", 337, 341], ["metastases", "OBSERVATION", 342, 352]]], ["Exclusion criteria were the following: (1) known AIDS or positive result of HIV test; (2) contraindications to diagnostic bronchoscopy, i.e., unstable hemodynamic status, gas exchange abnormalities resulting in hypoxemia (SaO 2 below 92 %) despite low flow oxygen therapy; and (3) respiratory failure requiring mechanical ventilation.Bronchoscopy ProcedureAll patients underwent fiberoptic bronchoscopy under local anesthesia.", [["respiratory", "ANATOMY", 281, 292], ["AIDS", "DISEASE", 49, 53], ["hypoxemia", "DISEASE", 211, 220], ["oxygen", "CHEMICAL", 257, 263], ["respiratory failure", "DISEASE", 281, 300], ["oxygen", "CHEMICAL", 257, 263], ["oxygen", "SIMPLE_CHEMICAL", 257, 263], ["patients", "ORGANISM", 360, 368], ["patients", "SPECIES", 360, 368], ["HIV", "SPECIES", 76, 79], ["known AIDS", "PROBLEM", 43, 53], ["HIV test", "PROBLEM", 76, 84], ["diagnostic bronchoscopy", "TEST", 111, 134], ["unstable hemodynamic status", "PROBLEM", 142, 169], ["gas exchange abnormalities", "PROBLEM", 171, 197], ["hypoxemia", "PROBLEM", 211, 220], ["SaO", "TEST", 222, 225], ["low flow oxygen therapy", "TREATMENT", 248, 271], ["respiratory failure", "PROBLEM", 281, 300], ["mechanical ventilation", "TREATMENT", 311, 333], ["Bronchoscopy", "TREATMENT", 334, 346], ["fiberoptic bronchoscopy", "TEST", 379, 402], ["local anesthesia", "TREATMENT", 409, 425], ["hypoxemia", "OBSERVATION", 211, 220], ["low flow", "OBSERVATION_MODIFIER", 248, 256], ["oxygen therapy", "OBSERVATION", 257, 271], ["respiratory", "ANATOMY", 281, 292], ["failure", "OBSERVATION", 293, 300], ["mechanical ventilation", "OBSERVATION", 311, 333]]], ["The insertion of a bronchoscope (Olympus BF 1 T180 or Pentax EB 1970 K; Tokyo, Japan) was preceded by premedication with atropine sulphate 0.5 mg s.c. and midazolam 7.5 mg p.o., and by local anesthesia of the upper airways with 2 % lidocaine.", [["upper airways", "ANATOMY", 209, 222], ["atropine sulphate", "CHEMICAL", 121, 138], ["midazolam", "CHEMICAL", 155, 164], ["lidocaine", "CHEMICAL", 232, 241], ["atropine sulphate", "CHEMICAL", 121, 138], ["midazolam", "CHEMICAL", 155, 164], ["lidocaine", "CHEMICAL", 232, 241], ["atropine sulphate", "SIMPLE_CHEMICAL", 121, 138], ["midazolam", "SIMPLE_CHEMICAL", 155, 164], ["upper airways", "ORGANISM_SUBDIVISION", 209, 222], ["lidocaine", "SIMPLE_CHEMICAL", 232, 241], ["a bronchoscope", "TREATMENT", 17, 31], ["Olympus BF", "TEST", 33, 43], ["atropine sulphate", "TREATMENT", 121, 138], ["midazolam", "TREATMENT", 155, 164], ["2 % lidocaine", "TREATMENT", 228, 241], ["upper", "ANATOMY_MODIFIER", 209, 214], ["airways", "ANATOMY", 215, 222]]], ["Suction was avoided in the upper airways and trachea to minimize contamination of the working channel of the bronchoscope.", [["upper airways", "ANATOMY", 27, 40], ["trachea", "ANATOMY", 45, 52], ["upper airways", "MULTI-TISSUE_STRUCTURE", 27, 40], ["trachea", "ORGAN", 45, 52], ["Suction", "TREATMENT", 0, 7], ["the bronchoscope", "TREATMENT", 105, 121], ["upper", "ANATOMY_MODIFIER", 27, 32], ["airways", "ANATOMY", 33, 40], ["trachea", "ANATOMY", 45, 52], ["bronchoscope", "OBSERVATION", 109, 121]]], ["Additional portions of lidocaine were applied to the lower airways when necessary.", [["lower airways", "ANATOMY", 53, 66], ["lidocaine", "CHEMICAL", 23, 32], ["lidocaine", "CHEMICAL", 23, 32], ["lidocaine", "SIMPLE_CHEMICAL", 23, 32], ["lower airways", "ORGANISM_SUBDIVISION", 53, 66], ["lidocaine", "TREATMENT", 23, 32], ["lidocaine", "OBSERVATION", 23, 32], ["lower", "ANATOMY_MODIFIER", 53, 58], ["airways", "ANATOMY", 59, 66]]], ["After visual inspection of the lower airways, bronchoscope was wedged in segmental or sub-segmental bronchus in accordance with the localization of radiological abnormalities.", [["lower airways", "ANATOMY", 31, 44], ["sub-segmental bronchus", "ANATOMY", 86, 108], ["lower airways", "MULTI-TISSUE_STRUCTURE", 31, 44], ["bronchus", "MULTI-TISSUE_STRUCTURE", 100, 108], ["visual inspection", "TEST", 6, 23], ["bronchoscope", "TREATMENT", 46, 58], ["radiological abnormalities", "PROBLEM", 148, 174], ["lower", "ANATOMY_MODIFIER", 31, 36], ["airways", "ANATOMY", 37, 44], ["bronchoscope", "OBSERVATION", 46, 58], ["wedged", "OBSERVATION_MODIFIER", 63, 69], ["segmental", "ANATOMY_MODIFIER", 73, 82], ["sub", "OBSERVATION_MODIFIER", 86, 89], ["segmental", "ANATOMY_MODIFIER", 90, 99], ["bronchus", "ANATOMY", 100, 108]]], ["In case of no relevant radiological abnormalities, bronchoscope was wedged in the medial or lateral segment of the right middle lobe (RB4 or RB5).", [["medial", "ANATOMY", 82, 88], ["lateral segment", "ANATOMY", 92, 107], ["right middle lobe", "ANATOMY", 115, 132], ["RB4", "ANATOMY", 134, 137], ["RB5", "ANATOMY", 141, 144], ["lateral segment", "MULTI-TISSUE_STRUCTURE", 92, 107], ["right middle lobe", "CANCER", 115, 132], ["RB5", "PROTEIN", 141, 144], ["relevant radiological abnormalities", "PROBLEM", 14, 49], ["bronchoscope", "TEST", 51, 63], ["no", "UNCERTAINTY", 11, 13], ["bronchoscope", "OBSERVATION", 51, 63], ["wedged", "OBSERVATION_MODIFIER", 68, 74], ["medial", "ANATOMY_MODIFIER", 82, 88], ["lateral", "ANATOMY_MODIFIER", 92, 99], ["segment", "ANATOMY_MODIFIER", 100, 107], ["right middle lobe", "ANATOMY", 115, 132]]], ["Two hundred milliliters of sterile, pre-warmed (37 C) 0.9 % saline solution were instilled either in ten 20 ml portions or four 50 ml portions and withdrawn by gentle suction.", [["0.9 % saline solution", "TREATMENT", 54, 75], ["gentle suction", "TREATMENT", 160, 174]]], ["Bronchoalveolar lavage fluid (BALF) was collected in sterile polypropylene tubes.Microbiological ProcedureSamples of BALF were sent for microbiological examination including direct microscopy, cultures, and fungal antigen detection, when appropriate.", [["Bronchoalveolar lavage fluid", "ANATOMY", 0, 28], ["BALF", "ANATOMY", 30, 34], ["BALF", "ANATOMY", 117, 121], ["polypropylene", "CHEMICAL", 61, 74], ["Bronchoalveolar lavage fluid", "ORGANISM_SUBSTANCE", 0, 28], ["BALF", "ORGANISM_SUBSTANCE", 30, 34], ["BALF", "ORGANISM_SUBSTANCE", 117, 121], ["Bronchoalveolar lavage fluid (BALF)", "TEST", 0, 35], ["sterile polypropylene tubes", "TREATMENT", 53, 80], ["Microbiological ProcedureSamples of BALF", "TEST", 81, 121], ["microbiological examination", "TEST", 136, 163], ["direct microscopy", "TEST", 174, 191], ["cultures", "TEST", 193, 201], ["fungal antigen detection", "TEST", 207, 231], ["lavage fluid", "OBSERVATION", 16, 28], ["polypropylene tubes", "OBSERVATION", 61, 80], ["BALF", "ANATOMY", 117, 121]]], ["One milliliter samples of BALF were frozen at \u00c020 C. Total DNA was extracted from 200 \u03bcl of BALF, using EXTRAcell \u00ae isolation kit.", [["samples", "ANATOMY", 15, 22], ["BALF", "ANATOMY", 26, 30], ["BALF", "ANATOMY", 92, 96], ["BALF", "CELL", 26, 30], ["DNA", "CELLULAR_COMPONENT", 59, 62], ["BALF", "ORGANISM_SUBSTANCE", 92, 96], ["BALF", "CELL_TYPE", 26, 30], ["BALF", "TEST", 26, 30], ["Total DNA", "TEST", 53, 62], ["EXTRAcell \u00ae isolation kit", "TREATMENT", 104, 129], ["BALF", "ANATOMY", 92, 96], ["isolation kit", "OBSERVATION", 116, 129]]], ["Commercial qualitative amplification assay (PNEUMOTRIS oligomix Alert Kit \u00ae ), based on nested PCR method, was used to detect specific DNA sequences of L. pneumophila, C. pneumoniae, and M. pneumoniae in defrozen BALF samples.", [["BALF samples", "ANATOMY", 213, 225], ["DNA", "CELLULAR_COMPONENT", 135, 138], ["L. pneumophila", "ORGANISM", 152, 166], ["C. pneumoniae", "ORGANISM", 168, 181], ["M. pneumoniae", "ORGANISM", 187, 200], ["BALF samples", "CANCER", 213, 225], ["L. pneumophila", "SPECIES", 152, 166], ["C. pneumoniae", "SPECIES", 168, 181], ["M. pneumoniae", "SPECIES", 187, 200], ["L. pneumophila", "SPECIES", 152, 166], ["C. pneumoniae", "SPECIES", 168, 181], ["M. pneumoniae", "SPECIES", 187, 200], ["Commercial qualitative amplification assay", "TEST", 0, 42], ["nested PCR method", "TEST", 88, 105], ["L. pneumophila", "PROBLEM", 152, 166], ["C. pneumoniae", "PROBLEM", 168, 181], ["M. pneumoniae", "PROBLEM", 187, 200], ["defrozen BALF samples", "TEST", 204, 225], ["pneumophila", "OBSERVATION", 155, 166], ["pneumoniae", "OBSERVATION", 171, 181], ["pneumoniae", "OBSERVATION", 190, 200]]], ["Also BETA-GLOBIN oligomix Alert Kit \u00ae , which uses the human \u03b2-globin gene as a standard, was used as an external control of DNA extraction and amplification.", [["human", "ORGANISM", 55, 60], ["\u03b2-globin", "GENE_OR_GENE_PRODUCT", 61, 69], ["DNA", "CELLULAR_COMPONENT", 125, 128], ["human \u03b2-globin gene", "DNA", 55, 74], ["human", "SPECIES", 55, 60], ["human", "SPECIES", 55, 60], ["BETA-GLOBIN oligomix", "TREATMENT", 5, 25], ["the human \u03b2-globin gene", "TREATMENT", 51, 74], ["an external control of DNA extraction", "TREATMENT", 102, 139], ["BETA-GLOBIN oligomix", "OBSERVATION", 5, 25]]], ["All reagents described above were supplied by Nanogen Advanced Diagnostics S.r.L. (Turin, Italy), and all investigations were performed in accordance to the manufacturer's instructions.", [["All reagents", "TREATMENT", 0, 12], ["all investigations", "TEST", 102, 120]]], ["A presumed limit of detection (LOD) of the PCR assay used was established as a few dozen copies/ml.Data Collection and AnalysisData on clinical and radiological signs and symptoms, and the results of microbiological examination of BALF were retrospectively collected and loaded in an electronic database.", [["BALF", "ANATOMY", 231, 235], ["BALF", "ORGANISM_SUBSTANCE", 231, 235], ["the PCR assay", "TEST", 39, 52], ["Data Collection", "TEST", 99, 114], ["radiological signs", "TEST", 148, 166], ["symptoms", "PROBLEM", 171, 179], ["microbiological examination of BALF", "TEST", 200, 235], ["an electronic database", "TEST", 281, 303]]], ["Additionally, results of other microbiological studies, including blood samples, throat swabs, sputum, urine, or stool were also analyzed.Data Collection and AnalysisConsistently with the aim of the study, results were assessed in patients with different types of immunosuppression.Data Collection and AnalysisQuantitative variables were presented as median, interquartile range (IQR) and/or ranges, while qualitative variables were presented as number and percentage.", [["blood samples", "ANATOMY", 66, 79], ["throat swabs", "ANATOMY", 81, 93], ["sputum", "ANATOMY", 95, 101], ["urine", "ANATOMY", 103, 108], ["stool", "ANATOMY", 113, 118], ["blood samples", "ORGANISM_SUBSTANCE", 66, 79], ["throat swabs", "MULTI-TISSUE_STRUCTURE", 81, 93], ["sputum", "ORGANISM_SUBSTANCE", 95, 101], ["urine", "ORGANISM_SUBSTANCE", 103, 108], ["stool", "ORGANISM_SUBSTANCE", 113, 118], ["patients", "ORGANISM", 231, 239], ["patients", "SPECIES", 231, 239], ["other microbiological studies", "TEST", 25, 54], ["blood samples", "TEST", 66, 79], ["throat swabs", "TEST", 81, 93], ["sputum, urine, or stool", "TEST", 95, 118], ["Data Collection", "TEST", 138, 153], ["the study", "TEST", 195, 204], ["immunosuppression", "TREATMENT", 264, 281], ["Data Collection", "TEST", 282, 297], ["AnalysisQuantitative variables", "TEST", 302, 332], ["throat", "ANATOMY", 81, 87], ["stool", "ANATOMY", 113, 118], ["immunosuppression", "OBSERVATION", 264, 281]]], ["A non-parametric Mann-Whitney U test or Chi-squared test was used to assess the difference between variables in different groups.", [["Whitney U test", "TEST", 22, 36], ["Chi-squared test", "TEST", 40, 56]]], ["A p-value below 0.05 was considered statistically significant.", [["A p-value", "TEST", 0, 9]]], ["Statistical analysis was performed using a statistical software package (STATISTICA, ver.", [["Statistical analysis", "TEST", 0, 20]]], ["9.0, StatSoft Inc., Tulsa, OK).ResultsDemographics and data on the underlying diseases are presented in Table 1 .", [["the underlying diseases", "PROBLEM", 63, 86], ["diseases", "OBSERVATION", 78, 86]]], ["Patients were unevenly distributed, with 61 (84.7 %) in the HDM group, 8 (11.1 %) in the MISC group, and 3 (4.2 %) patients in the SORT group.", [["Patients", "ORGANISM", 0, 8], ["MISC", "CANCER", 89, 93], ["patients", "ORGANISM", 115, 123], ["SORT", "CANCER", 131, 135], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 115, 123], ["the MISC group", "TEST", 85, 99], ["unevenly", "OBSERVATION_MODIFIER", 14, 22]]], ["The most common underlying disease was acute myeloid leukemia (AML) which was responsible for almost one third of all causes of immunosuppression.", [["acute myeloid leukemia", "ANATOMY", 39, 61], ["AML", "ANATOMY", 63, 66], ["acute myeloid leukemia", "DISEASE", 39, 61], ["AML", "DISEASE", 63, 66], ["acute myeloid leukemia", "CANCER", 39, 61], ["AML", "CANCER", 63, 66], ["acute myeloid leukemia", "PROBLEM", 39, 61], ["AML", "PROBLEM", 63, 66], ["immunosuppression", "TREATMENT", 128, 145], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["disease", "OBSERVATION", 27, 34], ["acute", "OBSERVATION_MODIFIER", 39, 44], ["myeloid leukemia", "OBSERVATION", 45, 61], ["AML", "OBSERVATION", 63, 66], ["immunosuppression", "OBSERVATION", 128, 145]]], ["AML was followed by chronic lymphocytic leukemia (n \u00bc 10; 13.9 % of causes) and non-Hodgkin lymphoma (n \u00bc 9; 12.5 % of causes).", [["AML", "ANATOMY", 0, 3], ["chronic lymphocytic leukemia", "ANATOMY", 20, 48], ["non-Hodgkin lymphoma", "ANATOMY", 80, 100], ["AML", "DISEASE", 0, 3], ["chronic lymphocytic leukemia", "DISEASE", 20, 48], ["non-Hodgkin lymphoma", "DISEASE", 80, 100], ["AML", "CANCER", 0, 3], ["chronic lymphocytic leukemia", "CANCER", 20, 48], ["non-Hodgkin lymphoma", "CANCER", 80, 100], ["AML", "PROBLEM", 0, 3], ["chronic lymphocytic leukemia", "PROBLEM", 20, 48], ["non-Hodgkin lymphoma", "PROBLEM", 80, 100], ["chronic", "OBSERVATION_MODIFIER", 20, 27], ["lymphocytic leukemia", "OBSERVATION", 28, 48], ["non-Hodgkin lymphoma", "OBSERVATION", 80, 100]]], ["Clinical signs and symptoms as well as radiographic data are demonstrated in Table 2 .", [["Clinical signs and symptoms", "PROBLEM", 0, 27], ["radiographic data", "TEST", 39, 56]]], ["The major clinical symptoms were fever found in 54 (75.0 %) patients and cough reported by 30 (41.6 %) patients.", [["fever", "DISEASE", 33, 38], ["cough", "DISEASE", 73, 78], ["patients", "ORGANISM", 60, 68], ["patients", "ORGANISM", 103, 111], ["patients", "SPECIES", 60, 68], ["patients", "SPECIES", 103, 111], ["The major clinical symptoms", "PROBLEM", 0, 27], ["fever", "PROBLEM", 33, 38], ["cough", "PROBLEM", 73, 78]]], ["There were no typical signs and symptoms of lower airway infection in 9 (12.5 %) patients, and pulmonary disease in these patients was diagnosed based on the new radiological findings.", [["lower airway", "ANATOMY", 44, 56], ["pulmonary", "ANATOMY", 95, 104], ["lower airway infection", "DISEASE", 44, 66], ["pulmonary disease", "DISEASE", 95, 112], ["lower airway", "ORGANISM_SUBDIVISION", 44, 56], ["patients", "ORGANISM", 81, 89], ["pulmonary", "ORGAN", 95, 104], ["patients", "ORGANISM", 122, 130], ["patients", "SPECIES", 81, 89], ["patients", "SPECIES", 122, 130], ["typical signs", "PROBLEM", 14, 27], ["symptoms", "PROBLEM", 32, 40], ["lower airway infection", "PROBLEM", 44, 66], ["pulmonary disease", "PROBLEM", 95, 112], ["no typical", "UNCERTAINTY", 11, 21], ["lower", "ANATOMY_MODIFIER", 44, 49], ["airway", "ANATOMY", 50, 56], ["infection", "OBSERVATION", 57, 66], ["pulmonary", "ANATOMY", 95, 104], ["disease", "OBSERVATION", 105, 112]]], ["Chest radiographs and thorax CT scans were available in 71 (98.6 %) and 66 (91.7 %) of patients, respectively.", [["thorax", "ANATOMY", 22, 28], ["thorax", "ORGAN", 22, 28], ["patients", "ORGANISM", 87, 95], ["patients", "SPECIES", 87, 95], ["Chest radiographs", "TEST", 0, 17], ["thorax CT scans", "TEST", 22, 37], ["thorax", "ANATOMY", 22, 28]]], ["The most common radiographic manifestation was lung consolidation, found in 50 (69.4 %) patients.", [["lung", "ANATOMY", 47, 51], ["lung consolidation", "DISEASE", 47, 65], ["lung", "ORGAN", 47, 51], ["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 88, 96], ["lung consolidation", "PROBLEM", 47, 65], ["lung", "ANATOMY", 47, 51], ["consolidation", "OBSERVATION", 52, 65]]], ["There was a predominance of bilateral radiographic lung involvement, which was Table 3 presents the clinical, radiological and microbiological characteristics of 9 patients in whom DNA of atypical pathogens was identified in BALF.", [["lung", "ANATOMY", 51, 55], ["BALF", "ANATOMY", 225, 229], ["lung", "ORGAN", 51, 55], ["patients", "ORGANISM", 164, 172], ["DNA", "CELLULAR_COMPONENT", 181, 184], ["BALF", "ORGANISM_SUBSTANCE", 225, 229], ["BALF", "CELL_TYPE", 225, 229], ["patients", "SPECIES", 164, 172], ["bilateral radiographic lung involvement", "PROBLEM", 28, 67], ["atypical pathogens", "PROBLEM", 188, 206], ["predominance", "OBSERVATION_MODIFIER", 12, 24], ["bilateral", "ANATOMY_MODIFIER", 28, 37], ["radiographic", "OBSERVATION_MODIFIER", 38, 50], ["lung", "ANATOMY", 51, 55], ["involvement", "OBSERVATION", 56, 67], ["atypical", "OBSERVATION_MODIFIER", 188, 196], ["pathogens", "OBSERVATION", 197, 206]]], ["In none of 72 samples specific L. pneumophila DNA sequences were found.", [["samples", "ANATOMY", 14, 21], ["L. pneumophila", "ORGANISM", 31, 45], ["DNA", "CELLULAR_COMPONENT", 46, 49], ["L. pneumophila", "SPECIES", 31, 45], ["L. pneumophila", "SPECIES", 31, 45], ["L. pneumophila DNA sequences", "TEST", 31, 59]]], ["M. pneumoniae specific DNA was identified in samples collected from 7 (9.7 %) patients.", [["samples", "ANATOMY", 45, 52], ["M. pneumoniae", "ORGANISM", 0, 13], ["DNA", "CELLULAR_COMPONENT", 23, 26], ["samples", "CANCER", 45, 52], ["patients", "ORGANISM", 78, 86], ["M. pneumoniae", "SPECIES", 0, 13], ["patients", "SPECIES", 78, 86], ["M. pneumoniae", "SPECIES", 0, 13], ["M. pneumoniae specific DNA", "PROBLEM", 0, 26], ["pneumoniae", "OBSERVATION", 3, 13]]], ["Two samples (2.8 %) tested positively for C. pneumoniae DNA.", [["samples", "ANATOMY", 4, 11], ["C. pneumoniae", "ORGANISM", 42, 55], ["DNA", "CELLULAR_COMPONENT", 56, 59], ["C. pneumoniae", "SPECIES", 42, 55], ["C. pneumoniae", "SPECIES", 42, 55], ["Two samples", "TEST", 0, 11], ["C. pneumoniae DNA", "PROBLEM", 42, 59], ["pneumoniae DNA", "OBSERVATION", 45, 59]]], ["In all patients with identified atypical pathogens, fever was the most commonly reported symptom.", [["fever", "DISEASE", 52, 57], ["patients", "ORGANISM", 7, 15], ["patients", "SPECIES", 7, 15], ["atypical pathogens", "PROBLEM", 32, 50], ["fever", "PROBLEM", 52, 57], ["symptom", "PROBLEM", 89, 96], ["atypical", "OBSERVATION_MODIFIER", 32, 40], ["pathogens", "OBSERVATION", 41, 50]]], ["In 6 out of the 9 patients bilateral lung involvement was demonstrated.", [["lung", "ANATOMY", 37, 41], ["patients", "ORGANISM", 18, 26], ["lung", "ORGAN", 37, 41], ["patients", "SPECIES", 18, 26], ["bilateral lung involvement", "PROBLEM", 27, 53], ["bilateral", "ANATOMY_MODIFIER", 27, 36], ["lung", "ANATOMY", 37, 41], ["involvement", "OBSERVATION", 42, 53]]], ["In 8 patients, co-infections with different microorganisms were detected based on BALF or blood microbiological studies.", [["BALF", "ANATOMY", 82, 86], ["blood", "ANATOMY", 90, 95], ["co-infections", "DISEASE", 15, 28], ["patients", "ORGANISM", 5, 13], ["BALF", "ORGANISM_SUBSTANCE", 82, 86], ["blood", "ORGANISM_SUBSTANCE", 90, 95], ["patients", "SPECIES", 5, 13], ["co-infections", "PROBLEM", 15, 28], ["different microorganisms", "PROBLEM", 34, 58], ["BALF", "TEST", 82, 86], ["blood microbiological studies", "TEST", 90, 119]]], ["Despite broad spectrum antibiotic and antifungal therapy, 3 patients died.", [["antifungal", "CANCER", 38, 48], ["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68], ["broad spectrum antibiotic", "TREATMENT", 8, 33], ["antifungal therapy", "TREATMENT", 38, 56], ["antifungal therapy", "OBSERVATION", 38, 56]]], ["All those patients had positive results of blood culture, with A. baumanii and P. aeruginosa found in two and one patients, respectively.DiscussionThe present study demonstrates a low prevalence of atypical pulmonary infections in non-HIV immunocompromised patients.", [["blood", "ANATOMY", 43, 48], ["pulmonary", "ANATOMY", 207, 216], ["pulmonary infections", "DISEASE", 207, 227], ["patients", "ORGANISM", 10, 18], ["blood", "ORGANISM_SUBSTANCE", 43, 48], ["A. baumanii", "ORGANISM", 63, 74], ["P. aeruginosa", "ORGANISM", 79, 92], ["patients", "ORGANISM", 114, 122], ["pulmonary", "ORGAN", 207, 216], ["patients", "ORGANISM", 257, 265], ["patients", "SPECIES", 10, 18], ["A. baumanii", "SPECIES", 63, 74], ["P. aeruginosa", "SPECIES", 79, 92], ["patients", "SPECIES", 114, 122], ["patients", "SPECIES", 257, 265], ["A. baumanii", "SPECIES", 63, 74], ["P. aeruginosa", "SPECIES", 79, 92], ["blood culture", "TEST", 43, 56], ["A. baumanii", "PROBLEM", 63, 74], ["P. aeruginosa", "PROBLEM", 79, 92], ["The present study", "TEST", 147, 164], ["atypical pulmonary infections", "PROBLEM", 198, 227], ["low prevalence", "OBSERVATION_MODIFIER", 180, 194], ["atypical", "OBSERVATION_MODIFIER", 198, 206], ["pulmonary", "ANATOMY", 207, 216], ["infections", "OBSERVATION", 217, 227], ["non-HIV immunocompromised", "OBSERVATION", 231, 256]]], ["M. pneumoniae, C. pneumoniae and L. pneumophila were found in 9.7 %, 2.8 %, and 0 % of patients, respectively.", [["M. pneumoniae", "ORGANISM", 0, 13], ["C. pneumoniae", "ORGANISM", 15, 28], ["L. pneumophila", "ORGANISM", 33, 47], ["patients", "ORGANISM", 87, 95], ["M. pneumoniae", "SPECIES", 0, 13], ["C. pneumoniae", "SPECIES", 15, 28], ["L. pneumophila", "SPECIES", 33, 47], ["patients", "SPECIES", 87, 95], ["M. pneumoniae", "SPECIES", 0, 13], ["C. pneumoniae", "SPECIES", 15, 28], ["L. pneumophila", "SPECIES", 33, 47], ["M. pneumoniae", "PROBLEM", 0, 13], ["C. pneumoniae", "PROBLEM", 15, 28], ["L. pneumophila", "TEST", 33, 47], ["pneumoniae", "OBSERVATION", 3, 13], ["pneumoniae", "OBSERVATION_MODIFIER", 18, 28], ["L.", "OBSERVATION_MODIFIER", 33, 35], ["pneumophila", "OBSERVATION_MODIFIER", 36, 47]]], ["Thus, the prevalence of these infections in this study was somewhat lower than that usually reported in immunocompetent patients with CAP (Capelastegui et al. 2012; Masi\u00e1 et al. 2007 ).", [["infections", "DISEASE", 30, 40], ["CAP", "DISEASE", 134, 137], ["patients", "ORGANISM", 120, 128], ["patients", "SPECIES", 120, 128], ["these infections", "PROBLEM", 24, 40], ["this study", "TEST", 44, 54], ["CAP", "PROBLEM", 134, 137], ["infections", "OBSERVATION", 30, 40]]], ["On the other hand, the percentage of patients in whom atypical pathogens (except L. pneumophila) were identified was slightly higher as compared with other studies in immunocompromised hosts (Cervera et al. 2006; Hohenthal et al. 2005; Jain et al. 2004; Dan\u00e9s et al. 2002) .", [["patients", "ORGANISM", 37, 45], ["L. pneumophila", "ORGANISM", 81, 95], ["patients", "SPECIES", 37, 45], ["L. pneumophila", "SPECIES", 81, 95], ["L. pneumophila", "SPECIES", 81, 95], ["atypical pathogens", "PROBLEM", 54, 72], ["L. pneumophila", "PROBLEM", 81, 95], ["other studies", "TEST", 150, 163], ["slightly", "OBSERVATION_MODIFIER", 117, 125], ["higher", "OBSERVATION_MODIFIER", 126, 132]]], ["This difference can be easily explained by multiple factors that can influence the results of various studies.", [["various studies", "TEST", 94, 109]]], ["These include: environmental factors (community or hospital acquired infection), seasonal and local epidemiological situation, type, severity and duration of immunosuppression, methods applied for pathogen detection and identification, reporting method (per entire study group or per subgroup with specific cause of immunoincompetence), and treatment applied prior to microbiological sampling.", [["infection", "DISEASE", 69, 78], ["environmental factors", "PROBLEM", 15, 36], ["hospital acquired infection", "PROBLEM", 51, 78], ["seasonal and local epidemiological situation", "PROBLEM", 81, 125], ["type, severity", "PROBLEM", 127, 141], ["immunosuppression", "TREATMENT", 158, 175], ["methods", "TREATMENT", 177, 184], ["pathogen detection", "TEST", 197, 215], ["immunoincompetence", "PROBLEM", 316, 334], ["treatment", "TREATMENT", 341, 350], ["microbiological sampling", "TEST", 368, 392]]], ["Despite all these conditions, most authors agree that atypical pulmonary infections in immunocompromised hosts are rather uncommon.", [["pulmonary", "ANATOMY", 63, 72], ["pulmonary infections", "DISEASE", 63, 83], ["pulmonary", "ORGAN", 63, 72], ["atypical pulmonary infections in immunocompromised hosts", "PROBLEM", 54, 110], ["atypical", "OBSERVATION_MODIFIER", 54, 62], ["pulmonary", "ANATOMY", 63, 72], ["infections", "OBSERVATION", 73, 83], ["immunocompromised", "OBSERVATION", 87, 104]]], ["Depending on the source of data, typical bacteria, fungi, and viruses have been responsible for 18-51 %, 8-38 %, and 9-23 % of pulmonary infections in non-HIV immunocompromised patients, respectively (Camps Serra et al. 2008; Jain et al. 2004; Dan\u00e9s et al. 2002; Ra\u00f1\u00f3 et al. 2001 ).", [["pulmonary", "ANATOMY", 127, 136], ["pulmonary infections", "DISEASE", 127, 147], ["pulmonary", "ORGAN", 127, 136], ["patients", "ORGANISM", 177, 185], ["patients", "SPECIES", 177, 185], ["typical bacteria", "PROBLEM", 33, 49], ["fungi", "PROBLEM", 51, 56], ["viruses", "PROBLEM", 62, 69], ["pulmonary infections in non-HIV immunocompromised patients", "PROBLEM", 127, 185], ["bacteria", "OBSERVATION", 41, 49], ["pulmonary", "ANATOMY", 127, 136], ["infections", "OBSERVATION", 137, 147]]], ["In addition, polymicrobial infections caused by the pathogens outlined above have been diagnosed in 7-13 % of patients.", [["infections", "DISEASE", 27, 37], ["patients", "ORGANISM", 110, 118], ["patients", "SPECIES", 110, 118], ["polymicrobial infections", "PROBLEM", 13, 37], ["the pathogens", "PROBLEM", 48, 61], ["polymicrobial", "OBSERVATION_MODIFIER", 13, 26], ["infections", "OBSERVATION", 27, 37], ["pathogens", "OBSERVATION", 52, 61]]], ["Atypical pathogens have been found in single cases only.DiscussionIn this study, diagnosis of pulmonary infection caused by atypical bacteria was based on a sole microbiological test, i.e., identification of specific DNA sequences in lavage fluid collected directly from the site of infection.", [["pulmonary", "ANATOMY", 94, 103], ["lavage fluid", "ANATOMY", 234, 246], ["pulmonary infection", "DISEASE", 94, 113], ["infection", "DISEASE", 283, 292], ["pulmonary", "ORGAN", 94, 103], ["DNA", "CELLULAR_COMPONENT", 217, 220], ["lavage fluid", "ORGANISM_SUBSTANCE", 234, 246], ["DNA sequences", "DNA", 217, 230], ["Atypical pathogens", "PROBLEM", 0, 18], ["this study", "TEST", 69, 79], ["pulmonary infection", "PROBLEM", 94, 113], ["atypical bacteria", "PROBLEM", 124, 141], ["a sole microbiological test", "TEST", 155, 182], ["specific DNA sequences in lavage fluid", "TEST", 208, 246], ["infection", "PROBLEM", 283, 292], ["pathogens", "OBSERVATION", 9, 18], ["pulmonary", "ANATOMY", 94, 103], ["infection", "OBSERVATION", 104, 113], ["atypical", "OBSERVATION_MODIFIER", 124, 132], ["bacteria", "OBSERVATION", 133, 141], ["infection", "OBSERVATION", 283, 292]]], ["The role of fiberoptic bronchoscopy and bronchoalveolar lavage as a diagnostic tool in immunocompromised patients with pulmonary infiltrates is well established.", [["bronchoalveolar lavage", "ANATOMY", 40, 62], ["pulmonary infiltrates", "ANATOMY", 119, 140], ["pulmonary infiltrates", "DISEASE", 119, 140], ["bronchoalveolar lavage", "MULTI-TISSUE_STRUCTURE", 40, 62], ["patients", "ORGANISM", 105, 113], ["pulmonary", "ORGAN", 119, 128], ["patients", "SPECIES", 105, 113], ["fiberoptic bronchoscopy", "TEST", 12, 35], ["bronchoalveolar lavage", "TEST", 40, 62], ["a diagnostic tool", "TEST", 66, 83], ["pulmonary infiltrates", "PROBLEM", 119, 140], ["bronchoalveolar lavage", "OBSERVATION", 40, 62], ["pulmonary", "ANATOMY", 119, 128], ["infiltrates", "OBSERVATION", 129, 140]]], ["It has been shown that an early bronchoscopy (<5 days) has a significantly higher diagnostic yield for pulmonary infections than the late bronchoscopy (78 vs. 23 %; p \u00bc 0.02) (Lucena et al. 2014) .", [["pulmonary", "ANATOMY", 103, 112], ["pulmonary infections", "DISEASE", 103, 123], ["pulmonary", "ORGAN", 103, 112], ["an early bronchoscopy", "TEST", 23, 44], ["pulmonary infections", "PROBLEM", 103, 123], ["the late bronchoscopy", "TEST", 129, 150], ["early", "OBSERVATION_MODIFIER", 26, 31], ["bronchoscopy", "OBSERVATION", 32, 44], ["pulmonary", "ANATOMY", 103, 112], ["infections", "OBSERVATION", 113, 123]]], ["The role of diagnostic methods other than culture in the work-up of immunocompromised patients with pulmonary infections has also been positively verified, albeit ELISA tests for the detection of C. pneumoniae and/or M. pneumoniae antibodies have some limitations, due to well-known cross reactions with other Chlamydia and Mycoplasma species.", [["pulmonary", "ANATOMY", 100, 109], ["pulmonary infections", "DISEASE", 100, 120], ["patients", "ORGANISM", 86, 94], ["pulmonary", "ORGAN", 100, 109], ["C. pneumoniae", "ORGANISM", 196, 209], ["M. pneumoniae", "ORGANISM", 217, 230], ["Mycoplasma species", "ORGANISM", 324, 342], ["patients", "SPECIES", 86, 94], ["C. pneumoniae", "SPECIES", 196, 209], ["M. pneumoniae", "SPECIES", 217, 230], ["C. pneumoniae", "SPECIES", 196, 209], ["M. pneumoniae", "SPECIES", 217, 230], ["diagnostic methods", "TEST", 12, 30], ["culture", "TEST", 42, 49], ["pulmonary infections", "PROBLEM", 100, 120], ["ELISA tests", "TEST", 163, 174], ["the detection", "TEST", 179, 192], ["C. pneumoniae", "PROBLEM", 196, 209], ["M. pneumoniae antibodies", "PROBLEM", 217, 241], ["known cross reactions", "PROBLEM", 277, 298], ["other Chlamydia", "PROBLEM", 304, 319], ["Mycoplasma species", "PROBLEM", 324, 342], ["pulmonary", "ANATOMY", 100, 109], ["infections", "OBSERVATION", 110, 120], ["pneumoniae", "OBSERVATION", 199, 209], ["Mycoplasma species", "OBSERVATION", 324, 342]]], ["Hohenthal et al. (2005) have shown that the use of PCR and antigen detection to identify infectious agents in BALF from patients with hematological malignancies significantly improves the diagnostic yield.", [["BALF", "ANATOMY", 110, 114], ["hematological malignancies", "ANATOMY", 134, 160], ["hematological malignancies", "DISEASE", 134, 160], ["BALF", "CELL", 110, 114], ["patients", "ORGANISM", 120, 128], ["hematological malignancies", "CANCER", 134, 160], ["patients", "SPECIES", 120, 128], ["PCR", "TEST", 51, 54], ["antigen detection", "TEST", 59, 76], ["infectious agents", "TREATMENT", 89, 106], ["hematological malignancies", "PROBLEM", 134, 160]]], ["Unfortunately, although M. pneumoniae and C. pneumoniae PCR tests were performed in 37 and 29 BALF samples, respectively, the authors have neither presented nor discussed these results.", [["BALF samples", "ANATOMY", 94, 106], ["M. pneumoniae", "ORGANISM", 24, 37], ["C. pneumoniae", "ORGANISM", 42, 55], ["M. pneumoniae", "SPECIES", 24, 37], ["C. pneumoniae", "SPECIES", 42, 55], ["M. pneumoniae", "SPECIES", 24, 37], ["C. pneumoniae", "SPECIES", 42, 55], ["M. pneumoniae", "PROBLEM", 24, 37], ["C. pneumoniae PCR tests", "TEST", 42, 65], ["BALF samples", "TEST", 94, 106], ["pneumoniae", "OBSERVATION", 27, 37]]], ["Similar to the present study, none of the BALF samples evaluated by Hohenthal et al. (2005) tested positively for Legionella spp. in PCR tests.", [["BALF samples", "ANATOMY", 42, 54], ["Legionella spp", "ORGANISM", 114, 128], ["the present study", "TEST", 11, 28], ["the BALF samples", "TEST", 38, 54], ["Legionella spp", "PROBLEM", 114, 128], ["PCR tests", "TEST", 133, 142]]], ["There are, however, two points which should be mentioned when comparing the results of these two studies.", [["these two studies", "TEST", 87, 104]]], ["Firstly, the number of BALF samples evaluated by Hohenthal et al. (2005) has been almost two-fold higher than that in the present study.", [["BALF samples", "ANATOMY", 23, 35], ["BALF samples", "TEST", 23, 35], ["the present study", "TEST", 118, 135]]], ["Secondly, In the Finnish study both PCR method and cultures have been applied and there was one patient with a positive culture but negative Legionella spp.", [["Legionella spp", "DISEASE", 141, 155], ["patient", "ORGANISM", 96, 103], ["Legionella spp", "ORGANISM", 141, 155], ["patient", "SPECIES", 96, 103], ["the Finnish study", "TEST", 13, 30], ["PCR method", "TEST", 36, 46], ["cultures", "TEST", 51, 59], ["a positive culture", "PROBLEM", 109, 127], ["Legionella spp", "PROBLEM", 141, 155], ["Legionella spp", "OBSERVATION", 141, 155]]], ["PCR test.", [["PCR test", "TEST", 0, 8]]], ["Thus, we cannot exclude that some patients with legionellosis could have been found in the present study, had other than PCR diagnostic methods been used.", [["legionellosis", "DISEASE", 48, 61], ["patients", "ORGANISM", 34, 42], ["patients", "SPECIES", 34, 42], ["legionellosis", "PROBLEM", 48, 61], ["the present study", "TEST", 87, 104], ["PCR diagnostic methods", "TEST", 121, 143], ["cannot exclude", "UNCERTAINTY", 9, 23], ["legionellosis", "OBSERVATION", 48, 61]]], ["Nevertheless, the results of both studies point to a very low prevalence of L. pneumophila pulmonary infection in immunocompromised patients.", [["pulmonary", "ANATOMY", 91, 100], ["L. pneumophila pulmonary infection", "DISEASE", 76, 110], ["L. pneumophila", "ORGANISM", 76, 90], ["pulmonary", "ORGAN", 91, 100], ["patients", "ORGANISM", 132, 140], ["L. pneumophila", "SPECIES", 76, 90], ["patients", "SPECIES", 132, 140], ["L. pneumophila", "SPECIES", 76, 90], ["both studies", "TEST", 29, 41], ["L. pneumophila pulmonary infection", "PROBLEM", 76, 110], ["L.", "OBSERVATION_MODIFIER", 76, 78], ["pneumophila", "OBSERVATION_MODIFIER", 79, 90], ["pulmonary", "ANATOMY", 91, 100], ["infection", "OBSERVATION", 101, 110]]], ["That seems inconsistent with the results of some earlier studies which showed that hematological malignancies are a significant risk factor (rate ratio 22.4) for L. pneumophila pneumonia (Marston et al. 1994) .", [["hematological malignancies", "ANATOMY", 83, 109], ["hematological malignancies", "DISEASE", 83, 109], ["L. pneumophila pneumonia", "DISEASE", 162, 186], ["malignancies", "CANCER", 97, 109], ["L. pneumophila", "ORGANISM", 162, 176], ["L. pneumophila", "SPECIES", 162, 176], ["L. pneumophila", "SPECIES", 162, 176], ["some earlier studies", "TEST", 44, 64], ["hematological malignancies", "PROBLEM", 83, 109], ["rate ratio", "TEST", 141, 151], ["L. pneumophila pneumonia", "PROBLEM", 162, 186], ["hematological malignancies", "OBSERVATION", 83, 109], ["pneumophila", "OBSERVATION_MODIFIER", 165, 176], ["pneumonia", "OBSERVATION", 177, 186]]], ["Furthermore, as the course of pulmonary infections in immunocompromised patients is often severe and L. pneumophila is a well-known pathogen responsible for severe pneumonias, a higher prevalence of this infection could be expected in immunocompromised patients.", [["pulmonary", "ANATOMY", 30, 39], ["pulmonary infections", "DISEASE", 30, 50], ["immunocompromised", "DISEASE", 54, 71], ["L. pneumophila", "DISEASE", 101, 115], ["pneumonias", "DISEASE", 164, 174], ["infection", "DISEASE", 204, 213], ["pulmonary", "ORGAN", 30, 39], ["patients", "ORGANISM", 72, 80], ["L. pneumophila", "ORGANISM", 101, 115], ["patients", "ORGANISM", 253, 261], ["patients", "SPECIES", 72, 80], ["L. pneumophila", "SPECIES", 101, 115], ["patients", "SPECIES", 253, 261], ["L. pneumophila", "SPECIES", 101, 115], ["pulmonary infections", "PROBLEM", 30, 50], ["often severe and L. pneumophila", "PROBLEM", 84, 115], ["known pathogen", "PROBLEM", 126, 140], ["severe pneumonias", "PROBLEM", 157, 174], ["this infection", "PROBLEM", 199, 213], ["pulmonary", "ANATOMY", 30, 39], ["infections", "OBSERVATION", 40, 50], ["immunocompromised", "OBSERVATION", 54, 71], ["severe", "OBSERVATION_MODIFIER", 90, 96], ["L.", "OBSERVATION_MODIFIER", 101, 103], ["pneumophila", "OBSERVATION", 104, 115], ["severe", "OBSERVATION_MODIFIER", 157, 163], ["pneumonias", "OBSERVATION", 164, 174], ["higher prevalence", "OBSERVATION_MODIFIER", 178, 195], ["infection", "OBSERVATION", 204, 213]]], ["Therefore, some methodological issues that could have negatively influenced the prevalence of L. pneumophila infections found in the present study should be considered.", [["L. pneumophila infections", "DISEASE", 94, 119], ["L. pneumophila", "ORGANISM", 94, 108], ["L. pneumophila", "SPECIES", 94, 108], ["L. pneumophila", "SPECIES", 94, 108], ["some methodological issues", "PROBLEM", 11, 37], ["L. pneumophila infections", "PROBLEM", 94, 119], ["the present study", "TEST", 129, 146], ["L.", "OBSERVATION_MODIFIER", 94, 96], ["pneumophila infections", "OBSERVATION", 97, 119]]], ["The hypothesis that extremely low prevalence of L. pneumophila infection was related to false negative PCR results is highly unlikely.", [["L. pneumophila infection", "DISEASE", 48, 72], ["L. pneumophila", "ORGANISM", 48, 62], ["L. pneumophila", "SPECIES", 48, 62], ["L. pneumophila", "SPECIES", 48, 62], ["L. pneumophila infection", "PROBLEM", 48, 72], ["false negative PCR results", "PROBLEM", 88, 114], ["pneumophila infection", "OBSERVATION", 51, 72], ["highly unlikely", "UNCERTAINTY", 118, 133]]], ["Contrary to the above mentioned data (positive L. pneumophila culture and false negative PCR test) numerous other studies demonstrate that Legionella PCR has a sensitivity equal to, or greater than, culture.", [["L. pneumophila", "SPECIES", 47, 61], ["L. pneumophila", "SPECIES", 47, 61], ["the above mentioned data", "TEST", 12, 36], ["pneumophila culture", "TEST", 50, 69], ["false negative PCR test", "TEST", 74, 97], ["numerous other studies", "TEST", 99, 121], ["Legionella PCR", "TEST", 139, 153], ["a sensitivity", "TEST", 158, 171], ["culture", "TEST", 199, 206]]], ["A PCR test can give false negative results when polymerase inhibitors are present in the biological sample (Hammerschlag 2000) .", [["A PCR test", "TEST", 0, 10], ["polymerase inhibitors", "TREATMENT", 48, 69]]], ["It has been shown that in M. pneumoniae infections, throat swabs are preferred over nasopharyngeal samples due to a lower rate of PCR inhibitors (Murdoch 2003) .", [["throat swabs", "ANATOMY", 52, 64], ["nasopharyngeal samples", "ANATOMY", 84, 106], ["M. pneumoniae infections", "DISEASE", 26, 50], ["M. pneumoniae", "ORGANISM", 26, 39], ["throat swabs", "PATHOLOGICAL_FORMATION", 52, 64], ["nasopharyngeal samples", "CANCER", 84, 106], ["M. pneumoniae", "SPECIES", 26, 39], ["M. pneumoniae", "SPECIES", 26, 39], ["M. pneumoniae infections", "PROBLEM", 26, 50], ["throat swabs", "PROBLEM", 52, 64], ["nasopharyngeal samples", "TEST", 84, 106], ["a lower rate of PCR inhibitors", "TREATMENT", 114, 144], ["pneumoniae", "OBSERVATION_MODIFIER", 29, 39], ["infections", "OBSERVATION", 40, 50]]], ["As PCR inhibitors are usually nonspecific, their presence would have caused false negative results not only in terms of L. pneumophila infection but also other pathogens,Discussioni.e., M. pneumoniae and C. pneumoniae.", [["L. pneumophila infection", "DISEASE", 120, 144], ["L. pneumophila", "ORGANISM", 120, 134], ["M. pneumoniae", "ORGANISM", 186, 199], ["C. pneumoniae", "ORGANISM", 204, 217], ["L. pneumophila", "SPECIES", 120, 134], ["M. pneumoniae", "SPECIES", 186, 199], ["C. pneumoniae", "SPECIES", 204, 217], ["L. pneumophila", "SPECIES", 120, 134], ["M. pneumoniae", "SPECIES", 186, 199], ["C. pneumoniae", "SPECIES", 204, 217], ["PCR inhibitors", "TREATMENT", 3, 17], ["false negative results", "PROBLEM", 76, 98], ["L. pneumophila infection", "PROBLEM", 120, 144], ["other pathogens", "PROBLEM", 154, 169], ["pneumoniae", "PROBLEM", 189, 199], ["C. pneumoniae", "PROBLEM", 204, 217], ["pneumophila", "OBSERVATION_MODIFIER", 123, 134], ["infection", "OBSERVATION", 135, 144], ["pneumoniae", "OBSERVATION", 189, 199], ["pneumoniae", "OBSERVATION", 207, 217]]], ["This was not the case in our study, as an external control of DNA extraction and amplification was used simultaneously and no inhibition was observed during this study.", [["DNA", "CELLULAR_COMPONENT", 62, 65], ["our study", "TEST", 25, 34], ["DNA extraction", "TREATMENT", 62, 76], ["amplification", "TREATMENT", 81, 94], ["inhibition", "PROBLEM", 126, 136], ["this study", "TEST", 157, 167]]], ["Early and adequate antibiotic therapy before sample collection can be another cause of false negative results of microbiological studies.", [["sample", "ANATOMY", 45, 51], ["adequate antibiotic therapy", "TREATMENT", 10, 37], ["sample collection", "PROBLEM", 45, 62], ["microbiological studies", "TEST", 113, 136]]], ["In fact, a significant proportion of our patients (65.3 %), including 7/9 patients with atypical bacterial infection, had been treated with macrolides or fluoroquinolones before or at the time of diagnostic bronchoscopy.", [["bacterial infection", "DISEASE", 97, 116], ["macrolides", "CHEMICAL", 140, 150], ["fluoroquinolones", "CHEMICAL", 154, 170], ["macrolides", "CHEMICAL", 140, 150], ["fluoroquinolones", "CHEMICAL", 154, 170], ["patients", "ORGANISM", 41, 49], ["patients", "ORGANISM", 74, 82], ["macrolides", "SIMPLE_CHEMICAL", 140, 150], ["fluoroquinolones", "SIMPLE_CHEMICAL", 154, 170], ["patients", "SPECIES", 41, 49], ["patients", "SPECIES", 74, 82], ["atypical bacterial infection", "PROBLEM", 88, 116], ["macrolides", "TREATMENT", 140, 150], ["fluoroquinolones", "TREATMENT", 154, 170], ["diagnostic bronchoscopy", "TEST", 196, 219], ["significant", "OBSERVATION_MODIFIER", 11, 22], ["atypical", "OBSERVATION_MODIFIER", 88, 96], ["bacterial", "OBSERVATION_MODIFIER", 97, 106], ["infection", "OBSERVATION", 107, 116]]], ["Prior studies in patients with pneumonia have shown that bronchoalveolar lavage performed within 3 days of antibiotic therapy onset has a diagnostic yield of 63.4 %, while the diagnostic value decreases to 57.6 % and 34.4 %, when lavage is done later on, before and after 14 days of treatment initiation, respectively (Kottmann et al. 2011) .", [["bronchoalveolar lavage", "ANATOMY", 57, 79], ["pneumonia", "DISEASE", 31, 40], ["patients", "ORGANISM", 17, 25], ["bronchoalveolar lavage", "MULTI-TISSUE_STRUCTURE", 57, 79], ["patients", "SPECIES", 17, 25], ["Prior studies", "TEST", 0, 13], ["pneumonia", "PROBLEM", 31, 40], ["bronchoalveolar lavage", "TEST", 57, 79], ["antibiotic therapy", "TREATMENT", 107, 125], ["lavage", "TEST", 230, 236], ["treatment initiation", "TREATMENT", 283, 303], ["pneumonia", "OBSERVATION", 31, 40], ["bronchoalveolar lavage", "OBSERVATION", 57, 79]]], ["The argument against the confounding role of prior treatment for the results obtained in the present study is that PCR tests allow detecting genetic material of causative pathogen even a few weeks after initiation of antibiotic therapy (Welti et al. 2003) .DiscussionInterestingly, atypical pathogens were identified in the present study exclusively in males.", [["prior treatment", "TREATMENT", 45, 60], ["the present study", "TEST", 89, 106], ["PCR tests", "TEST", 115, 124], ["causative pathogen", "PROBLEM", 161, 179], ["antibiotic therapy", "TREATMENT", 217, 235], ["atypical pathogens", "PROBLEM", 282, 300], ["atypical", "OBSERVATION_MODIFIER", 282, 290], ["pathogens", "OBSERVATION", 291, 300]]], ["This may be partially explained by a higher proportion of males (71 %).", [["may be partially explained", "UNCERTAINTY", 5, 31], ["higher", "OBSERVATION_MODIFIER", 37, 43], ["proportion", "OBSERVATION_MODIFIER", 44, 54]]], ["Some gender-related differences in the incidence of atypical bacterial infections have also been reported in previous studies.", [["bacterial infections", "DISEASE", 61, 81], ["atypical bacterial infections", "PROBLEM", 52, 81], ["previous studies", "TEST", 109, 125], ["related differences", "OBSERVATION_MODIFIER", 12, 31], ["atypical", "OBSERVATION_MODIFIER", 52, 60], ["bacterial", "OBSERVATION_MODIFIER", 61, 70], ["infections", "OBSERVATION", 71, 81]]], ["Guti\u00e9rrez et al. (2006) have found the incidence of CAP caused by C. pneumoniae and L. pneumophila in the general population two-fold and ten-fold higher in males than in females, respectively.", [["CAP", "DISEASE", 52, 55], ["C. pneumoniae", "ORGANISM", 66, 79], ["L. pneumophila", "ORGANISM", 84, 98], ["C. pneumoniae", "SPECIES", 66, 79], ["L. pneumophila", "SPECIES", 84, 98], ["C. pneumoniae", "SPECIES", 66, 79], ["L. pneumophila", "SPECIES", 84, 98], ["CAP", "PROBLEM", 52, 55], ["C. pneumoniae", "PROBLEM", 66, 79], ["L. pneumophila", "PROBLEM", 84, 98], ["CAP", "OBSERVATION_MODIFIER", 52, 55], ["pneumoniae", "OBSERVATION", 69, 79], ["L.", "OBSERVATION_MODIFIER", 84, 86], ["pneumophila", "OBSERVATION_MODIFIER", 87, 98], ["ten-fold", "OBSERVATION_MODIFIER", 138, 146], ["higher", "OBSERVATION_MODIFIER", 147, 153]]], ["Age-related differences in the prevalence of atypical pathogen infections should also be mentioned.", [["pathogen infections", "DISEASE", 54, 73], ["atypical pathogen infections", "PROBLEM", 45, 73], ["atypical", "OBSERVATION_MODIFIER", 45, 53], ["pathogen", "OBSERVATION_MODIFIER", 54, 62], ["infections", "OBSERVATION", 63, 73]]], ["In the present study, median age of patients with M. pneumoniae infection was 51 years.", [["M. pneumoniae infection", "DISEASE", 50, 73], ["patients", "ORGANISM", 36, 44], ["M. pneumoniae", "ORGANISM", 50, 63], ["patients", "SPECIES", 36, 44], ["M. pneumoniae", "SPECIES", 50, 63], ["M. pneumoniae", "SPECIES", 50, 63], ["M. pneumoniae infection", "PROBLEM", 50, 73], ["pneumoniae", "OBSERVATION", 53, 63]]], ["This is somewhat inconsistent with Guti\u00e9rrez et al.'s (2006) findings who have reported the highest incidence of M. pneumoniae CAP in young and very elderly people, and the lowest between 45 and 64 years of age.", [["M. pneumoniae CAP", "DISEASE", 113, 130], ["M. pneumoniae", "ORGANISM", 113, 126], ["people", "ORGANISM", 157, 163], ["M. pneumoniae", "SPECIES", 113, 126], ["people", "SPECIES", 157, 163], ["M. pneumoniae", "SPECIES", 113, 126], ["M. pneumoniae CAP", "PROBLEM", 113, 130], ["pneumoniae", "OBSERVATION", 116, 126]]], ["To our knowledge, no specific data have been published on the gender-related or age-related differences in the prevalence of atypical pathogen infection in immunocompromised patients.", [["pathogen infection", "DISEASE", 134, 152], ["patients", "ORGANISM", 174, 182], ["patients", "SPECIES", 174, 182], ["atypical pathogen infection", "PROBLEM", 125, 152], ["atypical", "OBSERVATION_MODIFIER", 125, 133], ["pathogen", "OBSERVATION_MODIFIER", 134, 142], ["infection", "OBSERVATION", 143, 152], ["immunocompromised patients", "OBSERVATION", 156, 182]]], ["We realize that the number of patients with atypical pathogen infections is too small to draw unequivocal conclusions on the relationship between age or gender and the prevalence of M. pneumoniae and C. pneumoniae infections.DiscussionThe mortality rate in our nine patients with M. pneumoniae or C. pneumoniae infection was relatively high (33.3 %), but we believe that neither was the course of disease nor mortality rate related exclusively to atypical bacterial infection.DiscussionIn this context, it should be underlined that in eight of these patients co-infection with other microorganisms was found (positive BALF and/or blood cultures).", [["BALF", "ANATOMY", 618, 622], ["blood cultures", "ANATOMY", 630, 644], ["pathogen infections", "DISEASE", 53, 72], ["M. pneumoniae", "DISEASE", 182, 195], ["C. pneumoniae infections", "DISEASE", 200, 224], ["M. pneumoniae or C. pneumoniae infection", "DISEASE", 280, 320], ["bacterial infection", "DISEASE", 456, 475], ["co-infection", "DISEASE", 559, 571], ["patients", "ORGANISM", 30, 38], ["M. pneumoniae", "ORGANISM", 182, 195], ["C. pneumoniae", "ORGANISM", 200, 213], ["patients", "ORGANISM", 266, 274], ["M. pneumoniae", "ORGANISM", 280, 293], ["C. pneumoniae", "ORGANISM", 297, 310], ["patients", "ORGANISM", 550, 558], ["blood", "ORGANISM_SUBSTANCE", 630, 635], ["patients", "SPECIES", 30, 38], ["M. pneumoniae", "SPECIES", 182, 195], ["C. pneumoniae", "SPECIES", 200, 213], ["patients", "SPECIES", 266, 274], ["M. pneumoniae", "SPECIES", 280, 293], ["C. pneumoniae", "SPECIES", 297, 310], ["patients", "SPECIES", 550, 558], ["M. pneumoniae", "SPECIES", 182, 195], ["C. pneumoniae", "SPECIES", 200, 213], ["M. pneumoniae", "SPECIES", 280, 293], ["C. pneumoniae", "SPECIES", 297, 310], ["atypical pathogen infections", "PROBLEM", 44, 72], ["M. pneumoniae", "PROBLEM", 182, 195], ["C. pneumoniae infections", "PROBLEM", 200, 224], ["The mortality rate", "TEST", 235, 253], ["M. pneumoniae", "PROBLEM", 280, 293], ["C. pneumoniae infection", "PROBLEM", 297, 320], ["disease", "PROBLEM", 397, 404], ["mortality rate", "PROBLEM", 409, 423], ["atypical bacterial infection", "PROBLEM", 447, 475], ["these patients co-infection", "PROBLEM", 544, 571], ["other microorganisms", "PROBLEM", 577, 597], ["positive BALF", "PROBLEM", 609, 622], ["blood cultures", "TEST", 630, 644], ["atypical", "OBSERVATION_MODIFIER", 44, 52], ["pathogen", "OBSERVATION_MODIFIER", 53, 61], ["infections", "OBSERVATION", 62, 72], ["too small to", "OBSERVATION_MODIFIER", 76, 88], ["pneumoniae", "OBSERVATION", 185, 195], ["pneumoniae", "OBSERVATION_MODIFIER", 203, 213], ["infections", "OBSERVATION", 214, 224], ["pneumoniae", "OBSERVATION", 283, 293], ["pneumoniae", "OBSERVATION", 300, 310], ["atypical", "OBSERVATION_MODIFIER", 447, 455], ["bacterial", "OBSERVATION_MODIFIER", 456, 465], ["infection", "OBSERVATION", 466, 475]]], ["Systemic bacterial co-infection was proved in all three patients who died (A. baumanii and P. aeruginosa cultured from blood samples).", [["blood samples", "ANATOMY", 119, 132], ["bacterial co-infection", "DISEASE", 9, 31], ["patients", "ORGANISM", 56, 64], ["A. baumanii", "ORGANISM", 75, 86], ["P. aeruginosa", "ORGANISM", 91, 104], ["blood samples", "MULTI-TISSUE_STRUCTURE", 119, 132], ["patients", "SPECIES", 56, 64], ["A. baumanii", "SPECIES", 75, 86], ["P. aeruginosa", "SPECIES", 91, 104], ["A. baumanii", "SPECIES", 75, 86], ["P. aeruginosa", "SPECIES", 91, 104], ["Systemic bacterial co-infection", "PROBLEM", 0, 31], ["P. aeruginosa", "PROBLEM", 91, 104], ["blood samples", "TEST", 119, 132], ["bacterial", "OBSERVATION_MODIFIER", 9, 18], ["co-infection", "OBSERVATION", 19, 31]]], ["This finding is consistent with the results of three earlier studies that have reported co-infection with at least one another pathogen in 33-64 %, 48-74 %, and 54-63 % patients with M. pneumoniae, C. pneumoniae, and L. pneumophila infections, respectively (Welti et al 2003; Gleason 2002; Hammerschlag 2000) .", [["co-infection", "DISEASE", 88, 100], ["M. pneumoniae, C. pneumoniae, and L. pneumophila infections", "DISEASE", 183, 242], ["patients", "ORGANISM", 169, 177], ["M. pneumoniae", "ORGANISM", 183, 196], ["C. pneumoniae", "ORGANISM", 198, 211], ["L. pneumophila", "ORGANISM", 217, 231], ["patients", "SPECIES", 169, 177], ["M. pneumoniae", "SPECIES", 183, 196], ["C. pneumoniae", "SPECIES", 198, 211], ["L. pneumophila", "SPECIES", 217, 231], ["M. pneumoniae", "SPECIES", 183, 196], ["C. pneumoniae", "SPECIES", 198, 211], ["L. pneumophila", "SPECIES", 217, 231], ["three earlier studies", "TEST", 47, 68], ["co-infection", "PROBLEM", 88, 100], ["another pathogen", "TEST", 119, 135], ["M. pneumoniae", "PROBLEM", 183, 196], ["C. pneumoniae", "PROBLEM", 198, 211], ["L. pneumophila infections", "PROBLEM", 217, 242], ["consistent with", "UNCERTAINTY", 16, 31], ["co-infection", "OBSERVATION", 88, 100], ["pneumoniae", "OBSERVATION", 186, 196], ["pneumoniae", "OBSERVATION", 201, 211], ["L.", "OBSERVATION_MODIFIER", 217, 219], ["pneumophila infections", "OBSERVATION", 220, 242]]], ["Perhaps, destruction of the airway epithelial layer and ciliostatic effect of these pathogens, facilitate other bacterial infections.DiscussionWe are aware of several limitations of this study.", [["airway epithelial layer", "ANATOMY", 28, 51], ["bacterial infections", "DISEASE", 112, 132], ["airway epithelial layer", "TISSUE", 28, 51], ["the airway epithelial layer", "PROBLEM", 24, 51], ["these pathogens", "PROBLEM", 78, 93], ["other bacterial infections", "PROBLEM", 106, 132], ["this study", "TEST", 182, 192], ["destruction", "OBSERVATION", 9, 20], ["airway", "ANATOMY", 28, 34], ["epithelial", "ANATOMY_MODIFIER", 35, 45], ["layer", "OBSERVATION_MODIFIER", 46, 51], ["ciliostatic", "OBSERVATION_MODIFIER", 56, 67], ["effect", "OBSERVATION_MODIFIER", 68, 74], ["pathogens", "OBSERVATION", 84, 93], ["bacterial", "OBSERVATION_MODIFIER", 112, 121], ["infections", "OBSERVATION", 122, 132]]], ["Due to a small sample size, 95 % confidence interval could be calculated as 2.9-17.0 % and 0.0-6.8 % for a proportion of M. pneumoniae and C. pneumoniae infections, respectively.", [["C. pneumoniae infections", "DISEASE", 139, 163], ["M. pneumoniae", "ORGANISM", 121, 134], ["C. pneumoniae", "ORGANISM", 139, 152], ["M. pneumoniae", "SPECIES", 121, 134], ["C. pneumoniae", "SPECIES", 139, 152], ["M. pneumoniae", "SPECIES", 121, 134], ["C. pneumoniae", "SPECIES", 139, 152], ["a small sample size", "PROBLEM", 7, 26], ["M. pneumoniae", "PROBLEM", 121, 134], ["C. pneumoniae infections", "PROBLEM", 139, 163], ["small", "OBSERVATION_MODIFIER", 9, 14], ["sample", "OBSERVATION_MODIFIER", 15, 21], ["size", "OBSERVATION_MODIFIER", 22, 26], ["pneumoniae", "OBSERVATION", 124, 134], ["pneumoniae", "OBSERVATION_MODIFIER", 142, 152], ["infections", "OBSERVATION", 153, 163]]], ["These values may question the confidence of a low prevalence of atypical pathogen infection in the study group.", [["pathogen infection", "DISEASE", 73, 91], ["These values", "TEST", 0, 12], ["atypical pathogen infection", "PROBLEM", 64, 91], ["low prevalence", "OBSERVATION_MODIFIER", 46, 60], ["atypical", "OBSERVATION_MODIFIER", 64, 72], ["pathogen", "OBSERVATION_MODIFIER", 73, 81], ["infection", "OBSERVATION", 82, 91]]], ["There is a marked disproportion between the number of patients with different causes of immunosuppression.", [["patients", "ORGANISM", 54, 62], ["patients", "SPECIES", 54, 62], ["a marked disproportion", "PROBLEM", 9, 31], ["immunosuppression", "TREATMENT", 88, 105], ["marked", "OBSERVATION_MODIFIER", 11, 17], ["disproportion", "OBSERVATION_MODIFIER", 18, 31], ["number", "OBSERVATION_MODIFIER", 44, 50], ["immunosuppression", "OBSERVATION", 88, 105]]], ["In fact, our study group included mainly patients with hematological malignancies; hence the results refer mostly to this group of immunocompromised patients.", [["hematological malignancies", "ANATOMY", 55, 81], ["hematological malignancies", "DISEASE", 55, 81], ["patients", "ORGANISM", 41, 49], ["hematological malignancies", "CANCER", 55, 81], ["patients", "ORGANISM", 149, 157], ["patients", "SPECIES", 41, 49], ["patients", "SPECIES", 149, 157], ["our study", "TEST", 9, 18], ["hematological malignancies", "PROBLEM", 55, 81], ["malignancies", "OBSERVATION", 69, 81]]], ["That is also why we could not analyze the relationship between underlying diseases and the prevalence or clinical course of atypical infections.DiscussionA significant limitation of our study is associated with the use of PCR only to identify atypical bacteria infection.", [["infections", "DISEASE", 133, 143], ["infection", "DISEASE", 261, 270], ["underlying diseases", "PROBLEM", 63, 82], ["atypical infections", "PROBLEM", 124, 143], ["our study", "TEST", 182, 191], ["PCR", "TREATMENT", 222, 225], ["atypical bacteria infection", "PROBLEM", 243, 270], ["diseases", "OBSERVATION", 74, 82], ["atypical", "OBSERVATION_MODIFIER", 124, 132], ["infections", "OBSERVATION", 133, 143], ["atypical", "OBSERVATION_MODIFIER", 243, 251], ["bacteria", "OBSERVATION_MODIFIER", 252, 260], ["infection", "OBSERVATION", 261, 270]]], ["In consequence, we were unable to assess and discuss potential false positive and false negative results.", [["potential false positive and false negative results", "PROBLEM", 53, 104]]], ["Previous studies, including that by Pignanelli et al. (2009) , have shown that a concomitant use of two or more different tests provides a higher diagnostic accuracy.", [["Previous studies", "TEST", 0, 16]]], ["Thus, the question on the true etiology of lower respiratory tract infection in some of our patients is still pending.", [["lower respiratory tract", "ANATOMY", 43, 66], ["lower respiratory tract infection", "DISEASE", 43, 76], ["lower respiratory", "ORGANISM_SUBDIVISION", 43, 60], ["tract", "ORGANISM_SUBDIVISION", 61, 66], ["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 92, 100], ["lower respiratory tract infection", "PROBLEM", 43, 76], ["lower", "ANATOMY_MODIFIER", 43, 48], ["respiratory tract", "ANATOMY", 49, 66], ["infection", "OBSERVATION", 67, 76]]], ["In cases in which we did not find any putative etiological agent, it could have been any of the common respiratory viruses (metapneumovirus, coronavirus, or bocavirus) that are not routinely detected.", [["respiratory viruses (metapneumovirus, coronavirus", "DISEASE", 103, 152], ["respiratory viruses", "ORGANISM", 103, 122], ["metapneumovirus", "ORGANISM", 124, 139], ["coronavirus", "ORGANISM", 141, 152], ["the common respiratory viruses", "PROBLEM", 92, 122], ["metapneumovirus", "PROBLEM", 124, 139], ["coronavirus", "PROBLEM", 141, 152], ["bocavirus", "PROBLEM", 157, 166]]], ["Therefore, use ofwide-range diagnostic tool, e.g., FilmArray \u00ae Respiratory Panel based on multiplex nested PCR assay, could be helpful to improve outcome in immunocompromised patients (Dzieciatkowski et al. 2013 ).DiscussionIn conclusion, we found that atypical lower airway infections are uncommon in immunocompromised patients.", [["lower airway", "ANATOMY", 262, 274], ["airway infections", "DISEASE", 268, 285], ["patients", "ORGANISM", 175, 183], ["lower airway", "MULTI-TISSUE_STRUCTURE", 262, 274], ["patients", "ORGANISM", 320, 328], ["patients", "SPECIES", 175, 183], ["patients", "SPECIES", 320, 328], ["diagnostic tool", "TEST", 28, 43], ["Respiratory Panel", "TEST", 63, 80], ["multiplex nested PCR assay", "TEST", 90, 116], ["atypical lower airway infections", "PROBLEM", 253, 285], ["atypical", "OBSERVATION_MODIFIER", 253, 261], ["lower", "ANATOMY_MODIFIER", 262, 267], ["airway", "ANATOMY", 268, 274], ["infections", "OBSERVATION", 275, 285]]], ["This particularly refers to L. pneumophila pneumonia.", [["L. pneumophila pneumonia", "DISEASE", 28, 52], ["L. pneumophila", "ORGANISM", 28, 42], ["L. pneumophila", "SPECIES", 28, 42], ["L. pneumophila", "SPECIES", 28, 42], ["L. pneumophila pneumonia", "PROBLEM", 28, 52], ["pneumophila", "OBSERVATION_MODIFIER", 31, 42], ["pneumonia", "OBSERVATION", 43, 52]]], ["The majority of atypical pulmonary infections are co-infections rather than single pathogen infections.", [["pulmonary", "ANATOMY", 25, 34], ["pulmonary infections", "DISEASE", 25, 45], ["co-infections", "DISEASE", 50, 63], ["pathogen infections", "DISEASE", 83, 102], ["pulmonary", "ORGAN", 25, 34], ["atypical pulmonary infections", "PROBLEM", 16, 45], ["co-infections", "PROBLEM", 50, 63], ["single pathogen infections", "PROBLEM", 76, 102], ["majority", "OBSERVATION_MODIFIER", 4, 12], ["atypical", "OBSERVATION_MODIFIER", 16, 24], ["pulmonary", "ANATOMY", 25, 34], ["infections", "OBSERVATION", 35, 45], ["pathogen", "OBSERVATION_MODIFIER", 83, 91], ["infections", "OBSERVATION", 92, 102]]]], "PMC7114537": [["Extrinsic apoptotic pathway and its inhibition by viral proteinsApoptosis is a highly conserved, physiological type of cell death, which is required to eliminate damaged, used-up and misplaced cells within a multicellular organism (Kerr et al., 1972, Hotchkiss et al., 2009).", [["cell", "ANATOMY", 119, 123], ["cells", "ANATOMY", 193, 198], ["multicellular organism", "ANATOMY", 208, 230], ["death", "DISEASE", 124, 129], ["cell", "CELL", 119, 123], ["cells", "CELL", 193, 198], ["viral proteins", "PROTEIN", 50, 64], ["Extrinsic apoptotic pathway", "PROBLEM", 0, 27], ["viral proteinsApoptosis", "PROBLEM", 50, 73], ["cell death", "PROBLEM", 119, 129], ["misplaced cells", "PROBLEM", 183, 198], ["apoptotic pathway", "OBSERVATION", 10, 27], ["cell death", "OBSERVATION", 119, 129], ["multicellular organism", "OBSERVATION", 208, 230]]], ["In contrast to necrosis or necroptosis, which often leads to pathological, chronic inflammatory immune reactions due to cell lysis, apoptotic cells do not fall apart but are discretely eaten up by macrophages and other non-professional phagocytes in a regulated and non-inflammatory manner (Vanlangenakker et al., 2012).", [["cell", "ANATOMY", 120, 124], ["cells", "ANATOMY", 142, 147], ["macrophages", "ANATOMY", 197, 208], ["phagocytes", "ANATOMY", 236, 246], ["necrosis", "DISEASE", 15, 23], ["necroptosis", "DISEASE", 27, 38], ["cell", "CELL", 120, 124], ["cells", "CELL", 142, 147], ["macrophages", "CELL", 197, 208], ["phagocytes", "CELL", 236, 246], ["apoptotic cells", "CELL_TYPE", 132, 147], ["macrophages", "CELL_TYPE", 197, 208], ["non-professional phagocytes", "CELL_TYPE", 219, 246], ["necrosis", "PROBLEM", 15, 23], ["necroptosis", "PROBLEM", 27, 38], ["chronic inflammatory immune reactions", "PROBLEM", 75, 112], ["cell lysis", "TREATMENT", 120, 130], ["apoptotic cells", "PROBLEM", 132, 147], ["necrosis", "OBSERVATION", 15, 23], ["necroptosis", "OBSERVATION", 27, 38], ["chronic", "OBSERVATION_MODIFIER", 75, 82], ["inflammatory immune", "OBSERVATION", 83, 102], ["cell lysis", "OBSERVATION", 120, 130], ["apoptotic cells", "OBSERVATION", 132, 147], ["non-professional phagocytes", "OBSERVATION", 219, 246]]], ["Apoptosis is induced by two distinct, yet tightly interconnected signaling pathways: the extrinsic (Fig. 1) and the intrinsic (Fig. 2) apoptotic pathways.", [["Apoptosis", "DISEASE", 0, 9], ["Fig. 1", "GENE_OR_GENE_PRODUCT", 100, 106]]], ["The extrinsic pathway is triggered by extracellular ligands such as those of the TNF superfamily (FasL, TNF\u03b1 or TRAIL), which specifically bind to their respective surface receptors causing their oligomerization (Strasser et al., 2009, Guicciardi and Gores, 2009, Gonzalvez and Ashkenazi, 2010, Li et al., 2013a, Li et al., 2013b).", [["extracellular", "ANATOMY", 38, 51], ["surface", "ANATOMY", 164, 171], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 38, 51], ["TNF", "GENE_OR_GENE_PRODUCT", 81, 84], ["FasL", "GENE_OR_GENE_PRODUCT", 98, 102], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 104, 108], ["TRAIL", "GENE_OR_GENE_PRODUCT", 112, 117], ["TNF superfamily", "PROTEIN", 81, 96], ["FasL", "PROTEIN", 98, 102], ["TNF\u03b1", "PROTEIN", 104, 108], ["TRAIL", "PROTEIN", 112, 117], ["surface receptors", "PROTEIN", 164, 181], ["the TNF superfamily", "TREATMENT", 77, 96], ["extrinsic", "OBSERVATION_MODIFIER", 4, 13], ["pathway", "OBSERVATION", 14, 21]]], ["A conformational change on the cytoplasmic side of these receptors leads to the recruitment of the adapter protein FADD whose function is to attract pro-caspase-8 from the cytosol to the death receptor in order to bring two monomeric pro-caspase-8 molecules in close proximity for autoprocessing and subsequent activation (Fig. 1).", [["cytoplasmic", "ANATOMY", 31, 42], ["cytosol", "ANATOMY", 172, 179], ["death", "DISEASE", 187, 192], ["cytoplasmic", "ORGANISM_SUBSTANCE", 31, 42], ["FADD", "GENE_OR_GENE_PRODUCT", 115, 119], ["pro-caspase-8", "GENE_OR_GENE_PRODUCT", 149, 162], ["cytosol", "CELLULAR_COMPONENT", 172, 179], ["pro-caspase-8", "GENE_OR_GENE_PRODUCT", 234, 247], ["adapter protein", "PROTEIN", 99, 114], ["FADD", "PROTEIN", 115, 119], ["pro-caspase-8", "PROTEIN", 149, 162], ["death receptor", "PROTEIN", 187, 201], ["monomeric pro-caspase-8 molecules", "PROTEIN", 224, 257], ["A conformational change", "PROBLEM", 0, 23], ["two monomeric pro-caspase", "TREATMENT", 220, 245], ["subsequent activation (Fig", "TREATMENT", 300, 326], ["recruitment", "OBSERVATION_MODIFIER", 80, 91]]], ["This complex, referred to as death inducing signaling complex (DISC), then interacts with already dimerized effector pro-caspase-3 and/or -7, which become activated through caspase-8-mediated cleavage followed by autoprocessing.", [["death", "DISEASE", 29, 34], ["death inducing signaling complex", "GENE_OR_GENE_PRODUCT", 29, 61], ["DISC", "GENE_OR_GENE_PRODUCT", 63, 67], ["pro-caspase-3", "GENE_OR_GENE_PRODUCT", 117, 130], ["-7", "GENE_OR_GENE_PRODUCT", 138, 140], ["caspase-8", "GENE_OR_GENE_PRODUCT", 173, 182], ["death inducing signaling complex", "PROTEIN", 29, 61], ["DISC", "PROTEIN", 63, 67], ["dimerized effector pro-caspase-3 and/or -7", "PROTEIN", 98, 140], ["caspase-8", "PROTEIN", 173, 182], ["signaling complex (DISC)", "PROBLEM", 44, 68], ["caspase", "TEST", 173, 180], ["DISC", "ANATOMY", 63, 67]]], ["Active effector caspases then cleave numerous substrates that lead to the disruption of the cytoskeleton, inhibition of DNA repair, initiation of DNA fragmentation and the exposure of so-called eat-me signals, which mediate the uptake and elimination of apoptotic cells by macrophages.Extrinsic apoptotic pathway and its inhibition by viral proteinsThe extrinsic, death receptor pathway is indispensable for the execution and limitation of both innate and adaptive immune responses.", [["cytoskeleton", "ANATOMY", 92, 104], ["cells", "ANATOMY", 264, 269], ["macrophages", "ANATOMY", 273, 284], ["death", "DISEASE", 364, 369], ["caspases", "GENE_OR_GENE_PRODUCT", 16, 24], ["cytoskeleton", "CELLULAR_COMPONENT", 92, 104], ["DNA", "CELLULAR_COMPONENT", 120, 123], ["DNA", "CELLULAR_COMPONENT", 146, 149], ["cells", "CELL", 264, 269], ["macrophages", "CELL", 273, 284], ["Active effector caspases", "PROTEIN", 0, 24], ["apoptotic cells", "CELL_TYPE", 254, 269], ["macrophages", "CELL_TYPE", 273, 284], ["viral proteins", "PROTEIN", 335, 349], ["Active effector caspases", "TREATMENT", 0, 24], ["the disruption of the cytoskeleton", "PROBLEM", 70, 104], ["DNA repair", "TREATMENT", 120, 130], ["DNA fragmentation", "PROBLEM", 146, 163], ["Extrinsic apoptotic pathway", "PROBLEM", 285, 312], ["viral proteins", "PROBLEM", 335, 349], ["effector caspases", "OBSERVATION", 7, 24], ["DNA repair", "OBSERVATION", 120, 130], ["apoptotic cells", "OBSERVATION", 254, 269], ["apoptotic pathway", "OBSERVATION", 295, 312], ["extrinsic", "OBSERVATION_MODIFIER", 353, 362]]], ["Cells of the innate immune system such as dendritic or natural killer (NK) cells generate a rapid antiviral immune response by directly detecting viral products such as dsRNA by Toll-like receptor 3 (TLR), by upregulating death ligands such as FasL, TRAIL and TNF\u03b1 and/or by killing infected cells by granule exocytosis (NK cells) (Medzhitov, 2001).", [["Cells", "ANATOMY", 0, 5], ["immune system", "ANATOMY", 20, 33], ["dendritic", "ANATOMY", 42, 51], ["natural killer (NK) cells", "ANATOMY", 55, 80], ["cells", "ANATOMY", 292, 297], ["granule", "ANATOMY", 301, 308], ["NK cells", "ANATOMY", 321, 329], ["death", "DISEASE", 222, 227], ["Cells", "CELL", 0, 5], ["dendritic", "CELL", 42, 51], ["natural killer (NK) cells", "CELL", 55, 80], ["Toll-like receptor 3", "GENE_OR_GENE_PRODUCT", 178, 198], ["TLR", "GENE_OR_GENE_PRODUCT", 200, 203], ["FasL", "GENE_OR_GENE_PRODUCT", 244, 248], ["TRAIL", "GENE_OR_GENE_PRODUCT", 250, 255], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 260, 264], ["cells", "CELL", 292, 297], ["granule exocytosis", "CELLULAR_COMPONENT", 301, 319], ["NK cells", "CELL", 321, 329], ["dendritic or natural killer (NK) cells", "CELL_TYPE", 42, 80], ["viral products", "PROTEIN", 146, 160], ["Toll-like receptor 3", "PROTEIN", 178, 198], ["TLR", "PROTEIN", 200, 203], ["FasL", "PROTEIN", 244, 248], ["TRAIL", "PROTEIN", 250, 255], ["TNF\u03b1", "PROTEIN", 260, 264], ["killing infected cells", "CELL_TYPE", 275, 297], ["NK cells", "CELL_TYPE", 321, 329], ["dendritic or natural killer (NK) cells", "PROBLEM", 42, 80], ["a rapid antiviral immune response", "PROBLEM", 90, 123], ["viral products", "TREATMENT", 146, 160], ["dsRNA", "PROBLEM", 169, 174], ["upregulating death ligands", "PROBLEM", 209, 235], ["FasL, TRAIL", "TREATMENT", 244, 255], ["TNF", "TREATMENT", 260, 263], ["natural killer", "OBSERVATION", 55, 69]]], ["Later during adaptive immunity, virally infected cells are killed by antigen-specific cytotoxic T cells (CTLs) via both the perforin/granzyme and the FasL/Fas pathways (Chavez-Galan et al., 2009).", [["cells", "ANATOMY", 49, 54], ["cytotoxic T cells", "ANATOMY", 86, 103], ["CTLs", "ANATOMY", 105, 109], ["cells", "CELL", 49, 54], ["antigen", "GENE_OR_GENE_PRODUCT", 69, 76], ["cytotoxic T cells", "CELL", 86, 103], ["CTLs", "CELL", 105, 109], ["perforin", "GENE_OR_GENE_PRODUCT", 124, 132], ["granzyme", "GENE_OR_GENE_PRODUCT", 133, 141], ["FasL", "GENE_OR_GENE_PRODUCT", 150, 154], ["Fas", "GENE_OR_GENE_PRODUCT", 155, 158], ["virally infected cells", "CELL_TYPE", 32, 54], ["cytotoxic T cells", "CELL_TYPE", 86, 103], ["CTLs", "CELL_TYPE", 105, 109], ["perforin", "PROTEIN", 124, 132], ["granzyme", "PROTEIN", 133, 141], ["FasL", "PROTEIN", 150, 154], ["Fas", "PROTEIN", 155, 158], ["virally infected cells", "PROBLEM", 32, 54], ["antigen", "TEST", 69, 76], ["CTLs", "TEST", 105, 109], ["the perforin/granzyme", "TREATMENT", 120, 141], ["infected cells", "OBSERVATION", 40, 54]]], ["Subsequently, activated T cells are eliminated by activation-induced cell death involving FasL/Fas-mediated killing of the same or an activated neighboring cell after an acute infection (Arakaki et al., 2014).", [["T cells", "ANATOMY", 24, 31], ["cell", "ANATOMY", 69, 73], ["cell", "ANATOMY", 156, 160], ["acute infection", "DISEASE", 170, 185], ["T cells", "CELL", 24, 31], ["cell", "CELL", 69, 73], ["FasL", "GENE_OR_GENE_PRODUCT", 90, 94], ["Fas-", "GENE_OR_GENE_PRODUCT", 95, 99], ["cell", "CELL", 156, 160], ["activated T cells", "CELL_TYPE", 14, 31], ["FasL", "PROTEIN", 90, 94], ["activated T cells", "TREATMENT", 14, 31], ["induced cell death", "PROBLEM", 61, 79], ["an acute infection", "PROBLEM", 167, 185], ["cell death", "OBSERVATION", 69, 79], ["neighboring cell", "OBSERVATION", 144, 160], ["acute", "OBSERVATION_MODIFIER", 170, 175], ["infection", "OBSERVATION", 176, 185]]], ["This ensures that highly proliferative, superfluous killer cells are disposed of accordingly, preventing the development of autoimmune or leukemic cells.", [["superfluous killer cells", "ANATOMY", 40, 64], ["leukemic cells", "ANATOMY", 138, 152], ["autoimmune or leukemic", "DISEASE", 124, 146], ["superfluous killer cells", "CELL", 40, 64], ["leukemic cells", "CELL", 138, 152], ["superfluous killer cells", "CELL_TYPE", 40, 64], ["autoimmune or leukemic cells", "CELL_TYPE", 124, 152], ["superfluous killer cells", "PROBLEM", 40, 64], ["autoimmune or leukemic cells", "PROBLEM", 124, 152], ["highly", "OBSERVATION_MODIFIER", 18, 24], ["proliferative", "OBSERVATION_MODIFIER", 25, 38], ["superfluous killer cells", "OBSERVATION", 40, 64], ["autoimmune", "OBSERVATION", 124, 134], ["leukemic cells", "OBSERVATION", 138, 152]]], ["It is therefore not surprising that viruses have evolved strategies to inhibit the death receptor signaling pathway at several steps although these cells may still be killed by granule exocytosis (Benedict et al., 2002, Hay and Kannouraki, 2002).", [["cells", "ANATOMY", 148, 153], ["granule", "ANATOMY", 177, 184], ["death", "DISEASE", 83, 88], ["cells", "CELL", 148, 153], ["granule exocytosis", "CELLULAR_COMPONENT", 177, 195], ["death receptor", "PROTEIN", 83, 97], ["viruses", "PROBLEM", 36, 43], ["these cells", "PROBLEM", 142, 153], ["granule exocytosis", "OBSERVATION", 177, 195]]], ["As a consequence infected cells are at least partially protected from cytolysis by CTLs, NK cells or neighboring cells which express FasL or TRAIL upon activation (Ashkenazi and Dixit, 1999) and TNF\u03b1 may not be able to induce a sufficient inflammatory response.Extrinsic apoptotic pathway and its inhibition by viral proteinsFor example, the Shope fibroma virus (rabbit poxvirus) produces a TNF receptor ortholog (TNFR2), which neutralizes TNF\u03b1 (Smith et al., 1991) (Fig. 1).", [["cells", "ANATOMY", 26, 31], ["CTLs", "ANATOMY", 83, 87], ["NK cells", "ANATOMY", 89, 97], ["cells", "ANATOMY", 113, 118], ["fibroma", "DISEASE", 348, 355], ["cells", "CELL", 26, 31], ["CTLs", "CELL", 83, 87], ["NK cells", "CELL", 89, 97], ["cells", "CELL", 113, 118], ["FasL", "GENE_OR_GENE_PRODUCT", 133, 137], ["TRAIL", "GENE_OR_GENE_PRODUCT", 141, 146], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 195, 199], ["Shope fibroma virus", "ORGANISM", 342, 361], ["rabbit poxvirus", "ORGANISM", 363, 378], ["TNF receptor", "GENE_OR_GENE_PRODUCT", 391, 403], ["TNFR2", "GENE_OR_GENE_PRODUCT", 414, 419], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 440, 444], ["infected cells", "CELL_TYPE", 17, 31], ["CTLs", "CELL_TYPE", 83, 87], ["NK cells", "CELL_TYPE", 89, 97], ["neighboring cells", "CELL_TYPE", 101, 118], ["FasL", "PROTEIN", 133, 137], ["TRAIL", "PROTEIN", 141, 146], ["TNF\u03b1", "PROTEIN", 195, 199], ["viral proteins", "PROTEIN", 311, 325], ["TNF receptor ortholog", "PROTEIN", 391, 412], ["TNFR2", "PROTEIN", 414, 419], ["TNF\u03b1", "PROTEIN", 440, 444], ["rabbit", "SPECIES", 363, 369], ["Shope fibroma virus", "SPECIES", 342, 361], ["rabbit", "SPECIES", 363, 369], ["a consequence infected cells", "PROBLEM", 3, 31], ["cytolysis", "PROBLEM", 70, 79], ["CTLs", "TEST", 83, 87], ["neighboring cells", "PROBLEM", 101, 118], ["TNF", "TREATMENT", 195, 198], ["a sufficient inflammatory response", "PROBLEM", 226, 260], ["Extrinsic apoptotic pathway", "PROBLEM", 261, 288], ["viral proteins", "PROBLEM", 311, 325], ["the Shope fibroma virus", "PROBLEM", 338, 361], ["rabbit poxvirus", "TREATMENT", 363, 378], ["a TNF receptor ortholog", "TREATMENT", 389, 412], ["infected cells", "OBSERVATION", 17, 31], ["cytolysis", "OBSERVATION", 70, 79], ["inflammatory", "OBSERVATION", 239, 251], ["apoptotic pathway", "OBSERVATION", 271, 288], ["fibroma", "OBSERVATION", 348, 355]]], ["Other TNFR orthologs have been identified in the genomes of lepri- and orthopoxviruses, including cowpox (CrmB) (Hu et al., 1994) and smallpox (CrmE) (Reading et al., 2002) and in the genome of CMV (UL144 orf) (Benedict et al., 1999).", [["TNFR", "GENE_OR_GENE_PRODUCT", 6, 10], ["lepri", "GENE_OR_GENE_PRODUCT", 60, 65], ["orthopoxviruses", "GENE_OR_GENE_PRODUCT", 71, 86], ["cowpox", "ORGANISM", 98, 104], ["CMV", "ORGANISM", 194, 197], ["UL144 orf", "ORGANISM", 199, 208], ["TNFR orthologs", "PROTEIN", 6, 20], ["Other TNFR orthologs", "TEST", 0, 20], ["orthopoxviruses", "PROBLEM", 71, 86], ["CMV", "OBSERVATION", 194, 197]]], ["They can either be expressed in the plasma membrane of infected cells or be shed as soluble decoy receptors (for example myxoma virus T2 protein) (Upton et al., 1991, Reading et al., 2002).", [["plasma membrane", "ANATOMY", 36, 51], ["cells", "ANATOMY", 64, 69], ["myxoma", "DISEASE", 121, 127], ["plasma membrane", "CELLULAR_COMPONENT", 36, 51], ["cells", "CELL", 64, 69], ["infected cells", "CELL_TYPE", 55, 69], ["decoy receptors", "PROTEIN", 92, 107], ["infected cells", "PROBLEM", 55, 69], ["soluble decoy receptors", "TREATMENT", 84, 107], ["infected cells", "OBSERVATION", 55, 69]]], ["These TNF signaling inhibitors clearly contribute to the high virulence of poxviruses because they are mutated in vaccinia viruses, an attenuated form of smallpox.", [["smallpox", "DISEASE", 154, 162], ["TNF", "GENE_OR_GENE_PRODUCT", 6, 9], ["poxviruses", "ORGANISM", 75, 85], ["vaccinia viruses", "ORGANISM", 114, 130], ["TNF", "PROTEIN", 6, 9], ["vaccinia viruses", "SPECIES", 114, 130], ["These TNF signaling inhibitors", "TREATMENT", 0, 30], ["the high virulence of poxviruses", "PROBLEM", 53, 85], ["vaccinia viruses", "PROBLEM", 114, 130], ["smallpox", "PROBLEM", 154, 162], ["vaccinia viruses", "OBSERVATION", 114, 130], ["smallpox", "OBSERVATION", 154, 162]]], ["In addition, a TRAIL receptor ortholog (TRAILR2) was detected in the genome of avian leukocytosis virus (Brojatsch et al., 1996).", [["avian leukocytosis", "DISEASE", 79, 97], ["TRAIL receptor", "GENE_OR_GENE_PRODUCT", 15, 29], ["TRAILR2", "GENE_OR_GENE_PRODUCT", 40, 47], ["avian leukocytosis virus", "ORGANISM", 79, 103], ["TRAIL receptor ortholog", "PROTEIN", 15, 38], ["TRAILR2", "PROTEIN", 40, 47], ["a TRAIL receptor ortholog", "TREATMENT", 13, 38], ["avian leukocytosis virus", "PROBLEM", 79, 103], ["leukocytosis virus", "OBSERVATION", 85, 103]]], ["On the other hand adenoviruses use several proteins encoded in the E3 gene region to promote the internalization and lysosomal degradation of Fas, TNFR, TRAILR1 and R2 (Shisler et al., 1997, Tollefson et al., 1998, Stewart et al., 1995, Benedict et al., 2001).", [["lysosomal", "ANATOMY", 117, 126], ["adenoviruses", "ORGANISM", 18, 30], ["E3", "GENE_OR_GENE_PRODUCT", 67, 69], ["lysosomal", "CELLULAR_COMPONENT", 117, 126], ["Fas", "GENE_OR_GENE_PRODUCT", 142, 145], ["TNFR", "GENE_OR_GENE_PRODUCT", 147, 151], ["TRAILR1", "GENE_OR_GENE_PRODUCT", 153, 160], ["E3 gene region", "DNA", 67, 81], ["Fas", "PROTEIN", 142, 145], ["TNFR", "PROTEIN", 147, 151], ["TRAILR1", "PROTEIN", 153, 160], ["R2", "PROTEIN", 165, 167], ["several proteins", "PROBLEM", 35, 51]]], ["Finally, several viruses produce proteins capable of blocking extrinsic death receptor signaling at the level of the DISC, i.e. by either inhibiting caspase-8 activation or its proteolytic activity.", [["death", "DISEASE", 72, 77], ["DISC", "GENE_OR_GENE_PRODUCT", 117, 121], ["caspase-8", "GENE_OR_GENE_PRODUCT", 149, 158], ["DISC", "PROTEIN", 117, 121], ["caspase-8", "PROTEIN", 149, 158], ["blocking extrinsic death receptor signaling", "PROBLEM", 53, 96], ["its proteolytic activity", "PROBLEM", 173, 197], ["viruses", "OBSERVATION", 17, 24], ["receptor signaling", "OBSERVATION", 78, 96], ["DISC", "ANATOMY", 117, 121], ["proteolytic activity", "OBSERVATION", 177, 197]]], ["For example, the viral FLIP proteins (vFLIPs) are inactive caspase-8 homologs, which are recruited by FADD to form a DISC that lacks caspase activity (Thome and Tschopp, 2001, Krueger et al., 2001, Subramaniam et al., 2013).", [["FLIP", "GENE_OR_GENE_PRODUCT", 23, 27], ["vFLIPs", "GENE_OR_GENE_PRODUCT", 38, 44], ["caspase-8", "GENE_OR_GENE_PRODUCT", 59, 68], ["FADD", "GENE_OR_GENE_PRODUCT", 102, 106], ["DISC", "GENE_OR_GENE_PRODUCT", 117, 121], ["caspase", "GENE_OR_GENE_PRODUCT", 133, 140], ["viral FLIP proteins", "PROTEIN", 17, 36], ["vFLIPs", "PROTEIN", 38, 44], ["inactive caspase-8 homologs", "PROTEIN", 50, 77], ["FADD", "PROTEIN", 102, 106], ["DISC", "PROTEIN", 117, 121], ["caspase", "PROTEIN", 133, 140], ["the viral FLIP proteins", "TEST", 13, 36], ["inactive caspase", "TREATMENT", 50, 66], ["a DISC", "PROBLEM", 115, 121], ["viral FLIP", "OBSERVATION", 17, 27], ["DISC", "ANATOMY", 117, 121]]], ["In addition, they can recruit TRAF2, RIP, NIK and IKK2, which favor the induction/activation of NF\u03baB, a crucial anti-apoptotic transcription factor (Kataoka et al., 2000, Subramaniam et al., 2013). vFLIPs are present in the genome of \u03b3-herpesviruses, including equine herpesvirus 2 (EHV-2), herpesvirus saimiri (HVS), KSHV (Kaposi), bovine herpesvirus (BHV-4) and moluscum contagiosum virus (MCV) (Bertin et al., 1997, Thome and Tschopp, 2001, Benedict et al., 2002).", [["moluscum contagiosum", "DISEASE", 364, 384], ["TRAF2", "GENE_OR_GENE_PRODUCT", 30, 35], ["RIP", "GENE_OR_GENE_PRODUCT", 37, 40], ["NIK", "GENE_OR_GENE_PRODUCT", 42, 45], ["IKK2", "GENE_OR_GENE_PRODUCT", 50, 54], ["NF\u03baB", "GENE_OR_GENE_PRODUCT", 96, 100], ["vFLIPs", "GENE_OR_GENE_PRODUCT", 198, 204], ["\u03b3-herpesviruses", "GENE_OR_GENE_PRODUCT", 234, 249], ["equine herpesvirus 2", "ORGANISM", 261, 281], ["EHV-2", "ORGANISM", 283, 288], ["herpesvirus saimiri", "ORGANISM", 291, 310], ["HVS", "ORGANISM", 312, 315], ["KSHV", "ORGANISM", 318, 322], ["Kaposi)", "ORGANISM", 324, 331], ["bovine herpesvirus", "ORGANISM", 333, 351], ["BHV-4", "ORGANISM", 353, 358], ["moluscum contagiosum virus", "ORGANISM", 364, 390], ["MCV", "ORGANISM", 392, 395], ["TRAF2", "PROTEIN", 30, 35], ["RIP", "PROTEIN", 37, 40], ["NIK", "PROTEIN", 42, 45], ["IKK2", "PROTEIN", 50, 54], ["NF\u03baB", "PROTEIN", 96, 100], ["anti-apoptotic transcription factor", "PROTEIN", 112, 147], ["vFLIPs", "PROTEIN", 198, 204], ["equine herpesvirus", "SPECIES", 261, 279], ["EHV-2", "SPECIES", 283, 288], ["herpesvirus saimiri", "SPECIES", 291, 310], ["KSHV", "SPECIES", 318, 322], ["bovine", "SPECIES", 333, 339], ["herpesvirus", "SPECIES", 340, 351], ["BHV-4", "SPECIES", 353, 358], ["moluscum contagiosum virus", "SPECIES", 364, 390], ["equine herpesvirus 2", "SPECIES", 261, 281], ["EHV-2", "SPECIES", 283, 288], ["HVS", "SPECIES", 312, 315], ["KSHV", "SPECIES", 318, 322], ["bovine herpesvirus (BHV-4", "SPECIES", 333, 358], ["moluscum contagiosum virus", "SPECIES", 364, 390], ["MCV", "SPECIES", 392, 395], ["TRAF2", "TEST", 30, 35], ["IKK2", "TREATMENT", 50, 54], ["equine herpesvirus", "TEST", 261, 279], ["EHV", "TEST", 283, 286], ["herpesvirus saimiri (HVS", "PROBLEM", 291, 315], ["KSHV (Kaposi)", "TEST", 318, 331], ["bovine herpesvirus", "TEST", 333, 351], ["BHV", "TEST", 353, 356], ["moluscum contagiosum virus", "PROBLEM", 364, 390], ["herpesvirus saimiri", "OBSERVATION", 291, 310]]], ["The vICA protein produced by the HCMV viral gene UL36 also associates with caspase-8 and blocks its activation but it has no sequence homology with caspases (Skaletskaya et al., 2001).", [["vICA", "GENE_OR_GENE_PRODUCT", 4, 8], ["HCMV", "ORGANISM", 33, 37], ["UL36", "GENE_OR_GENE_PRODUCT", 49, 53], ["caspase-8", "GENE_OR_GENE_PRODUCT", 75, 84], ["caspases", "GENE_OR_GENE_PRODUCT", 148, 156], ["vICA protein", "PROTEIN", 4, 16], ["HCMV viral gene", "DNA", 33, 48], ["UL36", "DNA", 49, 53], ["caspase-8", "PROTEIN", 75, 84], ["caspases", "PROTEIN", 148, 156], ["HCMV", "SPECIES", 33, 37], ["The vICA protein", "TEST", 0, 16], ["caspase", "TREATMENT", 75, 82]]], ["Last but not least, the CrmA protein from cowpox virus is able to inhibit the proteolytic activity of caspase-8 by binding to and blocking the catalytic center (Zhou et al., 1997).Intrinsic apoptotic pathway and its inhibition by viral proteinsThe intrinsic apoptotic pathway is activated by the lack of soluble survival factors or hormones, cell\u2013cell or cell\u2013matrix interactions (deprivation-induced cell death, also called anoikis), the exposure of cells to pathogens such as fungi, bacteria or viruses or the treatment with genotoxic/DNA damaging stimuli (irradiation, chemotherapeutic drugs), toxins or pro-oxidants, agents which stress the endoplasmic reticulum, inhibit protein kinases, proteasomal degradation, transcription, translation or perturb the cytoskeleton (Fig. 2) (Youle and Strasser, 2008, Hotchkiss et al., 2009, Chipuk et al., 2010).", [["cell\u2013cell", "ANATOMY", 342, 351], ["cell\u2013matrix", "ANATOMY", 355, 366], ["cell", "ANATOMY", 401, 405], ["cells", "ANATOMY", 451, 456], ["endoplasmic reticulum", "ANATOMY", 645, 666], ["cytoskeleton", "ANATOMY", 760, 772], ["death", "DISEASE", 406, 411], ["CrmA", "GENE_OR_GENE_PRODUCT", 24, 28], ["cowpox virus", "ORGANISM", 42, 54], ["caspase-8", "GENE_OR_GENE_PRODUCT", 102, 111], ["cell\u2013cell", "CELL", 342, 351], ["cell\u2013matrix", "GENE_OR_GENE_PRODUCT", 355, 366], ["cell", "CELL", 401, 405], ["cells", "CELL", 451, 456], ["DNA", "CELLULAR_COMPONENT", 537, 540], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 645, 666], ["cytoskeleton", "CELLULAR_COMPONENT", 760, 772], ["CrmA protein", "PROTEIN", 24, 36], ["caspase-8", "PROTEIN", 102, 111], ["viral proteins", "PROTEIN", 230, 244], ["soluble survival factors", "PROTEIN", 304, 328], ["protein kinases", "PROTEIN", 676, 691], ["cowpox virus", "SPECIES", 42, 54], ["the CrmA protein", "TEST", 20, 36], ["cowpox virus", "PROBLEM", 42, 54], ["caspase", "TEST", 102, 109], ["Intrinsic apoptotic pathway", "PROBLEM", 180, 207], ["viral proteins", "PROBLEM", 230, 244], ["soluble survival factors", "PROBLEM", 304, 328], ["cell\u2013cell or cell\u2013matrix interactions", "PROBLEM", 342, 379], ["induced cell death", "PROBLEM", 393, 411], ["anoikis", "PROBLEM", 425, 432], ["pathogens", "PROBLEM", 460, 469], ["fungi", "PROBLEM", 478, 483], ["bacteria", "PROBLEM", 485, 493], ["viruses", "PROBLEM", 497, 504], ["the treatment", "TREATMENT", 508, 521], ["genotoxic/DNA damaging stimuli", "TREATMENT", 527, 557], ["irradiation, chemotherapeutic drugs", "TREATMENT", 559, 594], ["toxins", "PROBLEM", 597, 603], ["pro-oxidants", "TREATMENT", 607, 619], ["agents", "TREATMENT", 621, 627], ["stress the endoplasmic reticulum", "PROBLEM", 634, 666], ["protein kinases", "TEST", 676, 691], ["proteasomal degradation", "PROBLEM", 693, 716], ["cowpox virus", "OBSERVATION", 42, 54], ["apoptotic pathway", "OBSERVATION", 190, 207], ["apoptotic pathway", "OBSERVATION", 258, 275], ["endoplasmic reticulum", "ANATOMY", 645, 666]]], ["The critical step of this pathway is the permeabilization of the mitochondrial outer membrane (MOMP), which results in the release of several apoptogenic factors from the intermembrane space of mitochondria.", [["mitochondrial outer membrane", "ANATOMY", 65, 93], ["intermembrane space", "ANATOMY", 171, 190], ["mitochondria", "ANATOMY", 194, 206], ["mitochondrial", "CELLULAR_COMPONENT", 65, 78], ["outer membrane", "CELLULAR_COMPONENT", 79, 93], ["MOMP", "CELLULAR_COMPONENT", 95, 99], ["intermembrane", "CELLULAR_COMPONENT", 171, 184], ["mitochondria", "CELLULAR_COMPONENT", 194, 206], ["MOMP", "PROTEIN", 95, 99], ["apoptogenic factors", "PROTEIN", 142, 161], ["several apoptogenic factors", "PROBLEM", 134, 161], ["step", "OBSERVATION_MODIFIER", 13, 17], ["mitochondrial outer membrane", "ANATOMY", 65, 93], ["several", "OBSERVATION_MODIFIER", 134, 141], ["apoptogenic factors", "OBSERVATION", 142, 161], ["intermembrane space", "OBSERVATION", 171, 190]]], ["One such protein, cytochrome c, binds to the adapter Apaf-1 which then recruits cytosolic pro-caspase-9 into a heptameric complex, called the apoptosome (Fig. 2).", [["cytosolic", "ANATOMY", 80, 89], ["cytochrome c", "GENE_OR_GENE_PRODUCT", 18, 30], ["Apaf-1", "GENE_OR_GENE_PRODUCT", 53, 59], ["pro-caspase-9", "GENE_OR_GENE_PRODUCT", 90, 103], ["cytochrome c", "PROTEIN", 18, 30], ["adapter Apaf-1", "PROTEIN", 45, 59], ["cytosolic pro-caspase-9", "PROTEIN", 80, 103], ["heptameric complex", "PROTEIN", 111, 129], ["apoptosome", "PROTEIN", 142, 152], ["cytochrome c", "PROBLEM", 18, 30], ["the adapter Apaf", "TEST", 41, 57], ["cytosolic pro-caspase", "TEST", 80, 101]]], ["In a similar way as caspase-8 aggregates on the DISC, monomeric caspase-9 dimerizes on the apoptosomal platform leading to proximity-induced autoprocessing and activation.", [["caspase-8", "GENE_OR_GENE_PRODUCT", 20, 29], ["DISC", "GENE_OR_GENE_PRODUCT", 48, 52], ["caspase-9", "GENE_OR_GENE_PRODUCT", 64, 73], ["caspase-8", "PROTEIN", 20, 29], ["DISC", "PROTEIN", 48, 52], ["monomeric caspase-9", "PROTEIN", 54, 73], ["caspase", "TEST", 20, 27], ["the DISC", "TREATMENT", 44, 52], ["monomeric caspase", "TEST", 54, 71], ["the apoptosomal platform", "TREATMENT", 87, 111], ["DISC", "ANATOMY", 48, 52]]], ["Active caspase-9 then cleaves and activates effector caspase-3 and -7.", [["caspase-9", "GENE_OR_GENE_PRODUCT", 7, 16], ["caspase-3", "GENE_OR_GENE_PRODUCT", 53, 62], ["-7", "GENE_OR_GENE_PRODUCT", 67, 69], ["caspase-9", "PROTEIN", 7, 16], ["effector caspase-3 and -7", "PROTEIN", 44, 69], ["Active caspase", "TREATMENT", 0, 14], ["caspase", "TEST", 53, 60]]], ["Other proteins released from mitochondria either stimulate yet unknown caspase-independent cell death processes or they enhance caspase-9 and -3 activation (Fig. 2).", [["mitochondria", "ANATOMY", 29, 41], ["cell", "ANATOMY", 91, 95], ["death", "DISEASE", 96, 101], ["mitochondria", "CELLULAR_COMPONENT", 29, 41], ["caspase", "GENE_OR_GENE_PRODUCT", 71, 78], ["cell", "CELL", 91, 95], ["caspase-9", "GENE_OR_GENE_PRODUCT", 128, 137], ["-3", "GENE_OR_GENE_PRODUCT", 142, 144], ["caspase", "PROTEIN", 71, 78], ["caspase-9 and -3", "PROTEIN", 128, 144], ["Other proteins", "PROBLEM", 0, 14], ["caspase", "PROBLEM", 71, 78], ["independent cell death processes", "PROBLEM", 79, 111], ["caspase", "TEST", 128, 135]]], ["For example Smac/DIABLO and Htr2A/Omi bind to XIAP, a member of the Inhibitors of Apoptosis Proteins (IAPs).", [["Smac", "GENE_OR_GENE_PRODUCT", 12, 16], ["DIABLO", "GENE_OR_GENE_PRODUCT", 17, 23], ["Htr2A", "GENE_OR_GENE_PRODUCT", 28, 33], ["Omi", "GENE_OR_GENE_PRODUCT", 34, 37], ["XIAP", "GENE_OR_GENE_PRODUCT", 46, 50], ["Inhibitors of Apoptosis Proteins", "GENE_OR_GENE_PRODUCT", 68, 100], ["IAPs", "GENE_OR_GENE_PRODUCT", 102, 106], ["Smac", "PROTEIN", 12, 16], ["DIABLO", "PROTEIN", 17, 23], ["Htr2A", "PROTEIN", 28, 33], ["Omi", "PROTEIN", 34, 37], ["XIAP", "PROTEIN", 46, 50], ["Inhibitors of Apoptosis Proteins", "PROTEIN", 68, 100], ["IAPs", "PROTEIN", 102, 106], ["Smac/DIABLO", "TREATMENT", 12, 23], ["Htr2A/Omi bind", "TREATMENT", 28, 42], ["XIAP", "TREATMENT", 46, 50], ["the Inhibitors", "TREATMENT", 64, 78], ["Apoptosis Proteins", "PROBLEM", 82, 100]]], ["XIAP is an endogenous caspase-9 and -3 inhibitor, which prevents accidental autoprocessing and activation of these caspases in healthy cells (Deveraux and Reed, 1999, Shi, 2002).", [["cells", "ANATOMY", 135, 140], ["XIAP", "GENE_OR_GENE_PRODUCT", 0, 4], ["caspase-9", "GENE_OR_GENE_PRODUCT", 22, 31], ["-3", "GENE_OR_GENE_PRODUCT", 36, 38], ["caspases", "GENE_OR_GENE_PRODUCT", 115, 123], ["cells", "CELL", 135, 140], ["XIAP", "PROTEIN", 0, 4], ["caspases", "PROTEIN", 115, 123], ["healthy cells", "CELL_TYPE", 127, 140], ["XIAP", "TEST", 0, 4], ["an endogenous caspase", "TEST", 8, 29], ["accidental autoprocessing", "TREATMENT", 65, 90]]], ["Upon sequestration by Smac or Omi, XIAP no longer binds to caspase-9 or -3, therefore allowing the full activation of these caspases in response to apoptotic stimuli, activating the intrinsic mitochondrial pathway (Fig. 2).Intrinsic apoptotic pathway and its inhibition by viral proteinsSince MOMP results in both caspase-dependent and independent cell death signaling it is a crucial life-or-death decision checkpoint (\u201ca point of no return\u201d) (Fig. 2).", [["mitochondrial", "ANATOMY", 192, 205], ["cell", "ANATOMY", 348, 352], ["death", "DISEASE", 353, 358], ["death", "DISEASE", 393, 398], ["Smac", "GENE_OR_GENE_PRODUCT", 22, 26], ["Omi", "GENE_OR_GENE_PRODUCT", 30, 33], ["XIAP", "GENE_OR_GENE_PRODUCT", 35, 39], ["caspase-9", "GENE_OR_GENE_PRODUCT", 59, 68], ["-3", "GENE_OR_GENE_PRODUCT", 72, 74], ["caspases", "GENE_OR_GENE_PRODUCT", 124, 132], ["mitochondrial", "CELLULAR_COMPONENT", 192, 205], ["MOMP", "GENE_OR_GENE_PRODUCT", 293, 297], ["caspase", "GENE_OR_GENE_PRODUCT", 314, 321], ["cell", "CELL", 348, 352], ["Smac", "PROTEIN", 22, 26], ["Omi", "PROTEIN", 30, 33], ["XIAP", "PROTEIN", 35, 39], ["caspase-9 or -3", "PROTEIN", 59, 74], ["caspases", "PROTEIN", 124, 132], ["viral proteins", "PROTEIN", 273, 287], ["MOMP", "PROTEIN", 293, 297], ["caspase", "PROTEIN", 314, 321], ["Omi", "PROBLEM", 30, 33], ["XIAP", "TREATMENT", 35, 39], ["caspase", "TEST", 59, 66], ["these caspases", "TREATMENT", 118, 132], ["apoptotic stimuli", "TEST", 148, 165], ["Intrinsic apoptotic pathway", "PROBLEM", 223, 250], ["viral proteins", "PROBLEM", 273, 287], ["independent cell death signaling", "PROBLEM", 336, 368], ["Smac", "ANATOMY", 22, 26], ["apoptotic stimuli", "OBSERVATION", 148, 165], ["apoptotic pathway", "OBSERVATION", 233, 250]]], ["This checkpoint is controled by the Bcl-2 family of proteins (Youle and Strasser, 2008; Chipuk et al., 2010).", [["Bcl-2", "GENE_OR_GENE_PRODUCT", 36, 41], ["Bcl-2 family", "PROTEIN", 36, 48]]], ["The Bcl-2 family is subdivided on the basis of structural conservation of so-called Bcl-2 homology (BH) domains and comes in three flavors.", [["Bcl-2", "GENE_OR_GENE_PRODUCT", 4, 9], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 84, 89], ["Bcl-2 family", "PROTEIN", 4, 16], ["Bcl-2 homology (BH) domains", "PROTEIN", 84, 111]]], ["The pro-apoptotic BH3-only proteins (Bim, Bid, Bad, Bik, Bmf, Hrk, Puma, Noxa) only share a ca.", [["Bim", "GENE_OR_GENE_PRODUCT", 37, 40], ["Bid", "GENE_OR_GENE_PRODUCT", 42, 45], ["Bad", "GENE_OR_GENE_PRODUCT", 47, 50], ["Bik", "GENE_OR_GENE_PRODUCT", 52, 55], ["Bmf", "GENE_OR_GENE_PRODUCT", 57, 60], ["Hrk", "GENE_OR_GENE_PRODUCT", 62, 65], ["Puma", "GENE_OR_GENE_PRODUCT", 67, 71], ["Noxa", "GENE_OR_GENE_PRODUCT", 73, 77], ["BH3", "PROTEIN", 18, 21], ["Bim", "PROTEIN", 37, 40], ["Bid", "PROTEIN", 42, 45], ["Bad", "PROTEIN", 47, 50], ["Bik", "PROTEIN", 52, 55], ["Bmf", "PROTEIN", 57, 60], ["Hrk", "PROTEIN", 62, 65], ["Puma", "PROTEIN", 67, 71], ["Noxa", "PROTEIN", 73, 77], ["The pro-apoptotic BH3", "TEST", 0, 21], ["proteins", "TEST", 27, 35], ["Bmf", "TEST", 57, 60], ["Hrk", "TEST", 62, 65], ["a ca", "PROBLEM", 90, 94], ["pro-apoptotic BH3", "OBSERVATION", 4, 21], ["ca", "OBSERVATION", 92, 94]]], ["20\u201330 amino acid long alpha-helical BH3 domain with the rest of the Bcl-2 family.", [["amino acid", "CHEMICAL", 6, 16], ["amino acid", "CHEMICAL", 6, 16], ["amino acid", "AMINO_ACID", 6, 16], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 68, 73], ["20\u201330 amino acid long alpha-helical BH3 domain", "PROTEIN", 0, 46], ["Bcl-2 family", "PROTEIN", 68, 80], ["amino acid long alpha-helical BH3 domain", "TREATMENT", 6, 46]]], ["They act as sentinels/sensors of apoptotic stimuli which activate the intrinsic mitochondrial pathway (Happo et al., 2012).", [["mitochondrial", "ANATOMY", 80, 93], ["mitochondrial", "CELLULAR_COMPONENT", 80, 93], ["apoptotic stimuli", "TEST", 33, 50]]], ["Depending on the apoptotic stimulus, particular sets of BH3-only proteins get transcriptionally induced or posttranslationally modified, migrate to and insert into the MOM and then activate at this site a second pro-apoptotic subclass of Bcl-2 family proteins, the so-called \u201ceffectors\u201d Bax and Bak (Happo et al., 2012).", [["BH3", "GENE_OR_GENE_PRODUCT", 56, 59], ["MOM", "GENE_OR_GENE_PRODUCT", 168, 171], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 238, 243], ["Bax", "GENE_OR_GENE_PRODUCT", 287, 290], ["Bak", "GENE_OR_GENE_PRODUCT", 295, 298], ["BH3", "PROTEIN", 56, 59], ["MOM", "PROTEIN", 168, 171], ["pro-apoptotic subclass", "PROTEIN", 212, 234], ["Bcl-2 family proteins", "PROTEIN", 238, 259], ["\u201ceffectors", "PROTEIN", 275, 285], ["\u201d", "PROTEIN", 285, 286], ["Bax", "PROTEIN", 287, 290], ["Bak", "PROTEIN", 295, 298], ["the apoptotic stimulus", "TEST", 13, 35], ["BH3", "TEST", 56, 59]]], ["For example, Bim is transcriptionally induced by Foxo3B in response to growth factor deprivation or phosphorylated by JNK during thymic selection and upon exposure to UV or gliotoxin (Happo et al., 2012, Geissler et al., 2013).", [["thymic", "ANATOMY", 129, 135], ["UV", "CHEMICAL", 167, 169], ["gliotoxin", "CHEMICAL", 173, 182], ["gliotoxin", "CHEMICAL", 173, 182], ["Bim", "GENE_OR_GENE_PRODUCT", 13, 16], ["Foxo3B", "GENE_OR_GENE_PRODUCT", 49, 55], ["JNK", "GENE_OR_GENE_PRODUCT", 118, 121], ["thymic", "ORGAN", 129, 135], ["gliotoxin", "SIMPLE_CHEMICAL", 173, 182], ["Bim", "PROTEIN", 13, 16], ["Foxo3B", "PROTEIN", 49, 55], ["growth factor", "PROTEIN", 71, 84], ["JNK", "PROTEIN", 118, 121], ["growth factor deprivation", "PROBLEM", 71, 96], ["phosphorylated", "PROBLEM", 100, 114], ["thymic selection", "TREATMENT", 129, 145], ["UV", "TREATMENT", 167, 169], ["gliotoxin", "TREATMENT", 173, 182]]], ["By contrast, Puma and Noxa are target genes of p53 after genotoxic stress.", [["Puma", "GENE_OR_GENE_PRODUCT", 13, 17], ["Noxa", "GENE_OR_GENE_PRODUCT", 22, 26], ["p53", "GENE_OR_GENE_PRODUCT", 47, 50], ["Puma", "PROTEIN", 13, 17], ["Noxa", "PROTEIN", 22, 26], ["p53", "PROTEIN", 47, 50], ["genotoxic stress", "PROBLEM", 57, 73], ["genotoxic stress", "OBSERVATION", 57, 73]]], ["Bid is proteolytically cleaved to truncated tBid by caspase-8 in response to death receptor ligands such as FasL, TRAIL or TNF\u03b1 defining a second, so called type II death receptor pathway that crosstalks with the mitochondrial pathway (Youle and Strasser, 2008; Chipuk et al., 2010, Happo et al., 2012).Intrinsic apoptotic pathway and its inhibition by viral proteinsBax and Bak directly induce MOMP.", [["mitochondrial", "ANATOMY", 213, 226], ["death", "DISEASE", 77, 82], ["Bid", "GENE_OR_GENE_PRODUCT", 0, 3], ["tBid", "GENE_OR_GENE_PRODUCT", 44, 48], ["caspase-8", "GENE_OR_GENE_PRODUCT", 52, 61], ["FasL", "GENE_OR_GENE_PRODUCT", 108, 112], ["TRAIL", "GENE_OR_GENE_PRODUCT", 114, 119], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 123, 127], ["type II death receptor", "GENE_OR_GENE_PRODUCT", 157, 179], ["mitochondrial", "CELLULAR_COMPONENT", 213, 226], ["Bax", "GENE_OR_GENE_PRODUCT", 367, 370], ["Bak", "GENE_OR_GENE_PRODUCT", 375, 378], ["MOMP", "GENE_OR_GENE_PRODUCT", 395, 399], ["Bid", "PROTEIN", 0, 3], ["tBid", "PROTEIN", 44, 48], ["caspase-8", "PROTEIN", 52, 61], ["FasL", "PROTEIN", 108, 112], ["TRAIL", "PROTEIN", 114, 119], ["TNF\u03b1", "PROTEIN", 123, 127], ["type II death receptor", "PROTEIN", 157, 179], ["viral proteins", "PROTEIN", 353, 367], ["Bax", "PROTEIN", 367, 370], ["Bak", "PROTEIN", 375, 378], ["MOMP", "PROTEIN", 395, 399], ["caspase", "TEST", 52, 59], ["Intrinsic apoptotic pathway", "TREATMENT", 303, 330], ["its inhibition", "TREATMENT", 335, 349], ["viral proteinsBax", "TREATMENT", 353, 370], ["MOMP", "PROBLEM", 395, 399], ["apoptotic pathway", "OBSERVATION", 313, 330]]], ["They contain BH1, BH2 and BH3 domains, which form an elongated hydrophobic binding pocket interacting with other members of the Bcl-2 family (Suzuki et al., 2000, Czabotar et al., 2013, Brouwer et al., 2014, Volkmann et al., 2014, Westphal et al., 2014, Borner and Andrews, 2014).", [["BH1", "GENE_OR_GENE_PRODUCT", 13, 16], ["BH2", "GENE_OR_GENE_PRODUCT", 18, 21], ["BH3", "GENE_OR_GENE_PRODUCT", 26, 29], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 128, 133], ["BH1", "PROTEIN", 13, 16], ["BH2", "PROTEIN", 18, 21], ["BH3 domains", "PROTEIN", 26, 37], ["hydrophobic binding pocket", "PROTEIN", 63, 89], ["Bcl-2 family", "PROTEIN", 128, 140], ["BH3 domains", "TREATMENT", 26, 37], ["an elongated hydrophobic binding pocket", "PROBLEM", 50, 89], ["elongated", "OBSERVATION_MODIFIER", 53, 62], ["hydrophobic binding pocket", "OBSERVATION", 63, 89]]], ["In healthy cells, Bax resides inactive in the cytoplasm (Suzuki et al., 2000, Schinzel et al., 2004) and constantly shuttles between the cytoplasm and the periphery of the MOM without stably inserting in the membrane (retrotranslocation) (Wolter et al., 1997, Edlich et al., 2011).", [["cells", "ANATOMY", 11, 16], ["cytoplasm", "ANATOMY", 46, 55], ["cytoplasm", "ANATOMY", 137, 146], ["membrane", "ANATOMY", 208, 216], ["cells", "CELL", 11, 16], ["Bax", "GENE_OR_GENE_PRODUCT", 18, 21], ["cytoplasm", "ORGANISM_SUBSTANCE", 46, 55], ["cytoplasm", "ORGANISM_SUBSTANCE", 137, 146], ["MOM", "CELLULAR_COMPONENT", 172, 175], ["membrane", "CELLULAR_COMPONENT", 208, 216], ["Bax", "PROTEIN", 18, 21], ["MOM", "PROTEIN", 172, 175], ["healthy cells", "OBSERVATION", 3, 16], ["inactive", "OBSERVATION_MODIFIER", 30, 38], ["periphery", "ANATOMY_MODIFIER", 155, 164]]], ["Bak on the other hand is stably inserted into the MOM but held in check by inhibitory proteins such as VDAC2 and Bcl-2 survival factors (Wang et al., 2001, Cheng et al., 2003, Willis et al., 2005).", [["Bak", "GENE_OR_GENE_PRODUCT", 0, 3], ["MOM", "GENE_OR_GENE_PRODUCT", 50, 53], ["VDAC2", "GENE_OR_GENE_PRODUCT", 103, 108], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 113, 118], ["Bak", "PROTEIN", 0, 3], ["inhibitory proteins", "PROTEIN", 75, 94], ["VDAC2", "PROTEIN", 103, 108], ["Bcl-2 survival factors", "PROTEIN", 113, 135], ["Bak", "TREATMENT", 0, 3], ["stably", "OBSERVATION", 25, 31]]], ["Three BH3-only proteins Bim, tBid and Puma are capable of directly activating Bax/Bak on the MOM (Letai et al., 2002, Cartron et al., 2004, Kuwana et al., 2005, Gavathiotis et al., 2008, Czabotar et al., 2013).", [["Bim", "GENE_OR_GENE_PRODUCT", 24, 27], ["tBid", "GENE_OR_GENE_PRODUCT", 29, 33], ["Puma", "GENE_OR_GENE_PRODUCT", 38, 42], ["Bax", "GENE_OR_GENE_PRODUCT", 78, 81], ["Bak", "GENE_OR_GENE_PRODUCT", 82, 85], ["BH3", "PROTEIN", 6, 9], ["Bim", "PROTEIN", 24, 27], ["tBid", "PROTEIN", 29, 33], ["Puma", "PROTEIN", 38, 42], ["Bax", "PROTEIN", 78, 81], ["Bak", "PROTEIN", 82, 85]]], ["Recent structural analysis of the activation process suggests that after their translocation to and insertion into the MOM, Bim and tBid bind to the hydrophobic pocket in Bax/Bak via their BH3-domain (Czabotar et al., 2013, Brouwer et al., 2014).", [["MOM", "GENE_OR_GENE_PRODUCT", 119, 122], ["Bim", "GENE_OR_GENE_PRODUCT", 124, 127], ["tBid", "GENE_OR_GENE_PRODUCT", 132, 136], ["Bax", "GENE_OR_GENE_PRODUCT", 171, 174], ["Bak", "GENE_OR_GENE_PRODUCT", 175, 178], ["MOM", "PROTEIN", 119, 122], ["Bim", "PROTEIN", 124, 127], ["tBid", "PROTEIN", 132, 136], ["Bax", "PROTEIN", 171, 174], ["Bak", "PROTEIN", 175, 178], ["BH3", "PROTEIN", 189, 192], ["Recent structural analysis", "TEST", 0, 26], ["the activation process", "PROBLEM", 30, 52]]], ["This changes the conformation of Bax and Bak in a way that their BH3-regions become exposed for dimeric interaction with the hydrophobic pocket of another Bax or Bak molecule (Dewson et al., 2009, Czabotar et al., 2013, Brouwer et al., 2014).", [["Bax", "GENE_OR_GENE_PRODUCT", 33, 36], ["Bak", "GENE_OR_GENE_PRODUCT", 41, 44], ["Bax", "GENE_OR_GENE_PRODUCT", 155, 158], ["Bak", "GENE_OR_GENE_PRODUCT", 162, 165], ["Bax", "PROTEIN", 33, 36], ["Bak", "PROTEIN", 41, 44], ["BH3", "PROTEIN", 65, 68], ["Bax", "PROTEIN", 155, 158], ["Bak molecule", "PROTEIN", 162, 174], ["Bax", "TREATMENT", 33, 36], ["Bak", "TREATMENT", 41, 44]]], ["For that purpose the BH3-only protein has to dissociate from the hydrophobic binding pocket, which explains why direct interaction between BH3-only proteins and Bax/Bak is only transient and difficult to detect biochemically.", [["BH3", "GENE_OR_GENE_PRODUCT", 21, 24], ["BH3", "GENE_OR_GENE_PRODUCT", 139, 142], ["Bax", "GENE_OR_GENE_PRODUCT", 161, 164], ["Bak", "GENE_OR_GENE_PRODUCT", 165, 168], ["BH3", "PROTEIN", 21, 24], ["hydrophobic binding pocket", "PROTEIN", 65, 91], ["BH3", "PROTEIN", 139, 142], ["Bax", "PROTEIN", 161, 164], ["Bak", "PROTEIN", 165, 168], ["the BH3", "TREATMENT", 17, 24], ["the hydrophobic binding pocket", "PROBLEM", 61, 91], ["BH3", "TEST", 139, 142], ["Bax/Bak", "TEST", 161, 168], ["Bak", "OBSERVATION", 165, 168]]], ["Presumably through an additional interaction site in the rear part of the molecule, Bax/Bak dimers can then assemble into multimers (Dewson et al., 2009).", [["Bax", "GENE_OR_GENE_PRODUCT", 84, 87], ["Bak", "GENE_OR_GENE_PRODUCT", 88, 91], ["Bax", "PROTEIN", 84, 87], ["Bak dimers", "PROTEIN", 88, 98], ["an additional interaction site", "PROBLEM", 19, 49], ["Bax/Bak dimers", "TREATMENT", 84, 98], ["interaction", "OBSERVATION", 33, 44], ["Bak", "ANATOMY", 88, 91]]], ["It is not yet clear if these multimers form a protein pore or perturb the lipid bilayer of the MOM to rearrange into a lipid pore that may be generated by a hemifusion intermediate (Montessuit et al., 2010, Bleicken et al., 2014, Borner and Andrews, 2014).", [["lipid bilayer", "ANATOMY", 74, 87], ["lipid pore", "ANATOMY", 119, 129], ["multimers", "GENE_OR_GENE_PRODUCT", 29, 38], ["lipid bilayer", "CELLULAR_COMPONENT", 74, 87], ["MOM", "SIMPLE_CHEMICAL", 95, 98], ["lipid pore", "CELLULAR_COMPONENT", 119, 129], ["a protein pore", "TREATMENT", 44, 58], ["a lipid pore", "TREATMENT", 117, 129]]], ["Newest findings from lipid nanodiscs and fluorescence measurements indicate that Bax/Bak may form pores of different sizes depending on whether they are monomeric, di- or multimeric (Xu et al., 2013, Volkmann et al., 2014).", [["Bax", "GENE_OR_GENE_PRODUCT", 81, 84], ["Bak", "GENE_OR_GENE_PRODUCT", 85, 88], ["Bax", "PROTEIN", 81, 84], ["Bak", "PROTEIN", 85, 88], ["lipid nanodiscs", "TEST", 21, 36], ["fluorescence measurements", "TEST", 41, 66], ["Bax/Bak", "TREATMENT", 81, 88], ["Bak", "OBSERVATION", 85, 88], ["different sizes", "OBSERVATION_MODIFIER", 107, 122]]], ["At one point the pores are large enough to allow the passage of cytochrome c or even bigger molecules such as Smac and Omi to the cytoplasm.Intrinsic apoptotic pathway and its inhibition by viral proteinsThe third subgroup of the Bcl-2 family is formed by the anti-apoptotic proteins Bcl-2, Bcl-xL, Mcl-1, Bcl-w and A1 (Youle and Strasser, 2008, Chipuk et al., 2010).", [["pores", "ANATOMY", 17, 22], ["cytoplasm", "ANATOMY", 130, 139], ["cytochrome c", "GENE_OR_GENE_PRODUCT", 64, 76], ["Smac", "GENE_OR_GENE_PRODUCT", 110, 114], ["Omi", "GENE_OR_GENE_PRODUCT", 119, 122], ["cytoplasm", "ORGANISM_SUBSTANCE", 130, 139], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 230, 235], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 284, 289], ["Bcl-xL", "GENE_OR_GENE_PRODUCT", 291, 297], ["Mcl-1", "GENE_OR_GENE_PRODUCT", 299, 304], ["Bcl-w", "GENE_OR_GENE_PRODUCT", 306, 311], ["A1", "GENE_OR_GENE_PRODUCT", 316, 318], ["cytochrome c", "PROTEIN", 64, 76], ["Smac", "PROTEIN", 110, 114], ["Omi", "PROTEIN", 119, 122], ["viral proteins", "PROTEIN", 190, 204], ["Bcl-2 family", "PROTEIN", 230, 242], ["anti-apoptotic proteins", "PROTEIN", 260, 283], ["Bcl-2", "PROTEIN", 284, 289], ["Bcl", "PROTEIN", 291, 294], ["-xL", "PROTEIN", 294, 297], ["Mcl", "PROTEIN", 299, 302], ["Bcl", "PROTEIN", 306, 309], ["A1", "PROTEIN", 316, 318], ["cytochrome c", "PROBLEM", 64, 76], ["Smac", "PROBLEM", 110, 114], ["Intrinsic apoptotic pathway", "PROBLEM", 140, 167], ["viral proteins", "PROBLEM", 190, 204], ["the anti-apoptotic proteins Bcl", "TEST", 256, 287], ["Bcl", "TEST", 291, 294], ["Mcl", "TEST", 299, 302], ["Bcl", "TEST", 306, 309], ["large", "OBSERVATION", 27, 32], ["Smac", "ANATOMY", 110, 114], ["cytoplasm", "OBSERVATION", 130, 139], ["apoptotic pathway", "OBSERVATION", 150, 167], ["Bcl", "ANATOMY", 230, 233], ["Mcl", "ANATOMY", 299, 302]]], ["They also contain BH1, BH2 and BH3 domains and some even have an additional BH4 domain at the N-terminus.", [["BH4", "CHEMICAL", 76, 79], ["BH4", "CHEMICAL", 76, 79], ["BH1", "GENE_OR_GENE_PRODUCT", 18, 21], ["BH2", "GENE_OR_GENE_PRODUCT", 23, 26], ["BH4", "SIMPLE_CHEMICAL", 76, 79], ["BH1", "PROTEIN", 18, 21], ["BH2", "PROTEIN", 23, 26], ["BH3 domains", "PROTEIN", 31, 42], ["BH4 domain", "PROTEIN", 76, 86], ["N-terminus", "PROTEIN", 94, 104], ["BH1", "TREATMENT", 18, 21], ["BH2 and BH3 domains", "TREATMENT", 23, 42], ["an additional BH4 domain at the N-terminus", "PROBLEM", 62, 104], ["BH4 domain", "OBSERVATION", 76, 86]]], ["The 3-dimensional structure of these survival factors looks very similar to that of Bax/Bak (Muchmore et al., 1996, Suzuki et al., 2000).", [["Bax", "GENE_OR_GENE_PRODUCT", 84, 87], ["Bak", "GENE_OR_GENE_PRODUCT", 88, 91], ["survival factors", "PROTEIN", 37, 53], ["Bax", "PROTEIN", 84, 87], ["Bak", "PROTEIN", 88, 91], ["these survival factors", "PROBLEM", 31, 53]]], ["However, in contrast to Bax/Bak, they are unable to undergo conformational changes to expose their BH3-domain, multimerize and form pores, except under unphysiological conditions such as low pH (Minn et al., 1997, Schendel et al., 1997).", [["Bax", "GENE_OR_GENE_PRODUCT", 24, 27], ["Bak", "GENE_OR_GENE_PRODUCT", 28, 31], ["Bax", "PROTEIN", 24, 27], ["Bak", "PROTEIN", 28, 31], ["BH3", "PROTEIN", 99, 102]]], ["Instead their hydrophobic binding pocket interacts with BH3-only proteins in a high affinity manner.", [["hydrophobic binding pocket", "PROTEIN", 14, 40], ["BH3", "PROTEIN", 56, 59], ["their hydrophobic binding pocket", "PROBLEM", 8, 40], ["BH3", "TREATMENT", 56, 59], ["hydrophobic binding", "OBSERVATION", 14, 33], ["pocket", "OBSERVATION_MODIFIER", 34, 40], ["high affinity", "OBSERVATION_MODIFIER", 79, 92]]], ["On one hand this inhibits the pro-apoptotic action of BH3-only proteins.", [["BH3", "PROTEIN", 54, 57], ["BH3", "TEST", 54, 57]]], ["On the other hand, pre-bound Bim, tBid and Puma can be released from the Bcl-2 survival factors by other BH3-only proteins activated by apoptotic stimuli such as Bik, Bad, Bmf, Hrk and Noxa (Borner and Andrews, 2014).", [["Bim", "GENE_OR_GENE_PRODUCT", 29, 32], ["tBid", "GENE_OR_GENE_PRODUCT", 34, 38], ["Puma", "GENE_OR_GENE_PRODUCT", 43, 47], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 73, 78], ["Bik", "GENE_OR_GENE_PRODUCT", 162, 165], ["Bad", "GENE_OR_GENE_PRODUCT", 167, 170], ["Bmf", "GENE_OR_GENE_PRODUCT", 172, 175], ["Hrk", "GENE_OR_GENE_PRODUCT", 177, 180], ["Noxa", "GENE_OR_GENE_PRODUCT", 185, 189], ["pre-bound Bim", "PROTEIN", 19, 32], ["tBid", "PROTEIN", 34, 38], ["Puma", "PROTEIN", 43, 47], ["Bcl-2 survival factors", "PROTEIN", 73, 95], ["BH3", "PROTEIN", 105, 108], ["Bik", "PROTEIN", 162, 165], ["Bad", "PROTEIN", 167, 170], ["Bmf", "PROTEIN", 172, 175], ["Hrk", "PROTEIN", 177, 180], ["Noxa", "PROTEIN", 185, 189], ["other BH3", "TEST", 99, 108], ["apoptotic stimuli", "TEST", 136, 153]]], ["Bim, tBid and Puma can then directly activate Bax/Bak as described above.", [["Bim", "GENE_OR_GENE_PRODUCT", 0, 3], ["tBid", "GENE_OR_GENE_PRODUCT", 5, 9], ["Puma", "GENE_OR_GENE_PRODUCT", 14, 18], ["Bax", "GENE_OR_GENE_PRODUCT", 46, 49], ["Bak", "GENE_OR_GENE_PRODUCT", 50, 53], ["Bim", "PROTEIN", 0, 3], ["tBid", "PROTEIN", 5, 9], ["Puma", "PROTEIN", 14, 18], ["Bax", "PROTEIN", 46, 49], ["Bak", "PROTEIN", 50, 53], ["Bax/Bak", "TREATMENT", 46, 53], ["Bak", "OBSERVATION", 50, 53]]], ["This explains the effectiveness of BH3-mimetics in anti-cancer therapy.", [["BH3", "GENE_OR_GENE_PRODUCT", 35, 38], ["anti-cancer", "CANCER", 51, 62], ["BH3", "PROTEIN", 35, 38], ["BH3-mimetics", "TREATMENT", 35, 47], ["anti-cancer therapy", "TREATMENT", 51, 70]]], ["These are small molecule compounds that bind with high affinity to the hydrophobic pocket of Bcl-2 survival factors and thereby release pre-bound Bim, tBid and Puma for MOMP activation (Oltersdorf et al., 2005, Happo et al., 2012).", [["Bcl-2", "GENE_OR_GENE_PRODUCT", 93, 98], ["Bim", "GENE_OR_GENE_PRODUCT", 146, 149], ["tBid", "GENE_OR_GENE_PRODUCT", 151, 155], ["Puma", "GENE_OR_GENE_PRODUCT", 160, 164], ["MOMP", "GENE_OR_GENE_PRODUCT", 169, 173], ["Bcl-2 survival factors", "PROTEIN", 93, 115], ["Bim", "PROTEIN", 146, 149], ["tBid", "PROTEIN", 151, 155], ["Puma", "PROTEIN", 160, 164], ["MOMP", "PROTEIN", 169, 173], ["small molecule compounds", "PROBLEM", 10, 34], ["high affinity", "PROBLEM", 50, 63], ["small", "OBSERVATION_MODIFIER", 10, 15], ["molecule", "OBSERVATION", 16, 24], ["high affinity", "OBSERVATION_MODIFIER", 50, 63], ["Bcl", "ANATOMY", 93, 96]]], ["It turns out that many cancer cells do not only upregulate Bcl-2 survival factors but also Bim, tBid and Puma, a mechanism called \u201caddiction\u201d (Certo et al., 2006).", [["cancer cells", "ANATOMY", 23, 35], ["cancer", "DISEASE", 23, 29], ["cancer cells", "CELL", 23, 35], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 59, 64], ["Bim", "GENE_OR_GENE_PRODUCT", 91, 94], ["tBid", "GENE_OR_GENE_PRODUCT", 96, 100], ["Puma", "GENE_OR_GENE_PRODUCT", 105, 109], ["cancer cells", "CELL_TYPE", 23, 35], ["Bcl-2 survival factors", "PROTEIN", 59, 81], ["Bim", "PROTEIN", 91, 94], ["tBid", "PROTEIN", 96, 100], ["Puma", "PROTEIN", 105, 109], ["many cancer cells", "PROBLEM", 18, 35], ["Bcl", "TEST", 59, 62], ["cancer", "OBSERVATION", 23, 29], ["Puma", "ANATOMY", 105, 109]]], ["This may explain the high sensitivity of cancer cells to be killed by BH3-mimetics such as ABT-267, ABT-199 and others (Tse et al., 2008, Wilson et al., 2010, Vandenberg and Cory, 2013).", [["cancer cells", "ANATOMY", 41, 53], ["cancer", "DISEASE", 41, 47], ["ABT-267", "CHEMICAL", 91, 98], ["ABT-199", "CHEMICAL", 100, 107], ["ABT-267", "CHEMICAL", 91, 98], ["ABT-199", "CHEMICAL", 100, 107], ["cancer cells", "CELL", 41, 53], ["BH3", "GENE_OR_GENE_PRODUCT", 70, 73], ["ABT-267", "SIMPLE_CHEMICAL", 91, 98], ["ABT-199", "SIMPLE_CHEMICAL", 100, 107], ["cancer cells", "CELL_TYPE", 41, 53], ["BH3", "PROTEIN", 70, 73], ["cancer cells", "PROBLEM", 41, 53], ["ABT", "TEST", 91, 94], ["ABT", "TEST", 100, 103], ["cancer", "OBSERVATION", 41, 47]]], ["Apart from interacting with BH3-only proteins, Bcl-2 survival factors also sequester accidently activated Bax and Bak in healthy cells.", [["cells", "ANATOMY", 129, 134], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 47, 52], ["Bax", "GENE_OR_GENE_PRODUCT", 106, 109], ["Bak", "GENE_OR_GENE_PRODUCT", 114, 117], ["cells", "CELL", 129, 134], ["BH3", "PROTEIN", 28, 31], ["Bcl-2 survival factors", "PROTEIN", 47, 69], ["Bax", "PROTEIN", 106, 109], ["Bak", "PROTEIN", 114, 117], ["healthy cells", "CELL_TYPE", 121, 134], ["BH3", "TEST", 28, 31], ["Bcl", "TEST", 47, 50], ["healthy cells", "OBSERVATION", 121, 134]]], ["Since active Bax/Bak expose their BH3-domain, this region can interact with the hydrophobic pocket of Bcl-2 survival factors and hence Bax/Bak are inhibited (Chen et al., 2005, Willis et al., 2005, Willis et al., 2007, Uren et al., 2007).", [["Bax", "GENE_OR_GENE_PRODUCT", 13, 16], ["Bak", "GENE_OR_GENE_PRODUCT", 17, 20], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 102, 107], ["Bax", "GENE_OR_GENE_PRODUCT", 135, 138], ["Bak", "GENE_OR_GENE_PRODUCT", 139, 142], ["Bax", "PROTEIN", 13, 16], ["Bak", "PROTEIN", 17, 20], ["BH3", "PROTEIN", 34, 37], ["Bcl-2 survival factors", "PROTEIN", 102, 124], ["Bax", "PROTEIN", 135, 138], ["Bak", "PROTEIN", 139, 142], ["active Bax/Bak", "TREATMENT", 6, 20], ["Bax/Bak", "TREATMENT", 135, 142], ["active", "OBSERVATION_MODIFIER", 6, 12], ["Bax", "OBSERVATION", 13, 16], ["Bak", "OBSERVATION", 17, 20]]], ["This may also constitute one of the mechanisms by which MOM-inserted Bak is kept in check by Bcl-2 survival factors.", [["MOM", "GENE_OR_GENE_PRODUCT", 56, 59], ["Bak", "GENE_OR_GENE_PRODUCT", 69, 72], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 93, 98], ["Bak", "PROTEIN", 69, 72], ["Bcl-2 survival factors", "PROTEIN", 93, 115], ["MOM-inserted Bak", "TREATMENT", 56, 72]]], ["When large amounts of Bax/Bak are bound by Bcl-2 survival factors, BH3-only proteins can displace appreciable numbers of Bax/Bak molecules from Bcl-2 and therefore make more pore-forming proteins available for the activation of MOMP (Youle and Strasser, 2008, Borner and Andrews, 2014).", [["pore", "ANATOMY", 174, 178], ["Bax", "GENE_OR_GENE_PRODUCT", 22, 25], ["Bak", "GENE_OR_GENE_PRODUCT", 26, 29], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 43, 48], ["BH3", "GENE_OR_GENE_PRODUCT", 67, 70], ["Bax", "GENE_OR_GENE_PRODUCT", 121, 124], ["Bak", "GENE_OR_GENE_PRODUCT", 125, 128], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 144, 149], ["MOMP", "GENE_OR_GENE_PRODUCT", 228, 232], ["Bax", "PROTEIN", 22, 25], ["Bak", "PROTEIN", 26, 29], ["Bcl-2 survival factors", "PROTEIN", 43, 65], ["BH3", "PROTEIN", 67, 70], ["Bax", "PROTEIN", 121, 124], ["Bak molecules", "PROTEIN", 125, 138], ["Bcl-2", "PROTEIN", 144, 149], ["pore-forming proteins", "PROTEIN", 174, 195], ["Bax/Bak", "TREATMENT", 22, 29], ["Bcl", "TEST", 43, 46], ["BH3", "TEST", 67, 70], ["Bax/Bak molecules", "TEST", 121, 138], ["Bcl", "TEST", 144, 147], ["large", "OBSERVATION_MODIFIER", 5, 10], ["amounts", "OBSERVATION_MODIFIER", 11, 18]]], ["Since Bcl-2 survival factors are able to sequester both the \u201cactivators\u201d (BH3-only proteins) and the \u201ceffectors\u201d (Bax/Bak) of MOMP and MOMP triggers both caspase-dependent and -independent cell death, overexpression of these survival factors is the most efficient way to block apoptosis, even allowing clonogenic survival (which caspase inhibitors are not able to do) (Borner, 2003).Intrinsic apoptotic pathway and its inhibition by viral proteinsGiven the importance of the intrinsic mitochondrial pathway for apoptosis induced by numerous stimuli, viruses have acquired gene products which mimick the action of Bcl-2 survival factors to potently inhibit MOMP in their host cells.", [["cell", "ANATOMY", 189, 193], ["mitochondrial", "ANATOMY", 485, 498], ["cells", "ANATOMY", 675, 680], ["death", "DISEASE", 194, 199], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 6, 11], ["BH3-only proteins", "GENE_OR_GENE_PRODUCT", 74, 91], ["Bax", "GENE_OR_GENE_PRODUCT", 114, 117], ["Bak", "GENE_OR_GENE_PRODUCT", 118, 121], ["MOMP", "GENE_OR_GENE_PRODUCT", 126, 130], ["MOMP", "CELLULAR_COMPONENT", 135, 139], ["caspase", "GENE_OR_GENE_PRODUCT", 154, 161], ["cell", "CELL", 189, 193], ["caspase", "GENE_OR_GENE_PRODUCT", 329, 336], ["mitochondrial", "CELLULAR_COMPONENT", 485, 498], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 613, 618], ["MOMP", "GENE_OR_GENE_PRODUCT", 656, 660], ["cells", "CELL", 675, 680], ["Bcl-2 survival factors", "PROTEIN", 6, 28], ["\u201cactivators\u201d", "PROTEIN", 60, 72], ["BH3", "PROTEIN", 74, 77], ["\u201ceffectors", "PROTEIN", 101, 111], ["\u201d", "PROTEIN", 111, 112], ["Bax", "PROTEIN", 114, 117], ["Bak", "PROTEIN", 118, 121], ["MOMP", "PROTEIN", 126, 130], ["MOMP", "PROTEIN", 135, 139], ["caspase", "PROTEIN", 154, 161], ["survival factors", "PROTEIN", 225, 241], ["viral proteins", "PROTEIN", 433, 447], ["Bcl-2 survival factors", "PROTEIN", 613, 635], ["MOMP", "PROTEIN", 656, 660], ["host cells", "CELL_TYPE", 670, 680], ["Bcl-2 survival factors", "PROBLEM", 6, 28], ["Bax/Bak", "TREATMENT", 114, 121], ["MOMP", "PROBLEM", 126, 130], ["MOMP", "PROBLEM", 135, 139], ["independent cell death", "PROBLEM", 177, 199], ["these survival factors", "PROBLEM", 219, 241], ["block apoptosis", "PROBLEM", 271, 286], ["clonogenic survival", "TREATMENT", 302, 321], ["caspase inhibitors", "TREATMENT", 329, 347], ["Intrinsic apoptotic pathway", "PROBLEM", 383, 410], ["viral proteins", "PROBLEM", 433, 447], ["the intrinsic mitochondrial pathway", "TREATMENT", 471, 506], ["apoptosis", "PROBLEM", 511, 520], ["viruses", "PROBLEM", 550, 557], ["acquired gene products", "TREATMENT", 563, 585], ["Bcl-2 survival factors", "PROBLEM", 613, 635], ["apoptotic pathway", "OBSERVATION", 393, 410], ["host cells", "OBSERVATION", 670, 680]]], ["Functional homologs of Bcl-2 are collectively called vBcl-2s.", [["Bcl-2", "GENE_OR_GENE_PRODUCT", 23, 28], ["vBcl-2s", "GENE_OR_GENE_PRODUCT", 53, 60], ["Bcl-2", "PROTEIN", 23, 28], ["vBcl-2s", "PROTEIN", 53, 60], ["Bcl", "TEST", 23, 26], ["vBcl", "TEST", 53, 57]]], ["They are present in various members of the Poxviridae (F1L, N1L, M11L, A179L, ORFV125), Herpesviridae (BHRF1, BALF1, vMIA, KSBcl-2, MHVBcl-2), Adenoviridae (E1B-19K) and Birnaviridae (VP5) family of viruses (Fig. 2) (Benedict et al., 2002, Galluzzi et al., 2008, Postigo and Ferrer, 2009).", [["Poxviridae", "GENE_OR_GENE_PRODUCT", 43, 53], ["F1L", "GENE_OR_GENE_PRODUCT", 55, 58], ["N1L", "GENE_OR_GENE_PRODUCT", 60, 63], ["M11L", "GENE_OR_GENE_PRODUCT", 65, 69], ["A179L", "GENE_OR_GENE_PRODUCT", 71, 76], ["ORFV125", "GENE_OR_GENE_PRODUCT", 78, 85], ["Herpesviridae", "GENE_OR_GENE_PRODUCT", 88, 101], ["BHRF1", "GENE_OR_GENE_PRODUCT", 103, 108], ["BALF1", "GENE_OR_GENE_PRODUCT", 110, 115], ["vMIA", "GENE_OR_GENE_PRODUCT", 117, 121], ["KSBcl-2", "GENE_OR_GENE_PRODUCT", 123, 130], ["MHVBcl-2", "GENE_OR_GENE_PRODUCT", 132, 140], ["Adenoviridae", "GENE_OR_GENE_PRODUCT", 143, 155], ["E1B-19K", "GENE_OR_GENE_PRODUCT", 157, 164], ["Birnaviridae", "GENE_OR_GENE_PRODUCT", 170, 182], ["VP5", "GENE_OR_GENE_PRODUCT", 184, 187], ["M11L", "PROTEIN", 65, 69], ["A179L", "PROTEIN", 71, 76], ["ORFV125", "PROTEIN", 78, 85], ["Herpesviridae", "PROTEIN", 88, 101], ["BHRF1", "PROTEIN", 103, 108], ["BALF1", "PROTEIN", 110, 115], ["MIA", "PROTEIN", 118, 121], ["KSBcl", "PROTEIN", 123, 128], ["MHVBcl", "PROTEIN", 132, 138], ["Adenoviridae", "PROTEIN", 143, 155], ["E1B", "PROTEIN", 157, 160], ["19K", "PROTEIN", 161, 164], ["Birnaviridae (VP5) family", "PROTEIN", 170, 195], ["Herpesviridae (BHRF1", "TREATMENT", 88, 108], ["BALF1", "TEST", 110, 115], ["vMIA", "TREATMENT", 117, 121], ["KSBcl", "TEST", 123, 128], ["MHVBcl", "TEST", 132, 138], ["Adenoviridae (E1B", "TREATMENT", 143, 160], ["Birnaviridae", "TREATMENT", 170, 182]]], ["While some of them like E1B-19K have extensive sequence homology with cellular Bcl-2 survival factors in all regions (White, 1998), others such as FPV039 from Fowlpoxvirus only retain sequence homology with the BH1 and BH2 domains while ORFV125 of Parapoxvirus is homologous in the BH1 and BH3 regions (Galluzzi et al., 2008, Westphal et al., 2007, Banadyga et al., 2007).", [["cellular", "ANATOMY", 70, 78], ["E1B", "GENE_OR_GENE_PRODUCT", 24, 27], ["19K", "GENE_OR_GENE_PRODUCT", 28, 31], ["cellular", "CELL", 70, 78], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 79, 84], ["FPV039", "GENE_OR_GENE_PRODUCT", 147, 153], ["BH1", "GENE_OR_GENE_PRODUCT", 211, 214], ["ORFV125", "GENE_OR_GENE_PRODUCT", 237, 244], ["Parapoxvirus", "GENE_OR_GENE_PRODUCT", 248, 260], ["BH1", "GENE_OR_GENE_PRODUCT", 282, 285], ["E1B", "PROTEIN", 24, 27], ["19K", "PROTEIN", 28, 31], ["cellular Bcl-2 survival factors", "PROTEIN", 70, 101], ["FPV039", "PROTEIN", 147, 153], ["BH1 and BH2 domains", "DNA", 211, 230], ["ORFV125", "DNA", 237, 244], ["Parapoxvirus", "DNA", 248, 260], ["BH1 and BH3 regions", "DNA", 282, 301], ["E1B", "TEST", 24, 27], ["extensive sequence homology", "TEST", 37, 64], ["cellular Bcl", "TEST", 70, 82], ["survival factors", "PROBLEM", 85, 101], ["Fowlpoxvirus", "TREATMENT", 159, 171], ["the BH1", "TEST", 207, 214], ["BH2 domains", "TEST", 219, 230], ["Parapoxvirus", "TREATMENT", 248, 260], ["cellular Bcl", "OBSERVATION", 70, 82], ["BH1", "ANATOMY", 282, 285], ["BH3", "ANATOMY", 290, 293], ["regions", "ANATOMY_MODIFIER", 294, 301]]], ["Other vBcl-2s such as vaccinia virus F1L and N1L, myxoma virus M11L and vMIA from cytomegalovirus do not even show any sequence homology with mammalian Bcl-2 proteins (Galluzzi et al., 2008).", [["myxoma", "DISEASE", 50, 56], ["vBcl-2s", "GENE_OR_GENE_PRODUCT", 6, 13], ["vaccinia virus F1L", "ORGANISM", 22, 40], ["N1L, myxoma virus M11L", "ORGANISM", 45, 67], ["vMIA", "GENE_OR_GENE_PRODUCT", 72, 76], ["cytomegalovirus", "ORGANISM", 82, 97], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 152, 157], ["vBcl-2s", "PROTEIN", 6, 13], ["mammalian Bcl-2 proteins", "PROTEIN", 142, 166], ["vaccinia virus", "SPECIES", 22, 36], ["myxoma virus", "SPECIES", 50, 62], ["vaccinia virus", "SPECIES", 22, 36], ["Other vBcl", "TEST", 0, 10], ["vaccinia virus F1L", "TREATMENT", 22, 40], ["N1L", "TREATMENT", 45, 48], ["myxoma virus M11L", "PROBLEM", 50, 67], ["vMIA", "PROBLEM", 72, 76], ["cytomegalovirus", "PROBLEM", 82, 97], ["mammalian Bcl", "TEST", 142, 155], ["myxoma", "OBSERVATION", 50, 56]]], ["However, the crystal structure of some of these vBcl-2s reveals a close conservation of the Bcl-2 family structural conformation.", [["vBcl-2s", "GENE_OR_GENE_PRODUCT", 48, 55], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 92, 97], ["vBcl-2s", "PROTEIN", 48, 55], ["Bcl", "PROTEIN", 92, 95], ["these vBcl", "TEST", 42, 52], ["crystal", "OBSERVATION_MODIFIER", 13, 20]]], ["Thus, it is not the primary amino acid sequence and/or the conserved BH-domains per se, which determine the function of a Bcl-2 survival factor but the helical bundle structure that makes up the hydrophobic pocket where BH3-only proteins and Bax/Bak are sequestered.Intrinsic apoptotic pathway and its inhibition by viral proteinsOther viral proteins inhibit the intrinsic, mitochondrial signaling pathway by modulating Bcl-2 family members on the transcriptional level or via post-translational modifications.", [["mitochondrial", "ANATOMY", 374, 387], ["amino acid", "CHEMICAL", 28, 38], ["amino acid", "CHEMICAL", 28, 38], ["amino acid", "AMINO_ACID", 28, 38], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 122, 127], ["Bax", "GENE_OR_GENE_PRODUCT", 242, 245], ["Bak", "GENE_OR_GENE_PRODUCT", 246, 249], ["mitochondrial", "CELLULAR_COMPONENT", 374, 387], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 420, 425], ["primary amino acid sequence", "PROTEIN", 20, 47], ["BH-domains", "PROTEIN", 69, 79], ["Bcl-2 survival factor", "PROTEIN", 122, 143], ["helical bundle structure", "PROTEIN", 152, 176], ["hydrophobic pocket", "PROTEIN", 195, 213], ["BH3", "PROTEIN", 220, 223], ["Bax", "PROTEIN", 242, 245], ["Bak", "PROTEIN", 246, 249], ["viral proteins", "PROTEIN", 316, 330], ["viral proteins", "PROTEIN", 336, 350], ["Bcl-2 family members", "PROTEIN", 420, 440], ["the primary amino acid sequence", "TEST", 16, 47], ["a Bcl-2 survival factor", "PROBLEM", 120, 143], ["the helical bundle structure", "PROBLEM", 148, 176], ["the hydrophobic pocket", "PROBLEM", 191, 213], ["BH3", "TEST", 220, 223], ["Bax/Bak", "TREATMENT", 242, 249], ["Intrinsic apoptotic pathway", "PROBLEM", 266, 293], ["viral proteins", "PROBLEM", 316, 330], ["Other viral proteins", "TEST", 330, 350], ["apoptotic pathway", "OBSERVATION", 276, 293]]], ["The tumor suppressor p53 is known to induce the transcription of the BH3-only proteins Noxa and Puma in response to genotoxic stress (Oda et al., 2000, Nakano and Vousden, 2001) and growth factor deprivation (Jabbour et al., 2010) contributing to the elimination of stressed and damaged cells (Fig. 2).", [["tumor", "ANATOMY", 4, 9], ["cells", "ANATOMY", 287, 292], ["tumor", "DISEASE", 4, 9], ["tumor", "CANCER", 4, 9], ["p53", "GENE_OR_GENE_PRODUCT", 21, 24], ["Noxa", "GENE_OR_GENE_PRODUCT", 87, 91], ["Puma", "GENE_OR_GENE_PRODUCT", 96, 100], ["cells", "CELL", 287, 292], ["tumor suppressor p53", "PROTEIN", 4, 24], ["BH3-only proteins", "PROTEIN", 69, 86], ["Noxa", "PROTEIN", 87, 91], ["Puma", "PROTEIN", 96, 100], ["growth factor", "PROTEIN", 182, 195], ["damaged cells", "CELL_TYPE", 279, 292], ["The tumor suppressor p53", "TREATMENT", 0, 24], ["the BH3", "TEST", 65, 72], ["proteins Noxa", "PROBLEM", 78, 91], ["growth factor deprivation", "PROBLEM", 182, 207], ["stressed and damaged cells", "PROBLEM", 266, 292], ["tumor", "OBSERVATION", 4, 9], ["suppressor p53", "OBSERVATION", 10, 24], ["genotoxic stress", "OBSERVATION", 116, 132], ["damaged cells", "OBSERVATION", 279, 292]]], ["Cells lacking functional p53 survive and proliferate and accumulate gene mutations eventually leading to cancer (Harvey et al., 1993).", [["Cells", "ANATOMY", 0, 5], ["cancer", "ANATOMY", 105, 111], ["cancer", "DISEASE", 105, 111], ["Cells", "CELL", 0, 5], ["p53", "GENE_OR_GENE_PRODUCT", 25, 28], ["cancer", "CANCER", 105, 111], ["p53", "PROTEIN", 25, 28], ["accumulate gene mutations", "PROBLEM", 57, 82], ["cancer", "PROBLEM", 105, 111], ["functional p53", "OBSERVATION", 14, 28]]], ["Also, p53-deficient mice are more prone to certain viral infections, indicating that p53 is not only crucial to prevent cancer but also to induce apoptosis of some infected host cells.", [["cancer", "ANATOMY", 120, 126], ["cells", "ANATOMY", 178, 183], ["viral infections", "DISEASE", 51, 67], ["cancer", "DISEASE", 120, 126], ["p53", "GENE_OR_GENE_PRODUCT", 6, 9], ["mice", "ORGANISM", 20, 24], ["p53", "GENE_OR_GENE_PRODUCT", 85, 88], ["cancer", "CANCER", 120, 126], ["host cells", "CELL", 173, 183], ["p53", "PROTEIN", 6, 9], ["p53", "PROTEIN", 85, 88], ["infected host cells", "CELL_TYPE", 164, 183], ["mice", "SPECIES", 20, 24], ["mice", "SPECIES", 20, 24], ["p53-deficient mice", "TREATMENT", 6, 24], ["viral infections", "PROBLEM", 51, 67], ["p53", "PROBLEM", 85, 88], ["cancer", "PROBLEM", 120, 126], ["some infected host cells", "PROBLEM", 159, 183], ["infections", "OBSERVATION", 57, 67], ["cancer", "OBSERVATION", 120, 126], ["infected", "OBSERVATION_MODIFIER", 164, 172], ["host cells", "OBSERVATION", 173, 183]]], ["Therefore, viruses have evolved strategies to inactivate p53.", [["p53", "GENE_OR_GENE_PRODUCT", 57, 60], ["p53", "PROTEIN", 57, 60], ["viruses", "PROBLEM", 11, 18], ["viruses", "OBSERVATION", 11, 18]]], ["The SV40 large T antigen binds to p53 and sequesters it in an inactive complex (Lane and Crawford, 1979, Linzer and Levine, 1979).", [["SV40", "ORGANISM", 4, 8], ["large T antigen", "GENE_OR_GENE_PRODUCT", 9, 24], ["p53", "GENE_OR_GENE_PRODUCT", 34, 37], ["SV40 large T antigen", "PROTEIN", 4, 24], ["p53", "PROTEIN", 34, 37], ["inactive complex", "PROTEIN", 62, 78], ["The SV40 large T antigen binds", "PROBLEM", 0, 30], ["large", "OBSERVATION_MODIFIER", 9, 14], ["inactive", "OBSERVATION_MODIFIER", 62, 70], ["complex", "OBSERVATION_MODIFIER", 71, 78]]], ["The human papillomavirus (HPV) E6 protein and the adenovirus E1B-55K protein induce the ubiquitination and proteasomal degradation of p53 (Scheffner et al., 1990, Werness et al., 1990, Steegenga et al., 1998, Querido et al., 2001).", [["proteasomal", "ANATOMY", 107, 118], ["human papillomavirus", "ORGANISM", 4, 24], ["HPV", "ORGANISM", 26, 29], ["E6", "GENE_OR_GENE_PRODUCT", 31, 33], ["adenovirus", "ORGANISM", 50, 60], ["E1B-55K", "GENE_OR_GENE_PRODUCT", 61, 68], ["p53", "GENE_OR_GENE_PRODUCT", 134, 137], ["human papillomavirus (HPV) E6 protein", "PROTEIN", 4, 41], ["adenovirus E1B-55K protein", "PROTEIN", 50, 76], ["p53", "PROTEIN", 134, 137], ["human", "SPECIES", 4, 9], ["human papillomavirus", "SPECIES", 4, 24], ["HPV", "SPECIES", 26, 29], ["The human papillomavirus (HPV) E6 protein", "TEST", 0, 41], ["the adenovirus E1B", "TEST", 46, 64], ["K protein", "TEST", 67, 76], ["the ubiquitination", "TEST", 84, 102], ["proteasomal degradation of p53", "PROBLEM", 107, 137]]], ["Also, the X protein of hepatitis B virus (HBx) interacts with p53 and prevents its transcriptional activation of target genes, thereby inhibiting apoptosis (Wang, 1995) (Fig. 2).", [["hepatitis B", "DISEASE", 23, 34], ["hepatitis B virus", "ORGANISM", 23, 40], ["HBx", "GENE_OR_GENE_PRODUCT", 42, 45], ["p53", "GENE_OR_GENE_PRODUCT", 62, 65], ["X protein", "PROTEIN", 10, 19], ["HBx", "PROTEIN", 42, 45], ["p53", "PROTEIN", 62, 65], ["target genes", "DNA", 113, 125], ["hepatitis B virus", "SPECIES", 23, 40], ["hepatitis B virus", "SPECIES", 23, 40], ["hepatitis B virus (HBx)", "TREATMENT", 23, 46], ["p53", "TREATMENT", 62, 65], ["hepatitis", "OBSERVATION", 23, 32]]], ["A similar strategy is used by the measles virus V protein, which blocks apoptosis by sequestering the p53 homolog p73 (Cruz et al., 2006).", [["measles virus V", "ORGANISM", 34, 49], ["p53", "GENE_OR_GENE_PRODUCT", 102, 105], ["p73", "GENE_OR_GENE_PRODUCT", 114, 117], ["measles virus V protein", "PROTEIN", 34, 57], ["p53 homolog p73", "PROTEIN", 102, 117], ["measles virus", "SPECIES", 34, 47], ["measles virus", "SPECIES", 34, 47], ["the measles virus V protein", "PROBLEM", 30, 57]]], ["A p53-independent mechanism to inhibit MOMP is exploited by the human T cell leukemia virus type I (HTLV-1) which uses the Tax protein to activate the Bcl-xL promoter and to repress the Bax promoter (Tsukahara et al., 1999).", [["p53", "GENE_OR_GENE_PRODUCT", 2, 5], ["MOMP", "GENE_OR_GENE_PRODUCT", 39, 43], ["human T cell leukemia virus type I", "ORGANISM", 64, 98], ["HTLV-1", "ORGANISM", 100, 106], ["Tax", "GENE_OR_GENE_PRODUCT", 123, 126], ["Bcl-xL", "GENE_OR_GENE_PRODUCT", 151, 157], ["Bax", "GENE_OR_GENE_PRODUCT", 186, 189], ["p53", "PROTEIN", 2, 5], ["MOMP", "PROTEIN", 39, 43], ["Tax protein", "PROTEIN", 123, 134], ["Bcl-xL promoter", "DNA", 151, 166], ["Bax promoter", "DNA", 186, 198], ["human", "SPECIES", 64, 69], ["leukemia virus", "SPECIES", 77, 91], ["HTLV-1", "SPECIES", 100, 106], ["human T cell leukemia virus type I", "SPECIES", 64, 98], ["HTLV-1", "SPECIES", 100, 106], ["MOMP", "PROBLEM", 39, 43], ["the human T cell leukemia virus type I (HTLV", "PROBLEM", 60, 104], ["the Tax protein", "TREATMENT", 119, 134], ["the Bcl-xL promoter", "TREATMENT", 147, 166], ["cell leukemia", "OBSERVATION", 72, 85]]], ["Moreover, viruses can effectively block both the intrinsic mitochondrial and the extrinsic death receptor signaling by engaging the transcription factor NF\u03baB (Sun and Cesarman, 2011).", [["mitochondrial", "ANATOMY", 59, 72], ["death", "DISEASE", 91, 96], ["mitochondrial", "CELLULAR_COMPONENT", 59, 72], ["NF\u03baB", "GENE_OR_GENE_PRODUCT", 153, 157], ["transcription factor", "PROTEIN", 132, 152], ["NF\u03baB", "PROTEIN", 153, 157], ["Sun", "PROTEIN", 159, 162], ["viruses", "PROBLEM", 10, 17], ["viruses", "OBSERVATION", 10, 17]]], ["NF\u03baB induces transcription of the survival factor Bcl-xL, the caspase-8 inhibitor FLIP or inhibitor of apoptosis proteins (IAPs), which often directly or indirectly act as caspase inhibitors (DiDonato et al., 2012).", [["NF\u03baB", "GENE_OR_GENE_PRODUCT", 0, 4], ["Bcl-xL", "GENE_OR_GENE_PRODUCT", 50, 56], ["caspase-8", "GENE_OR_GENE_PRODUCT", 62, 71], ["FLIP", "GENE_OR_GENE_PRODUCT", 82, 86], ["inhibitor of apoptosis proteins", "GENE_OR_GENE_PRODUCT", 90, 121], ["IAPs", "GENE_OR_GENE_PRODUCT", 123, 127], ["caspase", "GENE_OR_GENE_PRODUCT", 172, 179], ["NF\u03baB", "PROTEIN", 0, 4], ["survival factor", "PROTEIN", 34, 49], ["Bcl-xL", "PROTEIN", 50, 56], ["caspase-8 inhibitor", "PROTEIN", 62, 81], ["FLIP", "PROTEIN", 82, 86], ["apoptosis proteins", "PROTEIN", 103, 121], ["IAPs", "PROTEIN", 123, 127], ["the survival factor Bcl-xL", "TREATMENT", 30, 56], ["the caspase-8 inhibitor FLIP", "TREATMENT", 58, 86], ["apoptosis proteins", "PROBLEM", 103, 121]]], ["For example, herpes simplex virus-1 (HSV-1), through its envelope glycoprotein D uses a TNFR family member, herpes virus entry mediator (HVEM) for host surface binding and infection.", [["surface", "ANATOMY", 152, 159], ["herpes simplex", "DISEASE", 13, 27], ["infection", "DISEASE", 172, 181], ["herpes simplex virus-1", "ORGANISM", 13, 35], ["HSV-1", "ORGANISM", 37, 42], ["glycoprotein D", "GENE_OR_GENE_PRODUCT", 66, 80], ["TNFR", "GENE_OR_GENE_PRODUCT", 88, 92], ["herpes virus", "ORGANISM", 108, 120], ["HVEM", "GENE_OR_GENE_PRODUCT", 137, 141], ["envelope glycoprotein D", "PROTEIN", 57, 80], ["TNFR family member", "PROTEIN", 88, 106], ["herpes virus entry mediator", "PROTEIN", 108, 135], ["HVEM", "PROTEIN", 137, 141], ["herpes simplex virus-1", "SPECIES", 13, 35], ["HSV-1", "SPECIES", 37, 42], ["herpes virus", "SPECIES", 108, 120], ["herpes simplex virus-1", "SPECIES", 13, 35], ["HSV-1", "SPECIES", 37, 42], ["herpes simplex virus", "TEST", 13, 33], ["HSV", "TEST", 37, 40], ["a TNFR family member", "TREATMENT", 86, 106], ["herpes virus entry mediator", "TREATMENT", 108, 135], ["host surface binding", "PROBLEM", 147, 167], ["infection", "PROBLEM", 172, 181], ["infection", "OBSERVATION", 172, 181]]], ["Activation of this receptor triggers a signaling cascade that leads to NF\u03baB activation and apoptosis inhibition (Medici et al., 2003, Sciortino et al., 2008).", [["NF\u03ba", "GENE_OR_GENE_PRODUCT", 71, 74], ["B", "GENE_OR_GENE_PRODUCT", 74, 75], ["NF\u03ba", "PROTEIN", 71, 74], ["a signaling cascade", "TREATMENT", 37, 56]]], ["Similarly, the major B cell-transforming protein in EBV, LMP1, mimics activated CD40 and engages TRADD and TRAFs, which are crucial adaptors used by TNFR to activate NF\u03baB.", [["B cell", "ANATOMY", 21, 27], ["B cell", "CELL", 21, 27], ["EBV", "ORGANISM", 52, 55], ["LMP1", "GENE_OR_GENE_PRODUCT", 57, 61], ["CD40", "GENE_OR_GENE_PRODUCT", 80, 84], ["TRADD", "GENE_OR_GENE_PRODUCT", 97, 102], ["TRAFs", "GENE_OR_GENE_PRODUCT", 107, 112], ["TNFR", "GENE_OR_GENE_PRODUCT", 149, 153], ["NF\u03baB.", "GENE_OR_GENE_PRODUCT", 166, 171], ["major B cell-transforming protein", "PROTEIN", 15, 48], ["LMP1", "PROTEIN", 57, 61], ["CD40", "PROTEIN", 80, 84], ["TRADD", "PROTEIN", 97, 102], ["TRAFs", "PROTEIN", 107, 112], ["TNFR", "PROTEIN", 149, 153], ["NF\u03ba", "PROTEIN", 166, 169], ["EBV", "SPECIES", 52, 55], ["TRADD and TRAFs", "TREATMENT", 97, 112], ["B cell", "OBSERVATION", 21, 27]]], ["Thereby LMP1 prevents B cells from localizing to the follicle and protects cells harboring latent virus from interactions with T cells (Uchida et al., 1999).", [["B cells", "ANATOMY", 22, 29], ["follicle", "ANATOMY", 53, 61], ["cells", "ANATOMY", 75, 80], ["T cells", "ANATOMY", 127, 134], ["LMP1", "GENE_OR_GENE_PRODUCT", 8, 12], ["B cells", "CELL", 22, 29], ["follicle", "MULTI-TISSUE_STRUCTURE", 53, 61], ["cells", "CELL", 75, 80], ["latent virus", "ORGANISM", 91, 103], ["T cells", "CELL", 127, 134], ["LMP1", "PROTEIN", 8, 12], ["B cells", "CELL_TYPE", 22, 29], ["T cells", "CELL_TYPE", 127, 134], ["B cells", "PROBLEM", 22, 29], ["protects cells harboring latent virus", "PROBLEM", 66, 103], ["LMP1", "OBSERVATION", 8, 12], ["B cells", "OBSERVATION", 22, 29], ["latent virus", "OBSERVATION", 91, 103]]], ["Finally, the Nef protein of HIV (Wolf et al., 2001) and the U(S)3 protein kinase of HSV-1 (Munger and Roizman, 2001) were found to mediate phosphorylation of the BH3-only protein Bad, thereby preventing it from inducing apoptosis.Intrinsic apoptotic pathway and its inhibition by viral proteinsAnother possibility for viruses to interfere with apoptosis signaling is to block caspases.", [["Nef", "GENE_OR_GENE_PRODUCT", 13, 16], ["HIV", "ORGANISM", 28, 31], ["U(S)3", "GENE_OR_GENE_PRODUCT", 60, 65], ["HSV-1", "ORGANISM", 84, 89], ["Bad", "GENE_OR_GENE_PRODUCT", 179, 182], ["caspases", "GENE_OR_GENE_PRODUCT", 376, 384], ["Nef protein", "PROTEIN", 13, 24], ["U(S)3 protein kinase", "PROTEIN", 60, 80], ["BH3", "PROTEIN", 162, 165], ["Bad", "PROTEIN", 179, 182], ["viral proteins", "PROTEIN", 280, 294], ["caspases", "PROTEIN", 376, 384], ["HIV", "SPECIES", 28, 31], ["HIV", "SPECIES", 28, 31], ["HSV-1", "SPECIES", 84, 89], ["the Nef protein", "TEST", 9, 24], ["HIV", "PROBLEM", 28, 31], ["the U(S", "TEST", 56, 63], ["protein kinase", "TEST", 66, 80], ["HSV", "TEST", 84, 87], ["Roizman", "TEST", 102, 109], ["the BH3", "TEST", 158, 165], ["inducing apoptosis", "PROBLEM", 211, 229], ["Intrinsic apoptotic pathway", "PROBLEM", 230, 257], ["viral proteins", "PROBLEM", 280, 294], ["viruses", "PROBLEM", 318, 325], ["apoptosis signaling", "PROBLEM", 344, 363], ["block caspases", "PROBLEM", 370, 384], ["apoptosis", "OBSERVATION", 220, 229], ["apoptotic pathway", "OBSERVATION", 240, 257]]], ["As pointed out above cowpox viruses can effectively block initiator caspase-8 of the extrinsic death receptor pathway because this pathway is strictly caspase-dependent (Zhou et al., 1997).", [["death", "DISEASE", 95, 100], ["cowpox viruses", "ORGANISM", 21, 35], ["caspase-8", "GENE_OR_GENE_PRODUCT", 68, 77], ["caspase", "GENE_OR_GENE_PRODUCT", 151, 158], ["initiator caspase-8", "PROTEIN", 58, 77], ["cowpox viruses", "SPECIES", 21, 35], ["cowpox viruses", "PROBLEM", 21, 35], ["the extrinsic death receptor pathway", "TREATMENT", 81, 117]]], ["The major initiator and effector caspases of the intrinsic mitochondrial pathway, caspase-9 and caspase-3/-7 are held in check by cellular IAPs, in particular XIAP (Fig. 2) (Deveraux and Reed, 1999, Shi, 2002).", [["mitochondrial", "ANATOMY", 59, 72], ["cellular", "ANATOMY", 130, 138], ["caspases", "GENE_OR_GENE_PRODUCT", 33, 41], ["mitochondrial", "CELLULAR_COMPONENT", 59, 72], ["caspase-9", "GENE_OR_GENE_PRODUCT", 82, 91], ["caspase-3", "GENE_OR_GENE_PRODUCT", 96, 105], ["-7", "GENE_OR_GENE_PRODUCT", 106, 108], ["cellular", "CELL", 130, 138], ["IAPs", "GENE_OR_GENE_PRODUCT", 139, 143], ["XIAP", "GENE_OR_GENE_PRODUCT", 159, 163], ["effector caspases", "PROTEIN", 24, 41], ["caspase-9", "PROTEIN", 82, 91], ["caspase-3/-7", "PROTEIN", 96, 108], ["cellular IAPs", "PROTEIN", 130, 143], ["XIAP", "PROTEIN", 159, 163], ["effector caspases", "TREATMENT", 24, 41], ["the intrinsic mitochondrial pathway", "TREATMENT", 45, 80], ["caspase", "TREATMENT", 82, 89], ["caspase", "TREATMENT", 96, 103], ["cellular IAPs", "TEST", 130, 143], ["effector caspases", "OBSERVATION", 24, 41]]], ["However, MOMP also leads to caspase-independent death signaling (Fig. 2).", [["death", "DISEASE", 48, 53], ["MOMP", "CELLULAR_COMPONENT", 9, 13], ["caspase", "GENE_OR_GENE_PRODUCT", 28, 35], ["MOMP", "PROTEIN", 9, 13], ["caspase", "PROTEIN", 28, 35]]], ["Therefore blocking caspase-9 and/or -3 by viruses may not be sufficient to save infected host cells from apoptosis.", [["cells", "ANATOMY", 94, 99], ["caspase-9", "GENE_OR_GENE_PRODUCT", 19, 28], ["-3", "GENE_OR_GENE_PRODUCT", 36, 38], ["cells", "CELL", 94, 99], ["caspase-9 and/or -3", "PROTEIN", 19, 38], ["infected host cells", "CELL_TYPE", 80, 99], ["blocking caspase", "TREATMENT", 10, 26], ["apoptosis", "PROBLEM", 105, 114], ["host cells", "OBSERVATION", 89, 99], ["apoptosis", "OBSERVATION_MODIFIER", 105, 114]]], ["This explains why an IAP-ortholog strategy is infrequently used in mammalian viruses (in contrast to baculoviruses infecting insect cells) (Taylor and Barry, 2006).", [["cells", "ANATOMY", 132, 137], ["IAP", "GENE_OR_GENE_PRODUCT", 21, 24], ["mammalian viruses", "ORGANISM", 67, 84], ["insect cells", "CELL", 125, 137], ["IAP", "DNA", 21, 24], ["insect cells", "CELL_TYPE", 125, 137], ["an IAP", "TEST", 18, 24], ["ortholog strategy", "PROBLEM", 25, 42], ["mammalian viruses", "PROBLEM", 67, 84], ["viruses", "OBSERVATION", 77, 84]]], ["Accordingly, although African swine fever virus and Entomopoxviruses encode viral vIAP such as MsEPV and AmEPV these proteins do not contribute to the virulence of these viruses (Neilan, 1993, Taylor and Barry, 2006) (Fig. 2).Killing of virally infected cells by CTLs and NK cells ::: Mechanisms by which the intrinsic, mitochondrial apoptosis pathway is activated after viral infectionIn addition to the activation of the Fas signaling pathway (described above), CTLs and NK cells also kill virally infected target cells via the perforin/granzyme pathway.", [["cells", "ANATOMY", 254, 259], ["CTLs", "ANATOMY", 263, 267], ["NK cells", "ANATOMY", 272, 280], ["mitochondrial", "ANATOMY", 320, 333], ["CTLs", "ANATOMY", 464, 468], ["NK cells", "ANATOMY", 473, 481], ["cells", "ANATOMY", 516, 521], ["swine fever", "DISEASE", 30, 41], ["viral infection", "DISEASE", 371, 386], ["African swine fever virus", "ORGANISM", 22, 47], ["Entomopoxviruses", "GENE_OR_GENE_PRODUCT", 52, 68], ["vIAP", "GENE_OR_GENE_PRODUCT", 82, 86], ["MsEPV", "GENE_OR_GENE_PRODUCT", 95, 100], ["AmEPV", "GENE_OR_GENE_PRODUCT", 105, 110], ["cells", "CELL", 254, 259], ["CTLs", "CELL", 263, 267], ["NK cells", "CELL", 272, 280], ["mitochondrial", "CELLULAR_COMPONENT", 320, 333], ["Fas", "GENE_OR_GENE_PRODUCT", 423, 426], ["CTLs", "CELL", 464, 468], ["NK cells", "CELL", 473, 481], ["cells", "CELL", 516, 521], ["perforin", "GENE_OR_GENE_PRODUCT", 530, 538], ["granzyme", "GENE_OR_GENE_PRODUCT", 539, 547], ["viral vIAP", "PROTEIN", 76, 86], ["MsEPV", "PROTEIN", 95, 100], ["AmEPV", "PROTEIN", 105, 110], ["virally infected cells", "CELL_TYPE", 237, 259], ["CTLs", "CELL_TYPE", 263, 267], ["NK cells", "CELL_TYPE", 272, 280], ["Fas", "PROTEIN", 423, 426], ["CTLs", "CELL_TYPE", 464, 468], ["NK cells", "CELL_TYPE", 473, 481], ["virally infected target cells", "CELL_TYPE", 492, 521], ["perforin", "PROTEIN", 530, 538], ["granzyme", "PROTEIN", 539, 547], ["swine fever virus", "SPECIES", 30, 47], ["African swine fever virus", "SPECIES", 22, 47], ["MsEPV", "SPECIES", 95, 100], ["African swine fever virus", "PROBLEM", 22, 47], ["Entomopoxviruses", "TREATMENT", 52, 68], ["viral vIAP", "PROBLEM", 76, 86], ["MsEPV", "TEST", 95, 100], ["AmEPV these proteins", "PROBLEM", 105, 125], ["virally infected cells", "PROBLEM", 237, 259], ["mitochondrial apoptosis pathway", "PROBLEM", 320, 351], ["viral infection", "PROBLEM", 371, 386], ["CTLs and NK cells", "TEST", 464, 481], ["virally infected target cells", "PROBLEM", 492, 521], ["the perforin/granzyme pathway", "TREATMENT", 526, 555], ["virally", "OBSERVATION_MODIFIER", 237, 244], ["infected cells", "OBSERVATION", 245, 259], ["mitochondrial apoptosis", "OBSERVATION", 320, 343], ["infection", "OBSERVATION", 377, 386]]], ["After successful activation, these cells release perforin and granzyme A and B from their cytotoxic granules at the immunosynapse where they contact the virally infected cell via MHC-I/peptide/TCR and costimulatory molecular interactions (Chavez-Galan et al., 2009, Ewen et al., 2012, Thiery and Lieberman, 2014) (Fig. 2).", [["cells", "ANATOMY", 35, 40], ["granules", "ANATOMY", 100, 108], ["immunosynapse", "ANATOMY", 116, 129], ["cell", "ANATOMY", 170, 174], ["cells", "CELL", 35, 40], ["perforin", "GENE_OR_GENE_PRODUCT", 49, 57], ["granzyme A", "GENE_OR_GENE_PRODUCT", 62, 72], ["B", "GENE_OR_GENE_PRODUCT", 77, 78], ["granules", "ORGANISM_SUBSTANCE", 100, 108], ["cell", "CELL", 170, 174], ["MHC-I", "GENE_OR_GENE_PRODUCT", 179, 184], ["TCR", "GENE_OR_GENE_PRODUCT", 193, 196], ["perforin", "PROTEIN", 49, 57], ["granzyme A", "PROTEIN", 62, 72], ["MHC", "PROTEIN", 179, 182], ["TCR", "PROTEIN", 193, 196], ["these cells", "TREATMENT", 29, 40], ["their cytotoxic granules", "PROBLEM", 84, 108], ["TCR", "PROBLEM", 193, 196], ["cytotoxic granules", "OBSERVATION", 90, 108]]], ["Perforin oligomerizes into variously sized high molecular structures in the target cell membrane (Metkar et al., 2015).", [["cell membrane", "ANATOMY", 83, 96], ["Perforin", "CHEMICAL", 0, 8], ["Perforin", "GENE_OR_GENE_PRODUCT", 0, 8], ["cell membrane", "CELLULAR_COMPONENT", 83, 96], ["Perforin", "PROTEIN", 0, 8], ["Perforin oligomerizes into variously sized high molecular structures", "PROBLEM", 0, 68], ["variously", "OBSERVATION_MODIFIER", 27, 36], ["sized", "OBSERVATION_MODIFIER", 37, 42], ["high", "OBSERVATION_MODIFIER", 43, 47], ["molecular structures", "OBSERVATION", 48, 68], ["target cell membrane", "OBSERVATION", 76, 96]]], ["Most likely through membrane lipid perturbation, similar to what is proposed for Bax and Bak on the MOM (Bleicken et al., 2014), perforin forms a pore, which allows the entry of the serine proteases granzyme A and B (Metkar et al., 2015) (Fig. 2).", [["membrane", "ANATOMY", 20, 28], ["pore", "ANATOMY", 146, 150], ["serine", "CHEMICAL", 182, 188], ["membrane", "CELLULAR_COMPONENT", 20, 28], ["Bax", "GENE_OR_GENE_PRODUCT", 81, 84], ["Bak", "GENE_OR_GENE_PRODUCT", 89, 92], ["MOM", "CELLULAR_COMPONENT", 100, 103], ["perforin", "GENE_OR_GENE_PRODUCT", 129, 137], ["granzyme A", "GENE_OR_GENE_PRODUCT", 199, 209], ["B", "GENE_OR_GENE_PRODUCT", 214, 215], ["Bax", "PROTEIN", 81, 84], ["Bak", "PROTEIN", 89, 92], ["perforin", "PROTEIN", 129, 137], ["serine proteases", "PROTEIN", 182, 198], ["membrane lipid perturbation", "PROBLEM", 20, 47], ["lipid perturbation", "OBSERVATION", 29, 47]]], ["While granzyme A provokes a still not entirely identified caspase-independent death pathway and is also responsible for inflammatory responses (Pardo et al., 2009a, Pardo et al., 2009b, Joeckel and Bird, 2014), granzyme B induces classical apoptosis in the target cell by two pathways, (i) a direct cleavage and activation of caspase-3 and (ii) the cleavage of Bid (similar to what caspase-8 does) and the triggering of Bax/Bak-mediated MOMP (Pardo et al., 2009a, Pardo et al., 2009b, Ewen et al., 2012, Thiery and Lieberman, 2014).", [["cell", "ANATOMY", 264, 268], ["death", "DISEASE", 78, 83], ["granzyme B", "CHEMICAL", 211, 221], ["granzyme A", "GENE_OR_GENE_PRODUCT", 6, 16], ["caspase", "GENE_OR_GENE_PRODUCT", 58, 65], ["granzyme B", "GENE_OR_GENE_PRODUCT", 211, 221], ["cell", "CELL", 264, 268], ["caspase-3", "GENE_OR_GENE_PRODUCT", 326, 335], ["Bid", "GENE_OR_GENE_PRODUCT", 361, 364], ["caspase-8", "GENE_OR_GENE_PRODUCT", 382, 391], ["Bax", "GENE_OR_GENE_PRODUCT", 420, 423], ["Bak-", "GENE_OR_GENE_PRODUCT", 424, 428], ["MOMP", "CELLULAR_COMPONENT", 437, 441], ["granzyme A", "PROTEIN", 6, 16], ["caspase", "PROTEIN", 58, 65], ["granzyme B", "PROTEIN", 211, 221], ["target cell", "CELL_TYPE", 257, 268], ["caspase-3", "PROTEIN", 326, 335], ["Bid", "PROTEIN", 361, 364], ["caspase-8", "PROTEIN", 382, 391], ["Bax", "PROTEIN", 420, 423], ["inflammatory responses", "PROBLEM", 120, 142], ["classical apoptosis", "PROBLEM", 230, 249], ["a direct cleavage", "TREATMENT", 290, 307], ["activation of caspase", "TREATMENT", 312, 333], ["apoptosis", "OBSERVATION", 240, 249]]], ["Viruses counteract the granzyme B killing pathway by expressing vBcl-2 survival factors.", [["granzyme B", "GENE_OR_GENE_PRODUCT", 23, 33], ["vBcl-2", "GENE_OR_GENE_PRODUCT", 64, 70], ["granzyme B", "PROTEIN", 23, 33], ["vBcl-2 survival factors", "PROTEIN", 64, 87], ["Viruses", "PROBLEM", 0, 7]]], ["Alternatively they produce inhibitors of granzyme B, such as the L4-100K assembly protein from adenovirus (Andrade et al., 2001), CrmA from cowpox virus (which also inhibits caspase-8) (Komiyama et al., 1996) or Serp2 encoded by the leporipoxvirus myxoma virus (Turner et al., 1999) (Fig. 2).", [["leporipoxvirus myxoma", "DISEASE", 233, 254], ["granzyme B", "GENE_OR_GENE_PRODUCT", 41, 51], ["L4-100K", "GENE_OR_GENE_PRODUCT", 65, 72], ["adenovirus", "ORGANISM", 95, 105], ["CrmA", "GENE_OR_GENE_PRODUCT", 130, 134], ["cowpox virus", "ORGANISM", 140, 152], ["caspase-8", "GENE_OR_GENE_PRODUCT", 174, 183], ["Serp2", "GENE_OR_GENE_PRODUCT", 212, 217], ["leporipoxvirus myxoma virus", "ORGANISM", 233, 260], ["granzyme B", "PROTEIN", 41, 51], ["L4-100K assembly protein", "PROTEIN", 65, 89], ["caspase-8", "PROTEIN", 174, 183], ["Serp2", "PROTEIN", 212, 217], ["cowpox virus", "SPECIES", 140, 152], ["cowpox virus", "SPECIES", 140, 152], ["leporipoxvirus myxoma virus", "SPECIES", 233, 260], ["granzyme B", "PROBLEM", 41, 51], ["adenovirus", "PROBLEM", 95, 105], ["CrmA", "PROBLEM", 130, 134], ["cowpox virus", "PROBLEM", 140, 152], ["caspase", "TEST", 174, 181], ["Serp2", "TREATMENT", 212, 217], ["the leporipoxvirus myxoma virus", "PROBLEM", 229, 260], ["L4", "ANATOMY", 65, 67], ["cowpox virus", "OBSERVATION", 140, 152], ["leporipoxvirus myxoma", "ANATOMY", 233, 254]]], ["All these inhibitors clearly block granzyme B action in cell free systems.", [["cell", "ANATOMY", 56, 60], ["granzyme B", "CHEMICAL", 35, 45], ["granzyme B", "GENE_OR_GENE_PRODUCT", 35, 45], ["cell", "CELL", 56, 60], ["granzyme B", "PROTEIN", 35, 45], ["All these inhibitors", "TREATMENT", 0, 20]]], ["But while the L4-100K protein also potently inhibited granzyme B-mediated cell death (Andrade et al., 2001), this could not be effectively observed with cells overexpressing CrmA or Serp2 or infected with poxviruses (M\u00fcllbacher et al., 1999, Barry et al., 2000, Screpanti et al., 2001, Pardo et al., 2009a, Pardo et al., 2009b).Recognizing/sensing viruses in endosomal and cytosolic compartments and mounting an antiviral innate immune response ::: Mechanisms by which the intrinsic, mitochondrial apoptosis pathway is activated after viral infectionIn the following section we focus on RNA viruses (Fig. 3) but similar mechanisms have either been reported or are expected to occur for DNA viruses (Goubau et al., 2013, Unterholzner, 2013).", [["cell", "ANATOMY", 74, 78], ["cells", "ANATOMY", 153, 158], ["endosomal", "ANATOMY", 359, 368], ["cytosolic compartments", "ANATOMY", 373, 395], ["mitochondrial", "ANATOMY", 484, 497], ["K", "CHEMICAL", 20, 21], ["granzyme B", "CHEMICAL", 54, 64], ["death", "DISEASE", 79, 84], ["granzyme B", "GENE_OR_GENE_PRODUCT", 54, 64], ["cell", "CELL", 74, 78], ["cells", "CELL", 153, 158], ["CrmA", "GENE_OR_GENE_PRODUCT", 174, 178], ["Serp2", "GENE_OR_GENE_PRODUCT", 182, 187], ["endosomal", "CELLULAR_COMPONENT", 359, 368], ["cytosolic compartments", "CELLULAR_COMPONENT", 373, 395], ["mitochondrial", "CELLULAR_COMPONENT", 484, 497], ["DNA", "CELLULAR_COMPONENT", 686, 689], ["L4-100K protein", "PROTEIN", 14, 29], ["granzyme B", "PROTEIN", 54, 64], ["CrmA", "PROTEIN", 174, 178], ["Serp2", "PROTEIN", 182, 187], ["the L4-100K protein", "TEST", 10, 29], ["granzyme B-mediated cell death", "PROBLEM", 54, 84], ["cells overexpressing CrmA", "PROBLEM", 153, 178], ["Recognizing/sensing viruses in endosomal and cytosolic compartments", "PROBLEM", 328, 395], ["mitochondrial apoptosis pathway", "PROBLEM", 484, 515], ["viral infectionIn", "PROBLEM", 535, 552], ["RNA viruses", "PROBLEM", 587, 598], ["DNA viruses", "PROBLEM", 686, 697], ["L4", "ANATOMY", 14, 16], ["sensing viruses", "OBSERVATION", 340, 355], ["mitochondrial apoptosis", "OBSERVATION", 484, 507]]], ["Irrespective of whether virus replication and spread are blocked and viruses are finally eliminated by non-apoptotic or apoptotic mechanism, the infected host cells first have to recognize, i.e. \u201csense\u201d the respective viruses.", [["cells", "ANATOMY", 159, 164], ["host cells", "CELL", 154, 164], ["infected host cells", "CELL_TYPE", 145, 164], ["virus replication", "PROBLEM", 24, 41], ["viruses", "PROBLEM", 69, 76], ["the infected host cells", "PROBLEM", 141, 164], ["virus replication", "OBSERVATION", 24, 41], ["infected", "OBSERVATION_MODIFIER", 145, 153], ["host cells", "OBSERVATION", 154, 164], ["respective viruses", "OBSERVATION", 207, 225]]], ["This places the molecular mechanisms of sensing at the heart of all anti-viral effects, including the initation of cell death.", [["heart", "ANATOMY", 55, 60], ["cell", "ANATOMY", 115, 119], ["death", "DISEASE", 120, 125], ["heart", "ORGAN", 55, 60], ["cell", "CELL", 115, 119], ["cell death", "PROBLEM", 115, 125], ["heart", "ANATOMY", 55, 60], ["anti-viral effects", "OBSERVATION", 68, 86], ["cell death", "OBSERVATION", 115, 125]]], ["Virus spread is prevented if host cell apoptosis occurs before a virus can form progeny, or if an infected cell is successfully eliminated by CTLs.", [["cell", "ANATOMY", 34, 38], ["cell", "ANATOMY", 107, 111], ["CTLs", "ANATOMY", 142, 146], ["Virus", "ORGANISM", 0, 5], ["host cell", "CELL", 29, 38], ["cell", "CELL", 107, 111], ["CTLs", "CELL", 142, 146], ["CTLs", "CELL_TYPE", 142, 146], ["Virus spread", "PROBLEM", 0, 12], ["host cell apoptosis", "PROBLEM", 29, 48], ["a virus", "PROBLEM", 63, 70], ["an infected cell", "PROBLEM", 95, 111], ["host cell apoptosis", "OBSERVATION", 29, 48], ["infected cell", "OBSERVATION", 98, 111]]], ["If however the virus can inhibit cell death by expressing own survival factors after infection or if it kills cells after its reproduction, it can successfully propagate and evade the immune system.", [["cell", "ANATOMY", 33, 37], ["cells", "ANATOMY", 110, 115], ["immune system", "ANATOMY", 184, 197], ["death", "DISEASE", 38, 43], ["infection", "DISEASE", 85, 94], ["cell", "CELL", 33, 37], ["cells", "CELL", 110, 115], ["survival factors", "PROTEIN", 62, 78], ["the virus", "PROBLEM", 11, 20], ["cell death", "PROBLEM", 33, 43], ["infection", "PROBLEM", 85, 94]]], ["The best known antiviral \u201csensing\u201d mechanism of hosts for RNA viruses triggers the so called type I interferon response (Takeuchi and Akira, 2009, Ivashkiv and Donlin, 2014).", [["type I interferon", "GENE_OR_GENE_PRODUCT", 93, 110], ["RNA viruses", "PROBLEM", 58, 69], ["antiviral", "OBSERVATION", 15, 24]]], ["Type I interferons such as IFN\u03b1 and IFN\u03b2 are transcriptionally induced after viral infections and play a critical role in mounting innate responses against viruses (Fig. 3).", [["viral infections", "DISEASE", 77, 93], ["Type I interferons", "GENE_OR_GENE_PRODUCT", 0, 18], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 27, 31], ["IFN\u03b2", "GENE_OR_GENE_PRODUCT", 36, 40], ["Type I interferons", "PROTEIN", 0, 18], ["IFN\u03b1", "PROTEIN", 27, 31], ["IFN\u03b2", "PROTEIN", 36, 40], ["Type I interferons", "PROBLEM", 0, 18], ["IFN\u03b1", "TREATMENT", 27, 31], ["IFN", "PROBLEM", 36, 39], ["viral infections", "PROBLEM", 77, 93]]], ["They are secreted and bind to specific interferon receptors on the same as well as on neighboring cells in order to ensure a spreading of the antiviral state to as many cells as possible.", [["cells", "ANATOMY", 98, 103], ["cells", "ANATOMY", 169, 174], ["interferon receptors", "GENE_OR_GENE_PRODUCT", 39, 59], ["cells", "CELL", 98, 103], ["cells", "CELL", 169, 174], ["interferon receptors", "PROTEIN", 39, 59], ["neighboring cells", "CELL_TYPE", 86, 103], ["specific interferon receptors", "TREATMENT", 30, 59], ["the antiviral state", "TREATMENT", 138, 157]]], ["Activated interferon receptors then trigger a signaling cascade via the Janus protein kinase-signal transducer and activators of transcription pathway (JAK-STAT) that results in the induction of IFN-stimulated genes (ISGs) which can interfere with the viral life cycle at different steps, induce host cell apoptosis or both (Fig. 3) (Ivashkiv and Donlin, 2014).", [["cell", "ANATOMY", 301, 305], ["interferon receptors", "GENE_OR_GENE_PRODUCT", 10, 30], ["Janus protein kinase-signal transducer and activators of transcription", "GENE_OR_GENE_PRODUCT", 72, 142], ["JAK-STAT", "GENE_OR_GENE_PRODUCT", 152, 160], ["IFN-stimulated genes", "GENE_OR_GENE_PRODUCT", 195, 215], ["host cell", "CELL", 296, 305], ["Activated interferon receptors", "PROTEIN", 0, 30], ["Janus protein kinase", "PROTEIN", 72, 92], ["JAK", "PROTEIN", 152, 155], ["STAT", "PROTEIN", 156, 160], ["IFN-stimulated genes", "DNA", 195, 215], ["ISGs", "DNA", 217, 221], ["Activated interferon receptors", "TREATMENT", 0, 30], ["a signaling cascade", "PROBLEM", 44, 63], ["the Janus protein kinase", "TEST", 68, 92], ["signal transducer", "TEST", 93, 110], ["transcription pathway", "TEST", 129, 150], ["JAK", "TEST", 152, 155], ["IFN-stimulated genes", "TREATMENT", 195, 215], ["the viral life cycle", "TREATMENT", 248, 268], ["host cell apoptosis", "PROBLEM", 296, 315], ["host cell apoptosis", "OBSERVATION", 296, 315]]], ["Two major components of this IFN-induced signaling system are the RNA-dependent protein kinase (PKR) (Garcia et al., 2007) and the 2\u2032,5-oligoadenylate and RNase-L systems (Hovanessian, 2007).", [["IFN", "CHEMICAL", 29, 32], ["IFN", "GENE_OR_GENE_PRODUCT", 29, 32], ["RNA-dependent protein kinase", "GENE_OR_GENE_PRODUCT", 66, 94], ["PKR", "GENE_OR_GENE_PRODUCT", 96, 99], ["2\u2032,5-oligoadenylate", "SIMPLE_CHEMICAL", 131, 150], ["RNase-L", "GENE_OR_GENE_PRODUCT", 155, 162], ["IFN", "PROTEIN", 29, 32], ["RNA-dependent protein kinase", "PROTEIN", 66, 94], ["PKR", "PROTEIN", 96, 99], ["RNase", "PROTEIN", 155, 160], ["this IFN-induced signaling system", "PROBLEM", 24, 57], ["the RNA", "TEST", 62, 69], ["PKR", "TEST", 96, 99]]], ["Activation of RNaseL leads to the degradation of viral RNA therefore blocking further RNA replication and transcription.", [["RNaseL", "GENE_OR_GENE_PRODUCT", 14, 20], ["RNaseL", "PROTEIN", 14, 20], ["viral RNA", "RNA", 49, 58], ["Activation of RNaseL leads", "TREATMENT", 0, 26], ["viral RNA", "PROBLEM", 49, 58], ["further RNA replication", "TREATMENT", 78, 101], ["viral RNA", "OBSERVATION", 49, 58]]], ["On the other hand PKR activation inhibits host-cell protein translation via the phosphorylation of elongation initiation-factor 2a (eIF2\u03b1) (Garcia et al., 2007) (Fig. 3).", [["cell", "ANATOMY", 47, 51], ["PKR", "GENE_OR_GENE_PRODUCT", 18, 21], ["cell", "CELL", 47, 51], ["elongation initiation-factor 2a", "GENE_OR_GENE_PRODUCT", 99, 130], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 132, 137], ["PKR", "PROTEIN", 18, 21], ["elongation initiation-factor 2a", "PROTEIN", 99, 130], ["eIF2\u03b1", "PROTEIN", 132, 137], ["elongation initiation", "TEST", 99, 120], ["PKR", "OBSERVATION", 18, 21]]], ["In addition, active PKR was proposed to induce host cell apoptosis via NF\u03baB and IRF-1 activation, which then upregulated FasL and TRAIL respectively (Tan and Katze, 1999, Jagus et al., 1999).", [["cell", "ANATOMY", 52, 56], ["PKR", "GENE_OR_GENE_PRODUCT", 20, 23], ["cell", "CELL", 52, 56], ["NF\u03baB", "GENE_OR_GENE_PRODUCT", 71, 75], ["IRF-1", "GENE_OR_GENE_PRODUCT", 80, 85], ["FasL", "GENE_OR_GENE_PRODUCT", 121, 125], ["TRAIL", "GENE_OR_GENE_PRODUCT", 130, 135], ["PKR", "PROTEIN", 20, 23], ["NF\u03baB", "PROTEIN", 71, 75], ["IRF", "PROTEIN", 80, 83], ["FasL", "PROTEIN", 121, 125], ["TRAIL", "PROTEIN", 130, 135], ["active PKR", "PROBLEM", 13, 23], ["host cell apoptosis", "PROBLEM", 47, 66], ["active", "OBSERVATION_MODIFIER", 13, 19], ["PKR", "OBSERVATION", 20, 23], ["host cell apoptosis", "OBSERVATION", 47, 66]]], ["Although TRAIL is induced by IFNs in a variety of paradigms of viral infections and may indeed contribute to apoptosis of host cells, it is unclear if this is really mediated via the PKR/NF\u03baB axis (Allen and El-Deiry, 2012).", [["cells", "ANATOMY", 127, 132], ["TRAIL", "CHEMICAL", 9, 14], ["viral infections", "DISEASE", 63, 79], ["TRAIL", "GENE_OR_GENE_PRODUCT", 9, 14], ["IFNs", "GENE_OR_GENE_PRODUCT", 29, 33], ["host cells", "CELL", 122, 132], ["PKR", "GENE_OR_GENE_PRODUCT", 183, 186], ["NF\u03baB", "GENE_OR_GENE_PRODUCT", 187, 191], ["TRAIL", "PROTEIN", 9, 14], ["IFNs", "PROTEIN", 29, 33], ["host cells", "CELL_TYPE", 122, 132], ["PKR", "PROTEIN", 183, 186], ["NF\u03baB", "PROTEIN", 187, 191], ["viral infections", "PROBLEM", 63, 79], ["apoptosis of host cells", "PROBLEM", 109, 132], ["viral infections", "OBSERVATION", 63, 79], ["host cells", "OBSERVATION", 122, 132]]], ["Also, NF\u03baB often acts as a cell death protective rather than apoptosis-inducing transcription factor (DiDonato et al., 2012).", [["cell", "ANATOMY", 27, 31], ["death", "DISEASE", 32, 37], ["NF\u03baB", "GENE_OR_GENE_PRODUCT", 6, 10], ["cell", "CELL", 27, 31], ["NF\u03baB", "PROTEIN", 6, 10], ["transcription factor", "PROTEIN", 80, 100], ["a cell death protective", "TREATMENT", 25, 48]]], ["Moreover, we recently reported that PKR was not required for apoptosis induced by the RNA virus SFV although it was clearly activated and blocked protein synthesis via eIF2\u03b1 phosphorylation (El Maadidi et al., 2014).Recognizing/sensing viruses in endosomal and cytosolic compartments and mounting an antiviral innate immune response ::: Mechanisms by which the intrinsic, mitochondrial apoptosis pathway is activated after viral infectionIn order for a host cell to sense a virus it has to recognize it as non-self.", [["endosomal", "ANATOMY", 247, 256], ["cytosolic compartments", "ANATOMY", 261, 283], ["mitochondrial", "ANATOMY", 372, 385], ["cell", "ANATOMY", 458, 462], ["viral infection", "DISEASE", 423, 438], ["PKR", "GENE_OR_GENE_PRODUCT", 36, 39], ["RNA virus SFV", "ORGANISM", 86, 99], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 168, 173], ["endosomal", "CELLULAR_COMPONENT", 247, 256], ["cytosolic compartments", "CELLULAR_COMPONENT", 261, 283], ["mitochondrial", "CELLULAR_COMPONENT", 372, 385], ["host cell", "CELL", 453, 462], ["PKR", "PROTEIN", 36, 39], ["eIF2\u03b1", "PROTEIN", 168, 173], ["SFV", "SPECIES", 96, 99], ["PKR", "TEST", 36, 39], ["apoptosis", "PROBLEM", 61, 70], ["the RNA virus SFV", "PROBLEM", 82, 99], ["blocked protein synthesis", "TREATMENT", 138, 163], ["eIF2\u03b1 phosphorylation", "TREATMENT", 168, 189], ["Recognizing/sensing viruses in endosomal and cytosolic compartments", "PROBLEM", 216, 283], ["mitochondrial apoptosis pathway", "PROBLEM", 372, 403], ["viral infection", "PROBLEM", 423, 438], ["a host cell", "TREATMENT", 451, 462], ["a virus", "PROBLEM", 472, 479], ["sensing viruses", "OBSERVATION", 228, 243], ["mitochondrial apoptosis", "OBSERVATION", 372, 395], ["infection", "OBSERVATION", 429, 438]]], ["First, viruses are detected on the host cell surface by so-called pattern recognition receptors (PRR) which bind to pathogen associated molecular patterns (PAMPs) on the virus and other pathogens (Pichlmair and Reis e Sousa, 2007, Kumar et al., 2011).", [["cell surface", "ANATOMY", 40, 52], ["cell surface", "CELLULAR_COMPONENT", 40, 52], ["pattern recognition receptors", "GENE_OR_GENE_PRODUCT", 66, 95], ["PRR", "GENE_OR_GENE_PRODUCT", 97, 100], ["pathogen associated molecular patterns", "GENE_OR_GENE_PRODUCT", 116, 154], ["PAMPs", "GENE_OR_GENE_PRODUCT", 156, 161], ["pattern recognition receptors", "PROTEIN", 66, 95], ["PRR", "PROTEIN", 97, 100], ["pathogen associated molecular patterns", "PROTEIN", 116, 154], ["PAMPs", "PROTEIN", 156, 161], ["viruses", "PROBLEM", 7, 14], ["the virus", "PROBLEM", 166, 175], ["viruses", "OBSERVATION", 7, 14], ["host cell", "OBSERVATION_MODIFIER", 35, 44]]], ["A major class of cell surface transmembrane PRR are the Toll-like receptors (TLRs) whose PAMP-binding domains contain leucine-rich repeats (LRR).", [["cell surface transmembrane", "ANATOMY", 17, 43], ["leucine", "CHEMICAL", 118, 125], ["leucine", "CHEMICAL", 118, 125], ["cell", "CELL", 17, 21], ["transmembrane", "CELLULAR_COMPONENT", 30, 43], ["PRR", "GENE_OR_GENE_PRODUCT", 44, 47], ["Toll-like receptors", "GENE_OR_GENE_PRODUCT", 56, 75], ["TLRs", "GENE_OR_GENE_PRODUCT", 77, 81], ["PAMP", "GENE_OR_GENE_PRODUCT", 89, 93], ["leucine", "AMINO_ACID", 118, 125], ["cell surface transmembrane PRR", "PROTEIN", 17, 47], ["Toll-like receptors", "PROTEIN", 56, 75], ["TLRs", "PROTEIN", 77, 81], ["PAMP-binding domains", "PROTEIN", 89, 109], ["leucine-rich repeats", "PROTEIN", 118, 138], ["LRR", "PROTEIN", 140, 143], ["cell surface transmembrane PRR", "PROBLEM", 17, 47], ["leucine-rich repeats", "TREATMENT", 118, 138], ["cell surface", "OBSERVATION", 17, 29]]], ["TLR3, TLR7, TRL9 detect viral nucleic acid ligands such as long dsRNA, ssRNA or CpG DNA, respectively, mostly in the endosomal compartments (subsequent to endocytosis of the virus).", [["endosomal compartments", "ANATOMY", 117, 139], ["nucleic acid", "CHEMICAL", 30, 42], ["TLR3", "GENE_OR_GENE_PRODUCT", 0, 4], ["TLR7", "GENE_OR_GENE_PRODUCT", 6, 10], ["TRL9", "GENE_OR_GENE_PRODUCT", 12, 16], ["DNA", "CELLULAR_COMPONENT", 84, 87], ["endosomal compartments", "CELLULAR_COMPONENT", 117, 139], ["TLR3", "PROTEIN", 0, 4], ["TLR7", "PROTEIN", 6, 10], ["TRL9", "PROTEIN", 12, 16], ["long dsRNA, ssRNA or CpG DNA", "DNA", 59, 87], ["TLR3", "TREATMENT", 0, 4], ["TLR7", "TREATMENT", 6, 10], ["TRL9", "TREATMENT", 12, 16], ["viral nucleic acid ligands", "PROBLEM", 24, 50], ["long dsRNA", "PROBLEM", 59, 69], ["ssRNA", "PROBLEM", 71, 76], ["CpG DNA", "PROBLEM", 80, 87]]], ["After binding, they recruit adaptor proteins such as TRIF (for TLR3) or MyD88 (TLR7/TLR9), which bind specific members of the TRAF adaptor and activate the IRAK kinase families.", [["TRIF", "GENE_OR_GENE_PRODUCT", 53, 57], ["TLR3", "GENE_OR_GENE_PRODUCT", 63, 67], ["MyD88", "GENE_OR_GENE_PRODUCT", 72, 77], ["TLR7", "GENE_OR_GENE_PRODUCT", 79, 83], ["TLR9", "GENE_OR_GENE_PRODUCT", 84, 88], ["TRAF", "GENE_OR_GENE_PRODUCT", 126, 130], ["IRAK", "GENE_OR_GENE_PRODUCT", 156, 160], ["adaptor proteins", "PROTEIN", 28, 44], ["TRIF", "PROTEIN", 53, 57], ["TLR3", "PROTEIN", 63, 67], ["MyD88", "PROTEIN", 72, 77], ["TLR7", "PROTEIN", 79, 83], ["TLR9", "PROTEIN", 84, 88], ["TRAF adaptor", "PROTEIN", 126, 138], ["IRAK kinase families", "PROTEIN", 156, 176], ["adaptor proteins", "TREATMENT", 28, 44], ["TRIF (for TLR3)", "TREATMENT", 53, 68], ["MyD88 (TLR7/TLR9)", "TREATMENT", 72, 89], ["the TRAF adaptor", "TREATMENT", 122, 138]]], ["This ultimately leads to the nuclear translocation of NF\u03baB and IRF3 and IRF7 transcription factors through respective phosphorylation and activation of the IkB kinase (IKK) \u03b1,\u03b2,\u03b3 and IKK\u025b/TBK1 complexes (Pichlmair and Reis e Sousa, 2007, Bowie and Unterholzer, 2008, Kawai and Akira, 2008, Kumar et al., 2011) (Fig. 3).", [["nuclear", "ANATOMY", 29, 36], ["nuclear", "CELLULAR_COMPONENT", 29, 36], ["NF\u03baB", "GENE_OR_GENE_PRODUCT", 54, 58], ["IRF3", "GENE_OR_GENE_PRODUCT", 63, 67], ["IRF7", "GENE_OR_GENE_PRODUCT", 72, 76], ["IkB kinase", "GENE_OR_GENE_PRODUCT", 156, 166], ["IKK", "GENE_OR_GENE_PRODUCT", 168, 171], ["\u03b1", "GENE_OR_GENE_PRODUCT", 173, 174], ["\u03b2", "GENE_OR_GENE_PRODUCT", 175, 176], ["\u03b3", "GENE_OR_GENE_PRODUCT", 177, 178], ["IKK\u025b", "GENE_OR_GENE_PRODUCT", 183, 187], ["TBK1", "GENE_OR_GENE_PRODUCT", 188, 192], ["NF\u03baB", "PROTEIN", 54, 58], ["IRF3", "PROTEIN", 63, 67], ["IRF7", "PROTEIN", 72, 76], ["transcription factors", "PROTEIN", 77, 98], ["IkB kinase (IKK) \u03b1", "PROTEIN", 156, 174], ["\u03b2", "PROTEIN", 175, 176], ["\u03b3", "PROTEIN", 177, 178], ["IKK\u025b", "PROTEIN", 183, 187], ["TBK1 complexes", "PROTEIN", 188, 202], ["IRF7 transcription factors", "TREATMENT", 72, 98], ["respective phosphorylation", "TREATMENT", 107, 133], ["the IkB kinase", "TEST", 152, 166], ["IKK", "TEST", 168, 171], ["\u03b2", "TEST", 175, 176], ["\u03b3", "TEST", 177, 178], ["IKK\u025b", "TEST", 183, 187], ["/TBK1 complexes", "PROBLEM", 187, 202], ["Pichlmair", "TEST", 204, 213], ["TBK1 complexes", "OBSERVATION", 188, 202]]], ["NF\u03baB and IRF3/7 then cooperate to induce the transcription of IFN\u03b1 and IFN\u03b2.", [["NF\u03baB", "GENE_OR_GENE_PRODUCT", 0, 4], ["IRF3", "GENE_OR_GENE_PRODUCT", 9, 13], ["7", "GENE_OR_GENE_PRODUCT", 14, 15], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 62, 66], ["IFN\u03b2", "GENE_OR_GENE_PRODUCT", 71, 75], ["NF\u03baB", "PROTEIN", 0, 4], ["IRF3/7", "PROTEIN", 9, 15], ["IFN\u03b1", "PROTEIN", 62, 66], ["IFN\u03b2", "PROTEIN", 71, 75]]], ["Recently, it was reported that activation of the TLR3 pathway by the synthetic dsRNA homologs polyIC can induce apoptosis by recruiting caspase-8 to TLR3 (Weber et al., 2010, Estornes et al., 2012).", [["polyIC", "CHEMICAL", 94, 100], ["TLR3", "GENE_OR_GENE_PRODUCT", 49, 53], ["polyIC", "GENE_OR_GENE_PRODUCT", 94, 100], ["caspase-8", "GENE_OR_GENE_PRODUCT", 136, 145], ["TLR3", "GENE_OR_GENE_PRODUCT", 149, 153], ["TLR3", "PROTEIN", 49, 53], ["polyIC", "PROTEIN", 94, 100], ["caspase-8", "PROTEIN", 136, 145], ["TLR3", "PROTEIN", 149, 153], ["the TLR3 pathway", "TREATMENT", 45, 61], ["the synthetic dsRNA homologs", "TREATMENT", 65, 93], ["apoptosis", "PROBLEM", 112, 121]]], ["In an earlier report, TRIF, an adaptor for TLR3 was shown to induce apoptosis in a FADD/caspase-8-dependent manner (Kaiser and Offermann, 2005) (Fig. 3).", [["TRIF", "GENE_OR_GENE_PRODUCT", 22, 26], ["TLR3", "GENE_OR_GENE_PRODUCT", 43, 47], ["FADD", "GENE_OR_GENE_PRODUCT", 83, 87], ["caspase-8", "GENE_OR_GENE_PRODUCT", 88, 97], ["TRIF", "PROTEIN", 22, 26], ["TLR3", "PROTEIN", 43, 47], ["FADD", "PROTEIN", 83, 87], ["caspase-8", "PROTEIN", 88, 97], ["TLR3", "TREATMENT", 43, 47], ["apoptosis", "PROBLEM", 68, 77], ["a FADD/caspase", "TREATMENT", 81, 95]]], ["In all cases caspase-8 was activated by proximity-induced dimerization and then cleaved and activated caspase-3 (Fig. 3).", [["caspase-8", "GENE_OR_GENE_PRODUCT", 13, 22], ["caspase-3", "GENE_OR_GENE_PRODUCT", 102, 111], ["caspase-8", "PROTEIN", 13, 22], ["caspase-3", "PROTEIN", 102, 111], ["activated caspase", "TREATMENT", 92, 109]]], ["This defines a novel, death receptor- and mitochondria-independent death signaling pathway involving caspase-8.Recognizing/sensing viruses in endosomal and cytosolic compartments and mounting an antiviral innate immune response ::: Mechanisms by which the intrinsic, mitochondrial apoptosis pathway is activated after viral infectionViruses evolved strategies to inhibit this signaling pathway downstream of TLRs to avoid the transcription of type I interferons.", [["mitochondria", "ANATOMY", 42, 54], ["endosomal", "ANATOMY", 142, 151], ["cytosolic compartments", "ANATOMY", 156, 178], ["mitochondrial", "ANATOMY", 267, 280], ["death", "DISEASE", 22, 27], ["death", "DISEASE", 67, 72], ["mitochondria", "CELLULAR_COMPONENT", 42, 54], ["caspase-8", "GENE_OR_GENE_PRODUCT", 101, 110], ["endosomal", "CELLULAR_COMPONENT", 142, 151], ["cytosolic compartments", "CELLULAR_COMPONENT", 156, 178], ["mitochondrial", "CELLULAR_COMPONENT", 267, 280], ["TLRs", "GENE_OR_GENE_PRODUCT", 408, 412], ["type I interferons", "GENE_OR_GENE_PRODUCT", 443, 461], ["death receptor", "PROTEIN", 22, 36], ["caspase-8", "PROTEIN", 101, 110], ["TLRs", "PROTEIN", 408, 412], ["type I interferons", "PROTEIN", 443, 461], ["death receptor", "TEST", 22, 36], ["caspase", "TEST", 101, 108], ["Recognizing/sensing viruses in endosomal and cytosolic compartments", "PROBLEM", 111, 178], ["mitochondrial apoptosis pathway", "PROBLEM", 267, 298], ["viral infectionViruses", "PROBLEM", 318, 340], ["sensing viruses", "OBSERVATION", 123, 138], ["mitochondrial apoptosis", "OBSERVATION", 267, 290]]], ["For instance, the NS3-4A protease of hepatitis C virus (HCV) cleaves the adaptor TRIF (Roy and Mocarski, 2007) while the NS5A protein decreases the expression of TLR4 (Tamura et al., 2011).", [["hepatitis C", "DISEASE", 37, 48], ["NS3-4A", "GENE_OR_GENE_PRODUCT", 18, 24], ["hepatitis C virus", "ORGANISM", 37, 54], ["HCV", "ORGANISM", 56, 59], ["TRIF", "GENE_OR_GENE_PRODUCT", 81, 85], ["NS5A", "GENE_OR_GENE_PRODUCT", 121, 125], ["TLR4", "GENE_OR_GENE_PRODUCT", 162, 166], ["NS3-4A protease", "PROTEIN", 18, 33], ["adaptor TRIF", "PROTEIN", 73, 85], ["Mocarski", "PROTEIN", 95, 103], ["NS5A protein", "PROTEIN", 121, 133], ["TLR4", "PROTEIN", 162, 166], ["hepatitis C virus", "SPECIES", 37, 54], ["hepatitis C virus", "SPECIES", 37, 54], ["HCV", "SPECIES", 56, 59], ["the NS3", "TEST", 14, 21], ["hepatitis C virus", "PROBLEM", 37, 54], ["the NS5A protein", "TREATMENT", 117, 133]]], ["Vaccinia virus uses its A46 protein to inhibit all TLR-adaptors (MyD88, MAL, TRIF, TRAM), the A52 protein to block TRAF6 and the protein kinase IRAK2, the B14 protein to antagonize the IKK\u03b1,\u03b2,\u03b3 complex and the K7 protein to prevent the IKK\u025b/TBK1 complex from activating IRF3/7 (Bowie and Unterholzer, 2008).", [["Vaccinia virus", "ORGANISM", 0, 14], ["A46", "GENE_OR_GENE_PRODUCT", 24, 27], ["TLR", "GENE_OR_GENE_PRODUCT", 51, 54], ["MyD88", "GENE_OR_GENE_PRODUCT", 65, 70], ["MAL", "GENE_OR_GENE_PRODUCT", 72, 75], ["TRIF", "GENE_OR_GENE_PRODUCT", 77, 81], ["TRAM", "GENE_OR_GENE_PRODUCT", 83, 87], ["A52", "GENE_OR_GENE_PRODUCT", 94, 97], ["TRAF6", "GENE_OR_GENE_PRODUCT", 115, 120], ["IRAK2", "GENE_OR_GENE_PRODUCT", 144, 149], ["B14", "GENE_OR_GENE_PRODUCT", 155, 158], ["IKK\u03b1", "GENE_OR_GENE_PRODUCT", 185, 189], ["\u03b2", "GENE_OR_GENE_PRODUCT", 190, 191], ["\u03b3", "GENE_OR_GENE_PRODUCT", 192, 193], ["K7", "GENE_OR_GENE_PRODUCT", 210, 212], ["IKK\u025b", "GENE_OR_GENE_PRODUCT", 236, 240], ["TBK1", "GENE_OR_GENE_PRODUCT", 241, 245], ["IRF3", "GENE_OR_GENE_PRODUCT", 270, 274], ["A46 protein", "PROTEIN", 24, 35], ["TLR-adaptors", "PROTEIN", 51, 63], ["MyD88", "PROTEIN", 65, 70], ["MAL", "PROTEIN", 72, 75], ["TRIF", "PROTEIN", 77, 81], ["TRAM", "PROTEIN", 83, 87], ["A52 protein", "PROTEIN", 94, 105], ["TRAF6", "PROTEIN", 115, 120], ["protein kinase", "PROTEIN", 129, 143], ["IRAK2", "PROTEIN", 144, 149], ["B14 protein", "PROTEIN", 155, 166], ["IKK\u03b1,\u03b2,\u03b3 complex", "PROTEIN", 185, 201], ["K7 protein", "PROTEIN", 210, 220], ["IKK\u025b", "PROTEIN", 236, 240], ["TBK1 complex", "PROTEIN", 241, 253], ["IRF3", "PROTEIN", 270, 274], ["Vaccinia virus", "SPECIES", 0, 14], ["Vaccinia virus", "SPECIES", 0, 14], ["Vaccinia virus", "PROBLEM", 0, 14], ["the A52 protein", "TEST", 90, 105], ["TRAF6", "TEST", 115, 120], ["the protein kinase IRAK2", "TEST", 125, 149], ["the B14 protein", "TEST", 151, 166], ["the IKK\u03b1", "TEST", 181, 189], ["the K7 protein", "TEST", 206, 220], ["the IKK\u025b/TBK1 complex", "PROBLEM", 232, 253], ["TBK1 complex", "OBSERVATION", 241, 253]]], ["The latter strategy is also used by HCV NS3, rabies virus phosphoprotein and hantavirus G1.Recognizing/sensing viruses in endosomal and cytosolic compartments and mounting an antiviral innate immune response ::: Mechanisms by which the intrinsic, mitochondrial apoptosis pathway is activated after viral infectionIn addition to the recognition of viruses in the endosomal compartment, cells also contain viral sensors in the cytosol (Pichlmair and Reis e Sousa, 2007, Kawai and Akira, 2008, Takeuchi and Akira, 2009).", [["endosomal", "ANATOMY", 122, 131], ["cytosolic compartments", "ANATOMY", 136, 158], ["mitochondrial", "ANATOMY", 247, 260], ["endosomal compartment", "ANATOMY", 362, 383], ["cells", "ANATOMY", 385, 390], ["cytosol", "ANATOMY", 425, 432], ["viral infection", "DISEASE", 298, 313], ["HCV NS3", "ORGANISM", 36, 43], ["rabies virus phosphoprotein", "ORGANISM", 45, 72], ["endosomal", "CELLULAR_COMPONENT", 122, 131], ["cytosolic compartments", "CELLULAR_COMPONENT", 136, 158], ["mitochondrial", "CELLULAR_COMPONENT", 247, 260], ["endosomal compartment", "CELLULAR_COMPONENT", 362, 383], ["cells", "CELL", 385, 390], ["cytosol", "CELLULAR_COMPONENT", 425, 432], ["HCV NS3", "PROTEIN", 36, 43], ["rabies virus phosphoprotein", "PROTEIN", 45, 72], ["rabies virus", "SPECIES", 45, 57], ["HCV", "SPECIES", 36, 39], ["rabies virus", "SPECIES", 45, 57], ["HCV NS3", "TREATMENT", 36, 43], ["rabies virus phosphoprotein", "TREATMENT", 45, 72], ["Recognizing/sensing viruses in endosomal and cytosolic compartments", "PROBLEM", 91, 158], ["mitochondrial apoptosis pathway", "PROBLEM", 247, 278], ["viral infection", "PROBLEM", 298, 313], ["viruses", "PROBLEM", 347, 354], ["viral sensors", "TEST", 404, 417], ["sensing viruses", "OBSERVATION", 103, 118], ["mitochondrial apoptosis", "OBSERVATION", 247, 270], ["infection", "OBSERVATION", 304, 313], ["viruses", "OBSERVATION", 347, 354], ["endosomal compartment", "ANATOMY", 362, 383], ["viral sensors", "OBSERVATION", 404, 417]]], ["These are the RIG-like helicases (RLH) RIG-I, MDA5 and LGP-2 (Yoneyama et al., 2004, Kato et al., 2006).", [["RIG-like helicases", "GENE_OR_GENE_PRODUCT", 14, 32], ["RIG-I", "GENE_OR_GENE_PRODUCT", 39, 44], ["MDA5", "GENE_OR_GENE_PRODUCT", 46, 50], ["LGP-2", "GENE_OR_GENE_PRODUCT", 55, 60], ["RIG-like helicases", "PROTEIN", 14, 32], ["RLH", "PROTEIN", 34, 37], ["RIG-I", "PROTEIN", 39, 44], ["MDA5", "PROTEIN", 46, 50], ["LGP", "PROTEIN", 55, 58], ["the RIG", "TEST", 10, 17], ["MDA5", "TEST", 46, 50], ["LGP", "TEST", 55, 58], ["RIG", "OBSERVATION_MODIFIER", 14, 17], ["MDA5", "ANATOMY", 46, 50], ["LGP", "ANATOMY_MODIFIER", 55, 58]]], ["RIG-I and MDA5 both contain two caspase recruitment domains (CARDs), an ATPase and a helicase domain (Fig. 3).", [["RIG-I", "GENE_OR_GENE_PRODUCT", 0, 5], ["MDA5", "GENE_OR_GENE_PRODUCT", 10, 14], ["caspase", "GENE_OR_GENE_PRODUCT", 32, 39], ["CARDs", "GENE_OR_GENE_PRODUCT", 61, 66], ["ATPase", "GENE_OR_GENE_PRODUCT", 72, 78], ["RIG-I", "PROTEIN", 0, 5], ["MDA5", "PROTEIN", 10, 14], ["caspase recruitment domains", "PROTEIN", 32, 59], ["CARDs", "PROTEIN", 61, 66], ["ATPase", "PROTEIN", 72, 78], ["helicase domain", "PROTEIN", 85, 100], ["Fig. 3", "PROTEIN", 102, 108], ["MDA5", "TREATMENT", 10, 14], ["two caspase recruitment domains", "TREATMENT", 28, 59], ["an ATPase", "TEST", 69, 78]]], ["The helicase domain is used to recognize different kinds of nucleic acids.", [["nucleic acids", "CHEMICAL", 60, 73], ["nucleic acids", "SIMPLE_CHEMICAL", 60, 73], ["helicase domain", "PROTEIN", 4, 19], ["The helicase domain", "TREATMENT", 0, 19], ["nucleic acids", "TREATMENT", 60, 73], ["nucleic acids", "OBSERVATION", 60, 73]]], ["While MDA5 mainly senses long viral dsRNA molecules, RIG-I is often activated by short dsRNA fragments and ssRNAs that have a 5\u2032 triphosphate (Pichlmair and Reis e Sousa, 2007).", [["5\u2032 triphosphate", "CHEMICAL", 126, 141], ["5\u2032 triphosphate", "CHEMICAL", 126, 141], ["MDA5", "GENE_OR_GENE_PRODUCT", 6, 10], ["RIG-I", "GENE_OR_GENE_PRODUCT", 53, 58], ["ssRNAs", "GENE_OR_GENE_PRODUCT", 107, 113], ["5\u2032 triphosphate", "SIMPLE_CHEMICAL", 126, 141], ["MDA5", "PROTEIN", 6, 10], ["long viral dsRNA molecules", "PROTEIN", 25, 51], ["RIG-I", "PROTEIN", 53, 58], ["short dsRNA fragments", "DNA", 81, 102], ["long viral dsRNA molecules", "PROBLEM", 25, 51], ["short dsRNA fragments", "PROBLEM", 81, 102], ["ssRNAs", "TEST", 107, 113], ["long", "OBSERVATION_MODIFIER", 25, 29], ["viral dsRNA molecules", "OBSERVATION", 30, 51], ["short dsRNA", "OBSERVATION_MODIFIER", 81, 92]]], ["This concept ensures that cellular RNAs whose 5\u2032 ends are either capped or contain monophosphates, are not recognized by RLHs.", [["cellular", "ANATOMY", 26, 34], ["monophosphates", "CHEMICAL", 83, 97], ["cellular", "CELL", 26, 34], ["monophosphates", "SIMPLE_CHEMICAL", 83, 97], ["RLHs", "GENE_OR_GENE_PRODUCT", 121, 125], ["cellular RNAs", "RNA", 26, 39], ["5\u2032 ends", "DNA", 46, 53], ["RLHs", "PROTEIN", 121, 125], ["cellular RNAs", "PROBLEM", 26, 39], ["monophosphates", "TREATMENT", 83, 97], ["cellular RNAs", "OBSERVATION", 26, 39]]], ["Activated RIG-I and MDA5 then use their CARD domains to interact with the mitochondria-located adaptor protein MAVS (also known as IPS-1, VISA or Cardif) (Kawai et al., 2005, Meylan et al., 2005, Seth et al., 2005, Xu et al., 2005) (Fig. 3).", [["mitochondria", "ANATOMY", 74, 86], ["RIG-I", "GENE_OR_GENE_PRODUCT", 10, 15], ["MDA5", "GENE_OR_GENE_PRODUCT", 20, 24], ["CARD", "GENE_OR_GENE_PRODUCT", 40, 44], ["mitochondria", "CELLULAR_COMPONENT", 74, 86], ["MAVS", "GENE_OR_GENE_PRODUCT", 111, 115], ["IPS-1", "GENE_OR_GENE_PRODUCT", 131, 136], ["RIG-I", "PROTEIN", 10, 15], ["MDA5", "PROTEIN", 20, 24], ["CARD domains", "PROTEIN", 40, 52], ["mitochondria-located adaptor protein", "PROTEIN", 74, 110], ["MAVS", "PROTEIN", 111, 115], ["IPS", "PROTEIN", 131, 134], ["VISA", "PROTEIN", 138, 142], ["Cardif", "PROTEIN", 146, 152], ["their CARD domains", "TREATMENT", 34, 52], ["the mitochondria", "TREATMENT", 70, 86], ["adaptor protein MAVS", "TREATMENT", 95, 115], ["IPS", "TEST", 131, 134]]], ["MAVS in turn then triggers IKK\u03b1,\u03b2,\u03b3 as well as IKK\u025b/TBK1 phosphorylation that activate NFkB and IRF3 and IRF7 transcription factors for IFN\u03b1 and IFN\u03b2 induction (Takeuchi and Akira, 2009).", [["MAVS", "GENE_OR_GENE_PRODUCT", 0, 4], ["IKK\u03b1", "GENE_OR_GENE_PRODUCT", 27, 31], ["\u03b2", "GENE_OR_GENE_PRODUCT", 32, 33], ["\u03b3", "GENE_OR_GENE_PRODUCT", 34, 35], ["IKK\u025b", "GENE_OR_GENE_PRODUCT", 47, 51], ["TBK1", "GENE_OR_GENE_PRODUCT", 52, 56], ["NFkB", "GENE_OR_GENE_PRODUCT", 87, 91], ["IRF3", "GENE_OR_GENE_PRODUCT", 96, 100], ["IRF7", "GENE_OR_GENE_PRODUCT", 105, 109], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 136, 140], ["IFN\u03b2", "GENE_OR_GENE_PRODUCT", 145, 149], ["MAVS", "PROTEIN", 0, 4], ["IKK\u03b1", "PROTEIN", 27, 31], ["\u03b2", "PROTEIN", 32, 33], ["\u03b3", "PROTEIN", 34, 35], ["IKK\u025b", "PROTEIN", 47, 51], ["TBK1", "PROTEIN", 52, 56], ["NFkB", "PROTEIN", 87, 91], ["IRF3", "PROTEIN", 96, 100], ["IRF7", "PROTEIN", 105, 109], ["transcription factors", "PROTEIN", 110, 131], ["IFN\u03b1", "PROTEIN", 136, 140], ["IFN\u03b2", "PROTEIN", 145, 149], ["MAVS", "PROBLEM", 0, 4], ["IKK\u03b1", "TEST", 27, 31], ["IKK\u025b", "TEST", 47, 51], ["TBK1 phosphorylation", "PROBLEM", 52, 72], ["NFkB", "TEST", 87, 91], ["IRF3", "TREATMENT", 96, 100], ["IRF7 transcription factors", "TREATMENT", 105, 131], ["IFN\u03b1", "TREATMENT", 136, 140], ["IFN\u03b2 induction", "TREATMENT", 145, 159]]], ["Similar to TLR3 signaling, sensing through RIG-I/MDA5/MAVS is heavily antagonized by viruses.", [["TLR3", "GENE_OR_GENE_PRODUCT", 11, 15], ["RIG-I", "GENE_OR_GENE_PRODUCT", 43, 48], ["MDA5", "GENE_OR_GENE_PRODUCT", 49, 53], ["MAVS", "GENE_OR_GENE_PRODUCT", 54, 58], ["TLR3", "PROTEIN", 11, 15], ["RIG-I", "PROTEIN", 43, 48], ["MDA5", "PROTEIN", 49, 53], ["MAVS", "PROTEIN", 54, 58], ["MAVS", "PROBLEM", 54, 58], ["viruses", "PROBLEM", 85, 92], ["TLR3 signaling", "OBSERVATION", 11, 25], ["viruses", "OBSERVATION", 85, 92]]], ["Influenza NS1 binds the RIG-I/MAVS complex and thereby interferes with its signaling.", [["Influenza NS1", "ORGANISM", 0, 13], ["RIG-I", "GENE_OR_GENE_PRODUCT", 24, 29], ["MAVS", "GENE_OR_GENE_PRODUCT", 30, 34], ["Influenza NS1", "PROTEIN", 0, 13], ["RIG-I/MAVS complex", "PROTEIN", 24, 42], ["Influenza", "SPECIES", 0, 9], ["Influenza", "PROBLEM", 0, 9], ["MAVS complex", "PROBLEM", 30, 42]]], ["Moreover, paramyxovirus V and polivirus are able to inhibit the function of MDA5.", [["paramyxovirus V", "ORGANISM", 10, 25], ["polivirus", "GENE_OR_GENE_PRODUCT", 30, 39], ["MDA5", "GENE_OR_GENE_PRODUCT", 76, 80], ["MDA5", "PROTEIN", 76, 80], ["paramyxovirus V", "SPECIES", 10, 25], ["paramyxovirus V", "PROBLEM", 10, 25], ["polivirus", "TREATMENT", 30, 39], ["paramyxovirus V", "OBSERVATION", 10, 25]]], ["Finally, HCV NS3-4 abrogates MAVS signaling by cleaving it from the mitochondrial membrane.", [["mitochondrial membrane", "ANATOMY", 68, 90], ["HCV", "ORGANISM", 9, 12], ["NS3-4", "GENE_OR_GENE_PRODUCT", 13, 18], ["MAVS", "GENE_OR_GENE_PRODUCT", 29, 33], ["mitochondrial membrane", "CELLULAR_COMPONENT", 68, 90], ["HCV NS3-4", "PROTEIN", 9, 18], ["MAVS", "PROTEIN", 29, 33], ["HCV", "SPECIES", 9, 12], ["HCV NS3", "TREATMENT", 9, 16], ["MAVS signaling", "PROBLEM", 29, 43], ["mitochondrial membrane", "OBSERVATION", 68, 90]]], ["Similarly, MAVS is degraded by mitochondria-targeted hepatitis A virus 3ABC protein (Bowie and Unterholzer, 2008).", [["mitochondria", "ANATOMY", 31, 43], ["MAVS", "GENE_OR_GENE_PRODUCT", 11, 15], ["mitochondria", "CELLULAR_COMPONENT", 31, 43], ["hepatitis A virus 3ABC", "ORGANISM", 53, 75], ["MAVS", "PROTEIN", 11, 15], ["hepatitis A virus 3ABC protein", "PROTEIN", 53, 83], ["hepatitis A virus", "SPECIES", 53, 70], ["hepatitis A virus", "SPECIES", 53, 70], ["mitochondria", "TEST", 31, 43], ["MAVS", "OBSERVATION", 11, 15]]], ["The latter examples show that MAVS functions on mitochondria and suggests that this organelle either plays a so far unrecognized role in antiviral type I interferon signaling or that MAVS also mediates apoptosis and thereby crosstalks with Bax/Bak-induced MOMP.", [["mitochondria", "ANATOMY", 48, 60], ["organelle", "ANATOMY", 84, 93], ["MAVS", "GENE_OR_GENE_PRODUCT", 30, 34], ["mitochondria", "CELLULAR_COMPONENT", 48, 60], ["organelle", "CELLULAR_COMPONENT", 84, 93], ["type I interferon", "GENE_OR_GENE_PRODUCT", 147, 164], ["MAVS", "GENE_OR_GENE_PRODUCT", 183, 187], ["Bax", "GENE_OR_GENE_PRODUCT", 240, 243], ["Bak-", "GENE_OR_GENE_PRODUCT", 244, 248], ["MOMP", "GENE_OR_GENE_PRODUCT", 256, 260], ["MAVS", "PROTEIN", 30, 34], ["antiviral type I interferon", "PROTEIN", 137, 164], ["MAVS", "PROTEIN", 183, 187], ["Bax", "PROTEIN", 240, 243], ["Bak-", "PROTEIN", 244, 248], ["MOMP", "PROTEIN", 256, 260], ["MAVS functions on mitochondria", "PROBLEM", 30, 60], ["antiviral type I interferon signaling", "PROBLEM", 137, 174], ["apoptosis", "PROBLEM", 202, 211], ["MOMP", "PROBLEM", 256, 260]]], ["Indeed, Besch et al. reported that both RIG-1 and MDA5 could induce apoptosis of human melanoma cells in a type I interferon-independent manner, i.e. at a step before IFN\u03b1/\u03b2 induction (Besch et al., 2009).", [["melanoma cells", "ANATOMY", 87, 101], ["melanoma", "DISEASE", 87, 95], ["RIG-1", "GENE_OR_GENE_PRODUCT", 40, 45], ["MDA5", "GENE_OR_GENE_PRODUCT", 50, 54], ["human", "ORGANISM", 81, 86], ["melanoma cells", "CELL", 87, 101], ["type I interferon", "GENE_OR_GENE_PRODUCT", 107, 124], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 167, 171], ["\u03b2", "GENE_OR_GENE_PRODUCT", 172, 173], ["RIG-1", "PROTEIN", 40, 45], ["MDA5", "PROTEIN", 50, 54], ["human melanoma cells", "CELL_TYPE", 81, 101], ["IFN\u03b1", "PROTEIN", 167, 171], ["\u03b2", "PROTEIN", 172, 173], ["human", "SPECIES", 81, 86], ["human", "SPECIES", 81, 86], ["human melanoma cells", "PROBLEM", 81, 101], ["melanoma cells", "OBSERVATION", 87, 101]]], ["The molecular mechanisms of this new death signaling pathway had however not been defined at that time.Recognizing/sensing viruses in endosomal and cytosolic compartments and mounting an antiviral innate immune response ::: Mechanisms by which the intrinsic, mitochondrial apoptosis pathway is activated after viral infectionRecently, we published new insights into the mechanisms of host cell apoptosis induced by a single stranded, positive-sense RNA virus which does not encode for any cell death protective proteins (El Maadidi et al., 2014).", [["endosomal", "ANATOMY", 134, 143], ["cytosolic compartments", "ANATOMY", 148, 170], ["mitochondrial", "ANATOMY", 259, 272], ["cell", "ANATOMY", 389, 393], ["cell", "ANATOMY", 489, 493], ["death", "DISEASE", 37, 42], ["death", "DISEASE", 494, 499], ["endosomal", "CELLULAR_COMPONENT", 134, 143], ["cytosolic compartments", "CELLULAR_COMPONENT", 148, 170], ["mitochondrial", "CELLULAR_COMPONENT", 259, 272], ["host cell", "CELL", 384, 393], ["cell", "CELL", 489, 493], ["cell death protective proteins", "PROTEIN", 489, 519], ["this new death signaling pathway", "PROBLEM", 28, 60], ["Recognizing/sensing viruses in endosomal and cytosolic compartments", "PROBLEM", 103, 170], ["mitochondrial apoptosis pathway", "PROBLEM", 259, 290], ["viral infectionRecently", "PROBLEM", 310, 333], ["host cell apoptosis", "PROBLEM", 384, 403], ["a single stranded, positive-sense RNA virus", "PROBLEM", 415, 458], ["sensing viruses", "OBSERVATION", 115, 130], ["mitochondrial apoptosis", "OBSERVATION", 259, 282], ["host cell apoptosis", "OBSERVATION", 384, 403]]], ["Semliki Forest virus (SFV) is a neurotropic virus that kills mice during the first 21 days of their life, probably due to the induction of apoptosis of immature neurons (Strauss and Strauss, 1994).", [["neurons", "ANATOMY", 161, 168], ["Semliki Forest virus", "ORGANISM", 0, 20], ["SFV", "ORGANISM", 22, 25], ["neurotropic virus", "ORGANISM", 32, 49], ["mice", "ORGANISM", 61, 65], ["neurons", "CELL", 161, 168], ["immature neurons", "CELL_TYPE", 152, 168], ["Semliki Forest virus", "SPECIES", 0, 20], ["mice", "SPECIES", 61, 65], ["Semliki Forest virus", "SPECIES", 0, 20], ["SFV", "SPECIES", 22, 25], ["mice", "SPECIES", 61, 65], ["Semliki Forest virus (SFV", "PROBLEM", 0, 25], ["a neurotropic virus", "PROBLEM", 30, 49], ["immature neurons", "PROBLEM", 152, 168], ["Forest virus", "OBSERVATION", 8, 20]]], ["It also causes encephalitis in various animals but is mostly apathogenic for humans (Fazakerley, 2002).", [["encephalitis", "DISEASE", 15, 27], ["humans", "ORGANISM", 77, 83], ["humans", "SPECIES", 77, 83], ["humans", "SPECIES", 77, 83], ["encephalitis", "PROBLEM", 15, 27], ["encephalitis", "OBSERVATION", 15, 27], ["mostly", "OBSERVATION_MODIFIER", 54, 60], ["apathogenic", "OBSERVATION", 61, 72]]], ["We and others however found that SFV induces effective apoptosis of a variety of human and mouse cells in vitro via the intrinsic mitochondrial pathway, i.e. requiring Bax/Bak and the induction of MOMP (Ubol et al., 1994, Grandgirard et al., 1998, Murphy et al., 2001, Urban et al., 2008).", [["cells", "ANATOMY", 97, 102], ["mitochondrial", "ANATOMY", 130, 143], ["SFV", "ORGANISM", 33, 36], ["human", "ORGANISM", 81, 86], ["mouse", "ORGANISM", 91, 96], ["cells", "CELL", 97, 102], ["mitochondrial", "CELLULAR_COMPONENT", 130, 143], ["Bax", "GENE_OR_GENE_PRODUCT", 168, 171], ["Bak", "GENE_OR_GENE_PRODUCT", 172, 175], ["MOMP", "GENE_OR_GENE_PRODUCT", 197, 201], ["human and mouse cells", "CELL_TYPE", 81, 102], ["Bax", "PROTEIN", 168, 171], ["Bak", "PROTEIN", 172, 175], ["human", "SPECIES", 81, 86], ["mouse", "SPECIES", 91, 96], ["SFV", "SPECIES", 33, 36], ["human", "SPECIES", 81, 86], ["mouse", "SPECIES", 91, 96], ["SFV", "PROBLEM", 33, 36], ["human and mouse cells", "TREATMENT", 81, 102], ["Bax/Bak", "TREATMENT", 168, 175], ["SFV", "OBSERVATION", 33, 36]]], ["After infection, SFV produces high amounts of dsRNA during the RNA replication cycle, and although it is not entirely clear whether dsRNA is the trigger for SFV-induced apoptosis and how it could activate Bax/Bak (via which BH3-only protein?, see below) (Fig. 3), we reported that SFV-induced apoptosis is clearly RNA replication dependent (Urban et al., 2008).", [["infection", "DISEASE", 6, 15], ["SFV", "ORGANISM", 17, 20], ["SFV", "ORGANISM", 157, 160], ["Bax", "GENE_OR_GENE_PRODUCT", 205, 208], ["Bak", "GENE_OR_GENE_PRODUCT", 209, 212], ["BH3", "GENE_OR_GENE_PRODUCT", 224, 227], ["SFV", "ORGANISM", 281, 284], ["Bax", "PROTEIN", 205, 208], ["Bak", "PROTEIN", 209, 212], ["BH3", "PROTEIN", 224, 227], ["SFV", "SPECIES", 17, 20], ["SFV", "SPECIES", 157, 160], ["SFV", "SPECIES", 281, 284], ["infection", "PROBLEM", 6, 15], ["SFV", "PROBLEM", 17, 20], ["high amounts of dsRNA", "PROBLEM", 30, 51], ["the RNA replication cycle", "TREATMENT", 59, 84], ["dsRNA", "PROBLEM", 132, 137], ["SFV", "PROBLEM", 157, 160], ["induced apoptosis", "PROBLEM", 161, 178], ["Bax/Bak", "TREATMENT", 205, 212], ["BH3", "TEST", 224, 227], ["protein?", "TEST", 233, 241], ["SFV", "PROBLEM", 281, 284], ["infection", "OBSERVATION", 6, 15], ["SFV", "OBSERVATION", 17, 20], ["high", "OBSERVATION_MODIFIER", 30, 34], ["amounts", "OBSERVATION_MODIFIER", 35, 42], ["dsRNA", "OBSERVATION", 132, 137], ["SFV", "OBSERVATION", 281, 284], ["RNA replication", "OBSERVATION", 314, 329]]], ["Moreover, Bax/Bak double knock-out cells are not entirely protected from SFV-induced apoptosis but exhibit a Bax/Bak-independent cell death that still requires caspases but does not involve death-receptor signaling.", [["cells", "ANATOMY", 35, 40], ["cell", "ANATOMY", 129, 133], ["death", "DISEASE", 134, 139], ["death", "DISEASE", 190, 195], ["Bax", "GENE_OR_GENE_PRODUCT", 10, 13], ["Bak", "GENE_OR_GENE_PRODUCT", 14, 17], ["SFV", "ORGANISM", 73, 76], ["Bax", "GENE_OR_GENE_PRODUCT", 109, 112], ["Bak", "GENE_OR_GENE_PRODUCT", 113, 116], ["cell", "CELL", 129, 133], ["caspases", "GENE_OR_GENE_PRODUCT", 160, 168], ["death-receptor", "GENE_OR_GENE_PRODUCT", 190, 204], ["Bax", "PROTEIN", 10, 13], ["Bak", "PROTEIN", 14, 17], ["Bax", "PROTEIN", 109, 112], ["Bak", "PROTEIN", 113, 116], ["caspases", "PROTEIN", 160, 168], ["SFV", "SPECIES", 73, 76], ["Bax", "TEST", 10, 13], ["cells", "PROBLEM", 35, 40], ["SFV", "PROBLEM", 73, 76], ["apoptosis", "PROBLEM", 85, 94], ["independent cell death", "PROBLEM", 117, 139], ["caspases", "TREATMENT", 160, 168], ["death", "PROBLEM", 190, 195], ["receptor signaling", "PROBLEM", 196, 214], ["not entirely", "UNCERTAINTY", 45, 57], ["SFV", "OBSERVATION", 73, 76], ["cell death", "OBSERVATION", 129, 139]]], ["We then found that this novel Bax/Bak-independent death signaling pathway requires a MDA5-mediated activation of MAVS on mitochondria (El Maadidi et al., 2014).", [["mitochondria", "ANATOMY", 121, 133], ["death", "DISEASE", 50, 55], ["Bax", "GENE_OR_GENE_PRODUCT", 30, 33], ["Bak", "GENE_OR_GENE_PRODUCT", 34, 37], ["MDA5", "GENE_OR_GENE_PRODUCT", 85, 89], ["MAVS", "GENE_OR_GENE_PRODUCT", 113, 117], ["mitochondria", "CELLULAR_COMPONENT", 121, 133], ["Bax", "PROTEIN", 30, 33], ["Bak", "PROTEIN", 34, 37], ["MDA5", "PROTEIN", 85, 89], ["MAVS", "PROTEIN", 113, 117], ["this novel Bax/Bak", "TREATMENT", 19, 37], ["independent death signaling pathway", "PROBLEM", 38, 73], ["a MDA5", "TREATMENT", 83, 89]]], ["MAVS recruits caspase-8 from the cytosol to mitochondria forming a novel death inducing signaling complex that is capable of processing and activating caspase-3 and inducing apoptosis (Fig. 3).", [["cytosol", "ANATOMY", 33, 40], ["mitochondria", "ANATOMY", 44, 56], ["death", "DISEASE", 73, 78], ["MAVS", "GENE_OR_GENE_PRODUCT", 0, 4], ["caspase-8", "GENE_OR_GENE_PRODUCT", 14, 23], ["cytosol", "CELLULAR_COMPONENT", 33, 40], ["mitochondria", "CELLULAR_COMPONENT", 44, 56], ["death inducing signaling complex", "GENE_OR_GENE_PRODUCT", 73, 105], ["caspase-3", "GENE_OR_GENE_PRODUCT", 151, 160], ["MAVS", "PROTEIN", 0, 4], ["caspase-8", "PROTEIN", 14, 23], ["death inducing signaling complex", "PROTEIN", 73, 105], ["caspase-3", "PROTEIN", 151, 160], ["MAVS recruits caspase", "PROBLEM", 0, 21], ["a novel death", "PROBLEM", 65, 78], ["signaling complex", "PROBLEM", 88, 105], ["activating caspase", "TEST", 140, 158]]], ["Our results indicate that not only the TLR3/TRIF axis can induce apoptosis in addition to activating NF\u03baB, IRF3/7 and an antiviral type I interferon response (Kaiser and Offermann, 2005, Weber et al., 2010, Estornes et al., 2012), but the same can be achieved by the MDA5/MAVS pathway (El Maadidi et al., 2014).", [["TLR3", "GENE_OR_GENE_PRODUCT", 39, 43], ["TRIF", "GENE_OR_GENE_PRODUCT", 44, 48], ["NF\u03baB", "GENE_OR_GENE_PRODUCT", 101, 105], ["IRF3/7", "GENE_OR_GENE_PRODUCT", 107, 113], ["type I interferon", "GENE_OR_GENE_PRODUCT", 131, 148], ["MDA5", "GENE_OR_GENE_PRODUCT", 267, 271], ["MAVS", "GENE_OR_GENE_PRODUCT", 272, 276], ["TLR3", "PROTEIN", 39, 43], ["TRIF", "PROTEIN", 44, 48], ["NF\u03baB", "PROTEIN", 101, 105], ["IRF3/7", "PROTEIN", 107, 113], ["MDA5", "PROTEIN", 267, 271], ["MAVS", "PROTEIN", 272, 276], ["apoptosis", "PROBLEM", 65, 74]]], ["Both Bax/Bak- and death receptor-independent death signaling pathways use the initiator caspase-8 on novel death platforms (TLR3/TRIF/caspase-8 or MAVS/caspase-8) to activate caspase-3/-7 (Fig. 3).", [["death", "DISEASE", 18, 23], ["death", "DISEASE", 45, 50], ["death", "DISEASE", 107, 112], ["Bax", "GENE_OR_GENE_PRODUCT", 5, 8], ["Bak", "GENE_OR_GENE_PRODUCT", 9, 12], ["caspase-8", "GENE_OR_GENE_PRODUCT", 88, 97], ["TLR3", "GENE_OR_GENE_PRODUCT", 124, 128], ["TRIF", "GENE_OR_GENE_PRODUCT", 129, 133], ["caspase-8", "GENE_OR_GENE_PRODUCT", 134, 143], ["MAVS", "GENE_OR_GENE_PRODUCT", 147, 151], ["caspase-8", "GENE_OR_GENE_PRODUCT", 152, 161], ["caspase-3/-7", "GENE_OR_GENE_PRODUCT", 175, 187], ["Bax", "PROTEIN", 5, 8], ["Bak", "PROTEIN", 9, 12], ["death receptor", "PROTEIN", 18, 32], ["initiator caspase-8", "PROTEIN", 78, 97], ["TLR3", "PROTEIN", 124, 128], ["TRIF", "PROTEIN", 129, 133], ["caspase-8", "PROTEIN", 134, 143], ["MAVS", "PROTEIN", 147, 151], ["caspase-8", "PROTEIN", 152, 161], ["caspase-3/-7", "PROTEIN", 175, 187], ["Bak", "TREATMENT", 9, 12], ["death receptor", "PROBLEM", 18, 32], ["the initiator caspase", "TREATMENT", 74, 95], ["novel death platforms", "TREATMENT", 101, 122], ["TLR3/TRIF/caspase", "TREATMENT", 124, 141], ["MAVS/caspase", "TREATMENT", 147, 159], ["caspase", "TEST", 175, 182], ["Bak", "ANATOMY", 9, 12]]], ["Whether this innate immune signaling pathway also accounts for interferon responses and/or apoptosis in response to DNA viruses, which use TLR9 (Hemmi et al., 2000) and other intracellular sensors such as cGAS/STING (Sun et al., 2013) or DAI (Takaoka et al., 2007) remains to be determined.", [["intracellular", "ANATOMY", 175, 188], ["DNA", "CELLULAR_COMPONENT", 116, 119], ["TLR9", "GENE_OR_GENE_PRODUCT", 139, 143], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 175, 188], ["cGAS", "GENE_OR_GENE_PRODUCT", 205, 209], ["STING", "GENE_OR_GENE_PRODUCT", 210, 215], ["interferon", "PROTEIN", 63, 73], ["TLR9", "PROTEIN", 139, 143], ["cGAS", "PROTEIN", 205, 209], ["STING", "PROTEIN", 210, 215], ["interferon responses", "PROBLEM", 63, 83], ["apoptosis", "PROBLEM", 91, 100], ["DNA viruses", "PROBLEM", 116, 127], ["other intracellular sensors", "TREATMENT", 169, 196]]], ["Interestingly, it was recently shown that IPS-1/MAVS may also mediate innate immune signaling in response to DNA viruses (Zhang et al., 2011, Unterholzner, 2013).", [["IPS-1", "GENE_OR_GENE_PRODUCT", 42, 47], ["MAVS", "GENE_OR_GENE_PRODUCT", 48, 52], ["DNA", "CELLULAR_COMPONENT", 109, 112], ["IPS", "PROTEIN", 42, 45], ["MAVS", "PROTEIN", 48, 52], ["IPS", "TEST", 42, 45], ["MAVS", "PROBLEM", 48, 52], ["DNA viruses", "PROBLEM", 109, 120]]], ["Thus, this novel mitochondria-associated pathway may be used as a general defence mechanism of host cells against viruses.Host cell apoptosis induced by ER stress caused by viral overload ::: Mechanisms by which the intrinsic, mitochondrial apoptosis pathway is activated after viral infectionAnother possibility how cells can sense and react to virus infection is by mounting an ER-stress response (Li et al., 2013a, Li et al., 2013b).", [["mitochondria", "ANATOMY", 17, 29], ["cells", "ANATOMY", 100, 105], ["cell", "ANATOMY", 127, 131], ["mitochondrial", "ANATOMY", 227, 240], ["cells", "ANATOMY", 317, 322], ["viral overload", "DISEASE", 173, 187], ["viral infection", "DISEASE", 278, 293], ["infection", "DISEASE", 352, 361], ["mitochondria", "CELLULAR_COMPONENT", 17, 29], ["host cells", "CELL", 95, 105], ["Host cell", "CELL", 122, 131], ["ER", "GENE_OR_GENE_PRODUCT", 153, 155], ["mitochondrial", "CELLULAR_COMPONENT", 227, 240], ["cells", "CELL", 317, 322], ["ER", "GENE_OR_GENE_PRODUCT", 380, 382], ["host cells", "CELL_TYPE", 95, 105], ["ER", "PROTEIN", 153, 155], ["ER", "PROTEIN", 380, 382], ["viruses", "PROBLEM", 114, 121], ["Host cell apoptosis", "PROBLEM", 122, 141], ["viral overload", "PROBLEM", 173, 187], ["mitochondrial apoptosis pathway", "PROBLEM", 227, 258], ["viral infection", "PROBLEM", 278, 293], ["virus infection", "PROBLEM", 346, 361], ["host cells", "OBSERVATION", 95, 105], ["cell apoptosis", "OBSERVATION", 127, 141], ["viral overload", "OBSERVATION", 173, 187], ["mitochondrial apoptosis", "OBSERVATION", 227, 250]]], ["This is particularly the case for RNA viruses such as alphaviruses where the envelope proteins are co-translationally inserted into the ER membrane and travel through the exocytotic system to the cell surface for virus budding (Li and Stollar, 2004, He, 2006, Barry et al., 2010, Jheng et al., 2014).", [["ER membrane", "ANATOMY", 136, 147], ["cell surface", "ANATOMY", 196, 208], ["ER", "GENE_OR_GENE_PRODUCT", 136, 138], ["membrane", "CELLULAR_COMPONENT", 139, 147], ["exocytotic system", "CELLULAR_COMPONENT", 171, 188], ["cell surface", "CELLULAR_COMPONENT", 196, 208], ["envelope proteins", "PROTEIN", 77, 94], ["ER", "PROTEIN", 136, 138], ["RNA viruses", "PROBLEM", 34, 45], ["alphaviruses", "PROBLEM", 54, 66], ["the envelope proteins", "TREATMENT", 73, 94]]], ["In this case the high amount of ER-localized viral proteins induce a classical unfolded protein response (UPR).", [["ER", "GENE_OR_GENE_PRODUCT", 32, 34], ["ER", "PROTEIN", 32, 34], ["viral proteins", "PROTEIN", 45, 59], ["localized viral proteins", "PROBLEM", 35, 59], ["a classical unfolded protein response", "PROBLEM", 67, 104], ["viral proteins", "OBSERVATION", 45, 59], ["protein response", "OBSERVATION", 88, 104]]], ["While UPR responses are often cell protective by triggering the transcriptional upregulation of chaperones such as BiP/grp78 which help in the folding of the massive amount of proteins, a persistent, prolonged UPR response, for example via the IRE\u03b1/XBP1 pathway can also lead to apoptosis of the infected host cells (Lin et al., 2007, Sano and Reed, 2013, Lu et al., 2014).", [["cell", "ANATOMY", 30, 34], ["cells", "ANATOMY", 310, 315], ["UPR", "GENE_OR_GENE_PRODUCT", 6, 9], ["cell", "CELL", 30, 34], ["BiP", "GENE_OR_GENE_PRODUCT", 115, 118], ["grp78", "GENE_OR_GENE_PRODUCT", 119, 124], ["IRE\u03b1", "GENE_OR_GENE_PRODUCT", 244, 248], ["XBP1", "GENE_OR_GENE_PRODUCT", 249, 253], ["cells", "CELL", 310, 315], ["BiP", "PROTEIN", 115, 118], ["grp78", "PROTEIN", 119, 124], ["UPR", "PROTEIN", 210, 213], ["IRE\u03b1", "PROTEIN", 244, 248], ["XBP1", "PROTEIN", 249, 253], ["infected host cells", "CELL_TYPE", 296, 315], ["the transcriptional upregulation of chaperones", "TREATMENT", 60, 106], ["BiP/grp78", "TREATMENT", 115, 124], ["the massive amount of proteins", "PROBLEM", 154, 184], ["a persistent, prolonged UPR response", "PROBLEM", 186, 222], ["the IRE", "TEST", 240, 247], ["apoptosis", "PROBLEM", 279, 288], ["the infected host cells", "PROBLEM", 292, 315], ["massive", "OBSERVATION_MODIFIER", 158, 165], ["amount", "OBSERVATION_MODIFIER", 166, 172], ["persistent", "OBSERVATION_MODIFIER", 188, 198], ["infected", "OBSERVATION_MODIFIER", 296, 304], ["host cells", "OBSERVATION", 305, 315]]], ["In this case, the transcription factor CHOP1 is activated which upregulates the BH3-only proteins Bim and Puma, leading to Bax/Bak activation and MOMP via the intrinsic mitochondrial pathway (Reimertz et al., 2003, Puthalakath et al., 2007, Ghosh et al., 2012).", [["mitochondrial", "ANATOMY", 169, 182], ["CHOP1", "GENE_OR_GENE_PRODUCT", 39, 44], ["Bim", "GENE_OR_GENE_PRODUCT", 98, 101], ["Puma", "GENE_OR_GENE_PRODUCT", 106, 110], ["Bax", "GENE_OR_GENE_PRODUCT", 123, 126], ["Bak", "GENE_OR_GENE_PRODUCT", 127, 130], ["MOMP", "GENE_OR_GENE_PRODUCT", 146, 150], ["mitochondrial", "CELLULAR_COMPONENT", 169, 182], ["transcription factor", "PROTEIN", 18, 38], ["CHOP1", "PROTEIN", 39, 44], ["BH3", "PROTEIN", 80, 83], ["Bim", "PROTEIN", 98, 101], ["Puma", "PROTEIN", 106, 110], ["Bax", "PROTEIN", 123, 126], ["Bak", "PROTEIN", 127, 130], ["MOMP", "PROTEIN", 146, 150], ["the transcription factor CHOP1", "TEST", 14, 44], ["the BH3", "TEST", 76, 83], ["Bax/Bak activation", "TREATMENT", 123, 141]]], ["Viruses would then counteract host cell death by the expression of Bcl-2 orthologs (vBcl-2s).Viral components that directly impinge on the host cell apoptotic machinery ::: Mechanisms by which the intrinsic, mitochondrial apoptosis pathway is activated after viral infectionSome viruses have developed strategies to actively kill their infected hosts, probably to avoid the presentation of viral antigens to the adaptive immune system.", [["cell", "ANATOMY", 35, 39], ["cell", "ANATOMY", 144, 148], ["mitochondrial", "ANATOMY", 208, 221], ["immune system", "ANATOMY", 421, 434], ["viral infection", "DISEASE", 259, 274], ["host cell", "CELL", 30, 39], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 67, 72], ["vBcl-2s", "GENE_OR_GENE_PRODUCT", 84, 91], ["cell", "CELL", 144, 148], ["mitochondrial", "CELLULAR_COMPONENT", 208, 221], ["immune system", "ANATOMICAL_SYSTEM", 421, 434], ["Bcl-2 orthologs", "PROTEIN", 67, 82], ["vBcl", "PROTEIN", 84, 88], ["2s", "PROTEIN", 89, 91], ["viral antigens", "PROTEIN", 390, 404], ["Viruses", "PROBLEM", 0, 7], ["host cell death", "PROBLEM", 30, 45], ["Bcl", "TEST", 67, 70], ["vBcl", "TEST", 84, 88], ["Viral components", "PROBLEM", 93, 109], ["mitochondrial apoptosis pathway", "PROBLEM", 208, 239], ["viral infection", "PROBLEM", 259, 274], ["Some viruses", "PROBLEM", 274, 286], ["viral antigens", "PROBLEM", 390, 404], ["host cell death", "OBSERVATION", 30, 45], ["host cell apoptotic machinery", "OBSERVATION", 139, 168], ["mitochondrial apoptosis", "OBSERVATION", 208, 231]]], ["If this happens viruses have replicated and assembled into new virions so that host cell apoptosis does not eliminate the virus as well.", [["virions", "ANATOMY", 63, 70], ["cell", "ANATOMY", 84, 88], ["host cell", "CELL", 79, 88], ["viruses", "PROBLEM", 16, 23], ["new virions", "PROBLEM", 59, 70], ["host cell apoptosis", "PROBLEM", 79, 98], ["the virus", "PROBLEM", 118, 127], ["host cell apoptosis", "OBSERVATION", 79, 98], ["virus", "OBSERVATION", 122, 127]]], ["Both the activation of the extrinsic as well as the intrinsic apoptosis pathways have been observed.", [["the intrinsic apoptosis pathways", "PROBLEM", 48, 80], ["apoptosis", "OBSERVATION", 62, 71]]], ["Targeting the extrinsic pathway, the Nef protein of HIV downregulates CD4 and MHC-1 from the cell surface by crosslinking these proteins to the endocytic compartment (Piguet et al., 1999).", [["cell surface", "ANATOMY", 93, 105], ["endocytic compartment", "ANATOMY", 144, 165], ["Nef", "GENE_OR_GENE_PRODUCT", 37, 40], ["HIV", "ORGANISM", 52, 55], ["CD4", "GENE_OR_GENE_PRODUCT", 70, 73], ["MHC-1", "GENE_OR_GENE_PRODUCT", 78, 83], ["cell surface", "CELLULAR_COMPONENT", 93, 105], ["Nef protein", "PROTEIN", 37, 48], ["CD4", "PROTEIN", 70, 73], ["MHC-1", "PROTEIN", 78, 83], ["HIV", "SPECIES", 52, 55], ["the extrinsic pathway", "TEST", 10, 31], ["the Nef protein", "TEST", 33, 48], ["HIV", "PROBLEM", 52, 55], ["MHC", "TEST", 78, 81], ["the cell surface", "TEST", 89, 105], ["cell", "ANATOMY_MODIFIER", 93, 97], ["surface", "ANATOMY_MODIFIER", 98, 105], ["endocytic", "ANATOMY_MODIFIER", 144, 153], ["compartment", "ANATOMY_MODIFIER", 154, 165]]], ["As a consequence membrane-bound TNF\u03b1 and LIGHT are constitutively expressed on the surface of T cells, potentially contributing to the cytotoxic effects of HIV on infected T cells and uninfected bystander lymphocytes (Lama and Ware, 2000).", [["membrane", "ANATOMY", 17, 25], ["surface", "ANATOMY", 83, 90], ["T cells", "ANATOMY", 94, 101], ["T cells", "ANATOMY", 172, 179], ["bystander lymphocytes", "ANATOMY", 195, 216], ["membrane", "CELLULAR_COMPONENT", 17, 25], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 32, 36], ["LIGHT", "GENE_OR_GENE_PRODUCT", 41, 46], ["surface", "CELLULAR_COMPONENT", 83, 90], ["T cells", "CELL", 94, 101], ["HIV", "ORGANISM", 156, 159], ["T cells", "CELL", 172, 179], ["bystander lymphocytes", "CELL", 195, 216], ["Lama", "CELL", 218, 222], ["TNF\u03b1", "PROTEIN", 32, 36], ["LIGHT", "PROTEIN", 41, 46], ["T cells", "CELL_TYPE", 94, 101], ["infected T cells", "CELL_TYPE", 163, 179], ["uninfected bystander lymphocytes", "CELL_TYPE", 184, 216], ["HIV", "SPECIES", 156, 159], ["HIV", "SPECIES", 156, 159], ["a consequence membrane-bound TNF", "TEST", 3, 35], ["HIV on infected T cells", "PROBLEM", 156, 179]]], ["Moreover, HCMV and reoviruses were shown to actively induce the expression of TRAIL (Sedger et al., 1999, Vidalain et al., 2000) and HSV and HCMV can enhance the expression of FasL (Raftery et al., 1999, Raftery et al., 2001).", [["HCMV", "ORGANISM", 10, 14], ["reoviruses", "GENE_OR_GENE_PRODUCT", 19, 29], ["TRAIL", "GENE_OR_GENE_PRODUCT", 78, 83], ["HSV", "ORGANISM", 133, 136], ["HCMV", "ORGANISM", 141, 145], ["FasL", "GENE_OR_GENE_PRODUCT", 176, 180], ["TRAIL", "PROTEIN", 78, 83], ["FasL", "PROTEIN", 176, 180], ["HCMV", "SPECIES", 10, 14], ["HSV", "SPECIES", 133, 136], ["HCMV", "SPECIES", 141, 145], ["HCMV", "PROBLEM", 10, 14], ["reoviruses", "PROBLEM", 19, 29], ["HSV", "PROBLEM", 133, 136], ["HCMV", "PROBLEM", 141, 145], ["HCMV", "OBSERVATION", 10, 14]]], ["This mechanism is thought to constitute another viral immune evasion tactic to eliminate infiltrating immune cells such as CTLs and DCs by counterattack.Viral components that directly impinge on the host cell apoptotic machinery ::: Mechanisms by which the intrinsic, mitochondrial apoptosis pathway is activated after viral infectionTo activate the intrinsic mitochondrial pathway, the Vpr protein from HIV-1 induces swelling of mitochondria and MOM permeabilization in lymphoid and transformed cells (Stewart et al., 1999, Jacotot et al., 2000, Muthumani et al., 2002, Deniaud et al., 2004).", [["immune cells", "ANATOMY", 102, 114], ["CTLs", "ANATOMY", 123, 127], ["DCs", "ANATOMY", 132, 135], ["cell", "ANATOMY", 204, 208], ["mitochondrial", "ANATOMY", 268, 281], ["mitochondrial", "ANATOMY", 360, 373], ["mitochondria", "ANATOMY", 430, 442], ["lymphoid", "ANATOMY", 471, 479], ["cells", "ANATOMY", 496, 501], ["infiltrating immune cells", "CELL", 89, 114], ["CTLs", "CELL", 123, 127], ["DCs", "CELL", 132, 135], ["cell", "CELL", 204, 208], ["mitochondrial", "CELLULAR_COMPONENT", 268, 281], ["mitochondrial", "CELLULAR_COMPONENT", 360, 373], ["Vpr", "GENE_OR_GENE_PRODUCT", 387, 390], ["HIV-1", "ORGANISM", 404, 409], ["mitochondria", "CELLULAR_COMPONENT", 430, 442], ["MOM", "SIMPLE_CHEMICAL", 447, 450], ["lymphoid", "CELL", 471, 479], ["cells", "CELL", 496, 501], ["infiltrating immune cells", "CELL_TYPE", 89, 114], ["CTLs", "CELL_TYPE", 123, 127], ["DCs", "CELL_TYPE", 132, 135], ["Vpr protein", "PROTEIN", 387, 398], ["lymphoid and transformed cells", "CELL_TYPE", 471, 501], ["HIV-1", "SPECIES", 404, 409], ["HIV-1", "SPECIES", 404, 409], ["another viral immune evasion", "TREATMENT", 40, 68], ["infiltrating immune cells", "PROBLEM", 89, 114], ["CTLs", "PROBLEM", 123, 127], ["Viral components", "PROBLEM", 153, 169], ["mitochondrial apoptosis pathway", "PROBLEM", 268, 299], ["viral infectionTo activate", "PROBLEM", 319, 345], ["the Vpr protein", "TEST", 383, 398], ["HIV", "TEST", 404, 407], ["swelling of mitochondria", "PROBLEM", 418, 442], ["thought to constitute", "UNCERTAINTY", 18, 39], ["host cell apoptotic machinery", "OBSERVATION", 199, 228], ["mitochondrial apoptosis", "OBSERVATION", 268, 291], ["lymphoid", "ANATOMY", 471, 479]]], ["Severe acute respiratory syndrome coronavirus (SARS-CoV) 7a protein can directly inhibit Bcl-xL and other survival factors (Tan et al., 2007).", [["acute respiratory syndrome coronavirus", "DISEASE", 7, 45], ["Severe acute respiratory syndrome coronavirus", "ORGANISM", 0, 45], ["SARS-CoV) 7a", "GENE_OR_GENE_PRODUCT", 47, 59], ["Bcl-xL", "GENE_OR_GENE_PRODUCT", 89, 95], ["Bcl-xL", "PROTEIN", 89, 95], ["survival factors", "PROTEIN", 106, 122], ["Severe acute respiratory syndrome coronavirus", "SPECIES", 0, 45], ["SARS-CoV", "SPECIES", 47, 55], ["Severe acute respiratory syndrome coronavirus", "PROBLEM", 0, 45], ["Bcl-xL", "PROBLEM", 89, 95], ["other survival factors", "PROBLEM", 100, 122], ["acute", "OBSERVATION_MODIFIER", 7, 12], ["respiratory syndrome coronavirus", "OBSERVATION", 13, 45]]], ["Although to date viruses have not been found to express BH3-only orthologs, there is increasing evidence that they somehow activate cellular BH3-only proteins to engage the Bax/Bak pore machinery on the MOM.", [["cellular", "ANATOMY", 132, 140], ["BH3", "GENE_OR_GENE_PRODUCT", 56, 59], ["cellular", "CELL", 132, 140], ["Bax", "GENE_OR_GENE_PRODUCT", 173, 176], ["Bak", "GENE_OR_GENE_PRODUCT", 177, 180], ["MOM", "CELLULAR_COMPONENT", 203, 206], ["BH3", "PROTEIN", 56, 59], ["BH3", "PROTEIN", 141, 144], ["Bax", "PROTEIN", 173, 176], ["Bak", "PROTEIN", 177, 180]]], ["The Tat protein of HIV-1 was shown to release Bim from its inhibitory contraints on the cytoskeleton so that it can directly activate Bax/Bak (Puthalakath et al., 1999, Chen et al., 2002).", [["cytoskeleton", "ANATOMY", 88, 100], ["Tat", "GENE_OR_GENE_PRODUCT", 4, 7], ["HIV-1", "ORGANISM", 19, 24], ["Bim", "GENE_OR_GENE_PRODUCT", 46, 49], ["cytoskeleton", "CELLULAR_COMPONENT", 88, 100], ["Bax", "GENE_OR_GENE_PRODUCT", 134, 137], ["Bak", "GENE_OR_GENE_PRODUCT", 138, 141], ["Tat protein", "PROTEIN", 4, 15], ["Bim", "PROTEIN", 46, 49], ["Bax", "PROTEIN", 134, 137], ["Bak", "PROTEIN", 138, 141], ["HIV-1", "SPECIES", 19, 24], ["HIV-1", "SPECIES", 19, 24], ["The Tat protein", "TEST", 0, 15]]], ["Whether Bim indeed is held in check at the cytoskeleton is largely debated.", [["cytoskeleton", "ANATOMY", 43, 55], ["Bim", "GENE_OR_GENE_PRODUCT", 8, 11], ["cytoskeleton", "CELLULAR_COMPONENT", 43, 55], ["Bim", "PROTEIN", 8, 11]]], ["IFN\u03b1/\u03b2 production in response to vesicular stomatitis viral infection has been shown to induce expression of Noxa (Galluzzi et al., 2008), but the transcription factors involved were not identified.", [["vesicular", "ANATOMY", 33, 42], ["stomatitis viral infection", "DISEASE", 43, 69], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 0, 4], ["\u03b2", "GENE_OR_GENE_PRODUCT", 5, 6], ["vesicular stomatitis viral", "ORGANISM", 33, 59], ["Noxa", "GENE_OR_GENE_PRODUCT", 109, 113], ["IFN\u03b1", "PROTEIN", 0, 4], ["\u03b2", "PROTEIN", 5, 6], ["Noxa", "PROTEIN", 109, 113], ["transcription factors", "PROTEIN", 147, 168], ["vesicular stomatitis viral infection", "PROBLEM", 33, 69], ["vesicular stomatitis", "ANATOMY", 33, 53], ["infection", "OBSERVATION", 60, 69]]], ["Based on the finding that viruses can activate p53 and its homologs such as p73 (Kaelin, 1999), it is possible that Noxa, and maybe also Puma are transcriptionally induced by these factors in response to certain infections (Cruz et al., 2006, Liu et al., 2014).", [["infections", "DISEASE", 212, 222], ["p53", "GENE_OR_GENE_PRODUCT", 47, 50], ["p73", "GENE_OR_GENE_PRODUCT", 76, 79], ["Noxa", "GENE_OR_GENE_PRODUCT", 116, 120], ["Puma", "GENE_OR_GENE_PRODUCT", 137, 141], ["p53", "PROTEIN", 47, 50], ["p73", "PROTEIN", 76, 79], ["Noxa", "PROTEIN", 116, 120], ["Puma", "PROTEIN", 137, 141], ["viruses", "PROBLEM", 26, 33], ["Noxa", "PROBLEM", 116, 120], ["certain infections", "PROBLEM", 204, 222], ["Noxa", "OBSERVATION", 116, 120]]], ["Alternatively, virus-specific protein kinases could phosphorylate BH3-only proteins, as it was shown for the U(S)3 protein kinase of HSV-1 on Bad (Munger and Roizman, 2001).Viral components that directly impinge on the host cell apoptotic machinery ::: Mechanisms by which the intrinsic, mitochondrial apoptosis pathway is activated after viral infectionWe have recently shown that Bim phosphorylation on three sites by JNK1/2 enhances its proapoptotic activity toward Bax/Bak activation (Geissler et al., 2013).", [["cell", "ANATOMY", 224, 228], ["mitochondrial", "ANATOMY", 288, 301], ["U(S)3", "GENE_OR_GENE_PRODUCT", 109, 114], ["HSV-1", "ORGANISM", 133, 138], ["Bad", "GENE_OR_GENE_PRODUCT", 142, 145], ["cell", "CELL", 224, 228], ["mitochondrial", "CELLULAR_COMPONENT", 288, 301], ["Bim", "GENE_OR_GENE_PRODUCT", 382, 385], ["JNK1/2", "GENE_OR_GENE_PRODUCT", 420, 426], ["Bax", "GENE_OR_GENE_PRODUCT", 469, 472], ["Bak", "GENE_OR_GENE_PRODUCT", 473, 476], ["protein kinases", "PROTEIN", 30, 45], ["BH3", "PROTEIN", 66, 69], ["U(S)3 protein kinase", "PROTEIN", 109, 129], ["Bad", "PROTEIN", 142, 145], ["Bim", "PROTEIN", 382, 385], ["JNK1/2", "PROTEIN", 420, 426], ["Bax", "PROTEIN", 469, 472], ["Bak", "PROTEIN", 473, 476], ["HSV-1", "SPECIES", 133, 138], ["virus", "PROBLEM", 15, 20], ["specific protein kinases", "TEST", 21, 45], ["phosphorylate BH3", "TEST", 52, 69], ["the U(S", "TEST", 105, 112], ["protein kinase", "TEST", 115, 129], ["HSV", "TEST", 133, 136], ["Viral components", "PROBLEM", 173, 189], ["mitochondrial apoptosis pathway", "PROBLEM", 288, 319], ["viral infectionWe", "PROBLEM", 339, 356], ["Bim phosphorylation", "PROBLEM", 382, 401], ["host cell apoptotic machinery", "OBSERVATION", 219, 248], ["mitochondrial apoptosis", "OBSERVATION", 288, 311]]], ["Moreover, we have obtained evidence that dsRNA produced by SFV does not only trigger a Bax/Bak-independent death signaling pathway involving the formation of a mitochondrial MAVS/caspase-8 complex (see above) (El Maadidi et al., 2014) but also uses a so far unknown BH3-only protein to activate Bax/Bak and MOMP (Papaianni et al., submitted) (Fig. 3).", [["mitochondrial", "ANATOMY", 160, 173], ["death", "DISEASE", 107, 112], ["SFV", "ORGANISM", 59, 62], ["Bax", "GENE_OR_GENE_PRODUCT", 87, 90], ["Bak", "GENE_OR_GENE_PRODUCT", 91, 94], ["mitochondrial", "CELLULAR_COMPONENT", 160, 173], ["caspase-8", "GENE_OR_GENE_PRODUCT", 179, 188], ["BH3", "GENE_OR_GENE_PRODUCT", 266, 269], ["Bax", "GENE_OR_GENE_PRODUCT", 295, 298], ["Bak", "GENE_OR_GENE_PRODUCT", 299, 302], ["MOMP", "GENE_OR_GENE_PRODUCT", 307, 311], ["Bax", "PROTEIN", 87, 90], ["Bak", "PROTEIN", 91, 94], ["mitochondrial MAVS/caspase-8 complex", "PROTEIN", 160, 196], ["BH3", "PROTEIN", 266, 269], ["Bax", "PROTEIN", 295, 298], ["Bak", "PROTEIN", 299, 302], ["MOMP", "PROTEIN", 307, 311], ["SFV", "SPECIES", 59, 62], ["dsRNA", "PROBLEM", 41, 46], ["independent death signaling pathway", "PROBLEM", 95, 130], ["a mitochondrial MAVS/caspase", "TREATMENT", 158, 186], ["Bax/Bak", "TREATMENT", 295, 302], ["dsRNA", "OBSERVATION", 41, 46], ["mitochondrial MAVS", "OBSERVATION", 160, 178]]], ["How dsRNA links to such a BH3-only protein is currently investigated in our lab.", [["BH3", "GENE_OR_GENE_PRODUCT", 26, 29], ["BH3", "PROTEIN", 26, 29], ["a BH3", "TEST", 24, 29]]], ["Finally, it is possible that virus-encoded proteases may cleave BH3-only proteins such as Bid.", [["Bid", "GENE_OR_GENE_PRODUCT", 90, 93], ["virus-encoded proteases", "PROTEIN", 29, 52], ["BH3", "PROTEIN", 64, 67], ["Bid", "PROTEIN", 90, 93], ["virus", "PROBLEM", 29, 34]]], ["These proteases are required for the viral life cycle because they process large non-structural and structural polypeptide precusors into mature viral proteins (Strauss and Strauss, 1994).", [["proteases", "PROTEIN", 6, 15], ["mature viral proteins", "PROTEIN", 138, 159], ["These proteases", "TREATMENT", 0, 15], ["the viral life cycle", "TREATMENT", 33, 53], ["large non-structural and structural polypeptide precusors", "PROBLEM", 75, 132], ["large", "OBSERVATION_MODIFIER", 75, 80], ["non-structural", "OBSERVATION", 81, 95], ["viral proteins", "OBSERVATION", 145, 159]]], ["Since they often show degenerate substrate specificity, they could cleave important components of apoptosis signaling and thereby activate them.", [["apoptosis signaling", "PROBLEM", 98, 117]]], ["For example, PLV viruses express proteases (2Apro and 3Cpro), which activate caspase-dependent apoptosis (Barco et al., 2000, Goldstaub et al., 2000, Calandria et al., 2004).", [["PLV viruses", "ORGANISM", 13, 24], ["2Apro", "GENE_OR_GENE_PRODUCT", 44, 49], ["3Cpro", "GENE_OR_GENE_PRODUCT", 54, 59], ["caspase", "GENE_OR_GENE_PRODUCT", 77, 84], ["proteases", "PROTEIN", 33, 42], ["2Apro", "PROTEIN", 44, 49], ["3Cpro", "PROTEIN", 54, 59], ["caspase", "PROTEIN", 77, 84], ["PLV viruses", "PROBLEM", 13, 24], ["proteases (2Apro and 3Cpro)", "TREATMENT", 33, 60], ["dependent apoptosis", "PROBLEM", 85, 104], ["PLV viruses", "OBSERVATION", 13, 24], ["dependent", "OBSERVATION_MODIFIER", 85, 94], ["apoptosis", "OBSERVATION_MODIFIER", 95, 104]]], ["In addition, HIV-encoded protease is known to process and activate caspase-8 both in vitro and in T cells, which then leads to Bid cleavage and mitochondria-mediated apoptosis (Nie et al., 2002).", [["T cells", "ANATOMY", 98, 105], ["mitochondria", "ANATOMY", 144, 156], ["HIV", "ORGANISM", 13, 16], ["caspase-8", "GENE_OR_GENE_PRODUCT", 67, 76], ["T cells", "CELL", 98, 105], ["Bid", "GENE_OR_GENE_PRODUCT", 127, 130], ["mitochondria", "CELLULAR_COMPONENT", 144, 156], ["HIV-encoded protease", "PROTEIN", 13, 33], ["caspase-8", "PROTEIN", 67, 76], ["T cells", "CELL_TYPE", 98, 105], ["Bid", "PROTEIN", 127, 130], ["HIV", "SPECIES", 13, 16], ["HIV", "PROBLEM", 13, 16], ["encoded protease", "TREATMENT", 17, 33], ["caspase", "TEST", 67, 74]]], ["Indeed Bcl-2 overexpression protects cells from the pro-apoptotic effects of the HIV-protease and prevents apoptosis induced by HIV-1 infection of human lymphocytes (Strack et al., 1996).Concluding remarks and outlookThere is increasing evidence that innate immune signaling via TLRs and intracellular PRRs do not only trigger an antiviral interferon response and other mechanisms to limit the replication, assembly and spread of viruses, but they also cooperate with the intrinsic Bax/Bak-mediated mitchondrial pathway to induce apoptosis of the infected host cells.", [["cells", "ANATOMY", 37, 42], ["lymphocytes", "ANATOMY", 153, 164], ["intracellular", "ANATOMY", 288, 301], ["cells", "ANATOMY", 561, 566], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 7, 12], ["cells", "CELL", 37, 42], ["HIV-1", "ORGANISM", 128, 133], ["human", "ORGANISM", 147, 152], ["lymphocytes", "CELL", 153, 164], ["TLRs", "GENE_OR_GENE_PRODUCT", 279, 283], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 288, 301], ["Bax", "GENE_OR_GENE_PRODUCT", 482, 485], ["Bak", "GENE_OR_GENE_PRODUCT", 486, 489], ["host cells", "CELL", 556, 566], ["Bcl-2", "PROTEIN", 7, 12], ["HIV-protease", "PROTEIN", 81, 93], ["human lymphocytes", "CELL_TYPE", 147, 164], ["TLRs", "PROTEIN", 279, 283], ["intracellular PRRs", "PROTEIN", 288, 306], ["interferon", "PROTEIN", 340, 350], ["Bax", "PROTEIN", 482, 485], ["Bak", "PROTEIN", 486, 489], ["infected host cells", "CELL_TYPE", 547, 566], ["HIV-1", "SPECIES", 128, 133], ["human", "SPECIES", 147, 152], ["HIV", "SPECIES", 81, 84], ["HIV-1", "SPECIES", 128, 133], ["human", "SPECIES", 147, 152], ["the HIV-protease", "TREATMENT", 77, 93], ["apoptosis", "PROBLEM", 107, 116], ["HIV-1 infection of human lymphocytes", "PROBLEM", 128, 164], ["intracellular PRRs", "PROBLEM", 288, 306], ["an antiviral interferon response", "TREATMENT", 327, 359], ["viruses", "PROBLEM", 430, 437], ["the intrinsic Bax/Bak-mediated mitchondrial pathway", "TREATMENT", 468, 519], ["apoptosis", "PROBLEM", 530, 539], ["the infected host cells", "PROBLEM", 543, 566], ["2 overexpression", "OBSERVATION_MODIFIER", 11, 27], ["protects cells", "OBSERVATION", 28, 42], ["increasing", "OBSERVATION_MODIFIER", 226, 236], ["antiviral interferon", "OBSERVATION", 330, 350], ["viruses", "OBSERVATION", 430, 437], ["infected host cells", "OBSERVATION", 547, 566]]], ["As discussed above, some viruses have clearly evolved strategies to counteract both the intrinsic as well as the innate signaling branch so that they can effectively replicate and reproduce.", [["some viruses", "PROBLEM", 20, 32], ["viruses", "OBSERVATION", 25, 32], ["branch", "OBSERVATION_MODIFIER", 130, 136]]], ["However, other viruses, such as SFV and other alphaviruses, do not express any cell survival factors and may therefore use these pathways to kill their host cells after their successful reproduction, e.g. to evade detection by the immune system.", [["cell", "ANATOMY", 79, 83], ["cells", "ANATOMY", 157, 162], ["immune system", "ANATOMY", 231, 244], ["SFV", "ORGANISM", 32, 35], ["cell", "CELL", 79, 83], ["host cells", "CELL", 152, 162], ["immune system", "ANATOMICAL_SYSTEM", 231, 244], ["cell survival factors", "PROTEIN", 79, 100], ["host cells", "CELL_TYPE", 152, 162], ["SFV", "SPECIES", 32, 35], ["other viruses", "PROBLEM", 9, 22], ["SFV", "PROBLEM", 32, 35], ["other alphaviruses", "PROBLEM", 40, 58], ["any cell survival factors", "PROBLEM", 75, 100], ["viruses", "OBSERVATION", 15, 22], ["SFV", "ANATOMY", 32, 35], ["alphaviruses", "OBSERVATION", 46, 58]]], ["While we clearly understand how virus-encoded decoy receptors, caspase-8 and other caspase inhibitors as well as Bcl-2 orthologs work to inhibit apoptosis of infected cells, we need to further understand how viruses manage to activate BH3-only proteins and/or directly perturb the balance between Bcl-2-like survival factors and pore-forming Bax/Bak proteins on the MOM.", [["cells", "ANATOMY", 167, 172], ["caspase-8", "GENE_OR_GENE_PRODUCT", 63, 72], ["caspase", "GENE_OR_GENE_PRODUCT", 83, 90], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 113, 118], ["cells", "CELL", 167, 172], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 297, 302], ["Bax", "GENE_OR_GENE_PRODUCT", 342, 345], ["Bak", "GENE_OR_GENE_PRODUCT", 346, 349], ["MOM", "CELLULAR_COMPONENT", 366, 369], ["decoy receptors", "PROTEIN", 46, 61], ["caspase-8", "PROTEIN", 63, 72], ["Bcl-2 orthologs", "DNA", 113, 128], ["infected cells", "CELL_TYPE", 158, 172], ["BH3", "PROTEIN", 235, 238], ["Bcl-2-like survival factors", "PROTEIN", 297, 324], ["pore-forming Bax/Bak proteins", "PROTEIN", 329, 358], ["decoy receptors", "TREATMENT", 46, 61], ["caspase", "TREATMENT", 63, 70], ["other caspase inhibitors", "TREATMENT", 77, 101], ["infected cells", "PROBLEM", 158, 172], ["BH3", "TEST", 235, 238], ["Bcl", "TEST", 297, 300], ["survival factors", "PROBLEM", 308, 324], ["infected cells", "OBSERVATION", 158, 172]]], ["Further challenges will be to identify all the components of the TLR3/TRIF/caspase-8 and MAVS/caspase-8 complexes, which seem to constitute novel DISCs enhancing Bax/Bak-mediated MOMP and to investigate if other viruses such as DNA viruses also use innate signaling strategies to kill their hosts.", [["DISCs", "ANATOMY", 146, 151], ["TLR3", "GENE_OR_GENE_PRODUCT", 65, 69], ["TRIF", "GENE_OR_GENE_PRODUCT", 70, 74], ["caspase-8", "GENE_OR_GENE_PRODUCT", 75, 84], ["MAVS", "GENE_OR_GENE_PRODUCT", 89, 93], ["caspase-8", "GENE_OR_GENE_PRODUCT", 94, 103], ["DISCs", "GENE_OR_GENE_PRODUCT", 146, 151], ["Bax", "GENE_OR_GENE_PRODUCT", 162, 165], ["Bak-", "GENE_OR_GENE_PRODUCT", 166, 170], ["MOMP", "GENE_OR_GENE_PRODUCT", 179, 183], ["DNA", "CELLULAR_COMPONENT", 228, 231], ["TLR3", "PROTEIN", 65, 69], ["TRIF", "PROTEIN", 70, 74], ["caspase-8", "PROTEIN", 75, 84], ["MAVS", "PROTEIN", 89, 93], ["caspase-8 complexes", "PROTEIN", 94, 113], ["Bax", "PROTEIN", 162, 165], ["Bak-", "PROTEIN", 166, 170], ["MOMP", "PROTEIN", 179, 183], ["the TLR3/TRIF/caspase", "TREATMENT", 61, 82], ["MAVS/caspase-8 complexes", "TREATMENT", 89, 113], ["other viruses", "PROBLEM", 206, 219], ["DNA viruses", "PROBLEM", 228, 239], ["innate signaling strategies", "TREATMENT", 249, 276]]], ["Irrespective of whether viruses use apoptotic or anti-apoptotic mechanisms to win their competition with the host, a better understanding will continue to provide considerable insight into both viral and cellular biology, from initial virus sensing to viral clearance or persistence.", [["cellular", "ANATOMY", 204, 212], ["cellular", "CELL", 204, 212], ["viral clearance", "PROBLEM", 252, 267], ["viruses", "OBSERVATION", 24, 31]]], ["It is the hope that this will ultimately lead to the generation of more effective vaccines against viruses.", [["more effective vaccines", "TREATMENT", 67, 90], ["viruses", "PROBLEM", 99, 106]]]], "PMC7124289": [["Specific objectivesThe workshop's specific objectives, therefore, are as follows:\u2022To provide a forum for the exchange of ideas on current research on the role of the indoor environment in general and indoor air in particular in the spread of human pathogens;\u2022To discuss experimental facilities and test protocols for the study of airborne microbial survival;\u2022To review available means of recovering viable microbes from indoor air;\u2022To propose better surrogates for the study of indoor air as a vehicle for human pathogens;\u2022To model microbial movements in indoor air for further improvements in the design of experimental aerobiological facilities and test protocols; and\u2022To review ongoing research on physical and chemical means of indoor air decontamination.", [["human", "ORGANISM", 242, 247], ["human", "ORGANISM", 506, 511], ["human", "SPECIES", 242, 247], ["human", "SPECIES", 506, 511], ["human", "SPECIES", 242, 247], ["human", "SPECIES", 506, 511], ["test protocols", "TEST", 298, 312], ["the study", "TEST", 317, 326], ["the study", "TEST", 465, 474], ["human pathogens", "PROBLEM", 506, 521], ["experimental aerobiological facilities", "TREATMENT", 608, 646], ["test protocols", "TEST", 651, 665], ["air decontamination", "TREATMENT", 739, 758], ["microbial movements", "OBSERVATION", 532, 551]]]], "253333e67bcf5ab503f3ca8395b061cc7e98a0eb": [["Introduction:As of 10 th May 2020, nearly 4 million global citizens across 215 countries have tested positive for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).", [["acute respiratory syndrome coronavirus", "DISEASE", 121, 159], ["SARS-CoV-2", "ORGANISM", 163, 173], ["severe acute respiratory syndrome coronavirus", "SPECIES", 114, 159], ["SARS-CoV-2", "SPECIES", 163, 173], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 114, 159], ["CoV", "TEST", 168, 171], ["severe", "OBSERVATION_MODIFIER", 114, 120], ["acute", "OBSERVATION_MODIFIER", 121, 126], ["respiratory syndrome", "OBSERVATION", 127, 147]]], ["1 Post-viral olfactory dysfunction (OD) is well established, 2 and has been shown to be a key symptom of the Coronavirus diseases 2019 , with more than 66% European and U.S patients reporting some degree of loss of smell.", [["olfactory", "ANATOMY", 13, 22], ["viral olfactory dysfunction", "DISEASE", 7, 34], ["Coronavirus diseases", "DISEASE", 109, 129], ["loss of smell", "DISEASE", 207, 220], ["olfactory", "ORGAN", 13, 22], ["patients", "ORGANISM", 173, 181], ["patients", "SPECIES", 173, 181], ["Post-viral olfactory dysfunction", "PROBLEM", 2, 34], ["the Coronavirus diseases", "PROBLEM", 105, 129], ["loss of smell", "PROBLEM", 207, 220], ["viral olfactory dysfunction", "OBSERVATION", 7, 34], ["Coronavirus diseases", "OBSERVATION", 109, 129], ["some degree", "OBSERVATION_MODIFIER", 192, 203], ["loss", "OBSERVATION", 207, 211], ["smell", "OBSERVATION", 215, 220]]], ["[3] [4] [5] We have apparently overcome the worst part of the initial outbreak.", [["[3] [4] [5", "SIMPLE_CHEMICAL", 0, 10]]], ["However, persistent OD appears to be commonplace and will drive the demand for General Practitioner, Otolaryngology or Neurology consultation in the next months -evidence regarding recovery will be essential in counselling our patients.Method:In order to evaluate patterns of olfactory recovery, data from patients with confirmed COVID-19 were collected prospectively from 3 University Hospitals.", [["olfactory", "ANATOMY", 276, 285], ["patients", "ORGANISM", 227, 235], ["olfactory", "ANATOMICAL_SYSTEM", 276, 285], ["patients", "ORGANISM", 306, 314], ["patients", "SPECIES", 227, 235], ["patients", "SPECIES", 306, 314], ["COVID", "TEST", 330, 335], ["persistent", "OBSERVATION_MODIFIER", 9, 19]]], ["Adults (>18yo) with a positive test for SARS-CoV-2 via reverse transcription polymerase chain reaction (RT-PCR) or a positive IgG/IgM were included.", [["Adults", "ORGANISM", 0, 6], ["IgG", "GENE_OR_GENE_PRODUCT", 126, 129], ["IgM", "GENE_OR_GENE_PRODUCT", 130, 133], ["positive IgG", "PROTEIN", 117, 129], ["IgM", "PROTEIN", 130, 133], ["Adults", "SPECIES", 0, 6], ["SARS-CoV", "SPECIES", 40, 48], ["a positive test", "PROBLEM", 20, 35], ["SARS", "PROBLEM", 40, 44], ["CoV", "TEST", 45, 48], ["reverse transcription polymerase chain reaction", "PROBLEM", 55, 102], ["RT-PCR", "TEST", 104, 110], ["a positive IgG/IgM", "PROBLEM", 115, 133]]], ["Those with symptom duration <14 days were tested with a nasopharyngeal swab; in the case of negative RT-PCR or patients with symptoms for \u226514 days, serology testing was performed.", [["nasopharyngeal swab", "ANATOMY", 56, 75], ["patients", "ORGANISM", 111, 119], ["patients", "SPECIES", 111, 119], ["a nasopharyngeal swab", "TEST", 54, 75], ["symptoms", "PROBLEM", 125, 133], ["serology testing", "TEST", 148, 164]]], ["Only patients with a positive RT-PCR or with positive IgG/IgM were included ( Figure 1 ).Method:All patients had at least 30-days of follow-up after their last negative subsequent COVID-19 test.Accepted ArticleThis article is protected by copyright.", [["patients", "ORGANISM", 5, 13], ["IgG", "GENE_OR_GENE_PRODUCT", 54, 57], ["IgM", "GENE_OR_GENE_PRODUCT", 58, 61], ["patients", "ORGANISM", 100, 108], ["IgG", "PROTEIN", 54, 57], ["IgM", "PROTEIN", 58, 61], ["patients", "SPECIES", 5, 13], ["patients", "SPECIES", 100, 108], ["a positive RT-PCR", "PROBLEM", 19, 36], ["positive IgG/IgM", "PROBLEM", 45, 61]]], ["All rights reservedResults:All told, 1411 patients identified in the emergency room or primary care consultation were invited to participate in the study.", [["patients", "ORGANISM", 42, 50], ["patients", "SPECIES", 42, 50], ["the study", "TEST", 144, 153]]], ["A total of 1231 patients agreed to participate, and 751 patients completed the study (Supplementary material).", [["patients", "ORGANISM", 16, 24], ["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 16, 24], ["patients", "SPECIES", 56, 64], ["the study", "TEST", 75, 84]]], ["The mean age of patients was 41 \u00b1 13 (range: 18 -60).", [["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24]]], ["There were 621 patients (83%) who subjectively report a total loss of smell and 130 (17%) a partial loss.", [["loss of smell", "DISEASE", 62, 75], ["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23], ["a total loss of smell", "PROBLEM", 54, 75], ["a partial loss", "PROBLEM", 90, 104], ["partial loss", "OBSERVATION", 92, 104]]], ["After a mean follow-up of 47\u00b17 days (range: 30-71) from the first consultation, 277 (37%) of patients still reported a persistent subjective loss of smell, 107 (14%) reported partial recovery and 367 (49%) reported complete recovery.", [["loss of smell", "DISEASE", 141, 154], ["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 93, 101], ["a persistent subjective loss of smell", "PROBLEM", 117, 154], ["persistent", "OBSERVATION_MODIFIER", 119, 129]]], ["The mean duration of the OD was 10\u00b16 days (range: 3-31) in those patients who completely recovered and 12\u00b18 days (range: 7-35) in those patients who partially recovered (Table 1 and figure 1 ).Results:Treatments used during the follow-up period varied, with 71 patients (9%) using nasal corticosteroid spray, 58 (8%) using oral steroid and 149 (20%) using nasal saline irrigation.", [["nasal", "ANATOMY", 281, 286], ["oral", "ANATOMY", 323, 327], ["nasal", "ANATOMY", 356, 361], ["steroid", "CHEMICAL", 328, 335], ["steroid", "CHEMICAL", 328, 335], ["patients", "ORGANISM", 65, 73], ["patients", "ORGANISM", 136, 144], ["patients", "ORGANISM", 261, 269], ["nasal", "ORGANISM_SUBDIVISION", 281, 286], ["oral", "ORGANISM_SUBDIVISION", 323, 327], ["patients", "SPECIES", 65, 73], ["patients", "SPECIES", 136, 144], ["patients", "SPECIES", 261, 269], ["Treatments", "TREATMENT", 201, 211], ["nasal corticosteroid spray", "TREATMENT", 281, 307], ["oral steroid", "TREATMENT", 323, 335], ["nasal saline irrigation", "TREATMENT", 356, 379], ["mean", "OBSERVATION_MODIFIER", 4, 8]]], ["There was no significant correlation between the use of nasal spray (p=0.324), oral steroid (p=0.211) or nasal irrigation (p=0.453) and olfactory recovery.", [["nasal", "ANATOMY", 56, 61], ["oral", "ANATOMY", 79, 83], ["nasal", "ANATOMY", 105, 110], ["olfactory", "ANATOMY", 136, 145], ["steroid", "CHEMICAL", 84, 91], ["steroid", "CHEMICAL", 84, 91], ["nasal", "ORGANISM_SUBDIVISION", 56, 61], ["oral", "ORGANISM_SUBDIVISION", 79, 83], ["steroid", "SIMPLE_CHEMICAL", 84, 91], ["nasal", "ORGANISM_SUBDIVISION", 105, 110], ["olfactory", "ORGAN", 136, 145], ["nasal spray", "TREATMENT", 56, 67], ["oral steroid (p", "TREATMENT", 79, 94], ["nasal irrigation", "TREATMENT", 105, 121], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24]]], ["We found significant difference in initial nasal symptoms or sQOD-NS score with recovery being significantly lower in patients with a total loss of smell Accepted Article compared with those patients with a partial loss of smell or normosmic during the first consultation and after almost 30-days of follow-up (p=0.001).", [["nasal", "ANATOMY", 43, 48], ["loss of smell or normosmic", "DISEASE", 215, 241], ["nasal", "ORGAN", 43, 48], ["patients", "ORGANISM", 118, 126], ["patients", "ORGANISM", 191, 199], ["patients", "SPECIES", 118, 126], ["patients", "SPECIES", 191, 199], ["initial nasal symptoms", "PROBLEM", 35, 57], ["a total loss of smell", "PROBLEM", 132, 153], ["a partial loss of smell", "PROBLEM", 205, 228], ["significant", "OBSERVATION_MODIFIER", 9, 20], ["difference", "OBSERVATION_MODIFIER", 21, 31], ["nasal", "ANATOMY", 43, 48], ["symptoms", "OBSERVATION", 49, 57], ["lower", "OBSERVATION_MODIFIER", 109, 114]]], ["There was no significant association between comorbidities and the development or persistence of OD (Table 2) .Discussion:Hopkins et al. recently found that nearly 80% of patients experienced improvement in loss of smell within a few weeks of onset, with recovery rates appearing to plateau after 3 weeks.", [["loss of smell", "DISEASE", 207, 220], ["patients", "ORGANISM", 171, 179], ["patients", "SPECIES", 171, 179], ["significant association between comorbidities", "PROBLEM", 13, 58], ["loss of smell", "PROBLEM", 207, 220], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["loss", "OBSERVATION_MODIFIER", 207, 211]]], ["8 We found that nearly 63% of patients report improvement in their subjective loss of sense of smell after at least 4 weeks.", [["loss of sense of smell", "DISEASE", 78, 100], ["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 30, 38]]], ["However, the frequency of residual OD after 30 days of follow-up was significant and despite the possibility of a later recovery, it is necessary to highlight that the higher incidence of COVID-19 patients affected allow us to infer that a large amount of patients will suffer from a longterm OD.Discussion:Currently the mechanism for anosmia is not clear, some evidence suggests viral spread through the neuroepithelium of the olfactory cleft, with the consequent infiltration of the olfactory bulb and the central nervous system as the main cause.", [["neuroepithelium", "ANATOMY", 405, 420], ["olfactory cleft", "ANATOMY", 428, 443], ["olfactory bulb", "ANATOMY", 485, 499], ["central nervous system", "ANATOMY", 508, 530], ["anosmia", "DISEASE", 335, 342], ["olfactory cleft", "DISEASE", 428, 443], ["patients", "ORGANISM", 197, 205], ["patients", "ORGANISM", 256, 264], ["neuroepithelium", "TISSUE", 405, 420], ["olfactory cleft", "ORGAN", 428, 443], ["olfactory bulb", "MULTI-TISSUE_STRUCTURE", 485, 499], ["central nervous system", "ANATOMICAL_SYSTEM", 508, 530], ["patients", "SPECIES", 197, 205], ["patients", "SPECIES", 256, 264], ["residual OD", "PROBLEM", 26, 37], ["COVID", "TEST", 188, 193], ["a longterm OD", "PROBLEM", 282, 295], ["anosmia", "PROBLEM", 335, 342], ["viral spread", "PROBLEM", 380, 392], ["the consequent infiltration of the olfactory bulb", "PROBLEM", 450, 499], ["residual", "OBSERVATION_MODIFIER", 26, 34], ["large", "OBSERVATION_MODIFIER", 240, 245], ["amount", "OBSERVATION_MODIFIER", 246, 252], ["viral", "OBSERVATION", 380, 385], ["neuroepithelium", "ANATOMY_MODIFIER", 405, 420], ["olfactory cleft", "ANATOMY", 428, 443], ["consequent", "OBSERVATION_MODIFIER", 454, 464], ["infiltration", "OBSERVATION", 465, 477], ["olfactory bulb", "ANATOMY", 485, 499], ["central", "ANATOMY_MODIFIER", 508, 515], ["nervous system", "ANATOMY", 516, 530], ["main", "OBSERVATION_MODIFIER", 538, 542]]], ["This theory is supported by the increasing evidence about nasal respiratory epithelial cells and olfactory epithelial support cells who may express moderate-to-high levels of angiotensin converting enzyme-2 (ACE2) proteins used as a carrier by the SARS-CoV-2 to infect cells.", [["nasal respiratory epithelial cells", "ANATOMY", 58, 92], ["olfactory epithelial support cells", "ANATOMY", 97, 131], ["cells", "ANATOMY", 269, 274], ["angiotensin", "CHEMICAL", 175, 186], ["nasal respiratory epithelial cells", "CELL", 58, 92], ["olfactory epithelial support cells", "CELL", 97, 131], ["angiotensin converting enzyme-2", "GENE_OR_GENE_PRODUCT", 175, 206], ["ACE2", "GENE_OR_GENE_PRODUCT", 208, 212], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 248, 258], ["cells", "CELL", 269, 274], ["nasal respiratory epithelial cells", "CELL_TYPE", 58, 92], ["olfactory epithelial support cells", "CELL_TYPE", 97, 131], ["angiotensin converting enzyme-2 (ACE2) proteins", "PROTEIN", 175, 222], ["nasal respiratory epithelial cells", "PROBLEM", 58, 92], ["olfactory epithelial support cells", "PROBLEM", 97, 131], ["angiotensin converting enzyme-2 (ACE2) proteins", "TREATMENT", 175, 222], ["infect cells", "PROBLEM", 262, 274], ["nasal", "ANATOMY", 58, 63], ["respiratory epithelial cells", "OBSERVATION", 64, 92], ["olfactory epithelial", "OBSERVATION", 97, 117], ["support cells", "OBSERVATION", 118, 131], ["moderate", "OBSERVATION_MODIFIER", 148, 156], ["infect cells", "OBSERVATION", 262, 274]]], ["9 However, more evidence is necessary to elucidate the real mechanism for the OD.Discussion:Limitations of this study are the exclusion of patients with severe disease, the small proportion of older patients, the higher proportion of female respondents, loss to follow-up and recruitment from ENT-Clinics, potentially introducing a selection bias.", [["patients", "ORGANISM", 139, 147], ["patients", "ORGANISM", 199, 207], ["patients", "SPECIES", 139, 147], ["patients", "SPECIES", 199, 207], ["the OD", "PROBLEM", 74, 80], ["this study", "TEST", 107, 117], ["severe disease", "PROBLEM", 153, 167], ["a selection bias", "TEST", 330, 346], ["severe", "OBSERVATION_MODIFIER", 153, 159], ["disease", "OBSERVATION", 160, 167], ["small", "OBSERVATION_MODIFIER", 173, 178]]], ["Lack of objective testing to confirm anosmia is also a limitation.", [["anosmia", "DISEASE", 37, 44], ["objective testing", "TEST", 8, 25], ["anosmia", "PROBLEM", 37, 44]]], ["However, at this relatively early point in the pandemic, subjective patterns of recovery of OD in COVID-19 patients are valuable for our patients, hypothesis generation and treatment development.Authorship:All authors should have made substantial contributions to all of the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data, (2) drafting the article or revising it critically for important intellectual content, (3) final approval of the version to be submitted.Ethics approval and consent to participate:Four ethics committees approved the current study protocol (HAP2020-011; CHUSP20032020;Ethics approval and consent to participate:EpiCURA-2020-2303; CHU-Charleroi:B32522020).", [["HAP2020-011", "CHEMICAL", 634, 645], ["patients", "ORGANISM", 107, 115], ["patients", "ORGANISM", 137, 145], ["patients", "SPECIES", 107, 115], ["patients", "SPECIES", 137, 145], ["treatment development", "TREATMENT", 173, 194], ["the study", "TEST", 319, 328], ["analysis", "TEST", 357, 365], ["the version", "TREATMENT", 503, 514]]]], "e0ad030c1b8382ee731e6c2c4dc766c97322fd30": [["to present in the patient.", [["patient", "ORGANISM", 18, 25], ["patient", "SPECIES", 18, 25]]], ["But last Wednesday, the man became sick.", [["man", "ORGANISM", 24, 27], ["man", "SPECIES", 24, 27], ["sick", "PROBLEM", 35, 39]]], ["Dr. Edward Goodman, the top infectious disease specialist at Presbyterian, describes what happened next.", [["infectious disease", "DISEASE", 28, 46]]]], "PMC7494848": [["IntroductionThe novel virus Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (1, 2) is the first member of the Betacoronavirus genus to reach pandemic status (3).", [["Acute Respiratory Syndrome", "DISEASE", 35, 61], ["pandemic", "DISEASE", 154, 162], ["SARS-CoV-2", "ORGANISM", 77, 87], ["Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2", "SPECIES", 28, 87], ["The novel virus Severe Acute Respiratory Syndrome Coronavirus", "PROBLEM", 12, 73], ["SARS-CoV", "TEST", 77, 85], ["virus", "OBSERVATION_MODIFIER", 22, 27], ["Severe", "OBSERVATION_MODIFIER", 28, 34], ["Acute", "OBSERVATION_MODIFIER", 35, 40], ["Respiratory Syndrome", "OBSERVATION", 41, 61]]], ["This virus probably originated in bats and infects humans with the participation of an intermediate host (4\u20137), like its two highly human-infective relatives, SARS-CoV (8, 9) and MERS-CoV (10).", [["SARS", "DISEASE", 159, 163], ["bats", "ORGANISM", 34, 38], ["humans", "ORGANISM", 51, 57], ["human", "ORGANISM", 132, 137], ["SARS-CoV", "ORGANISM", 159, 167], ["MERS-CoV", "ORGANISM", 179, 187], ["humans", "SPECIES", 51, 57], ["human", "SPECIES", 132, 137], ["humans", "SPECIES", 51, 57], ["human", "SPECIES", 132, 137], ["SARS-CoV", "SPECIES", 159, 167], ["MERS-CoV", "SPECIES", 179, 187], ["This virus", "PROBLEM", 0, 10], ["infects", "OBSERVATION", 43, 50], ["intermediate host", "OBSERVATION_MODIFIER", 87, 104], ["infective", "OBSERVATION", 138, 147]]], ["It causes Coronavirus Disease 2019 (COVID-19), whose clinical symptoms include fever, cough, fatigue, sputum production, and difficulty breathing (11, 12).", [["sputum", "ANATOMY", 102, 108], ["Coronavirus Disease", "DISEASE", 10, 29], ["fever", "DISEASE", 79, 84], ["cough", "DISEASE", 86, 91], ["fatigue", "DISEASE", 93, 100], ["sputum production", "DISEASE", 102, 119], ["difficulty breathing", "DISEASE", 125, 145], ["Coronavirus Disease", "PROBLEM", 10, 29], ["COVID", "TEST", 36, 41], ["whose clinical symptoms", "PROBLEM", 47, 70], ["fever", "PROBLEM", 79, 84], ["cough", "PROBLEM", 86, 91], ["fatigue", "PROBLEM", 93, 100], ["sputum production", "PROBLEM", 102, 119], ["difficulty breathing", "PROBLEM", 125, 145], ["Coronavirus Disease", "OBSERVATION", 10, 29]]], ["Transmission is mostly human-to-human through respiratory droplets and direct contact, carrying infectious virions to the nose, mouth, and eyes (13, 14).", [["respiratory droplets", "ANATOMY", 46, 66], ["virions", "ANATOMY", 107, 114], ["nose", "ANATOMY", 122, 126], ["mouth", "ANATOMY", 128, 133], ["eyes", "ANATOMY", 139, 143], ["human", "ORGANISM", 23, 28], ["human", "ORGANISM", 32, 37], ["nose", "ORGAN", 122, 126], ["mouth", "ORGANISM_SUBDIVISION", 128, 133], ["eyes", "ORGAN", 139, 143], ["human", "SPECIES", 23, 28], ["human", "SPECIES", 32, 37], ["human", "SPECIES", 23, 28], ["human", "SPECIES", 32, 37], ["respiratory droplets", "TREATMENT", 46, 66], ["nose", "ANATOMY", 122, 126], ["mouth", "ANATOMY", 128, 133], ["eyes", "ANATOMY", 139, 143]]], ["It has spread to 216 countries, resulting in more than 4.3 million confirmed cases and 295,000 deaths worldwide as of May 15, 2020 (15).", [["deaths", "DISEASE", 95, 101]]], ["It has an estimated basic reproductive number (R0) of 2.24\u20133.58 (16).IntroductionSARS-CoV-2, as with other Coronaviruses, is characterized by a high recombination frequency and mutation rate, in addition to a relatively large and sophisticated genetic machinery compared to other RNA viruses.", [["IntroductionSARS-CoV-2", "GENE_OR_GENE_PRODUCT", 69, 91], ["IntroductionSARS", "TEST", 69, 85], ["other Coronaviruses", "PROBLEM", 101, 120], ["a high recombination frequency", "PROBLEM", 142, 172], ["mutation rate", "PROBLEM", 177, 190], ["a relatively large and sophisticated genetic machinery", "PROBLEM", 207, 261], ["other RNA viruses", "PROBLEM", 274, 291], ["estimated", "OBSERVATION_MODIFIER", 10, 19], ["basic", "OBSERVATION_MODIFIER", 20, 25], ["reproductive", "OBSERVATION_MODIFIER", 26, 38], ["number", "OBSERVATION_MODIFIER", 39, 45], ["large", "OBSERVATION_MODIFIER", 220, 225]]], ["At the 5\u2032 end of the genome, the cleavable polyprotein ab (ORF1ab) is processed into 16 non-structural proteins (NSPs).", [["genome", "CELLULAR_COMPONENT", 21, 27], ["ORF1ab", "GENE_OR_GENE_PRODUCT", 59, 65], ["NSPs", "GENE_OR_GENE_PRODUCT", 113, 117], ["5\u2032 end", "DNA", 7, 13], ["cleavable polyprotein ab", "PROTEIN", 33, 57], ["ORF1ab", "PROTEIN", 59, 65], ["16 non-structural proteins", "PROTEIN", 85, 111], ["NSPs", "PROTEIN", 113, 117], ["the cleavable polyprotein ab", "TEST", 29, 57]]], ["They are involved in the viral replication and assembly process, as well as in immune evasion (17, 18).", [["the viral replication", "TREATMENT", 21, 42]]], ["At the 3\u2032 end, the structural proteins Spike (S), envelope (E), membrane (M), and nucleocapsid (N) are interspersed by the accessory proteins ORF 3a, 6, 7a, 7b, 8, and 10 (19, 20).", [["membrane", "ANATOMY", 64, 72], ["Spike (S), envelope (E)", "GENE_OR_GENE_PRODUCT", 39, 62], ["membrane", "CELLULAR_COMPONENT", 64, 72], ["nucleocapsid (N)", "GENE_OR_GENE_PRODUCT", 82, 98], ["7b", "GENE_OR_GENE_PRODUCT", 157, 159], ["8", "GENE_OR_GENE_PRODUCT", 161, 162], ["structural proteins", "PROTEIN", 19, 38], ["Spike", "PROTEIN", 39, 44], ["S", "PROTEIN", 46, 47], ["envelope (E), membrane (M)", "PROTEIN", 50, 76], ["nucleocapsid (N)", "PROTEIN", 82, 98], ["accessory proteins", "PROTEIN", 123, 141], ["ORF 3a, 6, 7a, 7b, 8, and 10", "PROTEIN", 142, 170], ["the structural proteins Spike (S), envelope (E), membrane (M), and nucleocapsid (N)", "PROBLEM", 15, 98], ["proteins Spike", "OBSERVATION", 30, 44], ["nucleocapsid", "ANATOMY", 82, 94]]], ["A key factor in viral attachment and entry is the receptor-binding domain (RBD), located in the subunit 1 (S1) of the S protein.", [["S protein", "GENE_OR_GENE_PRODUCT", 118, 127], ["receptor-binding domain", "PROTEIN", 50, 73], ["RBD", "PROTEIN", 75, 78], ["subunit 1", "PROTEIN", 96, 105], ["S1", "PROTEIN", 107, 109], ["S protein", "PROTEIN", 118, 127], ["A key factor in viral attachment", "PROBLEM", 0, 32], ["viral attachment", "OBSERVATION", 16, 32]]], ["This binds strongly to the angiotensin-converting enzyme 2 (ACE2) receptors (21, 22).", [["angiotensin", "CHEMICAL", 27, 38], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 27, 58], ["ACE2", "GENE_OR_GENE_PRODUCT", 60, 64], ["angiotensin-converting enzyme 2 (ACE2) receptors", "PROTEIN", 27, 75], ["the angiotensin", "TEST", 23, 38]]], ["Other possible receptors, like CD209L (23), CD147 (24), and the protease TMPRSS2 (25), could also participate in the viral entry and processing.IntroductionPost-translational modifications (PTMs) are covalent modifications that regulate protein functions.", [["CD209L (23)", "GENE_OR_GENE_PRODUCT", 31, 42], ["CD147", "GENE_OR_GENE_PRODUCT", 44, 49], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 73, 80], ["CD209L", "PROTEIN", 31, 37], ["CD147", "PROTEIN", 44, 49], ["protease TMPRSS2 (25", "PROTEIN", 64, 84], ["PTMs", "PROTEIN", 190, 194], ["CD209L", "TEST", 31, 37], ["CD147", "TEST", 44, 49], ["the protease TMPRSS2", "TEST", 60, 80], ["IntroductionPost-translational modifications (PTMs)", "TREATMENT", 144, 195], ["covalent modifications", "TREATMENT", 200, 222], ["viral entry", "OBSERVATION", 117, 128]]], ["In coronaviruses, they are required for a successful viral cycle.", [["coronaviruses", "ORGANISM", 3, 16], ["coronaviruses", "PROBLEM", 3, 16], ["a successful viral cycle", "TREATMENT", 40, 64], ["coronaviruses", "OBSERVATION", 3, 16]]], ["Glycosylation and palmitoylation of S and E proteins are fundamental in terms of stability, enzymatic activity, subcellular localization, and protein interaction (26\u201329).", [["subcellular", "ANATOMY", 112, 123], ["S and E proteins", "GENE_OR_GENE_PRODUCT", 36, 52], ["S and E proteins", "PROTEIN", 36, 52], ["Glycosylation", "TREATMENT", 0, 13], ["palmitoylation of S and E proteins", "TREATMENT", 18, 52], ["stability", "OBSERVATION", 81, 90], ["enzymatic activity", "OBSERVATION", 92, 110]]], ["Similarly, glycosylation of the M protein (30, 31), phosphorylation, and ribosylation of the N protein (32, 33), as well as other PTMs in non-structural and accessory proteins, can play a determinant role in the viral cycle (34, 35).", [["M protein", "GENE_OR_GENE_PRODUCT", 32, 41], ["M protein", "PROTEIN", 32, 41], ["N protein", "PROTEIN", 93, 102], ["PTMs", "PROTEIN", 130, 134], ["non-structural and accessory proteins", "PROTEIN", 138, 175], ["the M protein", "TEST", 28, 41], ["phosphorylation", "TEST", 52, 67], ["the N protein", "TEST", 89, 102]]], ["Considering the relevant role of PTMs and the complex composition of N-glycans, it was proposed that inhibition with N-butyl-deoxynojirimycin (NB-DNJ) (35) or the addition of carbohydrate-binding agents (CBAs) could be considered as therapeutic strategies against SARS-CoV infections (36).", [["N-butyl-deoxynojirimycin", "CHEMICAL", 117, 141], ["NB-DNJ", "CHEMICAL", 143, 149], ["CBAs", "CHEMICAL", 204, 208], ["SARS-CoV infections", "DISEASE", 264, 283], ["N", "CHEMICAL", 69, 70], ["N-butyl-deoxynojirimycin", "CHEMICAL", 117, 141], ["NB-DNJ", "CHEMICAL", 143, 149], ["carbohydrate", "CHEMICAL", 175, 187], ["N-butyl-deoxynojirimycin", "SIMPLE_CHEMICAL", 117, 141], ["NB-DNJ", "SIMPLE_CHEMICAL", 143, 149], ["carbohydrate-binding agents", "SIMPLE_CHEMICAL", 175, 202], ["CBAs", "SIMPLE_CHEMICAL", 204, 208], ["SARS-CoV", "ORGANISM", 264, 272], ["PTMs", "PROTEIN", 33, 37], ["SARS-CoV", "SPECIES", 264, 272], ["N-glycans", "TREATMENT", 69, 78], ["N-butyl", "TREATMENT", 117, 124], ["deoxynojirimycin (NB-DNJ)", "TREATMENT", 125, 150], ["carbohydrate-binding agents", "TREATMENT", 175, 202], ["SARS", "PROBLEM", 264, 268], ["CoV infections", "PROBLEM", 269, 283]]], ["Nitric Oxide (NO) and its derivatives have been shown to inhibit SARS-CoV replication by reducing the palmitoylation on the nascent Spike protein, affecting the receptor binding.", [["Nitric Oxide", "CHEMICAL", 0, 12], ["NO", "CHEMICAL", 14, 16], ["Nitric Oxide", "CHEMICAL", 0, 12], ["NO", "CHEMICAL", 14, 16], ["Nitric Oxide", "SIMPLE_CHEMICAL", 0, 12], ["NO", "SIMPLE_CHEMICAL", 14, 16], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 65, 73], ["Spike", "GENE_OR_GENE_PRODUCT", 132, 137], ["nascent Spike protein", "PROTEIN", 124, 145], ["SARS-CoV", "SPECIES", 65, 73], ["Nitric Oxide", "TREATMENT", 0, 12], ["its derivatives", "TREATMENT", 22, 37], ["SARS", "PROBLEM", 65, 69], ["CoV replication", "TREATMENT", 70, 85], ["the palmitoylation", "TREATMENT", 98, 116]]], ["It also affects viral RNA production in the early steps of replication, potentially due to an effect on the ORF1a-encoded cysteine proteases (37).IntroductionEffective methods to control the pandemic include the development of vaccines and diagnostic tests.", [["cysteine", "CHEMICAL", 122, 130], ["ORF1a", "GENE_OR_GENE_PRODUCT", 108, 113], ["ORF1a", "PROTEIN", 108, 113], ["cysteine proteases", "PROTEIN", 122, 140], ["viral RNA production", "PROBLEM", 16, 36], ["IntroductionEffective methods", "TREATMENT", 146, 175], ["vaccines", "TREATMENT", 227, 235], ["diagnostic tests", "TEST", 240, 256], ["viral RNA", "OBSERVATION", 16, 25], ["production", "OBSERVATION_MODIFIER", 26, 36]]], ["The fast release of complete SARS-CoV-2 genomes boosted the development of molecular diagnostic methods, resulting in an increasing portfolio of nucleic acid approaches like RT-qPCR (38\u201340), serological-based approaches like ELISA (41, 42), immunochromatographic panels based on antibodies IgM/IgG (43) or antigens (44), and hybrid systems in Point-of-Care devices, consisting of viral genome pre-amplification followed by a cleavage assay in a lateral flow system (45).IntroductionVaccine development efforts are undergoing worldwide.", [["SARS", "DISEASE", 29, 33], ["nucleic acid", "CHEMICAL", 145, 157], ["nucleic acid", "SIMPLE_CHEMICAL", 145, 157], ["IgM", "GENE_OR_GENE_PRODUCT", 290, 293], ["SARS-CoV-2 genomes", "DNA", 29, 47], ["antibodies IgM", "PROTEIN", 279, 293], ["IgG", "PROTEIN", 294, 297], ["43", "PROTEIN", 299, 301], ["antigens", "PROTEIN", 306, 314], ["viral genome", "DNA", 380, 392], ["an increasing portfolio of nucleic acid approaches", "PROBLEM", 118, 168], ["RT-qPCR", "TEST", 174, 181], ["serological", "TEST", 191, 202], ["ELISA", "TEST", 225, 230], ["immunochromatographic panels", "TEST", 241, 269], ["antibodies IgM", "TEST", 279, 293], ["IgG", "TEST", 294, 297], ["antigens", "TEST", 306, 314], ["hybrid systems", "PROBLEM", 325, 339], ["Care devices", "TREATMENT", 352, 364], ["viral genome pre-amplification", "TREATMENT", 380, 410], ["a cleavage assay", "TEST", 423, 439], ["a lateral flow system", "TEST", 443, 464], ["increasing", "OBSERVATION_MODIFIER", 121, 131], ["nucleic acid", "OBSERVATION", 145, 157], ["viral genome", "OBSERVATION", 380, 392]]], ["There are 110 prophylactic vaccine candidates as of May 15, 2020.", [["110 prophylactic vaccine candidates", "TREATMENT", 10, 45]]], ["Three of them are based on live-attenuated virus, seven on inactivated virus, 27 on viral vectors (12 replicating and 15 non-replicating), 26 on nucleic acids (10 using DNA and 16 RNA), 38 on recombinant proteins, six on Virus-Like Particles (VLP), and three unknown (46, 47).", [["nucleic acids", "CHEMICAL", 145, 158], ["DNA", "CELLULAR_COMPONENT", 169, 172], ["Virus-Like Particles", "ORGANISM", 221, 241], ["recombinant proteins", "PROTEIN", 192, 212], ["VLP", "PROTEIN", 243, 246], ["attenuated virus", "PROBLEM", 32, 48], ["inactivated virus", "PROBLEM", 59, 76], ["viral vectors", "TEST", 84, 97], ["nucleic acids", "TEST", 145, 158], ["DNA", "TEST", 169, 172], ["RNA", "TEST", 180, 183], ["recombinant proteins", "TEST", 192, 212], ["Virus", "TEST", 221, 226]]], ["Some vaccines have already moved to a clinical phase.", [["Some vaccines", "TREATMENT", 0, 13]]], ["There are six in Phase I: Pathogen-specific aAPC (NCT04299724, Shenzhen Geno-Immune Medical Institute, China), Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (NCT04313127, CanSino Biologics Inc.), bacTRL-Spike (NCT04334980, Symvivo Corporation, Canada), INO-4800 (NCT04336410, Inovio Pharmaceuticals, USA), mRNA-1273 (NCT04283461, National Institute of Allergy and Infectious Diseases, USA), and SARS-CoV-2 rS (NCT04368988, Novavax).", [["INO-4800", "CHEMICAL", 272, 280], ["mRNA-1273", "CHEMICAL", 325, 334], ["Allergy and Infectious Diseases", "DISEASE", 371, 402], ["Adenovirus", "ORGANISM", 150, 160], ["SARS-CoV-2 rS", "SPECIES", 414, 427], ["Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector", "TREATMENT", 111, 174], ["bacTRL", "TREATMENT", 215, 221], ["INO", "TEST", 272, 275], ["mRNA", "TEST", 325, 329], ["Novavax", "TREATMENT", 442, 449]]], ["There are four vaccines on simultaneous Phase I-II: SARS-CoV-2 inactivated vaccine (NCT04352608, Sinovac Research and Development Co., Ltd.), LV-SMENP-DC (NCT04276896, Shenzhen Geno-Immune Medical Institute, China), ChAdOx1 (NCT04324606, University of Oxford, UK), and BNT162 (NCT04368728, Biontech SE, Pfizer).", [["BNT162", "CHEMICAL", 269, 275], ["SARS-CoV-2", "ORGANISM", 52, 62], ["four vaccines", "TREATMENT", 10, 23], ["SARS", "PROBLEM", 52, 56], ["CoV", "TEST", 57, 60], ["2 inactivated vaccine", "TREATMENT", 61, 82], ["LV", "TEST", 142, 144], ["LV", "ANATOMY", 142, 144]]], ["There is also one vaccine in Phase II: Ad5-nCoV (NCT04341389, Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China) (47, 48).", [["Ad5", "ORGANISM", 39, 42]]], ["Of note, six peptide-based vaccines are currently under development: FlowVax\u2122 by Flow Pharma Inc. (49), EPV-CoV19 by EpiVax (50), DPX-COVID-19 by IMV inc.", [["DPX-COVID-19", "CHEMICAL", 130, 142], ["FlowVax\u2122", "SIMPLE_CHEMICAL", 69, 77], ["EPV-CoV19", "SIMPLE_CHEMICAL", 104, 113], ["six peptide-based vaccines", "TREATMENT", 9, 35], ["EPV", "TEST", 104, 107], ["DPX-COVID", "TEST", 130, 139]]], ["(51), Vaxil Bio (US patent: 62/987,310) (52), OncoGen (53), and USask VIDO-InterVac (54).IntroductionIn this urgent race to develop a vaccine, immunoinformatic techniques represent a powerful approach that allows the screening of whole pathogen proteomes to identify potential immunogenic regions (55).", [["a vaccine", "TREATMENT", 132, 141], ["immunoinformatic techniques", "TREATMENT", 143, 170], ["the screening", "TEST", 213, 226], ["whole pathogen proteomes", "TEST", 230, 254]]], ["This includes predicting linear epitopes potentially presented by the Human Leukocyte Antigen (HLA) class I and II, which can be used to design peptide vaccines (56) and molecular diagnostic tests (57).", [["Human Leukocyte Antigen", "GENE_OR_GENE_PRODUCT", 70, 93], ["HLA) class I", "GENE_OR_GENE_PRODUCT", 95, 107], ["Human Leukocyte Antigen (HLA) class I and II", "PROTEIN", 70, 114], ["Human", "SPECIES", 70, 75], ["predicting linear epitopes", "PROBLEM", 14, 40], ["the Human Leukocyte Antigen", "TEST", 66, 93], ["peptide vaccines", "TREATMENT", 144, 160], ["molecular diagnostic tests", "TEST", 170, 196], ["linear", "OBSERVATION_MODIFIER", 25, 31], ["epitopes", "OBSERVATION", 32, 40]]], ["The state-of-the-art programs are based on artificial neural networks (58\u201361), and they require both the sequence of target protein(s) and the host HLA allele(s) at 4-digit resolution (62, 63).IntroductionTwo recent studies have extrapolated epitopes with experimental evidence in SARS-CoV to SARS-CoV-2, and selected candidates based on different criteria.", [["neural networks", "ANATOMY", 54, 69], ["neural networks", "MULTI-TISSUE_STRUCTURE", 54, 69], ["SARS-CoV", "ORGANISM", 281, 289], ["SARS-CoV-2", "ORGANISM", 293, 303], ["target protein", "PROTEIN", 117, 131], ["HLA allele", "DNA", 148, 158], ["SARS-CoV", "SPECIES", 281, 289], ["SARS-CoV", "SPECIES", 293, 301], ["artificial neural networks", "TEST", 43, 69], ["Two recent studies", "TEST", 205, 223], ["extrapolated epitopes", "PROBLEM", 229, 250], ["SARS", "PROBLEM", 281, 285], ["SARS", "TEST", 293, 297], ["CoV", "TEST", 298, 301]]], ["Grifoni et al. (64) intersected these extrapolated epitopes with a set of predicted epitopes using 12 HLA-I A and B supertypes (65).", [["B", "GENE_OR_GENE_PRODUCT", 114, 115], ["epitopes", "PROTEIN", 84, 92], ["HLA", "PROTEIN", 102, 105]]], ["They present 12 candidates in the S, M, and N proteins of SARS-CoV-2.", [["SARS", "DISEASE", 58, 62], ["SARS-CoV-2", "ORGANISM", 58, 68], ["S, M, and N proteins", "PROTEIN", 34, 54], ["SARS-CoV", "SPECIES", 58, 66]]], ["Ahmed et al. (66) subselected the extrapolated epitopes using the Population Tool of the Immune Epitope Database and Analysis Resource (IEDB) (67), resulting in candidates in the S and N proteins that may potentially cover the global population.", [["S and N proteins", "PROTEIN", 179, 195], ["the S and N proteins", "PROBLEM", 175, 195], ["global", "OBSERVATION_MODIFIER", 227, 233], ["population", "OBSERVATION", 234, 244]]], ["This tool is based on the HLA frequencies reported in the Allele Frequency Net Database (AFNDB), which is an important reference source for immunological studies worldwide (68).", [["the HLA frequencies", "PROBLEM", 22, 41], ["immunological studies", "TEST", 140, 161]]], ["Nevertheless, this database has little information about South America, missing large studies published in recent years comprising millions of people (see Table S3).IntroductionLack of knowledge about the HLA allelic distribution in South America can cause regional misrepresentation in immunological studies, which could result in diminished efficiency of vaccines and diagnostic tests.", [["people", "ORGANISM", 143, 149], ["HLA", "GENE_OR_GENE_PRODUCT", 205, 208], ["people", "SPECIES", 143, 149], ["missing large studies", "PROBLEM", 72, 93], ["immunological studies", "TEST", 287, 308], ["diminished efficiency of vaccines", "PROBLEM", 332, 365], ["diagnostic tests", "TEST", 370, 386]]], ["Additionally, knowledge on HLA allelic frequencies typified at 4-digit resolution or higher also plays a determinant role in other areas, like transplantation (69), response to cancer immunotherapy (70), and susceptibility to autoimmune diseases (71, 72).IntroductionHere, we performed a literature review of HLA allele frequencies of South American populations reported in scientific articles available in PubMed and datasets available in the AFNDB.", [["cancer", "ANATOMY", 177, 183], ["cancer", "DISEASE", 177, 183], ["autoimmune diseases", "DISEASE", 226, 245], ["HLA", "GENE_OR_GENE_PRODUCT", 27, 30], ["cancer", "CANCER", 177, 183], ["HLA allele", "DNA", 309, 319], ["HLA allelic frequencies", "PROBLEM", 27, 50], ["cancer immunotherapy", "TREATMENT", 177, 197], ["susceptibility to autoimmune diseases", "PROBLEM", 208, 245], ["cancer", "OBSERVATION", 177, 183], ["autoimmune diseases", "OBSERVATION", 226, 245]]], ["Then, HLA class I and II epitopes were predicted using only alleles with WAF \u2265 0.05.", [["HLA class I", "GENE_OR_GENE_PRODUCT", 6, 17], ["HLA class I and II epitopes", "PROTEIN", 6, 33], ["WAF", "TEST", 73, 76]]], ["Finally, we selected candidate epitopes covering all of these South American HLA alleles, reporting both candidates with existing experimental evidence in the IEDB database for other coronaviruses as well as novel candidates.", [["coronaviruses", "ORGANISM", 183, 196], ["South American HLA alleles", "DNA", 62, 88], ["other coronaviruses", "PROBLEM", 177, 196]]], ["Our findings may result in a better representation of South America, enriching current development efforts of vaccines and diagnostic tests.Alignment, Entropy, and Selection Pressure of the SARS-CoV-2 Proteins ::: MethodsA total of 2,123 genome sequences from human hosts, categorized as complete with high coverage in the Global Initiative on Sharing All Influenza Data (GISAID) database (73), were downloaded on March 31, 2020.", [["SARS", "DISEASE", 190, 194], ["human", "ORGANISM", 260, 265], ["2,123 genome sequences", "DNA", 232, 254], ["human", "SPECIES", 260, 265], ["SARS-CoV", "SPECIES", 190, 198], ["human", "SPECIES", 260, 265], ["vaccines", "TREATMENT", 110, 118], ["diagnostic tests", "TEST", 123, 139], ["Selection Pressure", "TEST", 164, 182], ["the SARS", "TEST", 186, 194], ["MethodsA", "TEST", 214, 222], ["human hosts", "TREATMENT", 260, 271]]], ["This comprises genomes from 55 countries, including 16 from Brazil, seven from Chile, and one from Peru (Tables S1, S2).", [["S2", "ANATOMY", 116, 118]]], ["The coding regions corresponding to the viral proteins were extracted and translated, using as reference the sequences with GenBank Gene IDs: 43740568 (Spike, S), 43740571 (Membrane, M), 43740575 (Nucleocapside, N), 43740570 (Envelope, E), 43740569 (ORF3a), 43740572 (ORF6), 43740573 (ORF7a), 43740574 (ORF7b), 43740577 (ORF8), 43740576 (ORF10), and 43740578 (Orf1ab and NSP1-16 proteins).Alignment, Entropy, and Selection Pressure of the SARS-CoV-2 Proteins ::: MethodsVariability at each amino acid position of the SARS-CoV-2 proteins was measured by Shannon Entropy (74), using the Shannon Entropy-One online tool (https://www.hiv.lanl.gov/content/sequence/ENTROPY/entropy_one.html).", [["SARS", "DISEASE", 439, 443], ["amino acid", "CHEMICAL", 490, 500], ["SARS", "DISEASE", 517, 521], ["amino acid", "CHEMICAL", 490, 500], ["NSP1-16 proteins", "GENE_OR_GENE_PRODUCT", 371, 387], ["amino acid", "AMINO_ACID", 490, 500], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 517, 527], ["viral proteins", "PROTEIN", 40, 54], ["ORF10", "DNA", 338, 343], ["Orf1ab", "DNA", 360, 366], ["NSP1", "DNA", 371, 375], ["SARS-CoV-2 proteins", "PROTEIN", 517, 536], ["SARS-CoV", "SPECIES", 439, 447], ["the viral proteins", "PROBLEM", 36, 54], ["Nucleocapside", "TEST", 197, 210], ["Envelope", "TEST", 226, 234], ["Orf1ab", "TEST", 360, 366], ["NSP1", "TEST", 371, 375], ["Selection Pressure", "TEST", 413, 431], ["the SARS", "TEST", 435, 443], ["MethodsVariability", "TREATMENT", 463, 481], ["the SARS", "TEST", 513, 521], ["CoV", "TEST", 522, 525], ["viral proteins", "OBSERVATION", 40, 54]]], ["Sites with positive selection pressure were obtained from the SARS-CoV-2 Natural Selection Analysis available in the Galaxy Project (https://covid19.galaxyproject.org/) (75), retrieved on May 3, 2020, considering the better-ranked sites (meeting at least four categories).South American HLA Alleles and Weighted Allele Frequencies (WAFs) ::: MethodsA review was performed considering first only datasets available in the AFNDB containing allelic frequencies of HLA-A, -B, -C, -DPA, -DPB, -DQA, -DQB, and -DRB1 in South American populations.", [["AFNDB", "CANCER", 421, 426], ["HLA-A", "GENE_OR_GENE_PRODUCT", 461, 466], ["-C, -DPA", "SIMPLE_CHEMICAL", 472, 480], ["-DPB", "SIMPLE_CHEMICAL", 482, 486], ["-DQA", "SIMPLE_CHEMICAL", 488, 492], ["-DQB", "SIMPLE_CHEMICAL", 494, 498], ["AFNDB", "DNA", 421, 426], ["DQA", "DNA", 489, 492], ["DQB", "DNA", 495, 498], ["DRB1", "DNA", 505, 509], ["positive selection pressure", "TEST", 11, 38], ["the SARS", "TEST", 58, 66], ["CoV", "TEST", 67, 70], ["Natural Selection Analysis", "TEST", 73, 99], ["HLA", "TEST", 461, 464], ["DPA", "TEST", 477, 480], ["DPB", "TREATMENT", 483, 486], ["DQB", "TEST", 495, 498], ["positive", "OBSERVATION_MODIFIER", 11, 19], ["selection pressure", "OBSERVATION", 20, 38]]], ["We selected studies using the following inclusion criteria: (i) we collected all the studies characterizing HLA alleles with at least 4-digit resolution in 100 or more individuals (N \u2265 100); and (ii) an auxiliary rule was exceptionally applied in low-information cases only, i.e., if just two or fewer articles were obtained, both barely passing the filter (100 \u2264 N \u2264 200).", [["HLA alleles", "DNA", 108, 119], ["selected studies", "TEST", 3, 19], ["the studies", "TEST", 81, 92], ["HLA alleles", "PROBLEM", 108, 119], ["an auxiliary rule", "TEST", 200, 217]]], ["This exception consisted of relaxing the lower cut-off to N \u2265 40, allowing smaller studies to pass the filter to rescue additional data.South American HLA Alleles and Weighted Allele Frequencies (WAFs) ::: MethodsTo expand the \u201ccurrent scenario,\u201d in addition to the previously described datasets, we collected articles in PubMed reporting Class I and Class II HLA alleles of South American populations using the same inclusion criteria.", [["Class I and Class II HLA alleles", "DNA", 339, 371], ["rescue additional data", "TEST", 113, 135], ["Methods", "TREATMENT", 206, 213]]], ["The selection criteria were applied to both published datasets in scientific articles and datasets available only in the AFNDB.", [["The selection criteria", "TEST", 0, 22]]], ["All alleles were matched to the current HLA nomenclature (76).South American HLA Alleles and Weighted Allele Frequencies (WAFs) ::: MethodsThen, for both current and updated scenarios, we calculated Weighted Allele Frequencies (WAFs) by country, using as approximation the weighted average of the allele frequencies in all the studies selected by country.", [["the studies", "TEST", 323, 334]]], ["This led to a few exceptions due to evident discrepancies in technology and resolution, resulting in the exclusion of some studies (see Figure 1 and Supplementary Methods for full detail).", [["some studies", "TEST", 118, 130]]], ["Only alleles with WAF \u2265 5% in the updated scenario were considered for further analysis.Epitope Prediction and Selection ::: MethodsLinear epitopes for HLA class I (HLA-A, -B, and -C) and HLA class II (HLA-DRB1) were predicted in the SARS-CoV-2 proteins using the alleles obtained in the previous step and the cut-offs recommended by each software.", [["HLA class I", "GENE_OR_GENE_PRODUCT", 152, 163], ["HLA-A", "GENE_OR_GENE_PRODUCT", 165, 170], ["-B", "GENE_OR_GENE_PRODUCT", 172, 174], ["-C", "GENE_OR_GENE_PRODUCT", 180, 182], ["HLA class II", "GENE_OR_GENE_PRODUCT", 188, 200], ["HLA-DRB1", "GENE_OR_GENE_PRODUCT", 202, 210], ["WAF", "DNA", 18, 21], ["MethodsLinear epitopes", "PROTEIN", 125, 147], ["HLA class I", "PROTEIN", 152, 163], ["HLA", "PROTEIN", 165, 168], ["B", "PROTEIN", 173, 174], ["HLA class II", "PROTEIN", 188, 200], ["SARS-CoV-2 proteins", "PROTEIN", 234, 253], ["SARS-CoV", "SPECIES", 234, 242], ["WAF \u2265", "TREATMENT", 18, 23], ["further analysis", "TEST", 71, 87], ["HLA class", "TEST", 152, 161], ["HLA", "TEST", 165, 168], ["A", "TEST", 169, 170], ["HLA-DRB1", "TEST", 202, 210], ["the SARS", "TEST", 230, 238], ["CoV", "TEST", 239, 242], ["the alleles", "TEST", 260, 271]]], ["For HLA class I, we predicted epitopes of 8-11aa using NetMHCpan v4.0 (59) with rank \u2264 2 and MHCflurry v1.6.0 (60) with an affinity (IC50) \u2264 500 nM.", [["HLA class I", "GENE_OR_GENE_PRODUCT", 4, 15], ["HLA class I", "PROTEIN", 4, 15], ["epitopes", "PROTEIN", 30, 38], ["epitopes", "TEST", 30, 38], ["NetMHCpan", "TEST", 55, 64], ["MHCflurry", "TEST", 93, 102], ["an affinity (IC50)", "TREATMENT", 120, 138]]], ["As these programs do not have the same collection of HLA alleles available for prediction, we used the consensus verdict whenever possible.", [["HLA alleles", "DNA", 53, 64]]], ["Otherwise, we only used the prediction of the software with the allele available.", [["allele", "DNA", 64, 70]]], ["For HLA class II, we predicted epitopes of 15aa using NetMHCIIpan v4.0 (61) with rank \u2264 10.", [["HLA class II", "GENE_OR_GENE_PRODUCT", 4, 16], ["HLA class II", "PROTEIN", 4, 16], ["epitopes", "PROTEIN", 31, 39], ["15aa", "PROTEIN", 43, 47], ["NetMHCIIpan", "TREATMENT", 54, 65]]], ["Then, we annotated which predicted epitopes have previous experimental evidence for other coronaviruses (identical match, either in full length from end to end or contained inside) in the IEDB Database (www.iedb.org) (67).Epitope Prediction and Selection ::: MethodsEach predicted epitope obtained corresponds to one or more HLA alleles, which have different WAFs by country.", [["epitopes", "PROTEIN", 35, 43], ["HLA alleles", "DNA", 325, 336], ["other coronaviruses", "PROBLEM", 84, 103]]], ["To combine these WAFs into a single value, we defined a Coverage Score (CS), which reflects how good a candidate epitope is for South America.", [["WAFs", "DNA", 17, 21], ["a Coverage Score", "TEST", 54, 70]]], ["This was calculated for each predicted epitope, by adding the proportion by country of alleles with WAF \u2265 5% that bind this predicted epitope.", [["WAF", "PROTEIN", 100, 103], ["WAF \u2265", "TREATMENT", 100, 105]]], ["Therefore, this CS varies in a range from 0 to P, where P is the number of countries.", [["this CS", "TEST", 11, 18]]], ["Additionally, for HLA-II only, we prioritized candidates based on their three-dimensional exposure.", [["HLA-II", "GENE_OR_GENE_PRODUCT", 18, 24], ["HLA-II", "PROTEIN", 18, 24]]], ["Sequence logos were generated using WebLogo 3 (78), showing the chemistry and frequency per amino acid of our best candidates.Epitope Prediction and Selection ::: MethodsAll the data was processed and analyzed using Python v3.8.2 (www.python.org) and R v3.6.3 (www.r-project.org) with Rstudio v1.2.5033 (www.rstudio.com).Prediction of Post-translational Modifications Events ::: MethodsSignal peptide was predicted using Signal-3L 2.0 (79).", [["amino acid", "CHEMICAL", 92, 102], ["amino acid", "CHEMICAL", 92, 102], ["amino acid", "AMINO_ACID", 92, 102], ["Sequence logos", "TEST", 0, 14], ["WebLogo", "TEST", 36, 43], ["the chemistry", "TEST", 60, 73], ["Methods", "TREATMENT", 163, 170], ["Python", "TEST", 216, 222], ["R v", "TEST", 251, 254], ["Rstudio v", "TEST", 285, 294], ["MethodsSignal peptide", "TREATMENT", 379, 400], ["Signal", "TEST", 421, 427], ["Post-translational Modifications", "OBSERVATION", 335, 367]]], ["Protein topology (inner, transmembrane, and outer regions) were predicted with MemBrain v3.1 (80).", [["inner", "ANATOMY", 18, 23], ["transmembrane", "ANATOMY", 25, 38], ["outer regions", "ANATOMY", 44, 57], ["transmembrane", "CELLULAR_COMPONENT", 25, 38], ["inner, transmembrane, and outer regions", "PROTEIN", 18, 57], ["Protein topology", "TEST", 0, 16], ["MemBrain", "TEST", 79, 87], ["outer", "ANATOMY_MODIFIER", 44, 49]]], ["N-Glycosylation and O-Glycosylation sites were predicted using N-Glycosite (81) and NetOGlyc v4 (82) (score \u2265 0.5), respectively.", [["N", "CHEMICAL", 0, 1], ["O", "CHEMICAL", 20, 21], ["Glycosylation", "TREATMENT", 2, 15], ["Glycosylation sites", "TREATMENT", 22, 41]]], ["Palmitoylation and Sumoylation sites were predicted using CSS-Palm 4.0 (83) (medium threshold, Sn = 86.92%, Sp = 89.97%) and GPS-SUMO v1.0 (84) (medium threshold, Sn = 68.94%, Sp = 95.01%), respectively.", [["Sumoylation sites", "DNA", 19, 36], ["SUMO", "PROTEIN", 129, 133], ["Palmitoylation and Sumoylation sites", "TREATMENT", 0, 36], ["CSS", "TEST", 58, 61], ["Palm", "TEST", 62, 66], ["Sn", "TEST", 95, 97], ["Sp", "TEST", 108, 110], ["GPS", "TEST", 125, 128], ["SUMO v", "TEST", 129, 135], ["medium threshold", "TEST", 145, 161], ["Sn", "TEST", 163, 165], ["Sp", "TEST", 176, 178]]], ["Prediction of ADP-ribosylation sites was performed using ADPredict v1.1 (85) (score \u2265 0.4).", [["ADP", "CHEMICAL", 14, 17], ["ADP", "CHEMICAL", 14, 17], ["ADP", "SIMPLE_CHEMICAL", 14, 17], ["ADP", "PROTEIN", 14, 17], ["ADP-ribosylation sites", "TREATMENT", 14, 36], ["ADPredict v", "TEST", 57, 68]]], ["All predictions were manually curated based on Uniprot available annotations for SARS-CoV-2.Structural Modeling and Graphical Representation ::: MethodsCandidate epitopes were mapped on the 3D structure of the S protein.", [["S protein", "PROTEIN", 210, 219], ["SARS-CoV", "SPECIES", 81, 89], ["SARS", "TEST", 81, 85], ["CoV", "TEST", 86, 89]]], ["To avoid missing residues in the current crystal structure, we modeled the consensus sequence of the S protein by homology using the SWISS-MODEL web server (86) (https://swissmodel.expasy.org/), with the crystal structure as template (Protein Data Bank ID: 6VXX).", [["S protein", "PROTEIN", 101, 110], ["SWISS", "PROTEIN", 133, 138], ["Protein Data Bank ID: 6VXX", "PROTEIN", 235, 261], ["missing residues", "PROBLEM", 9, 25]]], ["Figures were generated in PyMOL v2.3.4 (https://pymol.org/2/) (87).Alignment, Entropy, and Selection Pressure of the SARS-CoV-2 Proteins ::: ResultsDiversity at each amino acid position revealed high entropy values in the proteins NSP2 (T85I, score = 0.36), NSP5 (L37F, score = 0.42), NSP12 (P323L, score = 0.69), NSP13 (P504L, score = 0.46 and Y541C, score = 0.47), Spike (D614G, score = 0.69), ORF3a (Q57H, score = 0.41 and G251V, score = 0.31), ORF8 (L84S, score = 0.57), and Nucleocapsid (R203K, score = 0.41, and G204R, score = 0.41).Alignment, Entropy, and Selection Pressure of the SARS-CoV-2 Proteins ::: ResultsSites with the highest probability to be under positive selective pressure are located in NSP2 (T85, P568), NSP3 (K384, N444, P822, V1768, V1795), NSP6 (L75), NSP7 (S25), Spike (S943, G1124), ORF3a (A99, T14, L147), NSP12 (A97, L323, A449), NSP13 (V49), NSP14 (A482), and NSP16 (K160).", [["SARS", "DISEASE", 117, 121], ["amino acid", "CHEMICAL", 166, 176], ["SARS", "DISEASE", 589, 593], ["amino acid", "CHEMICAL", 166, 176], ["amino acid", "AMINO_ACID", 166, 176], ["NSP2", "GENE_OR_GENE_PRODUCT", 231, 235], ["NSP5", "GENE_OR_GENE_PRODUCT", 258, 262], ["NSP12", "GENE_OR_GENE_PRODUCT", 285, 290], ["NSP13", "GENE_OR_GENE_PRODUCT", 314, 319], ["Nucleocapsid", "GENE_OR_GENE_PRODUCT", 479, 491], ["NSP2", "GENE_OR_GENE_PRODUCT", 710, 714], ["NSP3", "GENE_OR_GENE_PRODUCT", 728, 732], ["NSP6", "GENE_OR_GENE_PRODUCT", 767, 771], ["NSP7", "GENE_OR_GENE_PRODUCT", 779, 783], ["Spike", "GENE_OR_GENE_PRODUCT", 791, 796], ["ORF3a", "GENE_OR_GENE_PRODUCT", 812, 817], ["NSP12", "GENE_OR_GENE_PRODUCT", 836, 841], ["NSP13 (V49)", "GENE_OR_GENE_PRODUCT", 861, 872], ["NSP14", "GENE_OR_GENE_PRODUCT", 874, 879], ["NSP16", "GENE_OR_GENE_PRODUCT", 892, 897], ["NSP2", "PROTEIN", 231, 235], ["T85I", "PROTEIN", 237, 241], ["NSP5", "PROTEIN", 258, 262], ["L37F", "PROTEIN", 264, 268], ["NSP12", "PROTEIN", 285, 290], ["P323L", "PROTEIN", 292, 297], ["NSP13", "PROTEIN", 314, 319], ["P504L", "PROTEIN", 321, 326], ["Spike", "PROTEIN", 367, 372], ["D614G", "PROTEIN", 374, 379], ["ORF3a", "PROTEIN", 396, 401], ["Q57H", "PROTEIN", 403, 407], ["G251V", "PROTEIN", 426, 431], ["ORF8", "PROTEIN", 448, 452], ["L84S", "PROTEIN", 454, 458], ["Nucleocapsid", "PROTEIN", 479, 491], ["R203K", "PROTEIN", 493, 498], ["NSP12", "DNA", 836, 841], ["NSP13", "DNA", 861, 866], ["V49", "DNA", 868, 871], ["NSP14", "DNA", 874, 879], ["A482", "DNA", 881, 885], ["NSP16", "DNA", 892, 897], ["K160", "DNA", 899, 903], ["SARS-CoV", "SPECIES", 117, 125], ["SARS-CoV", "SPECIES", 589, 597], ["Figures", "TEST", 0, 7], ["PyMOL", "TEST", 26, 31], ["Selection Pressure", "TEST", 91, 109], ["the SARS", "TEST", 113, 121], ["each amino acid position", "TEST", 161, 185], ["high entropy values", "PROBLEM", 195, 214], ["the proteins NSP2", "TEST", 218, 235], ["score", "TEST", 243, 248], ["NSP5", "TEST", 258, 262], ["score", "TEST", 270, 275], ["NSP12", "TEST", 285, 290], ["P323L", "TEST", 292, 297], ["score", "TEST", 299, 304], ["NSP13", "TEST", 314, 319], ["score", "TEST", 328, 333], ["Y541C", "TEST", 345, 350], ["score", "TEST", 352, 357], ["Spike", "TEST", 367, 372], ["score", "TEST", 381, 386], ["ORF3a", "TEST", 396, 401], ["score", "TEST", 409, 414], ["G251V", "TEST", 426, 431], ["score", "TEST", 433, 438], ["ORF8", "TEST", 448, 452], ["L84S", "TEST", 454, 458], ["score", "TEST", 460, 465], ["Nucleocapsid", "TEST", 479, 491], ["score", "TEST", 500, 505], ["G204R", "TEST", 518, 523], ["score", "TEST", 525, 530], ["Selection Pressure", "TEST", 563, 581], ["the SARS", "TEST", 585, 593], ["NSP2", "TEST", 710, 714], ["NSP3", "TEST", 728, 732], ["K384", "TEST", 734, 738], ["P822", "TEST", 746, 750], ["NSP6", "TEST", 767, 771], ["NSP7", "TEST", 779, 783], ["Spike", "TEST", 791, 796], ["ORF3a", "TEST", 812, 817], ["A99", "TEST", 819, 822], ["T14", "TEST", 824, 827], ["NSP12", "TEST", 836, 841], ["NSP13", "TEST", 861, 866], ["NSP14", "TEST", 874, 879], ["NSP16", "TEST", 892, 897], ["high entropy", "OBSERVATION", 195, 207]]], ["The selection process is provided in full detail in the Supplementary Methods and Table S3.South American HLA Alleles and Weighted Allele Frequencies (WAFs) ::: ResultsThe IEDB population coverage tool (http://tools.iedb.org/population/) uses information provided by the AFNDB at 4-digit resolution, which in the case of South America comprises just a small number of populations: two from Argentina, one from Bolivia, five from Brazil, two from Chile, three from Colombia, two from Ecuador, one from Paraguay, two from Peru, and four from Venezuela.", [["The selection process", "TREATMENT", 0, 21], ["The IEDB population coverage", "TREATMENT", 168, 196], ["small", "OBSERVATION_MODIFIER", 352, 357], ["number", "OBSERVATION_MODIFIER", 358, 364]]], ["In both scenarios (current and updated), we only obtained HLA-II and not HLA-I data from Bolivia.", [["HLA-II", "GENE_OR_GENE_PRODUCT", 58, 64], ["HLA-I", "GENE_OR_GENE_PRODUCT", 73, 78]]], ["All of the allele frequencies and sample sizes by study are provided in Table S4.", [["sample sizes", "TEST", 34, 46]]], ["The addition of new studies resulted in updated HLA allele frequencies.South American HLA Alleles and Weighted Allele Frequencies (WAFs) ::: ResultsWe then calculated WAFs for each country (see Table S5).", [["HLA", "GENE_OR_GENE_PRODUCT", 48, 51], ["HLA allele", "DNA", 48, 58], ["new studies", "TEST", 16, 27]]], ["Some alleles with WAF under 5% in the current scenario are now above in the updated scenario: 13 alleles of Argentina, 15 of Brazil, seven of Chile, seven of Ecuador, one of Paraguay, two of Peru, and 19 of Venezuela.", [["WAF", "DNA", 18, 21], ["Some alleles", "PROBLEM", 0, 12], ["WAF", "TREATMENT", 18, 21], ["WAF", "OBSERVATION_MODIFIER", 18, 21]]], ["Additionally, some alleles not reported in the AFNDB for South America were found with WAF \u2265 5% in the updated scenario: six alleles of HLA-I C in Argentina, two HLA-II DQA1 in Ecuador, two HLA-I A and six HLA-I B in Paraguay, two HLA-I C in Peru, five HLA-II DQB1 in Uruguay, and four HLA-II DPA1 in Venezuela (see Figure 2).", [["HLA-I C", "GENE_OR_GENE_PRODUCT", 136, 143], ["HLA-II DQA1", "GENE_OR_GENE_PRODUCT", 162, 173], ["HLA-I B", "GENE_OR_GENE_PRODUCT", 206, 213], ["HLA-I C", "GENE_OR_GENE_PRODUCT", 231, 238], ["HLA-I C", "DNA", 136, 143], ["HLA-II DQA1", "DNA", 162, 173], ["HLA-I A", "DNA", 190, 197], ["HLA-I B", "DNA", 206, 213], ["HLA-I C", "DNA", 231, 238], ["HLA-II DQB1", "DNA", 253, 264], ["HLA-II DPA1", "DNA", 286, 297], ["WAF", "TEST", 87, 90], ["HLA", "TEST", 136, 139]]], ["Details provided in Table S6.Epitope Prediction ::: ResultsWe obtained 11,644 predicted T cell epitopes in SARS-CoV-2 proteins: 7,517 for HLA-I and 4,127 for HLA-II.", [["T cell", "ANATOMY", 88, 94], ["T cell", "CELL", 88, 94], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 107, 117], ["HLA-I", "GENE_OR_GENE_PRODUCT", 138, 143], ["S6", "PROTEIN", 26, 28], ["T cell epitopes", "PROTEIN", 88, 103], ["SARS-CoV-2 proteins", "PROTEIN", 107, 126], ["SARS-CoV", "SPECIES", 107, 115], ["Epitope Prediction", "TEST", 29, 47], ["ResultsWe", "TEST", 52, 61], ["T cell epitopes", "TEST", 88, 103], ["SARS", "TEST", 107, 111], ["CoV", "TEST", 112, 115], ["HLA", "TEST", 138, 141], ["HLA", "TEST", 158, 161]]], ["We found that 1400 have previous experimental evidence in the IEDB: 25 in positive T cell assays, 1327 in positive MHC-ligand binding assays, and 48 in both (see Table S7).Epitope Prediction ::: ResultsIn the S protein, we predicted 961 HLA-I epitopes.", [["T cell", "ANATOMY", 83, 89], ["T cell", "CELL", 83, 89], ["HLA-I", "GENE_OR_GENE_PRODUCT", 237, 242], ["MHC", "PROTEIN", 115, 118], ["S protein", "PROTEIN", 209, 218], ["961 HLA-I epitopes", "PROTEIN", 233, 251], ["positive T cell assays", "TEST", 74, 96], ["ligand binding assays", "TEST", 119, 140], ["HLA", "TEST", 237, 240]]], ["The best two predicted epitopes with the highest CS (VVFLHVTYV, CS = 2.146, IEDB-ID: 71663 and LQIPFAMQM, CS = 2.043, IEDB-ID: 38855) cover almost one allele with WAF \u2265 5% by country.", [["epitopes", "PROTEIN", 23, 31], ["VVFLHVTYV", "TEST", 53, 62], ["CS", "TEST", 64, 66], ["IEDB", "TEST", 76, 80], ["LQIPFAMQM", "TEST", 95, 104], ["CS", "TEST", 106, 108], ["IEDB", "TEST", 118, 122]]], ["Other predicted epitopes already proposed as candidates in similar studies (64, 66) have lower CS.", [["epitopes", "PROTEIN", 16, 24]]], ["From the 848 predicted epitopes without experimental evidence, the top three with the highest CS cover at least one allele with WAF \u2265 5% by country.", [["allele", "DNA", 116, 122], ["WAF \u2265", "TREATMENT", 128, 133]]], ["These represent novel candidates (Table 1): MIAQYTSAL (CS = 4.127), SIIAYTMSL (CS = 3.739), and YLQPRTFLL (CS = 3.646).Epitope Prediction ::: ResultsWe predicted 6556 HLA-I epitopes in other SARS-CoV-2 proteins.", [["HLA-I", "GENE_OR_GENE_PRODUCT", 167, 172], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 191, 201], ["6556 HLA-I epitopes", "PROTEIN", 162, 181], ["SARS-CoV-2 proteins", "PROTEIN", 191, 210], ["SARS-CoV", "SPECIES", 191, 199], ["MIAQYTSAL (CS", "TEST", 44, 57], ["CS", "TEST", 79, 81], ["HLA", "TEST", 167, 170], ["other SARS", "TEST", 185, 195], ["CoV", "TEST", 196, 199]]], ["Experimental evidence was reported for 1122, and the 10 with the highest CS (2.520\u20133.346) cover at least one allele with WAF \u2265 5% by country.", [["WAF \u2265", "TREATMENT", 121, 126]]], ["These predicted epitopes are located in the ORF6 and NSP proteins, and represent novel candidates.", [["ORF6", "GENE_OR_GENE_PRODUCT", 44, 48], ["NSP", "GENE_OR_GENE_PRODUCT", 53, 56], ["epitopes", "PROTEIN", 16, 24], ["ORF6", "PROTEIN", 44, 48], ["NSP proteins", "PROTEIN", 53, 65], ["These predicted epitopes", "PROBLEM", 0, 24], ["NSP proteins", "TEST", 53, 65]]], ["The highest CS (3.346) corresponds to YADVFHLYL, located in the NSP12 protein.", [["NSP12", "GENE_OR_GENE_PRODUCT", 64, 69], ["YADVFHLYL", "PROTEIN", 38, 47], ["NSP12 protein", "PROTEIN", 64, 77], ["The highest CS", "TEST", 0, 14], ["YADVFHLYL", "TREATMENT", 38, 47]]], ["We also found 5434 predicted epitopes without experimental evidence.", [["without", "UNCERTAINTY", 38, 45]]], ["The top seven with the highest CS (3.148\u20134.013) are novel candidates, located in NSP proteins, and cover at least one allele with WAF \u2265 5% by country.", [["NSP", "GENE_OR_GENE_PRODUCT", 81, 84], ["NSP proteins", "PROTEIN", 81, 93], ["the highest CS", "TEST", 19, 33], ["NSP proteins", "TEST", 81, 93], ["WAF \u2265", "TREATMENT", 130, 135], ["NSP proteins", "OBSERVATION", 81, 93]]], ["The candidate with the highest CS (FAQDGNAAI, 4.013) is also located in the NSP12 protein (see Table 1).Epitope Prediction ::: ResultsFor HLA-II, we predicted 628 epitopes in the S protein.", [["NSP12", "GENE_OR_GENE_PRODUCT", 76, 81], ["HLA-II", "GENE_OR_GENE_PRODUCT", 138, 144], ["NSP12 protein", "PROTEIN", 76, 89], ["628 epitopes", "PROTEIN", 159, 171], ["S protein", "PROTEIN", 179, 188], ["HLA", "TEST", 138, 141]]], ["Twenty-eight have experimental evidence, and the two with the highest CS (RAAEIRASANLAATK, CS = 9.000, IEDB-ID: 100428 and IRAAEIRASANLAAT, CS = 8.148, IEDB-ID: 100428) are contiguous and belong to the CH region.", [["CS", "TEST", 91, 93], ["CS", "TEST", 140, 142]]], ["The next two, LDKYFKNHTSPDVDL (CS = 6.760, IEDB-ID: 35205) and DKYFKNHTSPDVDLG (CS = 6.760, IEDB-ID: 9006), are also contiguous and correspond to the HR2 region (Figure 3D).", [["HR2 region", "PROTEIN", 150, 160], ["LDKYFKNHTSPDVDL", "TEST", 14, 29], ["CS", "TEST", 31, 33], ["IEDB", "TEST", 43, 47], ["DKYFKNHTSPDVDLG", "TEST", 63, 78], ["CS", "TEST", 80, 82]]], ["These two were selected as candidates in a previous study (66).Epitope Prediction ::: ResultsWe also predicted 601 epitopes without experimental evidence in the S protein, where 41 had 6.017 \u2264 CS \u2264 9.000 (Figure 3D).", [["601 epitopes", "PROTEIN", 111, 123], ["S protein", "PROTEIN", 161, 170], ["a previous study", "TEST", 41, 57], ["the S protein", "TEST", 157, 170], ["CS", "TEST", 193, 195]]], ["Some of these are located in notoriously exposed regions (see Figure 4).", [["notoriously", "OBSERVATION_MODIFIER", 29, 40]]], ["All of these are novel candidates, including EKGIYQTSNFRVQPT (CS = 8.490), QTSNFRVQPTESIVR (CS = 8.714), and TSNFRVQPTESIVRF (CS = 9.000, the maximum possible score), which overlap in the RBD and have a remarkably high CS.Epitope Prediction ::: ResultsWe obtained 81 HLA-II predicted epitopes in the M protein.", [["RBD", "DISEASE", 188, 191], ["HLA-II", "GENE_OR_GENE_PRODUCT", 267, 273], ["RBD", "PROTEIN", 188, 191], ["HLA-II predicted epitopes", "PROTEIN", 267, 292], ["M protein", "PROTEIN", 300, 309], ["CS", "TEST", 62, 64], ["QTSNFRVQPTESIVR", "TEST", 75, 90], ["CS", "TEST", 92, 94], ["TSNFRVQPTESIVRF", "TEST", 109, 124], ["CS", "TEST", 126, 128], ["the RBD", "PROBLEM", 184, 191], ["a remarkably high CS", "PROBLEM", 201, 221], ["ResultsWe", "TEST", 245, 254], ["HLA", "TEST", 267, 270], ["RBD", "OBSERVATION", 188, 191], ["high", "OBSERVATION", 214, 218]]], ["Only one (PKEITVATSRTLSYY, CS = 6.110) has a reported experiment (IEDB-ID: 48051), an MHC-ligand assay presenting the peptide to the HLA-DRB1*01:01, measuring the affinity.", [["MHC", "PROTEIN", 86, 89], ["HLA-DRB1*01:01", "DNA", 133, 147], ["CS", "TEST", 27, 29]]], ["It was already selected as a candidate in another study (66).", [["another study", "TEST", 42, 55]]], ["Nevertheless, it is located in a predicted intra-virion region.", [["intra-virion region", "DNA", 43, 62]]], ["Of those without experimental evidence and located outside the virion, TITVEELKKLLEQWN has the best CS (3.326) (see Figure 3F).", [["TITVEELKKLLEQWN", "DNA", 71, 86], ["without", "UNCERTAINTY", 9, 16], ["virion", "ANATOMY", 63, 69]]], ["In the E protein, we predicted 15 HLA-II epitopes.", [["HLA-II", "GENE_OR_GENE_PRODUCT", 34, 40], ["E protein", "PROTEIN", 7, 16], ["HLA-II epitopes", "PROTEIN", 34, 49]]], ["Similarly, only LVTLAILTALRLCAY has previous experimental evidence, but a very low CS (0.143), and it is located in a predicted non-external region.", [["non-external region", "PROTEIN", 128, 147], ["a very low CS", "PROBLEM", 72, 85], ["experimental", "OBSERVATION_MODIFIER", 45, 57], ["very", "OBSERVATION_MODIFIER", 74, 78], ["low", "OBSERVATION_MODIFIER", 79, 82], ["non-external", "ANATOMY_MODIFIER", 128, 140], ["region", "ANATOMY_MODIFIER", 141, 147]]], ["However, the candidate MYSFVSEETGTLIVN (CS = 1.764) is located outside the virion (Figure 3H).", [["virion", "CELLULAR_COMPONENT", 75, 81]]], ["Sequence logos of our class-I and class-II candidate epitopes are presented in Figures S1, S2, respectively.Epitope Prediction ::: ResultsTo cover all the HLA alleles with WAF \u2265 5% in South America, we included five additional candidates.", [["S2", "PROTEIN", 91, 93], ["HLA alleles", "DNA", 155, 166], ["WAF \u2265", "TREATMENT", 172, 177], ["S2", "ANATOMY", 91, 93]]], ["We selected predicted epitopes that bind to HLA alleles not covered by any of the candidates already selected, choosing those with the highest CS.", [["HLA", "GENE_OR_GENE_PRODUCT", 44, 47], ["HLA alleles", "DNA", 44, 55]]], ["Two have experimental evidence: MPASWVMRI (in NSP6, CS: 2.292, IEDB ID: 42260 and 42261) and SEFDRDAAM (in NSP12, CS:1.832, IEDB ID: 57419).", [["CS", "TEST", 52, 54], ["SEFDRDAAM", "TEST", 93, 102], ["CS", "TEST", 114, 116]]], ["The remaining three have no experimental evidence: GEYSHVVAF (in NSP4, CS: 2.270), KLFDRYFKY (in NSP12, CS: 2.169) and GLNDNLLEI (in NSP2, CS: 1.705).Prediction of Post-translational Modifications Events ::: ResultsTwenty two potential N-linked glycosylation sites were predicted along the S protein in three clusters: (i) inside the NTD and RBD regions (N17, N61, N74, N122, N149, N165, N234, N282, N331, and N343); (ii) in the proximity of the S1/S2 and S2' cleavage sites (N603, N616, N657, N709, N717, and N801); and (iii) near the C-terminus (N1074, N1098, N1134, N1158, N1173, and N1194).", [["N", "CHEMICAL", 236, 237], ["N122", "CHEMICAL", 370, 374], ["N149", "CHEMICAL", 376, 380], ["N165, N234, N282, N331, and N343", "CHEMICAL", 382, 414], ["C", "CHEMICAL", 536, 537], ["S2", "GENE_OR_GENE_PRODUCT", 449, 451], ["NSP4", "PROTEIN", 65, 69], ["NSP12", "PROTEIN", 97, 102], ["NSP2", "PROTEIN", 133, 137], ["N-linked glycosylation sites", "PROTEIN", 236, 264], ["S protein", "PROTEIN", 290, 299], ["NTD", "PROTEIN", 334, 337], ["RBD regions", "PROTEIN", 342, 353], ["N17", "PROTEIN", 355, 358], ["N61", "PROTEIN", 360, 363], ["N74", "PROTEIN", 365, 368], ["N122", "PROTEIN", 370, 374], ["N149", "PROTEIN", 376, 380], ["N165", "PROTEIN", 382, 386], ["N234", "PROTEIN", 388, 392], ["N282", "PROTEIN", 394, 398], ["N331", "PROTEIN", 400, 404], ["N343", "PROTEIN", 410, 414], ["S1", "PROTEIN", 446, 448], ["S2", "PROTEIN", 449, 451], ["S2", "PROTEIN", 456, 458], ["cleavage sites", "PROTEIN", 460, 474], ["C-terminus", "PROTEIN", 536, 546], ["N1074", "PROTEIN", 548, 553], ["GEYSHVVAF", "PROBLEM", 51, 60], ["CS", "TEST", 71, 73], ["KLFDRYFKY", "TEST", 83, 92], ["NSP12", "TEST", 97, 102], ["CS", "TEST", 104, 106], ["GLNDNLLEI", "TEST", 119, 128], ["NSP2", "TEST", 133, 137], ["CS", "TEST", 139, 141], ["N-linked glycosylation sites", "TREATMENT", 236, 264], ["the S protein", "TEST", 286, 299], ["no", "UNCERTAINTY", 25, 27], ["Post-translational Modifications", "OBSERVATION", 164, 196], ["NTD", "ANATOMY", 334, 337], ["RBD", "ANATOMY", 342, 345], ["regions", "ANATOMY_MODIFIER", 346, 353], ["S1", "ANATOMY", 446, 448], ["S2", "ANATOMY", 449, 451]]], ["In the M protein, one predicted N-linked glycosylation site (N5) is located in the exposed region, and it has been associated with antigenicity and transport in some coronaviruses (88).", [["N", "CHEMICAL", 32, 33], ["M protein", "PROTEIN", 7, 16], ["N-linked glycosylation site", "PROTEIN", 32, 59], ["N5", "PROTEIN", 61, 63], ["glycosylation site", "OBSERVATION", 41, 59], ["exposed", "OBSERVATION", 83, 90], ["region", "ANATOMY_MODIFIER", 91, 97]]], ["The E protein presents two potential N-linked glycosylation sites: N48, probably non-functional (89), and N66, suggested in SARS-CoV to be potentially associated with monomeric forms (90).", [["N", "CHEMICAL", 37, 38], ["N48", "SIMPLE_CHEMICAL", 67, 70], ["N66", "GENE_OR_GENE_PRODUCT", 106, 109], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 124, 132], ["E protein", "PROTEIN", 4, 13], ["N-linked glycosylation sites", "PROTEIN", 37, 65], ["N48", "PROTEIN", 67, 70], ["N66", "PROTEIN", 106, 109], ["SARS-CoV", "SPECIES", 124, 132], ["The E protein", "TEST", 0, 13], ["SARS", "PROBLEM", 124, 128], ["CoV", "PROBLEM", 129, 132], ["probably", "UNCERTAINTY", 72, 80], ["non-functional", "OBSERVATION_MODIFIER", 81, 95]]], ["ORF8 also presents a potential N-linked glycosylation site in N78, which could stabilize and protect the protein from proteasomal degradation, as occurring in SARS-CoV (91).", [["proteasomal", "ANATOMY", 118, 129], ["N", "CHEMICAL", 31, 32], ["ORF8", "GENE_OR_GENE_PRODUCT", 0, 4], ["N78", "SIMPLE_CHEMICAL", 62, 65], ["SARS-CoV", "ORGANISM", 159, 167], ["ORF8", "PROTEIN", 0, 4], ["N-linked glycosylation site", "DNA", 31, 58], ["N78", "PROTEIN", 62, 65], ["SARS-CoV", "SPECIES", 159, 167], ["a potential N-linked glycosylation site", "PROBLEM", 19, 58], ["proteasomal degradation", "PROBLEM", 118, 141], ["CoV", "TEST", 164, 167], ["proteasomal degradation", "OBSERVATION", 118, 141]]], ["O-linked glycosylations were predicted in residues S673, T678, and S686 of the S protein and residues T32 and T34 of the ORF3a.", [["O", "CHEMICAL", 0, 1], ["O-linked glycosylations", "SIMPLE_CHEMICAL", 0, 23], ["S673", "AMINO_ACID", 51, 55], ["T678", "AMINO_ACID", 57, 61], ["S686", "AMINO_ACID", 67, 71], ["ORF3a", "GENE_OR_GENE_PRODUCT", 121, 126], ["O-linked glycosylations", "PROTEIN", 0, 23], ["S protein", "PROTEIN", 79, 88], ["T32", "PROTEIN", 102, 105], ["T34", "PROTEIN", 110, 113], ["ORF3a", "PROTEIN", 121, 126], ["the S protein", "TEST", 75, 88]]], ["These events were experimentally detected in SARS-CoV (92).", [["SARS-CoV", "ORGANISM", 45, 53], ["SARS-CoV", "SPECIES", 45, 53], ["CoV", "TEST", 50, 53]]], ["However, glycosylation in residues 686 (O-linked) and 1158 (N-linked) were not confirmed by mass spectrometry in a recent study (93).Prediction of Post-translational Modifications Events ::: ResultsThen, the predicted glycosylation sites were contrasted with the best HLA-II candidate epitopes for South America (Table 2).", [["1158", "AMINO_ACID", 54, 58], ["HLA-II candidate epitopes", "PROTEIN", 268, 293], ["glycosylation in residues", "PROBLEM", 9, 34], ["a recent study", "TEST", 113, 127], ["the predicted glycosylation sites", "TREATMENT", 204, 237], ["Post-translational Modifications", "OBSERVATION", 147, 179]]], ["Sites N61, N122, N801, N1074, N1098, and N1158 are located in nine HLA-II candidate epitopes.", [["N61, N122, N801, N1074, N1098, and N1158", "CHEMICAL", 6, 46], ["HLA-II", "GENE_OR_GENE_PRODUCT", 67, 73], ["HLA-II candidate epitopes", "PROTEIN", 67, 92], ["Sites", "TEST", 0, 5]]], ["Additionally, sites N234, N331, N709, and the O-linked 686 fall near eight candidate epitopes.Prediction of Post-translational Modifications Events ::: ResultsPredicted palmitoylation sites fall into the cytoplasmic tail (C1235, C1236, C1240, C1243, C1247, C1248, C1250, C1253, and C1254) of the S protein and three cysteines (C40, C43, and C44) of the E protein.", [["cytoplasmic tail", "ANATOMY", 204, 220], ["cysteines", "CHEMICAL", 316, 325], ["C40, C43, and C44", "CHEMICAL", 327, 344], ["cytoplasmic", "ORGANISM_SUBSTANCE", 204, 215], ["palmitoylation sites", "PROTEIN", 169, 189], ["cytoplasmic tail", "PROTEIN", 204, 220], ["S protein", "PROTEIN", 296, 305], ["C40", "PROTEIN", 327, 330], ["C43", "PROTEIN", 332, 335], ["C44", "PROTEIN", 341, 344], ["E protein", "PROTEIN", 353, 362], ["sites", "TEST", 14, 19], ["the O", "TEST", 42, 47], ["the cytoplasmic tail", "TEST", 200, 220], ["C1250", "TEST", 264, 269], ["the S protein", "TEST", 292, 305], ["three cysteines", "TEST", 310, 325], ["C40", "TEST", 327, 330], ["C43", "TEST", 332, 335], ["Post-translational Modifications", "OBSERVATION", 108, 140], ["cytoplasmic tail", "ANATOMY", 204, 220]]], ["These sites have been previously reported in SARS-CoV (94), being associated with protein subcellular trafficking, stability and viral assembly (95, 96).Prediction of Post-translational Modifications Events ::: ResultsIn the N protein, a potential sumoylation site was predicted in K338.", [["subcellular", "ANATOMY", 90, 101], ["SARS", "DISEASE", 45, 49], ["SARS-CoV", "ORGANISM", 45, 53], ["N protein", "PROTEIN", 225, 234], ["K338", "CELL_LINE", 282, 286], ["SARS-CoV", "SPECIES", 45, 53], ["SARS-CoV", "TEST", 45, 53], ["protein subcellular trafficking", "PROBLEM", 82, 113], ["a potential sumoylation site", "PROBLEM", 236, 264], ["subcellular trafficking", "OBSERVATION", 90, 113], ["stability", "OBSERVATION_MODIFIER", 115, 124], ["Post-translational Modifications", "OBSERVATION", 167, 199]]], ["Li et al. (97) explored sumoylation events experimentally in SARS-CoV, not finding K338 but detecting the site K62.", [["Li", "CHEMICAL", 0, 2], ["SARS-CoV", "ORGANISM", 61, 69], ["K338", "PROTEIN", 83, 87], ["site K62", "DNA", 106, 114], ["SARS-CoV", "SPECIES", 61, 69], ["sumoylation events", "PROBLEM", 24, 42]]], ["This site was also detected in our prediction using a less restrictive threshold.", [["a less restrictive threshold", "TREATMENT", 52, 80]]], ["This corresponds to K61 in SARS-CoV-2, having an Asp instead of Glu in the canonical consensus motif.", [["Glu", "CHEMICAL", 64, 67], ["Asp", "CHEMICAL", 49, 52], ["Glu", "CHEMICAL", 64, 67], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 27, 37], ["Glu", "AMINO_ACID", 64, 67], ["K61", "DNA", 20, 23], ["canonical consensus motif", "DNA", 75, 100], ["SARS-CoV", "SPECIES", 27, 35], ["K61", "TEST", 20, 23], ["SARS", "TEST", 27, 31], ["CoV", "TEST", 32, 35], ["an Asp", "TEST", 46, 52], ["Glu", "TEST", 64, 67]]], ["This site has been associated with self homo-oligomerization and host cell division interference.Prediction of Post-translational Modifications Events ::: ResultsADP-ribosylation prediction identified eight potential sites along the nucleocapsid (D22, E118, E136, E231, E253, E323, E378, and D415).", [["cell", "ANATOMY", 70, 74], ["ResultsADP", "CHEMICAL", 155, 165], ["host cell", "CELL", 65, 74], ["E118", "PROTEIN", 252, 256], ["E136", "PROTEIN", 258, 262], ["E231", "PROTEIN", 264, 268], ["E253", "PROTEIN", 270, 274], ["E323", "PROTEIN", 276, 280], ["E378", "PROTEIN", 282, 286], ["D415", "PROTEIN", 292, 296], ["self homo-oligomerization", "PROBLEM", 35, 60], ["ResultsADP", "TEST", 155, 165], ["ribosylation prediction", "PROBLEM", 166, 189], ["host cell division interference", "OBSERVATION", 65, 96], ["Post-translational Modifications", "OBSERVATION", 111, 143], ["nucleocapsid", "ANATOMY", 233, 245]]], ["This PTM was also reported in other coronaviruses, and can be related to the virus infective phase (33) (see Figure 3 and Table S8).Structural Modeling of the S Protein ::: ResultsThe monomer model generated is composed of the first 1147 residues of the SARS-CoV-2 Spike protein.", [["coronaviruses", "ORGANISM", 36, 49], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 254, 264], ["PTM", "PROTEIN", 5, 8], ["SARS-CoV-2 Spike protein", "PROTEIN", 254, 278], ["the virus infective phase", "PROBLEM", 73, 98], ["the SARS", "TEST", 250, 258], ["CoV", "TEST", 259, 262], ["Spike protein", "PROBLEM", 265, 278]]], ["It fills the gaps of the crystal structure PDB:6VXX at positions 1-26, 70-79, 144-164, 173-185, 246-262, 445-446, 455-461, 469-488, 502, 621-640, 677-688, and 828-853.Structural Modeling of the S Protein ::: ResultsHLA-II candidate epitopes shown in Figure 3 were mapped to the trimeric 3D-structure in order to visualize their exposure (Figure 4).", [["ResultsHLA-II", "GENE_OR_GENE_PRODUCT", 208, 221], ["ResultsHLA-II candidate epitopes", "PROTEIN", 208, 240], ["trimeric 3D-structure", "PROTEIN", 278, 299], ["ResultsHLA", "TEST", 208, 218], ["gaps", "OBSERVATION_MODIFIER", 13, 17], ["crystal", "OBSERVATION_MODIFIER", 25, 32], ["structure PDB", "OBSERVATION", 33, 46]]], ["However, residues 1148-1273 were not represented in our model as they are missing in the reference crystal (22).", [["1148-1273", "CHEMICAL", 18, 27]]], ["Candidates in this missing region are represented in Figure 3D only.DiscussionThere is an urgent need to develop vaccines and better diagnostic tests for COVID-19, targeting specific immunogenic regions and epitopes with protective potential and population representativeness.", [["epitopes", "PROTEIN", 207, 215], ["vaccines", "TREATMENT", 113, 121], ["diagnostic tests", "TEST", 133, 149], ["COVID", "TEST", 154, 159]]], ["Our research presents an updated report of HLA genotypes of South American populations, which led to a selection of candidate epitopes for HLA class I and II supported by experimental evidence as well as novel candidates, predicted to cover all South American countries.DiscussionThe AFNDB and the IEDB population coverage tools are frequently used by the scientific community worldwide as reference sources of HLA frequencies (68), meaning it is crucial to have them updated.", [["HLA class I", "GENE_OR_GENE_PRODUCT", 139, 150], ["candidate epitopes", "PROTEIN", 116, 134], ["HLA class I and II", "PROTEIN", 139, 157], ["AFNDB", "DNA", 284, 289], ["The AFNDB", "TREATMENT", 280, 289], ["the IEDB population coverage", "TREATMENT", 294, 322]]], ["However, their collection and curation of new data rely on the scientific community users (68, 98).", [["collection", "OBSERVATION_MODIFIER", 15, 25], ["new", "OBSERVATION_MODIFIER", 42, 45]]], ["For South America, these databases contain mostly small datasets coming from ethnic groups, not representative of the countries' diversity, resulting in a current inaccurate distribution of HLA frequencies (see Table S6).", [["S6", "PROTEIN", 217, 219], ["these databases", "TEST", 19, 34], ["mostly small datasets", "PROBLEM", 43, 64], ["HLA frequencies", "PROBLEM", 190, 205], ["mostly", "OBSERVATION_MODIFIER", 43, 49], ["small", "OBSERVATION_MODIFIER", 50, 55], ["datasets", "OBSERVATION", 56, 64]]], ["We have found 30 large datasets from 10 South American countries which were not included in the AFNDB.", [["30 large datasets", "PROBLEM", 14, 31], ["30 large", "OBSERVATION_MODIFIER", 14, 22]]], ["Our literature review represents a large update from a scenario of 20,124 to now 12,857,200 datapoints among all the alleles collected of HLA-A, -B, -C, -DPA1, -DPB1, -DQA1, -DQB1, and -DRB1.", [["HLA-A", "GENE_OR_GENE_PRODUCT", 138, 143], ["DPA1", "DNA", 154, 158], ["DPB1", "DNA", 161, 165], ["DQA1", "DNA", 168, 172], ["DQB1", "DNA", 175, 179], ["DRB1", "DNA", 186, 190], ["HLA", "TEST", 138, 141], ["A", "TEST", 142, 143], ["C", "TEST", 150, 151], ["DPA1", "TEST", 154, 158], ["DPB1", "TEST", 161, 165], ["DQA1", "TEST", 168, 172], ["DQB1", "TEST", 175, 179]]], ["This is reflected in 86 HLA alleles with WAF \u2265 5% in the updated scenario, which were previously considered with frequencies under 5% or missing in the current scenario.", [["HLA", "GENE_OR_GENE_PRODUCT", 24, 27], ["86 HLA alleles", "DNA", 21, 35], ["WAF \u2265", "TREATMENT", 41, 46]]], ["This issue results in a misrepresentation of South America that could be affecting multiple immunological studies using these sources, like Ahmed et al. (66) and other SARS-CoV-2 recent studies in the pre-print stage.", [["multiple immunological studies", "TEST", 83, 113], ["other SARS", "TEST", 162, 172], ["recent studies", "TEST", 179, 193]]], ["To encourage and facilitate using the information collected, we are providing the datasets by country in their full extent (Tables S3, S4) and averaged (Tables S5, S6), as well as the selection and matching process in full detail (Supplementary Methods).DiscussionWe are also presenting weighted allele frequencies by country, providing a one-sight representation of South America HLA abundances (Figure 2).", [["S6", "PROTEIN", 164, 166]]], ["This clearly shows that some HLA genes are understudied, especially in countries like Venezuela, Bolivia, and Paraguay.", [["HLA", "GENE_OR_GENE_PRODUCT", 29, 32], ["HLA genes", "DNA", 29, 38], ["some HLA genes", "PROBLEM", 24, 38], ["HLA genes", "OBSERVATION", 29, 38]]], ["Moreover, there is no data from Uruguay, Guyana, French Guiana, or Suriname (68).", [["no", "UNCERTAINTY", 19, 21]]], ["We recommend genotyping the HLA of large populations to reduce diversity misrepresentation, like the study of the Brazilian bone marrow registry (99), which provided HLA alleles of millions of people.DiscussionEpitopes were predicted using MHCflurry v1.6.0 (60), NetMHCpan v4.0 (59), and NetMHCIIpan v4.0 (61).", [["bone marrow", "ANATOMY", 124, 135], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 124, 135], ["people", "ORGANISM", 193, 199], ["HLA alleles", "DNA", 166, 177], ["people", "SPECIES", 193, 199], ["large populations", "PROBLEM", 35, 52], ["the study", "TEST", 97, 106], ["NetMHCpan", "TEST", 263, 272], ["NetMHCIIpan", "TEST", 288, 299], ["bone marrow", "ANATOMY", 124, 135]]], ["These state-of-the-art software are based on neural networks and use binding, stability, and eluted MHC-ligand mass spectrometry data (58).", [["neural networks", "ANATOMY", 45, 60], ["neural networks", "MULTI-TISSUE_STRUCTURE", 45, 60], ["MHC", "PROTEIN", 100, 103], ["ligand mass spectrometry data", "TEST", 104, 133]]], ["The recent update of NetMHCIIpan from v3.2 to v4.0 represents an evident improvement in prediction accuracy, being necessary to use the last version.", [["NetMHCIIpan", "DNA", 21, 32], ["NetMHCIIpan", "TREATMENT", 21, 32], ["improvement", "OBSERVATION_MODIFIER", 73, 84]]], ["We enriched our predictions, adding the experimental evidence reported in the IEDB for other coronaviruses.", [["coronaviruses", "ORGANISM", 93, 106], ["other coronaviruses", "PROBLEM", 87, 106]]], ["Nevertheless, certain class-II potential epitopes found in binding experiments (i.e., measuring the affinity of epitopes presented in-vitro to the MHC molecule) were located in transmembrane or internal regions.", [["transmembrane", "ANATOMY", 177, 190], ["transmembrane", "CELLULAR_COMPONENT", 177, 190], ["class-II potential epitopes", "PROTEIN", 22, 49], ["epitopes", "PROTEIN", 112, 120], ["MHC molecule", "PROTEIN", 147, 159], ["transmembrane or internal regions", "PROTEIN", 177, 210], ["epitopes", "PROBLEM", 112, 120], ["transmembrane", "ANATOMY_MODIFIER", 177, 190], ["internal", "ANATOMY_MODIFIER", 194, 202]]], ["As the conformational dynamics of SARS-CoV-2 proteins remains unknown, we opted for being extra cautious, selecting only class-II candidate epitopes in known exposed regions of the protein structure.DiscussionWe then define a Coverage Score (CS), a metric representing to what extent a candidate epitope covers the HLA alleles of South America.", [["SARS", "DISEASE", 34, 38], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 34, 44], ["SARS-CoV-2 proteins", "PROTEIN", 34, 53], ["class-II candidate epitopes", "PROTEIN", 121, 148], ["protein structure", "PROTEIN", 181, 198], ["HLA alleles", "DNA", 315, 326], ["SARS", "PROBLEM", 34, 38], ["CoV-2 proteins", "TEST", 39, 53], ["a Coverage Score", "TEST", 224, 240], ["protein structure", "OBSERVATION", 181, 198]]], ["Based on the CS, we are presenting the best predicted epitopes, with and without experimental evidence, as potential candidates.", [["epitopes", "PROTEIN", 54, 62]]], ["Remarkably, we found novel candidates with very high CS, some located in immunologically relevant regions like the RBD of the Spike protein.", [["Spike", "GENE_OR_GENE_PRODUCT", 126, 131], ["RBD", "PROTEIN", 115, 118], ["Spike protein", "PROTEIN", 126, 139], ["very high CS", "PROBLEM", 43, 55], ["the Spike protein", "PROBLEM", 122, 139], ["RBD", "OBSERVATION", 115, 118]]], ["And exposed regions of the M and E proteins (Figures 3, 4).DiscussionViral clearance of SARS-CoV-2 infection requires activating subsets of CD4+ and CD8+ T cells (100).", [["CD4+ and CD8+ T cells", "ANATOMY", 140, 161], ["SARS", "DISEASE", 88, 92], ["infection", "DISEASE", 99, 108], ["SARS-CoV-2", "ORGANISM", 88, 98], ["CD4", "GENE_OR_GENE_PRODUCT", 140, 143], ["CD8", "GENE_OR_GENE_PRODUCT", 149, 152], ["M and E proteins", "PROTEIN", 27, 43], ["CD4", "PROTEIN", 140, 143], ["CD8", "PROTEIN", 149, 152], ["T cells", "CELL_TYPE", 154, 161], ["SARS-CoV", "SPECIES", 88, 96], ["the M and E proteins", "TEST", 23, 43], ["SARS", "PROBLEM", 88, 92], ["CoV", "TEST", 93, 96], ["2 infection", "PROBLEM", 97, 108], ["CD4", "TEST", 140, 143]]], ["Whereas, HLA-I epitopes are derived from both structural and non-structural proteins due to their endogenous processing, HLA-II epitopes have exogenous processing, being structural proteins (like S, M, or E) of particular interest (64).", [["HLA-I", "GENE_OR_GENE_PRODUCT", 9, 14], ["HLA-II", "GENE_OR_GENE_PRODUCT", 121, 127], ["HLA-I epitopes", "PROTEIN", 9, 23], ["structural and non-structural proteins", "PROTEIN", 46, 84], ["HLA-II epitopes", "PROTEIN", 121, 136], ["structural proteins", "PROTEIN", 170, 189], ["E", "PROTEIN", 205, 206], ["their endogenous processing", "PROBLEM", 92, 119], ["exogenous processing", "PROBLEM", 142, 162], ["structural proteins", "PROBLEM", 170, 189], ["non-structural proteins", "OBSERVATION", 61, 84]]], ["In SARS-CoV, CD8+ T cell response was previously shown to be greater than CD4+, and it is widely elicited by different proteins including the replicase (ORF1ab) and NSPs (101).", [["CD8+ T cell", "ANATOMY", 13, 24], ["SARS", "DISEASE", 3, 7], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 3, 11], ["CD8", "GENE_OR_GENE_PRODUCT", 13, 16], ["CD4", "GENE_OR_GENE_PRODUCT", 74, 77], ["ORF1ab", "GENE_OR_GENE_PRODUCT", 153, 159], ["NSPs", "GENE_OR_GENE_PRODUCT", 165, 169], ["CD8", "PROTEIN", 13, 16], ["CD4", "PROTEIN", 74, 77], ["replicase", "PROTEIN", 142, 151], ["ORF1ab", "PROTEIN", 153, 159], ["NSPs", "PROTEIN", 165, 169], ["101", "PROTEIN", 171, 174], ["SARS-CoV", "SPECIES", 3, 11], ["SARS", "PROBLEM", 3, 7], ["NSPs", "TEST", 165, 169], ["CoV", "ANATOMY", 8, 11]]], ["Even though structural proteins are associated with stronger T-cell responses (102\u2013104), non-structural proteins can also induce an immune response and provide additional epitopes (101).", [["T-cell", "ANATOMY", 61, 67], ["T-cell", "CELL", 61, 67], ["structural proteins", "PROTEIN", 12, 31], ["non-structural proteins", "PROTEIN", 89, 112], ["epitopes", "PROTEIN", 171, 179], ["structural proteins", "PROBLEM", 12, 31], ["non-structural proteins", "PROBLEM", 89, 112], ["proteins", "OBSERVATION", 23, 31]]], ["Similar experimental studies are needed to corroborate the same behavior in SARS-CoV-2.", [["SARS", "DISEASE", 76, 80], ["SARS-CoV", "SPECIES", 76, 84], ["Similar experimental studies", "TEST", 0, 28], ["CoV", "TEST", 81, 84]]], ["In fact, we found several HLA-I candidate epitopes in NSP proteins with a high coverage of South American HLA alleles, with and without experimental evidence (Table 1).DiscussionSeveral studies had demonstrated the immunogenicity of protein S in beta-coronaviruses, being the main target for vaccine development (22, 105\u2013109).", [["HLA-I", "GENE_OR_GENE_PRODUCT", 26, 31], ["NSP proteins", "GENE_OR_GENE_PRODUCT", 54, 66], ["protein S", "GENE_OR_GENE_PRODUCT", 233, 242], ["beta-coronaviruses", "ORGANISM", 246, 264], ["HLA-I candidate epitopes", "PROTEIN", 26, 50], ["NSP proteins", "PROTEIN", 54, 66], ["South American HLA alleles", "DNA", 91, 117], ["protein S", "PROTEIN", 233, 242], ["NSP proteins", "TREATMENT", 54, 66], ["DiscussionSeveral studies", "TEST", 168, 193], ["protein S", "PROBLEM", 233, 242], ["beta-coronaviruses", "PROBLEM", 246, 264]]], ["Its receptor binding domain (RBD) interacts with the human receptor ACE2, playing a crucial role during the viral entry process (110).", [["human", "ORGANISM", 53, 58], ["ACE2", "GENE_OR_GENE_PRODUCT", 68, 72], ["receptor binding domain", "PROTEIN", 4, 27], ["RBD", "PROTEIN", 29, 32], ["human receptor ACE2", "PROTEIN", 53, 72], ["human", "SPECIES", 53, 58], ["human", "SPECIES", 53, 58], ["Its receptor binding domain (RBD)", "PROBLEM", 0, 33], ["the human receptor ACE2", "TREATMENT", 49, 72]]], ["Therefore, antibodies binding this region could potentially impede viral recognition.", [["antibodies", "PROTEIN", 11, 21], ["antibodies binding this region", "PROBLEM", 11, 41]]], ["We are presenting 32 HLA-II candidate epitopes in the S protein, including seven novel candidates located in the RBD and exposed in the 3D structure.", [["HLA-II candidate epitopes", "PROTEIN", 21, 46], ["S protein", "PROTEIN", 54, 63], ["RBD", "PROTEIN", 113, 116], ["the S protein", "TREATMENT", 50, 63], ["RBD", "OBSERVATION", 113, 116]]], ["This includes the candidate epitope TSNFRVQPTESIVRF, which covers all the HLA-II alleles of South America.", [["HLA-II", "GENE_OR_GENE_PRODUCT", 74, 80], ["HLA-II alleles", "DNA", 74, 88], ["the candidate epitope TSNFRVQPTESIVRF", "TREATMENT", 14, 51]]], ["Some of our candidates are located near the binding site of the monoclonal antibody CR3022 in the RBD (111, 112) (Figure 4C).", [["RBD", "DISEASE", 98, 101], ["binding site", "DNA", 44, 56], ["monoclonal antibody CR3022", "PROTEIN", 64, 90], ["RBD", "PROTEIN", 98, 101], ["the monoclonal antibody", "TEST", 60, 83], ["monoclonal antibody", "OBSERVATION", 64, 83], ["RBD", "ANATOMY", 98, 101]]], ["This antibody neutralizes SARS-CoV (113), opening the possibility of finding neutralizing antibodies against our HLA-II candidate epitopes.", [["SARS-CoV", "ORGANISM", 26, 34], ["HLA-II", "GENE_OR_GENE_PRODUCT", 113, 119], ["neutralizing antibodies", "PROTEIN", 77, 100], ["HLA-II candidate epitopes", "PROTEIN", 113, 138], ["SARS-CoV", "SPECIES", 26, 34], ["This antibody", "TEST", 0, 13], ["CoV", "TEST", 31, 34], ["neutralizing antibodies", "PROBLEM", 77, 100]]], ["Additionally, neutralizing monoclonal antibodies has been generated against S1 and S2 for SARS (104, 114), and against the RBD for SARS (115, 116) and MERS (117, 118).DiscussionOther domains of the S protein with predicted HLA-II epitopes are in accordance with previous evidence in other coronaviruses.", [["SARS", "DISEASE", 90, 94], ["RBD", "DISEASE", 123, 126], ["SARS", "DISEASE", 131, 135], ["HLA-II", "GENE_OR_GENE_PRODUCT", 223, 229], ["coronaviruses", "ORGANISM", 289, 302], ["neutralizing monoclonal antibodies", "PROTEIN", 14, 48], ["S1", "PROTEIN", 76, 78], ["S2", "PROTEIN", 83, 85], ["RBD", "PROTEIN", 123, 126], ["S protein", "PROTEIN", 198, 207], ["HLA-II epitopes", "PROTEIN", 223, 238], ["neutralizing monoclonal antibodies", "TEST", 14, 48], ["SARS", "PROBLEM", 90, 94], ["the RBD", "PROBLEM", 119, 126], ["SARS", "PROBLEM", 131, 135], ["MERS", "TEST", 151, 155], ["the S protein", "TEST", 194, 207], ["predicted HLA-II epitopes", "TREATMENT", 213, 238], ["other coronaviruses", "PROBLEM", 283, 302], ["coronaviruses", "OBSERVATION", 289, 302]]], ["It has been shown that the fusion peptide, the HR1 region, and the central helix are potential targets for broadly neutralizing antibodies (119).", [["HR1 region", "PROTEIN", 47, 57], ["neutralizing antibodies", "PROTEIN", 115, 138], ["the fusion peptide", "TEST", 23, 41], ["broadly neutralizing antibodies", "TEST", 107, 138], ["fusion", "OBSERVATION", 27, 33], ["HR1", "ANATOMY", 47, 50], ["region", "ANATOMY_MODIFIER", 51, 57], ["central helix", "ANATOMY", 67, 80]]], ["We also found candidate epitopes located in exposed regions of the NTD, the Subdomain 3 (SD3), the B-hairpin (BH), the Central Helix (CH), the Heptad Repeat (HR2), and linker regions, which could serve as potential antibody targets.", [["Subdomain 3", "GENE_OR_GENE_PRODUCT", 76, 87], ["SD3", "GENE_OR_GENE_PRODUCT", 89, 92], ["B-hairpin", "GENE_OR_GENE_PRODUCT", 99, 108], ["BH", "GENE_OR_GENE_PRODUCT", 110, 112], ["HR2", "GENE_OR_GENE_PRODUCT", 158, 161], ["NTD", "PROTEIN", 67, 70], ["Subdomain 3", "PROTEIN", 76, 87], ["SD3", "PROTEIN", 89, 92], ["B-hairpin", "PROTEIN", 99, 108], ["BH", "PROTEIN", 110, 112], ["Central Helix", "PROTEIN", 119, 132], ["CH", "PROTEIN", 134, 136], ["Heptad Repeat", "DNA", 143, 156], ["HR2", "PROTEIN", 158, 161], ["linker regions", "PROTEIN", 168, 182], ["epitopes", "PROBLEM", 24, 32], ["the Heptad Repeat (HR2", "TEST", 139, 161], ["linker regions", "PROBLEM", 168, 182], ["potential antibody targets", "PROBLEM", 205, 231], ["NTD", "ANATOMY", 67, 70], ["Central Helix", "ANATOMY", 119, 132]]], ["Peptides derived from the Heptad regions HR1 and HR2 have proven to be effective inhibitors of viral fusion in SARS (120, 121) and MERS (122, 123).", [["SARS", "DISEASE", 111, 115], ["HR1", "GENE_OR_GENE_PRODUCT", 41, 44], ["HR2", "GENE_OR_GENE_PRODUCT", 49, 52], ["Heptad regions", "PROTEIN", 26, 40], ["HR1", "PROTEIN", 41, 44], ["HR2", "PROTEIN", 49, 52], ["the Heptad regions HR1", "PROBLEM", 22, 44], ["HR2", "PROBLEM", 49, 52], ["viral fusion in SARS", "PROBLEM", 95, 115], ["MERS", "TEST", 131, 135], ["viral fusion", "OBSERVATION", 95, 107]]], ["Moreover, conformational changes of the S protein trimer could explain the presence of cryptic class-II epitopes (not accessible in the canonical 3D structure) (112).", [["S protein trimer", "PROTEIN", 40, 56], ["cryptic class-II epitopes", "PROTEIN", 87, 112], ["conformational changes of the S protein trimer", "PROBLEM", 10, 56], ["cryptic class-II epitopes", "PROBLEM", 87, 112]]], ["This opens up the possibility of finding candidate epitopes in unexposed regions of the protein, as hinted by our predicted epitopes with experimental MHC-peptide binding evidence (Figure 4B).DiscussionOur HLA-I and HLA-II candidate epitopes cover 100% of the alleles with WAF \u2265 5% in South America.", [["HLA-I", "GENE_OR_GENE_PRODUCT", 206, 211], ["HLA-II", "GENE_OR_GENE_PRODUCT", 216, 222], ["epitopes", "PROTEIN", 51, 59], ["epitopes", "PROTEIN", 124, 132], ["MHC", "PROTEIN", 151, 154], ["HLA-I and HLA-II candidate epitopes", "PROTEIN", 206, 241], ["WAF \u2265", "TREATMENT", 273, 278]]], ["Remarkably, we obtained two HLA-II candidate epitopes with the maximum CS possible (covering all the alleles), one with experimental evidence.DiscussionSome of our predicted epitopes have been previously reported by other studies using similar approaches (Tables 1, 2).", [["HLA-II candidate epitopes", "PROTEIN", 28, 53], ["epitopes", "PROTEIN", 174, 182]]], ["They collected experimentally-determined epitopes and the corresponding alleles against which these were tested.", [["epitopes", "PROTEIN", 41, 49]]], ["Then, they used the IEDB population coverage tool to select 87 candidate epitopes for one HLA-II and 32 HLA-I alleles in total, aiming to cover 96.29% of people worldwide.", [["HLA-II", "GENE_OR_GENE_PRODUCT", 90, 96], ["HLA-I", "GENE_OR_GENE_PRODUCT", 104, 109], ["people", "ORGANISM", 154, 160], ["HLA-II and 32 HLA-I alleles", "DNA", 90, 117], ["people", "SPECIES", 154, 160], ["the IEDB population coverage", "TREATMENT", 16, 44]]], ["These alleles represent only 18/47 (38.3%) of the HLA-I and 1/18 (5.6%) of the HLA-II alleles with WAF \u2265 5% in our literature review for South America.", [["HLA-I", "GENE_OR_GENE_PRODUCT", 50, 55], ["HLA-II", "GENE_OR_GENE_PRODUCT", 79, 85], ["HLA-II alleles", "DNA", 79, 93], ["These alleles", "TEST", 0, 13], ["the HLA", "TEST", 46, 53], ["WAF \u2265", "TREATMENT", 99, 104]]], ["Moreover, using the same tool with their candidates and alleles, but selecting South American populations only (according to the tool), we obtained a coverage of just 90.6% HLA-I and 4.1% HLA-II alleles.", [["HLA-I", "GENE_OR_GENE_PRODUCT", 173, 178], ["HLA-II", "GENE_OR_GENE_PRODUCT", 188, 194], ["HLA-II alleles", "DNA", 188, 202], ["a coverage", "TEST", 148, 158], ["HLA", "TEST", 173, 176], ["I", "TEST", 177, 178], ["HLA", "TEST", 188, 191]]], ["These comparisons were done using only the experimentally-determined binding alleles.", [["binding alleles", "DNA", 69, 84]]], ["Furthermore, we explored if their candidate epitopes could bind our alleles using our prediction methodology (i.e., calculating the affinity of their candidate epitopes to the South American HLA alleles with WAF \u2265 5%).", [["candidate epitopes", "PROTEIN", 150, 168], ["WAF \u2265", "TREATMENT", 208, 213]]], ["However, we obtained a match of just 43/47 (91.49%, HLA-I) and 11/18 (61.11%, HLA-II).", [["HLA-I", "GENE_OR_GENE_PRODUCT", 52, 57], ["HLA-II", "GENE_OR_GENE_PRODUCT", 78, 84], ["HLA", "TEST", 52, 55], ["HLA", "TEST", 78, 81]]], ["Altogether, this suggests a misrepresentation that leads to diminished coverage for South America.DiscussionGrifoni et al. (64) selected candidate epitopes in SARS-CoV-2 through: (i) sequence homology with epitopes with experimental evidence in SARS-CoV, and by (ii) epitope prediction, using 12 supertype representatives (the six most frequent HLA-I A and B alleles worldwide).", [["SARS-CoV-2", "ORGANISM", 159, 169], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 245, 253], ["HLA-I A", "GENE_OR_GENE_PRODUCT", 345, 352], ["B", "GENE_OR_GENE_PRODUCT", 357, 358], ["epitopes", "PROTEIN", 206, 214], ["SARS-CoV", "SPECIES", 159, 167], ["SARS-CoV", "SPECIES", 245, 253], ["SARS", "PROBLEM", 245, 249], ["frequent HLA-I A and B alleles worldwide", "TREATMENT", 336, 376], ["diminished", "OBSERVATION_MODIFIER", 60, 70], ["coverage", "OBSERVATION_MODIFIER", 71, 79]]], ["Intersecting these two sources, they selected 12 HLA-I candidate epitopes in common, having an identity \u2265 90% with SARS-CoV.", [["SARS-CoV", "DISEASE", 115, 123], ["HLA-I", "GENE_OR_GENE_PRODUCT", 49, 54], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 115, 123], ["HLA-I candidate epitopes", "PROTEIN", 49, 73], ["SARS-CoV", "SPECIES", 115, 123], ["an identity", "TEST", 92, 103]]], ["However, during their prediction, they obtained 12 HLA-I (CS: 0.095\u20133.739) and two HLA-II (CS: 6.474\u20136.593) predicted epitopes that have better scores for South America and match with some of our candidates.", [["HLA-I", "GENE_OR_GENE_PRODUCT", 51, 56], ["HLA-II", "GENE_OR_GENE_PRODUCT", 83, 89], ["epitopes", "PROTEIN", 118, 126], ["CS", "TEST", 58, 60], ["two HLA", "TEST", 79, 86], ["CS", "TEST", 91, 93]]], ["This is attributable to their strict filtering, due to the fact that they relied on experimental evidence from SARS-CoV only, as well as the small number of supertype alleles and epitopes chosen.DiscussionAn important improvement in selecting the best candidate epitopes is to consider problematic sites affected by entropy, selective pressure, post-translational modifications, and other effects.", [["SARS", "DISEASE", 111, 115], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 111, 119], ["supertype alleles", "DNA", 157, 174], ["epitopes", "PROTEIN", 179, 187], ["SARS-CoV", "SPECIES", 111, 119], ["SARS", "PROBLEM", 111, 115], ["supertype alleles", "PROBLEM", 157, 174], ["problematic sites", "PROBLEM", 286, 303], ["selective pressure", "TEST", 325, 343], ["translational modifications", "TREATMENT", 350, 377], ["SARS", "OBSERVATION", 111, 115], ["small", "OBSERVATION_MODIFIER", 141, 146], ["pressure", "OBSERVATION_MODIFIER", 335, 343]]], ["Some of these considerations have been demonstrated to assist in developing molecular diagnosis in coronaviruses and other species (124, 125).", [["coronaviruses", "ORGANISM", 99, 112], ["coronaviruses", "PROBLEM", 99, 112], ["molecular", "OBSERVATION_MODIFIER", 76, 85], ["diagnosis", "OBSERVATION", 86, 95]]], ["Amino acid variants can result in diverse changes affecting the infectious and adaptive virus behavior.", [["Amino acid", "CHEMICAL", 0, 10], ["Amino acid", "CHEMICAL", 0, 10], ["Amino acid", "AMINO_ACID", 0, 10], ["Amino acid variants", "PROBLEM", 0, 19], ["diverse changes", "PROBLEM", 34, 49], ["the infectious and adaptive virus behavior", "PROBLEM", 60, 102], ["acid variants", "OBSERVATION", 6, 19], ["diverse", "OBSERVATION_MODIFIER", 34, 41], ["infectious", "OBSERVATION", 64, 74]]], ["Entropy analysis revealed highly variable sites such as P323L in NSP12 (RdRp) or D614G in the S protein.", [["P323L", "GENE_OR_GENE_PRODUCT", 56, 61], ["NSP12 (RdRp)", "GENE_OR_GENE_PRODUCT", 65, 77], ["D614G", "AMINO_ACID", 81, 86], ["P323L", "DNA", 56, 61], ["NSP12", "PROTEIN", 65, 70], ["RdRp", "PROTEIN", 72, 76], ["S protein", "PROTEIN", 94, 103], ["Entropy analysis", "TEST", 0, 16], ["highly variable sites", "PROBLEM", 26, 47], ["P323L in NSP12 (RdRp", "TREATMENT", 56, 76], ["D614G", "TREATMENT", 81, 86], ["highly", "OBSERVATION_MODIFIER", 26, 32], ["variable", "OBSERVATION_MODIFIER", 33, 41]]], ["Further biological consequences could be obtained from the sites affected by positive selective pressures, like T85 in NSP2, S25 in NSP7, and A99 in ORF3a.", [["NSP2", "GENE_OR_GENE_PRODUCT", 119, 123], ["S25", "GENE_OR_GENE_PRODUCT", 125, 128], ["NSP7", "GENE_OR_GENE_PRODUCT", 132, 136], ["ORF3a", "GENE_OR_GENE_PRODUCT", 149, 154], ["T85", "DNA", 112, 115], ["NSP2", "DNA", 119, 123], ["S25", "PROTEIN", 125, 128], ["NSP7", "PROTEIN", 132, 136], ["A99", "PROTEIN", 142, 145], ["ORF3a", "PROTEIN", 149, 154], ["NSP2", "TEST", 119, 123], ["NSP7", "TEST", 132, 136], ["positive", "OBSERVATION_MODIFIER", 77, 85], ["selective pressures", "OBSERVATION", 86, 105]]], ["In the present study, we found that five of 27 HLA-I and two of 34 HLA-II candidate epitopes contain predicted sites affected by positive selective pressure (shown in bold in Tables 1, 2).", [["HLA-I", "GENE_OR_GENE_PRODUCT", 47, 52], ["HLA-II", "GENE_OR_GENE_PRODUCT", 67, 73], ["HLA-II candidate epitopes", "PROTEIN", 67, 92], ["HLA", "TEST", 47, 50], ["HLA", "TEST", 67, 70], ["predicted sites", "PROBLEM", 101, 116], ["positive", "OBSERVATION_MODIFIER", 129, 137], ["selective", "OBSERVATION_MODIFIER", 138, 147], ["pressure", "OBSERVATION_MODIFIER", 148, 156]]], ["However, we decided to keep these epitopes in our list of potential candidates due to their high CS and low amino acid variability (under 5%) in the current pandemic wave.DiscussionWe predicted PTMs, including glycosylation, palmitoylation, sumoylation, and ADP-ribosylation events, in order to find relevant sites for the viral cycle.", [["amino acid", "CHEMICAL", 108, 118], ["ADP", "CHEMICAL", 258, 261], ["amino acid", "CHEMICAL", 108, 118], ["ADP", "CHEMICAL", 258, 261], ["amino acid", "AMINO_ACID", 108, 118], ["ADP", "SIMPLE_CHEMICAL", 258, 261], ["epitopes", "PROTEIN", 34, 42], ["PTMs", "PROTEIN", 194, 198], ["their high CS", "PROBLEM", 86, 99], ["low amino acid variability", "PROBLEM", 104, 130], ["glycosylation", "TREATMENT", 210, 223], ["palmitoylation", "TREATMENT", 225, 239], ["sumoylation", "TREATMENT", 241, 252], ["ADP-ribosylation events", "TREATMENT", 258, 281], ["viral cycle", "OBSERVATION", 323, 334]]], ["N-linked glycosylation is one of the most frequents PTMs with potential effects over the folding, tropism, interactions with host proteases, antibody recognition, and antigenicity of the Spike protein (126\u2013131).", [["N", "CHEMICAL", 0, 1], ["Spike", "GENE_OR_GENE_PRODUCT", 187, 192], ["PTMs", "PROTEIN", 52, 56], ["host proteases", "PROTEIN", 125, 139], ["Spike protein", "PROTEIN", 187, 200], ["126\u2013131", "PROTEIN", 202, 209], ["glycosylation", "TREATMENT", 9, 22], ["host proteases", "TEST", 125, 139], ["antibody recognition", "TEST", 141, 161], ["the Spike protein", "TEST", 183, 200]]], ["N-linked glycosylations have been predicted in our candidate epitopes, including those with experimental evidence (Table S8).", [["N", "CHEMICAL", 0, 1], ["N-linked glycosylations", "PROTEIN", 0, 23], ["linked glycosylations", "PROBLEM", 2, 23]]], ["SARS-CoV-2 Spike protein possesses 22 potential N-linked glycosylation sites (Figure 3), mainly distributed in S1 and the C-terminal region of the S2 (119, 132).", [["SARS", "DISEASE", 0, 4], ["N", "CHEMICAL", 48, 49], ["C", "CHEMICAL", 122, 123], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["SARS-CoV-2 Spike protein", "PROTEIN", 0, 24], ["N-linked glycosylation sites", "PROTEIN", 48, 76], ["S1", "PROTEIN", 111, 113], ["C-terminal region", "PROTEIN", 122, 139], ["S2", "PROTEIN", 147, 149], ["SARS", "TEST", 0, 4], ["CoV", "TEST", 5, 8], ["Spike protein possesses", "TEST", 11, 34], ["potential N-linked glycosylation sites", "PROBLEM", 38, 76], ["S1", "ANATOMY_MODIFIER", 111, 113], ["C", "ANATOMY_MODIFIER", 122, 123], ["terminal", "ANATOMY_MODIFIER", 124, 132], ["region", "ANATOMY_MODIFIER", 133, 139], ["S2", "ANATOMY", 147, 149]]], ["Some of them are located in the NTD and near the S1/S2 cleavage region (N122, N165, N234, N603, and N717).", [["S1/S2 cleavage region", "DNA", 49, 70], ["NTD", "OBSERVATION", 32, 35], ["S1", "ANATOMY_MODIFIER", 49, 51], ["S2", "ANATOMY", 52, 54], ["cleavage", "ANATOMY_MODIFIER", 55, 63], ["region", "ANATOMY_MODIFIER", 64, 70]]], ["These sites surround the ACE2-binding domain and were shown to be critical for viral entry mediated by DC-SIGN (dendritic cell-specific ICAM-3-grabbing non-integrin) and L-SIGN (liver/lymph node-specific ICAM-3-grabbing non-integrin) (133), which are two C-type lectins that recognize high-mannose glycans (134).", [["DC", "ANATOMY", 103, 105], ["dendritic cell", "ANATOMY", 112, 126], ["liver", "ANATOMY", 178, 183], ["lymph node", "ANATOMY", 184, 194], ["mannose", "CHEMICAL", 290, 297], ["ACE2", "GENE_OR_GENE_PRODUCT", 25, 29], ["SIGN", "GENE_OR_GENE_PRODUCT", 106, 110], ["dendritic cell", "CELL", 112, 126], ["ICAM-3", "GENE_OR_GENE_PRODUCT", 136, 142], ["non-integrin", "GENE_OR_GENE_PRODUCT", 152, 164], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 170, 176], ["liver", "ORGAN", 178, 183], ["lymph node", "MULTI-TISSUE_STRUCTURE", 184, 194], ["ICAM-3", "GENE_OR_GENE_PRODUCT", 204, 210], ["non-integrin", "GENE_OR_GENE_PRODUCT", 220, 232], ["C-type lectins", "GENE_OR_GENE_PRODUCT", 255, 269], ["ACE2-binding domain", "PROTEIN", 25, 44], ["DC", "CELL_TYPE", 103, 105], ["SIGN", "PROTEIN", 106, 110], ["ICAM", "PROTEIN", 136, 140], ["grabbing non-integrin", "PROTEIN", 143, 164], ["SIGN", "PROTEIN", 172, 176], ["ICAM", "PROTEIN", 204, 208], ["grabbing non-integrin", "PROTEIN", 211, 232], ["C-type lectins", "PROTEIN", 255, 269], ["viral entry", "PROBLEM", 79, 90], ["ICAM", "TEST", 136, 140], ["non-integrin", "TEST", 152, 164], ["liver/lymph node", "TEST", 178, 194], ["specific ICAM", "TEST", 195, 208], ["two C-type lectins", "PROBLEM", 251, 269], ["dendritic cell", "OBSERVATION", 112, 126], ["liver", "ANATOMY", 178, 183], ["lymph node", "OBSERVATION", 184, 194], ["high", "OBSERVATION_MODIFIER", 285, 289]]], ["In contrast to SARS-CoV, SARS-CoV-2 presents an additional site (N657, near the S2 cleavage) and misses the glycosylation site N370 (in the RBD region), due to the absence of Ser/Thr to complete the sequon.", [["SARS", "DISEASE", 15, 19], ["SARS", "DISEASE", 25, 29], ["Ser", "CHEMICAL", 175, 178], ["Thr", "CHEMICAL", 179, 182], ["SARS-CoV", "ORGANISM", 15, 23], ["SARS-CoV-2", "ORGANISM", 25, 35], ["Ser", "AMINO_ACID", 175, 178], ["Thr", "AMINO_ACID", 179, 182], ["SARS-CoV-2", "DNA", 25, 35], ["N657", "DNA", 65, 69], ["glycosylation site N370", "DNA", 108, 131], ["RBD region", "DNA", 140, 150], ["Ser", "PROTEIN", 175, 178], ["SARS-CoV", "SPECIES", 15, 23], ["SARS-CoV", "SPECIES", 25, 33], ["SARS", "TEST", 15, 19], ["CoV", "PROBLEM", 20, 23], ["SARS", "PROBLEM", 25, 29], ["the glycosylation site", "PROBLEM", 104, 126], ["Ser/Thr", "TREATMENT", 175, 182]]], ["Although this does not alter the affinity to the ACE2 receptor (135), it can significantly reduce DC-SIGN binding capacity (136).", [["DC", "ANATOMY", 98, 100], ["ACE2", "GENE_OR_GENE_PRODUCT", 49, 53], ["ACE2 receptor", "PROTEIN", 49, 62], ["DC", "CELL_TYPE", 98, 100], ["SIGN", "PROTEIN", 101, 105], ["the ACE2 receptor", "TEST", 45, 62]]], ["Thus, availability of N-linked glycosylations sites and differential affinities to ACE2, DC-SIGN, or L-SIGN may act as either enhancer forces or alternative mechanisms for viral entry (23, 137).", [["N", "CHEMICAL", 22, 23], ["ACE2", "GENE_OR_GENE_PRODUCT", 83, 87], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 89, 96], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 101, 107], ["N-linked glycosylations sites", "PROTEIN", 22, 51], ["ACE2", "PROTEIN", 83, 87], ["DC", "PROTEIN", 89, 91], ["SIGN", "PROTEIN", 92, 96], ["SIGN", "PROTEIN", 103, 107], ["N-linked glycosylations sites", "TREATMENT", 22, 51], ["ACE2", "TEST", 83, 87], ["viral entry", "TEST", 172, 183]]], ["Additionally, sites N227 and N699 in SARS-CoV (equivalent to N234 and N717 in SARS-CoV-2) have been hypothesized to facilitate the zoonotic transmission of this virus (133).", [["SARS", "DISEASE", 37, 41], ["SARS-CoV", "ORGANISM", 37, 45], ["SARS-CoV-2", "ORGANISM", 78, 88], ["SARS-CoV", "SPECIES", 37, 45], ["SARS-CoV", "SPECIES", 78, 86], ["sites", "TEST", 14, 19], ["SARS", "TEST", 37, 41], ["CoV", "TEST", 42, 45], ["SARS", "TEST", 78, 82], ["CoV", "TEST", 83, 86], ["this virus", "PROBLEM", 156, 166]]], ["A recent study based on liquid-chromatography-mass spectrometry (LC-MS) (132) confirmed the occurrence of N-linked glycosylation in all of our predicted sites.", [["N", "CHEMICAL", 106, 107], ["A recent study", "TEST", 0, 14], ["liquid-chromatography", "TEST", 24, 45], ["mass spectrometry", "TEST", 46, 63], ["N-linked glycosylation", "PROBLEM", 106, 128]]], ["However, another study using LC-MS/MS (93) found only 17 out of 22 of the predicted sites.", [["another study", "TEST", 9, 22], ["LC", "TEST", 29, 31], ["MS", "TEST", 35, 37]]], ["These differences could be due to the different experimental design and procedures used.", [["could be due to", "UNCERTAINTY", 18, 33]]], ["Moreover, the composition diversity (oligomannose, complex, or hybrid-type), and frequency of these glycosylation events were dissimilar in both studies.DiscussionO-linked glycosylations were predicted at three previously proposed sites flanking the S1/S2 cleavage site (138).", [["oligomannose", "CHEMICAL", 37, 49], ["oligomannose", "SIMPLE_CHEMICAL", 37, 49], ["DiscussionO-linked glycosylations", "PROTEIN", 153, 186], ["S1/S2 cleavage site", "DNA", 250, 269], ["the composition diversity (oligomannose, complex, or hybrid-type)", "PROBLEM", 10, 75], ["these glycosylation events", "PROBLEM", 94, 120], ["DiscussionO-linked glycosylations", "TREATMENT", 153, 186], ["composition", "OBSERVATION_MODIFIER", 14, 25], ["diversity", "OBSERVATION_MODIFIER", 26, 35], ["S1", "ANATOMY", 250, 252], ["S2", "ANATOMY", 253, 255]]], ["These events were not found in two recent mass spectrometry studies (93, 132).", [["two recent mass spectrometry studies", "TEST", 31, 67], ["mass", "OBSERVATION", 42, 46]]], ["Thus, occurrence of these events could be very rare or affected by intra-host conditions.", [["these events", "PROBLEM", 20, 32]]], ["Interestingly, T323 and S325 in RBD were detected as O-glycosylated (93), which may be related to increasing affinity with the human receptor ACE2 (110, 139).", [["RBD", "DISEASE", 32, 35], ["O", "CHEMICAL", 53, 54], ["T323", "GENE_OR_GENE_PRODUCT", 15, 19], ["RBD", "GENE_OR_GENE_PRODUCT", 32, 35], ["human", "ORGANISM", 127, 132], ["ACE2", "GENE_OR_GENE_PRODUCT", 142, 146], ["T323", "PROTEIN", 15, 19], ["S325", "PROTEIN", 24, 28], ["RBD", "PROTEIN", 32, 35], ["human receptor", "PROTEIN", 127, 141], ["ACE2", "PROTEIN", 142, 146], ["human", "SPECIES", 127, 132], ["human", "SPECIES", 127, 132], ["increasing affinity", "PROBLEM", 98, 117], ["the human receptor ACE2", "TREATMENT", 123, 146], ["may be related to", "UNCERTAINTY", 80, 97], ["increasing", "OBSERVATION_MODIFIER", 98, 108], ["affinity", "OBSERVATION", 109, 117]]], ["N- and O-linked glycosylation events can influence not only their position but also the surrounding area under the glycan shield.", [["N", "CHEMICAL", 0, 1], ["O", "CHEMICAL", 7, 8], ["linked glycosylation events", "PROBLEM", 9, 36], ["glycan shield", "OBSERVATION", 115, 128]]], ["In fact, both N- and O-linked glycosylations could be associated with masking epitopes or important amino acids, resulting in immune evasion (129, 140, 141).", [["amino acids", "CHEMICAL", 100, 111], ["N", "CHEMICAL", 14, 15], ["O", "CHEMICAL", 21, 22], ["amino acids", "CHEMICAL", 100, 111], ["O-linked glycosylations", "SIMPLE_CHEMICAL", 21, 44], ["amino acids", "AMINO_ACID", 100, 111], ["epitopes", "PROTEIN", 78, 86], ["linked glycosylations", "PROBLEM", 23, 44], ["masking epitopes", "PROBLEM", 70, 86], ["important amino acids", "PROBLEM", 90, 111], ["immune evasion", "TEST", 126, 140]]], ["Further in-vivo studies should be performed to determine the real complexity and heterogeneity of these events.DiscussionMeanwhile, palmitoylation predicted sites in the cytoplasmic tail of the S protein (Table S8) have been reported in other Coronaviruses (34).", [["cytoplasmic tail", "ANATOMY", 170, 186], ["cytoplasmic", "ORGANISM_SUBSTANCE", 170, 181], ["S protein (Table S8", "GENE_OR_GENE_PRODUCT", 194, 213], ["cytoplasmic tail", "PROTEIN", 170, 186], ["S protein", "PROTEIN", 194, 203], ["S8", "PROTEIN", 211, 213], ["Further in-vivo studies", "TEST", 0, 23], ["these events", "PROBLEM", 98, 110], ["cytoplasmic tail", "ANATOMY", 170, 186]]], ["The presence of these sites supports the importance of membrane-proximal cysteine-rich clusters in processes like the Spike-mediated cell fusion (27, 95, 142), infectivity (143), and viral assembly (144, 145).DiscussionConservation of PTMs in amino acids can support the selection of candidate epitopes.", [["membrane", "ANATOMY", 55, 63], ["cell", "ANATOMY", 133, 137], ["amino acids", "CHEMICAL", 243, 254], ["cysteine", "CHEMICAL", 73, 81], ["amino acids", "CHEMICAL", 243, 254], ["membrane", "CELLULAR_COMPONENT", 55, 63], ["cysteine", "AMINO_ACID", 73, 81], ["Spike", "GENE_OR_GENE_PRODUCT", 118, 123], ["cell", "CELL", 133, 137], ["amino acids", "AMINO_ACID", 243, 254], ["Spike", "PROTEIN", 118, 123], ["PTMs", "PROTEIN", 235, 239], ["candidate epitopes", "PROTEIN", 284, 302], ["the Spike", "TEST", 114, 123], ["mediated cell fusion", "TREATMENT", 124, 144], ["infectivity", "PROBLEM", 160, 171], ["PTMs in amino acids", "TREATMENT", 235, 254], ["epitopes", "PROBLEM", 294, 302], ["cell fusion", "OBSERVATION", 133, 144]]], ["In contrast, their emergence or disappearance resulting in better fitness should be considered important evolutive events and must be particularly monitored.", [["evolutive events", "PROBLEM", 105, 121]]], ["In sum, the emergence/disappearance of alternative codons affecting PTMs in the evolutive course of the current pandemic is intriguing, and it has already been noticed in some SARS-CoV-2 genomes (73).", [["SARS-CoV-2", "ORGANISM", 176, 186], ["PTMs", "PROTEIN", 68, 72], ["SARS-CoV-2 genomes", "DNA", 176, 194], ["SARS-CoV", "SPECIES", 176, 184], ["alternative codons affecting PTMs", "PROBLEM", 39, 72], ["some SARS", "PROBLEM", 171, 180], ["evolutive", "OBSERVATION_MODIFIER", 80, 89]]], ["Additional studies may unravel the impact of these events and could help in the development of strategies to control the infectious viral cycle.DiscussionIn summary, our study provides updated HLA allele frequencies for South America, rectifying previously misrepresented alleles.", [["HLA allele", "DNA", 193, 203], ["Additional studies", "TEST", 0, 18], ["the infectious viral cycle", "PROBLEM", 117, 143], ["our study", "TEST", 166, 175], ["infectious", "OBSERVATION", 121, 131]]], ["This led to the identification of potential Class-I and -II epitopes in SARS-CoV-2 with high regional coverage.", [["Class-I", "GENE_OR_GENE_PRODUCT", 44, 51], ["SARS-CoV-2", "ORGANISM", 72, 82], ["Class-I and -II epitopes", "PROTEIN", 44, 68], ["SARS-CoV", "SPECIES", 72, 80], ["II epitopes in SARS", "PROBLEM", 57, 76], ["CoV", "TEST", 77, 80], ["high regional coverage", "TREATMENT", 88, 110]]], ["These could represent targets for neutralizing antibodies or could be used for the development of vaccines and diagnostics tests, which needs to be further studied.", [["neutralizing antibodies", "PROTEIN", 34, 57], ["neutralizing antibodies", "PROBLEM", 34, 57], ["vaccines", "TREATMENT", 98, 106], ["diagnostics tests", "TEST", 111, 128], ["could represent", "UNCERTAINTY", 6, 21]]], ["Our study highlights the advantage of a regionally-focused design.", [["Our study", "TEST", 0, 9]]], ["Approaches based on the global population have the advantage of broad coverage.", [["broad coverage", "TREATMENT", 64, 78]]], ["However, this may result in leaving aside the best regional candidates and reducing the regional population coverage, as shown in this study.", [["the regional population coverage", "TREATMENT", 84, 116], ["this study", "TEST", 130, 140], ["regional", "OBSERVATION_MODIFIER", 88, 96], ["population coverage", "OBSERVATION", 97, 116]]], ["Furthermore, incorrect HLA frequencies could result in misleading results and misrepresentation of certain populations.", [["incorrect HLA frequencies", "TEST", 13, 38], ["certain populations", "PROBLEM", 99, 118]]], ["We hope our findings may promote regional efforts with potentially better specificity.DiscussionAdditionally, the exuberant immune response against SARS-CoV-2 infections is related to disease severity (146, 147).", [["SARS", "DISEASE", 148, 152], ["infections", "DISEASE", 159, 169], ["SARS-CoV-2", "ORGANISM", 148, 158], ["SARS-CoV-2", "SPECIES", 148, 158], ["the exuberant immune response", "PROBLEM", 110, 139], ["SARS", "PROBLEM", 148, 152], ["CoV-2 infections", "PROBLEM", 153, 169], ["disease severity", "PROBLEM", 184, 200], ["exuberant", "OBSERVATION_MODIFIER", 114, 123], ["infections", "OBSERVATION", 159, 169]]], ["COVID-19 has shown cases of minimal manifestations in people within the risk group as well as fatal response in people without apparent risk, thereby suggesting a genetic predisposition (148).", [["people", "ORGANISM", 54, 60], ["people", "ORGANISM", 112, 118], ["people", "SPECIES", 54, 60], ["people", "SPECIES", 112, 118], ["COVID", "TEST", 0, 5], ["minimal manifestations", "PROBLEM", 28, 50], ["minimal", "OBSERVATION_MODIFIER", 28, 35], ["manifestations", "OBSERVATION", 36, 50]]], ["In that sense, information about the HLA allele frequencies distribution in different populations may contribute to study the magnitude of the immune response and its severity.DiscussionLack of knowledge of the HLA allele frequencies' distribution in South America also limits regional scientific studies in the field.", [["HLA", "GENE_OR_GENE_PRODUCT", 37, 40], ["HLA allele", "DNA", 37, 47], ["HLA allele", "DNA", 211, 221], ["the HLA allele frequencies distribution", "PROBLEM", 33, 72], ["regional scientific studies", "TEST", 277, 304]]], ["This impacts the study of infectious and autoimmune diseases, cancer immunotherapy, and transplantations.", [["cancer", "ANATOMY", 62, 68], ["infectious and autoimmune diseases", "DISEASE", 26, 60], ["cancer", "DISEASE", 62, 68], ["cancer", "CANCER", 62, 68], ["the study", "TEST", 13, 22], ["infectious", "PROBLEM", 26, 36], ["autoimmune diseases", "PROBLEM", 41, 60], ["cancer immunotherapy", "TREATMENT", 62, 82], ["transplantations", "TREATMENT", 88, 104], ["infectious", "OBSERVATION", 26, 36], ["autoimmune diseases", "OBSERVATION", 41, 60]]], ["Our results will serve as an immediate source of information for multiple ongoing studies based on HLA allele frequencies.DiscussionIn conclusion, the candidate epitopes presented may help in the fight against SARS-CoV-2, providing valuable information for the development of peptide vaccines and diagnostic tests.", [["SARS", "DISEASE", 210, 214], ["SARS-CoV-2", "ORGANISM", 210, 220], ["HLA allele", "DNA", 99, 109], ["SARS-CoV", "SPECIES", 210, 218], ["multiple ongoing studies", "TEST", 65, 89], ["peptide vaccines", "TREATMENT", 276, 292], ["diagnostic tests", "TEST", 297, 313]]], ["And updated HLA allele frequencies will impact on the study of many human diseases.", [["human", "ORGANISM", 68, 73], ["HLA allele", "DNA", 12, 22], ["human", "SPECIES", 68, 73], ["human", "SPECIES", 68, 73], ["the study", "TEST", 50, 59], ["many human diseases", "PROBLEM", 63, 82]]], ["We hope this literature review may result in a better representation of South America in future immunogenetic studies.Data Availability StatementAll datasets generated for this study are included in the article/Supplementary Material.Author ContributionsDR and RC devised the research project.", [["immunogenetic studies", "TEST", 96, 117], ["this study", "TEST", 172, 182]]], ["DR, MR, and RC selected and analyzed the viral genomes.", [["DR", "GENE_OR_GENE_PRODUCT", 0, 2], ["MR", "PROTEIN", 4, 6], ["viral genomes", "DNA", 41, 54], ["MR", "TEST", 4, 6], ["RC", "TEST", 12, 14], ["the viral genomes", "PROBLEM", 37, 54], ["viral genomes", "OBSERVATION", 41, 54]]], ["DR, AM, and MR performed the epitope predictions.", [["DR", "GENE_OR_GENE_PRODUCT", 0, 2], ["DR", "PROTEIN", 0, 2], ["MR", "PROTEIN", 12, 14], ["MR", "TEST", 12, 14]]], ["DR, AM, MR, and OM-S matched the predicted epitopes with previous experimental data and published predictions.", [["MR", "PROTEIN", 8, 10], ["MR", "TEST", 8, 10]]], ["AM and MR modeled the protein structures.", [["MR", "PROTEIN", 7, 9]]], ["AM, DR, and RC performed the prediction of selection pressures and post-translational modifications.", [["selection pressures", "TREATMENT", 43, 62], ["post-translational modifications", "TREATMENT", 67, 99], ["pressures", "OBSERVATION_MODIFIER", 53, 62], ["post-translational modifications", "OBSERVATION", 67, 99]]], ["All authors contributed to analyzing the results and manuscript preparation.Conflict of InterestThe authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.", [["manuscript preparation", "TREATMENT", 53, 75]]]], "338fc4e668c244be6f8cb7e9649650233765e998": [["Dear Editor, CORONAVIRUS (COVID-19) PANDEMIC: PERSONAL VIEW TO A NEW MODEL OF PAEDIATRIC PRACTICECoronavirus (COVID-19) pandemic is an unprecedented challenge to health-care professionals.", [["COVID-19", "CHEMICAL", 110, 118], ["COVID-19", "CELL", 110, 118]]], ["Central in its management remain social distancing, personal hygiene and wearing proper personal protective equipments.", [["Central in its management", "TREATMENT", 0, 25]]], ["Virtual consultations deploying recent technology have now replaced the normal practice of routine clinics.Dear Editor, CORONAVIRUS (COVID-19) PANDEMIC: PERSONAL VIEW TO A NEW MODEL OF PAEDIATRIC PRACTICEVirtual consultations minimise the risk of COVID-19 transmission, promote public protection and reduce the backlog of waiting lists during this time of testing.Dear Editor, CORONAVIRUS (COVID-19) PANDEMIC: PERSONAL VIEW TO A NEW MODEL OF PAEDIATRIC PRACTICEMany clinicians may feel uncomfortable with this new model of practice where the gold standard rule in medical practice is direct contact with patients.", [["patients", "ORGANISM", 604, 612], ["patients", "SPECIES", 604, 612], ["COVID", "TEST", 247, 252], ["public protection", "TREATMENT", 278, 295], ["testing", "TEST", 356, 363]]], ["Face to face consultations help build up rapport between doctors and patients.", [["patients", "ORGANISM", 69, 77], ["patients", "SPECIES", 69, 77]]], ["Face to face clinical practice enables clinicians to better identify clinical problems and provide meticulous clinical assessment.", [["meticulous clinical assessment", "TEST", 99, 129]]], ["Uplifting patient safety and sound clinical judgement are a top priority for physicians.Dear Editor, CORONAVIRUS (COVID-19) PANDEMIC: PERSONAL VIEW TO A NEW MODEL OF PAEDIATRIC PRACTICEVirtual clinics are useful tools at the time of COVID-19 pandemic when health-care demands are pressing.", [["patient", "ORGANISM", 10, 17], ["patient", "SPECIES", 10, 17], ["COVID", "TEST", 233, 238]]], ["Clinicians are at the front door in this battle and subsequently are at increased risks of contracting disease and transmitting it to their close contacts and loved ones, placing physicians under immense emotional pressures.Dear Editor, CORONAVIRUS (COVID-19) PANDEMIC: PERSONAL VIEW TO A NEW MODEL OF PAEDIATRIC PRACTICEChildren with allergy, such as food allergy, are a special cohort that may benefit well from virtual consultations.", [["allergy", "DISEASE", 335, 342], ["food allergy", "DISEASE", 352, 364], ["contracting disease", "PROBLEM", 91, 110], ["allergy", "PROBLEM", 335, 342], ["contracting disease", "OBSERVATION", 91, 110]]], ["The preponderance of them are well and parents can provide a detailed allergy focused clinical history guided by clinicians during virtual consultations.", [["allergy", "DISEASE", 70, 77]]], ["The quality of video recording can provide clues about various allergic skin manifestations.", [["skin", "ANATOMY", 72, 76], ["allergic skin manifestations", "DISEASE", 63, 91], ["skin", "ORGAN", 72, 76], ["video recording", "TEST", 15, 30], ["various allergic skin manifestations", "PROBLEM", 55, 91], ["skin", "ANATOMY", 72, 76]]], ["Obtaining allergy focused clinical history is a quality statement (The National Institute for Health and Care Excellence report -March 2016).Dear Editor, CORONAVIRUS (COVID-19) PANDEMIC: PERSONAL VIEW TO A NEW MODEL OF PAEDIATRIC PRACTICEIn our unit, paediatric allergy team had forethought to launch virtual clinics before recent recommendations from The British Society for Allergy and Clinical Immunology (BSACI) justified this model (BSACI report, on 24 March 2020).", [["allergy", "DISEASE", 10, 17], ["allergy", "DISEASE", 262, 269]]], ["Service started on 23 March 2020, eight clinics were run and 50 patients reviewed.", [["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 64, 72]]], ["No adverse events were reported and patient perception of the new service was encouraging.Dear Editor, CORONAVIRUS (COVID-19) PANDEMIC: PERSONAL VIEW TO A NEW MODEL OF PAEDIATRIC PRACTICEAdjustments were made related to specific allergy investigations such as skin prick tests, congruent with BSACI recommendations, those tests can be deferred during COVID-19 pandemic.", [["skin", "ANATOMY", 260, 264], ["allergy", "DISEASE", 229, 236], ["patient", "ORGANISM", 36, 43], ["skin", "ORGAN", 260, 264], ["patient", "SPECIES", 36, 43], ["adverse events", "PROBLEM", 3, 17], ["PAEDIATRIC PRACTICEAdjustments", "TREATMENT", 168, 198], ["specific allergy investigations", "TEST", 220, 251], ["skin prick tests", "TEST", 260, 276], ["those tests", "TEST", 316, 327], ["COVID", "TEST", 351, 356], ["pandemic", "PROBLEM", 360, 368], ["adverse", "OBSERVATION_MODIFIER", 3, 10], ["skin", "ANATOMY", 260, 264]]], ["1 In brief, virtual clinics are useful at times of pandemics although they lack direct clinical relationship with patients.Dear Editor, CORONAVIRUS (COVID-19) PANDEMIC: PERSONAL VIEW TO A NEW MODEL OF PAEDIATRIC PRACTICEVirtual consultations deploy recent technology in medicine and are recommended by professional bodies.", [["patients", "ORGANISM", 114, 122], ["patients", "SPECIES", 114, 122], ["pandemics", "PROBLEM", 51, 60]]], ["Although clinical confidence and appropriateness of use may vary in various aspects of clinical care, our experience in paediatric allergy is satisfactory.", [["allergy", "DISEASE", 131, 138], ["clinical care", "TREATMENT", 87, 100]]], ["Dear Editor,ACKNOWLEDGING LIMITS: STATISTICS AND THE CHILD'S QUALITY OF LIFE IN SPINAL MUSCULAR ATROPHYPaediatricians are increasingly confronted with complex challenges such as the diagnosis of incurable illness and the limitations posed by medicine itself.", [["illness", "DISEASE", 205, 212], ["incurable illness", "PROBLEM", 195, 212], ["SPINAL MUSCULAR", "ANATOMY", 80, 95]]], ["Even the definition of incurable illness can frequently be problematic; as time passes the prognosis can change, not only because of the child's evolving maturity and the unpredictable trajectory of the illness but also due to therapeutic innovations.", [["illness", "DISEASE", 33, 40], ["illness", "DISEASE", 203, 210], ["incurable illness", "PROBLEM", 23, 40], ["the child's evolving maturity", "PROBLEM", 133, 162], ["the illness", "PROBLEM", 199, 210], ["therapeutic innovations", "PROBLEM", 227, 250], ["incurable", "OBSERVATION_MODIFIER", 23, 32]]], ["The problem is relevant when dealing with rare diseases where the severity of the illness and the consequential risks to life justify a fervent quest for effective solutions.", [["illness", "DISEASE", 82, 89], ["rare diseases", "PROBLEM", 42, 55], ["the illness", "PROBLEM", 78, 89], ["effective solutions", "TREATMENT", 154, 173]]], ["However, at the same time, it must be acknowledged how the burden of the proposed treatments can condition their effectiveness and negatively impact the child and family's quality of life.ACKNOWLEDGING LIMITS: STATISTICS AND THE CHILD'S QUALITY OF LIFE IN SPINAL MUSCULAR ATROPHYSpinal muscular atrophy can be considered a paradigm: the availability of a recently approved drug has radically changed the course of the illness by offering patients an enhanced duration and quality of life.", [["muscular", "ANATOMY", 286, 294], ["muscular atrophy", "DISEASE", 286, 302], ["illness", "DISEASE", 418, 425], ["muscular", "ORGAN", 286, 294], ["patients", "ORGANISM", 438, 446], ["patients", "SPECIES", 438, 446], ["the proposed treatments", "TREATMENT", 69, 92], ["SPINAL MUSCULAR ATROPHYSpinal muscular atrophy", "PROBLEM", 256, 302], ["SPINAL MUSCULAR", "ANATOMY", 256, 271], ["ATROPHYSpinal muscular", "ANATOMY", 272, 294], ["atrophy", "OBSERVATION", 295, 302]]], ["However, if this ground-breaking treatment is initiated late in the course of the disease, it does not significantly improve their clinical situation.", [["breaking treatment", "TREATMENT", 24, 42], ["the disease", "PROBLEM", 78, 89]]], ["On the contrary, the anxiety and distress caused by the prospect of being subjected to a burdensome lifelong procedure (it is administered every 4 months via spinal canal injection), linked to the frustration, triggered by disappointing results or the lack of improvement, can significantly impact the child and family's quality of life.", [["spinal canal", "ANATOMY", 158, 170], ["anxiety", "DISEASE", 21, 28], ["distress", "DISEASE", 33, 41], ["spinal canal", "MULTI-TISSUE_STRUCTURE", 158, 170], ["the anxiety", "PROBLEM", 17, 28], ["distress", "PROBLEM", 33, 41], ["a burdensome lifelong procedure", "TREATMENT", 87, 118], ["spinal canal injection", "TREATMENT", 158, 180], ["spinal canal", "ANATOMY", 158, 170]]], ["1, 2 Therefore, when evaluating the introduction of new treatments, as opposed to applying standardised protocols, we should always aim to adopt a flexible approach that takes into consideration each individual patient's global needs.", [["patient", "ORGANISM", 211, 218], ["patient", "SPECIES", 211, 218], ["new treatments", "TREATMENT", 52, 66], ["standardised protocols", "TREATMENT", 91, 113], ["a flexible approach", "TREATMENT", 145, 164]]]], "PMC7177179": [["IntroductionThe World Health Organization (WHO) reported on December 31, 2019 cases of pneumonia of undetected etiology in the city of Wuhan, Hubei Province in China.", [["pneumonia", "DISEASE", 87, 96], ["pneumonia", "PROBLEM", 87, 96], ["pneumonia", "OBSERVATION", 87, 96]]], ["A novel coronavirus (CoViD-19) was identified as the source of the disease by the Chinese authorities on January 7, 2020.", [["coronavirus", "ORGANISM", 8, 19], ["CoViD-19", "ORGANISM", 21, 29], ["coronavirus", "SPECIES", 8, 19], ["A novel coronavirus (CoViD", "TEST", 0, 26], ["the disease", "PROBLEM", 63, 74], ["coronavirus", "OBSERVATION", 8, 19], ["disease", "OBSERVATION", 67, 74]]], ["Eventually, the International Committee on Taxonomy of Viruses on 11 February, 2020 named the Severe Acute Respiratory Syndrome Coronavirus as SARS-CoV-2 [1].", [["Acute Respiratory Syndrome Coronavirus", "DISEASE", 101, 139], ["SARS", "DISEASE", 143, 147], ["Severe Acute Respiratory Syndrome Coronavirus as SARS-CoV", "SPECIES", 94, 151], ["the Severe Acute Respiratory Syndrome Coronavirus", "PROBLEM", 90, 139], ["CoV", "TEST", 148, 151], ["Severe", "OBSERVATION_MODIFIER", 94, 100], ["Acute", "OBSERVATION_MODIFIER", 101, 106], ["Respiratory Syndrome", "OBSERVATION", 107, 127]]], ["Concerns on public health were dispersed on a global scale about potentially infected countries.", [["infected", "OBSERVATION", 77, 85]]], ["The virus might have been generated by animal populations and transmitted via the Huanan wholesale market [2], [3], [4] albeit not proven, while clinical findings demonstrated that international spread was caused mainly by commercial air travel [4], [5], [6], [7].", [["The virus", "PROBLEM", 0, 9], ["virus", "OBSERVATION", 4, 9]]], ["The WHO declared SARS-CoV-2 a pandemic on March 11, 2020.", [["SARS", "DISEASE", 17, 21], ["SARS-CoV", "SPECIES", 17, 25], ["SARS", "PROBLEM", 17, 21]]], ["Throughout the globe, huge efforts were in progress to limit the spread of the virus and find medications and vaccines.", [["the virus", "TREATMENT", 75, 84], ["medications", "TREATMENT", 94, 105], ["vaccines", "TREATMENT", 110, 118], ["globe", "ANATOMY", 15, 20], ["huge", "OBSERVATION_MODIFIER", 22, 26]]], ["However, the scientific community could not fully comprehend the dynamics of the spread [8], [9], [10].IntroductionSeveral outbreaks of infectious diseases have occurred in the past with immense impact on public health.", [["infectious diseases", "DISEASE", 136, 155], ["infectious diseases", "PROBLEM", 136, 155], ["infectious", "OBSERVATION", 136, 146]]], ["For instance, the Severe Acute Respiratory Syndrome (SARS) occurred in 2003, the swine flu in 2009 and the Middle East Respiratory Syndrome Coronavirus (MERS) in Saudi Arabia in 2012, which still survives at a sub-critical level causing some peaks [11], [12], [13], [14].", [["Acute Respiratory Syndrome", "DISEASE", 25, 51], ["SARS", "DISEASE", 53, 57], ["Respiratory Syndrome Coronavirus", "DISEASE", 119, 151], ["swine", "SPECIES", 81, 86], ["Middle East Respiratory Syndrome Coronavirus", "SPECIES", 107, 151], ["the Severe Acute Respiratory Syndrome (SARS)", "PROBLEM", 14, 58], ["the swine flu", "TEST", 77, 90], ["the Middle East Respiratory Syndrome Coronavirus", "PROBLEM", 103, 151], ["some peaks", "PROBLEM", 237, 247], ["Severe", "OBSERVATION_MODIFIER", 18, 24], ["Acute", "OBSERVATION_MODIFIER", 25, 30], ["Respiratory Syndrome", "OBSERVATION", 31, 51], ["Middle", "ANATOMY_MODIFIER", 107, 113], ["Respiratory Syndrome", "OBSERVATION", 119, 139]]], ["Additionally, the Ebola epidemic emerged between 2014 and 2016 and caused over 28,000 cases in West Africa [15].", [["Ebola", "DISEASE", 18, 23], ["Ebola", "ORGANISM", 18, 23]]], ["Its temporal decline coincided with the outbreak of Zika virus in Brazil [16].", [["Zika virus", "ORGANISM", 52, 62], ["Zika virus", "SPECIES", 52, 62], ["Its temporal decline", "PROBLEM", 0, 20], ["Zika virus", "PROBLEM", 52, 62], ["temporal", "OBSERVATION_MODIFIER", 4, 12], ["decline", "OBSERVATION", 13, 20]]], ["Consequently, the outbreak of severe pathogens such as the aforementioned, require global interdisciplinary efforts in order to decode key epidemiological features and their transmission dynamics, and develop possible control policies.IntroductionInsights from mathematical modelling can be extremely beneficial.", [["severe pathogens", "PROBLEM", 30, 46], ["global interdisciplinary efforts", "TREATMENT", 83, 115], ["IntroductionInsights", "TREATMENT", 235, 255], ["severe", "OBSERVATION_MODIFIER", 30, 36], ["pathogens", "OBSERVATION", 37, 46]]], ["Indeed, dealing with infectious diseases from a mathematical angle could reveal inherent patterns and underlying structures that govern outbreaks.", [["infectious diseases", "DISEASE", 21, 40], ["infectious diseases", "PROBLEM", 21, 40], ["underlying structures", "PROBLEM", 102, 123]]], ["Stakeholders utilize available data from current and previous outbreaks in order to forecast infection rates, identify how to restrict the spread of diseases, and eventually introduce vaccination policies that will be most effective.", [["infection", "DISEASE", 93, 102], ["forecast infection rates", "PROBLEM", 84, 108], ["diseases", "PROBLEM", 149, 157], ["vaccination policies", "TREATMENT", 184, 204]]], ["Most phenomena observed at population level are often very complex and difficult to decode just by observing the characteristics of isolated individuals [17].", [["Most phenomena", "PROBLEM", 0, 14], ["very complex", "PROBLEM", 54, 66], ["isolated individuals", "PROBLEM", 132, 152]]], ["Statistical analyses of epidemiological data help to characterize, quantify and summarize the way diseases spread in host populations.", [["epidemiological data", "TEST", 24, 44], ["the way diseases", "PROBLEM", 90, 106], ["host populations", "OBSERVATION", 117, 133]]], ["Interestingly, mathematical models appear as efficient ways to explore and test various epidemiological hypotheses, mostly due to the existence of ethical and practical limitations when deducting experiments on living populations.", [["test various epidemiological hypotheses", "PROBLEM", 75, 114]]], ["One additional element of epidemiological modeling is the link with data via statistical methods.", [["element", "OBSERVATION_MODIFIER", 15, 22], ["epidemiological modeling", "OBSERVATION", 26, 50]]], ["Although simple epidemiological models are often used, viral and bacterial infections commonly require increased complexity.", [["infections", "DISEASE", 75, 85], ["simple epidemiological models", "PROBLEM", 9, 38], ["viral and bacterial infections", "PROBLEM", 55, 85], ["increased complexity", "PROBLEM", 103, 123], ["bacterial", "OBSERVATION_MODIFIER", 65, 74], ["infections", "OBSERVATION", 75, 85], ["increased", "OBSERVATION_MODIFIER", 103, 112], ["complexity", "OBSERVATION_MODIFIER", 113, 123]]], ["There are many models in the literature on single epidemics, endemic diseases and spatiotemporal disease dynamics.", [["endemic diseases", "PROBLEM", 61, 77], ["spatiotemporal disease dynamics", "PROBLEM", 82, 113], ["many", "OBSERVATION_MODIFIER", 10, 14], ["models", "OBSERVATION_MODIFIER", 15, 21], ["endemic", "OBSERVATION_MODIFIER", 61, 68], ["diseases", "OBSERVATION", 69, 77], ["spatiotemporal disease", "OBSERVATION", 82, 104]]], ["The aim is to develop robust public health policies in defining optimal vaccination strategies.IntroductionOur study presents for the first time a new stochastic mathematical model for describing infectious dynamics and tracking virus temporal transmissibility on 3-dimensional space (earth).", [["optimal vaccination strategies", "TREATMENT", 64, 94], ["IntroductionOur study", "TEST", 95, 116], ["a new stochastic mathematical model", "TREATMENT", 145, 180], ["infectious dynamics", "PROBLEM", 196, 215], ["tracking virus temporal transmissibility", "PROBLEM", 220, 260], ["infectious", "OBSERVATION", 196, 206]]], ["This model can be adjusted to describe all past outbreaks as well as CoViD-19.", [["CoViD", "TEST", 69, 74]]], ["As a matter of fact, it introduces a novel approach to mathematical modelling of infectious dynamics of any disease, and sets a starting point for conducting simulations, forecasting and nowcasting investigations based on real-world stereographic and spherical tracking on earth.IntroductionIn short, a single epidemic outbreak as opposed to disease endemicity occurs in a time span short enough not to have the demographic changes perturbing the dynamics of contacts among individuals.", [["a novel approach", "TREATMENT", 35, 51], ["any disease", "PROBLEM", 104, 115], ["conducting simulations", "TEST", 147, 169], ["nowcasting investigations", "TEST", 187, 212], ["a single epidemic outbreak", "PROBLEM", 301, 327], ["disease endemicity", "PROBLEM", 342, 360], ["infectious", "OBSERVATION", 81, 91]]], ["The most popular mathematical model in this category is the Susceptible-Infected-Recovered (SIR) epidemic model, in which all individuals of a finite population interact in the same manner.", [["Susceptible", "OBSERVATION_MODIFIER", 60, 71], ["Infected", "OBSERVATION_MODIFIER", 72, 80]]], ["The final size of the epidemic will strongly depend upon the initial conditions of the number of susceptible and infected individuals as well as the infection parameter.", [["infection", "DISEASE", 149, 158], ["susceptible and infected individuals", "PROBLEM", 97, 133], ["the infection parameter", "PROBLEM", 145, 168], ["final", "OBSERVATION_MODIFIER", 4, 9], ["size", "OBSERVATION_MODIFIER", 10, 14], ["epidemic", "OBSERVATION", 22, 30], ["infected", "OBSERVATION", 113, 121], ["infection", "OBSERVATION", 149, 158]]], ["The final size distribution of the simple SIR model in most cases is bimodal presenting two local maxima.", [["final", "OBSERVATION_MODIFIER", 4, 9], ["size", "OBSERVATION_MODIFIER", 10, 14], ["distribution", "OBSERVATION_MODIFIER", 15, 27], ["simple", "OBSERVATION_MODIFIER", 35, 41], ["SIR model", "OBSERVATION", 42, 51], ["bimodal", "OBSERVATION_MODIFIER", 69, 76]]], ["This bimodal feature is caused by two likely scenarios; either the epidemic dies out quickly infecting few individuals, or it becomes long-lasting and substantial.", [["substantial", "OBSERVATION_MODIFIER", 151, 162]]], ["However, stochasticity in the form of random walk transmission mechanisms related to spreading processes has never been explored in epidemiology widely [18], [19], [20].", [["[19]", "SIMPLE_CHEMICAL", 158, 162], ["random walk transmission mechanisms", "PROBLEM", 38, 73], ["spreading processes", "PROBLEM", 85, 104]]], ["For example, in computer science, some artificially created viruses propagate randomly by a plethora of online communication channels.", [["viruses", "OBSERVATION", 60, 67]]], ["In this work, we assume that a biological carrier of virus Y is at position X(t) at any given time t.", [["a biological carrier of virus Y", "TREATMENT", 29, 60]]], ["We call this the inaugural contamination focal point on earth.IntroductionThe path defined by its motion is considered infectious.", [["infectious", "PROBLEM", 119, 129], ["infectious", "OBSERVATION", 119, 129]]], ["Xt, t \u2265 0 is supposed to follow a Brownian motion on a 2-dimensional sphere S2 of radius a, i.e the sphere in R of dimension 3.", [["Xt, t \u2265 0", "TEST", 0, 9], ["S2", "ANATOMY_MODIFIER", 76, 78], ["radius", "ANATOMY_MODIFIER", 82, 88], ["sphere", "OBSERVATION_MODIFIER", 100, 106]]], ["Next, using the Laplace-Beltrami operator we construct the Brownian motion infectious process on the 2-dimensional sphere, using spherical and stereographic coordinates as local coordinates.", [["Laplace", "DNA", 16, 23], ["Beltrami operator", "DNA", 24, 41], ["the Laplace-Beltrami operator", "TREATMENT", 12, 41], ["the Brownian motion infectious process", "PROBLEM", 55, 93], ["spherical and stereographic coordinates", "TREATMENT", 129, 168], ["Brownian motion", "OBSERVATION", 59, 74]]], ["We evaluate explicitly certain quantities related to generated diffusion processes.", [["generated diffusion processes", "PROBLEM", 53, 82], ["diffusion processes", "OBSERVATION", 63, 82]]], ["In what follows, we compute the transition and transmission density for the Xt, t \u2265 0, and we derive the stochastic differential equations that govern the infectious disease dynamics for Xt, t \u2265 0 in those local coordinates.", [["the stochastic differential equations", "PROBLEM", 101, 138], ["infectious", "OBSERVATION_MODIFIER", 155, 165]]], ["In mathematical terms, we derive the stochastic reflection principle on S2 for the infectious disease transmission process.", [["the infectious disease transmission process", "PROBLEM", 79, 122], ["infectious", "OBSERVATION", 83, 93]]], ["Reflection points can be extremely useful to calculate the distribution functions of certain temporal quantities related to the dynamics.", [["Reflection points", "TEST", 0, 17]]], ["Additionally, we evaluate boundary local times of first hitting of the outbreak for an epidemic or a hybrid endemic-epidemic model.", [["an epidemic", "PROBLEM", 84, 95]]], ["Hence, biological carrier(s) of a virus (infectious individuals) are tracked at any given time on earth coordinates, and the path(s) defined by each infectious dynamical motion.", [["a virus (infectious individuals", "PROBLEM", 32, 63], ["infectious", "OBSERVATION_MODIFIER", 149, 159], ["dynamical motion", "OBSERVATION", 160, 176]]], ["In the following two chapters we present a thorough literature review and a state-of-the-art analysis in order to pose clearly our novel approach optimally among the various methodologies followed thus far.IntroductionThe rest of paper is organized as follows: section 2 provides a brief literature review, past and recent, of mathematical epidemiology.", [["the various methodologies", "TEST", 162, 187]]], ["Section 3 presents the state-of-the-art, and focal concepts and term definitions required to introduce our novel model.", [["focal concepts and term definitions", "PROBLEM", 45, 80], ["our novel model", "TREATMENT", 103, 118], ["focal", "OBSERVATION_MODIFIER", 45, 50]]], ["It also states which category the new model falls into, according to the official taxonomy of the various methodologies already utilized so far in the relevant literature.", [["new", "OBSERVATION_MODIFIER", 34, 37]]], ["Lastly, section 5 discusses proposed policies and future paths of research, and concludes.Literature ReviewThe beginning of mathematical modeling in epidemiology dates back to 1766, when Bernoulli developed a mathematical model to analyze the mortality of smallpox in England [22].", [["smallpox", "DISEASE", 256, 264]]], ["Bernoulli used his model to show that inoculation against the virus would increase the life expectancy at birth by about three years.", [["inoculation", "PROBLEM", 38, 49], ["the virus", "PROBLEM", 58, 67]]], ["A revision of the main findings and a presentation of the criticism by D\u2019Alembert, appears recently in Dietz and Heesterbeek [23].", [["A revision", "TREATMENT", 0, 10], ["revision", "OBSERVATION", 2, 10], ["main", "OBSERVATION_MODIFIER", 18, 22]]], ["Ross used a set of equations to approximate the discrete-time dynamics of malaria via a mosquito-based pathogen transmission [27].", [["malaria", "DISEASE", 74, 81], ["malaria", "PROBLEM", 74, 81], ["malaria", "OBSERVATION", 74, 81]]], ["Importantly, the past century has witnessed the rapid emergence and development of substantial theories in epidemics.", [["epidemics", "PROBLEM", 107, 116], ["substantial", "OBSERVATION_MODIFIER", 83, 94], ["epidemics", "OBSERVATION", 107, 116]]], ["It predicts \u2013 depending on the transmission potential of the infection \u2013 the critical fraction of susceptibles in the population that must be exceeded if an epidemic is to occur.", [["infection", "DISEASE", 61, 70], ["the infection", "PROBLEM", 57, 70], ["infection", "OBSERVATION", 61, 70]]], ["Kermack and McKendrick published three seminal papers, establishing what is called the deterministic compartmental epidemic modelling [29], [30], [31], wherein they addressed the mass\u2013action incident in disease transmission cycles, assuming that the probability of infection of a susceptible is analogous to the number of its contacts with infected individuals.", [["infection", "DISEASE", 265, 274], ["disease transmission cycles", "PROBLEM", 203, 230], ["infection", "PROBLEM", 265, 274], ["infected individuals", "PROBLEM", 340, 360], ["infection", "OBSERVATION", 265, 274], ["infected", "OBSERVATION", 340, 348]]], ["This deterministic representation was in line with the Law of Mass Action [32] introduced by Guldberg and Waage in 1864 and renders the basic most commonly used SIR model, which assumes homogeneous mixing of the contacts and conservation of the total population and low rates of interaction.", [["the total population", "TREATMENT", 241, 261], ["Mass", "OBSERVATION", 62, 66], ["homogeneous", "OBSERVATION_MODIFIER", 186, 197], ["mixing", "OBSERVATION", 198, 204]]], ["MacDonald extended Ross\u2019s model to explain in depth the transmission process of malaria.", [["malaria", "DISEASE", 80, 87], ["malaria", "PROBLEM", 80, 87], ["malaria", "OBSERVATION", 80, 87]]], ["Utilizing modern computer power, the mathematical model for the dynamics and the control of mosquito-transmitted pathogens provided robust results in real-word applications.", [["transmitted pathogens", "PROBLEM", 101, 122]]], ["Moreover, the classic work of Bartlett [34] examined models and data to explore the factors that determine disease persistence in large populations.", [["disease persistence in large populations", "PROBLEM", 107, 147], ["large", "OBSERVATION_MODIFIER", 130, 135], ["populations", "OBSERVATION_MODIFIER", 136, 147]]], ["Given the diversity of infectious diseases studied since the middle of the 1950s, an impressive variety of epidemiological models have been developed.", [["infectious diseases", "DISEASE", 23, 42], ["infectious diseases", "PROBLEM", 23, 42], ["diversity", "OBSERVATION_MODIFIER", 10, 19], ["infectious", "OBSERVATION", 23, 33], ["middle", "ANATOMY_MODIFIER", 61, 67], ["impressive", "OBSERVATION_MODIFIER", 85, 95], ["variety", "OBSERVATION_MODIFIER", 96, 103]]], ["In addition, we should highlight the 19th century works by Enko [37], [38], [39], who first published a probabilistic model for describing the epidemic of measles, yet in discrete time.", [["measles", "DISEASE", 155, 162]]], ["It assumes that the infection spreads from an infected to a susceptible individual via a discrete time Markov chain, and set the basis of contemporary stochastic epidemic modelling, on which we will also focus in our present work.Literature ReviewMoving to the 21st century, we mention some interesting works; Xing et al., [41] introduced a mathematical model on H7N9 influenza among migrant and resident birds, domestic poultry and humans in China.", [["infection", "DISEASE", 20, 29], ["influenza", "DISEASE", 368, 377], ["H7N9 influenza", "ORGANISM", 363, 377], ["birds", "ORGANISM", 405, 410], ["humans", "ORGANISM", 433, 439], ["humans", "SPECIES", 433, 439], ["humans", "SPECIES", 433, 439], ["the infection", "PROBLEM", 16, 29], ["infection", "OBSERVATION", 20, 29], ["infected", "OBSERVATION", 46, 54]]], ["In this study they concluded that temperature seasonality might be a source of the disease, yet they suggested for the first time that controlling markets could help controlling outbreaks.", [["this study", "TEST", 3, 13], ["temperature seasonality", "PROBLEM", 34, 57], ["the disease", "PROBLEM", 79, 90], ["disease", "OBSERVATION", 83, 90]]], ["Lee and Pietz [42] developed a mathematical model for Zika virus using logistic growth in human populations.", [["Zika virus", "ORGANISM", 54, 64], ["human", "ORGANISM", 90, 95], ["human", "SPECIES", 90, 95], ["Zika virus", "SPECIES", 54, 64], ["human", "SPECIES", 90, 95], ["Zika virus", "PROBLEM", 54, 64], ["logistic growth in human populations", "PROBLEM", 71, 107]]], ["Sun et al., [43] proposed a transmission model for cholera in China and observed that reducing the spread requires extensive immunization coverage of the population.", [["cholera", "DISEASE", 51, 58], ["a transmission model", "TREATMENT", 26, 46], ["cholera", "PROBLEM", 51, 58], ["extensive immunization coverage", "TREATMENT", 115, 146], ["spread", "OBSERVATION_MODIFIER", 99, 105]]], ["Nishiura et al. [44] developed a Zika mathematical model which exhibited the same dynamics as dengue fever, and Khan et al. [45] introduced a model whereby a saturation function describes well the typhoid fever dynamics.", [["dengue fever", "DISEASE", 94, 106], ["typhoid fever", "DISEASE", 197, 210], ["a Zika mathematical model", "PROBLEM", 31, 56], ["dengue fever", "PROBLEM", 94, 106], ["a saturation function", "TEST", 156, 177], ["the typhoid fever dynamics", "PROBLEM", 193, 219]]], ["Gui and Zhang [46], developed a modified SIR model demonstrating nonlinearities in recovery rates.", [["nonlinearities", "OBSERVATION_MODIFIER", 65, 79]]], ["Their model exhibited a backward bifurcation phenomenon, which in turn implied that a plain reduction of the reproduction number less than one, was not rendered sufficient to stop the disease spread.", [["a backward bifurcation phenomenon", "PROBLEM", 22, 55], ["a plain reduction", "TREATMENT", 84, 101], ["the disease spread", "PROBLEM", 180, 198], ["backward", "OBSERVATION_MODIFIER", 24, 32], ["bifurcation phenomenon", "OBSERVATION", 33, 55], ["disease", "OBSERVATION", 184, 191]]], ["Li et al. [47] constructed a multi-group brucellosis model and found out that the best way to contain the disease is to avoid cross infection of animal populations.", [["Li", "CHEMICAL", 0, 2], ["brucellosis", "DISEASE", 41, 52], ["infection", "DISEASE", 132, 141], ["a multi-group brucellosis model", "TEST", 27, 58], ["the disease", "PROBLEM", 102, 113], ["cross infection of animal populations", "PROBLEM", 126, 163], ["disease", "OBSERVATION", 106, 113]]], ["Moreover, Yu and Lin [48] identified complex dynamical behaviour in epidemiological models and particularly the existence of multiple limit cycle bifurcations using a predictor-prey model.", [["complex dynamical behaviour in epidemiological models", "PROBLEM", 37, 90], ["a predictor-prey model", "TREATMENT", 165, 187], ["complex", "OBSERVATION_MODIFIER", 37, 44], ["dynamical behaviour", "OBSERVATION", 45, 64]]], ["Shi et al. [49] proposed an HIV model with a saturated reverse function to describe the dynamics of infected cells.", [["cells", "ANATOMY", 109, 114], ["HIV", "ORGANISM", 28, 31], ["cells", "CELL", 109, 114], ["infected cells", "CELL_TYPE", 100, 114], ["HIV", "SPECIES", 28, 31], ["an HIV model", "PROBLEM", 25, 37], ["a saturated reverse function", "PROBLEM", 43, 71], ["infected cells", "PROBLEM", 100, 114], ["infected cells", "OBSERVATION", 100, 114]]], ["Additionally, Bonyah et al. [50] developed a SIR model to study the dynamics of buruli ulcer and suggested policy measures to control the disease.", [["buruli ulcer", "ANATOMY", 80, 92], ["ulcer", "DISEASE", 87, 92], ["buruli ulcer", "PATHOLOGICAL_FORMATION", 80, 92], ["buruli ulcer", "PROBLEM", 80, 92], ["policy measures", "TREATMENT", 107, 122], ["the disease", "PROBLEM", 134, 145], ["buruli ulcer", "OBSERVATION", 80, 92], ["disease", "OBSERVATION", 138, 145]]], ["Lastly, Zhang et al. [51] developed a model with a latent period of the disease wherein the person is not infectious with saturated incidence rates and treatment functions, called SEIR epidemic model.State-of-the-Art Analysis and DefinitionsThe SIR model is the basic one used for modelling epidemics.", [["person", "SPECIES", 92, 98], ["the disease", "PROBLEM", 68, 79], ["modelling epidemics", "PROBLEM", 281, 300], ["latent", "OBSERVATION_MODIFIER", 51, 57], ["disease", "OBSERVATION", 72, 79]]], ["Kermack and McKendrick created the model in 1927 [29] in which they considered a fixed population with only three compartments, susceptible (S), infected (I) and recovered (R).", [["a fixed population", "PROBLEM", 79, 97], ["fixed", "OBSERVATION_MODIFIER", 81, 86], ["population", "OBSERVATION", 87, 97]]], ["There are a large number of modifications of the SIR model, including those that include births and deaths, the SIR without or with vital dynamics, a model where upon recovery there is no immunity called SIS and where immunity lasts for a short period of time, called SIRS model.", [["deaths", "DISEASE", 100, 106], ["SIRS", "DISEASE", 268, 272], ["large", "OBSERVATION_MODIFIER", 12, 17], ["number", "OBSERVATION_MODIFIER", 18, 24], ["no", "UNCERTAINTY", 185, 187]]], ["Furthermore, a model where there is a latent period of the disease and where the person is not infectious is indentified as SEIS and SEIR respectively, or where infants can be born with immunity is named MSIR.", [["infants", "ORGANISM", 161, 168], ["person", "SPECIES", 81, 87], ["infants", "SPECIES", 161, 168], ["the disease", "PROBLEM", 55, 66], ["infectious", "PROBLEM", 95, 105], ["latent", "OBSERVATION_MODIFIER", 38, 44], ["period", "OBSERVATION_MODIFIER", 45, 51], ["disease", "OBSERVATION", 59, 66], ["infectious", "OBSERVATION", 95, 105]]], ["Also, we mention the herd immunity model [52], [53].State-of-the-Art Analysis and DefinitionsOverall, the transmission mechanism from infective populations to susceptibles is not well-comprehended for many infectious diseases.", [["infectious diseases", "DISEASE", 206, 225], ["Art Analysis", "TEST", 65, 77], ["DefinitionsOverall", "TREATMENT", 82, 100], ["infective populations", "PROBLEM", 134, 155], ["many infectious diseases", "PROBLEM", 201, 225], ["infective", "OBSERVATION", 134, 143], ["infectious", "OBSERVATION", 206, 216]]], ["Interactions in a population are very complex, hence it is extremely difficult to capture the large scale dynamics of disease spread without formal mathematical modeling.", [["disease spread", "PROBLEM", 118, 132], ["large", "OBSERVATION_MODIFIER", 94, 99], ["disease", "OBSERVATION", 118, 125]]], ["An epidemiological model uses microscopic effects - the role of an infectious individual - to forecast the macroscopic behavior of disease spread via a population.State-of-the-Art Analysis and DefinitionsDeterministic models do not incorporate any form of uncertainty and as such, they can be thought to account for the mean trend of a process, alone.", [["an infectious individual", "PROBLEM", 64, 88], ["disease spread", "PROBLEM", 131, 145], ["Art Analysis", "TEST", 176, 188], ["infectious", "OBSERVATION", 67, 77]]], ["Two basic types of stochasticity are commonly used: demographic and environmental.", [["stochasticity", "OBSERVATION", 19, 32]]], ["Within the context of demographic stochasticity, all individuals are subject to the same potential events with the exact same probabilities but differences in the fates of population individuals.", [["demographic stochasticity", "PROBLEM", 22, 47]]], ["Disease propagation in large populations obeys to the weak law of large numbers, thus effects of demographic stochasticity can be decreased significantly, and many times a deterministic model becomes more suitable.", [["Disease propagation", "PROBLEM", 0, 19], ["large populations", "PROBLEM", 23, 40], ["demographic stochasticity", "PROBLEM", 97, 122], ["large", "OBSERVATION_MODIFIER", 23, 28], ["populations", "OBSERVATION", 29, 40], ["large", "OBSERVATION_MODIFIER", 66, 71], ["numbers", "OBSERVATION_MODIFIER", 72, 79]]], ["However, random events cannot be neglected and a stochastic model can be equally appropriate.", [["random events", "PROBLEM", 9, 22]]], ["Environmental stochasticity involves variations in the probability associated with an exogenous event.", [["an exogenous event", "PROBLEM", 83, 101]]], ["Model parameters of stochastic models are characterized by probability distributions, whilst for fixed parameter values deterministic models will always produce the same results, except when chaotic behaviour emerges.State-of-the-Art Analysis and DefinitionsIn the classic SIR model it is assumed that the individuals leave the infectious class at a constant rate and even if this assumption seems most intuitive, it is not always the most realistic, regarding the duration individuals stay infective [54], [55], [56].", [["fixed parameter values", "TEST", 97, 119], ["stochastic models", "OBSERVATION", 20, 37], ["probability distributions", "OBSERVATION", 59, 84], ["infectious", "OBSERVATION", 328, 338]]], ["Usually, random variables describe the time of recovery since infection.", [["infection", "DISEASE", 62, 71], ["infection", "PROBLEM", 62, 71], ["infection", "OBSERVATION", 62, 71]]], ["For discrete random variables (e.g., number of individuals) it is easy to define a probability distribution, whilst for continuous variables the time of recovery since infection is modelled.", [["infection", "DISEASE", 168, 177], ["discrete random variables", "PROBLEM", 4, 29], ["infection", "PROBLEM", 168, 177], ["infection", "OBSERVATION", 168, 177]]], ["Often, in this last category it is not possible to fix a probability as there is infinity of such times.", [["not possible", "UNCERTAINTY", 35, 47]]], ["Infectious periods are exponentially distributed with a mean infectious duration, however as frequently real data does not back up this assumption, we rather use constant duration.", [["Infectious periods", "PROBLEM", 0, 18], ["exponentially", "OBSERVATION_MODIFIER", 23, 36], ["infectious", "OBSERVATION_MODIFIER", 61, 71]]], ["To account for such more realistic distributions, the assumption that the probability of recovery does not depend on the time since infection, is often relaxed.", [["infection", "DISEASE", 132, 141], ["infection", "PROBLEM", 132, 141], ["infection", "OBSERVATION", 132, 141]]], ["Then, a common method of stages can be used to replace the infective compartment by a series of successive ones, each with an exponential distribution of the same parameter, leading to a total duration of the infectious period modelled by a gamma distribution [17].State-of-the-Art Analysis and DefinitionsEpidemic models presented above describe rapid outbreaks during which normally the host population is assumed to be in a constant state.", [["a common method of stages", "TREATMENT", 6, 31], ["Art Analysis", "TEST", 278, 290], ["Epidemic models", "PROBLEM", 306, 321], ["rapid outbreaks", "PROBLEM", 347, 362], ["infective", "OBSERVATION", 59, 68], ["infectious", "OBSERVATION", 209, 219], ["rapid", "OBSERVATION_MODIFIER", 347, 352], ["outbreaks", "OBSERVATION", 353, 362]]], ["For longer periods, deaths and births feed the population with new susceptibles, possibly allowing the disease to persist at a constant prevalence.", [["deaths", "DISEASE", 20, 26], ["the disease", "PROBLEM", 99, 110], ["disease", "OBSERVATION", 103, 110]]], ["This state renders an endemic state in the population [17].", [["endemic", "OBSERVATION_MODIFIER", 22, 29]]], ["In this case, we account for birth and death rate of the host population, whereby a good approximation is that the population size N=S+I+R is constant.", [["death", "DISEASE", 39, 44], ["I+R", "GENE_OR_GENE_PRODUCT", 135, 138], ["the population size", "TEST", 111, 130], ["size", "OBSERVATION_MODIFIER", 126, 130], ["constant", "OBSERVATION_MODIFIER", 142, 150]]], ["Conditions regarding this number guarantee the disease persistence, but in epidemic models such persistence can be dependent upon the magnitude of the stochastic fluctuations around the steady-state equilibrium.", [["the disease persistence", "PROBLEM", 43, 66], ["the stochastic fluctuations", "PROBLEM", 147, 174], ["disease", "OBSERVATION", 47, 54], ["persistence", "OBSERVATION_MODIFIER", 55, 66]]], ["Furthermore, many times diseases are in an endemo-epidemic state.", [["many times diseases", "PROBLEM", 13, 32]]], ["As endemic models exhibit damped oscillations which converge toward an endemic equilibrium, this equilibrium can be weakly stable with perturbations (intrinsic or extrinsic), which excite and sustain the inherent oscillation behaviour [57].", [["damped oscillations", "PROBLEM", 26, 45], ["an endemic equilibrium", "PROBLEM", 68, 90], ["damped oscillations", "OBSERVATION", 26, 45]]], ["This behaviour is due to heterogeneity that is added temporally to the coefficient of transmission, spatially in the context of meta-populations, or by cohorts for age-structured models.", [["heterogeneity", "PROBLEM", 25, 38], ["meta-populations", "PROBLEM", 128, 144], ["due to", "UNCERTAINTY", 18, 24], ["heterogeneity", "OBSERVATION", 25, 38]]], ["Lastly, heterogeneity can be added statistically in case of stochastic versions.", [["stochastic versions", "OBSERVATION", 60, 79]]], ["For example, a stochastic version of the endemic SIR model can utilize a Markov process, in which the future is independent of the past given the present, with a state space defined by the number of individuals in each of the three classes, and changes in the state space characterized by probabilistic transition events.", [["a Markov process", "PROBLEM", 71, 87], ["probabilistic transition events", "PROBLEM", 289, 320]]], ["And as future events are independent on past events, the time to the next event follows a negative exponential distribution.State-of-the-Art Analysis and DefinitionsOver the years, a vast number of mathematical modeling approaches has been proposed, tackling the problem from different perspectives.", [["mathematical modeling approaches", "TREATMENT", 198, 230]]], ["The prevailing taxonomy proposed by Siettos and Russo (2013) [58] encompasses three general categories: (1) statistical methods of outbreaks and their identification of spatial patterns in real epidemics, (2) state-space models of the evolution of a \u201chypothetical\u201d or on-going epidemic spread, and (3) machine learning methods, all utilized also for predictability purposes vis-\u00e0-vis an ongoing epidemic.", [["outbreaks", "PROBLEM", 131, 140], ["a \u201chypothetical\u201d", "PROBLEM", 248, 264]]], ["In particular, the first category includes i) regression methods [59], [60], [61], [62], [63], [64], ii) times series analysis, namely ARIMA and seasonal ARIMA approaches [65], [66], [67], [68], iii) process control methods including cumulative sum (CUSUM) charts [69], [70], [71], [72], [73], [74] and exponentially weighted moving average (EWMA) methods [75], [76], as well as iv) Hidden Markov models (HMM) [77], [78].", [["series analysis", "TEST", 111, 126], ["ARIMA", "TEST", 135, 140], ["seasonal ARIMA approaches", "TEST", 145, 170]]], ["The second category incorporates i) \u201ccontinuum\u201d models in the form of differential and/or (integro)-partial differential equations [79], [80], [81], [82], ii) discrete and continuous-time Markov-chain models [83], [84], [85], iii) complex network models which relax the hypotheses of the previous stochastic models that interactions among individuals are instantaneous and homogeneous [86], [87], [88], [89], [90], [91], and iv) Agent-based models [92], [93], [94], [95].", [["[93]", "SIMPLE_CHEMICAL", 454, 458], ["[94]", "SIMPLE_CHEMICAL", 460, 464], ["complex network models", "PROBLEM", 231, 253], ["Agent-based models", "TEST", 429, 447]]], ["Lastly, the third category includes well-known machine learning approaches widely used in computer science, such as i) artificial neural networks [96], ii) web-based data mining [97], [98] and iii) surveillance networks [99], to name a few.State-of-the-Art Analysis and DefinitionsFor the first time in the relevant literature, we introduce a new stochastic model laying in the intersection of categories (1) and (2), called \u201cStereographic Brownian Diffusion Epidemiology Model (SBDiEM)\u201d.", [["neural networks", "MULTI-TISSUE_STRUCTURE", 130, 145], ["a new stochastic model laying", "TREATMENT", 341, 370]]], ["Figure 1presents a graphical overview of the models utilized so far, and the \u201cpositioning\u201d of our novel approach for modelling infectious diseases.The n-Sphere Sn ::: Preliminaries ::: Mathematical Formulation", [["infectious diseases", "DISEASE", 127, 146], ["Sn", "CHEMICAL", 160, 162], ["modelling infectious diseases", "PROBLEM", 117, 146], ["Mathematical Formulation", "TREATMENT", 185, 209]]]]}